,tpid,tp_name,genename1,genename2,tp_moatype,tp_tcrd_tdl,gosemsinbp,gosemsincc,gosemsinmf,tp_keggpathways_no,tp_reactomepathways_no,tp_wikipathways_no,tp_associateddrugs_no,tp_associateddiseases_no,dcid,dc_name,dc_sourcetype,fdid,fd_name,md_name,maxphase
0,TP00001,ABCB1;CD33,ABCB1,CD33,CIT+CIT,Tchem+Tclin,0.245,0.663,0.325,0,0,0,1,1,DC01227,Gemtuzumab Ozogamicin;Zosuquidar,DrugComb,FD00021,Leukemia,Hematologic Malignancy,Phase 1|Phase 2
1,TP00002,ABL1;ALK,ABL1,ALK,CIT+CIT,Tclin+Tclin,0.479,0.358,0.653,1,0,1,1,2,DC00814,Crizotinib;Dasatinib,DrugComb,FD00017,Glioma,Glioma,Phase 1
2,TP00002,ABL1;ALK,ABL1,ALK,CIT+CIT,Tclin+Tclin,0.479,0.358,0.653,1,0,1,1,2,DC00814,Crizotinib;Dasatinib,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
3,TP00003,ABL1;CYP19A1,ABL1,CYP19A1,CIT+CIT,Tclin+Tclin,0.228,0.515,0.305,0,0,0,1,1,DC00192,Anastrozole;Saracatinib,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 1|Phase 2
4,TP00004,ABL1;EGFR,ABL1,EGFR,CIT+CIT,Tclin+Tclin,0.555,0.614,0.703,5,0,5,3,1,DC00861,Dasatinib;Osimertinib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
7,TP00005,ABL1;ERBB2,ABL1,ERBB2,CIT+CIT,Tclin+Tclin,0.528,0.577,0.658,3,0,4,1,1,DC00091,Afatinib;Dasatinib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
8,TP00006,ABL1;ERBB4,ABL1,ERBB4,CIT+CIT,Tclin+Tclin,0.495,0.647,0.687,1,0,1,1,1,DC00091,Afatinib;Dasatinib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
9,TP00007,ABL1;ESR1,ABL1,ESR1,CIT+CIT,Tclin+Tclin,0.457,0.715,0.55,1,0,1,1,1,DC00859,Dasatinib;Fulvestrant,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 2
10,TP00008,ABL1;ESR2,ABL1,ESR2,CIT+CIT,Tclin+Tclin,0.34,0.634,0.541,1,0,1,1,1,DC00859,Dasatinib;Fulvestrant,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 2
11,TP00009,ABL1;FLT1,ABL1,FLT1,CET+CIT,Tclin+Tclin,0.446,0.475,0.638,1,0,4,1,1,DC00687,Cediranib;Dasatinib,DrugComb,FD00038,Prostate Cancer,Prostate Cancer,Phase 2
12,TP00010,ABL1;FLT4,ABL1,FLT4,CET+CIT,Tclin+Tclin,0.488,0.609,0.633,2,0,2,1,1,DC00687,Cediranib;Dasatinib,DrugComb,FD00038,Prostate Cancer,Prostate Cancer,Phase 2
13,TP00011,ABL1;JAK1,ABL1,JAK1,CIT+CIT,Tclin+Tclin,0.406,0.666,0.68,1,0,3,1,1,DC01547,Nilotinib;Ruxolitinib,DrugComb,FD00021,Leukemia,Hematologic Malignancy,Phase 1|Phase 2
14,TP00012,ABL1;JAK2,ABL1,JAK2,CIT+CIT,Tclin+Tclin,0.568,0.692,0.752,1,2,2,1,1,DC01547,Nilotinib;Ruxolitinib,DrugComb,FD00021,Leukemia,Hematologic Malignancy,Phase 1|Phase 2
15,TP00013,ABL1;KDR,ABL1,KDR,CET+CIT,Tclin+Tclin,0.545,0.583,0.66,1,0,3,1,1,DC00687,Cediranib;Dasatinib,DrugComb,FD00038,Prostate Cancer,Prostate Cancer,Phase 2
16,TP00014,ABL1;MAP2K1,ABL1,MAP2K1,CIT+CIT,Tclin+Tclin,0.499,0.66,0.666,7,0,6,2,2,DC00536,Binimetinib;Nilotinib,DrugComb,FD00021,Leukemia,Hematologic Malignancy,Phase 1
17,TP00014,ABL1;MAP2K1,ABL1,MAP2K1,CIT+CIT,Tclin+Tclin,0.499,0.66,0.666,7,0,6,2,2,DC01826,Ponatinib;Trametinib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
18,TP00015,ABL1;MAP2K2,ABL1,MAP2K2,CIT+CIT,Tclin+Tclin,0.338,0.661,0.675,7,0,6,2,2,DC01826,Ponatinib;Trametinib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
19,TP00015,ABL1;MAP2K2,ABL1,MAP2K2,CIT+CIT,Tclin+Tclin,0.338,0.661,0.675,7,0,6,2,2,DC00536,Binimetinib;Nilotinib,DrugComb,FD00021,Leukemia,Hematologic Malignancy,Phase 1
20,TP00016,ABL1;MET,ABL1,MET,CIT+CIT,Tclin+Tclin,0.502,0.364,0.644,5,0,2,1,2,DC00814,Crizotinib;Dasatinib,DrugComb,FD00017,Glioma,Glioma,Phase 1
21,TP00016,ABL1;MET,ABL1,MET,CIT+CIT,Tclin+Tclin,0.502,0.364,0.644,5,0,2,1,2,DC00814,Crizotinib;Dasatinib,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
22,TP00017,ABL1;MKNK1,ABL1,MKNK1,CIT+CIT,Tchem+Tclin,0.313,0.698,0.683,0,0,1,1,1,DC00862,Dasatinib;Tinodasertib,DrugComb,FD00019,Hematologic Malignancies,Hematologic Malignancy,Phase 1
23,TP00018,ABL1;MKNK2,ABL1,MKNK2,CIT+CIT,Tchem+Tclin,0.384,0.704,0.683,0,0,0,1,1,DC00862,Dasatinib;Tinodasertib,DrugComb,FD00019,Hematologic Malignancies,Hematologic Malignancy,Phase 1
24,TP00019,ABL1;MTOR,ABL1,MTOR,CIT+CIT,Tclin+Tclin,0.507,0.723,0.692,3,0,6,1,1,DC00858,Dasatinib;Everolimus,DrugComb,FD00017,Glioma,Glioma,Phase 2
25,TP00020,ABL1;PDCD1,ABL1,PDCD1,CET+CIT,Tclin+Tclin,0.267,0.249,1.0,0,0,0,1,2,DC00860,Dasatinib;Nivolumab,DrugComb,FD00021,Leukemia,Hematologic Malignancy,Phase 1
26,TP00020,ABL1;PDCD1,ABL1,PDCD1,CET+CIT,Tclin+Tclin,0.267,0.249,1.0,0,0,0,1,2,DC00860,Dasatinib;Nivolumab,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 2
27,TP00021,ABL1;SMO,ABL1,SMO,CIT+CIT,Tclin+Tclin,0.423,0.548,0.449,2,0,1,1,1,DC00558,BMS833923;Dasatinib,DrugComb,FD00021,Leukemia,Hematologic Malignancy,Phase 2
28,TP00022,ABL1;VEGFA,ABL1,VEGFA,CET+CIT,Tclin+Tclin,0.529,0.483,0.479,4,0,3,1,1,DC00440,Bevacizumab;Dasatinib,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
29,TP00023,ADAM10;MS4A1,ADAM10,MS4A1,CIT+CIT,Tchem+Tclin,0.338,0.587,0.524,0,0,0,1,1,DC01316,INCB7839;Rituximab,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 1|Phase 2
30,TP00024,ADAM17;MS4A1,ADAM17,MS4A1,CIT+CIT,Tchem+Tclin,0.352,0.646,0.486,0,0,0,1,1,DC01316,INCB7839;Rituximab,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 1|Phase 2
31,TP00025,ADORA2A;AR,ADORA2A,AR,CET+CIT,Tclin+Tclin,0.444,0.452,0.522,0,0,0,1,1,DC01011,Enzalutamide;Imaradenant,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
32,TP00026,ADORA2A;CD274,ADORA2A,CD274,CET+CET,Tclin+Tclin,0.369,0.473,1.0,0,0,0,2,1,DC00924,Durvalumab;Imaradenant,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
34,TP00027,ADORA2A;CYP17A1,ADORA2A,CYP17A1,CET+CIT,Tclin+Tclin,0.126,0.41,0.262,0,0,0,1,1,DC00048,Abiraterone;Imaradenant,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
35,TP00028,ADORA2A;EGFR,ADORA2A,EGFR,CET+CIT,Tclin+Tclin,0.417,0.541,0.601,2,0,1,1,1,DC00916,Duligotuzumab;Etrumadenant,DrugComb,FD00038,Prostate Cancer,Prostate Cancer,Phase 1|Phase 2
36,TP00029,ADORA2A;ERBB3,ADORA2A,ERBB3,CET+CIT,Tclin+Tclin,0.473,0.573,0.658,1,0,0,1,1,DC00916,Duligotuzumab;Etrumadenant,DrugComb,FD00038,Prostate Cancer,Prostate Cancer,Phase 1|Phase 2
37,TP00030,ADORA2A;NT5E,ADORA2A,NT5E,CET+CIT,Tchem+Tclin,0.18,0.537,0.518,0,0,0,3,1,DC00773,Ciforadenant;Mupadolimab,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
40,TP00031,ADORA2A;PDCD1,ADORA2A,PDCD1,CET+CET,Tclin+Tclin,0.284,0.483,1.0,0,0,0,5,4,DC01093,Etrumadenant;Zimberelimab,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 2
41,TP00031,ADORA2A;PDCD1,ADORA2A,PDCD1,CET+CET,Tclin+Tclin,0.284,0.483,1.0,0,0,0,5,4,DC01093,Etrumadenant;Zimberelimab,DrugComb,FD00040,Soft Tissue Sarcoma,Other Cancer,Phase 2
45,TP00031,ADORA2A;PDCD1,ADORA2A,PDCD1,CET+CET,Tclin+Tclin,0.284,0.483,1.0,0,0,0,5,4,DC01928,Spartalizumab;Taminadenant,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 2
46,TP00031,ADORA2A;PDCD1,ADORA2A,PDCD1,CET+CET,Tclin+Tclin,0.284,0.483,1.0,0,0,0,5,4,DC01928,Spartalizumab;Taminadenant,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 2
48,TP00032,ADORA2A;TIGIT,ADORA2A,TIGIT,CET+CET,Tbio+Tclin,0.136,0.516,0.684,0,0,0,1,1,DC00416,Belrestotug;Inupadenant,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
49,TP00033,ADORA2B;EGFR,ADORA2B,EGFR,CIT+CIT,Tclin+Tclin,0.347,0.457,0.532,2,0,0,1,1,DC00916,Duligotuzumab;Etrumadenant,DrugComb,FD00038,Prostate Cancer,Prostate Cancer,Phase 1|Phase 2
50,TP00034,ADORA2B;ERBB3,ADORA2B,ERBB3,CIT+CIT,Tclin+Tclin,0.414,0.659,0.63,1,0,0,1,1,DC00916,Duligotuzumab;Etrumadenant,DrugComb,FD00038,Prostate Cancer,Prostate Cancer,Phase 1|Phase 2
51,TP00035,ADORA2B;PDCD1,ADORA2B,PDCD1,CET+CIT,Tclin+Tclin,0.213,0.648,1.0,0,0,0,3,2,DC01315,INCB106385;Retifanlimab,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
53,TP00035,ADORA2B;PDCD1,ADORA2B,PDCD1,CET+CIT,Tclin+Tclin,0.213,0.648,1.0,0,0,0,3,2,DC01093,Etrumadenant;Zimberelimab,DrugComb,FD00040,Soft Tissue Sarcoma,Other Cancer,Phase 2
55,TP00036,AKT1;AR,AKT1,AR,CIT+CIT,Tchem+Tclin,0.484,0.775,0.465,3,0,3,1,1,DC00650,Capivasertib;Enzalutamide,DrugComb,FD00038,Prostate Cancer,Prostate Cancer,Phase 2
56,TP00037,AKT1;CD274,AKT1,CD274,CET+CIT,Tchem+Tclin,0.384,0.584,1.0,1,0,1,1,2,DC00283,Atezolizumab;Ipatasertib,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 2
57,TP00037,AKT1;CD274,AKT1,CD274,CET+CIT,Tchem+Tclin,0.384,0.584,1.0,1,0,1,1,2,DC00283,Atezolizumab;Ipatasertib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 2
58,TP00038,AKT1;CYP17A1,AKT1,CYP17A1,CIT+CIT,Tchem+Tclin,0.144,0.434,0.241,1,0,2,2,2,DC00046,Abiraterone;Capivasertib,DrugComb,FD00038,Prostate Cancer,Prostate Cancer,Phase 3
59,TP00038,AKT1;CYP17A1,AKT1,CYP17A1,CIT+CIT,Tchem+Tclin,0.144,0.434,0.241,1,0,2,2,2,DC00049,Abiraterone;Ipatasertib,DrugComb,FD00035,Pancreatic Cancer,Pancreatic Cancer,Phase 3
61,TP00039,AKT1;CYP19A1,AKT1,CYP19A1,CIT+CIT,Tchem+Tclin,0.244,0.491,0.255,0,0,3,1,1,DC01326,Ipatasertib;Letrozole,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 1
62,TP00040,AKT1;EGFR,AKT1,EGFR,CIT+CIT,Tchem+Tclin,0.61,0.658,0.748,36,4,31,2,2,DC01054,Erlotinib;MK2206,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 2
63,TP00040,AKT1;EGFR,AKT1,EGFR,CIT+CIT,Tchem+Tclin,0.61,0.658,0.748,36,4,31,2,2,DC01054,Erlotinib;MK2206,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
65,TP00041,AKT1;ERBB2,AKT1,ERBB2,CIT+CIT,Tchem+Tclin,0.537,0.654,0.715,17,3,18,2,1,DC00653,Capivasertib;Trastuzumab Deruxtecan,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 1
67,TP00042,AKT1;ESR1,AKT1,ESR1,CIT+CIT,Tchem+Tclin,0.478,0.748,0.522,8,3,6,4,3,DC00651,Capivasertib;Fulvestrant,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 3
68,TP00042,AKT1;ESR1,AKT1,ESR1,CIT+CIT,Tchem+Tclin,0.478,0.748,0.522,8,3,6,4,3,DC00651,Capivasertib;Fulvestrant,DrugComb,FD00038,Prostate Cancer,Prostate Cancer,Phase 1
71,TP00042,AKT1;ESR1,AKT1,ESR1,CIT+CIT,Tchem+Tclin,0.478,0.748,0.522,8,3,6,4,3,DC01192,Fulvestrant;Vevorisertib,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
72,TP00043,AKT1;ESR2,AKT1,ESR2,CIT+CIT,Tchem+Tclin,0.373,0.599,0.413,7,3,4,4,3,DC00651,Capivasertib;Fulvestrant,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 3
73,TP00043,AKT1;ESR2,AKT1,ESR2,CIT+CIT,Tchem+Tclin,0.373,0.599,0.413,7,3,4,4,3,DC00651,Capivasertib;Fulvestrant,DrugComb,FD00038,Prostate Cancer,Prostate Cancer,Phase 1
76,TP00043,AKT1;ESR2,AKT1,ESR2,CIT+CIT,Tchem+Tclin,0.373,0.599,0.413,7,3,4,4,3,DC01192,Fulvestrant;Vevorisertib,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
77,TP00044,AKT1;IGF1R,AKT1,IGF1R,CIT+CIT,Tchem+Tclin,0.533,0.667,0.706,23,1,23,1,1,DC00841,Dalotuzumab;MK2206,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
78,TP00045,AKT1;MAP2K1,AKT1,MAP2K1,CIT+CIT,Tchem+Tclin,0.484,0.738,0.742,72,0,68,3,3,DC01485,MK2206;Selumetinib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 2
79,TP00045,AKT1;MAP2K1,AKT1,MAP2K1,CIT+CIT,Tchem+Tclin,0.484,0.738,0.742,72,0,68,3,3,DC01485,MK2206;Selumetinib,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
80,TP00045,AKT1;MAP2K1,AKT1,MAP2K1,CIT+CIT,Tchem+Tclin,0.484,0.738,0.742,72,0,68,3,3,DC00106,Afuresertib;Trametinib,DrugComb,FD00030,Myeloma,Hematologic Malignancy,Phase 1
83,TP00046,AKT1;MAP2K2,AKT1,MAP2K2,CIT+CIT,Tchem+Tclin,0.355,0.718,0.724,64,0,58,3,3,DC01968,Trametinib;Uprosertib,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
84,TP00046,AKT1;MAP2K2,AKT1,MAP2K2,CIT+CIT,Tchem+Tclin,0.355,0.718,0.724,64,0,58,3,3,DC00106,Afuresertib;Trametinib,DrugComb,FD00030,Myeloma,Hematologic Malignancy,Phase 1
86,TP00046,AKT1;MAP2K2,AKT1,MAP2K2,CIT+CIT,Tchem+Tclin,0.355,0.718,0.724,64,0,58,3,3,DC01485,MK2206;Selumetinib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 2
88,TP00047,AKT1;MTOR,AKT1,MTOR,CIT+CIT,Tchem+Tclin,0.563,0.646,0.735,43,7,64,1,1,DC01484,MK2206;Ridaforolimus,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
89,TP00048,AKT1;PARP1,AKT1,PARP1,CIT+CIT,Tchem+Tclin,0.466,0.705,0.581,2,0,5,1,1,DC00652,Capivasertib;Olaparib,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
90,TP00049,AKT1;PARP2,AKT1,PARP2,CIT+CIT,Tchem+Tclin,0.304,0.555,0.485,1,0,1,1,1,DC00652,Capivasertib;Olaparib,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
91,TP00050,AKT2;AR,AKT2,AR,CIT+CIT,Tchem+Tclin,0.424,0.874,0.467,3,0,1,1,1,DC00650,Capivasertib;Enzalutamide,DrugComb,FD00038,Prostate Cancer,Prostate Cancer,Phase 2
92,TP00051,AKT2;CD274,AKT2,CD274,CET+CIT,Tchem+Tclin,0.328,0.643,1.0,1,0,1,1,2,DC00283,Atezolizumab;Ipatasertib,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 2
93,TP00051,AKT2;CD274,AKT2,CD274,CET+CIT,Tchem+Tclin,0.328,0.643,1.0,1,0,1,1,2,DC00283,Atezolizumab;Ipatasertib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 2
94,TP00052,AKT2;CYP17A1,AKT2,CYP17A1,CIT+CIT,Tchem+Tclin,0.148,0.461,0.322,1,0,0,2,2,DC00046,Abiraterone;Capivasertib,DrugComb,FD00038,Prostate Cancer,Prostate Cancer,Phase 3
95,TP00052,AKT2;CYP17A1,AKT2,CYP17A1,CIT+CIT,Tchem+Tclin,0.148,0.461,0.322,1,0,0,2,2,DC00049,Abiraterone;Ipatasertib,DrugComb,FD00035,Pancreatic Cancer,Pancreatic Cancer,Phase 3
97,TP00053,AKT2;CYP19A1,AKT2,CYP19A1,CIT+CIT,Tchem+Tclin,0.248,0.549,0.316,0,0,1,1,1,DC01326,Ipatasertib;Letrozole,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 1
98,TP00054,AKT2;EGFR,AKT2,EGFR,CIT+CIT,Tchem+Tclin,0.533,0.719,0.673,36,2,20,2,2,DC01054,Erlotinib;MK2206,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 2
99,TP00054,AKT2;EGFR,AKT2,EGFR,CIT+CIT,Tchem+Tclin,0.533,0.719,0.673,36,2,20,2,2,DC01054,Erlotinib;MK2206,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
101,TP00055,AKT2;ERBB2,AKT2,ERBB2,CIT+CIT,Tchem+Tclin,0.549,0.769,0.741,17,2,11,2,1,DC00653,Capivasertib;Trastuzumab Deruxtecan,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 1
103,TP00056,AKT2;ESR1,AKT2,ESR1,CIT+CIT,Tchem+Tclin,0.418,0.805,0.443,8,1,4,4,3,DC00651,Capivasertib;Fulvestrant,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 3
104,TP00056,AKT2;ESR1,AKT2,ESR1,CIT+CIT,Tchem+Tclin,0.418,0.805,0.443,8,1,4,4,3,DC00651,Capivasertib;Fulvestrant,DrugComb,FD00038,Prostate Cancer,Prostate Cancer,Phase 1
106,TP00056,AKT2;ESR1,AKT2,ESR1,CIT+CIT,Tchem+Tclin,0.418,0.805,0.443,8,1,4,4,3,DC01192,Fulvestrant;Vevorisertib,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
108,TP00057,AKT2;ESR2,AKT2,ESR2,CIT+CIT,Tchem+Tclin,0.364,0.633,0.39,7,1,2,4,3,DC01192,Fulvestrant;Vevorisertib,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
109,TP00057,AKT2;ESR2,AKT2,ESR2,CIT+CIT,Tchem+Tclin,0.364,0.633,0.39,7,1,2,4,3,DC01160,Fulvestrant;Ipatasertib,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 3
111,TP00057,AKT2;ESR2,AKT2,ESR2,CIT+CIT,Tchem+Tclin,0.364,0.633,0.39,7,1,2,4,3,DC00651,Capivasertib;Fulvestrant,DrugComb,FD00038,Prostate Cancer,Prostate Cancer,Phase 1
113,TP00058,AKT2;IGF1R,AKT2,IGF1R,CIT+CIT,Tchem+Tclin,0.498,0.715,0.722,23,0,13,1,1,DC00841,Dalotuzumab;MK2206,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
114,TP00059,AKT2;MAP2K1,AKT2,MAP2K1,CIT+CIT,Tchem+Tclin,0.445,0.778,0.781,72,0,34,3,3,DC01485,MK2206;Selumetinib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 2
115,TP00059,AKT2;MAP2K1,AKT2,MAP2K1,CIT+CIT,Tchem+Tclin,0.445,0.778,0.781,72,0,34,3,3,DC01485,MK2206;Selumetinib,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
116,TP00059,AKT2;MAP2K1,AKT2,MAP2K1,CIT+CIT,Tchem+Tclin,0.445,0.778,0.781,72,0,34,3,3,DC00106,Afuresertib;Trametinib,DrugComb,FD00030,Myeloma,Hematologic Malignancy,Phase 1
119,TP00060,AKT2;MAP2K2,AKT2,MAP2K2,CIT+CIT,Tchem+Tclin,0.392,0.695,0.852,64,0,30,3,3,DC01485,MK2206;Selumetinib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 2
120,TP00060,AKT2;MAP2K2,AKT2,MAP2K2,CIT+CIT,Tchem+Tclin,0.392,0.695,0.852,64,0,30,3,3,DC01485,MK2206;Selumetinib,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
122,TP00060,AKT2;MAP2K2,AKT2,MAP2K2,CIT+CIT,Tchem+Tclin,0.392,0.695,0.852,64,0,30,3,3,DC00106,Afuresertib;Trametinib,DrugComb,FD00030,Myeloma,Hematologic Malignancy,Phase 1
124,TP00061,AKT2;MTOR,AKT2,MTOR,CIT+CIT,Tchem+Tclin,0.428,0.69,0.744,43,6,27,1,1,DC01484,MK2206;Ridaforolimus,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
125,TP00062,AKT2;PARP1,AKT2,PARP1,CIT+CIT,Tchem+Tclin,0.439,0.734,0.549,2,0,1,1,1,DC00652,Capivasertib;Olaparib,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
126,TP00063,AKT2;PARP2,AKT2,PARP2,CIT+CIT,Tchem+Tclin,0.337,0.601,0.444,1,0,0,1,1,DC00652,Capivasertib;Olaparib,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
127,TP00064,AKT3;AR,AKT3,AR,CIT+CIT,Tchem+Tclin,0.379,0.755,0.426,3,0,2,1,1,DC00650,Capivasertib;Enzalutamide,DrugComb,FD00038,Prostate Cancer,Prostate Cancer,Phase 2
128,TP00065,AKT3;CD274,AKT3,CD274,CET+CIT,Tchem+Tclin,0.311,0.531,1.0,1,0,1,1,2,DC00283,Atezolizumab;Ipatasertib,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 2
129,TP00065,AKT3;CD274,AKT3,CD274,CET+CIT,Tchem+Tclin,0.311,0.531,1.0,1,0,1,1,2,DC00283,Atezolizumab;Ipatasertib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 2
130,TP00066,AKT3;CYP17A1,AKT3,CYP17A1,CIT+CIT,Tchem+Tclin,0.136,0.479,0.237,1,0,0,2,2,DC00046,Abiraterone;Capivasertib,DrugComb,FD00038,Prostate Cancer,Prostate Cancer,Phase 3
131,TP00066,AKT3;CYP17A1,AKT3,CYP17A1,CIT+CIT,Tchem+Tclin,0.136,0.479,0.237,1,0,0,2,2,DC00049,Abiraterone;Ipatasertib,DrugComb,FD00035,Pancreatic Cancer,Pancreatic Cancer,Phase 3
133,TP00067,AKT3;CYP19A1,AKT3,CYP19A1,CIT+CIT,Tchem+Tclin,0.234,0.71,0.253,0,0,1,1,1,DC01326,Ipatasertib;Letrozole,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 1
134,TP00068,AKT3;EGFR,AKT3,EGFR,CIT+CIT,Tchem+Tclin,0.465,0.584,0.706,36,2,21,2,2,DC01054,Erlotinib;MK2206,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 2
135,TP00068,AKT3;EGFR,AKT3,EGFR,CIT+CIT,Tchem+Tclin,0.465,0.584,0.706,36,2,21,2,2,DC01054,Erlotinib;MK2206,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
137,TP00069,AKT3;ERBB2,AKT3,ERBB2,CIT+CIT,Tchem+Tclin,0.55,0.628,0.781,17,2,11,2,1,DC00653,Capivasertib;Trastuzumab Deruxtecan,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 1
139,TP00070,AKT3;ESR1,AKT3,ESR1,CIT+CIT,Tchem+Tclin,0.334,0.695,0.409,8,1,3,4,3,DC00651,Capivasertib;Fulvestrant,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 3
140,TP00070,AKT3;ESR1,AKT3,ESR1,CIT+CIT,Tchem+Tclin,0.334,0.695,0.409,8,1,3,4,3,DC00651,Capivasertib;Fulvestrant,DrugComb,FD00038,Prostate Cancer,Prostate Cancer,Phase 1
142,TP00070,AKT3;ESR1,AKT3,ESR1,CIT+CIT,Tchem+Tclin,0.334,0.695,0.409,8,1,3,4,3,DC01192,Fulvestrant;Vevorisertib,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
144,TP00071,AKT3;ESR2,AKT3,ESR2,CIT+CIT,Tchem+Tclin,0.346,0.687,0.333,7,1,2,4,3,DC00651,Capivasertib;Fulvestrant,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 3
145,TP00071,AKT3;ESR2,AKT3,ESR2,CIT+CIT,Tchem+Tclin,0.346,0.687,0.333,7,1,2,4,3,DC00651,Capivasertib;Fulvestrant,DrugComb,FD00038,Prostate Cancer,Prostate Cancer,Phase 1
147,TP00071,AKT3;ESR2,AKT3,ESR2,CIT+CIT,Tchem+Tclin,0.346,0.687,0.333,7,1,2,4,3,DC01192,Fulvestrant;Vevorisertib,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
149,TP00072,AKT3;IGF1R,AKT3,IGF1R,CIT+CIT,Tchem+Tclin,0.439,0.638,0.768,23,0,11,1,1,DC00841,Dalotuzumab;MK2206,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
150,TP00073,AKT3;MAP2K1,AKT3,MAP2K1,CIT+CIT,Tchem+Tclin,0.475,0.681,0.824,72,0,31,3,3,DC01485,MK2206;Selumetinib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 2
151,TP00073,AKT3;MAP2K1,AKT3,MAP2K1,CIT+CIT,Tchem+Tclin,0.475,0.681,0.824,72,0,31,3,3,DC01485,MK2206;Selumetinib,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
152,TP00073,AKT3;MAP2K1,AKT3,MAP2K1,CIT+CIT,Tchem+Tclin,0.475,0.681,0.824,72,0,31,3,3,DC00106,Afuresertib;Trametinib,DrugComb,FD00030,Myeloma,Hematologic Malignancy,Phase 1
155,TP00074,AKT3;MAP2K2,AKT3,MAP2K2,CIT+CIT,Tchem+Tclin,0.447,0.621,0.817,64,0,27,3,3,DC01485,MK2206;Selumetinib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 2
156,TP00074,AKT3;MAP2K2,AKT3,MAP2K2,CIT+CIT,Tchem+Tclin,0.447,0.621,0.817,64,0,27,3,3,DC01485,MK2206;Selumetinib,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
158,TP00074,AKT3;MAP2K2,AKT3,MAP2K2,CIT+CIT,Tchem+Tclin,0.447,0.621,0.817,64,0,27,3,3,DC00106,Afuresertib;Trametinib,DrugComb,FD00030,Myeloma,Hematologic Malignancy,Phase 1
160,TP00075,AKT3;MTOR,AKT3,MTOR,CIT+CIT,Tchem+Tclin,0.395,0.641,0.785,43,6,21,1,1,DC01484,MK2206;Ridaforolimus,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
161,TP00076,AKT3;PARP1,AKT3,PARP1,CIT+CIT,Tchem+Tclin,0.367,0.629,0.522,2,0,1,1,1,DC00652,Capivasertib;Olaparib,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
162,TP00077,AKT3;PARP2,AKT3,PARP2,CIT+CIT,Tchem+Tclin,0.375,0.653,0.458,1,0,0,1,1,DC00652,Capivasertib;Olaparib,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
163,TP00078,ALCAM;CD274,ALCAM,CD274,CET+CIT,Tbio+Tclin,0.349,0.603,1.0,1,0,0,1,1,DC01649,Pacmilimab;Praluzatamab Ravtansine,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 2
164,TP00079,ALK;AR,ALK,AR,CIT+CIT,Tclin+Tclin,0.521,0.57,0.441,1,0,1,1,1,DC00815,Crizotinib;Enzalutamide,DrugComb,FD00038,Prostate Cancer,Prostate Cancer,Phase 1
165,TP00080,ALK;CD274,ALK,CD274,CET+CIT,Tclin+Tclin,0.338,0.571,1.0,1,0,0,4,1,DC00341,Avelumab;Crizotinib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
169,TP00081,ALK;CDK4,ALK,CDK4,CIT+CIT,Tclin+Tclin,0.512,0.365,0.781,2,0,2,1,1,DC00715,Ceritinib;Ribociclib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
170,TP00082,ALK;CDK6,ALK,CDK6,CIT+CIT,Tclin+Tclin,0.527,0.32,0.79,2,0,2,1,1,DC00715,Ceritinib;Ribociclib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
171,TP00083,ALK;CTLA4,ALK,CTLA4,CET+CIT,Tclin+Tclin,0.302,0.657,1.0,0,0,0,1,1,DC00818,Crizotinib;Ipilimumab,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
172,TP00084,ALK;EGFR,ALK,EGFR,CIT+CIT,Tclin+Tclin,0.585,0.557,0.77,3,0,2,3,1,DC00816,Crizotinib;Erlotinib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
175,TP00085,ALK;HSP90AA1,ALK,HSP90AA1,CIT+CIT,Tchem+Tclin,0.378,0.51,0.618,1,0,1,3,1,DC00821,Crizotinib;Onalespib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
178,TP00086,ALK;HSP90AB1,ALK,HSP90AB1,CIT+CIT,Tchem+Tclin,0.401,0.51,0.614,1,0,1,3,1,DC00817,Crizotinib;Ganetespib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
181,TP00087,ALK;KDR,ALK,KDR,CET+CIT,Tclin+Tclin,0.564,0.612,0.862,0,0,0,1,1,DC01451,Lorlatinib;Ramucirumab,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
182,TP00088,ALK;MAP2K1,ALK,MAP2K1,CIT+CIT,Tclin+Tclin,0.59,0.394,0.774,3,0,4,3,2,DC00716,Ceritinib;Trametinib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
183,TP00088,ALK;MAP2K1,ALK,MAP2K1,CIT+CIT,Tclin+Tclin,0.59,0.394,0.774,3,0,4,3,2,DC00716,Ceritinib;Trametinib,DrugComb,FD00026,Melanoma,Melanoma,Phase 1
186,TP00089,ALK;MAP2K2,ALK,MAP2K2,CIT+CIT,Tclin+Tclin,0.504,0.345,0.76,3,0,4,2,2,DC00535,Binimetinib;Lorlatinib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
188,TP00089,ALK;MAP2K2,ALK,MAP2K2,CIT+CIT,Tclin+Tclin,0.504,0.345,0.76,3,0,4,2,2,DC00716,Ceritinib;Trametinib,DrugComb,FD00026,Melanoma,Melanoma,Phase 1
189,TP00090,ALK;MTOR,ALK,MTOR,CIT+CIT,Tclin+Tclin,0.466,0.354,0.71,2,0,1,1,1,DC00712,Ceritinib;Everolimus,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
190,TP00091,ALK;PDCD1,ALK,PDCD1,CET+CIT,Tclin+Tclin,0.363,0.578,1.0,1,0,0,3,1,DC00820,Crizotinib;Nivolumab,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
193,TP00092,ALK;PTPN11,ALK,PTPN11,CIT+CIT,Tchem+Tclin,0.47,0.483,0.483,1,0,1,1,1,DC00392,Batoprotafib;Lorlatinib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
194,TP00093,ALK;VEGFA,ALK,VEGFA,CET+CIT,Tclin+Tclin,0.48,0.424,0.525,1,0,2,3,1,DC00439,Bevacizumab;Crizotinib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 2
197,TP00094,ANGPT1;MTOR,ANGPT1,MTOR,CIT+CIT,Tbio+Tclin,0.402,0.365,0.459,2,0,3,1,1,DC01952,Temsirolimus;Trebananib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
198,TP00095,ANGPT1;PDCD1,ANGPT1,PDCD1,CET+CIT,Tbio+Tclin,0.306,0.512,1.0,0,0,0,1,1,DC01747,Pembrolizumab;Trebananib,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
199,TP00096,ANGPT2;CD40,ANGPT2,CD40,CET+CET,Tchem+Tclin,0.412,0.672,0.646,0,0,0,1,1,DC01894,Selicrelumab;Vanucizumab,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
200,TP00097,ANGPT2;CD79B,ANGPT2,CD79B,CET+CIT,Tclin+Tclin,0.359,0.626,0.656,0,0,0,1,1,DC01823,Polatuzumab Vedotin;Vanucizumab,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 2
201,TP00098,ANGPT2;CRBN,ANGPT2,CRBN,CET+CIT,Tclin+Tclin,0.151,0.558,0.866,0,0,0,1,1,DC01414,Lenalidomide;Vanucizumab,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 1|Phase 2
202,TP00099,ANGPT2;MTOR,ANGPT2,MTOR,CET+CIT,Tclin+Tclin,0.354,0.526,0.412,3,0,3,1,1,DC01952,Temsirolimus;Trebananib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
203,TP00100,ANGPT2;PDCD1,ANGPT2,PDCD1,CET+CET,Tclin+Tclin,0.315,0.539,1.0,0,0,0,2,3,DC00515,BI836880;Ezabenlimab,DrugComb,FD00002,Anal Cancer,Other Cancer,Phase 2
204,TP00100,ANGPT2;PDCD1,ANGPT2,PDCD1,CET+CET,Tclin+Tclin,0.315,0.539,1.0,0,0,0,2,3,DC00515,BI836880;Ezabenlimab,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
205,TP00100,ANGPT2;PDCD1,ANGPT2,PDCD1,CET+CET,Tclin+Tclin,0.315,0.539,1.0,0,0,0,2,3,DC00515,BI836880;Ezabenlimab,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
207,TP00101,ANGPT2;VEGFA,ANGPT2,VEGFA,CET+CET,Tclin+Tclin,0.466,0.658,0.636,6,0,4,4,7,DC00458,Bevacizumab;MEDI3617,DrugComb,FD00034,Ovarian Cancer,Ovarian Cancer,Phase 1
208,TP00101,ANGPT2;VEGFA,ANGPT2,VEGFA,CET+CET,Tclin+Tclin,0.466,0.658,0.636,6,0,4,4,7,DC02041,BI836880,BsAb,FD00002,Anal Cancer,Other Cancer,Phase 2
209,TP00101,ANGPT2;VEGFA,ANGPT2,VEGFA,CET+CET,Tclin+Tclin,0.466,0.658,0.636,6,0,4,4,7,DC02041,BI836880,BsAb,FD00018,Head and Neck Cancer,Head and Neck Cancer,Phase 1
210,TP00101,ANGPT2;VEGFA,ANGPT2,VEGFA,CET+CET,Tclin+Tclin,0.466,0.658,0.636,6,0,4,4,7,DC02041,BI836880,BsAb,FD00022,Liver Cancer,Liver Cancer,Phase 1
211,TP00101,ANGPT2;VEGFA,ANGPT2,VEGFA,CET+CET,Tclin+Tclin,0.466,0.658,0.636,6,0,4,4,7,DC02041,BI836880,BsAb,FD00023,Lung Cancer,Lung Cancer,Phase 2
212,TP00101,ANGPT2;VEGFA,ANGPT2,VEGFA,CET+CET,Tclin+Tclin,0.466,0.658,0.636,6,0,4,4,7,DC02041,BI836880,BsAb,FD00033,Other Cancer,Other Cancer,Phase 1
214,TP00101,ANGPT2;VEGFA,ANGPT2,VEGFA,CET+CET,Tclin+Tclin,0.466,0.658,0.636,6,0,4,4,7,DC02287,Vanucizumab,BsAb,FD00011,Colorectal Cancer,Colorectal Cancer,Phase 2
216,TP00102,AR;BRD2,AR,BRD2,CIT+CIT,Tchem+Tclin,0.338,0.879,0.525,0,0,0,2,1,DC01020,Enzalutamide;ZEN003694,DrugComb,FD00038,Prostate Cancer,Prostate Cancer,Phase 2
218,TP00103,AR;BRD3,AR,BRD3,CIT+CIT,Tchem+Tclin,0.217,0.663,0.544,0,0,0,2,1,DC01020,Enzalutamide;ZEN003694,DrugComb,FD00038,Prostate Cancer,Prostate Cancer,Phase 2
220,TP00104,AR;BRD4,AR,BRD4,CIT+CIT,Tchem+Tclin,0.353,0.733,0.578,0,0,0,2,1,DC01020,Enzalutamide;ZEN003694,DrugComb,FD00038,Prostate Cancer,Prostate Cancer,Phase 2
222,TP00105,AR;BRDT,AR,BRDT,CIT+CIT,Tchem+Tclin,0.365,0.663,0.415,0,0,1,2,1,DC00140,Alobresib;Enzalutamide,DrugComb,FD00038,Prostate Cancer,Prostate Cancer,Phase 1|Phase 2
224,TP00106,AR;CD274,AR,CD274,CET+CIT,Tclin+Tclin,0.32,0.624,1.0,0,0,0,1,1,DC00270,Atezolizumab;Enzalutamide,DrugComb,FD00038,Prostate Cancer,Prostate Cancer,Phase 3
225,TP00107,AR;CDK2,AR,CDK2,CIT+CIT,Tchem+Tclin,0.435,0.723,0.447,3,0,2,1,1,DC01014,Enzalutamide;NUV422,DrugComb,FD00038,Prostate Cancer,Prostate Cancer,Phase 1|Phase 2
226,TP00108,AR;CDK4,AR,CDK4,CIT+CIT,Tclin+Tclin,0.505,0.73,0.427,1,0,2,4,2,DC00013,Abemaciclib;Bicalutamide,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 1|Phase 2
228,TP00108,AR;CDK4,AR,CDK4,CIT+CIT,Tclin+Tclin,0.505,0.73,0.427,1,0,2,4,2,DC01014,Enzalutamide;NUV422,DrugComb,FD00038,Prostate Cancer,Prostate Cancer,Phase 1|Phase 2
230,TP00109,AR;CDK6,AR,CDK6,CIT+CIT,Tclin+Tclin,0.466,0.732,0.452,1,0,1,4,2,DC00013,Abemaciclib;Bicalutamide,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 1|Phase 2
232,TP00109,AR;CDK6,AR,CDK6,CIT+CIT,Tclin+Tclin,0.466,0.732,0.452,1,0,1,4,2,DC01014,Enzalutamide;NUV422,DrugComb,FD00038,Prostate Cancer,Prostate Cancer,Phase 1|Phase 2
234,TP00110,AR;CYP19A1,AR,CYP19A1,CIT+CIT,Tclin+Tclin,0.365,0.524,0.291,0,0,0,2,1,DC00520,Bicalutamide;Letrozole,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 2
236,TP00111,AR;ENG,AR,ENG,CIT+CIT,Tbio+Tclin,0.471,0.636,0.482,0,0,0,2,1,DC00230,Apalutamide;Carotuximab,DrugComb,FD00038,Prostate Cancer,Prostate Cancer,Phase 2
238,TP00112,AR;ERBB2,AR,ERBB2,CIT+CIT,Tclin+Tclin,0.54,0.73,0.495,2,0,1,1,1,DC01019,Enzalutamide;Trastuzumab,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 2
239,TP00113,AR;FASN,AR,FASN,CIT+CIT,Tchem+Tclin,0.281,0.712,0.367,0,0,0,1,1,DC00877,Denifanstat;Enzalutamide,DrugComb,FD00038,Prostate Cancer,Prostate Cancer,Phase 1
240,TP00114,AR;FLT1,AR,FLT1,CET+CIT,Tclin+Tclin,0.455,0.574,0.436,0,0,0,1,1,DC01018,Enzalutamide;Tivozanib,DrugComb,FD00038,Prostate Cancer,Prostate Cancer,Phase 2
241,TP00115,AR;FLT4,AR,FLT4,CET+CIT,Tclin+Tclin,0.483,0.812,0.464,1,0,1,1,1,DC01018,Enzalutamide;Tivozanib,DrugComb,FD00038,Prostate Cancer,Prostate Cancer,Phase 2
242,TP00116,AR;GNRHR,AR,GNRHR,CIT+CIT,Tclin+Tclin,0.373,0.518,0.242,0,0,0,3,1,DC00517,Bicalutamide;Degarelix,DrugComb,FD00038,Prostate Cancer,Prostate Cancer,Phase 2
245,TP00117,AR;HDAC1,AR,HDAC1,CIT+CIT,Tclin+Tclin,0.525,0.851,0.653,1,0,3,2,1,DC00522,Bicalutamide;Panobinostat,DrugComb,FD00038,Prostate Cancer,Prostate Cancer,Phase 1|Phase 2
247,TP00118,AR;HDAC10,AR,HDAC10,CIT+CIT,Tclin+Tclin,0.255,0.795,0.519,0,0,0,1,1,DC00522,Bicalutamide;Panobinostat,DrugComb,FD00038,Prostate Cancer,Prostate Cancer,Phase 1|Phase 2
248,TP00119,AR;HDAC11,AR,HDAC11,CIT+CIT,Tclin+Tclin,0.158,0.697,0.489,0,0,0,1,1,DC00522,Bicalutamide;Panobinostat,DrugComb,FD00038,Prostate Cancer,Prostate Cancer,Phase 1|Phase 2
249,TP00120,AR;HDAC2,AR,HDAC2,CIT+CIT,Tclin+Tclin,0.481,0.858,0.598,1,0,1,2,1,DC00522,Bicalutamide;Panobinostat,DrugComb,FD00038,Prostate Cancer,Prostate Cancer,Phase 1|Phase 2
251,TP00121,AR;HDAC3,AR,HDAC3,CIT+CIT,Tclin+Tclin,0.393,0.857,0.589,0,1,0,2,1,DC00522,Bicalutamide;Panobinostat,DrugComb,FD00038,Prostate Cancer,Prostate Cancer,Phase 1|Phase 2
253,TP00122,AR;HDAC4,AR,HDAC4,CIT+CIT,Tclin+Tclin,0.42,0.851,0.639,0,1,0,1,1,DC00522,Bicalutamide;Panobinostat,DrugComb,FD00038,Prostate Cancer,Prostate Cancer,Phase 1|Phase 2
254,TP00123,AR;HDAC5,AR,HDAC5,CIT+CIT,Tclin+Tclin,0.36,0.833,0.642,0,0,0,1,1,DC00522,Bicalutamide;Panobinostat,DrugComb,FD00038,Prostate Cancer,Prostate Cancer,Phase 1|Phase 2
255,TP00124,AR;HDAC6,AR,HDAC6,CIT+CIT,Tclin+Tclin,0.371,0.682,0.633,0,1,0,1,1,DC00522,Bicalutamide;Panobinostat,DrugComb,FD00038,Prostate Cancer,Prostate Cancer,Phase 1|Phase 2
256,TP00125,AR;HDAC7,AR,HDAC7,CIT+CIT,Tclin+Tclin,0.33,0.823,0.564,0,0,0,1,1,DC00522,Bicalutamide;Panobinostat,DrugComb,FD00038,Prostate Cancer,Prostate Cancer,Phase 1|Phase 2
257,TP00126,AR;HDAC8,AR,HDAC8,CIT+CIT,Tclin+Tclin,0.257,0.861,0.527,0,0,0,2,1,DC00995,Entinostat;Enzalutamide,DrugComb,FD00038,Prostate Cancer,Prostate Cancer,Phase 1
259,TP00127,AR;HDAC9,AR,HDAC9,CIT+CIT,Tclin+Tclin,0.35,0.821,0.552,0,0,1,1,1,DC00522,Bicalutamide;Panobinostat,DrugComb,FD00038,Prostate Cancer,Prostate Cancer,Phase 1|Phase 2
260,TP00128,AR;KDR,AR,KDR,CET+CIT,Tclin+Tclin,0.505,0.663,0.477,0,0,0,1,1,DC01018,Enzalutamide;Tivozanib,DrugComb,FD00038,Prostate Cancer,Prostate Cancer,Phase 2
261,TP00129,AR;MET,AR,MET,CIT+CIT,Tclin+Tclin,0.518,0.552,0.436,1,0,1,1,1,DC00815,Crizotinib;Enzalutamide,DrugComb,FD00038,Prostate Cancer,Prostate Cancer,Phase 1
262,TP00130,AR;MTOR,AR,MTOR,CIT+CIT,Tclin+Tclin,0.438,0.692,0.493,3,0,3,3,1,DC01016,Enzalutamide;Samotolisib,DrugComb,FD00038,Prostate Cancer,Prostate Cancer,Phase 2
265,TP00131,AR;PARP1,AR,PARP1,CIT+CIT,Tclin+Tclin,0.417,0.808,0.608,0,0,1,2,1,DC01017,Enzalutamide;Talazoparib,DrugComb,FD00038,Prostate Cancer,Prostate Cancer,Approval
267,TP00132,AR;PARP2,AR,PARP2,CIT+CIT,Tclin+Tclin,0.239,0.707,0.533,0,0,0,2,1,DC01013,Enzalutamide;Niraparib,DrugComb,FD00038,Prostate Cancer,Prostate Cancer,Phase 1
269,TP00133,AR;PIK3CA,AR,PIK3CA,CIT+CIT,Tclin+Tclin,0.427,0.612,0.37,3,0,3,2,2,DC01016,Enzalutamide;Samotolisib,DrugComb,FD00038,Prostate Cancer,Prostate Cancer,Phase 2
270,TP00133,AR;PIK3CA,AR,PIK3CA,CIT+CIT,Tclin+Tclin,0.427,0.612,0.37,3,0,3,2,2,DC00147,Alpelisib;Enzalutamide,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 1
271,TP00134,AR;PIK3CB,AR,PIK3CB,CIT+CIT,Tchem+Tclin,0.406,0.798,0.406,3,0,1,1,1,DC01010,Enzalutamide;GSK2636771,DrugComb,FD00038,Prostate Cancer,Prostate Cancer,Phase 1
272,TP00135,AR;TGFBR1,AR,TGFBR1,CIT+CIT,Tchem+Tclin,0.571,0.635,0.475,1,1,1,1,1,DC01009,Enzalutamide;Galunisertib,DrugComb,FD00038,Prostate Cancer,Prostate Cancer,Phase 2
273,TP00136,AR;TNFSF11,AR,TNFSF11,CIT+CIT,Tclin+Tclin,0.518,0.634,0.527,1,0,0,1,1,DC00880,Denosumab;Enzalutamide,DrugComb,FD00038,Prostate Cancer,Prostate Cancer,Phase 2
274,TP00137,ARAF;AURKA,ARAF,AURKA,CIT+CIT,Tchem+Tchem,0.406,0.494,0.881,1,0,0,1,1,DC00138,Alisertib;Tovorafenib,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
275,TP00138,ARAF;EGFR,ARAF,EGFR,CIT+CIT,Tchem+Tclin,0.416,0.457,0.708,22,0,11,1,1,DC00761,Cetuximab;Tovorafenib,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
276,TP00139,ARAF;KRAS,ARAF,KRAS,CIT+CIT,Tchem+Tclin,0.434,0.581,0.383,34,3,20,2,1,DC00072,Adagrasib;Avutometinib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
278,TP00140,ARAF;MAP2K1,ARAF,MAP2K1,CIT+CIT,Tchem+Tclin,0.384,0.649,0.806,36,8,22,4,5,DC00767,CFT1946;Trametinib,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1|Phase 2
280,TP00140,ARAF;MAP2K1,ARAF,MAP2K1,CIT+CIT,Tchem+Tclin,0.384,0.649,0.806,36,8,22,4,5,DC01969,Trametinib;XP102,DrugComb,FD00011,Colorectal Cancer,Colorectal Cancer,Phase 1|Phase 2
281,TP00140,ARAF;MAP2K1,ARAF,MAP2K1,CIT+CIT,Tchem+Tclin,0.384,0.649,0.806,36,8,22,4,5,DC01969,Trametinib;XP102,DrugComb,FD00018,Head and Neck Cancer,Head and Neck Cancer,Phase 1|Phase 2
282,TP00140,ARAF;MAP2K1,ARAF,MAP2K1,CIT+CIT,Tchem+Tclin,0.384,0.649,0.806,36,8,22,4,5,DC01969,Trametinib;XP102,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
283,TP00140,ARAF;MAP2K1,ARAF,MAP2K1,CIT+CIT,Tchem+Tclin,0.384,0.649,0.806,36,8,22,4,5,DC01969,Trametinib;XP102,DrugComb,FD00026,Melanoma,Melanoma,Phase 1|Phase 2
285,TP00141,ARAF;MAP2K2,ARAF,MAP2K2,CIT+CIT,Tchem+Tclin,0.58,0.612,0.862,31,8,21,4,5,DC00767,CFT1946;Trametinib,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1|Phase 2
287,TP00141,ARAF;MAP2K2,ARAF,MAP2K2,CIT+CIT,Tchem+Tclin,0.58,0.612,0.862,31,8,21,4,5,DC01969,Trametinib;XP102,DrugComb,FD00011,Colorectal Cancer,Colorectal Cancer,Phase 1|Phase 2
288,TP00141,ARAF;MAP2K2,ARAF,MAP2K2,CIT+CIT,Tchem+Tclin,0.58,0.612,0.862,31,8,21,4,5,DC01969,Trametinib;XP102,DrugComb,FD00018,Head and Neck Cancer,Head and Neck Cancer,Phase 1|Phase 2
289,TP00141,ARAF;MAP2K2,ARAF,MAP2K2,CIT+CIT,Tchem+Tclin,0.58,0.612,0.862,31,8,21,4,5,DC01969,Trametinib;XP102,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
290,TP00141,ARAF;MAP2K2,ARAF,MAP2K2,CIT+CIT,Tchem+Tclin,0.58,0.612,0.862,31,8,21,4,5,DC01969,Trametinib;XP102,DrugComb,FD00026,Melanoma,Melanoma,Phase 1|Phase 2
292,TP00142,ARAF;MTOR,ARAF,MTOR,CIT+CIT,Tchem+Tclin,0.319,0.567,0.77,16,0,10,1,2,DC00356,Avutometinib;Everolimus,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
293,TP00142,ARAF;MTOR,ARAF,MTOR,CIT+CIT,Tchem+Tclin,0.319,0.567,0.77,16,0,10,1,2,DC00356,Avutometinib;Everolimus,DrugComb,FD00030,Myeloma,Hematologic Malignancy,Phase 1
294,TP00143,ARAF;PDCD1,ARAF,PDCD1,CET+CIT,Tchem+Tclin,0.302,0.292,1.0,0,0,0,1,1,DC01588,Nivolumab;Tovorafenib,DrugComb,FD00026,Melanoma,Melanoma,Phase 1
295,TP00144,ARAF;PTK2,ARAF,PTK2,CET+CIT,Tchem+Tclin,0.437,0.561,0.768,6,0,4,1,3,DC00355,Avutometinib;Defactinib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 2
296,TP00144,ARAF;PTK2,ARAF,PTK2,CET+CIT,Tchem+Tclin,0.437,0.561,0.768,6,0,4,1,3,DC00355,Avutometinib;Defactinib,DrugComb,FD00034,Ovarian Cancer,Ovarian Cancer,Phase 1
297,TP00144,ARAF;PTK2,ARAF,PTK2,CET+CIT,Tchem+Tclin,0.437,0.561,0.768,6,0,4,1,3,DC00355,Avutometinib;Defactinib,DrugComb,FD00035,Pancreatic Cancer,Pancreatic Cancer,Phase 1
298,TP00145,ARG1;PDCD1,ARG1,PDCD1,CET+CIT,Tchem+Tclin,0.284,0.273,1.0,0,0,1,1,1,DC01604,Numidargistat;Pembrolizumab,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
299,TP00146,ATR;BTK,ATR,BTK,CIT+CIT,Tchem+Tclin,0.357,0.574,0.698,0,0,0,1,1,DC00056,Acalabrutinib;Ceralasertib,DrugComb,FD00021,Leukemia,Hematologic Malignancy,Phase 1
300,TP00147,ATR;CD274,ATR,CD274,CET+CIT,Tchem+Tclin,0.238,0.546,1.0,0,0,0,2,4,DC00255,Atezolizumab;Camonsertib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
301,TP00147,ATR;CD274,ATR,CD274,CET+CIT,Tchem+Tclin,0.238,0.546,1.0,0,0,0,2,4,DC00709,Ceralasertib;Durvalumab,DrugComb,FD00022,Liver Cancer,Liver Cancer,Phase 2
303,TP00147,ATR;CD274,ATR,CD274,CET+CIT,Tchem+Tclin,0.238,0.546,1.0,0,0,0,2,4,DC00709,Ceralasertib;Durvalumab,DrugComb,FD00026,Melanoma,Melanoma,Phase 2
304,TP00147,ATR;CD274,ATR,CD274,CET+CIT,Tchem+Tclin,0.238,0.546,1.0,0,0,0,2,4,DC00709,Ceralasertib;Durvalumab,DrugComb,FD00041,Stomach Cancer,Stomach Cancer,Phase 2
305,TP00148,ATR;PARP1,ATR,PARP1,CIT+CIT,Tchem+Tclin,0.516,0.773,0.569,0,0,4,2,4,DC00710,Ceralasertib;Olaparib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 2
306,TP00148,ATR;PARP1,ATR,PARP1,CIT+CIT,Tchem+Tclin,0.516,0.773,0.569,0,0,4,2,4,DC00710,Ceralasertib;Olaparib,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 2
307,TP00148,ATR;PARP1,ATR,PARP1,CIT+CIT,Tchem+Tclin,0.516,0.773,0.569,0,0,4,2,4,DC00710,Ceralasertib;Olaparib,DrugComb,FD00034,Ovarian Cancer,Ovarian Cancer,Phase 2
308,TP00148,ATR;PARP1,ATR,PARP1,CIT+CIT,Tchem+Tclin,0.516,0.773,0.569,0,0,4,2,4,DC00710,Ceralasertib;Olaparib,DrugComb,FD00040,Soft Tissue Sarcoma,Other Cancer,Phase 2
310,TP00149,ATR;PARP2,ATR,PARP2,CIT+CIT,Tchem+Tclin,0.444,0.859,0.535,0,0,1,2,4,DC00710,Ceralasertib;Olaparib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 2
311,TP00149,ATR;PARP2,ATR,PARP2,CIT+CIT,Tchem+Tclin,0.444,0.859,0.535,0,0,1,2,4,DC00710,Ceralasertib;Olaparib,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 2
312,TP00149,ATR;PARP2,ATR,PARP2,CIT+CIT,Tchem+Tclin,0.444,0.859,0.535,0,0,1,2,4,DC00710,Ceralasertib;Olaparib,DrugComb,FD00034,Ovarian Cancer,Ovarian Cancer,Phase 2
313,TP00149,ATR;PARP2,ATR,PARP2,CIT+CIT,Tchem+Tclin,0.444,0.859,0.535,0,0,1,2,4,DC00710,Ceralasertib;Olaparib,DrugComb,FD00040,Soft Tissue Sarcoma,Other Cancer,Phase 2
315,TP00150,ATR;PDCD1,ATR,PDCD1,CET+CIT,Tchem+Tclin,0.227,0.204,1.0,0,0,0,1,1,DC00706,Cemiplimab;Tuvusertib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
316,TP00151,ATR;PIK3CA,ATR,PIK3CA,CIT+CIT,Tchem+Tclin,0.36,0.347,0.738,4,0,2,1,1,DC00798,Copanlisib;Elimusertib,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
317,TP00152,ATR;PIK3CD,ATR,PIK3CD,CIT+CIT,Tchem+Tclin,0.319,0.375,0.649,4,0,1,1,1,DC00798,Copanlisib;Elimusertib,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
318,TP00153,ATR;PKMYT1,ATR,PKMYT1,CIT+CIT,Tchem+Tchem,0.306,0.766,0.828,1,0,1,1,1,DC00640,Camonsertib;RP6306,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
319,TP00154,AURKA;BRAF,AURKA,BRAF,CIT+CIT,Tchem+Tclin,0.401,0.583,0.858,1,0,0,1,1,DC00138,Alisertib;Tovorafenib,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
320,TP00155,AURKA;EGFR,AURKA,EGFR,CIT+CIT,Tchem+Tclin,0.405,0.487,0.736,0,0,1,4,1,DC00133,Alisertib;Erlotinib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
324,TP00156,AURKA;KRAS,AURKA,KRAS,CIT+CIT,Tchem+Tclin,0.384,0.458,0.425,1,0,0,1,1,DC01924,Sotorasib;VIC1911,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
325,TP00157,AURKA;MTOR,AURKA,MTOR,CIT+CIT,Tchem+Tclin,0.399,0.575,0.763,0,0,1,1,2,DC00136,Alisertib;Sapanisertib,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 1
326,TP00157,AURKA;MTOR,AURKA,MTOR,CIT+CIT,Tchem+Tclin,0.399,0.575,0.763,0,0,1,1,2,DC00136,Alisertib;Sapanisertib,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
327,TP00158,AURKA;PIK3CA,AURKA,PIK3CA,CIT+CIT,Tchem+Tclin,0.4,0.478,0.773,1,0,0,1,1,DC00137,Alisertib;Serabelisib,DrugComb,FD00041,Stomach Cancer,Stomach Cancer,Phase 1
328,TP00159,AURKA;RAF1,AURKA,RAF1,CIT+CIT,Tchem+Tclin,0.458,0.557,0.883,1,0,0,1,1,DC00138,Alisertib;Tovorafenib,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
329,TP00160,AURKA;TNFRSF8,AURKA,TNFRSF8,CIT+CIT,Tchem+Tclin,0.243,0.422,0.176,0,0,0,1,1,DC00132,Alisertib;Brentuximab Vedotin,DrugComb,FD00019,Hematologic Malignancies,Hematologic Malignancy,Phase 1
330,TP00161,AXL;BTK,AXL,BTK,CIT+CIT,Tchem+Tclin,0.523,0.547,0.742,0,0,0,1,2,DC00914,Dubermatinib;Ibrutinib,DrugComb,FD00021,Leukemia,Hematologic Malignancy,Phase 1|Phase 2
331,TP00161,AXL;BTK,AXL,BTK,CIT+CIT,Tchem+Tclin,0.523,0.547,0.742,0,0,0,1,2,DC00914,Dubermatinib;Ibrutinib,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 1|Phase 2
332,TP00162,AXL;CD274,AXL,CD274,CET+CIT,Tchem+Tclin,0.456,0.676,1.0,0,0,0,3,2,DC00931,Durvalumab;Mecbotamab Vedotin,DrugComb,FD00034,Ovarian Cancer,Ovarian Cancer,Phase 2
334,TP00162,AXL;CD274,AXL,CD274,CET+CIT,Tchem+Tclin,0.456,0.676,1.0,0,0,0,3,2,DC00338,Avelumab;Batiraxcept,DrugComb,FD00006,Bladder Cancer,Bladder Cancer,Phase 1
335,TP00163,AXL;EGFR,AXL,EGFR,CIT+CIT,Tchem+Tclin,0.552,0.659,0.753,1,0,2,3,1,DC00422,Bemcentinib;Erlotinib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
338,TP00164,AXL;PDCD1,AXL,PDCD1,CET+CIT,Tchem+Tclin,0.364,0.49,1.0,0,0,0,4,6,DC01698,Pembrolizumab;Q702,DrugComb,FD00014,Esophageal Cancer,Esophageal Cancer,Phase 1|Phase 2
339,TP00164,AXL;PDCD1,AXL,PDCD1,CET+CIT,Tchem+Tclin,0.364,0.49,1.0,0,0,0,4,6,DC01698,Pembrolizumab;Q702,DrugComb,FD00022,Liver Cancer,Liver Cancer,Phase 1|Phase 2
340,TP00164,AXL;PDCD1,AXL,PDCD1,CET+CIT,Tchem+Tclin,0.364,0.49,1.0,0,0,0,4,6,DC01698,Pembrolizumab;Q702,DrugComb,FD00034,Ovarian Cancer,Ovarian Cancer,Phase 1|Phase 2
341,TP00164,AXL;PDCD1,AXL,PDCD1,CET+CIT,Tchem+Tclin,0.364,0.49,1.0,0,0,0,4,6,DC01698,Pembrolizumab;Q702,DrugComb,FD00041,Stomach Cancer,Stomach Cancer,Phase 1|Phase 2
342,TP00164,AXL;PDCD1,AXL,PDCD1,CET+CIT,Tchem+Tclin,0.364,0.49,1.0,0,0,0,4,6,DC01314,INCB081776;Retifanlimab,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
343,TP00164,AXL;PDCD1,AXL,PDCD1,CET+CIT,Tchem+Tclin,0.364,0.49,1.0,0,0,0,4,6,DC00423,Bemcentinib;Pembrolizumab,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 2
345,TP00165,BCL2;BTK,BCL2,BTK,CIT+CIT,Tclin+Tclin,0.408,0.703,0.5,2,0,0,3,2,DC01819,Pirtobrutinib;Venetoclax,DrugComb,FD00021,Leukemia,Hematologic Malignancy,Phase 2
346,TP00165,BCL2;BTK,BCL2,BTK,CIT+CIT,Tclin+Tclin,0.408,0.703,0.5,2,0,0,3,2,DC01819,Pirtobrutinib;Venetoclax,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 2
351,TP00166,BCL2;CD37,BCL2,CD37,CET+CIT,Tbio+Tclin,,0.46,1.0,0,0,0,1,1,DC00514,BI836826;Venetoclax,DrugComb,FD00021,Leukemia,Hematologic Malignancy,Phase 1
352,TP00167,BCL2;CD70,BCL2,CD70,CIT+CIT,Tbio+Tclin,0.281,0.359,0.628,0,0,0,1,1,DC00827,Cusatuzumab;Venetoclax,DrugComb,FD00021,Leukemia,Hematologic Malignancy,Phase 1
353,TP00168,BCL2;CDK1,BCL2,CDK1,CIT+CIT,Tchem+Tclin,0.477,0.732,0.425,2,0,3,2,1,DC00887,Dinaciclib;Venetoclax,DrugComb,FD00021,Leukemia,Hematologic Malignancy,Phase 1
355,TP00169,BCL2;CDK2,BCL2,CDK2,CIT+CIT,Tchem+Tclin,0.358,0.626,0.452,9,0,9,3,2,DC00887,Dinaciclib;Venetoclax,DrugComb,FD00021,Leukemia,Hematologic Malignancy,Phase 1
357,TP00169,BCL2;CDK2,BCL2,CDK2,CIT+CIT,Tchem+Tclin,0.358,0.626,0.452,9,0,9,3,2,DC01140,Fadraciclib;Venetoclax,DrugComb,FD00030,Myeloma,Hematologic Malignancy,Phase 1
359,TP00170,BCL2;CDK4,BCL2,CDK4,CIT+CIT,Tclin+Tclin,0.431,0.677,0.462,8,0,8,3,2,DC01443,Lisaftoclax;Palbociclib,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 1|Phase 2
360,TP00170,BCL2;CDK4,BCL2,CDK4,CIT+CIT,Tclin+Tclin,0.431,0.677,0.462,8,0,8,3,2,DC00170,Alvocidib;Venetoclax,DrugComb,FD00021,Leukemia,Hematologic Malignancy,Phase 1
362,TP00171,BCL2;CDK5,BCL2,CDK5,CIT+CIT,Tchem+Tclin,0.459,0.581,0.472,1,0,0,2,2,DC01140,Fadraciclib;Venetoclax,DrugComb,FD00021,Leukemia,Hematologic Malignancy,Phase 1
363,TP00171,BCL2;CDK5,BCL2,CDK5,CIT+CIT,Tchem+Tclin,0.459,0.581,0.472,1,0,0,2,2,DC01140,Fadraciclib;Venetoclax,DrugComb,FD00030,Myeloma,Hematologic Malignancy,Phase 1
365,TP00172,BCL2;CDK6,BCL2,CDK6,CIT+CIT,Tclin+Tclin,0.424,0.666,0.487,7,0,4,3,2,DC01443,Lisaftoclax;Palbociclib,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 1|Phase 2
366,TP00172,BCL2;CDK6,BCL2,CDK6,CIT+CIT,Tclin+Tclin,0.424,0.666,0.487,7,0,4,3,2,DC01987,Venetoclax;Voruciclib,DrugComb,FD00021,Leukemia,Hematologic Malignancy,Phase 1
368,TP00173,BCL2;CDK9,BCL2,CDK9,CIT+CIT,Tchem+Tclin,0.335,0.707,0.479,0,1,1,3,2,DC01140,Fadraciclib;Venetoclax,DrugComb,FD00021,Leukemia,Hematologic Malignancy,Phase 1
369,TP00173,BCL2;CDK9,BCL2,CDK9,CIT+CIT,Tchem+Tclin,0.335,0.707,0.479,0,1,1,3,2,DC01140,Fadraciclib;Venetoclax,DrugComb,FD00030,Myeloma,Hematologic Malignancy,Phase 1
372,TP00174,BCL2;EGFR,BCL2,EGFR,CIT+CIT,Tclin+Tclin,0.519,0.69,0.575,15,1,11,2,1,DC01516,Navitoclax;Osimertinib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
374,TP00175,BCL2;ESR1,BCL2,ESR1,CIT+CIT,Tclin+Tclin,0.427,0.804,0.561,4,1,3,1,1,DC01191,Fulvestrant;Venetoclax,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 2
375,TP00176,BCL2;ESR2,BCL2,ESR2,CIT+CIT,Tclin+Tclin,0.282,0.655,0.542,4,0,2,1,1,DC01191,Fulvestrant;Venetoclax,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 2
376,TP00177,BCL2;EZH2,BCL2,EZH2,CIT+CIT,Tclin+Tclin,0.426,0.659,0.496,1,0,1,1,1,DC01948,Tazemetostat;Venetoclax,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 1
377,TP00178,BCL2;FLT3,BCL2,FLT3,CIT+CIT,Tclin+Tclin,0.461,0.741,0.473,2,0,4,3,2,DC01478,Mivavotinib;Venetoclax,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 1
378,TP00178,BCL2;FLT3,BCL2,FLT3,CIT+CIT,Tclin+Tclin,0.461,0.741,0.473,2,0,4,3,2,DC01837,Quizartinib;Venetoclax,DrugComb,FD00021,Leukemia,Hematologic Malignancy,Phase 1|Phase 2
380,TP00179,BCL2;HDAC1,BCL2,HDAC1,CIT+CIT,Tclin+Tclin,0.423,0.72,0.59,3,2,2,1,1,DC01692,Pelcitoclax;Tucidinostat,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 1|Phase 2
381,TP00180,BCL2;HDAC10,BCL2,HDAC10,CIT+CIT,Tclin+Tclin,0.194,0.699,0.491,0,0,0,1,1,DC01692,Pelcitoclax;Tucidinostat,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 1|Phase 2
382,TP00181,BCL2;HDAC2,BCL2,HDAC2,CIT+CIT,Tclin+Tclin,0.44,0.72,0.597,3,0,1,1,1,DC01692,Pelcitoclax;Tucidinostat,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 1|Phase 2
383,TP00182,BCL2;HDAC3,BCL2,HDAC3,CIT+CIT,Tclin+Tclin,0.34,0.754,0.587,0,0,1,1,1,DC01692,Pelcitoclax;Tucidinostat,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 1|Phase 2
384,TP00183,BCL2;IDH2,BCL2,IDH2,CIT+CIT,Tclin+Tclin,0.131,0.646,0.191,0,0,1,1,1,DC00982,Enasidenib;Venetoclax,DrugComb,FD00021,Leukemia,Hematologic Malignancy,Phase 1|Phase 2
385,TP00184,BCL2;IRAK4,BCL2,IRAK4,CET+CIT,Tchem+Tclin,0.279,0.68,0.474,12,0,2,1,2,DC00978,Emavusertib;Venetoclax,DrugComb,FD00021,Leukemia,Hematologic Malignancy,Phase 1|Phase 2
386,TP00184,BCL2;IRAK4,BCL2,IRAK4,CET+CIT,Tchem+Tclin,0.279,0.68,0.474,12,0,2,1,2,DC00978,Emavusertib;Venetoclax,DrugComb,FD00030,Myeloma,Hematologic Malignancy,Phase 1|Phase 2
387,TP00185,BCL2;JAK1,BCL2,JAK1,CIT+CIT,Tclin+Tclin,0.376,0.708,0.549,12,1,12,2,3,DC01518,Navitoclax;Ruxolitinib,DrugComb,FD00030,Myeloma,Hematologic Malignancy,Phase 2
388,TP00185,BCL2;JAK1,BCL2,JAK1,CIT+CIT,Tclin+Tclin,0.376,0.708,0.549,12,1,12,2,3,DC01518,Navitoclax;Ruxolitinib,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
389,TP00185,BCL2;JAK1,BCL2,JAK1,CIT+CIT,Tclin+Tclin,0.376,0.708,0.549,12,1,12,2,3,DC01887,Ruxolitinib;Venetoclax,DrugComb,FD00021,Leukemia,Hematologic Malignancy,Phase 1
390,TP00186,BCL2;JAK2,BCL2,JAK2,CIT+CIT,Tclin+Tclin,0.525,0.654,0.546,13,1,9,2,3,DC01518,Navitoclax;Ruxolitinib,DrugComb,FD00030,Myeloma,Hematologic Malignancy,Phase 2
391,TP00186,BCL2;JAK2,BCL2,JAK2,CIT+CIT,Tclin+Tclin,0.525,0.654,0.546,13,1,9,2,3,DC01518,Navitoclax;Ruxolitinib,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
392,TP00186,BCL2;JAK2,BCL2,JAK2,CIT+CIT,Tclin+Tclin,0.525,0.654,0.546,13,1,9,2,3,DC01887,Ruxolitinib;Venetoclax,DrugComb,FD00021,Leukemia,Hematologic Malignancy,Phase 1
393,TP00187,BCL2;KDM1A,BCL2,KDM1A,CET+CIT,Tchem+Tclin,0.391,0.655,0.54,0,1,1,1,1,DC00570,Bomedemstat;Venetoclax,DrugComb,FD00021,Leukemia,Hematologic Malignancy,Phase 1
394,TP00188,BCL2;MAP2K1,BCL2,MAP2K1,CIT+CIT,Tclin+Tclin,0.434,0.715,0.435,22,0,15,1,1,DC00790,Cobimetinib;Venetoclax,DrugComb,FD00021,Leukemia,Hematologic Malignancy,Phase 1
395,TP00189,BCL2;MCL1,BCL2,MCL1,CIT+CIT,Tchem+Tclin,0.406,0.879,0.718,4,1,10,2,3,DC01473,MIK665;VOB560,DrugComb,FD00021,Leukemia,Hematologic Malignancy,Phase 1
396,TP00189,BCL2;MCL1,BCL2,MCL1,CIT+CIT,Tchem+Tclin,0.406,0.879,0.718,4,1,10,2,3,DC01473,MIK665;VOB560,DrugComb,FD00030,Myeloma,Hematologic Malignancy,Phase 1
398,TP00189,BCL2;MCL1,BCL2,MCL1,CIT+CIT,Tchem+Tclin,0.406,0.879,0.718,4,1,10,2,3,DC01946,Tapotoclax;Venetoclax,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 1
399,TP00190,BCL2;MDM2,BCL2,MDM2,CIT+CIT,Tchem+Tclin,0.449,0.77,0.59,9,0,11,3,4,DC00161,Alrizomadlin;Lisaftoclax,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 2
400,TP00190,BCL2;MDM2,BCL2,MDM2,CIT+CIT,Tchem+Tclin,0.449,0.77,0.59,9,0,11,3,4,DC00161,Alrizomadlin;Lisaftoclax,DrugComb,FD00031,Neuroblastoma,Other Cancer,Phase 1
401,TP00190,BCL2;MDM2,BCL2,MDM2,CIT+CIT,Tchem+Tclin,0.449,0.77,0.59,9,0,11,3,4,DC01295,Idasanutlin;Venetoclax,DrugComb,FD00021,Leukemia,Hematologic Malignancy,Phase 1|Phase 2
404,TP00190,BCL2;MDM2,BCL2,MDM2,CIT+CIT,Tchem+Tclin,0.449,0.77,0.59,9,0,11,3,4,DC01907,Siremadlin;Venetoclax,DrugComb,FD00030,Myeloma,Hematologic Malignancy,Phase 1
405,TP00191,BCL2;MEN1,BCL2,MEN1,CIT+CIT,Tchem+Tclin,0.424,0.746,0.613,0,0,1,1,1,DC01988,Venetoclax;Ziftomenib,DrugComb,FD00021,Leukemia,Hematologic Malignancy,Phase 1
406,TP00192,BCL2;MS4A1,BCL2,MS4A1,CIT+CIT,Tclin+Tclin,0.327,0.536,0.603,0,0,0,4,3,DC01873,Rituximab;Venetoclax,DrugComb,FD00021,Leukemia,Hematologic Malignancy,Phase 1
407,TP00192,BCL2;MS4A1,BCL2,MS4A1,CIT+CIT,Tclin+Tclin,0.327,0.536,0.603,0,0,0,4,3,DC01873,Rituximab;Venetoclax,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 2
408,TP00192,BCL2;MS4A1,BCL2,MS4A1,CIT+CIT,Tclin+Tclin,0.327,0.536,0.603,0,0,0,4,3,DC01517,Navitoclax;Rituximab,DrugComb,FD00019,Hematologic Malignancies,Hematologic Malignancy,Phase 1
413,TP00193,BCL2;NOTCH1,BCL2,NOTCH1,CIT+CIT,Tchem+Tclin,0.496,0.739,0.619,3,1,3,1,1,DC00682,CB103;Venetoclax,DrugComb,FD00021,Leukemia,Hematologic Malignancy,Phase 2
414,TP00194,BCL2;NOTCH2,BCL2,NOTCH2,CIT+CIT,Tchem+Tclin,0.441,0.714,0.589,4,0,1,1,1,DC00682,CB103;Venetoclax,DrugComb,FD00021,Leukemia,Hematologic Malignancy,Phase 2
415,TP00195,BCL2;PDCD1,BCL2,PDCD1,CET+CIT,Tclin+Tclin,0.359,0.378,1.0,0,0,0,2,2,DC00610,Budigalimab;Venetoclax,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
416,TP00195,BCL2;PDCD1,BCL2,PDCD1,CET+CIT,Tclin+Tclin,0.359,0.378,1.0,0,0,0,2,2,DC01761,Pembrolizumab;Venetoclax,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
417,TP00196,BCL2;PIK3CA,BCL2,PIK3CA,CIT+CIT,Tclin+Tclin,0.47,0.604,0.379,30,0,13,1,1,DC00808,Copanlisib;Venetoclax,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 1|Phase 2
418,TP00197,BCL2;PIK3CD,BCL2,PIK3CD,CIT+CIT,Tclin+Tclin,0.407,0.631,0.406,30,0,11,3,2,DC00959,Duvelisib;Venetoclax,DrugComb,FD00021,Leukemia,Hematologic Malignancy,Phase 1|Phase 2
419,TP00197,BCL2;PIK3CD,BCL2,PIK3CD,CIT+CIT,Tclin+Tclin,0.407,0.631,0.406,30,0,11,3,2,DC00959,Duvelisib;Venetoclax,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 1|Phase 2
422,TP00198,BCL2;PIK3CG,BCL2,PIK3CG,CIT+CIT,Tclin+Tclin,0.404,0.621,0.407,5,0,4,1,2,DC00959,Duvelisib;Venetoclax,DrugComb,FD00021,Leukemia,Hematologic Malignancy,Phase 1|Phase 2
423,TP00198,BCL2;PIK3CG,BCL2,PIK3CG,CIT+CIT,Tclin+Tclin,0.404,0.621,0.407,5,0,4,1,2,DC00959,Duvelisib;Venetoclax,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 1|Phase 2
424,TP00199,BCL2;ROR1,BCL2,ROR1,CIT+CIT,Tbio+Tclin,0.298,0.565,0.519,0,0,1,1,1,DC00776,Cirmtuzumab;Venetoclax,DrugComb,FD00021,Leukemia,Hematologic Malignancy,Phase 2
425,TP00200,BCL2;SLAMF7,BCL2,SLAMF7,CIT+CIT,Tclin+Tclin,0.21,0.378,1.0,0,0,0,1,1,DC00380,Azintuxizumab Vedotin;Venetoclax,DrugComb,FD00030,Myeloma,Hematologic Malignancy,Phase 1
426,TP00201,BCL2;SYK,BCL2,SYK,CIT+CIT,Tclin+Tclin,0.448,0.703,0.518,5,0,2,1,1,DC01478,Mivavotinib;Venetoclax,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 1
427,TP00202,BCL2;TNFRSF10A,BCL2,TNFRSF10A,CIT+CIT,Tchem+Tclin,0.295,0.674,0.633,5,0,1,1,2,DC00967,Eftozanermin Alfa;Venetoclax,DrugComb,FD00019,Hematologic Malignancies,Hematologic Malignancy,Phase 1
428,TP00202,BCL2;TNFRSF10A,BCL2,TNFRSF10A,CIT+CIT,Tchem+Tclin,0.295,0.674,0.633,5,0,1,1,2,DC00967,Eftozanermin Alfa;Venetoclax,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
429,TP00203,BCL2;TNFRSF10B,BCL2,TNFRSF10B,CIT+CIT,Tbio+Tclin,0.314,0.429,0.543,5,0,3,1,2,DC00967,Eftozanermin Alfa;Venetoclax,DrugComb,FD00019,Hematologic Malignancies,Hematologic Malignancy,Phase 1
430,TP00203,BCL2;TNFRSF10B,BCL2,TNFRSF10B,CIT+CIT,Tbio+Tclin,0.314,0.429,0.543,5,0,3,1,2,DC00967,Eftozanermin Alfa;Venetoclax,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
431,TP00204,BIRC2;CD274,BIRC2,CD274,CET+CET,Tchem+Tclin,0.363,0.51,1.0,0,0,0,1,1,DC00354,Avelumab;Xevinapant,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
432,TP00205,BIRC2;PDCD1,BIRC2,PDCD1,CET+CET,Tchem+Tclin,0.359,0.445,1.0,0,0,0,6,6,DC01774,Pembrolizumab;Xevinapant,DrugComb,FD00011,Colorectal Cancer,Colorectal Cancer,Phase 1
433,TP00205,BIRC2;PDCD1,BIRC2,PDCD1,CET+CET,Tchem+Tclin,0.359,0.445,1.0,0,0,0,6,6,DC01774,Pembrolizumab;Xevinapant,DrugComb,FD00035,Pancreatic Cancer,Pancreatic Cancer,Phase 1
434,TP00205,BIRC2;PDCD1,BIRC2,PDCD1,CET+CET,Tchem+Tclin,0.359,0.445,1.0,0,0,0,6,6,DC00549,Birinapant;Pembrolizumab,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1|Phase 2
435,TP00205,BIRC2;PDCD1,BIRC2,PDCD1,CET+CET,Tchem+Tclin,0.359,0.445,1.0,0,0,0,6,6,DC01738,Pembrolizumab;Tolinapant,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 1
436,TP00205,BIRC2;PDCD1,BIRC2,PDCD1,CET+CET,Tchem+Tclin,0.359,0.445,1.0,0,0,0,6,6,DC01738,Pembrolizumab;Tolinapant,DrugComb,FD00034,Ovarian Cancer,Ovarian Cancer,Phase 1
437,TP00205,BIRC2;PDCD1,BIRC2,PDCD1,CET+CET,Tchem+Tclin,0.359,0.445,1.0,0,0,0,6,6,DC00516,BI891065;Ezabenlimab,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
441,TP00206,BIRC2;TNFRSF10B,BIRC2,TNFRSF10B,CET+CIT,Tbio+Tchem,0.512,0.469,0.5,3,1,2,1,1,DC00548,Birinapant;Conatumumab,DrugComb,FD00034,Ovarian Cancer,Ovarian Cancer,Phase 1
442,TP00207,BIRC3;CD274,BIRC3,CD274,CET+CIT,Tchem+Tclin,0.363,0.482,1.0,0,0,0,1,1,DC00354,Avelumab;Xevinapant,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
443,TP00208,BIRC3;PDCD1,BIRC3,PDCD1,CET+CIT,Tchem+Tclin,0.414,0.319,1.0,0,0,0,5,4,DC01774,Pembrolizumab;Xevinapant,DrugComb,FD00011,Colorectal Cancer,Colorectal Cancer,Phase 1
444,TP00208,BIRC3;PDCD1,BIRC3,PDCD1,CET+CIT,Tchem+Tclin,0.414,0.319,1.0,0,0,0,5,4,DC01774,Pembrolizumab;Xevinapant,DrugComb,FD00035,Pancreatic Cancer,Pancreatic Cancer,Phase 1
445,TP00208,BIRC3;PDCD1,BIRC3,PDCD1,CET+CIT,Tchem+Tclin,0.414,0.319,1.0,0,0,0,5,4,DC00516,BI891065;Ezabenlimab,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
446,TP00208,BIRC3;PDCD1,BIRC3,PDCD1,CET+CIT,Tchem+Tclin,0.414,0.319,1.0,0,0,0,5,4,DC00516,BI891065;Ezabenlimab,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
450,TP00209,BIRC3;TNFRSF10B,BIRC3,TNFRSF10B,CIT+CIT,Tbio+Tchem,0.599,0.389,0.419,3,1,2,1,1,DC00548,Birinapant;Conatumumab,DrugComb,FD00034,Ovarian Cancer,Ovarian Cancer,Phase 1
451,TP00210,BIRC5;CD3D,BIRC5,CD3D,CET+CIT,Tchem+Tclin,0.203,0.436,0.669,0,0,0,1,2,DC01995,ABBV184,BsAb,FD00021,Leukemia,Hematologic Malignancy,Phase 1
452,TP00210,BIRC5;CD3D,BIRC5,CD3D,CET+CIT,Tchem+Tclin,0.203,0.436,0.669,0,0,0,1,2,DC01995,ABBV184,BsAb,FD00023,Lung Cancer,Lung Cancer,Phase 1
453,TP00211,BIRC5;CD3E,BIRC5,CD3E,CET+CIT,Tchem+Tclin,0.322,0.403,0.629,0,0,1,1,2,DC01995,ABBV184,BsAb,FD00021,Leukemia,Hematologic Malignancy,Phase 1
454,TP00211,BIRC5;CD3E,BIRC5,CD3E,CET+CIT,Tchem+Tclin,0.322,0.403,0.629,0,0,1,1,2,DC01995,ABBV184,BsAb,FD00023,Lung Cancer,Lung Cancer,Phase 1
455,TP00212,BIRC5;CD3G,BIRC5,CD3G,CET+CIT,Tchem+Tclin,0.308,0.415,0.623,0,0,1,1,2,DC01995,ABBV184,BsAb,FD00021,Leukemia,Hematologic Malignancy,Phase 1
456,TP00212,BIRC5;CD3G,BIRC5,CD3G,CET+CIT,Tchem+Tclin,0.308,0.415,0.623,0,0,1,1,2,DC01995,ABBV184,BsAb,FD00023,Lung Cancer,Lung Cancer,Phase 1
457,TP00213,BRAF;CDK4,BRAF,CDK4,CIT+CIT,Tclin+Tclin,0.408,0.533,0.822,12,0,9,2,2,DC01511,Naporafenib;Ribociclib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
458,TP00213,BRAF;CDK4,BRAF,CDK4,CIT+CIT,Tclin+Tclin,0.408,0.533,0.822,12,0,9,2,2,DC01511,Naporafenib;Ribociclib,DrugComb,FD00026,Melanoma,Melanoma,Phase 1
460,TP00214,BRAF;CDK6,BRAF,CDK6,CIT+CIT,Tclin+Tclin,0.408,0.643,0.858,10,0,6,2,2,DC01511,Naporafenib;Ribociclib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
461,TP00214,BRAF;CDK6,BRAF,CDK6,CIT+CIT,Tclin+Tclin,0.408,0.643,0.858,10,0,6,2,2,DC01511,Naporafenib;Ribociclib,DrugComb,FD00026,Melanoma,Melanoma,Phase 1
463,TP00215,BRAF;CSF1R,BRAF,CSF1R,CET+CIT,Tclin+Tclin,0.486,0.673,0.787,4,0,2,1,1,DC01803,Pexidartinib;Vemurafenib,DrugComb,FD00026,Melanoma,Melanoma,Phase 1
464,TP00216,BRAF;CTLA4,BRAF,CTLA4,CET+CIT,Tclin+Tclin,0.269,0.678,1.0,0,0,0,1,1,DC01353,Ipilimumab;Vemurafenib,DrugComb,FD00026,Melanoma,Melanoma,Phase 1
465,TP00217,BRAF;EGFR,BRAF,EGFR,CIT+CIT,Tclin+Tclin,0.535,0.581,0.718,25,0,15,6,4,DC00761,Cetuximab;Tovorafenib,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
466,TP00217,BRAF;EGFR,BRAF,EGFR,CIT+CIT,Tclin+Tclin,0.535,0.581,0.718,25,0,15,6,4,DC00559,BMS908662;Cetuximab,DrugComb,FD00011,Colorectal Cancer,Colorectal Cancer,Phase 1|Phase 2
467,TP00217,BRAF;EGFR,BRAF,EGFR,CIT+CIT,Tclin+Tclin,0.535,0.581,0.718,25,0,15,6,4,DC00752,Cetuximab;PF07799933,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
468,TP00217,BRAF;EGFR,BRAF,EGFR,CIT+CIT,Tclin+Tclin,0.535,0.581,0.718,25,0,15,6,4,DC00765,Cetuximab;Vemurafenib,DrugComb,FD00030,Myeloma,Hematologic Malignancy,Phase 2
471,TP00218,BRAF;ERBB3,BRAF,ERBB3,CIT+CIT,Tclin+Tclin,0.557,0.579,0.711,4,0,3,1,1,DC01375,KTN3379;Vemurafenib,DrugComb,FD00018,Head and Neck Cancer,Head and Neck Cancer,Phase 1
472,TP00219,BRAF;IL2RA,BRAF,IL2RA,CET+CIT,Tclin+Tclin,0.307,0.549,0.408,1,0,1,1,1,DC00118,Aldesleukin;Vemurafenib,DrugComb,FD00026,Melanoma,Melanoma,Phase 2
473,TP00220,BRAF;IL2RB,BRAF,IL2RB,CET+CIT,Tclin+Tclin,0.428,0.678,0.37,1,0,1,1,1,DC00118,Aldesleukin;Vemurafenib,DrugComb,FD00026,Melanoma,Melanoma,Phase 2
474,TP00221,BRAF;IL2RG,BRAF,IL2RG,CIT+CIT,Tclin+Tclin,0.385,0.655,0.365,1,0,1,1,1,DC00118,Aldesleukin;Vemurafenib,DrugComb,FD00026,Melanoma,Melanoma,Phase 2
475,TP00222,BRAF;KRAS,BRAF,KRAS,CIT+CIT,Tclin+Tclin,0.485,0.685,0.43,39,3,28,2,1,DC00072,Adagrasib;Avutometinib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
477,TP00223,BRAF;MAP2K1,BRAF,MAP2K1,CIT+CIT,Tclin+Tclin,0.561,0.771,0.82,44,10,33,15,8,DC00767,CFT1946;Trametinib,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1|Phase 2
479,TP00223,BRAF;MAP2K1,BRAF,MAP2K1,CIT+CIT,Tclin+Tclin,0.561,0.771,0.82,44,10,33,15,8,DC00526,Binimetinib;Encorafenib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Approval
480,TP00223,BRAF;MAP2K1,BRAF,MAP2K1,CIT+CIT,Tclin+Tclin,0.561,0.771,0.82,44,10,33,15,8,DC00526,Binimetinib;Encorafenib,DrugComb,FD00026,Melanoma,Melanoma,Approval
481,TP00223,BRAF;MAP2K1,BRAF,MAP2K1,CIT+CIT,Tclin+Tclin,0.561,0.771,0.82,44,10,33,15,8,DC00526,Binimetinib;Encorafenib,DrugComb,FD00030,Myeloma,Hematologic Malignancy,Phase 2
482,TP00223,BRAF;MAP2K1,BRAF,MAP2K1,CIT+CIT,Tclin+Tclin,0.561,0.771,0.82,44,10,33,15,8,DC00526,Binimetinib;Encorafenib,DrugComb,FD00035,Pancreatic Cancer,Pancreatic Cancer,Phase 2
483,TP00223,BRAF;MAP2K1,BRAF,MAP2K1,CIT+CIT,Tclin+Tclin,0.561,0.771,0.82,44,10,33,15,8,DC01983,Tunlametinib;Vemurafenib,DrugComb,FD00011,Colorectal Cancer,Colorectal Cancer,Phase 2
488,TP00223,BRAF;MAP2K1,BRAF,MAP2K1,CIT+CIT,Tclin+Tclin,0.561,0.771,0.82,44,10,33,15,8,DC00832,Dabrafenib;Trametinib,DrugComb,FD00017,Glioma,Glioma,Approval
489,TP00223,BRAF;MAP2K1,BRAF,MAP2K1,CIT+CIT,Tclin+Tclin,0.561,0.771,0.82,44,10,33,15,8,DC00832,Dabrafenib;Trametinib,DrugComb,FD00018,Head and Neck Cancer,Head and Neck Cancer,Approval
506,TP00224,BRAF;MAP2K2,BRAF,MAP2K2,CIT+CIT,Tclin+Tclin,0.529,0.671,0.859,37,10,27,13,8,DC00767,CFT1946;Trametinib,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1|Phase 2
508,TP00224,BRAF;MAP2K2,BRAF,MAP2K2,CIT+CIT,Tclin+Tclin,0.529,0.671,0.859,37,10,27,13,8,DC00526,Binimetinib;Encorafenib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Approval
509,TP00224,BRAF;MAP2K2,BRAF,MAP2K2,CIT+CIT,Tclin+Tclin,0.529,0.671,0.859,37,10,27,13,8,DC00526,Binimetinib;Encorafenib,DrugComb,FD00026,Melanoma,Melanoma,Approval
510,TP00224,BRAF;MAP2K2,BRAF,MAP2K2,CIT+CIT,Tclin+Tclin,0.529,0.671,0.859,37,10,27,13,8,DC00526,Binimetinib;Encorafenib,DrugComb,FD00030,Myeloma,Hematologic Malignancy,Phase 2
511,TP00224,BRAF;MAP2K2,BRAF,MAP2K2,CIT+CIT,Tclin+Tclin,0.529,0.671,0.859,37,10,27,13,8,DC00526,Binimetinib;Encorafenib,DrugComb,FD00035,Pancreatic Cancer,Pancreatic Cancer,Phase 2
512,TP00224,BRAF;MAP2K2,BRAF,MAP2K2,CIT+CIT,Tclin+Tclin,0.529,0.671,0.859,37,10,27,13,8,DC01969,Trametinib;XP102,DrugComb,FD00011,Colorectal Cancer,Colorectal Cancer,Phase 1|Phase 2
513,TP00224,BRAF;MAP2K2,BRAF,MAP2K2,CIT+CIT,Tclin+Tclin,0.529,0.671,0.859,37,10,27,13,8,DC01969,Trametinib;XP102,DrugComb,FD00018,Head and Neck Cancer,Head and Neck Cancer,Phase 1|Phase 2
516,TP00224,BRAF;MAP2K2,BRAF,MAP2K2,CIT+CIT,Tclin+Tclin,0.529,0.671,0.859,37,10,27,13,8,DC00832,Dabrafenib;Trametinib,DrugComb,FD00017,Glioma,Glioma,Approval
532,TP00225,BRAF;MAPK1,BRAF,MAPK1,CIT+CIT,Tchem+Tclin,0.476,0.646,0.866,44,11,36,1,2,DC01512,Naporafenib;Rineterkib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
533,TP00225,BRAF;MAPK1,BRAF,MAPK1,CIT+CIT,Tchem+Tclin,0.476,0.646,0.866,44,11,36,1,2,DC01512,Naporafenib;Rineterkib,DrugComb,FD00026,Melanoma,Melanoma,Phase 2
534,TP00226,BRAF;MAPK3,BRAF,MAPK3,CIT+CIT,Tchem+Tclin,0.491,0.728,0.894,44,11,29,1,2,DC01512,Naporafenib;Rineterkib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
535,TP00226,BRAF;MAPK3,BRAF,MAPK3,CIT+CIT,Tchem+Tclin,0.491,0.728,0.894,44,11,29,1,2,DC01512,Naporafenib;Rineterkib,DrugComb,FD00026,Melanoma,Melanoma,Phase 2
536,TP00227,BRAF;MTOR,BRAF,MTOR,CIT+CIT,Tclin+Tclin,0.377,0.632,0.777,17,0,15,3,3,DC00356,Avutometinib;Everolimus,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
537,TP00227,BRAF;MTOR,BRAF,MTOR,CIT+CIT,Tclin+Tclin,0.377,0.632,0.777,17,0,15,3,3,DC00356,Avutometinib;Everolimus,DrugComb,FD00030,Myeloma,Hematologic Malignancy,Phase 1
538,TP00227,BRAF;MTOR,BRAF,MTOR,CIT+CIT,Tclin+Tclin,0.377,0.632,0.777,17,0,15,3,3,DC01125,Everolimus;Vemurafenib,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
540,TP00228,BRAF;PDCD1,BRAF,PDCD1,CET+CIT,Tclin+Tclin,0.321,0.552,1.0,0,0,0,3,3,DC01263,HLX208;Serplulimab,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
541,TP00228,BRAF;PDCD1,BRAF,PDCD1,CET+CIT,Tclin+Tclin,0.321,0.552,1.0,0,0,0,3,3,DC00831,Dabrafenib;Spartalizumab,DrugComb,FD00018,Head and Neck Cancer,Head and Neck Cancer,Phase 2
542,TP00228,BRAF;PDCD1,BRAF,PDCD1,CET+CIT,Tclin+Tclin,0.321,0.552,1.0,0,0,0,3,3,DC01588,Nivolumab;Tovorafenib,DrugComb,FD00026,Melanoma,Melanoma,Phase 1
543,TP00229,BRAF;PIK3CA,BRAF,PIK3CA,CIT+CIT,Tclin+Tclin,0.432,0.604,0.769,33,0,22,1,1,DC01914,Sonolisib;Vemurafenib,DrugComb,FD00026,Melanoma,Melanoma,Phase 1|Phase 2
544,TP00230,BRAF;PIK3CB,BRAF,PIK3CB,CIT+CIT,Tchem+Tclin,0.412,0.791,0.693,33,0,18,1,1,DC01891,SAR260301;Vemurafenib,DrugComb,FD00026,Melanoma,Melanoma,Phase 1
545,TP00231,BRAF;PIK3CD,BRAF,PIK3CD,CIT+CIT,Tclin+Tclin,0.394,0.696,0.688,33,0,19,1,1,DC01914,Sonolisib;Vemurafenib,DrugComb,FD00026,Melanoma,Melanoma,Phase 1|Phase 2
546,TP00232,BRAF;PIK3CG,BRAF,PIK3CG,CIT+CIT,Tclin+Tclin,0.389,0.658,0.822,1,0,6,1,1,DC01914,Sonolisib;Vemurafenib,DrugComb,FD00026,Melanoma,Melanoma,Phase 1|Phase 2
547,TP00233,BRAF;PTK2,BRAF,PTK2,CET+CIT,Tclin+Tclin,0.473,0.734,0.757,8,0,9,1,3,DC00355,Avutometinib;Defactinib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 2
548,TP00233,BRAF;PTK2,BRAF,PTK2,CET+CIT,Tclin+Tclin,0.473,0.734,0.757,8,0,9,1,3,DC00355,Avutometinib;Defactinib,DrugComb,FD00034,Ovarian Cancer,Ovarian Cancer,Phase 1
549,TP00233,BRAF;PTK2,BRAF,PTK2,CET+CIT,Tclin+Tclin,0.473,0.734,0.757,8,0,9,1,3,DC00355,Avutometinib;Defactinib,DrugComb,FD00035,Pancreatic Cancer,Pancreatic Cancer,Phase 1
550,TP00234,BRAF;RXRA,BRAF,RXRA,CIT+CIT,Tclin+Tclin,0.361,0.685,0.409,6,0,2,1,1,DC00069,Acitretin;Vemurafenib,DrugComb,FD00026,Melanoma,Melanoma,Phase 2
551,TP00235,BRAF;RXRB,BRAF,RXRB,CIT+CIT,Tclin+Tclin,0.333,0.751,0.343,5,0,2,1,1,DC00069,Acitretin;Vemurafenib,DrugComb,FD00026,Melanoma,Melanoma,Phase 2
552,TP00236,BRAF;RXRG,BRAF,RXRG,CIT+CIT,Tclin+Tclin,0.364,0.655,0.362,5,0,2,1,1,DC00069,Acitretin;Vemurafenib,DrugComb,FD00026,Melanoma,Melanoma,Phase 2
553,TP00237,BRAF;TP53,BRAF,TP53,CIT+CIT,Tchem+Tclin,0.382,0.635,0.487,20,0,12,1,1,DC00828,Dabrafenib;Eprenetapopt,DrugComb,FD00026,Melanoma,Melanoma,Phase 1|Phase 2
554,TP00238,BRAF;VEGFA,BRAF,VEGFA,CET+CIT,Tclin+Tclin,0.416,0.507,0.507,10,0,5,1,1,DC00486,Bevacizumab;Vemurafenib,DrugComb,FD00026,Melanoma,Melanoma,Phase 2
555,TP00239,BRD2;CD274,BRD2,CD274,CET+CIT,Tchem+Tclin,0.117,0.553,1.0,0,0,0,1,2,DC00298,Atezolizumab;RO6870810,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 1
556,TP00239,BRD2;CD274,BRD2,CD274,CET+CIT,Tchem+Tclin,0.117,0.553,1.0,0,0,0,1,2,DC00298,Atezolizumab;RO6870810,DrugComb,FD00034,Ovarian Cancer,Ovarian Cancer,Phase 1
557,TP00240,BRD2;CYP19A1,BRD2,CYP19A1,CIT+CIT,Tchem+Tclin,0.216,0.498,0.269,0,0,0,1,1,DC00141,Alobresib;Exemestane,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 1|Phase 2
558,TP00241,BRD2;ESR1,BRD2,ESR1,CIT+CIT,Tchem+Tclin,0.378,0.72,0.489,0,0,0,1,1,DC00142,Alobresib;Fulvestrant,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 1|Phase 2
559,TP00242,BRD2;ESR2,BRD2,ESR2,CIT+CIT,Tchem+Tclin,0.43,0.907,0.405,0,0,0,1,1,DC00142,Alobresib;Fulvestrant,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 1|Phase 2
560,TP00243,BRD2;PARP1,BRD2,PARP1,CIT+CIT,Tchem+Tclin,0.308,0.705,0.534,0,0,0,1,2,DC01942,Talazoparib;ZEN003694,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 2
561,TP00243,BRD2;PARP1,BRD2,PARP1,CIT+CIT,Tchem+Tclin,0.308,0.705,0.534,0,0,0,1,2,DC01942,Talazoparib;ZEN003694,DrugComb,FD00034,Ovarian Cancer,Ovarian Cancer,Phase 2
562,TP00244,BRD2;PARP2,BRD2,PARP2,CIT+CIT,Tchem+Tclin,0.354,0.848,0.612,0,0,0,1,2,DC01942,Talazoparib;ZEN003694,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 2
563,TP00244,BRD2;PARP2,BRD2,PARP2,CIT+CIT,Tchem+Tclin,0.354,0.848,0.612,0,0,0,1,2,DC01942,Talazoparib;ZEN003694,DrugComb,FD00034,Ovarian Cancer,Ovarian Cancer,Phase 2
564,TP00245,BRD2;PDCD1,BRD2,PDCD1,CET+CIT,Tchem+Tclin,0.139,0.268,1.0,0,0,0,1,1,DC00562,BMS986158;Nivolumab,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1|Phase 2
565,TP00246,BRD3;CD274,BRD3,CD274,CET+CIT,Tchem+Tclin,0.119,0.414,1.0,0,0,0,1,2,DC00298,Atezolizumab;RO6870810,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 1
566,TP00246,BRD3;CD274,BRD3,CD274,CET+CIT,Tchem+Tclin,0.119,0.414,1.0,0,0,0,1,2,DC00298,Atezolizumab;RO6870810,DrugComb,FD00034,Ovarian Cancer,Ovarian Cancer,Phase 1
567,TP00247,BRD3;CYP19A1,BRD3,CYP19A1,CIT+CIT,Tchem+Tclin,0.131,0.459,0.268,0,0,0,1,1,DC00141,Alobresib;Exemestane,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 1|Phase 2
568,TP00248,BRD3;ESR1,BRD3,ESR1,CIT+CIT,Tchem+Tclin,0.32,0.56,0.503,0,0,0,1,1,DC00142,Alobresib;Fulvestrant,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 1|Phase 2
569,TP00249,BRD3;ESR2,BRD3,ESR2,CIT+CIT,Tchem+Tclin,0.515,0.898,0.424,0,0,0,1,1,DC00142,Alobresib;Fulvestrant,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 1|Phase 2
570,TP00250,BRD3;PARP1,BRD3,PARP1,CIT+CIT,Tchem+Tclin,0.241,0.612,0.52,0,0,0,1,2,DC01942,Talazoparib;ZEN003694,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 2
571,TP00250,BRD3;PARP1,BRD3,PARP1,CIT+CIT,Tchem+Tclin,0.241,0.612,0.52,0,0,0,1,2,DC01942,Talazoparib;ZEN003694,DrugComb,FD00034,Ovarian Cancer,Ovarian Cancer,Phase 2
572,TP00251,BRD3;PARP2,BRD3,PARP2,CIT+CIT,Tchem+Tclin,0.231,0.814,0.593,0,0,0,1,2,DC01942,Talazoparib;ZEN003694,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 2
573,TP00251,BRD3;PARP2,BRD3,PARP2,CIT+CIT,Tchem+Tclin,0.231,0.814,0.593,0,0,0,1,2,DC01942,Talazoparib;ZEN003694,DrugComb,FD00034,Ovarian Cancer,Ovarian Cancer,Phase 2
574,TP00252,BRD3;PDCD1,BRD3,PDCD1,CET+CIT,Tchem+Tclin,0.09,0.236,1.0,0,0,0,1,1,DC00562,BMS986158;Nivolumab,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1|Phase 2
575,TP00253,BRD4;CD274,BRD4,CD274,CET+CIT,Tchem+Tclin,0.205,0.508,1.0,0,0,0,1,2,DC00298,Atezolizumab;RO6870810,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 1
576,TP00253,BRD4;CD274,BRD4,CD274,CET+CIT,Tchem+Tclin,0.205,0.508,1.0,0,0,0,1,2,DC00298,Atezolizumab;RO6870810,DrugComb,FD00034,Ovarian Cancer,Ovarian Cancer,Phase 1
577,TP00254,BRD4;CYP19A1,BRD4,CYP19A1,CIT+CIT,Tchem+Tclin,0.212,0.455,0.254,0,0,0,1,1,DC00141,Alobresib;Exemestane,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 1|Phase 2
578,TP00255,BRD4;ESR1,BRD4,ESR1,CIT+CIT,Tchem+Tclin,0.451,0.609,0.55,0,0,0,1,1,DC00142,Alobresib;Fulvestrant,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 1|Phase 2
579,TP00256,BRD4;ESR2,BRD4,ESR2,CIT+CIT,Tchem+Tclin,0.565,0.918,0.473,0,0,0,1,1,DC00142,Alobresib;Fulvestrant,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 1|Phase 2
580,TP00257,BRD4;PARP1,BRD4,PARP1,CIT+CIT,Tchem+Tclin,0.439,0.682,0.543,0,0,0,1,2,DC01942,Talazoparib;ZEN003694,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 2
581,TP00257,BRD4;PARP1,BRD4,PARP1,CIT+CIT,Tchem+Tclin,0.439,0.682,0.543,0,0,0,1,2,DC01942,Talazoparib;ZEN003694,DrugComb,FD00034,Ovarian Cancer,Ovarian Cancer,Phase 2
582,TP00258,BRD4;PARP2,BRD4,PARP2,CIT+CIT,Tchem+Tclin,0.405,0.881,0.559,0,0,0,1,2,DC01942,Talazoparib;ZEN003694,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 2
583,TP00258,BRD4;PARP2,BRD4,PARP2,CIT+CIT,Tchem+Tclin,0.405,0.881,0.559,0,0,0,1,2,DC01942,Talazoparib;ZEN003694,DrugComb,FD00034,Ovarian Cancer,Ovarian Cancer,Phase 2
584,TP00259,BRD4;PDCD1,BRD4,PDCD1,CET+CIT,Tchem+Tclin,0.149,0.216,1.0,0,1,0,1,1,DC00562,BMS986158;Nivolumab,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1|Phase 2
585,TP00260,BRDT;CD274,BRDT,CD274,CET+CIT,Tchem+Tclin,0.153,0.414,0.788,0,0,0,1,2,DC00298,Atezolizumab;RO6870810,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 1
586,TP00260,BRDT;CD274,BRDT,CD274,CET+CIT,Tchem+Tclin,0.153,0.414,0.788,0,0,0,1,2,DC00298,Atezolizumab;RO6870810,DrugComb,FD00034,Ovarian Cancer,Ovarian Cancer,Phase 1
587,TP00261,BRDT;CYP19A1,BRDT,CYP19A1,CIT+CIT,Tchem+Tclin,0.236,0.459,0.187,0,0,0,1,1,DC00141,Alobresib;Exemestane,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 1|Phase 2
588,TP00262,BRDT;ESR1,BRDT,ESR1,CIT+CIT,Tchem+Tclin,0.421,0.56,0.387,0,0,1,1,1,DC00142,Alobresib;Fulvestrant,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 1|Phase 2
589,TP00263,BRDT;ESR2,BRDT,ESR2,CIT+CIT,Tchem+Tclin,0.441,0.898,0.344,0,0,1,1,1,DC00142,Alobresib;Fulvestrant,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 1|Phase 2
590,TP00264,BRDT;PARP1,BRDT,PARP1,CIT+CIT,Tchem+Tclin,0.321,0.612,0.387,0,0,1,1,2,DC01942,Talazoparib;ZEN003694,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 2
591,TP00264,BRDT;PARP1,BRDT,PARP1,CIT+CIT,Tchem+Tclin,0.321,0.612,0.387,0,0,1,1,2,DC01942,Talazoparib;ZEN003694,DrugComb,FD00034,Ovarian Cancer,Ovarian Cancer,Phase 2
592,TP00265,BRDT;PARP2,BRDT,PARP2,CIT+CIT,Tchem+Tclin,0.29,0.814,0.352,0,0,0,1,2,DC01942,Talazoparib;ZEN003694,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 2
593,TP00265,BRDT;PARP2,BRDT,PARP2,CIT+CIT,Tchem+Tclin,0.29,0.814,0.352,0,0,0,1,2,DC01942,Talazoparib;ZEN003694,DrugComb,FD00034,Ovarian Cancer,Ovarian Cancer,Phase 2
594,TP00266,BRDT;PDCD1,BRDT,PDCD1,CET+CIT,Tchem+Tclin,0.145,0.236,0.788,0,0,0,1,1,DC00562,BMS986158;Nivolumab,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1|Phase 2
595,TP00267,BTK;CD19,BTK,CD19,CIT+CIT,Tclin+Tclin,0.399,0.585,,3,1,1,2,2,DC00960,Duvortuxizumab;Ibrutinib,DrugComb,FD00021,Leukemia,Hematologic Malignancy,Phase 1
596,TP00267,BTK;CD19,BTK,CD19,CIT+CIT,Tclin+Tclin,0.399,0.585,,3,1,1,2,2,DC00960,Duvortuxizumab;Ibrutinib,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 1
598,TP00268,BTK;CD274,BTK,CD274,CET+CIT,Tclin+Tclin,0.504,0.578,1.0,0,0,0,2,3,DC00923,Durvalumab;Ibrutinib,DrugComb,FD00021,Leukemia,Hematologic Malignancy,Phase 1|Phase 2
599,TP00268,BTK;CD274,BTK,CD274,CET+CIT,Tclin+Tclin,0.504,0.578,1.0,0,0,0,2,3,DC00923,Durvalumab;Ibrutinib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
600,TP00268,BTK;CD274,BTK,CD274,CET+CIT,Tclin+Tclin,0.504,0.578,1.0,0,0,0,2,3,DC00923,Durvalumab;Ibrutinib,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 1|Phase 2
602,TP00269,BTK;CD37,BTK,CD37,CET+CIT,Tbio+Tclin,,0.553,1.0,0,0,0,1,1,DC00512,BI836826;Ibrutinib,DrugComb,FD00021,Leukemia,Hematologic Malignancy,Phase 1
603,TP00270,BTK;CD3D,BTK,CD3D,CET+CIT,Tclin+Tclin,0.321,0.709,0.468,2,0,0,1,2,DC00960,Duvortuxizumab;Ibrutinib,DrugComb,FD00021,Leukemia,Hematologic Malignancy,Phase 1
604,TP00270,BTK;CD3D,BTK,CD3D,CET+CIT,Tclin+Tclin,0.321,0.709,0.468,2,0,0,1,2,DC00960,Duvortuxizumab;Ibrutinib,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 1
605,TP00271,BTK;CD3E,BTK,CD3E,CET+CIT,Tclin+Tclin,0.468,0.593,0.474,2,0,0,1,2,DC00960,Duvortuxizumab;Ibrutinib,DrugComb,FD00021,Leukemia,Hematologic Malignancy,Phase 1
606,TP00271,BTK;CD3E,BTK,CD3E,CET+CIT,Tclin+Tclin,0.468,0.593,0.474,2,0,0,1,2,DC00960,Duvortuxizumab;Ibrutinib,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 1
607,TP00272,BTK;CD3G,BTK,CD3G,CET+CIT,Tclin+Tclin,0.374,0.711,0.455,1,2,0,1,2,DC00960,Duvortuxizumab;Ibrutinib,DrugComb,FD00021,Leukemia,Hematologic Malignancy,Phase 1
608,TP00272,BTK;CD3G,BTK,CD3G,CET+CIT,Tclin+Tclin,0.374,0.711,0.455,1,2,0,1,2,DC00960,Duvortuxizumab;Ibrutinib,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 1
609,TP00273,BTK;CDK4,BTK,CDK4,CIT+CIT,Tclin+Tclin,0.493,0.528,0.71,1,0,0,1,1,DC01282,Ibrutinib;Palbociclib,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 2
610,TP00274,BTK;CDK6,BTK,CDK6,CIT+CIT,Tclin+Tclin,0.43,0.653,0.733,1,0,0,1,1,DC01282,Ibrutinib;Palbociclib,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 2
611,TP00275,BTK;CDK9,BTK,CDK9,CIT+CIT,Tchem+Tclin,0.402,0.634,0.667,0,0,0,1,1,DC00370,AZD4573;Acalabrutinib,DrugComb,FD00019,Hematologic Malignancies,Hematologic Malignancy,Phase 1|Phase 2
612,TP00276,BTK;CRBN,BTK,CRBN,CIT+CIT,Tclin+Tclin,0.18,0.828,0.551,0,1,0,3,3,DC01405,Lenalidomide;Spebrutinib,DrugComb,FD00021,Leukemia,Hematologic Malignancy,Phase 1
613,TP00276,BTK;CRBN,BTK,CRBN,CIT+CIT,Tclin+Tclin,0.18,0.828,0.551,0,1,0,3,3,DC01405,Lenalidomide;Spebrutinib,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 1
615,TP00276,BTK;CRBN,BTK,CRBN,CIT+CIT,Tclin+Tclin,0.18,0.828,0.551,0,1,0,3,3,DC01276,Ibrutinib;Lenalidomide,DrugComb,FD00030,Myeloma,Hematologic Malignancy,Phase 1
616,TP00277,BTK;CSNK1E,BTK,CSNK1E,CIT+CIT,Tclin+Tclin,0.446,0.802,0.738,0,0,0,1,2,DC01290,Ibrutinib;Umbralisib,DrugComb,FD00021,Leukemia,Hematologic Malignancy,Phase 1
617,TP00277,BTK;CSNK1E,BTK,CSNK1E,CIT+CIT,Tclin+Tclin,0.446,0.802,0.738,0,0,0,1,2,DC01290,Ibrutinib;Umbralisib,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 1
618,TP00278,BTK;EGFR,BTK,EGFR,CIT+CIT,Tclin+Tclin,0.471,0.701,0.701,0,0,0,1,1,DC00735,Cetuximab;Ibrutinib,DrugComb,FD00018,Head and Neck Cancer,Head and Neck Cancer,Phase 2
619,TP00279,BTK;JAK1,BTK,JAK1,CIT+CIT,Tclin+Tclin,0.492,0.804,0.792,2,1,2,2,2,DC01883,Ruxolitinib;TL895,DrugComb,FD00030,Myeloma,Hematologic Malignancy,Phase 1|Phase 2
620,TP00279,BTK;JAK1,BTK,JAK1,CIT+CIT,Tclin+Tclin,0.492,0.804,0.792,2,1,2,2,2,DC01275,Ibrutinib;Itacitinib,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 1|Phase 2
621,TP00280,BTK;JAK2,BTK,JAK2,CIT+CIT,Tclin+Tclin,0.522,0.742,0.776,0,1,3,2,3,DC01281,Ibrutinib;Pacritinib,DrugComb,FD00021,Leukemia,Hematologic Malignancy,Phase 1|Phase 2
622,TP00280,BTK;JAK2,BTK,JAK2,CIT+CIT,Tclin+Tclin,0.522,0.742,0.776,0,1,3,2,3,DC01281,Ibrutinib;Pacritinib,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 1|Phase 2
623,TP00280,BTK;JAK2,BTK,JAK2,CIT+CIT,Tclin+Tclin,0.522,0.742,0.776,0,1,3,2,3,DC01883,Ruxolitinib;TL895,DrugComb,FD00030,Myeloma,Hematologic Malignancy,Phase 1|Phase 2
624,TP00281,BTK;MALT1,BTK,MALT1,CIT+CIT,Tchem+Tclin,0.531,0.778,0.534,2,0,1,2,1,DC01371,JNJ64264681;Safimaltib,DrugComb,FD00021,Leukemia,Hematologic Malignancy,Phase 1
626,TP00282,BTK;MAPK1,BTK,MAPK1,CIT+CIT,Tchem+Tclin,0.478,0.691,0.713,4,3,5,1,2,DC01287,Ibrutinib;Temuterkib,DrugComb,FD00021,Leukemia,Hematologic Malignancy,Phase 1
627,TP00282,BTK;MAPK1,BTK,MAPK1,CIT+CIT,Tchem+Tclin,0.478,0.691,0.713,4,3,5,1,2,DC01287,Ibrutinib;Temuterkib,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 1
628,TP00283,BTK;MAPK3,BTK,MAPK3,CIT+CIT,Tchem+Tclin,0.488,0.757,0.735,4,3,5,1,2,DC01287,Ibrutinib;Temuterkib,DrugComb,FD00021,Leukemia,Hematologic Malignancy,Phase 1
629,TP00283,BTK;MAPK3,BTK,MAPK3,CIT+CIT,Tchem+Tclin,0.488,0.757,0.735,4,3,5,1,2,DC01287,Ibrutinib;Temuterkib,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 1
630,TP00284,BTK;MDM2,BTK,MDM2,CIT+CIT,Tchem+Tclin,0.35,0.761,0.565,1,0,0,2,3,DC01521,Navtemadlin;TL895,DrugComb,FD00021,Leukemia,Hematologic Malignancy,Phase 1|Phase 2
631,TP00284,BTK;MDM2,BTK,MDM2,CIT+CIT,Tchem+Tclin,0.35,0.761,0.565,1,0,0,2,3,DC01521,Navtemadlin;TL895,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 1|Phase 2
632,TP00284,BTK;MDM2,BTK,MDM2,CIT+CIT,Tchem+Tclin,0.35,0.761,0.565,1,0,0,2,3,DC01521,Navtemadlin;TL895,DrugComb,FD00030,Myeloma,Hematologic Malignancy,Phase 1|Phase 2
635,TP00285,BTK;MS4A1,BTK,MS4A1,CIT+CIT,Tclin+Tclin,0.46,0.602,0.484,0,0,0,7,2,DC01284,Ibrutinib;Rituximab,DrugComb,FD00021,Leukemia,Hematologic Malignancy,Approval
636,TP00285,BTK;MS4A1,BTK,MS4A1,CIT+CIT,Tclin+Tclin,0.46,0.602,0.484,0,0,0,7,2,DC01284,Ibrutinib;Rituximab,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Approval
648,TP00286,BTK;MTOR,BTK,MTOR,CIT+CIT,Tclin+Tclin,0.397,0.657,0.678,0,0,1,2,1,DC01292,Ibrutinib;Vistusertib,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 1
650,TP00287,BTK;PDCD1,BTK,PDCD1,CET+CIT,Tclin+Tclin,0.365,0.497,1.0,0,1,0,3,4,DC01961,Tislelizumab;Zanubrutinib,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 2
651,TP00287,BTK;PDCD1,BTK,PDCD1,CET+CIT,Tclin+Tclin,0.365,0.497,1.0,0,1,0,3,4,DC00062,Acalabrutinib;Pembrolizumab,DrugComb,FD00018,Head and Neck Cancer,Head and Neck Cancer,Phase 2
652,TP00287,BTK;PDCD1,BTK,PDCD1,CET+CIT,Tclin+Tclin,0.365,0.497,1.0,0,1,0,3,4,DC00062,Acalabrutinib;Pembrolizumab,DrugComb,FD00019,Hematologic Malignancies,Hematologic Malignancy,Phase 1|Phase 2
653,TP00287,BTK;PDCD1,BTK,PDCD1,CET+CIT,Tclin+Tclin,0.365,0.497,1.0,0,1,0,3,4,DC00062,Acalabrutinib;Pembrolizumab,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 2
657,TP00288,BTK;PIK3CD,BTK,PIK3CD,CIT+CIT,Tclin+Tclin,0.54,0.755,0.612,5,1,0,3,2,DC01290,Ibrutinib;Umbralisib,DrugComb,FD00021,Leukemia,Hematologic Malignancy,Phase 1
658,TP00288,BTK;PIK3CD,BTK,PIK3CD,CIT+CIT,Tclin+Tclin,0.54,0.755,0.612,5,1,0,3,2,DC01290,Ibrutinib;Umbralisib,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 1
662,TP00289,BTK;ROR1,BTK,ROR1,CIT+CIT,Tbio+Tclin,0.377,0.644,0.506,0,0,0,1,2,DC01534,Nemtabrutinib;Zilovertamab Vedotin,DrugComb,FD00021,Leukemia,Hematologic Malignancy,Phase 2
663,TP00289,BTK;ROR1,BTK,ROR1,CIT+CIT,Tbio+Tclin,0.377,0.644,0.506,0,0,0,1,2,DC01534,Nemtabrutinib;Zilovertamab Vedotin,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 2
664,TP00290,BTK;SYK,BTK,SYK,CIT+CIT,Tclin+Tclin,0.55,0.791,0.777,6,6,2,1,1,DC01004,Entospletinib;Tirabrutinib,DrugComb,FD00021,Leukemia,Hematologic Malignancy,Phase 2
665,TP00291,BTLA;PDCD1,BTLA,PDCD1,CET+CET,Tbio+Tclin,0.465,0.809,1.0,0,0,1,2,1,DC01957,Tifcemalimab;Toripalimab,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
667,TP00292,CAPRIN1;PDCD1,CAPRIN1,PDCD1,CET+CIT,Tbio+Tclin,0.098,0.38,1.0,0,0,0,2,2,DC01748,Pembrolizumab;TRK950,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
668,TP00292,CAPRIN1;PDCD1,CAPRIN1,PDCD1,CET+CIT,Tbio+Tclin,0.098,0.38,1.0,0,0,0,2,2,DC01748,Pembrolizumab;TRK950,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
671,TP00293,CAPRIN1;VEGFA,CAPRIN1,VEGFA,CET+CIT,Tbio+Tclin,0.178,0.586,0.582,0,0,0,1,2,DC00484,Bevacizumab;TRK950,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
672,TP00293,CAPRIN1;VEGFA,CAPRIN1,VEGFA,CET+CIT,Tbio+Tclin,0.178,0.586,0.582,0,0,0,1,2,DC00484,Bevacizumab;TRK950,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
673,TP00294,CBLB;PDCD1,CBLB,PDCD1,CET+CIT,Tchem+Tclin,0.334,0.59,1.0,1,0,0,1,1,DC00695,Cemiplimab;HST1011,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1|Phase 2
674,TP00295,CCR2;PDCD1,CCR2,PDCD1,CET+CET,Tchem+Tclin,0.307,0.646,1.0,0,0,0,2,2,DC01727,Pembrolizumab;TAK500,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
675,TP00295,CCR2;PDCD1,CCR2,PDCD1,CET+CET,Tchem+Tclin,0.307,0.646,1.0,0,0,0,2,2,DC01566,Nivolumab;Plozalizumab,DrugComb,FD00026,Melanoma,Melanoma,Phase 1
676,TP00296,CCR2;STING1,CCR2,STING1,CET+CET,Tchem+Tchem,0.318,0.594,0.56,0,0,0,1,1,DC02269,TAK500,BsAb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
677,TP00297,CCR4;CTLA4,CCR4,CTLA4,CET+CIT,Tclin+Tclin,0.367,0.645,1.0,0,0,0,1,1,DC01351,Ipilimumab;Tivumecirnon,DrugComb,FD00026,Melanoma,Melanoma,Phase 2
678,TP00298,CCR4;IDO1,CCR4,IDO1,CET+CIT,Tchem+Tclin,0.314,0.28,0.195,0,0,0,1,1,DC01374,KHK2455;Mogamulizumab,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
679,TP00299,CCR4;PDCD1,CCR4,PDCD1,CET+CIT,Tclin+Tclin,0.375,0.801,1.0,0,0,0,2,6,DC01736,Pembrolizumab;Tivumecirnon,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1|Phase 2
680,TP00299,CCR4;PDCD1,CCR4,PDCD1,CET+CIT,Tclin+Tclin,0.375,0.801,1.0,0,0,0,2,6,DC01736,Pembrolizumab;Tivumecirnon,DrugComb,FD00041,Stomach Cancer,Stomach Cancer,Phase 2
681,TP00299,CCR4;PDCD1,CCR4,PDCD1,CET+CIT,Tclin+Tclin,0.375,0.801,1.0,0,0,0,2,6,DC01498,Mogamulizumab;Nivolumab,DrugComb,FD00014,Esophageal Cancer,Esophageal Cancer,Phase 1
682,TP00299,CCR4;PDCD1,CCR4,PDCD1,CET+CIT,Tclin+Tclin,0.375,0.801,1.0,0,0,0,2,6,DC01498,Mogamulizumab;Nivolumab,DrugComb,FD00018,Head and Neck Cancer,Head and Neck Cancer,Phase 1
683,TP00299,CCR4;PDCD1,CCR4,PDCD1,CET+CIT,Tclin+Tclin,0.375,0.801,1.0,0,0,0,2,6,DC01498,Mogamulizumab;Nivolumab,DrugComb,FD00020,Kidney Cancer,Kidney Cancer,Phase 1
684,TP00299,CCR4;PDCD1,CCR4,PDCD1,CET+CIT,Tclin+Tclin,0.375,0.801,1.0,0,0,0,2,6,DC01498,Mogamulizumab;Nivolumab,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
686,TP00300,CCR4;TNFRSF9,CCR4,TNFRSF9,CET+CIT,Tbio+Tclin,0.196,0.894,0.665,1,0,0,1,1,DC01499,Mogamulizumab;Utomilumab,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
687,TP00301,CCR5;PDCD1,CCR5,PDCD1,CET+CET,Tclin+Tclin,0.318,0.712,1.0,0,0,0,1,1,DC01763,Pembrolizumab;Vicriviroc,DrugComb,FD00011,Colorectal Cancer,Colorectal Cancer,Phase 2
688,TP00302,CCR8;PDCD1,CCR8,PDCD1,CET+CET,Tchem+Tclin,0.357,0.89,0.573,0,0,0,5,2,DC00567,BMS986340;Nivolumab,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
690,TP00302,CCR8;PDCD1,CCR8,PDCD1,CET+CET,Tchem+Tclin,0.357,0.89,0.573,0,0,0,5,2,DC01709,Pembrolizumab;S531011,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1|Phase 2
693,TP00303,CD163;PDCD1,CD163,PDCD1,CET+CIT,Tbio+Tclin,0.147,0.696,1.0,0,0,0,1,1,DC00698,Cemiplimab;OR2805,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
694,TP00304,CD19;CD22,CD19,CD22,CIT+CIT,Tclin+Tclin,0.472,0.718,,2,2,2,1,2,DC02081,DT2219ARL,BsAb,FD00019,Hematologic Malignancies,Hematologic Malignancy,Phase 1
695,TP00304,CD19;CD22,CD19,CD22,CIT+CIT,Tclin+Tclin,0.472,0.718,,2,2,2,1,2,DC02081,DT2219ARL,BsAb,FD00024,Lymphoma,Hematologic Malignancy,Phase 1|Phase 2
696,TP00305,CD19;CD28,CD19,CD28,CET+CIT,Tbio+Tclin,0.372,0.76,,0,3,0,1,1,DC02248,RO7443904,BsAb,FD00024,Lymphoma,Hematologic Malignancy,Phase 1
697,TP00306,CD19;CD3D,CD19,CD3D,CET+CIT,Tclin+Tclin,0.355,0.618,,3,1,0,10,4,DC01820,Plamotamab;Tafasitamab,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 2
698,TP00306,CD19;CD3D,CD19,CD3D,CET+CIT,Tclin+Tclin,0.355,0.618,,3,1,0,10,4,DC02047,Blinatumomab,BsAb,FD00019,Hematologic Malignancies,Hematologic Malignancy,Phase 2
699,TP00306,CD19;CD3D,CD19,CD3D,CET+CIT,Tclin+Tclin,0.355,0.618,,3,1,0,10,4,DC02047,Blinatumomab,BsAb,FD00021,Leukemia,Hematologic Malignancy,Approval
701,TP00306,CD19;CD3D,CD19,CD3D,CET+CIT,Tclin+Tclin,0.355,0.618,,3,1,0,10,4,DC02047,Blinatumomab,BsAb,FD00030,Myeloma,Hematologic Malignancy,Early Phase 1
712,TP00307,CD19;CD3E,CD19,CD3E,CET+CIT,Tclin+Tclin,0.33,0.633,,3,1,0,10,4,DC01820,Plamotamab;Tafasitamab,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 2
714,TP00307,CD19;CD3E,CD19,CD3E,CET+CIT,Tclin+Tclin,0.33,0.633,,3,1,0,10,4,DC02047,Blinatumomab,BsAb,FD00019,Hematologic Malignancies,Hematologic Malignancy,Phase 2
715,TP00307,CD19;CD3E,CD19,CD3E,CET+CIT,Tclin+Tclin,0.33,0.633,,3,1,0,10,4,DC02047,Blinatumomab,BsAb,FD00021,Leukemia,Hematologic Malignancy,Approval
717,TP00307,CD19;CD3E,CD19,CD3E,CET+CIT,Tclin+Tclin,0.33,0.633,,3,1,0,10,4,DC02047,Blinatumomab,BsAb,FD00030,Myeloma,Hematologic Malignancy,Early Phase 1
727,TP00308,CD19;CD3G,CD19,CD3G,CET+CIT,Tclin+Tclin,0.325,0.674,,2,1,0,10,4,DC01820,Plamotamab;Tafasitamab,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 2
728,TP00308,CD19;CD3G,CD19,CD3G,CET+CIT,Tclin+Tclin,0.325,0.674,,2,1,0,10,4,DC02047,Blinatumomab,BsAb,FD00019,Hematologic Malignancies,Hematologic Malignancy,Phase 2
729,TP00308,CD19;CD3G,CD19,CD3G,CET+CIT,Tclin+Tclin,0.325,0.674,,2,1,0,10,4,DC02047,Blinatumomab,BsAb,FD00021,Leukemia,Hematologic Malignancy,Approval
731,TP00308,CD19;CD3G,CD19,CD3G,CET+CIT,Tclin+Tclin,0.325,0.674,,2,1,0,10,4,DC02047,Blinatumomab,BsAb,FD00030,Myeloma,Hematologic Malignancy,Early Phase 1
742,TP00309,CD19;CD47,CD19,CD47,CET+CIT,Tchem+Tclin,0.232,0.704,,0,0,0,1,2,DC02306,Zeripatamig,BsAb,FD00021,Leukemia,Hematologic Malignancy,Phase 1
743,TP00309,CD19;CD47,CD19,CD47,CET+CIT,Tchem+Tclin,0.232,0.704,,0,0,0,1,2,DC02306,Zeripatamig,BsAb,FD00024,Lymphoma,Hematologic Malignancy,Phase 1
744,TP00310,CD19;CD79B,CD19,CD79B,CIT+CIT,Tclin+Tclin,0.624,0.761,,1,1,1,1,1,DC01447,Loncastuximab Tesirine;Polatuzumab Vedotin,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 1
745,TP00311,CD19;CRBN,CD19,CRBN,CIT+CIT,Tclin+Tclin,0.138,0.441,,0,0,0,5,1,DC00552,Blinatumomab;Lenalidomide,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 1
750,TP00312,CD19;CSNK1E,CD19,CSNK1E,CIT+CIT,Tclin+Tclin,0.277,0.292,,0,0,0,1,1,DC01449,Loncastuximab Tesirine;Umbralisib,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 1
751,TP00313,CD19;MS4A1,CD19,MS4A1,CIT+CIT,Tclin+Tclin,0.57,0.788,,1,0,2,5,3,DC01986,Ublituximab;Zeripatamig,DrugComb,FD00021,Leukemia,Hematologic Malignancy,Phase 1
752,TP00313,CD19;MS4A1,CD19,MS4A1,CIT+CIT,Tclin+Tclin,0.57,0.788,,1,0,2,5,3,DC01986,Ublituximab;Zeripatamig,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 1
755,TP00313,CD19;MS4A1,CD19,MS4A1,CIT+CIT,Tclin+Tclin,0.57,0.788,,1,0,2,5,3,DC01320,Inebilizumab;Rituximab,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1|Phase 2
757,TP00314,CD19;PDCD1,CD19,PDCD1,CET+CIT,Tclin+Tclin,0.354,0.688,,0,0,1,1,3,DC00553,Blinatumomab;Pembrolizumab,DrugComb,FD00019,Hematologic Malignancies,Hematologic Malignancy,Phase 1
758,TP00314,CD19;PDCD1,CD19,PDCD1,CET+CIT,Tclin+Tclin,0.354,0.688,,0,0,1,1,3,DC00553,Blinatumomab;Pembrolizumab,DrugComb,FD00021,Leukemia,Hematologic Malignancy,Phase 1|Phase 2
759,TP00314,CD19;PDCD1,CD19,PDCD1,CET+CIT,Tclin+Tclin,0.354,0.688,,0,0,1,1,3,DC00553,Blinatumomab;Pembrolizumab,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 1
760,TP00315,CD19;PIK3CD,CD19,PIK3CD,CIT+CIT,Tclin+Tclin,0.369,0.55,,3,4,1,2,2,DC01449,Loncastuximab Tesirine;Umbralisib,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 1
761,TP00315,CD19;PIK3CD,CD19,PIK3CD,CIT+CIT,Tclin+Tclin,0.369,0.55,,3,4,1,2,2,DC01677,Parsaclisib;Tafasitamab,DrugComb,FD00021,Leukemia,Hematologic Malignancy,Phase 1|Phase 2
763,TP00316,CD19;TNFRSF8,CD19,TNFRSF8,CIT+CIT,Tclin+Tclin,0.285,0.707,,0,0,0,1,2,DC01990,4G7xH22,BsAb,FD00021,Leukemia,Hematologic Malignancy,Phase 1
764,TP00316,CD19;TNFRSF8,CD19,TNFRSF8,CIT+CIT,Tclin+Tclin,0.285,0.707,,0,0,0,1,2,DC01990,4G7xH22,BsAb,FD00024,Lymphoma,Hematologic Malignancy,Phase 1
765,TP00317,CD19;TNFRSF9,CD19,TNFRSF9,CET+CIT,Tbio+Tclin,0.215,0.76,,0,0,0,1,1,DC02094,Ensomafusp Alfa,BsAb,FD00024,Lymphoma,Hematologic Malignancy,Phase 1
766,TP00318,CD22;CD28,CD22,CD28,CET+CIT,Tbio+Tclin,0.389,0.776,0.62,1,0,0,1,1,DC02238,REGN5837,BsAb,FD00024,Lymphoma,Hematologic Malignancy,Phase 1
767,TP00319,CD22;CD3D,CD22,CD3D,CET+CIT,Tclin+Tclin,0.309,0.739,0.621,1,1,0,1,1,DC02159,JNJ75348780,BsAb,FD00021,Leukemia,Hematologic Malignancy,Phase 1
768,TP00320,CD22;CD3E,CD22,CD3E,CET+CIT,Tclin+Tclin,0.391,0.67,0.597,1,1,0,1,1,DC02159,JNJ75348780,BsAb,FD00021,Leukemia,Hematologic Malignancy,Phase 1
769,TP00321,CD22;CD3G,CD22,CD3G,CET+CIT,Tclin+Tclin,0.367,0.717,0.594,1,1,0,1,1,DC02159,JNJ75348780,BsAb,FD00021,Leukemia,Hematologic Malignancy,Phase 1
770,TP00322,CD22;MS4A1,CD22,MS4A1,CIT+CIT,Tclin+Tclin,0.47,0.776,0.698,1,0,1,2,2,DC01325,Inotuzumab Ozogamicin;Rituximab,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 1|Phase 2
771,TP00322,CD22;MS4A1,CD22,MS4A1,CIT+CIT,Tclin+Tclin,0.47,0.776,0.698,1,0,1,2,2,DC01818,Pinatuzumab Vedotin;Rituximab,DrugComb,FD00021,Leukemia,Hematologic Malignancy,Phase 1
773,TP00323,CD27;CD274,CD27,CD274,CET+CET,Tbio+Tclin,0.428,0.606,1.0,0,0,0,2,1,DC00317,Atezolizumab;Varlilumab,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
775,TP00324,CD27;PDCD1,CD27,PDCD1,CET+CET,Tbio+Tclin,0.433,0.818,1.0,0,0,0,2,2,DC01597,Nivolumab;Varlilumab,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 2
776,TP00324,CD27;PDCD1,CD27,PDCD1,CET+CET,Tbio+Tclin,0.433,0.818,1.0,0,0,0,2,2,DC00593,Boserolimab;Pembrolizumab,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 2
777,TP00325,CD274;CD28,CD274,CD28,CET+CET,Tbio+Tclin,0.579,0.587,1.0,2,0,1,1,1,DC02077,Davoceticept,BsAb,FD00033,Other Cancer,Other Cancer,Phase 1
778,TP00326,CD274;CD38,CD274,CD38,CET+CET,Tclin+Tclin,0.39,0.753,0.788,0,0,0,2,2,DC00284,Atezolizumab;Isatuximab,DrugComb,FD00011,Colorectal Cancer,Colorectal Cancer,Phase 1|Phase 2
779,TP00326,CD274;CD38,CD274,CD38,CET+CET,Tclin+Tclin,0.39,0.753,0.788,0,0,0,2,2,DC00261,Atezolizumab;Daratumumab,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
780,TP00327,CD274;CD3D,CD274,CD3D,CET+CET,Tclin+Tclin,0.259,0.649,1.0,1,1,1,2,3,DC00256,Atezolizumab;Cibisatamab,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
781,TP00327,CD274;CD3D,CD274,CD3D,CET+CET,Tclin+Tclin,0.259,0.649,1.0,1,1,1,2,3,DC00256,Atezolizumab;Cibisatamab,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
782,TP00327,CD274;CD3D,CD274,CD3D,CET+CET,Tclin+Tclin,0.259,0.649,1.0,1,1,1,2,3,DC00946,Durvalumab;Tebentafusp,DrugComb,FD00026,Melanoma,Melanoma,Phase 1|Phase 2
783,TP00328,CD274;CD3E,CD274,CD3E,CET+CET,Tclin+Tclin,0.545,0.591,1.0,1,1,1,2,3,DC00946,Durvalumab;Tebentafusp,DrugComb,FD00026,Melanoma,Melanoma,Phase 1|Phase 2
784,TP00328,CD274;CD3E,CD274,CD3E,CET+CET,Tclin+Tclin,0.545,0.591,1.0,1,1,1,2,3,DC00256,Atezolizumab;Cibisatamab,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
785,TP00328,CD274;CD3E,CD274,CD3E,CET+CET,Tclin+Tclin,0.545,0.591,1.0,1,1,1,2,3,DC00256,Atezolizumab;Cibisatamab,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
786,TP00329,CD274;CD3G,CD274,CD3G,CET+CET,Tclin+Tclin,0.338,0.594,1.0,1,1,1,2,3,DC00946,Durvalumab;Tebentafusp,DrugComb,FD00026,Melanoma,Melanoma,Phase 1|Phase 2
787,TP00329,CD274;CD3G,CD274,CD3G,CET+CET,Tclin+Tclin,0.338,0.594,1.0,1,1,1,2,3,DC00256,Atezolizumab;Cibisatamab,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
788,TP00329,CD274;CD3G,CD274,CD3G,CET+CET,Tclin+Tclin,0.338,0.594,1.0,1,1,1,2,3,DC00256,Atezolizumab;Cibisatamab,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
789,TP00330,CD274;CD40,CD274,CD40,CET+CET,Tchem+Tclin,0.436,0.716,1.0,1,0,1,2,2,DC00299,Atezolizumab;RO7300490,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
790,TP00330,CD274;CD40,CD274,CD40,CET+CET,Tchem+Tclin,0.436,0.716,1.0,1,0,1,2,2,DC00306,Atezolizumab;Selicrelumab,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 1
792,TP00331,CD274;CD47,CD274,CD47,CET+CET,Tchem+Tclin,0.521,0.65,1.0,0,0,1,9,12,DC00263,Atezolizumab;DSP107,DrugComb,FD00011,Colorectal Cancer,Colorectal Cancer,Phase 1|Phase 2
793,TP00331,CD274;CD47,CD274,CD47,CET+CET,Tchem+Tclin,0.521,0.65,1.0,0,0,1,9,12,DC00263,Atezolizumab;DSP107,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
794,TP00331,CD274;CD47,CD274,CD47,CET+CET,Tchem+Tclin,0.521,0.65,1.0,0,0,1,9,12,DC00292,Atezolizumab;Magrolimab,DrugComb,FD00006,Bladder Cancer,Bladder Cancer,Phase 1|Phase 2
795,TP00331,CD274;CD47,CD274,CD47,CET+CET,Tchem+Tclin,0.521,0.65,1.0,0,0,1,9,12,DC00292,Atezolizumab;Magrolimab,DrugComb,FD00021,Leukemia,Hematologic Malignancy,Phase 1
796,TP00331,CD274;CD47,CD274,CD47,CET+CET,Tchem+Tclin,0.521,0.65,1.0,0,0,1,9,12,DC00345,Avelumab;Magrolimab,DrugComb,FD00034,Ovarian Cancer,Ovarian Cancer,Phase 1
797,TP00331,CD274;CD47,CD274,CD47,CET+CET,Tchem+Tclin,0.521,0.65,1.0,0,0,1,9,12,DC01991,6MW3211,BsAb,FD00020,Kidney Cancer,Kidney Cancer,Phase 2
800,TP00331,CD274;CD47,CD274,CD47,CET+CET,Tchem+Tclin,0.521,0.65,1.0,0,0,1,9,12,DC01991,6MW3211,BsAb,FD00024,Lymphoma,Hematologic Malignancy,Phase 2
801,TP00331,CD274;CD47,CD274,CD47,CET+CET,Tchem+Tclin,0.521,0.65,1.0,0,0,1,9,12,DC01991,6MW3211,BsAb,FD00030,Myeloma,Hematologic Malignancy,Phase 1|Phase 2
802,TP00331,CD274;CD47,CD274,CD47,CET+CET,Tchem+Tclin,0.521,0.65,1.0,0,0,1,9,12,DC01991,6MW3211,BsAb,FD00033,Other Cancer,Other Cancer,Phase 1|Phase 2
803,TP00331,CD274;CD47,CD274,CD47,CET+CET,Tchem+Tclin,0.521,0.65,1.0,0,0,1,9,12,DC02143,IMM2520,BsAb,FD00007,Breast Cancer,Breast Cancer,Phase 1
805,TP00331,CD274;CD47,CD274,CD47,CET+CET,Tchem+Tclin,0.521,0.65,1.0,0,0,1,9,12,DC02143,IMM2520,BsAb,FD00018,Head and Neck Cancer,Head and Neck Cancer,Phase 1
810,TP00331,CD274;CD47,CD274,CD47,CET+CET,Tchem+Tclin,0.521,0.65,1.0,0,0,1,9,12,DC02264,Simridarlimab,BsAb,FD00019,Hematologic Malignancies,Hematologic Malignancy,Phase 1
816,TP00332,CD274;CDK4,CD274,CDK4,CET+CIT,Tclin+Tclin,0.403,0.405,1.0,0,0,1,3,5,DC00428,Benmelstobart;TQB3616,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1|Phase 2
817,TP00332,CD274;CDK4,CD274,CDK4,CET+CIT,Tclin+Tclin,0.403,0.405,1.0,0,0,1,3,5,DC00024,Abemaciclib;Lodapolimab,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 1
818,TP00332,CD274;CDK4,CD274,CDK4,CET+CIT,Tclin+Tclin,0.403,0.405,1.0,0,0,1,3,5,DC00024,Abemaciclib;Lodapolimab,DrugComb,FD00026,Melanoma,Melanoma,Phase 1
819,TP00332,CD274;CDK4,CD274,CDK4,CET+CIT,Tclin+Tclin,0.403,0.405,1.0,0,0,1,3,5,DC00024,Abemaciclib;Lodapolimab,DrugComb,FD00035,Pancreatic Cancer,Pancreatic Cancer,Phase 1
820,TP00332,CD274;CDK4,CD274,CDK4,CET+CIT,Tclin+Tclin,0.403,0.405,1.0,0,0,1,3,5,DC00009,Abemaciclib;Atezolizumab,DrugComb,FD00038,Prostate Cancer,Prostate Cancer,Phase 2
821,TP00333,CD274;CDK6,CD274,CDK6,CET+CIT,Tclin+Tclin,0.339,0.445,1.0,0,0,0,3,5,DC00024,Abemaciclib;Lodapolimab,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 1
822,TP00333,CD274;CDK6,CD274,CDK6,CET+CIT,Tclin+Tclin,0.339,0.445,1.0,0,0,0,3,5,DC00024,Abemaciclib;Lodapolimab,DrugComb,FD00026,Melanoma,Melanoma,Phase 1
823,TP00333,CD274;CDK6,CD274,CDK6,CET+CIT,Tclin+Tclin,0.339,0.445,1.0,0,0,0,3,5,DC00024,Abemaciclib;Lodapolimab,DrugComb,FD00035,Pancreatic Cancer,Pancreatic Cancer,Phase 1
824,TP00333,CD274;CDK6,CD274,CDK6,CET+CIT,Tclin+Tclin,0.339,0.445,1.0,0,0,0,3,5,DC00009,Abemaciclib;Atezolizumab,DrugComb,FD00038,Prostate Cancer,Prostate Cancer,Phase 2
825,TP00333,CD274;CDK6,CD274,CDK6,CET+CIT,Tclin+Tclin,0.339,0.445,1.0,0,0,0,3,5,DC00428,Benmelstobart;TQB3616,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1|Phase 2
826,TP00334,CD274;CEACAM5,CD274,CEACAM5,CET+CIT,Tbio+Tclin,0.173,0.633,1.0,0,0,0,1,2,DC00256,Atezolizumab;Cibisatamab,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
827,TP00334,CD274;CEACAM5,CD274,CEACAM5,CET+CIT,Tbio+Tclin,0.173,0.633,1.0,0,0,0,1,2,DC00256,Atezolizumab;Cibisatamab,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
828,TP00335,CD274;CHEK1,CD274,CHEK1,CET+CIT,Tchem+Tclin,0.301,0.541,1.0,0,0,0,1,1,DC01445,Lodapolimab;Prexasertib,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
829,TP00336,CD274;CLDN18,CD274,CLDN18,CET+CIT,Tbio+Tclin,0.262,0.539,1.0,1,0,0,1,1,DC02229,Q1802,BsAb,FD00033,Other Cancer,Other Cancer,Phase 1
830,TP00337,CD274;CRBN,CD274,CRBN,CET+CIT,Tclin+Tclin,0.146,0.47,1.0,0,0,0,2,2,DC00927,Durvalumab;Lenalidomide,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 2
831,TP00337,CD274;CRBN,CD274,CRBN,CET+CIT,Tclin+Tclin,0.146,0.47,1.0,0,0,0,2,2,DC00941,Durvalumab;Pomalidomide,DrugComb,FD00030,Myeloma,Hematologic Malignancy,Phase 1
832,TP00338,CD274;CREBBP,CD274,CREBBP,CET+CIT,Tchem+Tclin,0.289,0.542,1.0,0,0,0,1,1,DC00282,Atezolizumab;Inobrodib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
833,TP00339,CD274;CSF1R,CD274,CSF1R,CET+CET,Tclin+Tclin,0.391,0.599,1.0,0,0,1,4,5,DC00930,Durvalumab;LY3022855,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
834,TP00339,CD274;CSF1R,CD274,CSF1R,CET+CET,Tclin+Tclin,0.391,0.599,1.0,0,0,1,4,5,DC00266,Atezolizumab;Emactuzumab,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 1
836,TP00339,CD274;CSF1R,CD274,CSF1R,CET+CET,Tclin+Tclin,0.391,0.599,1.0,0,0,1,4,5,DC00940,Durvalumab;Pexidartinib,DrugComb,FD00011,Colorectal Cancer,Colorectal Cancer,Phase 1
837,TP00339,CD274;CSF1R,CD274,CSF1R,CET+CET,Tclin+Tclin,0.391,0.599,1.0,0,0,1,4,5,DC00940,Durvalumab;Pexidartinib,DrugComb,FD00035,Pancreatic Cancer,Pancreatic Cancer,Phase 1
838,TP00339,CD274;CSF1R,CD274,CSF1R,CET+CET,Tclin+Tclin,0.391,0.599,1.0,0,0,1,4,5,DC00358,Axatilimab;Durvalumab,DrugComb,FD00022,Liver Cancer,Liver Cancer,Phase 2
840,TP00340,CD274;CTLA4,CD274,CTLA4,CET+CET,Tclin+Tclin,0.548,0.582,1.0,1,0,2,4,18,DC00951,Durvalumab;Tremelimumab,DrugComb,FD00006,Bladder Cancer,Bladder Cancer,Phase 2
841,TP00340,CD274;CTLA4,CD274,CTLA4,CET+CET,Tclin+Tclin,0.548,0.582,1.0,1,0,2,4,18,DC00951,Durvalumab;Tremelimumab,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 1
842,TP00340,CD274;CTLA4,CD274,CTLA4,CET+CET,Tclin+Tclin,0.548,0.582,1.0,1,0,2,4,18,DC00951,Durvalumab;Tremelimumab,DrugComb,FD00011,Colorectal Cancer,Colorectal Cancer,Phase 2
843,TP00340,CD274;CTLA4,CD274,CTLA4,CET+CET,Tclin+Tclin,0.548,0.582,1.0,1,0,2,4,18,DC00951,Durvalumab;Tremelimumab,DrugComb,FD00015,Germ Cell Tumor,Other Cancer,Phase 2
844,TP00340,CD274;CTLA4,CD274,CTLA4,CET+CET,Tclin+Tclin,0.548,0.582,1.0,1,0,2,4,18,DC00951,Durvalumab;Tremelimumab,DrugComb,FD00018,Head and Neck Cancer,Head and Neck Cancer,Phase 2
845,TP00340,CD274;CTLA4,CD274,CTLA4,CET+CET,Tclin+Tclin,0.548,0.582,1.0,1,0,2,4,18,DC00951,Durvalumab;Tremelimumab,DrugComb,FD00020,Kidney Cancer,Kidney Cancer,Phase 3
846,TP00340,CD274;CTLA4,CD274,CTLA4,CET+CET,Tclin+Tclin,0.548,0.582,1.0,1,0,2,4,18,DC00951,Durvalumab;Tremelimumab,DrugComb,FD00022,Liver Cancer,Liver Cancer,Approval
847,TP00340,CD274;CTLA4,CD274,CTLA4,CET+CET,Tclin+Tclin,0.548,0.582,1.0,1,0,2,4,18,DC00951,Durvalumab;Tremelimumab,DrugComb,FD00023,Lung Cancer,Lung Cancer,Approval
848,TP00340,CD274;CTLA4,CD274,CTLA4,CET+CET,Tclin+Tclin,0.548,0.582,1.0,1,0,2,4,18,DC00951,Durvalumab;Tremelimumab,DrugComb,FD00029,Mesothelioma,Other Cancer,Phase 2
849,TP00340,CD274;CTLA4,CD274,CTLA4,CET+CET,Tclin+Tclin,0.548,0.582,1.0,1,0,2,4,18,DC00951,Durvalumab;Tremelimumab,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 2
850,TP00340,CD274;CTLA4,CD274,CTLA4,CET+CET,Tclin+Tclin,0.548,0.582,1.0,1,0,2,4,18,DC00951,Durvalumab;Tremelimumab,DrugComb,FD00034,Ovarian Cancer,Ovarian Cancer,Phase 2
851,TP00340,CD274;CTLA4,CD274,CTLA4,CET+CET,Tclin+Tclin,0.548,0.582,1.0,1,0,2,4,18,DC00951,Durvalumab;Tremelimumab,DrugComb,FD00035,Pancreatic Cancer,Pancreatic Cancer,Phase 1
852,TP00340,CD274;CTLA4,CD274,CTLA4,CET+CET,Tclin+Tclin,0.548,0.582,1.0,1,0,2,4,18,DC00951,Durvalumab;Tremelimumab,DrugComb,FD00037,Pleural Mesothelioma,Other Cancer,Phase 2
853,TP00340,CD274;CTLA4,CD274,CTLA4,CET+CET,Tclin+Tclin,0.548,0.582,1.0,1,0,2,4,18,DC00951,Durvalumab;Tremelimumab,DrugComb,FD00041,Stomach Cancer,Stomach Cancer,Phase 2
854,TP00340,CD274;CTLA4,CD274,CTLA4,CET+CET,Tclin+Tclin,0.548,0.582,1.0,1,0,2,4,18,DC01343,Ipilimumab;Pacmilimab,DrugComb,FD00026,Melanoma,Melanoma,Phase 2
856,TP00340,CD274;CTLA4,CD274,CTLA4,CET+CET,Tclin+Tclin,0.548,0.582,1.0,1,0,2,4,18,DC02097,Erfonrilimab,BsAb,FD00014,Esophageal Cancer,Esophageal Cancer,Phase 2
859,TP00340,CD274;CTLA4,CD274,CTLA4,CET+CET,Tclin+Tclin,0.548,0.582,1.0,1,0,2,4,18,DC02097,Erfonrilimab,BsAb,FD00024,Lymphoma,Hematologic Malignancy,Phase 1
863,TP00340,CD274;CTLA4,CD274,CTLA4,CET+CET,Tclin+Tclin,0.548,0.582,1.0,1,0,2,4,18,DC02097,Erfonrilimab,BsAb,FD00042,Thymic Carcinoma,Other Cancer,Phase 2
865,TP00341,CD274;CXCR4,CD274,CXCR4,CET+CIT,Tclin+Tclin,0.38,0.702,1.0,0,0,0,2,5,DC00293,Atezolizumab;Motixafortide,DrugComb,FD00014,Esophageal Cancer,Esophageal Cancer,Phase 1|Phase 2
866,TP00341,CD274;CXCR4,CD274,CXCR4,CET+CIT,Tclin+Tclin,0.38,0.702,1.0,0,0,0,2,5,DC00293,Atezolizumab;Motixafortide,DrugComb,FD00021,Leukemia,Hematologic Malignancy,Phase 1|Phase 2
867,TP00341,CD274;CXCR4,CD274,CXCR4,CET+CIT,Tclin+Tclin,0.38,0.702,1.0,0,0,0,2,5,DC00293,Atezolizumab;Motixafortide,DrugComb,FD00035,Pancreatic Cancer,Pancreatic Cancer,Phase 1|Phase 2
868,TP00341,CD274;CXCR4,CD274,CXCR4,CET+CIT,Tclin+Tclin,0.38,0.702,1.0,0,0,0,2,5,DC00293,Atezolizumab;Motixafortide,DrugComb,FD00041,Stomach Cancer,Stomach Cancer,Phase 1|Phase 2
869,TP00341,CD274;CXCR4,CD274,CXCR4,CET+CIT,Tclin+Tclin,0.38,0.702,1.0,0,0,0,2,5,DC00929,Durvalumab;LY2510924,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
870,TP00342,CD274;CYP19A1,CD274,CYP19A1,CET+CIT,Tclin+Tclin,0.171,0.567,0.428,0,0,0,3,1,DC00545,Bintrafusp Alfa;Letrozole,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 2
873,TP00343,CD274;DPP4,CD274,DPP4,CET+CIT,Tclin+Tclin,0.316,0.596,1.0,0,0,0,1,1,DC00289,Atezolizumab;Linagliptin,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
874,TP00344,CD274;EGFR,CD274,EGFR,CET+CIT,Tclin+Tclin,0.346,0.59,1.0,1,0,1,10,5,DC00331,Aumolertinib;Retlirafusp Alfa,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
875,TP00344,CD274;EGFR,CD274,EGFR,CET+CIT,Tclin+Tclin,0.346,0.59,1.0,1,0,1,10,5,DC00340,Avelumab;Cetuximab,DrugComb,FD00002,Anal Cancer,Other Cancer,Phase 2
876,TP00344,CD274;EGFR,CD274,EGFR,CET+CIT,Tclin+Tclin,0.346,0.59,1.0,1,0,1,10,5,DC00340,Avelumab;Cetuximab,DrugComb,FD00011,Colorectal Cancer,Colorectal Cancer,Phase 2
877,TP00344,CD274;EGFR,CD274,EGFR,CET+CIT,Tclin+Tclin,0.346,0.59,1.0,1,0,1,10,5,DC00340,Avelumab;Cetuximab,DrugComb,FD00018,Head and Neck Cancer,Head and Neck Cancer,Phase 2
880,TP00344,CD274;EGFR,CD274,EGFR,CET+CIT,Tclin+Tclin,0.346,0.59,1.0,1,0,1,10,5,DC00260,Atezolizumab;D2C7IT,DrugComb,FD00017,Glioma,Glioma,Phase 1
886,TP00345,CD274;EP300,CD274,EP300,CET+CIT,Tchem+Tclin,0.245,0.481,1.0,0,1,0,1,1,DC00282,Atezolizumab;Inobrodib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
887,TP00346,CD274;EPCAM,CD274,EPCAM,CET+CIT,Tbio+Tclin,0.311,0.665,1.0,0,0,0,1,1,DC00936,Durvalumab;Oportuzumab Monatox,DrugComb,FD00006,Bladder Cancer,Bladder Cancer,Phase 1
888,TP00347,CD274;ERBB2,CD274,ERBB2,CET+CIT,Tclin+Tclin,0.384,0.665,1.0,0,0,0,6,5,DC00201,Anbenitamab;Erfonrilimab,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 2
889,TP00347,CD274;ERBB2,CD274,ERBB2,CET+CIT,Tclin+Tclin,0.384,0.665,1.0,0,0,0,6,5,DC00201,Anbenitamab;Erfonrilimab,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 2
890,TP00347,CD274;ERBB2,CD274,ERBB2,CET+CIT,Tclin+Tclin,0.384,0.665,1.0,0,0,0,6,5,DC00201,Anbenitamab;Erfonrilimab,DrugComb,FD00041,Stomach Cancer,Stomach Cancer,Phase 2
891,TP00347,CD274;ERBB2,CD274,ERBB2,CET+CIT,Tclin+Tclin,0.384,0.665,1.0,0,0,0,6,5,DC00888,Disitamab Vedotin;Envafolimab,DrugComb,FD00022,Liver Cancer,Liver Cancer,Phase 2
892,TP00347,CD274;ERBB2,CD274,ERBB2,CET+CIT,Tclin+Tclin,0.384,0.665,1.0,0,0,0,6,5,DC00939,Durvalumab;Pertuzumab;Trastuzumab,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 2
898,TP00348,CD274;ESR1,CD274,ESR1,CET+CIT,Tclin+Tclin,0.33,0.605,1.0,0,0,0,2,1,DC00279,Atezolizumab;Giredestrant,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 1|Phase 2
900,TP00349,CD274;ESR2,CD274,ESR2,CET+CIT,Tclin+Tclin,0.353,0.516,1.0,0,0,0,2,1,DC00275,Atezolizumab;Fulvestrant,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 1|Phase 2
902,TP00350,CD274;EZH2,CD274,EZH2,CET+CIT,Tclin+Tclin,0.289,0.52,1.0,0,0,1,1,1,DC00309,Atezolizumab;Tazemetostat,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 1
903,TP00351,CD274;FAP,CD274,FAP,CET+CIT,Tchem+Tclin,0.245,0.538,1.0,0,0,1,2,2,DC00299,Atezolizumab;RO7300490,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
904,TP00351,CD274;FAP,CD274,FAP,CET+CIT,Tchem+Tclin,0.245,0.538,1.0,0,0,1,2,2,DC00307,Atezolizumab;Simlukafusp Alfa,DrugComb,FD00035,Pancreatic Cancer,Pancreatic Cancer,Phase 1|Phase 2
905,TP00352,CD274;FGFR1,CD274,FGFR1,CET+CIT,Tclin+Tclin,0.337,0.65,1.0,0,0,1,1,1,DC00302,Atezolizumab;Rogaratinib,DrugComb,FD00006,Bladder Cancer,Bladder Cancer,Phase 1
906,TP00353,CD274;FGFR3,CD274,FGFR3,CET+CIT,Tclin+Tclin,0.288,0.576,1.0,0,0,1,1,1,DC00302,Atezolizumab;Rogaratinib,DrugComb,FD00006,Bladder Cancer,Bladder Cancer,Phase 1
907,TP00354,CD274;FLT1,CD274,FLT1,CET+CET,Tclin+Tclin,0.341,0.669,1.0,0,0,1,7,14,DC00337,Avelumab;Axitinib,DrugComb,FD00017,Glioma,Glioma,Phase 2
908,TP00354,CD274;FLT1,CD274,FLT1,CET+CET,Tclin+Tclin,0.341,0.669,1.0,0,0,1,7,14,DC00337,Avelumab;Axitinib,DrugComb,FD00018,Head and Neck Cancer,Head and Neck Cancer,Phase 2
909,TP00354,CD274;FLT1,CD274,FLT1,CET+CET,Tclin+Tclin,0.341,0.669,1.0,0,0,1,7,14,DC00337,Avelumab;Axitinib,DrugComb,FD00020,Kidney Cancer,Kidney Cancer,Approval
910,TP00354,CD274;FLT1,CD274,FLT1,CET+CET,Tclin+Tclin,0.341,0.669,1.0,0,0,1,7,14,DC00337,Avelumab;Axitinib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 3
913,TP00354,CD274;FLT1,CD274,FLT1,CET+CET,Tclin+Tclin,0.341,0.669,1.0,0,0,1,7,14,DC00948,Durvalumab;Tivozanib,DrugComb,FD00022,Liver Cancer,Liver Cancer,Phase 1|Phase 2
914,TP00354,CD274;FLT1,CD274,FLT1,CET+CET,Tclin+Tclin,0.341,0.669,1.0,0,0,1,7,14,DC00312,Atezolizumab;Tivozanib,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 1|Phase 2
916,TP00354,CD274;FLT1,CD274,FLT1,CET+CET,Tclin+Tclin,0.341,0.669,1.0,0,0,1,7,14,DC00312,Atezolizumab;Tivozanib,DrugComb,FD00032,Neuroendocrine Tumor,Other Cancer,Phase 1|Phase 2
917,TP00354,CD274;FLT1,CD274,FLT1,CET+CET,Tclin+Tclin,0.341,0.669,1.0,0,0,1,7,14,DC00312,Atezolizumab;Tivozanib,DrugComb,FD00034,Ovarian Cancer,Ovarian Cancer,Phase 1|Phase 2
918,TP00354,CD274;FLT1,CD274,FLT1,CET+CET,Tclin+Tclin,0.341,0.669,1.0,0,0,1,7,14,DC00312,Atezolizumab;Tivozanib,DrugComb,FD00035,Pancreatic Cancer,Pancreatic Cancer,Phase 1|Phase 2
919,TP00354,CD274;FLT1,CD274,FLT1,CET+CET,Tclin+Tclin,0.341,0.669,1.0,0,0,1,7,14,DC00312,Atezolizumab;Tivozanib,DrugComb,FD00038,Prostate Cancer,Prostate Cancer,Phase 1|Phase 2
920,TP00354,CD274;FLT1,CD274,FLT1,CET+CET,Tclin+Tclin,0.341,0.669,1.0,0,0,1,7,14,DC00312,Atezolizumab;Tivozanib,DrugComb,FD00043,Vulvar Cancer,Other Cancer,Phase 1|Phase 2
922,TP00354,CD274;FLT1,CD274,FLT1,CET+CET,Tclin+Tclin,0.341,0.669,1.0,0,0,1,7,14,DC00688,Cediranib;Durvalumab,DrugComb,FD00011,Colorectal Cancer,Colorectal Cancer,Phase 1|Phase 2
924,TP00354,CD274;FLT1,CD274,FLT1,CET+CET,Tclin+Tclin,0.341,0.669,1.0,0,0,1,7,14,DC00688,Cediranib;Durvalumab,DrugComb,FD00026,Melanoma,Melanoma,Phase 2
925,TP00354,CD274;FLT1,CD274,FLT1,CET+CET,Tclin+Tclin,0.341,0.669,1.0,0,0,1,7,14,DC02266,Sotiburafusp Alfa,BsAb,FD00033,Other Cancer,Other Cancer,Phase 1
926,TP00355,CD274;FLT3,CD274,FLT3,CET+CIT,Tclin+Tclin,0.35,0.648,1.0,0,0,1,1,1,DC00278,Atezolizumab;Gilteritinib,DrugComb,FD00021,Leukemia,Hematologic Malignancy,Phase 1|Phase 2
927,TP00356,CD274;FLT4,CD274,FLT4,CET+CET,Tclin+Tclin,0.355,0.605,1.0,0,0,1,6,13,DC00337,Avelumab;Axitinib,DrugComb,FD00017,Glioma,Glioma,Phase 2
928,TP00356,CD274;FLT4,CD274,FLT4,CET+CET,Tclin+Tclin,0.355,0.605,1.0,0,0,1,6,13,DC00337,Avelumab;Axitinib,DrugComb,FD00018,Head and Neck Cancer,Head and Neck Cancer,Phase 2
929,TP00356,CD274;FLT4,CD274,FLT4,CET+CET,Tclin+Tclin,0.355,0.605,1.0,0,0,1,6,13,DC00337,Avelumab;Axitinib,DrugComb,FD00020,Kidney Cancer,Kidney Cancer,Approval
930,TP00356,CD274;FLT4,CD274,FLT4,CET+CET,Tclin+Tclin,0.355,0.605,1.0,0,0,1,6,13,DC00337,Avelumab;Axitinib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 3
933,TP00356,CD274;FLT4,CD274,FLT4,CET+CET,Tclin+Tclin,0.355,0.605,1.0,0,0,1,6,13,DC00688,Cediranib;Durvalumab,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 1|Phase 2
934,TP00356,CD274;FLT4,CD274,FLT4,CET+CET,Tclin+Tclin,0.355,0.605,1.0,0,0,1,6,13,DC00688,Cediranib;Durvalumab,DrugComb,FD00011,Colorectal Cancer,Colorectal Cancer,Phase 1|Phase 2
936,TP00356,CD274;FLT4,CD274,FLT4,CET+CET,Tclin+Tclin,0.355,0.605,1.0,0,0,1,6,13,DC00688,Cediranib;Durvalumab,DrugComb,FD00026,Melanoma,Melanoma,Phase 2
938,TP00356,CD274;FLT4,CD274,FLT4,CET+CET,Tclin+Tclin,0.355,0.605,1.0,0,0,1,6,13,DC00312,Atezolizumab;Tivozanib,DrugComb,FD00022,Liver Cancer,Liver Cancer,Phase 1|Phase 2
939,TP00356,CD274;FLT4,CD274,FLT4,CET+CET,Tclin+Tclin,0.355,0.605,1.0,0,0,1,6,13,DC00312,Atezolizumab;Tivozanib,DrugComb,FD00032,Neuroendocrine Tumor,Other Cancer,Phase 1|Phase 2
940,TP00356,CD274;FLT4,CD274,FLT4,CET+CET,Tclin+Tclin,0.355,0.605,1.0,0,0,1,6,13,DC00312,Atezolizumab;Tivozanib,DrugComb,FD00034,Ovarian Cancer,Ovarian Cancer,Phase 1|Phase 2
941,TP00356,CD274;FLT4,CD274,FLT4,CET+CET,Tclin+Tclin,0.355,0.605,1.0,0,0,1,6,13,DC00312,Atezolizumab;Tivozanib,DrugComb,FD00035,Pancreatic Cancer,Pancreatic Cancer,Phase 1|Phase 2
942,TP00356,CD274;FLT4,CD274,FLT4,CET+CET,Tclin+Tclin,0.355,0.605,1.0,0,0,1,6,13,DC00312,Atezolizumab;Tivozanib,DrugComb,FD00038,Prostate Cancer,Prostate Cancer,Phase 1|Phase 2
943,TP00356,CD274;FLT4,CD274,FLT4,CET+CET,Tclin+Tclin,0.355,0.605,1.0,0,0,1,6,13,DC00312,Atezolizumab;Tivozanib,DrugComb,FD00043,Vulvar Cancer,Other Cancer,Phase 1|Phase 2
945,TP00357,CD274;FOXP3,CD274,FOXP3,CET+CET,Tbio+Tclin,0.495,0.505,1.0,0,0,0,1,1,DC00374,AZD8701;Durvalumab,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
946,TP00358,CD274;GEM,CD274,GEM,CET+CIT,Tbio+Tclin,0.389,0.601,1.0,0,0,0,1,1,DC00290,Atezolizumab;Lirilumab,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
947,TP00359,CD274;HAVCR2,CD274,HAVCR2,CET+CET,Tchem+Tclin,0.622,0.63,1.0,0,0,1,3,4,DC01459,LY3321367;Lodapolimab,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 1
948,TP00359,CD274;HAVCR2,CD274,HAVCR2,CET+CET,Tchem+Tclin,0.622,0.63,1.0,0,0,1,3,4,DC01459,LY3321367;Lodapolimab,DrugComb,FD00026,Melanoma,Melanoma,Phase 1
949,TP00359,CD274;HAVCR2,CD274,HAVCR2,CET+CET,Tchem+Tclin,0.622,0.63,1.0,0,0,1,3,4,DC01459,LY3321367;Lodapolimab,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
950,TP00359,CD274;HAVCR2,CD274,HAVCR2,CET+CET,Tchem+Tclin,0.622,0.63,1.0,0,0,1,3,4,DC01459,LY3321367;Lodapolimab,DrugComb,FD00035,Pancreatic Cancer,Pancreatic Cancer,Phase 1
953,TP00360,CD274;HDAC1,CD274,HDAC1,CET+CIT,Tclin+Tclin,0.295,0.492,1.0,0,1,0,2,2,DC01007,Envafolimab;Tucidinostat,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 2
954,TP00360,CD274;HDAC1,CD274,HDAC1,CET+CIT,Tclin+Tclin,0.295,0.492,1.0,0,1,0,2,2,DC00269,Atezolizumab;Entinostat,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 1|Phase 2
955,TP00361,CD274;HDAC10,CD274,HDAC10,CET+CIT,Tclin+Tclin,0.148,0.527,1.0,0,0,0,1,1,DC01007,Envafolimab;Tucidinostat,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 2
956,TP00362,CD274;HDAC2,CD274,HDAC2,CET+CIT,Tclin+Tclin,0.314,0.545,1.0,0,1,0,2,2,DC00269,Atezolizumab;Entinostat,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 1|Phase 2
957,TP00362,CD274;HDAC2,CD274,HDAC2,CET+CIT,Tclin+Tclin,0.314,0.545,1.0,0,1,0,2,2,DC01007,Envafolimab;Tucidinostat,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 2
958,TP00363,CD274;HDAC3,CD274,HDAC3,CET+CIT,Tclin+Tclin,0.263,0.613,1.0,0,1,0,2,2,DC00269,Atezolizumab;Entinostat,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 1|Phase 2
959,TP00363,CD274;HDAC3,CD274,HDAC3,CET+CIT,Tclin+Tclin,0.263,0.613,1.0,0,1,0,2,2,DC01007,Envafolimab;Tucidinostat,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 2
960,TP00364,CD274;HDAC8,CD274,HDAC8,CET+CIT,Tclin+Tclin,0.148,0.664,1.0,0,0,0,1,1,DC00269,Atezolizumab;Entinostat,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 1|Phase 2
961,TP00365,CD274;ICOS,CD274,ICOS,CET+CET,Tbio+Tclin,0.394,0.603,1.0,1,0,1,1,1,DC00143,Alomfilimab;Atezolizumab,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
962,TP00366,CD274;IDO1,CD274,IDO1,CET+CET,Tchem+Tclin,0.498,0.362,0.357,0,0,2,4,2,DC00271,Atezolizumab;Epacadostat,DrugComb,FD00006,Bladder Cancer,Bladder Cancer,Phase 1
963,TP00366,CD274;IDO1,CD274,IDO1,CET+CET,Tchem+Tclin,0.498,0.362,0.357,0,0,2,4,2,DC00271,Atezolizumab;Epacadostat,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
967,TP00367,CD274;IL15,CD274,IL15,CET+CET,Tchem+Tclin,0.484,0.591,1.0,0,0,0,3,1,DC00323,Atezolizumab;XmAb24306;XmAb24306,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
970,TP00368,CD274;IL15RA,CD274,IL15RA,CET+CET,Tbio+Tclin,0.261,0.655,1.0,0,0,0,4,2,DC00323,Atezolizumab;XmAb24306;XmAb24306,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
971,TP00368,CD274;IL15RA,CD274,IL15RA,CET+CET,Tbio+Tclin,0.261,0.655,1.0,0,0,0,4,2,DC00164,ALT803;Atezolizumab,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 2
974,TP00369,CD274;IL2RA,CD274,IL2RA,CET+CET,Tclin+Tclin,0.568,0.544,1.0,0,0,1,3,2,DC00264,Atezolizumab;Eciskafusp Alfa,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
975,TP00369,CD274;IL2RA,CD274,IL2RA,CET+CET,Tclin+Tclin,0.568,0.544,1.0,0,0,1,3,2,DC00307,Atezolizumab;Simlukafusp Alfa,DrugComb,FD00035,Pancreatic Cancer,Pancreatic Cancer,Phase 1|Phase 2
977,TP00370,CD274;IL2RB,CD274,IL2RB,CET+CET,Tclin+Tclin,0.36,0.653,1.0,0,0,1,4,4,DC00264,Atezolizumab;Eciskafusp Alfa,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
978,TP00370,CD274;IL2RB,CD274,IL2RB,CET+CET,Tclin+Tclin,0.36,0.653,1.0,0,0,1,4,4,DC00307,Atezolizumab;Simlukafusp Alfa,DrugComb,FD00035,Pancreatic Cancer,Pancreatic Cancer,Phase 1|Phase 2
979,TP00370,CD274;IL2RB,CD274,IL2RB,CET+CET,Tclin+Tclin,0.36,0.653,1.0,0,0,1,4,4,DC00339,Avelumab;Bempegaldesleukin,DrugComb,FD00006,Bladder Cancer,Bladder Cancer,Phase 2
980,TP00370,CD274;IL2RB,CD274,IL2RB,CET+CET,Tclin+Tclin,0.36,0.653,1.0,0,0,1,4,4,DC00245,Atezolizumab;Bempegaldesleukin,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
981,TP00371,CD274;IL2RG,CD274,IL2RG,CET+CIT,Tclin+Tclin,0.45,0.634,1.0,0,1,1,2,2,DC00264,Atezolizumab;Eciskafusp Alfa,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
982,TP00371,CD274;IL2RG,CD274,IL2RG,CET+CIT,Tclin+Tclin,0.45,0.634,1.0,0,1,1,2,2,DC00307,Atezolizumab;Simlukafusp Alfa,DrugComb,FD00035,Pancreatic Cancer,Pancreatic Cancer,Phase 1|Phase 2
983,TP00372,CD274;IL6R,CD274,IL6R,CET+CET,Tclin+Tclin,0.453,0.547,1.0,0,0,0,1,2,DC00313,Atezolizumab;Tocilizumab,DrugComb,FD00006,Bladder Cancer,Bladder Cancer,Phase 1|Phase 2
984,TP00372,CD274;IL6R,CD274,IL6R,CET+CET,Tclin+Tclin,0.453,0.547,1.0,0,0,0,1,2,DC00313,Atezolizumab;Tocilizumab,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
985,TP00373,CD274;IL7R,CD274,IL7R,CET+CIT,Tbio+Tclin,0.478,0.721,1.0,0,0,0,1,4,DC00265,Atezolizumab;Efineptakin Alfa,DrugComb,FD00012,Cutaneous Squamous Cell Carcinoma,Other Cancer,Phase 1|Phase 2
986,TP00373,CD274;IL7R,CD274,IL7R,CET+CIT,Tbio+Tclin,0.478,0.721,1.0,0,0,0,1,4,DC00265,Atezolizumab;Efineptakin Alfa,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 2
987,TP00373,CD274;IL7R,CD274,IL7R,CET+CIT,Tbio+Tclin,0.478,0.721,1.0,0,0,0,1,4,DC00265,Atezolizumab;Efineptakin Alfa,DrugComb,FD00026,Melanoma,Melanoma,Phase 1|Phase 2
988,TP00373,CD274;IL7R,CD274,IL7R,CET+CIT,Tbio+Tclin,0.478,0.721,1.0,0,0,0,1,4,DC00265,Atezolizumab;Efineptakin Alfa,DrugComb,FD00028,Merkel Cell Carcinoma,Other Cancer,Phase 1|Phase 2
989,TP00374,CD274;KDM1A,CD274,KDM1A,CET+CET,Tchem+Tclin,0.237,0.434,1.0,0,0,0,1,1,DC00253,Atezolizumab;Bomedemstat,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
990,TP00375,CD274;KDR,CD274,KDR,CET+CET,Tclin+Tclin,0.358,0.644,1.0,0,0,1,13,15,DC00322,Atezolizumab;Vorolanib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 2
993,TP00375,CD274;KDR,CD274,KDR,CET+CET,Tclin+Tclin,0.358,0.644,1.0,0,0,1,13,15,DC00337,Avelumab;Axitinib,DrugComb,FD00017,Glioma,Glioma,Phase 2
994,TP00375,CD274;KDR,CD274,KDR,CET+CET,Tclin+Tclin,0.358,0.644,1.0,0,0,1,13,15,DC00337,Avelumab;Axitinib,DrugComb,FD00018,Head and Neck Cancer,Head and Neck Cancer,Phase 2
995,TP00375,CD274;KDR,CD274,KDR,CET+CET,Tclin+Tclin,0.358,0.644,1.0,0,0,1,13,15,DC00337,Avelumab;Axitinib,DrugComb,FD00020,Kidney Cancer,Kidney Cancer,Approval
998,TP00375,CD274;KDR,CD274,KDR,CET+CET,Tclin+Tclin,0.358,0.644,1.0,0,0,1,13,15,DC00942,Durvalumab;Ramucirumab,DrugComb,FD00022,Liver Cancer,Liver Cancer,Phase 1
1000,TP00375,CD274;KDR,CD274,KDR,CET+CET,Tclin+Tclin,0.358,0.644,1.0,0,0,1,13,15,DC00942,Durvalumab;Ramucirumab,DrugComb,FD00041,Stomach Cancer,Stomach Cancer,Phase 1
1001,TP00375,CD274;KDR,CD274,KDR,CET+CET,Tclin+Tclin,0.358,0.644,1.0,0,0,1,13,15,DC00312,Atezolizumab;Tivozanib,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 1|Phase 2
1003,TP00375,CD274;KDR,CD274,KDR,CET+CET,Tclin+Tclin,0.358,0.644,1.0,0,0,1,13,15,DC00312,Atezolizumab;Tivozanib,DrugComb,FD00032,Neuroendocrine Tumor,Other Cancer,Phase 1|Phase 2
1004,TP00375,CD274;KDR,CD274,KDR,CET+CET,Tclin+Tclin,0.358,0.644,1.0,0,0,1,13,15,DC00312,Atezolizumab;Tivozanib,DrugComb,FD00034,Ovarian Cancer,Ovarian Cancer,Phase 1|Phase 2
1005,TP00375,CD274;KDR,CD274,KDR,CET+CET,Tclin+Tclin,0.358,0.644,1.0,0,0,1,13,15,DC00312,Atezolizumab;Tivozanib,DrugComb,FD00035,Pancreatic Cancer,Pancreatic Cancer,Phase 1|Phase 2
1006,TP00375,CD274;KDR,CD274,KDR,CET+CET,Tclin+Tclin,0.358,0.644,1.0,0,0,1,13,15,DC00312,Atezolizumab;Tivozanib,DrugComb,FD00038,Prostate Cancer,Prostate Cancer,Phase 1|Phase 2
1007,TP00375,CD274;KDR,CD274,KDR,CET+CET,Tclin+Tclin,0.358,0.644,1.0,0,0,1,13,15,DC00312,Atezolizumab;Tivozanib,DrugComb,FD00043,Vulvar Cancer,Other Cancer,Phase 1|Phase 2
1010,TP00375,CD274;KDR,CD274,KDR,CET+CET,Tclin+Tclin,0.358,0.644,1.0,0,0,1,13,15,DC00688,Cediranib;Durvalumab,DrugComb,FD00011,Colorectal Cancer,Colorectal Cancer,Phase 1|Phase 2
1012,TP00375,CD274;KDR,CD274,KDR,CET+CET,Tclin+Tclin,0.358,0.644,1.0,0,0,1,13,15,DC00688,Cediranib;Durvalumab,DrugComb,FD00026,Melanoma,Melanoma,Phase 2
1018,TP00375,CD274;KDR,CD274,KDR,CET+CET,Tclin+Tclin,0.358,0.644,1.0,0,0,1,13,15,DC00343,Avelumab;Lenvatinib,DrugComb,FD00008,Central Nervous System Tumor,Other Cancer,Phase 1
1019,TP00376,CD274;KLRC1,CD274,KLRC1,CET+CET,Tbio+Tclin,0.37,0.545,1.0,0,0,0,1,1,DC00932,Durvalumab;Monalizumab,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 3
1020,TP00377,CD274;KRAS,CD274,KRAS,CET+CIT,Tclin+Tclin,0.331,0.516,1.0,1,0,0,3,1,DC00262,Atezolizumab;Divarasib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
1023,TP00378,CD274;LAG3,CD274,LAG3,CET+CET,Tclin+Tclin,0.532,0.661,1.0,0,0,0,3,3,DC02000,ABL501,BsAb,FD00033,Other Cancer,Other Cancer,Phase 1
1024,TP00378,CD274;LAG3,CD274,LAG3,CET+CET,Tclin+Tclin,0.532,0.661,1.0,0,0,0,3,3,DC02133,IBI323,BsAb,FD00023,Lung Cancer,Lung Cancer,Phase 2
1026,TP00378,CD274;LAG3,CD274,LAG3,CET+CET,Tclin+Tclin,0.532,0.661,1.0,0,0,0,3,3,DC02108,FS118,BsAb,FD00018,Head and Neck Cancer,Head and Neck Cancer,Phase 1|Phase 2
1027,TP00379,CD274;LGALS3,CD274,LGALS3,CET+CIT,Tchem+Tclin,0.399,0.64,1.0,0,0,1,1,1,DC00277,Atezolizumab;GB1211,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
1028,TP00380,CD274;MAP2K1,CD274,MAP2K1,CET+CIT,Tclin+Tclin,0.33,0.611,1.0,1,0,1,4,11,DC00546,Bintrafusp Alfa;Pimasertib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
1029,TP00380,CD274;MAP2K1,CD274,MAP2K1,CET+CIT,Tclin+Tclin,0.33,0.611,1.0,1,0,1,4,11,DC00258,Atezolizumab;Cobimetinib,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 2
1030,TP00380,CD274;MAP2K1,CD274,MAP2K1,CET+CIT,Tclin+Tclin,0.33,0.611,1.0,1,0,1,4,11,DC00258,Atezolizumab;Cobimetinib,DrugComb,FD00011,Colorectal Cancer,Colorectal Cancer,Phase 3
1031,TP00380,CD274;MAP2K1,CD274,MAP2K1,CET+CIT,Tclin+Tclin,0.33,0.611,1.0,1,0,1,4,11,DC00258,Atezolizumab;Cobimetinib,DrugComb,FD00014,Esophageal Cancer,Esophageal Cancer,Phase 1|Phase 2
1033,TP00380,CD274;MAP2K1,CD274,MAP2K1,CET+CIT,Tclin+Tclin,0.33,0.611,1.0,1,0,1,4,11,DC00258,Atezolizumab;Cobimetinib,DrugComb,FD00035,Pancreatic Cancer,Pancreatic Cancer,Phase 1|Phase 2
1034,TP00380,CD274;MAP2K1,CD274,MAP2K1,CET+CIT,Tclin+Tclin,0.33,0.611,1.0,1,0,1,4,11,DC00258,Atezolizumab;Cobimetinib,DrugComb,FD00040,Soft Tissue Sarcoma,Other Cancer,Phase 1|Phase 2
1035,TP00380,CD274;MAP2K1,CD274,MAP2K1,CET+CIT,Tclin+Tclin,0.33,0.611,1.0,1,0,1,4,11,DC00258,Atezolizumab;Cobimetinib,DrugComb,FD00041,Stomach Cancer,Stomach Cancer,Phase 1|Phase 2
1036,TP00380,CD274;MAP2K1,CD274,MAP2K1,CET+CIT,Tclin+Tclin,0.33,0.611,1.0,1,0,1,4,11,DC00944,Durvalumab;Selumetinib,DrugComb,FD00006,Bladder Cancer,Bladder Cancer,Phase 1
1039,TP00380,CD274;MAP2K1,CD274,MAP2K1,CET+CIT,Tclin+Tclin,0.33,0.611,1.0,1,0,1,4,11,DC00944,Durvalumab;Selumetinib,DrugComb,FD00018,Head and Neck Cancer,Head and Neck Cancer,Phase 1
1040,TP00380,CD274;MAP2K1,CD274,MAP2K1,CET+CIT,Tclin+Tclin,0.33,0.611,1.0,1,0,1,4,11,DC00944,Durvalumab;Selumetinib,DrugComb,FD00022,Liver Cancer,Liver Cancer,Phase 1
1042,TP00380,CD274;MAP2K1,CD274,MAP2K1,CET+CIT,Tclin+Tclin,0.33,0.611,1.0,1,0,1,4,11,DC00944,Durvalumab;Selumetinib,DrugComb,FD00026,Melanoma,Melanoma,Phase 1
1046,TP00381,CD274;MAP2K2,CD274,MAP2K2,CET+CIT,Tclin+Tclin,0.282,0.526,1.0,1,0,1,3,9,DC00546,Bintrafusp Alfa;Pimasertib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
1047,TP00381,CD274;MAP2K2,CD274,MAP2K2,CET+CIT,Tclin+Tclin,0.282,0.526,1.0,1,0,1,3,9,DC00944,Durvalumab;Selumetinib,DrugComb,FD00006,Bladder Cancer,Bladder Cancer,Phase 1
1048,TP00381,CD274;MAP2K2,CD274,MAP2K2,CET+CIT,Tclin+Tclin,0.282,0.526,1.0,1,0,1,3,9,DC00944,Durvalumab;Selumetinib,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 1
1049,TP00381,CD274;MAP2K2,CD274,MAP2K2,CET+CIT,Tclin+Tclin,0.282,0.526,1.0,1,0,1,3,9,DC00944,Durvalumab;Selumetinib,DrugComb,FD00011,Colorectal Cancer,Colorectal Cancer,Phase 1
1050,TP00381,CD274;MAP2K2,CD274,MAP2K2,CET+CIT,Tclin+Tclin,0.282,0.526,1.0,1,0,1,3,9,DC00944,Durvalumab;Selumetinib,DrugComb,FD00018,Head and Neck Cancer,Head and Neck Cancer,Phase 1
1051,TP00381,CD274;MAP2K2,CD274,MAP2K2,CET+CIT,Tclin+Tclin,0.282,0.526,1.0,1,0,1,3,9,DC00944,Durvalumab;Selumetinib,DrugComb,FD00022,Liver Cancer,Liver Cancer,Phase 1
1053,TP00381,CD274;MAP2K2,CD274,MAP2K2,CET+CIT,Tclin+Tclin,0.282,0.526,1.0,1,0,1,3,9,DC00944,Durvalumab;Selumetinib,DrugComb,FD00026,Melanoma,Melanoma,Phase 1
1054,TP00381,CD274;MAP2K2,CD274,MAP2K2,CET+CIT,Tclin+Tclin,0.282,0.526,1.0,1,0,1,3,9,DC00944,Durvalumab;Selumetinib,DrugComb,FD00035,Pancreatic Cancer,Pancreatic Cancer,Phase 1
1055,TP00381,CD274;MAP2K2,CD274,MAP2K2,CET+CIT,Tclin+Tclin,0.282,0.526,1.0,1,0,1,3,9,DC00944,Durvalumab;Selumetinib,DrugComb,FD00041,Stomach Cancer,Stomach Cancer,Phase 1
1057,TP00382,CD274;MDM2,CD274,MDM2,CET+CIT,Tchem+Tclin,0.251,0.613,1.0,0,0,1,2,3,DC00280,Atezolizumab;Idasanutlin,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 1|Phase 2
1058,TP00382,CD274;MDM2,CD274,MDM2,CET+CIT,Tchem+Tclin,0.251,0.613,1.0,0,0,1,2,3,DC00280,Atezolizumab;Idasanutlin,DrugComb,FD00011,Colorectal Cancer,Colorectal Cancer,Phase 1|Phase 2
1059,TP00382,CD274;MDM2,CD274,MDM2,CET+CIT,Tchem+Tclin,0.251,0.613,1.0,0,0,1,2,3,DC00347,Avelumab;Navtemadlin,DrugComb,FD00028,Merkel Cell Carcinoma,Other Cancer,Phase 1|Phase 2
1060,TP00383,CD274;MET,CD274,MET,CET+CIT,Tclin+Tclin,0.349,0.579,1.0,0,0,1,4,5,DC00341,Avelumab;Crizotinib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
1061,TP00383,CD274;MET,CD274,MET,CET+CIT,Tclin+Tclin,0.349,0.579,1.0,0,0,1,4,5,DC01444,Lodapolimab;Merestinib,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 1
1062,TP00383,CD274;MET,CD274,MET,CET+CIT,Tclin+Tclin,0.349,0.579,1.0,0,0,1,4,5,DC01444,Lodapolimab;Merestinib,DrugComb,FD00026,Melanoma,Melanoma,Phase 1
1063,TP00383,CD274;MET,CD274,MET,CET+CIT,Tclin+Tclin,0.349,0.579,1.0,0,0,1,4,5,DC01444,Lodapolimab;Merestinib,DrugComb,FD00035,Pancreatic Cancer,Pancreatic Cancer,Phase 1
1065,TP00383,CD274;MET,CD274,MET,CET+CIT,Tclin+Tclin,0.349,0.579,1.0,0,0,1,4,5,DC00943,Durvalumab;Savolitinib,DrugComb,FD00041,Stomach Cancer,Stomach Cancer,Phase 2
1067,TP00384,CD274;MKNK1,CD274,MKNK1,CET+CIT,Tchem+Tclin,0.241,0.489,1.0,0,0,1,1,1,DC00352,Avelumab;Tomivosertib,DrugComb,FD00011,Colorectal Cancer,Colorectal Cancer,Phase 2
1068,TP00385,CD274;MKNK2,CD274,MKNK2,CET+CIT,Tchem+Tclin,0.308,0.561,1.0,0,0,1,1,1,DC00352,Avelumab;Tomivosertib,DrugComb,FD00011,Colorectal Cancer,Colorectal Cancer,Phase 2
1069,TP00386,CD274;MS4A1,CD274,MS4A1,CET+CIT,Tclin+Tclin,0.383,0.747,1.0,0,0,0,1,1,DC00295,Atezolizumab;Obinutuzumab,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 1
1070,TP00387,CD274;MSLN,CD274,MSLN,CET+CIT,Tbio+Tclin,0.166,0.619,1.0,0,0,0,1,1,DC00203,Anetumab Ravtansine;Atezolizumab,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
1071,TP00388,CD274;MTOR,CD274,MTOR,CET+CIT,Tclin+Tclin,0.296,0.488,1.0,1,0,1,1,2,DC00953,Durvalumab;Vistusertib,DrugComb,FD00006,Bladder Cancer,Bladder Cancer,Phase 1
1072,TP00388,CD274;MTOR,CD274,MTOR,CET+CIT,Tclin+Tclin,0.296,0.488,1.0,1,0,1,1,2,DC00953,Durvalumab;Vistusertib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 2
1073,TP00389,CD274;NECTIN4,CD274,NECTIN4,CET+CIT,Tclin+Tclin,0.097,0.659,1.0,0,0,0,2,1,DC00268,Atezolizumab;Enfortumab Vedotin,DrugComb,FD00006,Bladder Cancer,Bladder Cancer,Phase 1|Phase 2
1075,TP00390,CD274;NR1H2,CD274,NR1H2,CET+CIT,Tchem+Tclin,0.302,0.511,1.0,0,0,0,1,1,DC00040,Abequolixron;Durvalumab,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
1076,TP00391,CD274;NT5E,CD274,NT5E,CET+CIT,Tchem+Tclin,0.158,0.744,1.0,0,0,1,2,4,DC00935,Durvalumab;Oleclumab,DrugComb,FD00006,Bladder Cancer,Bladder Cancer,Phase 1
1077,TP00391,CD274;NT5E,CD274,NT5E,CET+CIT,Tchem+Tclin,0.158,0.744,1.0,0,0,1,2,4,DC00935,Durvalumab;Oleclumab,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 3
1079,TP00391,CD274;NT5E,CD274,NT5E,CET+CIT,Tchem+Tclin,0.158,0.744,1.0,0,0,1,2,4,DC00316,Atezolizumab;Uliledlimab,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
1080,TP00391,CD274;NT5E,CD274,NT5E,CET+CIT,Tchem+Tclin,0.158,0.744,1.0,0,0,1,2,4,DC00316,Atezolizumab;Uliledlimab,DrugComb,FD00034,Ovarian Cancer,Ovarian Cancer,Phase 2
1081,TP00392,CD274;PARP1,CD274,PARP1,CET+CIT,Tclin+Tclin,0.265,0.562,1.0,0,0,0,6,6,DC01197,Fuzuloparib;Retlirafusp Alfa,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 2
1082,TP00392,CD274;PARP1,CD274,PARP1,CET+CIT,Tclin+Tclin,0.265,0.562,1.0,0,0,0,6,6,DC00351,Avelumab;Talazoparib,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 1|Phase 2
1084,TP00392,CD274;PARP1,CD274,PARP1,CET+CIT,Tclin+Tclin,0.265,0.562,1.0,0,0,0,6,6,DC00351,Avelumab;Talazoparib,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 2
1085,TP00392,CD274;PARP1,CD274,PARP1,CET+CIT,Tclin+Tclin,0.265,0.562,1.0,0,0,0,6,6,DC00934,Durvalumab;Olaparib,DrugComb,FD00006,Bladder Cancer,Bladder Cancer,Phase 2
1087,TP00392,CD274;PARP1,CD274,PARP1,CET+CIT,Tclin+Tclin,0.265,0.562,1.0,0,0,0,6,6,DC00934,Durvalumab;Olaparib,DrugComb,FD00011,Colorectal Cancer,Colorectal Cancer,Phase 1|Phase 2
1089,TP00392,CD274;PARP1,CD274,PARP1,CET+CIT,Tclin+Tclin,0.265,0.562,1.0,0,0,0,6,6,DC00934,Durvalumab;Olaparib,DrugComb,FD00034,Ovarian Cancer,Ovarian Cancer,Phase 2
1094,TP00393,CD274;PARP2,CD274,PARP2,CET+CIT,Tclin+Tclin,0.205,0.517,1.0,0,0,0,5,6,DC01197,Fuzuloparib;Retlirafusp Alfa,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 2
1096,TP00393,CD274;PARP2,CD274,PARP2,CET+CIT,Tclin+Tclin,0.205,0.517,1.0,0,0,0,5,6,DC00351,Avelumab;Talazoparib,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 1|Phase 2
1098,TP00393,CD274;PARP2,CD274,PARP2,CET+CIT,Tclin+Tclin,0.205,0.517,1.0,0,0,0,5,6,DC00351,Avelumab;Talazoparib,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 2
1099,TP00393,CD274;PARP2,CD274,PARP2,CET+CIT,Tclin+Tclin,0.205,0.517,1.0,0,0,0,5,6,DC00934,Durvalumab;Olaparib,DrugComb,FD00006,Bladder Cancer,Bladder Cancer,Phase 2
1101,TP00393,CD274;PARP2,CD274,PARP2,CET+CIT,Tclin+Tclin,0.205,0.517,1.0,0,0,0,5,6,DC00934,Durvalumab;Olaparib,DrugComb,FD00011,Colorectal Cancer,Colorectal Cancer,Phase 1|Phase 2
1103,TP00393,CD274;PARP2,CD274,PARP2,CET+CIT,Tclin+Tclin,0.205,0.517,1.0,0,0,0,5,6,DC00934,Durvalumab;Olaparib,DrugComb,FD00034,Ovarian Cancer,Ovarian Cancer,Phase 2
1105,TP00394,CD274;PCSK9,CD274,PCSK9,CET+CET,Tclin+Tclin,0.263,0.55,1.0,0,0,0,1,1,DC00274,Atezolizumab;Evolocumab,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
1106,TP00395,CD274;PDCD1,CD274,PDCD1,CET+CET,Tclin+Tclin,0.389,0.641,1.0,2,1,3,8,5,DC00067,Acasunlimab;Pembrolizumab,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 2
1107,TP00395,CD274;PDCD1,CD274,PDCD1,CET+CET,Tclin+Tclin,0.389,0.641,1.0,2,1,3,8,5,DC00264,Atezolizumab;Eciskafusp Alfa,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
1112,TP00395,CD274;PDCD1,CD274,PDCD1,CET+CET,Tclin+Tclin,0.389,0.641,1.0,2,1,3,8,5,DC02130,IBI318,BsAb,FD00012,Cutaneous Squamous Cell Carcinoma,Other Cancer,Phase 1|Phase 2
1113,TP00395,CD274;PDCD1,CD274,PDCD1,CET+CET,Tclin+Tclin,0.389,0.641,1.0,2,1,3,8,5,DC02130,IBI318,BsAb,FD00022,Liver Cancer,Liver Cancer,Phase 1
1115,TP00395,CD274;PDCD1,CD274,PDCD1,CET+CET,Tclin+Tclin,0.389,0.641,1.0,2,1,3,8,5,DC02130,IBI318,BsAb,FD00024,Lymphoma,Hematologic Malignancy,Phase 1|Phase 2
1118,TP00396,CD274;PDGFRA,CD274,PDGFRA,CET+CIT,Tclin+Tclin,0.308,0.594,1.0,0,0,1,1,1,DC00322,Atezolizumab;Vorolanib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 2
1119,TP00397,CD274;PDGFRB,CD274,PDGFRB,CET+CIT,Tclin+Tclin,0.354,0.604,1.0,0,0,1,3,4,DC00322,Atezolizumab;Vorolanib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 2
1120,TP00397,CD274;PDGFRB,CD274,PDGFRB,CET+CIT,Tclin+Tclin,0.354,0.604,1.0,0,0,1,3,4,DC00337,Avelumab;Axitinib,DrugComb,FD00017,Glioma,Glioma,Phase 2
1121,TP00397,CD274;PDGFRB,CD274,PDGFRB,CET+CIT,Tclin+Tclin,0.354,0.604,1.0,0,0,1,3,4,DC00337,Avelumab;Axitinib,DrugComb,FD00018,Head and Neck Cancer,Head and Neck Cancer,Phase 2
1122,TP00397,CD274;PDGFRB,CD274,PDGFRB,CET+CIT,Tclin+Tclin,0.354,0.604,1.0,0,0,1,3,4,DC00337,Avelumab;Axitinib,DrugComb,FD00020,Kidney Cancer,Kidney Cancer,Approval
1125,TP00398,CD274;PLK4,CD274,PLK4,CET+CIT,Tchem+Tclin,0.142,0.534,1.0,0,0,0,1,1,DC00933,Durvalumab;Ocifisertib,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 2
1126,TP00399,CD274;PMEL,CD274,PMEL,CET+CIT,Tclin+Tclin,0.077,0.599,1.0,0,0,0,1,1,DC00946,Durvalumab;Tebentafusp,DrugComb,FD00026,Melanoma,Melanoma,Phase 1|Phase 2
1127,TP00400,CD274;PRKDC,CD274,PRKDC,CET+CIT,Tchem+Tclin,0.266,0.474,1.0,0,0,0,1,1,DC00349,Avelumab;Peposertib,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
1128,TP00401,CD274;PTGER4,CD274,PTGER4,CET+CIT,Tclin+Tclin,0.476,0.576,1.0,0,0,0,1,1,DC00285,Atezolizumab;KF0210,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
1129,TP00402,CD274;ROR2,CD274,ROR2,CET+CIT,Tbio+Tclin,0.371,0.499,1.0,0,0,1,1,1,DC00938,Durvalumab;Ozuriftamab Vedotin,DrugComb,FD00034,Ovarian Cancer,Ovarian Cancer,Phase 2
1130,TP00403,CD274;ROS1,CD274,ROS1,CET+CIT,Tclin+Tclin,0.255,0.442,1.0,0,0,0,1,1,DC00344,Avelumab;Lorlatinib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
1131,TP00404,CD274;SEMA4D,CD274,SEMA4D,CET+CIT,Tbio+Tclin,0.38,0.562,1.0,0,0,0,1,1,DC00348,Avelumab;Pepinemab,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
1132,TP00405,CD274;SLC39A6,CD274,SLC39A6,CET+CIT,Tbio+Tclin,0.074,0.584,0.1,0,0,0,1,1,DC00286,Atezolizumab;Ladiratuzumab Vedotin,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 1|Phase 2
1133,TP00406,CD274;SMO,CD274,SMO,CET+CIT,Tclin+Tclin,0.289,0.636,1.0,0,0,0,1,1,DC00319,Atezolizumab;Vismodegib,DrugComb,FD00034,Ovarian Cancer,Ovarian Cancer,Phase 2
1134,TP00407,CD274;STAT3,CD274,STAT3,CET+CIT,Tchem+Tclin,0.419,0.596,1.0,1,1,2,1,2,DC00844,Danvatirsen;Durvalumab,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 2
1135,TP00407,CD274;STAT3,CD274,STAT3,CET+CIT,Tchem+Tclin,0.419,0.596,1.0,1,1,2,1,2,DC00844,Danvatirsen;Durvalumab,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
1136,TP00408,CD274;STING1,CD274,STING1,CET+CET,Tchem+Tclin,0.302,0.571,1.0,0,0,0,1,2,DC00305,Atezolizumab;SB11285,DrugComb,FD00018,Head and Neck Cancer,Head and Neck Cancer,Phase 1
1137,TP00408,CD274;STING1,CD274,STING1,CET+CET,Tchem+Tclin,0.302,0.571,1.0,0,0,0,1,2,DC00305,Atezolizumab;SB11285,DrugComb,FD00026,Melanoma,Melanoma,Phase 1
1138,TP00409,CD274;TACSTD2,CD274,TACSTD2,CET+CIT,Tclin+Tclin,0.289,0.693,1.0,0,0,0,3,1,DC00864,Datopotamab Deruxtecan;Durvalumab,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
1141,TP00410,CD274;TGFB1,CD274,TGFB1,CET+CET,Tbio+Tclin,0.361,0.544,1.0,0,0,3,9,13,DC00300,Atezolizumab;RO7496353,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
1142,TP00410,CD274;TGFB1,CD274,TGFB1,CET+CET,Tbio+Tclin,0.361,0.544,1.0,0,0,3,9,13,DC02044,Bintrafusp Alfa,BsAb,FD00006,Bladder Cancer,Bladder Cancer,Phase 2
1143,TP00410,CD274;TGFB1,CD274,TGFB1,CET+CET,Tbio+Tclin,0.361,0.544,1.0,0,0,3,9,13,DC02044,Bintrafusp Alfa,BsAb,FD00007,Breast Cancer,Breast Cancer,Phase 2
1144,TP00410,CD274;TGFB1,CD274,TGFB1,CET+CET,Tbio+Tclin,0.361,0.544,1.0,0,0,3,9,13,DC02044,Bintrafusp Alfa,BsAb,FD00011,Colorectal Cancer,Colorectal Cancer,Phase 1|Phase 2
1145,TP00410,CD274;TGFB1,CD274,TGFB1,CET+CET,Tbio+Tclin,0.361,0.544,1.0,0,0,3,9,13,DC02044,Bintrafusp Alfa,BsAb,FD00018,Head and Neck Cancer,Head and Neck Cancer,Phase 2
1146,TP00410,CD274;TGFB1,CD274,TGFB1,CET+CET,Tbio+Tclin,0.361,0.544,1.0,0,0,3,9,13,DC02044,Bintrafusp Alfa,BsAb,FD00022,Liver Cancer,Liver Cancer,Phase 2|Phase 3
1148,TP00410,CD274;TGFB1,CD274,TGFB1,CET+CET,Tbio+Tclin,0.361,0.544,1.0,0,0,3,9,13,DC02044,Bintrafusp Alfa,BsAb,FD00031,Neuroblastoma,Other Cancer,Phase 2
1149,TP00410,CD274;TGFB1,CD274,TGFB1,CET+CET,Tbio+Tclin,0.361,0.544,1.0,0,0,3,9,13,DC02044,Bintrafusp Alfa,BsAb,FD00033,Other Cancer,Other Cancer,Phase 2
1150,TP00410,CD274;TGFB1,CD274,TGFB1,CET+CET,Tbio+Tclin,0.361,0.544,1.0,0,0,3,9,13,DC02044,Bintrafusp Alfa,BsAb,FD00034,Ovarian Cancer,Ovarian Cancer,Phase 2
1151,TP00410,CD274;TGFB1,CD274,TGFB1,CET+CET,Tbio+Tclin,0.361,0.544,1.0,0,0,3,9,13,DC02044,Bintrafusp Alfa,BsAb,FD00035,Pancreatic Cancer,Pancreatic Cancer,Phase 1|Phase 2
1152,TP00410,CD274;TGFB1,CD274,TGFB1,CET+CET,Tbio+Tclin,0.361,0.544,1.0,0,0,3,9,13,DC02044,Bintrafusp Alfa,BsAb,FD00040,Soft Tissue Sarcoma,Other Cancer,Phase 2
1153,TP00410,CD274;TGFB1,CD274,TGFB1,CET+CET,Tbio+Tclin,0.361,0.544,1.0,0,0,3,9,13,DC02044,Bintrafusp Alfa,BsAb,FD00041,Stomach Cancer,Stomach Cancer,Phase 1|Phase 2
1154,TP00410,CD274;TGFB1,CD274,TGFB1,CET+CET,Tbio+Tclin,0.361,0.544,1.0,0,0,3,9,13,DC02044,Bintrafusp Alfa,BsAb,FD00042,Thymic Carcinoma,Other Cancer,Phase 2
1165,TP00411,CD274;TGFB2,CD274,TGFB2,CET+CET,Tbio+Tclin,0.291,0.373,1.0,0,0,2,1,1,DC00314,Atezolizumab;Trabedersen,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 2
1166,TP00412,CD274;TGFBR1,CD274,TGFBR1,CET+CIT,Tchem+Tclin,0.314,0.559,1.0,0,0,0,4,3,DC01457,LY3200882;Lodapolimab,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
1167,TP00412,CD274;TGFBR1,CD274,TGFBR1,CET+CIT,Tchem+Tclin,0.314,0.559,1.0,0,0,0,4,3,DC00921,Durvalumab;Galunisertib,DrugComb,FD00035,Pancreatic Cancer,Pancreatic Cancer,Phase 1
1168,TP00412,CD274;TGFBR1,CD274,TGFBR1,CET+CIT,Tchem+Tclin,0.314,0.559,1.0,0,0,0,4,3,DC00952,Durvalumab;Vactosertib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
1170,TP00413,CD274;TGFBR2,CD274,TGFBR2,CET+CIT,Tchem+Tclin,0.329,0.601,1.0,0,0,1,1,2,DC02045,BJ005,BsAb,FD00024,Lymphoma,Hematologic Malignancy,Phase 1
1171,TP00413,CD274;TGFBR2,CD274,TGFBR2,CET+CIT,Tchem+Tclin,0.329,0.601,1.0,0,0,1,1,2,DC02045,BJ005,BsAb,FD00033,Other Cancer,Other Cancer,Phase 1
1172,TP00414,CD274;TIGIT,CD274,TIGIT,CET+CET,Tbio+Tclin,0.462,0.591,1.0,1,0,1,4,9,DC00311,Atezolizumab;Tiragolumab,DrugComb,FD00006,Bladder Cancer,Bladder Cancer,Phase 1|Phase 2
1173,TP00414,CD274;TIGIT,CD274,TIGIT,CET+CET,Tbio+Tclin,0.462,0.591,1.0,1,0,1,4,9,DC00311,Atezolizumab;Tiragolumab,DrugComb,FD00011,Colorectal Cancer,Colorectal Cancer,Phase 1
1174,TP00414,CD274;TIGIT,CD274,TIGIT,CET+CET,Tbio+Tclin,0.462,0.591,1.0,1,0,1,4,9,DC00311,Atezolizumab;Tiragolumab,DrugComb,FD00014,Esophageal Cancer,Esophageal Cancer,Phase 1|Phase 2
1175,TP00414,CD274;TIGIT,CD274,TIGIT,CET+CET,Tbio+Tclin,0.462,0.591,1.0,1,0,1,4,9,DC00311,Atezolizumab;Tiragolumab,DrugComb,FD00018,Head and Neck Cancer,Head and Neck Cancer,Phase 2
1176,TP00414,CD274;TIGIT,CD274,TIGIT,CET+CET,Tbio+Tclin,0.462,0.591,1.0,1,0,1,4,9,DC00311,Atezolizumab;Tiragolumab,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 3
1177,TP00414,CD274;TIGIT,CD274,TIGIT,CET+CET,Tbio+Tclin,0.462,0.591,1.0,1,0,1,4,9,DC00311,Atezolizumab;Tiragolumab,DrugComb,FD00026,Melanoma,Melanoma,Phase 2
1178,TP00414,CD274;TIGIT,CD274,TIGIT,CET+CET,Tbio+Tclin,0.462,0.591,1.0,1,0,1,4,9,DC00311,Atezolizumab;Tiragolumab,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 2
1179,TP00414,CD274;TIGIT,CD274,TIGIT,CET+CET,Tbio+Tclin,0.462,0.591,1.0,1,0,1,4,9,DC00311,Atezolizumab;Tiragolumab,DrugComb,FD00041,Stomach Cancer,Stomach Cancer,Phase 1|Phase 2
1182,TP00414,CD274;TIGIT,CD274,TIGIT,CET+CET,Tbio+Tclin,0.462,0.591,1.0,1,0,1,4,9,DC02127,HLX301,BsAb,FD00024,Lymphoma,Hematologic Malignancy,Phase 1|Phase 2
1185,TP00415,CD274;TLR7,CD274,TLR7,CET+CET,Tclin+Tclin,0.431,0.628,1.0,0,0,1,2,2,DC00947,Durvalumab;Telratolimod,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 1
1186,TP00415,CD274;TLR7,CD274,TLR7,CET+CET,Tclin+Tclin,0.431,0.628,1.0,0,0,1,2,2,DC00244,Atezolizumab;BDB001,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
1187,TP00416,CD274;TLR8,CD274,TLR8,CET+CET,Tchem+Tclin,0.476,0.732,0.325,0,0,1,2,2,DC00244,Atezolizumab;BDB001,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
1188,TP00416,CD274;TLR8,CD274,TLR8,CET+CET,Tchem+Tclin,0.476,0.732,0.325,0,0,1,2,2,DC00947,Durvalumab;Telratolimod,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 1
1189,TP00417,CD274;TLR9,CD274,TLR9,CET+CIT,Tclin+Tclin,0.522,0.645,0.576,1,0,0,1,1,DC00318,Atezolizumab;Vidutolimod,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
1190,TP00418,CD274;TNFRSF4,CD274,TNFRSF4,CET+CET,Tchem+Tclin,0.404,0.595,1.0,0,0,1,2,1,DC02091,EMB09,BsAb,FD00033,Other Cancer,Other Cancer,Phase 1
1192,TP00419,CD274;TNFRSF9,CD274,TNFRSF9,CET+CET,Tbio+Tclin,0.245,0.58,1.0,0,0,1,12,11,DC00263,Atezolizumab;DSP107,DrugComb,FD00011,Colorectal Cancer,Colorectal Cancer,Phase 1|Phase 2
1193,TP00419,CD274;TNFRSF9,CD274,TNFRSF9,CET+CET,Tbio+Tclin,0.245,0.58,1.0,0,0,1,12,11,DC00263,Atezolizumab;DSP107,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
1194,TP00419,CD274;TNFRSF9,CD274,TNFRSF9,CET+CET,Tbio+Tclin,0.245,0.58,1.0,0,0,1,12,11,DC02187,MCLA145,BsAb,FD00019,Hematologic Malignancies,Hematologic Malignancy,Phase 1
1195,TP00419,CD274;TNFRSF9,CD274,TNFRSF9,CET+CET,Tbio+Tclin,0.245,0.58,1.0,0,0,1,12,11,DC02187,MCLA145,BsAb,FD00033,Other Cancer,Other Cancer,Phase 1
1197,TP00419,CD274;TNFRSF9,CD274,TNFRSF9,CET+CET,Tbio+Tclin,0.245,0.58,1.0,0,0,1,12,11,DC02003,Acasunlimab,BsAb,FD00006,Bladder Cancer,Bladder Cancer,Phase 1|Phase 2
1198,TP00419,CD274;TNFRSF9,CD274,TNFRSF9,CET+CET,Tbio+Tclin,0.245,0.58,1.0,0,0,1,12,11,DC02003,Acasunlimab,BsAb,FD00007,Breast Cancer,Breast Cancer,Phase 1|Phase 2
1199,TP00419,CD274;TNFRSF9,CD274,TNFRSF9,CET+CET,Tbio+Tclin,0.245,0.58,1.0,0,0,1,12,11,DC02003,Acasunlimab,BsAb,FD00018,Head and Neck Cancer,Head and Neck Cancer,Phase 1|Phase 2
1201,TP00419,CD274;TNFRSF9,CD274,TNFRSF9,CET+CET,Tbio+Tclin,0.245,0.58,1.0,0,0,1,12,11,DC02003,Acasunlimab,BsAb,FD00034,Ovarian Cancer,Ovarian Cancer,Phase 1|Phase 2
1203,TP00419,CD274;TNFRSF9,CD274,TNFRSF9,CET+CET,Tbio+Tclin,0.245,0.58,1.0,0,0,1,12,11,DC02230,QLF31907,BsAb,FD00026,Melanoma,Melanoma,Phase 2
1205,TP00419,CD274;TNFRSF9,CD274,TNFRSF9,CET+CET,Tbio+Tclin,0.245,0.58,1.0,0,0,1,12,11,DC02022,AP203,BsAb,FD00014,Esophageal Cancer,Esophageal Cancer,Phase 1|Phase 2
1211,TP00419,CD274;TNFRSF9,CD274,TNFRSF9,CET+CET,Tbio+Tclin,0.245,0.58,1.0,0,0,1,12,11,DC02026,ATG101,BsAb,FD00024,Lymphoma,Hematologic Malignancy,Phase 1
1215,TP00420,CD274;TNFSF4,CD274,TNFSF4,CET+CIT,Tbio+Tclin,0.589,0.563,1.0,0,0,1,1,1,DC00320,Atezolizumab;Vonlerolizumab,DrugComb,FD00006,Bladder Cancer,Bladder Cancer,Phase 2
1216,TP00421,CD274;VEGFA,CD274,VEGFA,CET+CET,Tclin+Tclin,0.318,0.497,1.0,0,0,2,4,12,DC00443,Bevacizumab;Durvalumab,DrugComb,FD00007,Breast Cancer,Breast Cancer,Early Phase 1
1217,TP00421,CD274;VEGFA,CD274,VEGFA,CET+CET,Tclin+Tclin,0.318,0.497,1.0,0,0,2,4,12,DC00443,Bevacizumab;Durvalumab,DrugComb,FD00022,Liver Cancer,Liver Cancer,Phase 2
1218,TP00421,CD274;VEGFA,CD274,VEGFA,CET+CET,Tclin+Tclin,0.318,0.497,1.0,0,0,2,4,12,DC00246,Atezolizumab;Bevacizumab,DrugComb,FD00006,Bladder Cancer,Bladder Cancer,Phase 2
1219,TP00421,CD274;VEGFA,CD274,VEGFA,CET+CET,Tclin+Tclin,0.318,0.497,1.0,0,0,2,4,12,DC00246,Atezolizumab;Bevacizumab,DrugComb,FD00011,Colorectal Cancer,Colorectal Cancer,Phase 2
1220,TP00421,CD274;VEGFA,CD274,VEGFA,CET+CET,Tclin+Tclin,0.318,0.497,1.0,0,0,2,4,12,DC00246,Atezolizumab;Bevacizumab,DrugComb,FD00018,Head and Neck Cancer,Head and Neck Cancer,Phase 2
1221,TP00421,CD274;VEGFA,CD274,VEGFA,CET+CET,Tclin+Tclin,0.318,0.497,1.0,0,0,2,4,12,DC00246,Atezolizumab;Bevacizumab,DrugComb,FD00020,Kidney Cancer,Kidney Cancer,Phase 3
1223,TP00421,CD274;VEGFA,CD274,VEGFA,CET+CET,Tclin+Tclin,0.318,0.497,1.0,0,0,2,4,12,DC00246,Atezolizumab;Bevacizumab,DrugComb,FD00023,Lung Cancer,Lung Cancer,Approval
1224,TP00421,CD274;VEGFA,CD274,VEGFA,CET+CET,Tclin+Tclin,0.318,0.497,1.0,0,0,2,4,12,DC00246,Atezolizumab;Bevacizumab,DrugComb,FD00026,Melanoma,Melanoma,Phase 2
1225,TP00421,CD274;VEGFA,CD274,VEGFA,CET+CET,Tclin+Tclin,0.318,0.497,1.0,0,0,2,4,12,DC00246,Atezolizumab;Bevacizumab,DrugComb,FD00034,Ovarian Cancer,Ovarian Cancer,Phase 2
1229,TP00421,CD274;VEGFA,CD274,VEGFA,CET+CET,Tclin+Tclin,0.318,0.497,1.0,0,0,2,4,12,DC02223,PM8002,BsAb,FD00029,Mesothelioma,Other Cancer,Phase 2
1230,TP00421,CD274;VEGFA,CD274,VEGFA,CET+CET,Tclin+Tclin,0.318,0.497,1.0,0,0,2,4,12,DC02223,PM8002,BsAb,FD00032,Neuroendocrine Tumor,Other Cancer,Phase 2
1231,TP00421,CD274;VEGFA,CD274,VEGFA,CET+CET,Tclin+Tclin,0.318,0.497,1.0,0,0,2,4,12,DC02030,B1962,BsAb,FD00033,Other Cancer,Other Cancer,Phase 1
1232,TP00422,CD274;WEE1,CD274,WEE1,CET+CIT,Tchem+Tclin,0.141,0.532,1.0,0,0,0,1,1,DC00083,Adavosertib;Durvalumab,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
1233,TP00423,CD274;XIAP,CD274,XIAP,CET+CIT,Tchem+Tclin,0.326,0.5,1.0,0,0,0,1,1,DC00354,Avelumab;Xevinapant,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
1234,TP00424,CD276;CD28,CD276,CD28,CET+CIT,Tbio+Tbio,0.601,0.629,0.712,1,0,1,1,1,DC02299,XmAb808,BsAb,FD00023,Lung Cancer,Lung Cancer,Phase 1
1235,TP00425,CD276;CD3D,CD276,CD3D,CET+CIT,Tbio+Tclin,0.359,0.663,0.75,0,0,0,2,3,DC02057,CC-3,BsAb,FD00011,Colorectal Cancer,Colorectal Cancer,Phase 1
1236,TP00425,CD276;CD3D,CD276,CD3D,CET+CIT,Tbio+Tclin,0.359,0.663,0.75,0,0,0,2,3,DC02205,Obrindatamab,BsAb,FD00023,Lung Cancer,Lung Cancer,Phase 1
1237,TP00425,CD276;CD3D,CD276,CD3D,CET+CIT,Tbio+Tclin,0.359,0.663,0.75,0,0,0,2,3,DC02205,Obrindatamab,BsAb,FD00033,Other Cancer,Other Cancer,Phase 1
1238,TP00426,CD276;CD3E,CD276,CD3E,CET+CIT,Tbio+Tclin,0.533,0.535,0.651,0,0,0,2,3,DC02057,CC-3,BsAb,FD00011,Colorectal Cancer,Colorectal Cancer,Phase 1
1239,TP00426,CD276;CD3E,CD276,CD3E,CET+CIT,Tbio+Tclin,0.533,0.535,0.651,0,0,0,2,3,DC02205,Obrindatamab,BsAb,FD00023,Lung Cancer,Lung Cancer,Phase 1
1240,TP00426,CD276;CD3E,CD276,CD3E,CET+CIT,Tbio+Tclin,0.533,0.535,0.651,0,0,0,2,3,DC02205,Obrindatamab,BsAb,FD00033,Other Cancer,Other Cancer,Phase 1
1241,TP00427,CD276;CD3G,CD276,CD3G,CET+CIT,Tbio+Tclin,0.394,0.611,0.661,0,0,0,2,3,DC02205,Obrindatamab,BsAb,FD00023,Lung Cancer,Lung Cancer,Phase 1
1242,TP00427,CD276;CD3G,CD276,CD3G,CET+CIT,Tbio+Tclin,0.394,0.611,0.661,0,0,0,2,3,DC02205,Obrindatamab,BsAb,FD00033,Other Cancer,Other Cancer,Phase 1
1243,TP00427,CD276;CD3G,CD276,CD3G,CET+CIT,Tbio+Tclin,0.394,0.611,0.661,0,0,0,2,3,DC02057,CC-3,BsAb,FD00011,Colorectal Cancer,Colorectal Cancer,Phase 1
1244,TP00428,CD276;CTLA4,CD276,CTLA4,CET+CIT,Tbio+Tclin,0.509,0.54,1.0,1,0,1,2,8,DC01450,Lorigerlimab;Vobramitamab Duocarmazine,DrugComb,FD00020,Kidney Cancer,Kidney Cancer,Phase 1
1245,TP00428,CD276;CTLA4,CD276,CTLA4,CET+CIT,Tbio+Tclin,0.509,0.54,1.0,1,0,1,2,8,DC01450,Lorigerlimab;Vobramitamab Duocarmazine,DrugComb,FD00022,Liver Cancer,Liver Cancer,Phase 1
1246,TP00428,CD276;CTLA4,CD276,CTLA4,CET+CIT,Tbio+Tclin,0.509,0.54,1.0,1,0,1,2,8,DC01450,Lorigerlimab;Vobramitamab Duocarmazine,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
1247,TP00428,CD276;CTLA4,CD276,CTLA4,CET+CIT,Tbio+Tclin,0.509,0.54,1.0,1,0,1,2,8,DC01450,Lorigerlimab;Vobramitamab Duocarmazine,DrugComb,FD00026,Melanoma,Melanoma,Phase 1
1248,TP00428,CD276;CTLA4,CD276,CTLA4,CET+CIT,Tbio+Tclin,0.509,0.54,1.0,1,0,1,2,8,DC01450,Lorigerlimab;Vobramitamab Duocarmazine,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
1249,TP00428,CD276;CTLA4,CD276,CTLA4,CET+CIT,Tbio+Tclin,0.509,0.54,1.0,1,0,1,2,8,DC01450,Lorigerlimab;Vobramitamab Duocarmazine,DrugComb,FD00034,Ovarian Cancer,Ovarian Cancer,Phase 1
1250,TP00428,CD276;CTLA4,CD276,CTLA4,CET+CIT,Tbio+Tclin,0.509,0.54,1.0,1,0,1,2,8,DC01450,Lorigerlimab;Vobramitamab Duocarmazine,DrugComb,FD00035,Pancreatic Cancer,Pancreatic Cancer,Phase 1
1251,TP00428,CD276;CTLA4,CD276,CTLA4,CET+CIT,Tbio+Tclin,0.509,0.54,1.0,1,0,1,2,8,DC01450,Lorigerlimab;Vobramitamab Duocarmazine,DrugComb,FD00038,Prostate Cancer,Prostate Cancer,Phase 1
1253,TP00429,CD276;EGFR,CD276,EGFR,CIT+CIT,Tbio+Tclin,0.21,0.363,0.474,0,0,0,1,1,DC02134,IBI334,BsAb,FD00033,Other Cancer,Other Cancer,Phase 1|Phase 2
1254,TP00430,CD276;LAG3,CD276,LAG3,CET+CIT,Tbio+Tclin,0.581,0.849,0.699,0,0,0,1,1,DC00993,Enoblituzumab;Tebotelimab,DrugComb,FD00018,Head and Neck Cancer,Head and Neck Cancer,Phase 2|Phase 3
1255,TP00431,CD276;PDCD1,CD276,PDCD1,CET+CIT,Tbio+Tclin,0.399,0.941,1.0,1,0,1,7,10,DC01450,Lorigerlimab;Vobramitamab Duocarmazine,DrugComb,FD00020,Kidney Cancer,Kidney Cancer,Phase 1
1256,TP00431,CD276;PDCD1,CD276,PDCD1,CET+CIT,Tbio+Tclin,0.399,0.941,1.0,1,0,1,7,10,DC01450,Lorigerlimab;Vobramitamab Duocarmazine,DrugComb,FD00022,Liver Cancer,Liver Cancer,Phase 1
1257,TP00431,CD276;PDCD1,CD276,PDCD1,CET+CIT,Tbio+Tclin,0.399,0.941,1.0,1,0,1,7,10,DC01450,Lorigerlimab;Vobramitamab Duocarmazine,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
1258,TP00431,CD276;PDCD1,CD276,PDCD1,CET+CIT,Tbio+Tclin,0.399,0.941,1.0,1,0,1,7,10,DC01450,Lorigerlimab;Vobramitamab Duocarmazine,DrugComb,FD00026,Melanoma,Melanoma,Phase 1
1259,TP00431,CD276;PDCD1,CD276,PDCD1,CET+CIT,Tbio+Tclin,0.399,0.941,1.0,1,0,1,7,10,DC01450,Lorigerlimab;Vobramitamab Duocarmazine,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
1260,TP00431,CD276;PDCD1,CD276,PDCD1,CET+CIT,Tbio+Tclin,0.399,0.941,1.0,1,0,1,7,10,DC01450,Lorigerlimab;Vobramitamab Duocarmazine,DrugComb,FD00034,Ovarian Cancer,Ovarian Cancer,Phase 1
1261,TP00431,CD276;PDCD1,CD276,PDCD1,CET+CIT,Tbio+Tclin,0.399,0.941,1.0,1,0,1,7,10,DC01450,Lorigerlimab;Vobramitamab Duocarmazine,DrugComb,FD00035,Pancreatic Cancer,Pancreatic Cancer,Phase 1
1262,TP00431,CD276;PDCD1,CD276,PDCD1,CET+CIT,Tbio+Tclin,0.399,0.941,1.0,1,0,1,7,10,DC01450,Lorigerlimab;Vobramitamab Duocarmazine,DrugComb,FD00038,Prostate Cancer,Prostate Cancer,Phase 1
1264,TP00431,CD276;PDCD1,CD276,PDCD1,CET+CIT,Tbio+Tclin,0.399,0.941,1.0,1,0,1,7,10,DC00993,Enoblituzumab;Tebotelimab,DrugComb,FD00018,Head and Neck Cancer,Head and Neck Cancer,Phase 2|Phase 3
1268,TP00431,CD276;PDCD1,CD276,PDCD1,CET+CIT,Tbio+Tclin,0.399,0.941,1.0,1,0,1,7,10,DC00991,Enoblituzumab;Pembrolizumab,DrugComb,FD00006,Bladder Cancer,Bladder Cancer,Phase 2
1272,TP00432,CD28;CTLA4,CD28,CTLA4,CET+CET,Tbio+Tclin,0.429,0.833,1.0,4,0,7,1,1,DC02077,Davoceticept,BsAb,FD00033,Other Cancer,Other Cancer,Phase 1
1273,TP00433,CD28;EGFR,CD28,EGFR,CET+CIT,Tbio+Tclin,0.425,0.616,0.56,1,3,0,1,1,DC02239,REGN7075,BsAb,FD00033,Other Cancer,Other Cancer,Phase 1|Phase 2
1274,TP00434,CD28;FOLH1,CD28,FOLH1,CET+CET,Tbio+Tclin,0.122,0.802,0.289,0,0,0,1,1,DC02199,Nezastomig,BsAb,FD00038,Prostate Cancer,Prostate Cancer,Phase 1|Phase 2
1275,TP00435,CD28;MUC16,CD28,MUC16,CET+CIT,Tbio+Tbio,0.268,0.576,1.0,0,0,0,1,1,DC02237,REGN5668,BsAb,FD00034,Ovarian Cancer,Ovarian Cancer,Phase 1|Phase 2
1276,TP00436,CD28;PDCD1,CD28,PDCD1,CET+CET,Tbio+Tclin,0.375,0.72,1.0,3,0,3,3,2,DC00870,Davoceticept;Pembrolizumab,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
1277,TP00436,CD28;PDCD1,CD28,PDCD1,CET+CET,Tbio+Tclin,0.375,0.72,1.0,3,0,3,3,2,DC01775,Pembrolizumab;XmAb808,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
1279,TP00437,CD33;CD3D,CD33,CD3D,CET+CIT,Tclin+Tclin,0.326,0.666,0.725,1,1,0,5,3,DC02092,Emerfetamab,BsAb,FD00021,Leukemia,Hematologic Malignancy,Early Phase 1
1281,TP00437,CD33;CD3D,CD33,CD3D,CET+CIT,Tclin+Tclin,0.326,0.666,0.725,1,1,0,5,3,DC02290,Vixtimotamab,BsAb,FD00030,Myeloma,Hematologic Malignancy,Phase 1
1282,TP00437,CD33;CD3D,CD33,CD3D,CET+CIT,Tclin+Tclin,0.326,0.666,0.725,1,1,0,5,3,DC02290,Vixtimotamab,BsAb,FD00033,Other Cancer,Other Cancer,Phase 1
1288,TP00438,CD33;CD3E,CD33,CD3E,CET+CIT,Tclin+Tclin,0.453,0.686,0.648,1,1,0,5,3,DC02290,Vixtimotamab,BsAb,FD00021,Leukemia,Hematologic Malignancy,Phase 1
1289,TP00438,CD33;CD3E,CD33,CD3E,CET+CIT,Tclin+Tclin,0.453,0.686,0.648,1,1,0,5,3,DC02290,Vixtimotamab,BsAb,FD00030,Myeloma,Hematologic Malignancy,Phase 1
1290,TP00438,CD33;CD3E,CD33,CD3E,CET+CIT,Tclin+Tclin,0.453,0.686,0.648,1,1,0,5,3,DC02290,Vixtimotamab,BsAb,FD00033,Other Cancer,Other Cancer,Phase 1
1297,TP00439,CD33;CD3G,CD33,CD3G,CET+CIT,Tclin+Tclin,0.373,0.697,0.654,1,1,0,5,3,DC02092,Emerfetamab,BsAb,FD00021,Leukemia,Hematologic Malignancy,Early Phase 1
1299,TP00439,CD33;CD3G,CD33,CD3G,CET+CIT,Tclin+Tclin,0.373,0.697,0.654,1,1,0,5,3,DC02157,JNJ67571244,BsAb,FD00030,Myeloma,Hematologic Malignancy,Phase 1
1304,TP00439,CD33;CD3G,CD33,CD3G,CET+CIT,Tclin+Tclin,0.373,0.697,0.654,1,1,0,5,3,DC02290,Vixtimotamab,BsAb,FD00033,Other Cancer,Other Cancer,Phase 1
1306,TP00440,CD33;CRBN,CD33,CRBN,CIT+CIT,Tclin+Tclin,0.21,0.522,0.602,0,0,0,1,1,DC01393,Lenalidomide;lintuzumab,DrugComb,FD00030,Myeloma,Hematologic Malignancy,Phase 1
1307,TP00441,CD33;PDCD1,CD33,PDCD1,CET+CIT,Tclin+Tclin,0.307,0.577,1.0,0,0,0,1,1,DC00975,Eluvixtamab;Pembrolizumab,DrugComb,FD00021,Leukemia,Hematologic Malignancy,Phase 1
1308,TP00442,CD37;MS4A1,CD37,MS4A1,CET+CIT,Tbio+Tclin,,0.749,1.0,1,0,0,1,1,DC01514,Naratuximab Emtansine;Rituximab,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 2
1309,TP00443,CD37;PIK3CD,CD37,PIK3CD,CET+CIT,Tbio+Tclin,,0.638,1.0,0,0,0,1,1,DC00513,BI836826;Idelalisib,DrugComb,FD00021,Leukemia,Hematologic Malignancy,Phase 1
1310,TP00444,CD38;CD3D,CD38,CD3D,CET+CET,Tclin+Tclin,0.247,0.66,0.415,1,0,0,6,3,DC01356,Isatuximab;Teclistamab,DrugComb,FD00030,Myeloma,Hematologic Malignancy,Phase 1
1315,TP00444,CD38;CD3D,CD38,CD3D,CET+CET,Tclin+Tclin,0.247,0.66,0.415,1,0,0,6,3,DC02297,XmAb18968,BsAb,FD00021,Leukemia,Hematologic Malignancy,Phase 1
1316,TP00444,CD38;CD3D,CD38,CD3D,CET+CET,Tclin+Tclin,0.247,0.66,0.415,1,0,0,6,3,DC02297,XmAb18968,BsAb,FD00024,Lymphoma,Hematologic Malignancy,Phase 1
1317,TP00445,CD38;CD3E,CD38,CD3E,CET+CET,Tclin+Tclin,0.398,0.611,0.404,1,0,0,6,3,DC01356,Isatuximab;Teclistamab,DrugComb,FD00030,Myeloma,Hematologic Malignancy,Phase 1
1320,TP00445,CD38;CD3E,CD38,CD3E,CET+CET,Tclin+Tclin,0.398,0.611,0.404,1,0,0,6,3,DC02297,XmAb18968,BsAb,FD00021,Leukemia,Hematologic Malignancy,Phase 1
1321,TP00445,CD38;CD3E,CD38,CD3E,CET+CET,Tclin+Tclin,0.398,0.611,0.404,1,0,0,6,3,DC02297,XmAb18968,BsAb,FD00024,Lymphoma,Hematologic Malignancy,Phase 1
1324,TP00446,CD38;CD3G,CD38,CD3G,CET+CET,Tclin+Tclin,0.282,0.611,0.395,1,0,0,6,3,DC01356,Isatuximab;Teclistamab,DrugComb,FD00030,Myeloma,Hematologic Malignancy,Phase 1
1328,TP00446,CD38;CD3G,CD38,CD3G,CET+CET,Tclin+Tclin,0.282,0.611,0.395,1,0,0,6,3,DC02297,XmAb18968,BsAb,FD00021,Leukemia,Hematologic Malignancy,Phase 1
1329,TP00446,CD38;CD3G,CD38,CD3G,CET+CET,Tclin+Tclin,0.282,0.611,0.395,1,0,0,6,3,DC02297,XmAb18968,BsAb,FD00024,Lymphoma,Hematologic Malignancy,Phase 1
1331,TP00447,CD38;CD47,CD38,CD47,CET+CET,Tchem+Tclin,0.314,0.832,0.331,0,0,0,3,2,DC00849,Daratumumab;Maplirpacept,DrugComb,FD00030,Myeloma,Hematologic Malignancy,Phase 1
1332,TP00447,CD38;CD47,CD38,CD47,CET+CET,Tchem+Tclin,0.314,0.832,0.331,0,0,0,3,2,DC02257,SG2501,BsAb,FD00019,Hematologic Malignancies,Hematologic Malignancy,Phase 1
1334,TP00448,CD38;CRBN,CD38,CRBN,CET+CIT,Tclin+Tclin,0.171,0.605,0.358,0,0,0,5,5,DC01497,Modakafusp Alfa;Pomalidomide,DrugComb,FD00030,Myeloma,Hematologic Malignancy,Phase 1
1336,TP00448,CD38;CRBN,CD38,CRBN,CET+CIT,Tclin+Tclin,0.171,0.605,0.358,0,0,0,5,5,DC00853,Daratumumab;Pomalidomide,DrugComb,FD00020,Kidney Cancer,Kidney Cancer,Approval
1337,TP00448,CD38;CRBN,CD38,CRBN,CET+CIT,Tclin+Tclin,0.171,0.605,0.358,0,0,0,5,5,DC00853,Daratumumab;Pomalidomide,DrugComb,FD00026,Melanoma,Melanoma,Approval
1339,TP00448,CD38;CRBN,CD38,CRBN,CET+CIT,Tclin+Tclin,0.171,0.605,0.358,0,0,0,5,5,DC00853,Daratumumab;Pomalidomide,DrugComb,FD00034,Ovarian Cancer,Ovarian Cancer,Approval
1340,TP00448,CD38;CRBN,CD38,CRBN,CET+CIT,Tclin+Tclin,0.171,0.605,0.358,0,0,0,5,5,DC00853,Daratumumab;Pomalidomide,DrugComb,FD00041,Stomach Cancer,Stomach Cancer,Approval
1343,TP00449,CD38;ICAM1,CD38,ICAM1,CET+CIT,Tchem+Tclin,0.262,0.742,0.317,0,0,0,1,3,DC02293,VP301,BsAb,FD00024,Lymphoma,Hematologic Malignancy,Phase 1
1344,TP00449,CD38;ICAM1,CD38,ICAM1,CET+CIT,Tchem+Tclin,0.262,0.742,0.317,0,0,0,1,3,DC02293,VP301,BsAb,FD00030,Myeloma,Hematologic Malignancy,Phase 1
1345,TP00449,CD38;ICAM1,CD38,ICAM1,CET+CIT,Tchem+Tclin,0.262,0.742,0.317,0,0,0,1,3,DC02293,VP301,BsAb,FD00033,Other Cancer,Other Cancer,Phase 1
1346,TP00450,CD38;IL15,CD38,IL15,CET+CET,Tchem+Tclin,0.377,0.588,0.354,0,0,0,1,1,DC00856,Daratumumab;XmAb24306,DrugComb,FD00030,Myeloma,Hematologic Malignancy,Phase 1
1347,TP00451,CD38;IL15RA,CD38,IL15RA,CET+CET,Tbio+Tclin,0.229,0.751,0.301,0,0,0,1,1,DC00856,Daratumumab;XmAb24306,DrugComb,FD00030,Myeloma,Hematologic Malignancy,Phase 1
1348,TP00452,CD38;PDCD1,CD38,PDCD1,CET+CET,Tclin+Tclin,0.308,0.65,0.788,0,0,0,4,4,DC01496,Modakafusp Alfa;Pembrolizumab,DrugComb,FD00026,Melanoma,Melanoma,Phase 1|Phase 2
1349,TP00452,CD38;PDCD1,CD38,PDCD1,CET+CET,Tclin+Tclin,0.308,0.65,0.788,0,0,0,4,4,DC00718,Cetrelimab;Daratumumab,DrugComb,FD00030,Myeloma,Hematologic Malignancy,Phase 2|Phase 3
1350,TP00452,CD38;PDCD1,CD38,PDCD1,CET+CET,Tclin+Tclin,0.308,0.65,0.788,0,0,0,4,4,DC00697,Cemiplimab;Isatuximab,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
1351,TP00452,CD38;PDCD1,CD38,PDCD1,CET+CET,Tclin+Tclin,0.308,0.65,0.788,0,0,0,4,4,DC00852,Daratumumab;Nivolumab,DrugComb,FD00011,Colorectal Cancer,Colorectal Cancer,Phase 2
1354,TP00453,CD38;TIGIT,CD38,TIGIT,CET+CET,Tbio+Tclin,0.137,0.734,0.463,0,0,0,1,2,DC00855,Daratumumab;Tiragolumab,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 1
1355,TP00453,CD38;TIGIT,CD38,TIGIT,CET+CET,Tbio+Tclin,0.137,0.734,0.463,0,0,0,1,2,DC00855,Daratumumab;Tiragolumab,DrugComb,FD00030,Myeloma,Hematologic Malignancy,Phase 1
1356,TP00454,CD38;TNFRSF17,CD38,TNFRSF17,CET+CIT,Tclin+Tclin,0.324,0.66,0.322,0,0,0,1,1,DC01356,Isatuximab;Teclistamab,DrugComb,FD00030,Myeloma,Hematologic Malignancy,Phase 1
1357,TP00455,CD3D;CDH17,CD3D,CDH17,CET+CIT,Tbio+Tclin,0.362,0.647,0.547,0,0,0,1,4,DC02024,ARB202,BsAb,FD00011,Colorectal Cancer,Colorectal Cancer,Phase 1
1358,TP00455,CD3D;CDH17,CD3D,CDH17,CET+CIT,Tbio+Tclin,0.362,0.647,0.547,0,0,0,1,4,DC02024,ARB202,BsAb,FD00022,Liver Cancer,Liver Cancer,Phase 1
1359,TP00455,CD3D;CDH17,CD3D,CDH17,CET+CIT,Tbio+Tclin,0.362,0.647,0.547,0,0,0,1,4,DC02024,ARB202,BsAb,FD00035,Pancreatic Cancer,Pancreatic Cancer,Phase 1
1360,TP00455,CD3D;CDH17,CD3D,CDH17,CET+CIT,Tbio+Tclin,0.362,0.647,0.547,0,0,0,1,4,DC02024,ARB202,BsAb,FD00041,Stomach Cancer,Stomach Cancer,Phase 1
1361,TP00456,CD3D;CDH3,CD3D,CDH3,CET+CIT,Tbio+Tclin,0.233,0.727,0.494,0,0,0,1,1,DC02213,PF06671008,BsAb,FD00033,Other Cancer,Other Cancer,Phase 1
1362,TP00457,CD3D;CEACAM5,CD3D,CEACAM5,CET+CIT,Tbio+Tclin,0.177,0.609,0.737,0,0,0,3,3,DC02063,Cibisatamab,BsAb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
1363,TP00457,CD3D;CEACAM5,CD3D,CEACAM5,CET+CIT,Tbio+Tclin,0.177,0.609,0.737,0,0,0,3,3,DC02063,Cibisatamab,BsAb,FD00033,Other Cancer,Other Cancer,Phase 1
1364,TP00457,CD3D;CEACAM5,CD3D,CEACAM5,CET+CIT,Tbio+Tclin,0.177,0.609,0.737,0,0,0,3,3,DC02012,AMG211,BsAb,FD00041,Stomach Cancer,Stomach Cancer,Phase 1
1366,TP00458,CD3D;CLDN18,CD3D,CLDN18,CET+CIT,Tbio+Tclin,0.265,0.656,0.759,0,0,0,4,3,DC02025,ASP2138,BsAb,FD00035,Pancreatic Cancer,Pancreatic Cancer,Phase 1
1367,TP00458,CD3D;CLDN18,CD3D,CLDN18,CET+CIT,Tbio+Tclin,0.265,0.656,0.759,0,0,0,4,3,DC02025,ASP2138,BsAb,FD00041,Stomach Cancer,Stomach Cancer,Phase 1
1368,TP00458,CD3D;CLDN18,CD3D,CLDN18,CET+CIT,Tbio+Tclin,0.265,0.656,0.759,0,0,0,4,3,DC02136,IBI389,BsAb,FD00033,Other Cancer,Other Cancer,Phase 1
1371,TP00459,CD3D;CLDN6,CD3D,CLDN6,CET+CIT,Tbio+Tclin,0.157,0.665,0.711,0,0,0,3,3,DC02018,AMG794,BsAb,FD00023,Lung Cancer,Lung Cancer,Phase 1
1372,TP00459,CD3D;CLDN6,CD3D,CLDN6,CET+CIT,Tbio+Tclin,0.157,0.665,0.711,0,0,0,3,3,DC02018,AMG794,BsAb,FD00034,Ovarian Cancer,Ovarian Cancer,Phase 1
1373,TP00459,CD3D;CLDN6,CD3D,CLDN6,CET+CIT,Tbio+Tclin,0.157,0.665,0.711,0,0,0,3,3,DC02049,BNT142,BsAb,FD00033,Other Cancer,Other Cancer,Phase 1|Phase 2
1375,TP00460,CD3D;CLEC12A,CD3D,CLEC12A,CET+CIT,Tbio+Tclin,,0.692,0.622,0,0,0,1,1,DC02276,Tepoditamab,BsAb,FD00021,Leukemia,Hematologic Malignancy,Phase 1
1376,TP00461,CD3D;CRBN,CD3D,CRBN,CET+CIT,Tclin+Tclin,0.142,0.605,0.685,0,0,0,3,2,DC01408,Lenalidomide;Teclistamab,DrugComb,FD00030,Myeloma,Hematologic Malignancy,Phase 3
1377,TP00461,CD3D;CRBN,CD3D,CRBN,CET+CIT,Tclin+Tclin,0.142,0.605,0.685,0,0,0,3,2,DC00552,Blinatumomab;Lenalidomide,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 1
1379,TP00462,CD3D;CTLA4,CD3D,CTLA4,CET+CET,Tclin+Tclin,0.322,0.735,1.0,1,0,2,1,1,DC01950,Tebentafusp;Tremelimumab,DrugComb,FD00026,Melanoma,Melanoma,Phase 1|Phase 2
1380,TP00463,CD3D;DLL3,CD3D,DLL3,CET+CIT,Tbio+Tclin,0.387,1.0,0.445,1,0,0,3,5,DC02038,BI764532,BsAb,FD00017,Glioma,Glioma,Phase 1
1381,TP00463,CD3D;DLL3,CD3D,DLL3,CET+CIT,Tbio+Tclin,0.387,1.0,0.445,1,0,0,3,5,DC02038,BI764532,BsAb,FD00023,Lung Cancer,Lung Cancer,Phase 2
1382,TP00463,CD3D;DLL3,CD3D,DLL3,CET+CIT,Tbio+Tclin,0.387,1.0,0.445,1,0,0,3,5,DC02038,BI764532,BsAb,FD00032,Neuroendocrine Tumor,Other Cancer,Phase 1|Phase 2
1384,TP00463,CD3D;DLL3,CD3D,DLL3,CET+CIT,Tbio+Tclin,0.387,1.0,0.445,1,0,0,3,5,DC02271,Tarlatamab,BsAb,FD00038,Prostate Cancer,Prostate Cancer,Phase 1
1385,TP00463,CD3D;DLL3,CD3D,DLL3,CET+CIT,Tbio+Tclin,0.387,1.0,0.445,1,0,0,3,5,DC02232,QLS31904,BsAb,FD00033,Other Cancer,Other Cancer,Phase 1
1386,TP00464,CD3D;EGFR,CD3D,EGFR,CET+CIT,Tclin+Tclin,0.285,0.607,0.578,1,2,1,5,5,DC01493,MM151;Talquetamab,DrugComb,FD00011,Colorectal Cancer,Colorectal Cancer,Phase 1
1387,TP00464,CD3D;EGFR,CD3D,EGFR,CET+CIT,Tclin+Tclin,0.285,0.607,0.578,1,2,1,5,5,DC01493,MM151;Talquetamab,DrugComb,FD00018,Head and Neck Cancer,Head and Neck Cancer,Phase 1
1388,TP00464,CD3D;EGFR,CD3D,EGFR,CET+CIT,Tclin+Tclin,0.285,0.607,0.578,1,2,1,5,5,DC01493,MM151;Talquetamab,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
1389,TP00464,CD3D;EGFR,CD3D,EGFR,CET+CIT,Tclin+Tclin,0.285,0.607,0.578,1,2,1,5,5,DC02074,CX904,BsAb,FD00033,Other Cancer,Other Cancer,Phase 1
1390,TP00464,CD3D;EGFR,CD3D,EGFR,CET+CIT,Tclin+Tclin,0.285,0.607,0.578,1,2,1,5,5,DC02247,RO7428731,BsAb,FD00017,Glioma,Glioma,Phase 1
1395,TP00465,CD3D;ENPP3,CD3D,ENPP3,CET+CIT,Tchem+Tclin,0.15,0.695,0.217,0,0,0,1,1,DC02300,XmAb819,BsAb,FD00020,Kidney Cancer,Kidney Cancer,Phase 1
1396,TP00466,CD3D;EPCAM,CD3D,EPCAM,CET+CIT,Tbio+Tclin,0.32,0.646,0.662,0,0,0,4,6,DC02265,Solitomab,BsAb,FD00033,Other Cancer,Other Cancer,Phase 1
1398,TP00466,CD3D;EPCAM,CD3D,EPCAM,CET+CIT,Tbio+Tclin,0.32,0.646,0.662,0,0,0,4,6,DC02053,Catumaxomab,BsAb,FD00006,Bladder Cancer,Bladder Cancer,Phase 1
1399,TP00466,CD3D;EPCAM,CD3D,EPCAM,CET+CIT,Tbio+Tclin,0.32,0.646,0.662,0,0,0,4,6,DC02053,Catumaxomab,BsAb,FD00034,Ovarian Cancer,Ovarian Cancer,Phase 2
1400,TP00466,CD3D;EPCAM,CD3D,EPCAM,CET+CIT,Tbio+Tclin,0.32,0.646,0.662,0,0,0,4,6,DC02053,Catumaxomab,BsAb,FD00041,Stomach Cancer,Stomach Cancer,Phase 3
1401,TP00466,CD3D;EPCAM,CD3D,EPCAM,CET+CIT,Tbio+Tclin,0.32,0.646,0.662,0,0,0,4,6,DC02053,Catumaxomab,BsAb,FD00047,Malignant Ascites,Other Cancer,Approval
1402,TP00466,CD3D;EPCAM,CD3D,EPCAM,CET+CIT,Tbio+Tclin,0.32,0.646,0.662,0,0,0,4,6,DC02182,M701,BsAb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
1404,TP00467,CD3D;ERBB2,CD3D,ERBB2,CET+CIT,Tclin+Tclin,0.353,0.715,0.677,0,0,0,5,2,DC02098,Ertumaxomab,BsAb,FD00007,Breast Cancer,Breast Cancer,Phase 2
1405,TP00467,CD3D;ERBB2,CD3D,ERBB2,CET+CIT,Tclin+Tclin,0.353,0.715,0.677,0,0,0,5,2,DC02098,Ertumaxomab,BsAb,FD00033,Other Cancer,Other Cancer,Phase 1|Phase 2
1411,TP00468,CD3D;FAP,CD3D,FAP,CET+CIT,Tchem+Tclin,0.212,0.622,0.516,0,0,0,1,2,DC02200,NG641,BsAb,FD00018,Head and Neck Cancer,Head and Neck Cancer,Phase 1
1412,TP00468,CD3D;FAP,CD3D,FAP,CET+CIT,Tchem+Tclin,0.212,0.622,0.516,0,0,0,1,2,DC02200,NG641,BsAb,FD00033,Other Cancer,Other Cancer,Phase 1
1413,TP00469,CD3D;FCRL5,CD3D,FCRL5,CET+CET,Tbio+Tclin,1.0,0.505,0.958,0,0,0,1,1,DC02062,Cevostamab,BsAb,FD00030,Myeloma,Hematologic Malignancy,Phase 2
1414,TP00470,CD3D;FLT3,CD3D,FLT3,CET+CIT,Tclin+Tclin,0.372,0.645,0.572,1,0,1,2,2,DC02066,CLN049,BsAb,FD00021,Leukemia,Hematologic Malignancy,Phase 1
1415,TP00470,CD3D;FLT3,CD3D,FLT3,CET+CIT,Tclin+Tclin,0.372,0.645,0.572,1,0,1,2,2,DC02066,CLN049,BsAb,FD00030,Myeloma,Hematologic Malignancy,Phase 1
1417,TP00471,CD3D;FOLH1,CD3D,FOLH1,CET+CET,Tclin+Tclin,0.091,0.687,0.28,0,0,0,9,5,DC02235,REGN4336,BsAb,FD00038,Prostate Cancer,Prostate Cancer,Phase 1|Phase 2
1419,TP00471,CD3D;FOLH1,CD3D,FOLH1,CET+CET,Tclin+Tclin,0.091,0.687,0.28,0,0,0,9,5,DC02114,GEM3PSCA,BsAb,FD00006,Bladder Cancer,Bladder Cancer,Phase 1
1420,TP00471,CD3D;FOLH1,CD3D,FOLH1,CET+CET,Tclin+Tclin,0.091,0.687,0.28,0,0,0,9,5,DC02114,GEM3PSCA,BsAb,FD00020,Kidney Cancer,Kidney Cancer,Phase 1
1421,TP00471,CD3D;FOLH1,CD3D,FOLH1,CET+CET,Tclin+Tclin,0.091,0.687,0.28,0,0,0,9,5,DC02114,GEM3PSCA,BsAb,FD00023,Lung Cancer,Lung Cancer,Phase 1
1424,TP00471,CD3D;FOLH1,CD3D,FOLH1,CET+CET,Tclin+Tclin,0.091,0.687,0.28,0,0,0,9,5,DC02292,Voxalatamab,BsAb,FD00033,Other Cancer,Other Cancer,Phase 1
1431,TP00472,CD3D;GPA33,CD3D,GPA33,CET+CIT,Tbio+Tclin,,0.595,0.873,0,0,0,1,1,DC02191,MGD007,BsAb,FD00011,Colorectal Cancer,Colorectal Cancer,Phase 1|Phase 2
1432,TP00473,CD3D;GPC3,CD3D,GPC3,CET+CIT,Tbio+Tclin,0.288,0.574,0.616,0,0,0,2,2,DC02099,ERY974,BsAb,FD00022,Liver Cancer,Liver Cancer,Phase 1
1433,TP00473,CD3D;GPC3,CD3D,GPC3,CET+CIT,Tbio+Tclin,0.288,0.574,0.616,0,0,0,2,2,DC02099,ERY974,BsAb,FD00033,Other Cancer,Other Cancer,Phase 1
1435,TP00474,CD3D;GPRC5D,CD3D,GPRC5D,CET+CIT,Tbio+Tclin,0.465,0.638,0.753,0,0,0,2,1,DC02270,Talquetamab,BsAb,FD00030,Myeloma,Hematologic Malignancy,Approval
1437,TP00475,CD3D;GSAP,CD3D,GSAP,CET+CIT,Tchem+Tclin,0.109,0.486,0.664,0,0,0,1,1,DC01556,Nirogacestat;Teclistamab,DrugComb,FD00030,Myeloma,Hematologic Malignancy,Phase 1
1438,TP00476,CD3D;GUCY2C,CD3D,GUCY2C,CET+CIT,Tclin+Tclin,0.486,0.688,0.496,0,0,0,1,3,DC02214,PF07062119,BsAb,FD00011,Colorectal Cancer,Colorectal Cancer,Phase 1
1439,TP00476,CD3D;GUCY2C,CD3D,GUCY2C,CET+CIT,Tclin+Tclin,0.486,0.688,0.496,0,0,0,1,3,DC02214,PF07062119,BsAb,FD00014,Esophageal Cancer,Esophageal Cancer,Phase 1
1440,TP00476,CD3D;GUCY2C,CD3D,GUCY2C,CET+CIT,Tclin+Tclin,0.486,0.688,0.496,0,0,0,1,3,DC02214,PF07062119,BsAb,FD00041,Stomach Cancer,Stomach Cancer,Phase 1
1441,TP00477,CD3D;HLA-G,CD3D,HLA-G,CET+CET,Tbio+Tclin,0.22,0.617,0.742,3,1,1,1,1,DC02161,JNJ78306358,BsAb,FD00033,Other Cancer,Other Cancer,Phase 1
1442,TP00478,CD3D;IL3RA,CD3D,IL3RA,CET+CIT,Tclin+Tclin,0.485,0.738,0.806,1,0,0,6,3,DC02289,Vibecotamab,BsAb,FD00019,Hematologic Malignancies,Hematologic Malignancy,Phase 1
1443,TP00478,CD3D;IL3RA,CD3D,IL3RA,CET+CIT,Tclin+Tclin,0.485,0.738,0.806,1,0,0,6,3,DC02289,Vibecotamab,BsAb,FD00021,Leukemia,Hematologic Malignancy,Phase 2
1444,TP00478,CD3D;IL3RA,CD3D,IL3RA,CET+CIT,Tclin+Tclin,0.485,0.738,0.806,1,0,0,6,3,DC02289,Vibecotamab,BsAb,FD00030,Myeloma,Hematologic Malignancy,Phase 2
1454,TP00479,CD3D;KLK2,CD3D,KLK2,CET+CIT,Tchem+Tclin,0.09,0.363,0.099,0,0,0,1,1,DC02160,JNJ78278343,BsAb,FD00038,Prostate Cancer,Prostate Cancer,Phase 1
1455,TP00480,CD3D;LY6G6D,CD3D,LY6G6D,CET+CIT,Tbio+Tclin,0.424,0.613,0.716,0,0,0,1,1,DC02048,BLYG8824A,BsAb,FD00011,Colorectal Cancer,Colorectal Cancer,Phase 1
1456,TP00481,CD3D;MAGEA4,CD3D,MAGEA4,CET+CIT,Tbio+Tclin,0.229,0.299,0.715,0,0,0,2,1,DC02249,RO7444973,BsAb,FD00033,Other Cancer,Other Cancer,Phase 1
1458,TP00482,CD3D;MS4A1,CD3D,MS4A1,CET+CIT,Tclin+Tclin,0.405,0.621,0.692,1,0,0,13,6,DC02185,MBS303,BsAb,FD00024,Lymphoma,Hematologic Malignancy,Phase 1|Phase 2
1460,TP00482,CD3D;MS4A1,CD3D,MS4A1,CET+CIT,Tclin+Tclin,0.405,0.621,0.692,1,0,0,13,6,DC02095,Epcoritamab,BsAb,FD00021,Leukemia,Hematologic Malignancy,Phase 1|Phase 2
1464,TP00482,CD3D;MS4A1,CD3D,MS4A1,CET+CIT,Tclin+Tclin,0.405,0.621,0.692,1,0,0,13,6,DC02194,Mosunetuzumab,BsAb,FD00019,Hematologic Malignancies,Hematologic Malignancy,Phase 1|Phase 2
1472,TP00482,CD3D;MS4A1,CD3D,MS4A1,CET+CIT,Tclin+Tclin,0.405,0.621,0.692,1,0,0,13,6,DC02280,TQB2825,BsAb,FD00033,Other Cancer,Other Cancer,Phase 1|Phase 2
1473,TP00482,CD3D;MS4A1,CD3D,MS4A1,CET+CIT,Tclin+Tclin,0.405,0.621,0.692,1,0,0,13,6,DC02280,TQB2825,BsAb,FD00034,Ovarian Cancer,Ovarian Cancer,Phase 1
1474,TP00482,CD3D;MS4A1,CD3D,MS4A1,CET+CIT,Tclin+Tclin,0.405,0.621,0.692,1,0,0,13,6,DC02280,TQB2825,BsAb,FD00040,Soft Tissue Sarcoma,Other Cancer,Phase 2
1480,TP00483,CD3D;MUC16,CD3D,MUC16,CET+CIT,Tbio+Tclin,0.243,0.624,1.0,0,0,0,2,2,DC02174,LBL033,BsAb,FD00033,Other Cancer,Other Cancer,Phase 1|Phase 2
1481,TP00483,CD3D;MUC16,CD3D,MUC16,CET+CIT,Tbio+Tclin,0.243,0.624,1.0,0,0,0,2,2,DC02286,Ubamatamab,BsAb,FD00034,Ovarian Cancer,Ovarian Cancer,Phase 1|Phase 2
1482,TP00484,CD3D;MUC17,CD3D,MUC17,CET+CIT,Tbio+Tclin,0.285,0.698,0.633,0,0,0,1,3,DC02288,Vepsitamab,BsAb,FD00011,Colorectal Cancer,Colorectal Cancer,Phase 1
1483,TP00484,CD3D;MUC17,CD3D,MUC17,CET+CIT,Tbio+Tclin,0.285,0.698,0.633,0,0,0,1,3,DC02288,Vepsitamab,BsAb,FD00035,Pancreatic Cancer,Pancreatic Cancer,Phase 1
1484,TP00484,CD3D;MUC17,CD3D,MUC17,CET+CIT,Tbio+Tclin,0.285,0.698,0.633,0,0,0,1,3,DC02288,Vepsitamab,BsAb,FD00041,Stomach Cancer,Stomach Cancer,Phase 1
1485,TP00485,CD3D;NCR3LG1,CD3D,NCR3LG1,CET+CET,Tbio+Tclin,0.275,0.704,0.701,0,1,0,1,5,DC02039,BI765049,BsAb,FD00011,Colorectal Cancer,Colorectal Cancer,Phase 1
1486,TP00485,CD3D;NCR3LG1,CD3D,NCR3LG1,CET+CET,Tbio+Tclin,0.275,0.704,0.701,0,1,0,1,5,DC02039,BI765049,BsAb,FD00018,Head and Neck Cancer,Head and Neck Cancer,Phase 1
1487,TP00485,CD3D;NCR3LG1,CD3D,NCR3LG1,CET+CET,Tbio+Tclin,0.275,0.704,0.701,0,1,0,1,5,DC02039,BI765049,BsAb,FD00022,Liver Cancer,Liver Cancer,Phase 1
1488,TP00485,CD3D;NCR3LG1,CD3D,NCR3LG1,CET+CET,Tbio+Tclin,0.275,0.704,0.701,0,1,0,1,5,DC02039,BI765049,BsAb,FD00023,Lung Cancer,Lung Cancer,Phase 1
1489,TP00485,CD3D;NCR3LG1,CD3D,NCR3LG1,CET+CET,Tbio+Tclin,0.275,0.704,0.701,0,1,0,1,5,DC02039,BI765049,BsAb,FD00035,Pancreatic Cancer,Pancreatic Cancer,Phase 1
1490,TP00486,CD3D;PDCD1,CD3D,PDCD1,CET+CET,Tclin+Tclin,0.249,0.763,1.0,2,1,2,14,15,DC00181,AMX-818;Pembrolizumab,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1|Phase 2
1491,TP00486,CD3D;PDCD1,CD3D,PDCD1,CET+CET,Tclin+Tclin,0.249,0.763,1.0,2,1,2,14,15,DC00508,BI765049;Ezabenlimab,DrugComb,FD00011,Colorectal Cancer,Colorectal Cancer,Phase 1
1492,TP00486,CD3D;PDCD1,CD3D,PDCD1,CET+CET,Tclin+Tclin,0.249,0.763,1.0,2,1,2,14,15,DC00508,BI765049;Ezabenlimab,DrugComb,FD00018,Head and Neck Cancer,Head and Neck Cancer,Phase 1
1493,TP00486,CD3D;PDCD1,CD3D,PDCD1,CET+CET,Tclin+Tclin,0.249,0.763,1.0,2,1,2,14,15,DC00508,BI765049;Ezabenlimab,DrugComb,FD00022,Liver Cancer,Liver Cancer,Phase 1
1494,TP00486,CD3D;PDCD1,CD3D,PDCD1,CET+CET,Tclin+Tclin,0.249,0.763,1.0,2,1,2,14,15,DC00508,BI765049;Ezabenlimab,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
1495,TP00486,CD3D;PDCD1,CD3D,PDCD1,CET+CET,Tclin+Tclin,0.249,0.763,1.0,2,1,2,14,15,DC00508,BI765049;Ezabenlimab,DrugComb,FD00035,Pancreatic Cancer,Pancreatic Cancer,Phase 1
1496,TP00486,CD3D;PDCD1,CD3D,PDCD1,CET+CET,Tclin+Tclin,0.249,0.763,1.0,2,1,2,14,15,DC01090,Etevritamab;Zeluvalimab,DrugComb,FD00017,Glioma,Glioma,Phase 1
1500,TP00486,CD3D;PDCD1,CD3D,PDCD1,CET+CET,Tclin+Tclin,0.249,0.763,1.0,2,1,2,14,15,DC00771,Cibisatamab;Nivolumab,DrugComb,FD00030,Myeloma,Hematologic Malignancy,Phase 2
1503,TP00486,CD3D;PDCD1,CD3D,PDCD1,CET+CET,Tclin+Tclin,0.249,0.763,1.0,2,1,2,14,15,DC00507,BI764532;Ezabenlimab,DrugComb,FD00032,Neuroendocrine Tumor,Other Cancer,Phase 1|Phase 2
1504,TP00486,CD3D;PDCD1,CD3D,PDCD1,CET+CET,Tclin+Tclin,0.249,0.763,1.0,2,1,2,14,15,DC00553,Blinatumomab;Pembrolizumab,DrugComb,FD00019,Hematologic Malignancies,Hematologic Malignancy,Phase 1
1505,TP00486,CD3D;PDCD1,CD3D,PDCD1,CET+CET,Tclin+Tclin,0.249,0.763,1.0,2,1,2,14,15,DC00553,Blinatumomab;Pembrolizumab,DrugComb,FD00021,Leukemia,Hematologic Malignancy,Phase 1|Phase 2
1506,TP00486,CD3D;PDCD1,CD3D,PDCD1,CET+CET,Tclin+Tclin,0.249,0.763,1.0,2,1,2,14,15,DC00553,Blinatumomab;Pembrolizumab,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 1
1507,TP00486,CD3D;PDCD1,CD3D,PDCD1,CET+CET,Tclin+Tclin,0.249,0.763,1.0,2,1,2,14,15,DC00707,Cemiplimab;Ubamatamab,DrugComb,FD00034,Ovarian Cancer,Ovarian Cancer,Phase 1|Phase 2
1508,TP00486,CD3D;PDCD1,CD3D,PDCD1,CET+CET,Tclin+Tclin,0.249,0.763,1.0,2,1,2,14,15,DC01729,Pembrolizumab;Tebentafusp,DrugComb,FD00026,Melanoma,Melanoma,Phase 2|Phase 3
1510,TP00486,CD3D;PDCD1,CD3D,PDCD1,CET+CET,Tclin+Tclin,0.249,0.763,1.0,2,1,2,14,15,DC00720,Cetrelimab;JNJ78278343,DrugComb,FD00038,Prostate Cancer,Prostate Cancer,Phase 1
1513,TP00487,CD3D;PMEL,CD3D,PMEL,CET+CIT,Tclin+Tclin,0.114,0.601,0.835,0,0,0,1,1,DC02272,Tebentafusp,BsAb,FD00026,Melanoma,Melanoma,Approval
1514,TP00488,CD3D;PRAME,CD3D,PRAME,CET+CIT,Tbio+Tclin,0.28,0.607,0.595,0,0,0,1,1,DC02141,IMCF106C,BsAb,FD00033,Other Cancer,Other Cancer,Phase 1|Phase 2
1515,TP00489,CD3D;ROR1,CD3D,ROR1,CET+CIT,Tbio+Tclin,0.288,0.646,0.724,0,0,0,2,3,DC02204,NVG111,BsAb,FD00021,Leukemia,Hematologic Malignancy,Phase 1
1516,TP00489,CD3D;ROR1,CD3D,ROR1,CET+CIT,Tbio+Tclin,0.288,0.646,0.724,0,0,0,2,3,DC02204,NVG111,BsAb,FD00024,Lymphoma,Hematologic Malignancy,Phase 1
1517,TP00489,CD3D;ROR1,CD3D,ROR1,CET+CIT,Tbio+Tclin,0.288,0.646,0.724,0,0,0,2,3,DC02090,EMB07,BsAb,FD00033,Other Cancer,Other Cancer,Phase 1
1518,TP00490,CD3D;SLAMF7,CD3D,SLAMF7,CET+CIT,Tclin+Tclin,0.309,0.763,1.0,0,1,0,1,1,DC00770,Cibisatamab;Elotuzumab,DrugComb,FD00030,Myeloma,Hematologic Malignancy,Phase 1
1519,TP00491,CD3D;SSTR2,CD3D,SSTR2,CET+CIT,Tclin+Tclin,0.358,0.674,0.71,0,0,0,1,3,DC02277,Tidutamab,BsAb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
1520,TP00491,CD3D;SSTR2,CD3D,SSTR2,CET+CIT,Tclin+Tclin,0.358,0.674,0.71,0,0,0,1,3,DC02277,Tidutamab,BsAb,FD00028,Merkel Cell Carcinoma,Other Cancer,Phase 1|Phase 2
1521,TP00491,CD3D;SSTR2,CD3D,SSTR2,CET+CIT,Tclin+Tclin,0.358,0.674,0.71,0,0,0,1,3,DC02277,Tidutamab,BsAb,FD00041,Stomach Cancer,Stomach Cancer,Phase 1
1522,TP00492,CD3D;STEAP1,CD3D,STEAP1,CET+CIT,Tbio+Tclin,0.148,0.634,0.272,0,0,0,1,1,DC02016,AMG509,BsAb,FD00038,Prostate Cancer,Prostate Cancer,Phase 1
1523,TP00493,CD3D;TMEFF2,CD3D,TMEFF2,CET+CIT,Tbio+Tclin,0.208,0.661,0.727,0,0,0,1,1,DC02158,JNJ70218902,BsAb,FD00033,Other Cancer,Other Cancer,Phase 1
1524,TP00494,CD3D;TNFRSF17,CD3D,TNFRSF17,CET+CIT,Tclin+Tclin,0.511,0.694,0.873,0,0,0,13,1,DC02104,F182112,BsAb,FD00030,Myeloma,Hematologic Malignancy,Phase 1
1537,TP00495,CD3D;TPBG,CD3D,TPBG,CET+CIT,Tbio+Tclin,0.26,0.59,,0,0,0,1,1,DC02115,GEN1044,BsAb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
1538,TP00496,CD3D;TYRP1,CD3D,TYRP1,CET+CIT,Tbio+Tclin,0.144,0.666,0.547,0,0,0,1,1,DC02244,RO7293583,BsAb,FD00026,Melanoma,Melanoma,Phase 1
1539,TP00497,CD3D;VTCN1,CD3D,VTCN1,CET+CIT,Tbio+Tclin,0.245,0.663,0.606,0,0,0,2,3,DC02116,GEN1047,BsAb,FD00007,Breast Cancer,Breast Cancer,Phase 1|Phase 2
1540,TP00497,CD3D;VTCN1,CD3D,VTCN1,CET+CIT,Tbio+Tclin,0.245,0.663,0.606,0,0,0,2,3,DC02116,GEN1047,BsAb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
1541,TP00497,CD3D;VTCN1,CD3D,VTCN1,CET+CIT,Tbio+Tclin,0.245,0.663,0.606,0,0,0,2,3,DC02116,GEN1047,BsAb,FD00034,Ovarian Cancer,Ovarian Cancer,Phase 1|Phase 2
1544,TP00498,CD3E;CDH17,CD3E,CDH17,CET+CIT,Tbio+Tclin,0.353,0.649,0.551,0,0,0,1,4,DC02024,ARB202,BsAb,FD00011,Colorectal Cancer,Colorectal Cancer,Phase 1
1545,TP00498,CD3E;CDH17,CD3E,CDH17,CET+CIT,Tbio+Tclin,0.353,0.649,0.551,0,0,0,1,4,DC02024,ARB202,BsAb,FD00022,Liver Cancer,Liver Cancer,Phase 1
1546,TP00498,CD3E;CDH17,CD3E,CDH17,CET+CIT,Tbio+Tclin,0.353,0.649,0.551,0,0,0,1,4,DC02024,ARB202,BsAb,FD00035,Pancreatic Cancer,Pancreatic Cancer,Phase 1
1547,TP00498,CD3E;CDH17,CD3E,CDH17,CET+CIT,Tbio+Tclin,0.353,0.649,0.551,0,0,0,1,4,DC02024,ARB202,BsAb,FD00041,Stomach Cancer,Stomach Cancer,Phase 1
1548,TP00499,CD3E;CDH3,CD3E,CDH3,CET+CIT,Tbio+Tclin,0.384,0.685,0.437,0,0,0,1,1,DC02213,PF06671008,BsAb,FD00033,Other Cancer,Other Cancer,Phase 1
1549,TP00500,CD3E;CEACAM5,CD3E,CEACAM5,CET+CIT,Tbio+Tclin,0.241,0.631,0.648,0,0,0,3,3,DC02012,AMG211,BsAb,FD00041,Stomach Cancer,Stomach Cancer,Phase 1
1550,TP00500,CD3E;CEACAM5,CD3E,CEACAM5,CET+CIT,Tbio+Tclin,0.241,0.631,0.648,0,0,0,3,3,DC02063,Cibisatamab,BsAb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
1551,TP00500,CD3E;CEACAM5,CD3E,CEACAM5,CET+CIT,Tbio+Tclin,0.241,0.631,0.648,0,0,0,3,3,DC02063,Cibisatamab,BsAb,FD00033,Other Cancer,Other Cancer,Phase 1
1553,TP00501,CD3E;CLDN18,CD3E,CLDN18,CET+CIT,Tbio+Tclin,0.289,0.618,0.659,0,0,0,4,3,DC02122,Gresonitamab,BsAb,FD00041,Stomach Cancer,Stomach Cancer,Phase 1
1554,TP00501,CD3E;CLDN18,CD3E,CLDN18,CET+CIT,Tbio+Tclin,0.289,0.618,0.659,0,0,0,4,3,DC02025,ASP2138,BsAb,FD00035,Pancreatic Cancer,Pancreatic Cancer,Phase 1
1556,TP00501,CD3E;CLDN18,CD3E,CLDN18,CET+CIT,Tbio+Tclin,0.289,0.618,0.659,0,0,0,4,3,DC02136,IBI389,BsAb,FD00033,Other Cancer,Other Cancer,Phase 1
1558,TP00502,CD3E;CLDN6,CD3E,CLDN6,CET+CIT,Tbio+Tclin,0.189,0.628,0.638,0,0,0,3,3,DC02251,SAIL66,BsAb,FD00033,Other Cancer,Other Cancer,Phase 1
1560,TP00502,CD3E;CLDN6,CD3E,CLDN6,CET+CIT,Tbio+Tclin,0.189,0.628,0.638,0,0,0,3,3,DC02018,AMG794,BsAb,FD00023,Lung Cancer,Lung Cancer,Phase 1
1561,TP00502,CD3E;CLDN6,CD3E,CLDN6,CET+CIT,Tbio+Tclin,0.189,0.628,0.638,0,0,0,3,3,DC02018,AMG794,BsAb,FD00034,Ovarian Cancer,Ovarian Cancer,Phase 1
1562,TP00503,CD3E;CLEC12A,CD3E,CLEC12A,CET+CIT,Tbio+Tclin,,0.57,0.57,0,0,0,1,1,DC02276,Tepoditamab,BsAb,FD00021,Leukemia,Hematologic Malignancy,Phase 1
1563,TP00504,CD3E;CRBN,CD3E,CRBN,CET+CIT,Tclin+Tclin,0.206,0.491,0.608,0,0,0,3,2,DC01682,Pavurutamab;Pomalidomide,DrugComb,FD00030,Myeloma,Hematologic Malignancy,Phase 1
1564,TP00504,CD3E;CRBN,CD3E,CRBN,CET+CIT,Tclin+Tclin,0.206,0.491,0.608,0,0,0,3,2,DC00552,Blinatumomab;Lenalidomide,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 1
1566,TP00505,CD3E;CTLA4,CD3E,CTLA4,CET+CET,Tclin+Tclin,0.337,0.686,1.0,1,0,1,1,1,DC01950,Tebentafusp;Tremelimumab,DrugComb,FD00026,Melanoma,Melanoma,Phase 1|Phase 2
1567,TP00506,CD3E;DLL3,CD3E,DLL3,CET+CIT,Tbio+Tclin,0.335,0.67,0.4,1,0,0,3,5,DC02038,BI764532,BsAb,FD00017,Glioma,Glioma,Phase 1
1568,TP00506,CD3E;DLL3,CD3E,DLL3,CET+CIT,Tbio+Tclin,0.335,0.67,0.4,1,0,0,3,5,DC02038,BI764532,BsAb,FD00023,Lung Cancer,Lung Cancer,Phase 2
1569,TP00506,CD3E;DLL3,CD3E,DLL3,CET+CIT,Tbio+Tclin,0.335,0.67,0.4,1,0,0,3,5,DC02038,BI764532,BsAb,FD00032,Neuroendocrine Tumor,Other Cancer,Phase 1|Phase 2
1571,TP00506,CD3E;DLL3,CD3E,DLL3,CET+CIT,Tbio+Tclin,0.335,0.67,0.4,1,0,0,3,5,DC02271,Tarlatamab,BsAb,FD00038,Prostate Cancer,Prostate Cancer,Phase 1
1572,TP00506,CD3E;DLL3,CD3E,DLL3,CET+CIT,Tbio+Tclin,0.335,0.67,0.4,1,0,0,3,5,DC02232,QLS31904,BsAb,FD00033,Other Cancer,Other Cancer,Phase 1
1573,TP00507,CD3E;EGFR,CD3E,EGFR,CET+CIT,Tclin+Tclin,0.464,0.607,0.581,1,0,0,5,5,DC01493,MM151;Talquetamab,DrugComb,FD00011,Colorectal Cancer,Colorectal Cancer,Phase 1
1574,TP00507,CD3E;EGFR,CD3E,EGFR,CET+CIT,Tclin+Tclin,0.464,0.607,0.581,1,0,0,5,5,DC01493,MM151;Talquetamab,DrugComb,FD00018,Head and Neck Cancer,Head and Neck Cancer,Phase 1
1575,TP00507,CD3E;EGFR,CD3E,EGFR,CET+CIT,Tclin+Tclin,0.464,0.607,0.581,1,0,0,5,5,DC01493,MM151;Talquetamab,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
1576,TP00507,CD3E;EGFR,CD3E,EGFR,CET+CIT,Tclin+Tclin,0.464,0.607,0.581,1,0,0,5,5,DC02247,RO7428731,BsAb,FD00017,Glioma,Glioma,Phase 1
1580,TP00507,CD3E;EGFR,CD3E,EGFR,CET+CIT,Tclin+Tclin,0.464,0.607,0.581,1,0,0,5,5,DC02074,CX904,BsAb,FD00033,Other Cancer,Other Cancer,Phase 1
1582,TP00508,CD3E;ENPP3,CD3E,ENPP3,CET+CIT,Tchem+Tclin,0.187,0.552,0.21,0,0,0,1,1,DC02300,XmAb819,BsAb,FD00020,Kidney Cancer,Kidney Cancer,Phase 1
1583,TP00509,CD3E;EPCAM,CD3E,EPCAM,CET+CIT,Tbio+Tclin,0.378,0.632,0.607,0,0,0,4,6,DC02053,Catumaxomab,BsAb,FD00006,Bladder Cancer,Bladder Cancer,Phase 1
1584,TP00509,CD3E;EPCAM,CD3E,EPCAM,CET+CIT,Tbio+Tclin,0.378,0.632,0.607,0,0,0,4,6,DC02053,Catumaxomab,BsAb,FD00034,Ovarian Cancer,Ovarian Cancer,Phase 2
1585,TP00509,CD3E;EPCAM,CD3E,EPCAM,CET+CIT,Tbio+Tclin,0.378,0.632,0.607,0,0,0,4,6,DC02053,Catumaxomab,BsAb,FD00041,Stomach Cancer,Stomach Cancer,Phase 3
1586,TP00509,CD3E;EPCAM,CD3E,EPCAM,CET+CIT,Tbio+Tclin,0.378,0.632,0.607,0,0,0,4,6,DC02053,Catumaxomab,BsAb,FD00047,Malignant Ascites,Other Cancer,Approval
1587,TP00509,CD3E;EPCAM,CD3E,EPCAM,CET+CIT,Tbio+Tclin,0.378,0.632,0.607,0,0,0,4,6,DC02265,Solitomab,BsAb,FD00033,Other Cancer,Other Cancer,Phase 1
1588,TP00509,CD3E;EPCAM,CD3E,EPCAM,CET+CIT,Tbio+Tclin,0.378,0.632,0.607,0,0,0,4,6,DC02182,M701,BsAb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
1591,TP00510,CD3E;ERBB2,CD3E,ERBB2,CET+CIT,Tclin+Tclin,0.515,0.663,0.64,0,0,0,5,2,DC02098,Ertumaxomab,BsAb,FD00007,Breast Cancer,Breast Cancer,Phase 2
1592,TP00510,CD3E;ERBB2,CD3E,ERBB2,CET+CIT,Tclin+Tclin,0.515,0.663,0.64,0,0,0,5,2,DC02098,Ertumaxomab,BsAb,FD00033,Other Cancer,Other Cancer,Phase 1|Phase 2
1598,TP00511,CD3E;FAP,CD3E,FAP,CET+CIT,Tchem+Tclin,0.293,0.58,0.523,0,0,0,1,2,DC02200,NG641,BsAb,FD00018,Head and Neck Cancer,Head and Neck Cancer,Phase 1
1599,TP00511,CD3E;FAP,CD3E,FAP,CET+CIT,Tchem+Tclin,0.293,0.58,0.523,0,0,0,1,2,DC02200,NG641,BsAb,FD00033,Other Cancer,Other Cancer,Phase 1
1600,TP00512,CD3E;FCRL5,CD3E,FCRL5,CET+CET,Tbio+Tclin,1.0,0.542,0.751,0,0,0,1,1,DC02062,Cevostamab,BsAb,FD00030,Myeloma,Hematologic Malignancy,Phase 2
1601,TP00513,CD3E;FLT3,CD3E,FLT3,CET+CIT,Tclin+Tclin,0.496,0.692,0.561,1,0,0,2,2,DC02066,CLN049,BsAb,FD00021,Leukemia,Hematologic Malignancy,Phase 1
1602,TP00513,CD3E;FLT3,CD3E,FLT3,CET+CIT,Tclin+Tclin,0.496,0.692,0.561,1,0,0,2,2,DC02066,CLN049,BsAb,FD00030,Myeloma,Hematologic Malignancy,Phase 1
1604,TP00514,CD3E;FOLH1,CD3E,FOLH1,CET+CET,Tclin+Tclin,0.12,0.654,0.283,0,0,0,9,5,DC02056,CC-1,BsAb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
1605,TP00514,CD3E;FOLH1,CD3E,FOLH1,CET+CET,Tclin+Tclin,0.12,0.654,0.283,0,0,0,9,5,DC02056,CC-1,BsAb,FD00038,Prostate Cancer,Prostate Cancer,Phase 1
1607,TP00514,CD3E;FOLH1,CD3E,FOLH1,CET+CET,Tclin+Tclin,0.12,0.654,0.283,0,0,0,9,5,DC02114,GEM3PSCA,BsAb,FD00006,Bladder Cancer,Bladder Cancer,Phase 1
1608,TP00514,CD3E;FOLH1,CD3E,FOLH1,CET+CET,Tclin+Tclin,0.12,0.654,0.283,0,0,0,9,5,DC02114,GEM3PSCA,BsAb,FD00020,Kidney Cancer,Kidney Cancer,Phase 1
1617,TP00514,CD3E;FOLH1,CD3E,FOLH1,CET+CET,Tclin+Tclin,0.12,0.654,0.283,0,0,0,9,5,DC02292,Voxalatamab,BsAb,FD00033,Other Cancer,Other Cancer,Phase 1
1618,TP00515,CD3E;GPA33,CD3E,GPA33,CET+CIT,Tbio+Tclin,,0.618,0.704,0,0,0,1,1,DC02191,MGD007,BsAb,FD00011,Colorectal Cancer,Colorectal Cancer,Phase 1|Phase 2
1619,TP00516,CD3E;GPC3,CD3E,GPC3,CET+CIT,Tbio+Tclin,0.367,0.65,0.561,0,0,0,2,2,DC02069,CM350,BsAb,FD00033,Other Cancer,Other Cancer,Phase 1|Phase 2
1620,TP00516,CD3E;GPC3,CD3E,GPC3,CET+CIT,Tbio+Tclin,0.367,0.65,0.561,0,0,0,2,2,DC02099,ERY974,BsAb,FD00022,Liver Cancer,Liver Cancer,Phase 1
1622,TP00517,CD3E;GPRC5D,CD3E,GPRC5D,CET+CIT,Tbio+Tclin,0.353,0.607,0.649,0,0,0,2,1,DC02234,QLS32015,BsAb,FD00030,Myeloma,Hematologic Malignancy,Phase 1
1624,TP00518,CD3E;GSAP,CD3E,GSAP,CET+CIT,Tchem+Tclin,0.154,0.672,0.588,0,0,0,1,1,DC01556,Nirogacestat;Teclistamab,DrugComb,FD00030,Myeloma,Hematologic Malignancy,Phase 1
1625,TP00519,CD3E;GUCY2C,CD3E,GUCY2C,CET+CIT,Tclin+Tclin,0.389,0.633,0.495,0,0,0,1,3,DC02214,PF07062119,BsAb,FD00011,Colorectal Cancer,Colorectal Cancer,Phase 1
1626,TP00519,CD3E;GUCY2C,CD3E,GUCY2C,CET+CIT,Tclin+Tclin,0.389,0.633,0.495,0,0,0,1,3,DC02214,PF07062119,BsAb,FD00014,Esophageal Cancer,Esophageal Cancer,Phase 1
1627,TP00519,CD3E;GUCY2C,CD3E,GUCY2C,CET+CIT,Tclin+Tclin,0.389,0.633,0.495,0,0,0,1,3,DC02214,PF07062119,BsAb,FD00041,Stomach Cancer,Stomach Cancer,Phase 1
1628,TP00520,CD3E;HLA-G,CD3E,HLA-G,CET+CET,Tbio+Tclin,0.436,0.601,0.676,3,1,0,1,1,DC02161,JNJ78306358,BsAb,FD00033,Other Cancer,Other Cancer,Phase 1
1629,TP00521,CD3E;IL3RA,CD3E,IL3RA,CET+CIT,Tclin+Tclin,0.239,0.628,0.692,1,0,0,6,3,DC02023,APVO436,BsAb,FD00021,Leukemia,Hematologic Malignancy,Phase 1
1630,TP00521,CD3E;IL3RA,CD3E,IL3RA,CET+CIT,Tclin+Tclin,0.239,0.628,0.692,1,0,0,6,3,DC02023,APVO436,BsAb,FD00030,Myeloma,Hematologic Malignancy,Phase 1
1631,TP00521,CD3E;IL3RA,CD3E,IL3RA,CET+CIT,Tclin+Tclin,0.239,0.628,0.692,1,0,0,6,3,DC02107,Flotetuzumab,BsAb,FD00019,Hematologic Malignancies,Hematologic Malignancy,Phase 2
1641,TP00522,CD3E;KLK2,CD3E,KLK2,CET+CIT,Tchem+Tclin,0.113,0.371,0.099,0,0,0,1,1,DC02160,JNJ78278343,BsAb,FD00038,Prostate Cancer,Prostate Cancer,Phase 1
1642,TP00523,CD3E;LY6G6D,CD3E,LY6G6D,CET+CIT,Tbio+Tclin,0.234,0.619,0.627,0,0,0,1,1,DC02048,BLYG8824A,BsAb,FD00011,Colorectal Cancer,Colorectal Cancer,Phase 1
1643,TP00524,CD3E;MAGEA4,CD3E,MAGEA4,CET+CIT,Tbio+Tclin,0.271,0.353,0.645,0,0,0,2,1,DC02140,IMCC103C,BsAb,FD00033,Other Cancer,Other Cancer,Phase 1|Phase 2
1645,TP00525,CD3E;MS4A1,CD3E,MS4A1,CET+CIT,Tclin+Tclin,0.417,0.67,0.634,1,0,0,13,6,DC02185,MBS303,BsAb,FD00024,Lymphoma,Hematologic Malignancy,Phase 1|Phase 2
1646,TP00525,CD3E;MS4A1,CD3E,MS4A1,CET+CIT,Tclin+Tclin,0.417,0.67,0.634,1,0,0,13,6,DC02206,Odronextamab,BsAb,FD00021,Leukemia,Hematologic Malignancy,Phase 1
1651,TP00525,CD3E;MS4A1,CD3E,MS4A1,CET+CIT,Tclin+Tclin,0.417,0.67,0.634,1,0,0,13,6,DC02194,Mosunetuzumab,BsAb,FD00019,Hematologic Malignancies,Hematologic Malignancy,Phase 1|Phase 2
1655,TP00525,CD3E;MS4A1,CD3E,MS4A1,CET+CIT,Tclin+Tclin,0.417,0.67,0.634,1,0,0,13,6,DC02280,TQB2825,BsAb,FD00033,Other Cancer,Other Cancer,Phase 1|Phase 2
1656,TP00525,CD3E;MS4A1,CD3E,MS4A1,CET+CIT,Tclin+Tclin,0.417,0.67,0.634,1,0,0,13,6,DC02280,TQB2825,BsAb,FD00034,Ovarian Cancer,Ovarian Cancer,Phase 1
1657,TP00525,CD3E;MS4A1,CD3E,MS4A1,CET+CIT,Tclin+Tclin,0.417,0.67,0.634,1,0,0,13,6,DC02280,TQB2825,BsAb,FD00040,Soft Tissue Sarcoma,Other Cancer,Phase 2
1667,TP00526,CD3E;MUC16,CD3E,MUC16,CET+CIT,Tbio+Tclin,0.392,0.598,1.0,0,0,0,2,2,DC02174,LBL033,BsAb,FD00033,Other Cancer,Other Cancer,Phase 1|Phase 2
1668,TP00526,CD3E;MUC16,CD3E,MUC16,CET+CIT,Tbio+Tclin,0.392,0.598,1.0,0,0,0,2,2,DC02286,Ubamatamab,BsAb,FD00034,Ovarian Cancer,Ovarian Cancer,Phase 1|Phase 2
1669,TP00527,CD3E;MUC17,CD3E,MUC17,CET+CIT,Tbio+Tclin,0.285,0.669,0.577,0,0,0,1,3,DC02288,Vepsitamab,BsAb,FD00011,Colorectal Cancer,Colorectal Cancer,Phase 1
1670,TP00527,CD3E;MUC17,CD3E,MUC17,CET+CIT,Tbio+Tclin,0.285,0.669,0.577,0,0,0,1,3,DC02288,Vepsitamab,BsAb,FD00035,Pancreatic Cancer,Pancreatic Cancer,Phase 1
1671,TP00527,CD3E;MUC17,CD3E,MUC17,CET+CIT,Tbio+Tclin,0.285,0.669,0.577,0,0,0,1,3,DC02288,Vepsitamab,BsAb,FD00041,Stomach Cancer,Stomach Cancer,Phase 1
1672,TP00528,CD3E;NCR3LG1,CD3E,NCR3LG1,CET+CET,Tbio+Tclin,0.281,0.585,0.609,0,1,0,1,5,DC02039,BI765049,BsAb,FD00011,Colorectal Cancer,Colorectal Cancer,Phase 1
1673,TP00528,CD3E;NCR3LG1,CD3E,NCR3LG1,CET+CET,Tbio+Tclin,0.281,0.585,0.609,0,1,0,1,5,DC02039,BI765049,BsAb,FD00018,Head and Neck Cancer,Head and Neck Cancer,Phase 1
1674,TP00528,CD3E;NCR3LG1,CD3E,NCR3LG1,CET+CET,Tbio+Tclin,0.281,0.585,0.609,0,1,0,1,5,DC02039,BI765049,BsAb,FD00022,Liver Cancer,Liver Cancer,Phase 1
1675,TP00528,CD3E;NCR3LG1,CD3E,NCR3LG1,CET+CET,Tbio+Tclin,0.281,0.585,0.609,0,1,0,1,5,DC02039,BI765049,BsAb,FD00023,Lung Cancer,Lung Cancer,Phase 1
1676,TP00528,CD3E;NCR3LG1,CD3E,NCR3LG1,CET+CET,Tbio+Tclin,0.281,0.585,0.609,0,1,0,1,5,DC02039,BI765049,BsAb,FD00035,Pancreatic Cancer,Pancreatic Cancer,Phase 1
1677,TP00529,CD3E;PDCD1,CD3E,PDCD1,CET+CET,Tclin+Tclin,0.319,0.639,1.0,2,1,1,14,15,DC00507,BI764532;Ezabenlimab,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
1678,TP00529,CD3E;PDCD1,CD3E,PDCD1,CET+CET,Tclin+Tclin,0.319,0.639,1.0,2,1,1,14,15,DC00507,BI764532;Ezabenlimab,DrugComb,FD00032,Neuroendocrine Tumor,Other Cancer,Phase 1|Phase 2
1679,TP00529,CD3E;PDCD1,CD3E,PDCD1,CET+CET,Tclin+Tclin,0.319,0.639,1.0,2,1,1,14,15,DC00771,Cibisatamab;Nivolumab,DrugComb,FD00018,Head and Neck Cancer,Head and Neck Cancer,Phase 2
1680,TP00529,CD3E;PDCD1,CD3E,PDCD1,CET+CET,Tclin+Tclin,0.319,0.639,1.0,2,1,1,14,15,DC00771,Cibisatamab;Nivolumab,DrugComb,FD00030,Myeloma,Hematologic Malignancy,Phase 2
1682,TP00529,CD3E;PDCD1,CD3E,PDCD1,CET+CET,Tclin+Tclin,0.319,0.639,1.0,2,1,1,14,15,DC01612,Obrindatamab;Retifanlimab,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
1683,TP00529,CD3E;PDCD1,CD3E,PDCD1,CET+CET,Tclin+Tclin,0.319,0.639,1.0,2,1,1,14,15,DC00975,Eluvixtamab;Pembrolizumab,DrugComb,FD00021,Leukemia,Hematologic Malignancy,Phase 1
1684,TP00529,CD3E;PDCD1,CD3E,PDCD1,CET+CET,Tclin+Tclin,0.319,0.639,1.0,2,1,1,14,15,DC01729,Pembrolizumab;Tebentafusp,DrugComb,FD00026,Melanoma,Melanoma,Phase 2|Phase 3
1686,TP00529,CD3E;PDCD1,CD3E,PDCD1,CET+CET,Tclin+Tclin,0.319,0.639,1.0,2,1,1,14,15,DC00553,Blinatumomab;Pembrolizumab,DrugComb,FD00019,Hematologic Malignancies,Hematologic Malignancy,Phase 1
1688,TP00529,CD3E;PDCD1,CD3E,PDCD1,CET+CET,Tclin+Tclin,0.319,0.639,1.0,2,1,1,14,15,DC00553,Blinatumomab;Pembrolizumab,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 1
1689,TP00529,CD3E;PDCD1,CD3E,PDCD1,CET+CET,Tclin+Tclin,0.319,0.639,1.0,2,1,1,14,15,DC00720,Cetrelimab;JNJ78278343,DrugComb,FD00038,Prostate Cancer,Prostate Cancer,Phase 1
1690,TP00529,CD3E;PDCD1,CD3E,PDCD1,CET+CET,Tclin+Tclin,0.319,0.639,1.0,2,1,1,14,15,DC00508,BI765049;Ezabenlimab,DrugComb,FD00011,Colorectal Cancer,Colorectal Cancer,Phase 1
1692,TP00529,CD3E;PDCD1,CD3E,PDCD1,CET+CET,Tclin+Tclin,0.319,0.639,1.0,2,1,1,14,15,DC00508,BI765049;Ezabenlimab,DrugComb,FD00022,Liver Cancer,Liver Cancer,Phase 1
1694,TP00529,CD3E;PDCD1,CD3E,PDCD1,CET+CET,Tclin+Tclin,0.319,0.639,1.0,2,1,1,14,15,DC00508,BI765049;Ezabenlimab,DrugComb,FD00035,Pancreatic Cancer,Pancreatic Cancer,Phase 1
1697,TP00529,CD3E;PDCD1,CD3E,PDCD1,CET+CET,Tclin+Tclin,0.319,0.639,1.0,2,1,1,14,15,DC01090,Etevritamab;Zeluvalimab,DrugComb,FD00017,Glioma,Glioma,Phase 1
1698,TP00529,CD3E;PDCD1,CD3E,PDCD1,CET+CET,Tclin+Tclin,0.319,0.639,1.0,2,1,1,14,15,DC00707,Cemiplimab;Ubamatamab,DrugComb,FD00034,Ovarian Cancer,Ovarian Cancer,Phase 1|Phase 2
1700,TP00530,CD3E;PMEL,CD3E,PMEL,CET+CIT,Tclin+Tclin,0.105,0.705,0.683,0,0,0,1,1,DC02272,Tebentafusp,BsAb,FD00026,Melanoma,Melanoma,Approval
1701,TP00531,CD3E;PRAME,CD3E,PRAME,CET+CIT,Tbio+Tclin,0.375,0.601,0.62,0,0,0,1,1,DC02141,IMCF106C,BsAb,FD00033,Other Cancer,Other Cancer,Phase 1|Phase 2
1702,TP00532,CD3E;ROR1,CD3E,ROR1,CET+CIT,Tbio+Tclin,0.381,0.641,0.647,0,0,0,2,3,DC02090,EMB07,BsAb,FD00033,Other Cancer,Other Cancer,Phase 1
1703,TP00532,CD3E;ROR1,CD3E,ROR1,CET+CIT,Tbio+Tclin,0.381,0.641,0.647,0,0,0,2,3,DC02204,NVG111,BsAb,FD00021,Leukemia,Hematologic Malignancy,Phase 1
1704,TP00532,CD3E;ROR1,CD3E,ROR1,CET+CIT,Tbio+Tclin,0.381,0.641,0.647,0,0,0,2,3,DC02204,NVG111,BsAb,FD00024,Lymphoma,Hematologic Malignancy,Phase 1
1705,TP00533,CD3E;SLAMF7,CD3E,SLAMF7,CET+CIT,Tclin+Tclin,0.279,0.639,1.0,0,1,0,1,1,DC00770,Cibisatamab;Elotuzumab,DrugComb,FD00030,Myeloma,Hematologic Malignancy,Phase 1
1706,TP00534,CD3E;SSTR2,CD3E,SSTR2,CET+CIT,Tclin+Tclin,0.385,0.668,0.643,0,0,0,1,3,DC02277,Tidutamab,BsAb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
1707,TP00534,CD3E;SSTR2,CD3E,SSTR2,CET+CIT,Tclin+Tclin,0.385,0.668,0.643,0,0,0,1,3,DC02277,Tidutamab,BsAb,FD00028,Merkel Cell Carcinoma,Other Cancer,Phase 1|Phase 2
1708,TP00534,CD3E;SSTR2,CD3E,SSTR2,CET+CIT,Tclin+Tclin,0.385,0.668,0.643,0,0,0,1,3,DC02277,Tidutamab,BsAb,FD00041,Stomach Cancer,Stomach Cancer,Phase 1
1709,TP00535,CD3E;STEAP1,CD3E,STEAP1,CET+CIT,Tbio+Tclin,0.13,0.736,0.248,0,0,0,1,1,DC02016,AMG509,BsAb,FD00038,Prostate Cancer,Prostate Cancer,Phase 1
1710,TP00536,CD3E;TMEFF2,CD3E,TMEFF2,CET+CIT,Tbio+Tclin,0.232,0.592,0.643,0,0,0,1,1,DC02158,JNJ70218902,BsAb,FD00033,Other Cancer,Other Cancer,Phase 1
1711,TP00537,CD3E;TNFRSF17,CD3E,TNFRSF17,CET+CIT,Tclin+Tclin,0.404,0.628,0.704,0,0,0,13,1,DC02104,F182112,BsAb,FD00030,Myeloma,Hematologic Malignancy,Phase 1
1724,TP00538,CD3E;TPBG,CD3E,TPBG,CET+CIT,Tbio+Tclin,0.33,0.744,,0,0,0,1,1,DC02115,GEN1044,BsAb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
1725,TP00539,CD3E;TYRP1,CD3E,TYRP1,CET+CIT,Tbio+Tclin,0.15,0.419,0.529,0,0,0,1,1,DC02244,RO7293583,BsAb,FD00026,Melanoma,Melanoma,Phase 1
1726,TP00540,CD3E;VTCN1,CD3E,VTCN1,CET+CIT,Tbio+Tclin,0.496,0.535,0.555,0,0,0,2,3,DC02116,GEN1047,BsAb,FD00007,Breast Cancer,Breast Cancer,Phase 1|Phase 2
1727,TP00540,CD3E;VTCN1,CD3E,VTCN1,CET+CIT,Tbio+Tclin,0.496,0.535,0.555,0,0,0,2,3,DC02116,GEN1047,BsAb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
1728,TP00540,CD3E;VTCN1,CD3E,VTCN1,CET+CIT,Tbio+Tclin,0.496,0.535,0.555,0,0,0,2,3,DC02116,GEN1047,BsAb,FD00034,Ovarian Cancer,Ovarian Cancer,Phase 1|Phase 2
1731,TP00541,CD3G;CDH17,CD3G,CDH17,CET+CIT,Tbio+Tclin,0.476,0.592,0.54,0,0,0,1,4,DC02024,ARB202,BsAb,FD00011,Colorectal Cancer,Colorectal Cancer,Phase 1
1732,TP00541,CD3G;CDH17,CD3G,CDH17,CET+CIT,Tbio+Tclin,0.476,0.592,0.54,0,0,0,1,4,DC02024,ARB202,BsAb,FD00022,Liver Cancer,Liver Cancer,Phase 1
1733,TP00541,CD3G;CDH17,CD3G,CDH17,CET+CIT,Tbio+Tclin,0.476,0.592,0.54,0,0,0,1,4,DC02024,ARB202,BsAb,FD00035,Pancreatic Cancer,Pancreatic Cancer,Phase 1
1734,TP00541,CD3G;CDH17,CD3G,CDH17,CET+CIT,Tbio+Tclin,0.476,0.592,0.54,0,0,0,1,4,DC02024,ARB202,BsAb,FD00041,Stomach Cancer,Stomach Cancer,Phase 1
1735,TP00542,CD3G;CDH3,CD3G,CDH3,CET+CIT,Tbio+Tclin,0.262,0.653,0.458,0,0,0,1,1,DC02213,PF06671008,BsAb,FD00033,Other Cancer,Other Cancer,Phase 1
1736,TP00543,CD3G;CEACAM5,CD3G,CEACAM5,CET+CIT,Tbio+Tclin,0.295,0.64,0.656,0,0,0,3,3,DC02012,AMG211,BsAb,FD00041,Stomach Cancer,Stomach Cancer,Phase 1
1737,TP00543,CD3G;CEACAM5,CD3G,CEACAM5,CET+CIT,Tbio+Tclin,0.295,0.64,0.656,0,0,0,3,3,DC02063,Cibisatamab,BsAb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
1738,TP00543,CD3G;CEACAM5,CD3G,CEACAM5,CET+CIT,Tbio+Tclin,0.295,0.64,0.656,0,0,0,3,3,DC02063,Cibisatamab,BsAb,FD00033,Other Cancer,Other Cancer,Phase 1
1740,TP00544,CD3G;CLDN18,CD3G,CLDN18,CET+CIT,Tbio+Tclin,0.31,0.588,0.669,0,0,0,4,3,DC02122,Gresonitamab,BsAb,FD00041,Stomach Cancer,Stomach Cancer,Phase 1
1741,TP00544,CD3G;CLDN18,CD3G,CLDN18,CET+CIT,Tbio+Tclin,0.31,0.588,0.669,0,0,0,4,3,DC02025,ASP2138,BsAb,FD00035,Pancreatic Cancer,Pancreatic Cancer,Phase 1
1743,TP00544,CD3G;CLDN18,CD3G,CLDN18,CET+CIT,Tbio+Tclin,0.31,0.588,0.669,0,0,0,4,3,DC02233,QLS31905,BsAb,FD00033,Other Cancer,Other Cancer,Phase 1
1745,TP00545,CD3G;CLDN6,CD3G,CLDN6,CET+CIT,Tbio+Tclin,0.27,0.604,0.643,0,0,0,3,3,DC02049,BNT142,BsAb,FD00033,Other Cancer,Other Cancer,Phase 1|Phase 2
1746,TP00545,CD3G;CLDN6,CD3G,CLDN6,CET+CIT,Tbio+Tclin,0.27,0.604,0.643,0,0,0,3,3,DC02018,AMG794,BsAb,FD00023,Lung Cancer,Lung Cancer,Phase 1
1747,TP00545,CD3G;CLDN6,CD3G,CLDN6,CET+CIT,Tbio+Tclin,0.27,0.604,0.643,0,0,0,3,3,DC02018,AMG794,BsAb,FD00034,Ovarian Cancer,Ovarian Cancer,Phase 1
1749,TP00546,CD3G;CLEC12A,CD3G,CLEC12A,CET+CIT,Tbio+Tclin,,0.634,0.559,0,0,0,1,1,DC02276,Tepoditamab,BsAb,FD00021,Leukemia,Hematologic Malignancy,Phase 1
1750,TP00547,CD3G;CRBN,CD3G,CRBN,CET+CIT,Tclin+Tclin,0.249,0.585,0.606,0,0,0,3,2,DC01408,Lenalidomide;Teclistamab,DrugComb,FD00030,Myeloma,Hematologic Malignancy,Phase 3
1751,TP00547,CD3G;CRBN,CD3G,CRBN,CET+CIT,Tclin+Tclin,0.249,0.585,0.606,0,0,0,3,2,DC00552,Blinatumomab;Lenalidomide,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 1
1753,TP00548,CD3G;CTLA4,CD3G,CTLA4,CET+CET,Tclin+Tclin,0.341,0.769,1.0,1,0,1,1,1,DC01950,Tebentafusp;Tremelimumab,DrugComb,FD00026,Melanoma,Melanoma,Phase 1|Phase 2
1754,TP00549,CD3G;DLL3,CD3G,DLL3,CET+CIT,Tbio+Tclin,0.295,0.67,0.414,1,0,0,3,5,DC02271,Tarlatamab,BsAb,FD00023,Lung Cancer,Lung Cancer,Phase 3
1755,TP00549,CD3G;DLL3,CD3G,DLL3,CET+CIT,Tbio+Tclin,0.295,0.67,0.414,1,0,0,3,5,DC02271,Tarlatamab,BsAb,FD00038,Prostate Cancer,Prostate Cancer,Phase 1
1756,TP00549,CD3G;DLL3,CD3G,DLL3,CET+CIT,Tbio+Tclin,0.295,0.67,0.414,1,0,0,3,5,DC02038,BI764532,BsAb,FD00017,Glioma,Glioma,Phase 1
1758,TP00549,CD3G;DLL3,CD3G,DLL3,CET+CIT,Tbio+Tclin,0.295,0.67,0.414,1,0,0,3,5,DC02038,BI764532,BsAb,FD00032,Neuroendocrine Tumor,Other Cancer,Phase 1|Phase 2
1759,TP00549,CD3G;DLL3,CD3G,DLL3,CET+CIT,Tbio+Tclin,0.295,0.67,0.414,1,0,0,3,5,DC02232,QLS31904,BsAb,FD00033,Other Cancer,Other Cancer,Phase 1
1760,TP00550,CD3G;EGFR,CD3G,EGFR,CET+CIT,Tclin+Tclin,0.305,0.596,0.562,1,2,0,5,5,DC01493,MM151;Talquetamab,DrugComb,FD00011,Colorectal Cancer,Colorectal Cancer,Phase 1
1761,TP00550,CD3G;EGFR,CD3G,EGFR,CET+CIT,Tclin+Tclin,0.305,0.596,0.562,1,2,0,5,5,DC01493,MM151;Talquetamab,DrugComb,FD00018,Head and Neck Cancer,Head and Neck Cancer,Phase 1
1762,TP00550,CD3G;EGFR,CD3G,EGFR,CET+CIT,Tclin+Tclin,0.305,0.596,0.562,1,2,0,5,5,DC01493,MM151;Talquetamab,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
1766,TP00550,CD3G;EGFR,CD3G,EGFR,CET+CIT,Tclin+Tclin,0.305,0.596,0.562,1,2,0,5,5,DC02074,CX904,BsAb,FD00033,Other Cancer,Other Cancer,Phase 1
1767,TP00550,CD3G;EGFR,CD3G,EGFR,CET+CIT,Tclin+Tclin,0.305,0.596,0.562,1,2,0,5,5,DC02247,RO7428731,BsAb,FD00017,Glioma,Glioma,Phase 1
1769,TP00551,CD3G;ENPP3,CD3G,ENPP3,CET+CIT,Tchem+Tclin,0.202,0.636,0.209,0,0,0,1,1,DC02300,XmAb819,BsAb,FD00020,Kidney Cancer,Kidney Cancer,Phase 1
1770,TP00552,CD3G;EPCAM,CD3G,EPCAM,CET+CIT,Tbio+Tclin,0.3,0.599,0.605,0,0,0,4,6,DC02053,Catumaxomab,BsAb,FD00006,Bladder Cancer,Bladder Cancer,Phase 1
1771,TP00552,CD3G;EPCAM,CD3G,EPCAM,CET+CIT,Tbio+Tclin,0.3,0.599,0.605,0,0,0,4,6,DC02053,Catumaxomab,BsAb,FD00034,Ovarian Cancer,Ovarian Cancer,Phase 2
1772,TP00552,CD3G;EPCAM,CD3G,EPCAM,CET+CIT,Tbio+Tclin,0.3,0.599,0.605,0,0,0,4,6,DC02053,Catumaxomab,BsAb,FD00041,Stomach Cancer,Stomach Cancer,Phase 3
1773,TP00552,CD3G;EPCAM,CD3G,EPCAM,CET+CIT,Tbio+Tclin,0.3,0.599,0.605,0,0,0,4,6,DC02053,Catumaxomab,BsAb,FD00047,Malignant Ascites,Other Cancer,Approval
1774,TP00552,CD3G;EPCAM,CD3G,EPCAM,CET+CIT,Tbio+Tclin,0.3,0.599,0.605,0,0,0,4,6,DC02182,M701,BsAb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
1776,TP00552,CD3G;EPCAM,CD3G,EPCAM,CET+CIT,Tbio+Tclin,0.3,0.599,0.605,0,0,0,4,6,DC02265,Solitomab,BsAb,FD00033,Other Cancer,Other Cancer,Phase 1
1778,TP00553,CD3G;ERBB2,CD3G,ERBB2,CET+CIT,Tclin+Tclin,0.365,0.706,0.643,0,0,0,5,2,DC02250,Runimotamab,BsAb,FD00033,Other Cancer,Other Cancer,Phase 1
1779,TP00553,CD3G;ERBB2,CD3G,ERBB2,CET+CIT,Tclin+Tclin,0.365,0.706,0.643,0,0,0,5,2,DC02098,Ertumaxomab,BsAb,FD00007,Breast Cancer,Breast Cancer,Phase 2
1785,TP00554,CD3G;FAP,CD3G,FAP,CET+CIT,Tchem+Tclin,0.282,0.561,0.511,0,0,0,1,2,DC02200,NG641,BsAb,FD00018,Head and Neck Cancer,Head and Neck Cancer,Phase 1
1786,TP00554,CD3G;FAP,CD3G,FAP,CET+CIT,Tchem+Tclin,0.282,0.561,0.511,0,0,0,1,2,DC02200,NG641,BsAb,FD00033,Other Cancer,Other Cancer,Phase 1
1787,TP00555,CD3G;FCRL5,CD3G,FCRL5,CET+CET,Tbio+Tclin,1.0,0.573,0.79,0,0,0,1,1,DC02062,Cevostamab,BsAb,FD00030,Myeloma,Hematologic Malignancy,Phase 2
1788,TP00556,CD3G;FLT3,CD3G,FLT3,CET+CIT,Tclin+Tclin,0.409,0.704,0.555,1,0,0,2,2,DC02066,CLN049,BsAb,FD00021,Leukemia,Hematologic Malignancy,Phase 1
1789,TP00556,CD3G;FLT3,CD3G,FLT3,CET+CIT,Tclin+Tclin,0.409,0.704,0.555,1,0,0,2,2,DC02066,CLN049,BsAb,FD00030,Myeloma,Hematologic Malignancy,Phase 1
1791,TP00557,CD3G;FOLH1,CD3G,FOLH1,CET+CET,Tclin+Tclin,0.119,0.724,0.274,0,0,0,9,5,DC02013,AMG340,BsAb,FD00038,Prostate Cancer,Prostate Cancer,Phase 1
1792,TP00557,CD3G;FOLH1,CD3G,FOLH1,CET+CET,Tclin+Tclin,0.119,0.724,0.274,0,0,0,9,5,DC02114,GEM3PSCA,BsAb,FD00006,Bladder Cancer,Bladder Cancer,Phase 1
1793,TP00557,CD3G;FOLH1,CD3G,FOLH1,CET+CET,Tclin+Tclin,0.119,0.724,0.274,0,0,0,9,5,DC02114,GEM3PSCA,BsAb,FD00020,Kidney Cancer,Kidney Cancer,Phase 1
1794,TP00557,CD3G;FOLH1,CD3G,FOLH1,CET+CET,Tclin+Tclin,0.119,0.724,0.274,0,0,0,9,5,DC02114,GEM3PSCA,BsAb,FD00023,Lung Cancer,Lung Cancer,Phase 1
1803,TP00557,CD3G;FOLH1,CD3G,FOLH1,CET+CET,Tclin+Tclin,0.119,0.724,0.274,0,0,0,9,5,DC02292,Voxalatamab,BsAb,FD00033,Other Cancer,Other Cancer,Phase 1
1805,TP00558,CD3G;GPA33,CD3G,GPA33,CET+CIT,Tbio+Tclin,,0.667,0.729,0,0,0,1,1,DC02191,MGD007,BsAb,FD00011,Colorectal Cancer,Colorectal Cancer,Phase 1|Phase 2
1806,TP00559,CD3G;GPC3,CD3G,GPC3,CET+CIT,Tbio+Tclin,0.283,0.578,0.546,0,0,0,2,2,DC02099,ERY974,BsAb,FD00022,Liver Cancer,Liver Cancer,Phase 1
1807,TP00559,CD3G;GPC3,CD3G,GPC3,CET+CIT,Tbio+Tclin,0.283,0.578,0.546,0,0,0,2,2,DC02099,ERY974,BsAb,FD00033,Other Cancer,Other Cancer,Phase 1
1809,TP00560,CD3G;GPRC5D,CD3G,GPRC5D,CET+CIT,Tbio+Tclin,0.299,0.571,0.657,0,0,0,2,1,DC02270,Talquetamab,BsAb,FD00030,Myeloma,Hematologic Malignancy,Approval
1811,TP00561,CD3G;GSAP,CD3G,GSAP,CET+CIT,Tchem+Tclin,0.081,0.401,0.58,0,0,0,1,1,DC01556,Nirogacestat;Teclistamab,DrugComb,FD00030,Myeloma,Hematologic Malignancy,Phase 1
1812,TP00562,CD3G;GUCY2C,CD3G,GUCY2C,CET+CIT,Tclin+Tclin,0.394,0.614,0.478,0,0,0,1,3,DC02214,PF07062119,BsAb,FD00011,Colorectal Cancer,Colorectal Cancer,Phase 1
1813,TP00562,CD3G;GUCY2C,CD3G,GUCY2C,CET+CIT,Tclin+Tclin,0.394,0.614,0.478,0,0,0,1,3,DC02214,PF07062119,BsAb,FD00014,Esophageal Cancer,Esophageal Cancer,Phase 1
1814,TP00562,CD3G;GUCY2C,CD3G,GUCY2C,CET+CIT,Tclin+Tclin,0.394,0.614,0.478,0,0,0,1,3,DC02214,PF07062119,BsAb,FD00041,Stomach Cancer,Stomach Cancer,Phase 1
1815,TP00563,CD3G;HLA-G,CD3G,HLA-G,CET+CET,Tbio+Tclin,0.265,0.594,0.687,3,1,0,1,1,DC02161,JNJ78306358,BsAb,FD00033,Other Cancer,Other Cancer,Phase 1
1816,TP00564,CD3G;IL3RA,CD3G,IL3RA,CET+CIT,Tclin+Tclin,0.3,0.684,0.709,1,0,0,6,3,DC02107,Flotetuzumab,BsAb,FD00019,Hematologic Malignancies,Hematologic Malignancy,Phase 2
1817,TP00564,CD3G;IL3RA,CD3G,IL3RA,CET+CIT,Tclin+Tclin,0.3,0.684,0.709,1,0,0,6,3,DC02107,Flotetuzumab,BsAb,FD00021,Leukemia,Hematologic Malignancy,Phase 2
1818,TP00564,CD3G;IL3RA,CD3G,IL3RA,CET+CIT,Tclin+Tclin,0.3,0.684,0.709,1,0,0,6,3,DC02107,Flotetuzumab,BsAb,FD00030,Myeloma,Hematologic Malignancy,Phase 2
1828,TP00565,CD3G;KLK2,CD3G,KLK2,CET+CIT,Tchem+Tclin,0.085,0.337,0.099,0,0,0,1,1,DC02160,JNJ78278343,BsAb,FD00038,Prostate Cancer,Prostate Cancer,Phase 1
1829,TP00566,CD3G;LY6G6D,CD3G,LY6G6D,CET+CIT,Tbio+Tclin,0.249,0.586,0.629,0,0,0,1,1,DC02048,BLYG8824A,BsAb,FD00011,Colorectal Cancer,Colorectal Cancer,Phase 1
1830,TP00567,CD3G;MAGEA4,CD3G,MAGEA4,CET+CIT,Tbio+Tclin,0.256,0.275,0.652,0,0,0,2,1,DC02249,RO7444973,BsAb,FD00033,Other Cancer,Other Cancer,Phase 1
1832,TP00568,CD3G;MS4A1,CD3G,MS4A1,CET+CIT,Tclin+Tclin,0.509,0.663,0.638,1,0,0,13,6,DC02120,Glofitamab,BsAb,FD00024,Lymphoma,Hematologic Malignancy,Approval
1833,TP00568,CD3G;MS4A1,CD3G,MS4A1,CET+CIT,Tclin+Tclin,0.509,0.663,0.638,1,0,0,13,6,DC02111,GB261,BsAb,FD00021,Leukemia,Hematologic Malignancy,Phase 1|Phase 2
1835,TP00568,CD3G;MS4A1,CD3G,MS4A1,CET+CIT,Tclin+Tclin,0.509,0.663,0.638,1,0,0,13,6,DC02194,Mosunetuzumab,BsAb,FD00019,Hematologic Malignancies,Hematologic Malignancy,Phase 1|Phase 2
1842,TP00568,CD3G;MS4A1,CD3G,MS4A1,CET+CIT,Tclin+Tclin,0.509,0.663,0.638,1,0,0,13,6,DC02280,TQB2825,BsAb,FD00033,Other Cancer,Other Cancer,Phase 1|Phase 2
1843,TP00568,CD3G;MS4A1,CD3G,MS4A1,CET+CIT,Tclin+Tclin,0.509,0.663,0.638,1,0,0,13,6,DC02280,TQB2825,BsAb,FD00034,Ovarian Cancer,Ovarian Cancer,Phase 1
1844,TP00568,CD3G;MS4A1,CD3G,MS4A1,CET+CIT,Tclin+Tclin,0.509,0.663,0.638,1,0,0,13,6,DC02280,TQB2825,BsAb,FD00040,Soft Tissue Sarcoma,Other Cancer,Phase 2
1854,TP00569,CD3G;MUC16,CD3G,MUC16,CET+CIT,Tbio+Tclin,0.469,0.564,1.0,0,0,0,2,2,DC02286,Ubamatamab,BsAb,FD00034,Ovarian Cancer,Ovarian Cancer,Phase 1|Phase 2
1855,TP00569,CD3G;MUC16,CD3G,MUC16,CET+CIT,Tbio+Tclin,0.469,0.564,1.0,0,0,0,2,2,DC02174,LBL033,BsAb,FD00033,Other Cancer,Other Cancer,Phase 1|Phase 2
1856,TP00570,CD3G;MUC17,CD3G,MUC17,CET+CIT,Tbio+Tclin,0.403,0.645,0.567,0,0,0,1,3,DC02288,Vepsitamab,BsAb,FD00011,Colorectal Cancer,Colorectal Cancer,Phase 1
1857,TP00570,CD3G;MUC17,CD3G,MUC17,CET+CIT,Tbio+Tclin,0.403,0.645,0.567,0,0,0,1,3,DC02288,Vepsitamab,BsAb,FD00035,Pancreatic Cancer,Pancreatic Cancer,Phase 1
1858,TP00570,CD3G;MUC17,CD3G,MUC17,CET+CIT,Tbio+Tclin,0.403,0.645,0.567,0,0,0,1,3,DC02288,Vepsitamab,BsAb,FD00041,Stomach Cancer,Stomach Cancer,Phase 1
1859,TP00571,CD3G;NCR3LG1,CD3G,NCR3LG1,CET+CET,Tbio+Tclin,0.275,0.635,0.607,0,1,0,1,5,DC02039,BI765049,BsAb,FD00011,Colorectal Cancer,Colorectal Cancer,Phase 1
1860,TP00571,CD3G;NCR3LG1,CD3G,NCR3LG1,CET+CET,Tbio+Tclin,0.275,0.635,0.607,0,1,0,1,5,DC02039,BI765049,BsAb,FD00018,Head and Neck Cancer,Head and Neck Cancer,Phase 1
1861,TP00571,CD3G;NCR3LG1,CD3G,NCR3LG1,CET+CET,Tbio+Tclin,0.275,0.635,0.607,0,1,0,1,5,DC02039,BI765049,BsAb,FD00022,Liver Cancer,Liver Cancer,Phase 1
1862,TP00571,CD3G;NCR3LG1,CD3G,NCR3LG1,CET+CET,Tbio+Tclin,0.275,0.635,0.607,0,1,0,1,5,DC02039,BI765049,BsAb,FD00023,Lung Cancer,Lung Cancer,Phase 1
1863,TP00571,CD3G;NCR3LG1,CD3G,NCR3LG1,CET+CET,Tbio+Tclin,0.275,0.635,0.607,0,1,0,1,5,DC02039,BI765049,BsAb,FD00035,Pancreatic Cancer,Pancreatic Cancer,Phase 1
1864,TP00572,CD3G;PDCD1,CD3G,PDCD1,CET+CET,Tclin+Tclin,0.333,0.709,1.0,2,1,1,14,15,DC01947,Tarlatamab;Zeluvalimab,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
1865,TP00572,CD3G;PDCD1,CD3G,PDCD1,CET+CET,Tclin+Tclin,0.333,0.709,1.0,2,1,1,14,15,DC00720,Cetrelimab;JNJ78278343,DrugComb,FD00038,Prostate Cancer,Prostate Cancer,Phase 1
1866,TP00572,CD3G;PDCD1,CD3G,PDCD1,CET+CET,Tclin+Tclin,0.333,0.709,1.0,2,1,1,14,15,DC01090,Etevritamab;Zeluvalimab,DrugComb,FD00017,Glioma,Glioma,Phase 1
1868,TP00572,CD3G;PDCD1,CD3G,PDCD1,CET+CET,Tclin+Tclin,0.333,0.709,1.0,2,1,1,14,15,DC00507,BI764532;Ezabenlimab,DrugComb,FD00032,Neuroendocrine Tumor,Other Cancer,Phase 1|Phase 2
1869,TP00572,CD3G;PDCD1,CD3G,PDCD1,CET+CET,Tclin+Tclin,0.333,0.709,1.0,2,1,1,14,15,DC00553,Blinatumomab;Pembrolizumab,DrugComb,FD00019,Hematologic Malignancies,Hematologic Malignancy,Phase 1
1870,TP00572,CD3G;PDCD1,CD3G,PDCD1,CET+CET,Tclin+Tclin,0.333,0.709,1.0,2,1,1,14,15,DC00553,Blinatumomab;Pembrolizumab,DrugComb,FD00021,Leukemia,Hematologic Malignancy,Phase 1|Phase 2
1871,TP00572,CD3G;PDCD1,CD3G,PDCD1,CET+CET,Tclin+Tclin,0.333,0.709,1.0,2,1,1,14,15,DC00553,Blinatumomab;Pembrolizumab,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 1
1872,TP00572,CD3G;PDCD1,CD3G,PDCD1,CET+CET,Tclin+Tclin,0.333,0.709,1.0,2,1,1,14,15,DC01542,NG641;Pembrolizumab,DrugComb,FD00018,Head and Neck Cancer,Head and Neck Cancer,Phase 1
1873,TP00572,CD3G;PDCD1,CD3G,PDCD1,CET+CET,Tclin+Tclin,0.333,0.709,1.0,2,1,1,14,15,DC00181,AMX-818;Pembrolizumab,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1|Phase 2
1875,TP00572,CD3G;PDCD1,CD3G,PDCD1,CET+CET,Tclin+Tclin,0.333,0.709,1.0,2,1,1,14,15,DC00771,Cibisatamab;Nivolumab,DrugComb,FD00030,Myeloma,Hematologic Malignancy,Phase 2
1876,TP00572,CD3G;PDCD1,CD3G,PDCD1,CET+CET,Tclin+Tclin,0.333,0.709,1.0,2,1,1,14,15,DC00707,Cemiplimab;Ubamatamab,DrugComb,FD00034,Ovarian Cancer,Ovarian Cancer,Phase 1|Phase 2
1877,TP00572,CD3G;PDCD1,CD3G,PDCD1,CET+CET,Tclin+Tclin,0.333,0.709,1.0,2,1,1,14,15,DC00508,BI765049;Ezabenlimab,DrugComb,FD00011,Colorectal Cancer,Colorectal Cancer,Phase 1
1879,TP00572,CD3G;PDCD1,CD3G,PDCD1,CET+CET,Tclin+Tclin,0.333,0.709,1.0,2,1,1,14,15,DC00508,BI765049;Ezabenlimab,DrugComb,FD00022,Liver Cancer,Liver Cancer,Phase 1
1881,TP00572,CD3G;PDCD1,CD3G,PDCD1,CET+CET,Tclin+Tclin,0.333,0.709,1.0,2,1,1,14,15,DC00508,BI765049;Ezabenlimab,DrugComb,FD00035,Pancreatic Cancer,Pancreatic Cancer,Phase 1
1885,TP00572,CD3G;PDCD1,CD3G,PDCD1,CET+CET,Tclin+Tclin,0.333,0.709,1.0,2,1,1,14,15,DC01729,Pembrolizumab;Tebentafusp,DrugComb,FD00026,Melanoma,Melanoma,Phase 2|Phase 3
1887,TP00573,CD3G;PMEL,CD3G,PMEL,CET+CIT,Tclin+Tclin,0.159,0.614,0.702,0,0,0,1,1,DC02272,Tebentafusp,BsAb,FD00026,Melanoma,Melanoma,Approval
1888,TP00574,CD3G;PRAME,CD3G,PRAME,CET+CIT,Tbio+Tclin,0.322,0.579,0.621,0,0,0,1,1,DC02141,IMCF106C,BsAb,FD00033,Other Cancer,Other Cancer,Phase 1|Phase 2
1889,TP00575,CD3G;ROR1,CD3G,ROR1,CET+CIT,Tbio+Tclin,0.249,0.672,0.653,0,0,0,2,3,DC02204,NVG111,BsAb,FD00021,Leukemia,Hematologic Malignancy,Phase 1
1890,TP00575,CD3G;ROR1,CD3G,ROR1,CET+CIT,Tbio+Tclin,0.249,0.672,0.653,0,0,0,2,3,DC02204,NVG111,BsAb,FD00024,Lymphoma,Hematologic Malignancy,Phase 1
1891,TP00575,CD3G;ROR1,CD3G,ROR1,CET+CIT,Tbio+Tclin,0.249,0.672,0.653,0,0,0,2,3,DC02090,EMB07,BsAb,FD00033,Other Cancer,Other Cancer,Phase 1
1892,TP00576,CD3G;SLAMF7,CD3G,SLAMF7,CET+CIT,Tclin+Tclin,0.438,0.709,1.0,0,1,0,1,1,DC00770,Cibisatamab;Elotuzumab,DrugComb,FD00030,Myeloma,Hematologic Malignancy,Phase 1
1893,TP00577,CD3G;SSTR2,CD3G,SSTR2,CET+CIT,Tclin+Tclin,0.313,0.78,0.648,0,0,0,1,3,DC02277,Tidutamab,BsAb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
1894,TP00577,CD3G;SSTR2,CD3G,SSTR2,CET+CIT,Tclin+Tclin,0.313,0.78,0.648,0,0,0,1,3,DC02277,Tidutamab,BsAb,FD00028,Merkel Cell Carcinoma,Other Cancer,Phase 1|Phase 2
1895,TP00577,CD3G;SSTR2,CD3G,SSTR2,CET+CIT,Tclin+Tclin,0.313,0.78,0.648,0,0,0,1,3,DC02277,Tidutamab,BsAb,FD00041,Stomach Cancer,Stomach Cancer,Phase 1
1896,TP00578,CD3G;STEAP1,CD3G,STEAP1,CET+CIT,Tbio+Tclin,0.28,0.677,0.259,0,0,0,1,1,DC02016,AMG509,BsAb,FD00038,Prostate Cancer,Prostate Cancer,Phase 1
1897,TP00579,CD3G;TMEFF2,CD3G,TMEFF2,CET+CIT,Tbio+Tclin,0.215,0.596,0.651,0,0,0,1,1,DC02158,JNJ70218902,BsAb,FD00033,Other Cancer,Other Cancer,Phase 1
1898,TP00580,CD3G;TNFRSF17,CD3G,TNFRSF17,CET+CIT,Tclin+Tclin,0.391,0.625,0.729,0,0,0,13,1,DC02284,TQB2934,BsAb,FD00030,Myeloma,Hematologic Malignancy,Phase 1
1911,TP00581,CD3G;TPBG,CD3G,TPBG,CET+CIT,Tbio+Tclin,0.292,0.626,,0,0,0,1,1,DC02115,GEN1044,BsAb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
1912,TP00582,CD3G;TYRP1,CD3G,TYRP1,CET+CIT,Tbio+Tclin,0.177,0.61,0.512,0,0,0,1,1,DC02244,RO7293583,BsAb,FD00026,Melanoma,Melanoma,Phase 1
1913,TP00583,CD3G;VTCN1,CD3G,VTCN1,CET+CIT,Tbio+Tclin,0.293,0.611,0.584,0,0,0,2,3,DC02216,PF07260437,BsAb,FD00007,Breast Cancer,Breast Cancer,Phase 1
1914,TP00583,CD3G;VTCN1,CD3G,VTCN1,CET+CIT,Tbio+Tclin,0.293,0.611,0.584,0,0,0,2,3,DC02216,PF07260437,BsAb,FD00034,Ovarian Cancer,Ovarian Cancer,Phase 1
1916,TP00583,CD3G;VTCN1,CD3G,VTCN1,CET+CIT,Tbio+Tclin,0.293,0.611,0.584,0,0,0,2,3,DC02116,GEN1047,BsAb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
1918,TP00584,CD40;CSF1R,CD40,CSF1R,CET+CET,Tchem+Tclin,0.501,0.786,0.533,2,0,0,2,2,DC00977,Emactuzumab;Selicrelumab,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
1919,TP00584,CD40;CSF1R,CD40,CSF1R,CET+CET,Tchem+Tclin,0.501,0.786,0.533,2,0,0,2,2,DC00626,Cabiralizumab;Sotigalimab,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
1920,TP00585,CD40;EGFR,CD40,EGFR,CET+CIT,Tchem+Tclin,0.466,0.614,0.603,0,0,0,1,1,DC00001,2141-V11;D2C7IT,DrugComb,FD00017,Glioma,Glioma,Phase 1|Phase 2
1921,TP00586,CD40;FAP,CD40,FAP,CET+CIT,Tchem+Tchem,0.278,0.608,0.499,0,0,1,3,1,DC02197,MP0317,BsAb,FD00033,Other Cancer,Other Cancer,Phase 1
1924,TP00587,CD40;FLT3,CD40,FLT3,CET+CIT,Tchem+Tclin,0.469,0.691,0.543,1,0,0,1,2,DC00684,CDX1140;CDX301,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
1925,TP00587,CD40;FLT3,CD40,FLT3,CET+CIT,Tchem+Tclin,0.469,0.691,0.543,1,0,0,1,2,DC00684,CDX1140;CDX301,DrugComb,FD00035,Pancreatic Cancer,Pancreatic Cancer,Phase 2
1926,TP00588,CD40;MSLN,CD40,MSLN,CET+CIT,Tbio+Tchem,0.152,0.718,1.0,0,0,0,2,1,DC01997,ABBV428,BsAb,FD00033,Other Cancer,Other Cancer,Phase 1
1928,TP00589,CD40;PDCD1,CD40,PDCD1,CET+CET,Tchem+Tclin,0.263,0.674,1.0,1,0,2,8,6,DC01730,Pembrolizumab;Tecaginlimab,DrugComb,FD00011,Colorectal Cancer,Colorectal Cancer,Phase 1|Phase 2
1929,TP00589,CD40;PDCD1,CD40,PDCD1,CET+CET,Tchem+Tclin,0.263,0.674,1.0,1,0,2,8,6,DC01730,Pembrolizumab;Tecaginlimab,DrugComb,FD00018,Head and Neck Cancer,Head and Neck Cancer,Phase 1|Phase 2
1930,TP00589,CD40;PDCD1,CD40,PDCD1,CET+CET,Tchem+Tclin,0.263,0.674,1.0,1,0,2,8,6,DC01730,Pembrolizumab;Tecaginlimab,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
1931,TP00589,CD40;PDCD1,CD40,PDCD1,CET+CET,Tchem+Tclin,0.263,0.674,1.0,1,0,2,8,6,DC01730,Pembrolizumab;Tecaginlimab,DrugComb,FD00026,Melanoma,Melanoma,Phase 1|Phase 2
1932,TP00589,CD40;PDCD1,CD40,PDCD1,CET+CET,Tchem+Tclin,0.263,0.674,1.0,1,0,2,8,6,DC01730,Pembrolizumab;Tecaginlimab,DrugComb,FD00035,Pancreatic Cancer,Pancreatic Cancer,Phase 1|Phase 2
1933,TP00589,CD40;PDCD1,CD40,PDCD1,CET+CET,Tchem+Tclin,0.263,0.674,1.0,1,0,2,8,6,DC01322,Inezetamab;Zeluvalimab,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
1943,TP00590,CD40;TNFRSF9,CD40,TNFRSF9,CET+CET,Tbio+Tchem,0.204,0.762,0.837,1,0,1,1,5,DC02274,Tecaginlimab,BsAb,FD00011,Colorectal Cancer,Colorectal Cancer,Phase 1|Phase 2
1944,TP00590,CD40;TNFRSF9,CD40,TNFRSF9,CET+CET,Tbio+Tchem,0.204,0.762,0.837,1,0,1,1,5,DC02274,Tecaginlimab,BsAb,FD00018,Head and Neck Cancer,Head and Neck Cancer,Phase 1|Phase 2
1945,TP00590,CD40;TNFRSF9,CD40,TNFRSF9,CET+CET,Tbio+Tchem,0.204,0.762,0.837,1,0,1,1,5,DC02274,Tecaginlimab,BsAb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
1946,TP00590,CD40;TNFRSF9,CD40,TNFRSF9,CET+CET,Tbio+Tchem,0.204,0.762,0.837,1,0,1,1,5,DC02274,Tecaginlimab,BsAb,FD00026,Melanoma,Melanoma,Phase 1|Phase 2
1947,TP00590,CD40;TNFRSF9,CD40,TNFRSF9,CET+CET,Tbio+Tchem,0.204,0.762,0.837,1,0,1,1,5,DC02274,Tecaginlimab,BsAb,FD00035,Pancreatic Cancer,Pancreatic Cancer,Phase 1|Phase 2
1948,TP00591,CD40;TNFSF4,CD40,TNFSF4,CET+CIT,Tbio+Tchem,0.538,0.807,0.648,1,0,2,1,2,DC01231,Giloralimab;Revdofilimab,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 1
1949,TP00591,CD40;TNFSF4,CD40,TNFSF4,CET+CIT,Tbio+Tchem,0.538,0.807,0.648,1,0,2,1,2,DC01231,Giloralimab;Revdofilimab,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
1950,TP00592,CD40;VEGFA,CD40,VEGFA,CET+CET,Tchem+Tclin,0.453,0.548,0.585,0,0,2,1,1,DC01894,Selicrelumab;Vanucizumab,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
1951,TP00593,CD47;CLDN18,CD47,CLDN18,CET+CIT,Tbio+Tchem,0.281,0.509,0.633,0,0,0,2,3,DC02228,PT886,BsAb,FD00035,Pancreatic Cancer,Pancreatic Cancer,Phase 1|Phase 2
1952,TP00593,CD47;CLDN18,CD47,CLDN18,CET+CIT,Tbio+Tchem,0.281,0.509,0.633,0,0,0,2,3,DC02228,PT886,BsAb,FD00041,Stomach Cancer,Stomach Cancer,Phase 1|Phase 2
1953,TP00593,CD47;CLDN18,CD47,CLDN18,CET+CIT,Tbio+Tchem,0.281,0.509,0.633,0,0,0,2,3,DC02256,SG1906,BsAb,FD00033,Other Cancer,Other Cancer,Phase 1
1954,TP00594,CD47;DLL3,CD47,DLL3,CET+CIT,Tbio+Tchem,0.2,0.67,0.388,0,0,0,1,1,DC02227,PT217,BsAb,FD00023,Lung Cancer,Lung Cancer,Phase 1
1955,TP00595,CD47;EGFR,CD47,EGFR,CET+CIT,Tchem+Tclin,0.345,0.584,0.504,0,0,2,1,1,DC00741,Cetuximab;Magrolimab,DrugComb,FD00011,Colorectal Cancer,Colorectal Cancer,Phase 1|Phase 2
1956,TP00596,CD47;ERBB2,CD47,ERBB2,CET+CIT,Tchem+Tclin,0.382,0.612,0.573,0,0,0,2,4,DC01130,Evorpacept;Zanidatamab,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1|Phase 2
1957,TP00596,CD47;ERBB2,CD47,ERBB2,CET+CIT,Tchem+Tclin,0.382,0.612,0.573,0,0,0,2,4,DC02144,IMM2902,BsAb,FD00022,Liver Cancer,Liver Cancer,Phase 1|Phase 2
1958,TP00596,CD47;ERBB2,CD47,ERBB2,CET+CIT,Tchem+Tclin,0.382,0.612,0.573,0,0,0,2,4,DC02144,IMM2902,BsAb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
1959,TP00596,CD47;ERBB2,CD47,ERBB2,CET+CIT,Tchem+Tclin,0.382,0.612,0.573,0,0,0,2,4,DC02144,IMM2902,BsAb,FD00041,Stomach Cancer,Stomach Cancer,Phase 1|Phase 2
1960,TP00597,CD47;MS4A1,CD47,MS4A1,CET+CIT,Tchem+Tclin,0.265,0.764,0.601,0,0,0,5,3,DC01986,Ublituximab;Zeripatamig,DrugComb,FD00021,Leukemia,Hematologic Malignancy,Phase 1
1961,TP00597,CD47;MS4A1,CD47,MS4A1,CET+CIT,Tchem+Tclin,0.265,0.764,0.601,0,0,0,5,3,DC01986,Ublituximab;Zeripatamig,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 1
1963,TP00597,CD47;MS4A1,CD47,MS4A1,CET+CIT,Tchem+Tclin,0.265,0.764,0.601,0,0,0,5,3,DC01391,Lemzoparlimab;Rituximab,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
1967,TP00598,CD47;MSLN,CD47,MSLN,CET+CIT,Tbio+Tchem,0.213,0.64,1.0,0,0,0,1,3,DC02202,NI1801,BsAb,FD00007,Breast Cancer,Breast Cancer,Phase 1
1968,TP00598,CD47;MSLN,CD47,MSLN,CET+CIT,Tbio+Tchem,0.213,0.64,1.0,0,0,0,1,3,DC02202,NI1801,BsAb,FD00023,Lung Cancer,Lung Cancer,Phase 1
1969,TP00598,CD47;MSLN,CD47,MSLN,CET+CIT,Tbio+Tchem,0.213,0.64,1.0,0,0,0,1,3,DC02202,NI1801,BsAb,FD00034,Ovarian Cancer,Ovarian Cancer,Phase 1
1970,TP00599,CD47;NECTIN4,CD47,NECTIN4,CET+CIT,Tchem+Tclin,0.146,0.651,0.64,0,0,0,1,1,DC00987,Enfortumab Vedotin;Evorpacept,DrugComb,FD00006,Bladder Cancer,Bladder Cancer,Phase 1
1971,TP00600,CD47;PDCD1,CD47,PDCD1,CET+CET,Tchem+Tclin,0.216,0.575,1.0,0,0,0,6,5,DC01129,Evorpacept;Pembrolizumab,DrugComb,FD00018,Head and Neck Cancer,Head and Neck Cancer,Phase 2
1972,TP00600,CD47;PDCD1,CD47,PDCD1,CET+CET,Tchem+Tclin,0.216,0.575,1.0,0,0,0,6,5,DC01425,Letaplimab;Sintilimab,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
1973,TP00600,CD47;PDCD1,CD47,PDCD1,CET+CET,Tchem+Tclin,0.216,0.575,1.0,0,0,0,6,5,DC01390,Lemzoparlimab;Pembrolizumab,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 1
1974,TP00600,CD47;PDCD1,CD47,PDCD1,CET+CET,Tchem+Tclin,0.216,0.575,1.0,0,0,0,6,5,DC01390,Lemzoparlimab;Pembrolizumab,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
1978,TP00600,CD47;PDCD1,CD47,PDCD1,CET+CET,Tchem+Tclin,0.216,0.575,1.0,0,0,0,6,5,DC02178,LX039,BsAb,FD00007,Breast Cancer,Breast Cancer,Phase 1
1979,TP00601,CD47;TNFRSF9,CD47,TNFRSF9,CET+CET,Tbio+Tchem,0.26,0.648,0.779,0,0,0,1,4,DC02080,DSP107,BsAb,FD00011,Colorectal Cancer,Colorectal Cancer,Phase 1|Phase 2
1980,TP00601,CD47;TNFRSF9,CD47,TNFRSF9,CET+CET,Tbio+Tchem,0.26,0.648,0.779,0,0,0,1,4,DC02080,DSP107,BsAb,FD00021,Leukemia,Hematologic Malignancy,Phase 1
1981,TP00601,CD47;TNFRSF9,CD47,TNFRSF9,CET+CET,Tbio+Tchem,0.26,0.648,0.779,0,0,0,1,4,DC02080,DSP107,BsAb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
1982,TP00601,CD47;TNFRSF9,CD47,TNFRSF9,CET+CET,Tbio+Tchem,0.26,0.648,0.779,0,0,0,1,4,DC02080,DSP107,BsAb,FD00030,Myeloma,Hematologic Malignancy,Phase 1
1983,TP00602,CD52;MS4A1,CD52,MS4A1,CIT+CIT,Tclin+Tclin,0.192,0.669,,0,0,0,1,1,DC00123,Alemtuzumab;Rituximab,DrugComb,FD00021,Leukemia,Hematologic Malignancy,Phase 2
1984,TP00603,CD70;MTOR,CD70,MTOR,CIT+CIT,Tbio+Tclin,0.251,0.305,0.432,0,0,0,1,1,DC01127,Everolimus;Vorsetzumab Mafodotin,DrugComb,FD00020,Kidney Cancer,Kidney Cancer,Phase 1
1985,TP00604,CD79B;FCGR2B,CD79B,FCGR2B,CIT+CIT,Tbio+Tclin,0.421,0.677,0.735,1,0,0,1,1,DC02225,PRV3279,BsAb,FD00033,Other Cancer,Other Cancer,Phase 1
1986,TP00605,CD79B;MS4A1,CD79B,MS4A1,CIT+CIT,Tclin+Tclin,0.652,0.847,0.692,0,0,0,1,2,DC01821,Polatuzumab Vedotin;Rituximab,DrugComb,FD00021,Leukemia,Hematologic Malignancy,Phase 1
1987,TP00605,CD79B;MS4A1,CD79B,MS4A1,CIT+CIT,Tclin+Tclin,0.652,0.847,0.692,0,0,0,1,2,DC01821,Polatuzumab Vedotin;Rituximab,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 1|Phase 2
1988,TP00606,CD79B;VEGFA,CD79B,VEGFA,CET+CIT,Tclin+Tclin,0.264,0.527,0.618,0,0,0,1,1,DC01823,Polatuzumab Vedotin;Vanucizumab,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 2
1989,TP00607,CD80;IL2RA,CD80,IL2RA,CET+CET,Tclin+Tclin,0.56,0.708,0.628,0,0,4,1,6,DC02117,GI101,BsAb,FD00006,Bladder Cancer,Bladder Cancer,Phase 1|Phase 2
1990,TP00607,CD80;IL2RA,CD80,IL2RA,CET+CET,Tclin+Tclin,0.56,0.708,0.628,0,0,4,1,6,DC02117,GI101,BsAb,FD00018,Head and Neck Cancer,Head and Neck Cancer,Phase 1|Phase 2
1991,TP00607,CD80;IL2RA,CD80,IL2RA,CET+CET,Tclin+Tclin,0.56,0.708,0.628,0,0,4,1,6,DC02117,GI101,BsAb,FD00020,Kidney Cancer,Kidney Cancer,Phase 1|Phase 2
1992,TP00607,CD80;IL2RA,CD80,IL2RA,CET+CET,Tclin+Tclin,0.56,0.708,0.628,0,0,4,1,6,DC02117,GI101,BsAb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
1993,TP00607,CD80;IL2RA,CD80,IL2RA,CET+CET,Tclin+Tclin,0.56,0.708,0.628,0,0,4,1,6,DC02117,GI101,BsAb,FD00026,Melanoma,Melanoma,Phase 1|Phase 2
1994,TP00607,CD80;IL2RA,CD80,IL2RA,CET+CET,Tclin+Tclin,0.56,0.708,0.628,0,0,4,1,6,DC02117,GI101,BsAb,FD00040,Soft Tissue Sarcoma,Other Cancer,Phase 1|Phase 2
1995,TP00608,CD80;IL2RB,CD80,IL2RB,CET+CET,Tclin+Tclin,0.379,0.725,0.58,0,0,3,1,1,DC02118,GI102,BsAb,FD00033,Other Cancer,Other Cancer,Phase 1|Phase 2
1996,TP00609,CD80;KDR,CD80,KDR,CET+CET,Tclin+Tclin,0.353,0.558,0.515,0,0,1,1,6,DC01229,GI101;Lenvatinib,DrugComb,FD00006,Bladder Cancer,Bladder Cancer,Phase 1|Phase 2
1997,TP00609,CD80;KDR,CD80,KDR,CET+CET,Tclin+Tclin,0.353,0.558,0.515,0,0,1,1,6,DC01229,GI101;Lenvatinib,DrugComb,FD00018,Head and Neck Cancer,Head and Neck Cancer,Phase 1|Phase 2
1998,TP00609,CD80;KDR,CD80,KDR,CET+CET,Tclin+Tclin,0.353,0.558,0.515,0,0,1,1,6,DC01229,GI101;Lenvatinib,DrugComb,FD00020,Kidney Cancer,Kidney Cancer,Phase 1|Phase 2
1999,TP00609,CD80;KDR,CD80,KDR,CET+CET,Tclin+Tclin,0.353,0.558,0.515,0,0,1,1,6,DC01229,GI101;Lenvatinib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
2000,TP00609,CD80;KDR,CD80,KDR,CET+CET,Tclin+Tclin,0.353,0.558,0.515,0,0,1,1,6,DC01229,GI101;Lenvatinib,DrugComb,FD00026,Melanoma,Melanoma,Phase 1|Phase 2
2001,TP00609,CD80;KDR,CD80,KDR,CET+CET,Tclin+Tclin,0.353,0.558,0.515,0,0,1,1,6,DC01229,GI101;Lenvatinib,DrugComb,FD00040,Soft Tissue Sarcoma,Other Cancer,Phase 1|Phase 2
2002,TP00610,CD80;PDCD1,CD80,PDCD1,CET+CET,Tclin+Tclin,0.298,0.836,1.0,1,0,3,1,6,DC01230,GI101;Pembrolizumab,DrugComb,FD00006,Bladder Cancer,Bladder Cancer,Phase 1|Phase 2
2003,TP00610,CD80;PDCD1,CD80,PDCD1,CET+CET,Tclin+Tclin,0.298,0.836,1.0,1,0,3,1,6,DC01230,GI101;Pembrolizumab,DrugComb,FD00018,Head and Neck Cancer,Head and Neck Cancer,Phase 1|Phase 2
2004,TP00610,CD80;PDCD1,CD80,PDCD1,CET+CET,Tclin+Tclin,0.298,0.836,1.0,1,0,3,1,6,DC01230,GI101;Pembrolizumab,DrugComb,FD00020,Kidney Cancer,Kidney Cancer,Phase 1|Phase 2
2005,TP00610,CD80;PDCD1,CD80,PDCD1,CET+CET,Tclin+Tclin,0.298,0.836,1.0,1,0,3,1,6,DC01230,GI101;Pembrolizumab,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
2006,TP00610,CD80;PDCD1,CD80,PDCD1,CET+CET,Tclin+Tclin,0.298,0.836,1.0,1,0,3,1,6,DC01230,GI101;Pembrolizumab,DrugComb,FD00026,Melanoma,Melanoma,Phase 1|Phase 2
2007,TP00610,CD80;PDCD1,CD80,PDCD1,CET+CET,Tclin+Tclin,0.298,0.836,1.0,1,0,3,1,6,DC01230,GI101;Pembrolizumab,DrugComb,FD00040,Soft Tissue Sarcoma,Other Cancer,Phase 1|Phase 2
2008,TP00611,CD8A;CLDN18,CD8A,CLDN18,CET+CIT,Tbio+Tbio,0.272,0.605,0.605,1,0,0,1,1,DC02171,LB4330,BsAb,FD00033,Other Cancer,Other Cancer,Phase 1
2009,TP00612,CD8B;CLDN18,CD8B,CLDN18,CET+CIT,Tbio+Tbio,0.217,0.574,0.652,1,0,0,1,1,DC02171,LB4330,BsAb,FD00033,Other Cancer,Other Cancer,Phase 1
2010,TP00613,CD8B;IL2RA,CD8B,IL2RA,CET+CET,Tbio+Tclin,0.478,0.653,0.652,1,0,0,1,4,DC01994,AB248,BsAb,FD00018,Head and Neck Cancer,Head and Neck Cancer,Phase 1
2011,TP00613,CD8B;IL2RA,CD8B,IL2RA,CET+CET,Tbio+Tclin,0.478,0.653,0.652,1,0,0,1,4,DC01994,AB248,BsAb,FD00020,Kidney Cancer,Kidney Cancer,Phase 1
2012,TP00613,CD8B;IL2RA,CD8B,IL2RA,CET+CET,Tbio+Tclin,0.478,0.653,0.652,1,0,0,1,4,DC01994,AB248,BsAb,FD00023,Lung Cancer,Lung Cancer,Phase 1
2013,TP00613,CD8B;IL2RA,CD8B,IL2RA,CET+CET,Tbio+Tclin,0.478,0.653,0.652,1,0,0,1,4,DC01994,AB248,BsAb,FD00026,Melanoma,Melanoma,Phase 1
2014,TP00614,CD8B;IL2RB,CD8B,IL2RB,CET+CET,Tbio+Tclin,0.487,0.793,0.598,0,0,0,1,4,DC01994,AB248,BsAb,FD00018,Head and Neck Cancer,Head and Neck Cancer,Phase 1
2015,TP00614,CD8B;IL2RB,CD8B,IL2RB,CET+CET,Tbio+Tclin,0.487,0.793,0.598,0,0,0,1,4,DC01994,AB248,BsAb,FD00020,Kidney Cancer,Kidney Cancer,Phase 1
2016,TP00614,CD8B;IL2RB,CD8B,IL2RB,CET+CET,Tbio+Tclin,0.487,0.793,0.598,0,0,0,1,4,DC01994,AB248,BsAb,FD00023,Lung Cancer,Lung Cancer,Phase 1
2017,TP00614,CD8B;IL2RB,CD8B,IL2RB,CET+CET,Tbio+Tclin,0.487,0.793,0.598,0,0,0,1,4,DC01994,AB248,BsAb,FD00026,Melanoma,Melanoma,Phase 1
2018,TP00615,CD8B;IL2RG,CD8B,IL2RG,CET+CIT,Tbio+Tclin,0.588,0.772,0.576,1,0,0,1,4,DC01994,AB248,BsAb,FD00018,Head and Neck Cancer,Head and Neck Cancer,Phase 1
2019,TP00615,CD8B;IL2RG,CD8B,IL2RG,CET+CIT,Tbio+Tclin,0.588,0.772,0.576,1,0,0,1,4,DC01994,AB248,BsAb,FD00020,Kidney Cancer,Kidney Cancer,Phase 1
2020,TP00615,CD8B;IL2RG,CD8B,IL2RG,CET+CIT,Tbio+Tclin,0.588,0.772,0.576,1,0,0,1,4,DC01994,AB248,BsAb,FD00023,Lung Cancer,Lung Cancer,Phase 1
2021,TP00615,CD8B;IL2RG,CD8B,IL2RG,CET+CIT,Tbio+Tclin,0.588,0.772,0.576,1,0,0,1,4,DC01994,AB248,BsAb,FD00026,Melanoma,Melanoma,Phase 1
2022,TP00616,CD8B;PDCD1,CD8B,PDCD1,CET+CET,Tbio+Tclin,0.413,0.64,1.0,2,0,2,1,4,DC00002,AB248;Pembrolizumab,DrugComb,FD00018,Head and Neck Cancer,Head and Neck Cancer,Phase 1
2023,TP00616,CD8B;PDCD1,CD8B,PDCD1,CET+CET,Tbio+Tclin,0.413,0.64,1.0,2,0,2,1,4,DC00002,AB248;Pembrolizumab,DrugComb,FD00020,Kidney Cancer,Kidney Cancer,Phase 1
2024,TP00616,CD8B;PDCD1,CD8B,PDCD1,CET+CET,Tbio+Tclin,0.413,0.64,1.0,2,0,2,1,4,DC00002,AB248;Pembrolizumab,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
2025,TP00616,CD8B;PDCD1,CD8B,PDCD1,CET+CET,Tbio+Tclin,0.413,0.64,1.0,2,0,2,1,4,DC00002,AB248;Pembrolizumab,DrugComb,FD00026,Melanoma,Melanoma,Phase 1
2026,TP00617,CD9;PDCD1,CD9,PDCD1,CET+CET,Tbio+Tclin,0.253,0.519,1.0,0,0,0,1,1,DC01372,KBA1412;Pembrolizumab,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
2027,TP00618,CDH17;TNFRSF10B,CDH17,TNFRSF10B,CIT+CIT,Tbio+Tbio,0.333,0.804,0.517,0,0,0,1,3,DC02043,BI905711,BsAb,FD00011,Colorectal Cancer,Colorectal Cancer,Phase 1
2028,TP00618,CDH17;TNFRSF10B,CDH17,TNFRSF10B,CIT+CIT,Tbio+Tbio,0.333,0.804,0.517,0,0,0,1,3,DC02043,BI905711,BsAb,FD00022,Liver Cancer,Liver Cancer,Phase 1
2029,TP00618,CDH17;TNFRSF10B,CDH17,TNFRSF10B,CIT+CIT,Tbio+Tbio,0.333,0.804,0.517,0,0,0,1,3,DC02043,BI905711,BsAb,FD00035,Pancreatic Cancer,Pancreatic Cancer,Phase 1
2030,TP00619,CDK1;MS4A1,CDK1,MS4A1,CIT+CIT,Tchem+Tclin,0.245,0.545,0.4,0,0,0,1,2,DC00886,Dinaciclib;Rituximab,DrugComb,FD00021,Leukemia,Hematologic Malignancy,Phase 1
2031,TP00619,CDK1;MS4A1,CDK1,MS4A1,CIT+CIT,Tchem+Tclin,0.245,0.545,0.4,0,0,0,1,2,DC00886,Dinaciclib;Rituximab,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 1
2032,TP00620,CDK1;PDCD1,CDK1,PDCD1,CET+CIT,Tchem+Tclin,0.283,0.298,1.0,0,0,0,1,1,DC00885,Dinaciclib;Pembrolizumab,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 1
2033,TP00621,CDK2;ESR1,CDK2,ESR1,CIT+CIT,Tchem+Tclin,0.444,0.701,0.425,1,0,2,2,2,DC01168,Fulvestrant;NUV422,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 1|Phase 2
2034,TP00621,CDK2;ESR1,CDK2,ESR1,CIT+CIT,Tchem+Tclin,0.444,0.701,0.425,1,0,2,2,2,DC01173,Fulvestrant;PF07224826,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
2035,TP00622,CDK2;ESR2,CDK2,ESR2,CIT+CIT,Tchem+Tclin,0.49,0.56,0.373,1,0,1,2,2,DC01173,Fulvestrant;PF07224826,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
2036,TP00622,CDK2;ESR2,CDK2,ESR2,CIT+CIT,Tchem+Tclin,0.49,0.56,0.373,1,0,1,2,2,DC01168,Fulvestrant;NUV422,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 1|Phase 2
2037,TP00623,CDK2;MS4A1,CDK2,MS4A1,CIT+CIT,Tchem+Tclin,0.27,0.377,0.428,0,0,0,1,2,DC00886,Dinaciclib;Rituximab,DrugComb,FD00021,Leukemia,Hematologic Malignancy,Phase 1
2038,TP00623,CDK2;MS4A1,CDK2,MS4A1,CIT+CIT,Tchem+Tclin,0.27,0.377,0.428,0,0,0,1,2,DC00886,Dinaciclib;Rituximab,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 1
2039,TP00624,CDK2;PDCD1,CDK2,PDCD1,CET+CIT,Tchem+Tclin,0.171,0.193,1.0,0,0,0,1,1,DC00885,Dinaciclib;Pembrolizumab,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 1
2040,TP00625,CDK4;CYP19A1,CDK4,CYP19A1,CIT+CIT,Tclin+Tclin,0.317,0.373,0.236,0,0,1,9,2,DC01433,Letrozole;Ribociclib,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 3
2042,TP00625,CDK4;CYP19A1,CDK4,CYP19A1,CIT+CIT,Tclin+Tclin,0.317,0.373,0.236,0,0,1,9,2,DC01427,Letrozole;Palbociclib,DrugComb,FD00034,Ovarian Cancer,Ovarian Cancer,Phase 2
2050,TP00626,CDK4;EGFR,CDK4,EGFR,CIT+CIT,Tclin+Tclin,0.526,0.517,0.679,14,0,12,8,4,DC00104,Afatinib;XH30002,DrugComb,FD00014,Esophageal Cancer,Esophageal Cancer,Phase 1
2051,TP00626,CDK4;EGFR,CDK4,EGFR,CIT+CIT,Tclin+Tclin,0.526,0.517,0.679,14,0,12,8,4,DC01467,Mavelertinib;Palbociclib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
2053,TP00626,CDK4;EGFR,CDK4,EGFR,CIT+CIT,Tclin+Tclin,0.526,0.517,0.679,14,0,12,8,4,DC00096,Afatinib;Palbociclib,DrugComb,FD00041,Stomach Cancer,Stomach Cancer,Phase 2
2058,TP00626,CDK4;EGFR,CDK4,EGFR,CIT+CIT,Tclin+Tclin,0.526,0.517,0.679,14,0,12,8,4,DC00750,Cetuximab;Palbociclib,DrugComb,FD00018,Head and Neck Cancer,Head and Neck Cancer,Phase 3
2059,TP00627,CDK4;EPAS1,CDK4,EPAS1,CIT+CIT,Tclin+Tclin,0.378,0.693,0.374,1,0,1,2,1,DC00012,Abemaciclib;Belzutifan,DrugComb,FD00020,Kidney Cancer,Kidney Cancer,Phase 1
2061,TP00628,CDK4;ERBB2,CDK4,ERBB2,CIT+CIT,Tclin+Tclin,0.537,0.492,0.722,8,0,7,8,4,DC00096,Afatinib;Palbociclib,DrugComb,FD00014,Esophageal Cancer,Esophageal Cancer,Phase 2
2062,TP00628,CDK4;ERBB2,CDK4,ERBB2,CIT+CIT,Tclin+Tclin,0.537,0.492,0.722,8,0,7,8,4,DC00096,Afatinib;Palbociclib,DrugComb,FD00041,Stomach Cancer,Stomach Cancer,Phase 2
2064,TP00628,CDK4;ERBB2,CDK4,ERBB2,CIT+CIT,Tclin+Tclin,0.537,0.492,0.722,8,0,7,8,4,DC01860,Ribociclib;Trastuzumab,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 1|Phase 2
2065,TP00628,CDK4;ERBB2,CDK4,ERBB2,CIT+CIT,Tclin+Tclin,0.537,0.492,0.722,8,0,7,8,4,DC01537,Neratinib;Palbociclib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
2070,TP00629,CDK4;ERBB4,CDK4,ERBB4,CIT+CIT,Tclin+Tclin,0.488,0.509,0.724,1,0,1,2,2,DC00096,Afatinib;Palbociclib,DrugComb,FD00014,Esophageal Cancer,Esophageal Cancer,Phase 2
2071,TP00629,CDK4;ERBB4,CDK4,ERBB4,CIT+CIT,Tclin+Tclin,0.488,0.509,0.724,1,0,1,2,2,DC00096,Afatinib;Palbociclib,DrugComb,FD00041,Stomach Cancer,Stomach Cancer,Phase 2
2073,TP00630,CDK4;ESR1,CDK4,ESR1,CIT+CIT,Tclin+Tclin,0.512,0.71,0.428,3,0,3,26,4,DC01651,Palbociclib;Rintodestrant,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 1
2081,TP00630,CDK4;ESR1,CDK4,ESR1,CIT+CIT,Tclin+Tclin,0.512,0.71,0.428,3,0,3,26,4,DC00018,Abemaciclib;Fulvestrant,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1|Phase 2
2082,TP00630,CDK4;ESR1,CDK4,ESR1,CIT+CIT,Tclin+Tclin,0.512,0.71,0.428,3,0,3,26,4,DC00018,Abemaciclib;Fulvestrant,DrugComb,FD00034,Ovarian Cancer,Ovarian Cancer,Phase 2
2089,TP00630,CDK4;ESR1,CDK4,ESR1,CIT+CIT,Tclin+Tclin,0.512,0.71,0.428,3,0,3,26,4,DC00497,BGB43395;Fulvestrant,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
2101,TP00631,CDK4;ESR2,CDK4,ESR2,CIT+CIT,Tclin+Tclin,0.505,0.584,0.344,3,0,3,22,4,DC01177,Fulvestrant;Ribociclib,DrugComb,FD00007,Breast Cancer,Breast Cancer,Approval
2106,TP00631,CDK4;ESR2,CDK4,ESR2,CIT+CIT,Tclin+Tclin,0.505,0.584,0.344,3,0,3,22,4,DC00018,Abemaciclib;Fulvestrant,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1|Phase 2
2107,TP00631,CDK4;ESR2,CDK4,ESR2,CIT+CIT,Tclin+Tclin,0.505,0.584,0.344,3,0,3,22,4,DC00018,Abemaciclib;Fulvestrant,DrugComb,FD00034,Ovarian Cancer,Ovarian Cancer,Phase 2
2109,TP00631,CDK4;ESR2,CDK4,ESR2,CIT+CIT,Tclin+Tclin,0.505,0.584,0.344,3,0,3,22,4,DC00497,BGB43395;Fulvestrant,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
2125,TP00632,CDK4;IGF1,CDK4,IGF1,CIT+CIT,Tbio+Tclin,0.511,0.287,0.445,7,0,6,1,2,DC00038,Abemaciclib;Xentuzumab,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 1
2126,TP00632,CDK4;IGF1,CDK4,IGF1,CIT+CIT,Tbio+Tclin,0.511,0.287,0.445,7,0,6,1,2,DC00038,Abemaciclib;Xentuzumab,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
2127,TP00633,CDK4;IGF2,CDK4,IGF2,CIT+CIT,Tbio+Tclin,0.527,0.259,0.474,3,0,4,1,2,DC00038,Abemaciclib;Xentuzumab,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 1
2128,TP00633,CDK4;IGF2,CDK4,IGF2,CIT+CIT,Tbio+Tclin,0.527,0.259,0.474,3,0,4,1,2,DC00038,Abemaciclib;Xentuzumab,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
2129,TP00634,CDK4;KDR,CDK4,KDR,CET+CIT,Tclin+Tclin,0.457,0.488,0.742,1,0,3,1,3,DC00030,Abemaciclib;Ramucirumab,DrugComb,FD00011,Colorectal Cancer,Colorectal Cancer,Phase 1
2130,TP00634,CDK4;KDR,CDK4,KDR,CET+CIT,Tclin+Tclin,0.457,0.488,0.742,1,0,3,1,3,DC00030,Abemaciclib;Ramucirumab,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
2131,TP00634,CDK4;KDR,CDK4,KDR,CET+CIT,Tclin+Tclin,0.457,0.488,0.742,1,0,3,1,3,DC00030,Abemaciclib;Ramucirumab,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 1
2132,TP00635,CDK4;KRAS,CDK4,KRAS,CIT+CIT,Tclin+Tclin,0.412,0.42,0.411,20,0,11,4,2,DC01653,Palbociclib;Sotorasib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
2134,TP00635,CDK4;KRAS,CDK4,KRAS,CIT+CIT,Tclin+Tclin,0.412,0.42,0.411,20,0,11,4,2,DC00081,Adagrasib;Palbociclib,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
2136,TP00636,CDK4;MAP2K1,CDK4,MAP2K1,CIT+CIT,Tclin+Tclin,0.471,0.527,0.818,20,0,12,5,4,DC01474,Mirdametinib;Palbociclib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
2137,TP00636,CDK4;MAP2K1,CDK4,MAP2K1,CIT+CIT,Tclin+Tclin,0.471,0.527,0.818,20,0,12,5,4,DC01656,Palbociclib;Trametinib,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
2138,TP00636,CDK4;MAP2K1,CDK4,MAP2K1,CIT+CIT,Tclin+Tclin,0.471,0.527,0.818,20,0,12,5,4,DC01859,Ribociclib;Trametinib,DrugComb,FD00025,Medulloblastoma,Other Cancer,Phase 1
2141,TP00636,CDK4;MAP2K1,CDK4,MAP2K1,CIT+CIT,Tclin+Tclin,0.471,0.527,0.818,20,0,12,5,4,DC00542,Binimetinib;Ribociclib,DrugComb,FD00026,Melanoma,Melanoma,Phase 1|Phase 2
2142,TP00637,CDK4;MAP2K2,CDK4,MAP2K2,CIT+CIT,Tclin+Tclin,0.389,0.534,0.796,19,0,11,5,4,DC01474,Mirdametinib;Palbociclib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
2143,TP00637,CDK4;MAP2K2,CDK4,MAP2K2,CIT+CIT,Tclin+Tclin,0.389,0.534,0.796,19,0,11,5,4,DC01859,Ribociclib;Trametinib,DrugComb,FD00025,Medulloblastoma,Other Cancer,Phase 1
2144,TP00637,CDK4;MAP2K2,CDK4,MAP2K2,CIT+CIT,Tclin+Tclin,0.389,0.534,0.796,19,0,11,5,4,DC01859,Ribociclib;Trametinib,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
2147,TP00637,CDK4;MAP2K2,CDK4,MAP2K2,CIT+CIT,Tclin+Tclin,0.389,0.534,0.796,19,0,11,5,4,DC00542,Binimetinib;Ribociclib,DrugComb,FD00026,Melanoma,Melanoma,Phase 1|Phase 2
2148,TP00638,CDK4;MAPK1,CDK4,MAPK1,CIT+CIT,Tchem+Tclin,0.508,0.546,0.814,22,3,14,2,6,DC00034,Abemaciclib;Temuterkib,DrugComb,FD00011,Colorectal Cancer,Colorectal Cancer,Phase 1
2149,TP00638,CDK4;MAPK1,CDK4,MAPK1,CIT+CIT,Tchem+Tclin,0.508,0.546,0.814,22,3,14,2,6,DC00034,Abemaciclib;Temuterkib,DrugComb,FD00017,Glioma,Glioma,Early Phase 1
2150,TP00638,CDK4;MAPK1,CDK4,MAPK1,CIT+CIT,Tchem+Tclin,0.508,0.546,0.814,22,3,14,2,6,DC00034,Abemaciclib;Temuterkib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
2151,TP00638,CDK4;MAPK1,CDK4,MAPK1,CIT+CIT,Tchem+Tclin,0.508,0.546,0.814,22,3,14,2,6,DC00034,Abemaciclib;Temuterkib,DrugComb,FD00026,Melanoma,Melanoma,Phase 1
2152,TP00638,CDK4;MAPK1,CDK4,MAPK1,CIT+CIT,Tchem+Tclin,0.508,0.546,0.814,22,3,14,2,6,DC00034,Abemaciclib;Temuterkib,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 2
2154,TP00638,CDK4;MAPK1,CDK4,MAPK1,CIT+CIT,Tchem+Tclin,0.508,0.546,0.814,22,3,14,2,6,DC01658,Palbociclib;Ulixertinib,DrugComb,FD00035,Pancreatic Cancer,Pancreatic Cancer,Phase 1
2155,TP00639,CDK4;MAPK3,CDK4,MAPK3,CIT+CIT,Tchem+Tclin,0.521,0.58,0.825,22,3,13,2,6,DC00034,Abemaciclib;Temuterkib,DrugComb,FD00011,Colorectal Cancer,Colorectal Cancer,Phase 1
2156,TP00639,CDK4;MAPK3,CDK4,MAPK3,CIT+CIT,Tchem+Tclin,0.521,0.58,0.825,22,3,13,2,6,DC00034,Abemaciclib;Temuterkib,DrugComb,FD00017,Glioma,Glioma,Early Phase 1
2157,TP00639,CDK4;MAPK3,CDK4,MAPK3,CIT+CIT,Tchem+Tclin,0.521,0.58,0.825,22,3,13,2,6,DC00034,Abemaciclib;Temuterkib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
2158,TP00639,CDK4;MAPK3,CDK4,MAPK3,CIT+CIT,Tchem+Tclin,0.521,0.58,0.825,22,3,13,2,6,DC00034,Abemaciclib;Temuterkib,DrugComb,FD00026,Melanoma,Melanoma,Phase 1
2159,TP00639,CDK4;MAPK3,CDK4,MAPK3,CIT+CIT,Tchem+Tclin,0.521,0.58,0.825,22,3,13,2,6,DC00034,Abemaciclib;Temuterkib,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 2
2161,TP00639,CDK4;MAPK3,CDK4,MAPK3,CIT+CIT,Tchem+Tclin,0.521,0.58,0.825,22,3,13,2,6,DC01658,Palbociclib;Ulixertinib,DrugComb,FD00035,Pancreatic Cancer,Pancreatic Cancer,Phase 1
2162,TP00640,CDK4;MDM2,CDK4,MDM2,CIT+CIT,Tchem+Tclin,0.485,0.71,0.515,14,2,14,1,2,DC01855,Ribociclib;Siremadlin,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 2
2163,TP00640,CDK4;MDM2,CDK4,MDM2,CIT+CIT,Tchem+Tclin,0.485,0.71,0.515,14,2,14,1,2,DC01855,Ribociclib;Siremadlin,DrugComb,FD00040,Soft Tissue Sarcoma,Other Cancer,Phase 1
2164,TP00641,CDK4;MTOR,CDK4,MTOR,CIT+CIT,Tclin+Tclin,0.437,0.574,0.728,11,0,12,3,6,DC00031,Abemaciclib;Samotolisib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
2165,TP00641,CDK4;MTOR,CDK4,MTOR,CIT+CIT,Tclin+Tclin,0.437,0.574,0.728,11,0,12,3,6,DC00031,Abemaciclib;Samotolisib,DrugComb,FD00035,Pancreatic Cancer,Pancreatic Cancer,Phase 2
2166,TP00641,CDK4;MTOR,CDK4,MTOR,CIT+CIT,Tclin+Tclin,0.437,0.574,0.728,11,0,12,3,6,DC01210,Gedatolisib;Palbociclib,DrugComb,FD00018,Head and Neck Cancer,Head and Neck Cancer,Phase 1
2169,TP00641,CDK4;MTOR,CDK4,MTOR,CIT+CIT,Tclin+Tclin,0.437,0.574,0.728,11,0,12,3,6,DC01114,Everolimus;Ribociclib,DrugComb,FD00017,Glioma,Glioma,Early Phase 1
2170,TP00641,CDK4;MTOR,CDK4,MTOR,CIT+CIT,Tclin+Tclin,0.437,0.574,0.728,11,0,12,3,6,DC01114,Everolimus;Ribociclib,DrugComb,FD00032,Neuroendocrine Tumor,Other Cancer,Phase 2
2171,TP00641,CDK4;MTOR,CDK4,MTOR,CIT+CIT,Tclin+Tclin,0.437,0.574,0.728,11,0,12,3,6,DC01114,Everolimus;Ribociclib,DrugComb,FD00040,Soft Tissue Sarcoma,Other Cancer,Phase 2
2172,TP00642,CDK4;NOTCH1,CDK4,NOTCH1,CIT+CIT,Tchem+Tclin,0.418,0.569,0.441,4,0,6,1,3,DC00014,Abemaciclib;Crenigacestat,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 1
2173,TP00642,CDK4;NOTCH1,CDK4,NOTCH1,CIT+CIT,Tchem+Tclin,0.418,0.569,0.441,4,0,6,1,3,DC00014,Abemaciclib;Crenigacestat,DrugComb,FD00011,Colorectal Cancer,Colorectal Cancer,Phase 1
2174,TP00642,CDK4;NOTCH1,CDK4,NOTCH1,CIT+CIT,Tchem+Tclin,0.418,0.569,0.441,4,0,6,1,3,DC00014,Abemaciclib;Crenigacestat,DrugComb,FD00022,Liver Cancer,Liver Cancer,Phase 1
2175,TP00643,CDK4;PDCD1,CDK4,PDCD1,CET+CIT,Tclin+Tclin,0.244,0.188,1.0,1,0,1,5,6,DC00029,Abemaciclib;Pembrolizumab,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 1
2176,TP00643,CDK4;PDCD1,CDK4,PDCD1,CET+CIT,Tclin+Tclin,0.244,0.188,1.0,1,0,1,5,6,DC00029,Abemaciclib;Pembrolizumab,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
2177,TP00643,CDK4;PDCD1,CDK4,PDCD1,CET+CIT,Tclin+Tclin,0.244,0.188,1.0,1,0,1,5,6,DC00029,Abemaciclib;Pembrolizumab,DrugComb,FD00041,Stomach Cancer,Stomach Cancer,Phase 2
2178,TP00643,CDK4;PDCD1,CDK4,PDCD1,CET+CIT,Tclin+Tclin,0.244,0.188,1.0,1,0,1,5,6,DC00027,Abemaciclib;Nivolumab,DrugComb,FD00018,Head and Neck Cancer,Head and Neck Cancer,Phase 1|Phase 2
2179,TP00643,CDK4;PDCD1,CDK4,PDCD1,CET+CIT,Tclin+Tclin,0.244,0.188,1.0,1,0,1,5,6,DC01650,Palbociclib;Retifanlimab,DrugComb,FD00040,Soft Tissue Sarcoma,Other Cancer,Phase 2
2180,TP00643,CDK4;PDCD1,CDK4,PDCD1,CET+CIT,Tclin+Tclin,0.244,0.188,1.0,1,0,1,5,6,DC01857,Ribociclib;Spartalizumab,DrugComb,FD00026,Melanoma,Melanoma,Phase 2
2182,TP00644,CDK4;PIK3CA,CDK4,PIK3CA,CIT+CIT,Tclin+Tclin,0.466,0.441,0.767,23,0,14,3,4,DC00031,Abemaciclib;Samotolisib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
2183,TP00644,CDK4;PIK3CA,CDK4,PIK3CA,CIT+CIT,Tclin+Tclin,0.466,0.441,0.767,23,0,14,3,4,DC00031,Abemaciclib;Samotolisib,DrugComb,FD00035,Pancreatic Cancer,Pancreatic Cancer,Phase 2
2184,TP00644,CDK4;PIK3CA,CDK4,PIK3CA,CIT+CIT,Tclin+Tclin,0.466,0.441,0.767,23,0,14,3,4,DC01210,Gedatolisib;Palbociclib,DrugComb,FD00018,Head and Neck Cancer,Head and Neck Cancer,Phase 1
2187,TP00644,CDK4;PIK3CA,CDK4,PIK3CA,CIT+CIT,Tclin+Tclin,0.466,0.441,0.767,23,0,14,3,4,DC00158,Alpelisib;Ribociclib,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 2
2188,TP00645,CDK4;PTPN11,CDK4,PTPN11,CIT+CIT,Tchem+Tclin,0.444,0.701,0.47,2,0,1,1,1,DC00394,Batoprotafib;Ribociclib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
2189,TP00646,CDK4;RAF1,CDK4,RAF1,CIT+CIT,Tclin+Tclin,0.467,0.506,0.837,18,0,13,1,2,DC01511,Naporafenib;Ribociclib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
2190,TP00646,CDK4;RAF1,CDK4,RAF1,CIT+CIT,Tclin+Tclin,0.467,0.506,0.837,18,0,13,1,2,DC01511,Naporafenib;Ribociclib,DrugComb,FD00026,Melanoma,Melanoma,Phase 1
2191,TP00647,CDK4;SMO,CDK4,SMO,CIT+CIT,Tclin+Tclin,0.445,0.381,0.392,1,0,2,1,1,DC01856,Ribociclib;Sonidegib,DrugComb,FD00025,Medulloblastoma,Other Cancer,Phase 1
2192,TP00648,CDK5;MS4A1,CDK5,MS4A1,CIT+CIT,Tchem+Tclin,0.241,0.484,0.433,0,0,0,1,2,DC00886,Dinaciclib;Rituximab,DrugComb,FD00021,Leukemia,Hematologic Malignancy,Phase 1
2193,TP00648,CDK5;MS4A1,CDK5,MS4A1,CIT+CIT,Tchem+Tclin,0.241,0.484,0.433,0,0,0,1,2,DC00886,Dinaciclib;Rituximab,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 1
2194,TP00649,CDK5;PDCD1,CDK5,PDCD1,CET+CIT,Tchem+Tclin,0.257,0.342,1.0,0,0,0,1,1,DC00885,Dinaciclib;Pembrolizumab,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 1
2195,TP00650,CDK6;CYP19A1,CDK6,CYP19A1,CIT+CIT,Tclin+Tclin,0.271,0.422,0.252,0,0,0,9,2,DC01427,Letrozole;Palbociclib,DrugComb,FD00007,Breast Cancer,Breast Cancer,Approval
2196,TP00650,CDK6;CYP19A1,CDK6,CYP19A1,CIT+CIT,Tclin+Tclin,0.271,0.422,0.252,0,0,0,9,2,DC01427,Letrozole;Palbociclib,DrugComb,FD00034,Ovarian Cancer,Ovarian Cancer,Phase 2
2205,TP00651,CDK6;EGFR,CDK6,EGFR,CIT+CIT,Tclin+Tclin,0.473,0.516,0.683,13,0,7,8,4,DC00750,Cetuximab;Palbociclib,DrugComb,FD00018,Head and Neck Cancer,Head and Neck Cancer,Phase 3
2206,TP00651,CDK6;EGFR,CDK6,EGFR,CIT+CIT,Tclin+Tclin,0.473,0.516,0.683,13,0,7,8,4,DC00026,Abemaciclib;Necitumumab,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
2209,TP00651,CDK6;EGFR,CDK6,EGFR,CIT+CIT,Tclin+Tclin,0.473,0.516,0.683,13,0,7,8,4,DC00104,Afatinib;XH30002,DrugComb,FD00014,Esophageal Cancer,Esophageal Cancer,Phase 1
2212,TP00651,CDK6;EGFR,CDK6,EGFR,CIT+CIT,Tclin+Tclin,0.473,0.516,0.683,13,0,7,8,4,DC00096,Afatinib;Palbociclib,DrugComb,FD00041,Stomach Cancer,Stomach Cancer,Phase 2
2214,TP00652,CDK6;EPAS1,CDK6,EPAS1,CIT+CIT,Tclin+Tclin,0.408,0.646,0.41,1,0,1,2,1,DC00012,Abemaciclib;Belzutifan,DrugComb,FD00020,Kidney Cancer,Kidney Cancer,Phase 1
2216,TP00653,CDK6;ERBB2,CDK6,ERBB2,CIT+CIT,Tclin+Tclin,0.518,0.52,0.754,6,0,6,8,4,DC00096,Afatinib;Palbociclib,DrugComb,FD00014,Esophageal Cancer,Esophageal Cancer,Phase 2
2217,TP00653,CDK6;ERBB2,CDK6,ERBB2,CIT+CIT,Tclin+Tclin,0.518,0.52,0.754,6,0,6,8,4,DC00096,Afatinib;Palbociclib,DrugComb,FD00041,Stomach Cancer,Stomach Cancer,Phase 2
2219,TP00653,CDK6;ERBB2,CDK6,ERBB2,CIT+CIT,Tclin+Tclin,0.518,0.52,0.754,6,0,6,8,4,DC00035,Abemaciclib;Trastuzumab,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 2
2222,TP00653,CDK6;ERBB2,CDK6,ERBB2,CIT+CIT,Tclin+Tclin,0.518,0.52,0.754,6,0,6,8,4,DC01537,Neratinib;Palbociclib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
2225,TP00654,CDK6;ERBB4,CDK6,ERBB4,CIT+CIT,Tclin+Tclin,0.511,0.526,0.765,1,0,1,2,2,DC00096,Afatinib;Palbociclib,DrugComb,FD00014,Esophageal Cancer,Esophageal Cancer,Phase 2
2226,TP00654,CDK6;ERBB4,CDK6,ERBB4,CIT+CIT,Tclin+Tclin,0.511,0.526,0.765,1,0,1,2,2,DC00096,Afatinib;Palbociclib,DrugComb,FD00041,Stomach Cancer,Stomach Cancer,Phase 2
2228,TP00655,CDK6;ESR1,CDK6,ESR1,CIT+CIT,Tclin+Tclin,0.442,0.64,0.432,2,0,2,25,4,DC01654,Palbociclib;Tamoxifen,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 2
2235,TP00655,CDK6;ESR1,CDK6,ESR1,CIT+CIT,Tclin+Tclin,0.442,0.64,0.432,2,0,2,25,4,DC01173,Fulvestrant;PF07224826,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
2237,TP00655,CDK6;ESR1,CDK6,ESR1,CIT+CIT,Tclin+Tclin,0.442,0.64,0.432,2,0,2,25,4,DC00018,Abemaciclib;Fulvestrant,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1|Phase 2
2238,TP00655,CDK6;ESR1,CDK6,ESR1,CIT+CIT,Tclin+Tclin,0.442,0.64,0.432,2,0,2,25,4,DC00018,Abemaciclib;Fulvestrant,DrugComb,FD00034,Ovarian Cancer,Ovarian Cancer,Phase 2
2255,TP00656,CDK6;ESR2,CDK6,ESR2,CIT+CIT,Tclin+Tclin,0.387,0.615,0.377,2,0,2,21,4,DC01173,Fulvestrant;PF07224826,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
2256,TP00656,CDK6;ESR2,CDK6,ESR2,CIT+CIT,Tclin+Tclin,0.387,0.615,0.377,2,0,2,21,4,DC00399,Bazedoxifene;Palbociclib,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 1|Phase 2
2266,TP00656,CDK6;ESR2,CDK6,ESR2,CIT+CIT,Tclin+Tclin,0.387,0.615,0.377,2,0,2,21,4,DC00018,Abemaciclib;Fulvestrant,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1|Phase 2
2267,TP00656,CDK6;ESR2,CDK6,ESR2,CIT+CIT,Tclin+Tclin,0.387,0.615,0.377,2,0,2,21,4,DC00018,Abemaciclib;Fulvestrant,DrugComb,FD00034,Ovarian Cancer,Ovarian Cancer,Phase 2
2278,TP00657,CDK6;IGF1,CDK6,IGF1,CIT+CIT,Tbio+Tclin,0.461,0.328,0.493,6,0,3,1,2,DC00038,Abemaciclib;Xentuzumab,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 1
2279,TP00657,CDK6;IGF1,CDK6,IGF1,CIT+CIT,Tbio+Tclin,0.461,0.328,0.493,6,0,3,1,2,DC00038,Abemaciclib;Xentuzumab,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
2280,TP00658,CDK6;IGF2,CDK6,IGF2,CIT+CIT,Tbio+Tclin,0.456,0.322,0.469,3,0,2,1,2,DC00038,Abemaciclib;Xentuzumab,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 1
2281,TP00658,CDK6;IGF2,CDK6,IGF2,CIT+CIT,Tbio+Tclin,0.456,0.322,0.469,3,0,2,1,2,DC00038,Abemaciclib;Xentuzumab,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
2282,TP00659,CDK6;KDR,CDK6,KDR,CET+CIT,Tclin+Tclin,0.486,0.499,0.774,1,0,2,1,3,DC00030,Abemaciclib;Ramucirumab,DrugComb,FD00011,Colorectal Cancer,Colorectal Cancer,Phase 1
2283,TP00659,CDK6;KDR,CDK6,KDR,CET+CIT,Tclin+Tclin,0.486,0.499,0.774,1,0,2,1,3,DC00030,Abemaciclib;Ramucirumab,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
2284,TP00659,CDK6;KDR,CDK6,KDR,CET+CIT,Tclin+Tclin,0.486,0.499,0.774,1,0,2,1,3,DC00030,Abemaciclib;Ramucirumab,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 1
2285,TP00660,CDK6;KRAS,CDK6,KRAS,CIT+CIT,Tclin+Tclin,0.494,0.492,0.458,16,0,8,4,2,DC01625,Opnurasib;Ribociclib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
2287,TP00660,CDK6;KRAS,CDK6,KRAS,CIT+CIT,Tclin+Tclin,0.494,0.492,0.458,16,0,8,4,2,DC00081,Adagrasib;Palbociclib,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
2289,TP00661,CDK6;MAP2K1,CDK6,MAP2K1,CIT+CIT,Tclin+Tclin,0.544,0.639,0.791,17,0,7,5,4,DC01474,Mirdametinib;Palbociclib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
2290,TP00661,CDK6;MAP2K1,CDK6,MAP2K1,CIT+CIT,Tclin+Tclin,0.544,0.639,0.791,17,0,7,5,4,DC00542,Binimetinib;Ribociclib,DrugComb,FD00026,Melanoma,Melanoma,Phase 1|Phase 2
2291,TP00661,CDK6;MAP2K1,CDK6,MAP2K1,CIT+CIT,Tclin+Tclin,0.544,0.639,0.791,17,0,7,5,4,DC01656,Palbociclib;Trametinib,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
2292,TP00661,CDK6;MAP2K1,CDK6,MAP2K1,CIT+CIT,Tclin+Tclin,0.544,0.639,0.791,17,0,7,5,4,DC01859,Ribociclib;Trametinib,DrugComb,FD00025,Medulloblastoma,Other Cancer,Phase 1
2295,TP00662,CDK6;MAP2K2,CDK6,MAP2K2,CIT+CIT,Tclin+Tclin,0.319,0.588,0.792,16,0,7,5,4,DC01474,Mirdametinib;Palbociclib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
2296,TP00662,CDK6;MAP2K2,CDK6,MAP2K2,CIT+CIT,Tclin+Tclin,0.319,0.588,0.792,16,0,7,5,4,DC00542,Binimetinib;Ribociclib,DrugComb,FD00026,Melanoma,Melanoma,Phase 1|Phase 2
2298,TP00662,CDK6;MAP2K2,CDK6,MAP2K2,CIT+CIT,Tclin+Tclin,0.319,0.588,0.792,16,0,7,5,4,DC01859,Ribociclib;Trametinib,DrugComb,FD00025,Medulloblastoma,Other Cancer,Phase 1
2299,TP00662,CDK6;MAP2K2,CDK6,MAP2K2,CIT+CIT,Tclin+Tclin,0.319,0.588,0.792,16,0,7,5,4,DC01859,Ribociclib;Trametinib,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
2301,TP00663,CDK6;MAPK1,CDK6,MAPK1,CIT+CIT,Tchem+Tclin,0.475,0.648,0.849,18,3,8,2,6,DC00034,Abemaciclib;Temuterkib,DrugComb,FD00011,Colorectal Cancer,Colorectal Cancer,Phase 1
2302,TP00663,CDK6;MAPK1,CDK6,MAPK1,CIT+CIT,Tchem+Tclin,0.475,0.648,0.849,18,3,8,2,6,DC00034,Abemaciclib;Temuterkib,DrugComb,FD00017,Glioma,Glioma,Early Phase 1
2303,TP00663,CDK6;MAPK1,CDK6,MAPK1,CIT+CIT,Tchem+Tclin,0.475,0.648,0.849,18,3,8,2,6,DC00034,Abemaciclib;Temuterkib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
2304,TP00663,CDK6;MAPK1,CDK6,MAPK1,CIT+CIT,Tchem+Tclin,0.475,0.648,0.849,18,3,8,2,6,DC00034,Abemaciclib;Temuterkib,DrugComb,FD00026,Melanoma,Melanoma,Phase 1
2305,TP00663,CDK6;MAPK1,CDK6,MAPK1,CIT+CIT,Tchem+Tclin,0.475,0.648,0.849,18,3,8,2,6,DC00034,Abemaciclib;Temuterkib,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 2
2307,TP00663,CDK6;MAPK1,CDK6,MAPK1,CIT+CIT,Tchem+Tclin,0.475,0.648,0.849,18,3,8,2,6,DC01658,Palbociclib;Ulixertinib,DrugComb,FD00035,Pancreatic Cancer,Pancreatic Cancer,Phase 1
2308,TP00664,CDK6;MAPK3,CDK6,MAPK3,CIT+CIT,Tchem+Tclin,0.454,0.673,0.864,18,3,7,2,6,DC00034,Abemaciclib;Temuterkib,DrugComb,FD00011,Colorectal Cancer,Colorectal Cancer,Phase 1
2309,TP00664,CDK6;MAPK3,CDK6,MAPK3,CIT+CIT,Tchem+Tclin,0.454,0.673,0.864,18,3,7,2,6,DC00034,Abemaciclib;Temuterkib,DrugComb,FD00017,Glioma,Glioma,Early Phase 1
2310,TP00664,CDK6;MAPK3,CDK6,MAPK3,CIT+CIT,Tchem+Tclin,0.454,0.673,0.864,18,3,7,2,6,DC00034,Abemaciclib;Temuterkib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
2311,TP00664,CDK6;MAPK3,CDK6,MAPK3,CIT+CIT,Tchem+Tclin,0.454,0.673,0.864,18,3,7,2,6,DC00034,Abemaciclib;Temuterkib,DrugComb,FD00026,Melanoma,Melanoma,Phase 1
2312,TP00664,CDK6;MAPK3,CDK6,MAPK3,CIT+CIT,Tchem+Tclin,0.454,0.673,0.864,18,3,7,2,6,DC00034,Abemaciclib;Temuterkib,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 2
2314,TP00664,CDK6;MAPK3,CDK6,MAPK3,CIT+CIT,Tchem+Tclin,0.454,0.673,0.864,18,3,7,2,6,DC01658,Palbociclib;Ulixertinib,DrugComb,FD00035,Pancreatic Cancer,Pancreatic Cancer,Phase 1
2315,TP00665,CDK6;MDM2,CDK6,MDM2,CIT+CIT,Tchem+Tclin,0.436,0.699,0.541,13,2,10,1,2,DC01855,Ribociclib;Siremadlin,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 2
2316,TP00665,CDK6;MDM2,CDK6,MDM2,CIT+CIT,Tchem+Tclin,0.436,0.699,0.541,13,2,10,1,2,DC01855,Ribociclib;Siremadlin,DrugComb,FD00040,Soft Tissue Sarcoma,Other Cancer,Phase 1
2317,TP00666,CDK6;MTOR,CDK6,MTOR,CIT+CIT,Tclin+Tclin,0.401,0.614,0.758,11,0,7,3,6,DC00031,Abemaciclib;Samotolisib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
2318,TP00666,CDK6;MTOR,CDK6,MTOR,CIT+CIT,Tclin+Tclin,0.401,0.614,0.758,11,0,7,3,6,DC00031,Abemaciclib;Samotolisib,DrugComb,FD00035,Pancreatic Cancer,Pancreatic Cancer,Phase 2
2319,TP00666,CDK6;MTOR,CDK6,MTOR,CIT+CIT,Tclin+Tclin,0.401,0.614,0.758,11,0,7,3,6,DC01210,Gedatolisib;Palbociclib,DrugComb,FD00018,Head and Neck Cancer,Head and Neck Cancer,Phase 1
2322,TP00666,CDK6;MTOR,CDK6,MTOR,CIT+CIT,Tclin+Tclin,0.401,0.614,0.758,11,0,7,3,6,DC01114,Everolimus;Ribociclib,DrugComb,FD00017,Glioma,Glioma,Early Phase 1
2323,TP00666,CDK6;MTOR,CDK6,MTOR,CIT+CIT,Tclin+Tclin,0.401,0.614,0.758,11,0,7,3,6,DC01114,Everolimus;Ribociclib,DrugComb,FD00032,Neuroendocrine Tumor,Other Cancer,Phase 2
2324,TP00666,CDK6;MTOR,CDK6,MTOR,CIT+CIT,Tclin+Tclin,0.401,0.614,0.758,11,0,7,3,6,DC01114,Everolimus;Ribociclib,DrugComb,FD00040,Soft Tissue Sarcoma,Other Cancer,Phase 2
2325,TP00667,CDK6;NOTCH1,CDK6,NOTCH1,CIT+CIT,Tchem+Tclin,0.459,0.564,0.446,4,0,4,1,3,DC00014,Abemaciclib;Crenigacestat,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 1
2326,TP00667,CDK6;NOTCH1,CDK6,NOTCH1,CIT+CIT,Tchem+Tclin,0.459,0.564,0.446,4,0,4,1,3,DC00014,Abemaciclib;Crenigacestat,DrugComb,FD00011,Colorectal Cancer,Colorectal Cancer,Phase 1
2327,TP00667,CDK6;NOTCH1,CDK6,NOTCH1,CIT+CIT,Tchem+Tclin,0.459,0.564,0.446,4,0,4,1,3,DC00014,Abemaciclib;Crenigacestat,DrugComb,FD00022,Liver Cancer,Liver Cancer,Phase 1
2328,TP00668,CDK6;PDCD1,CDK6,PDCD1,CET+CIT,Tclin+Tclin,0.327,0.232,1.0,0,0,0,5,6,DC00641,Camrelizumab;Dalpiciclib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
2329,TP00668,CDK6;PDCD1,CDK6,PDCD1,CET+CIT,Tclin+Tclin,0.327,0.232,1.0,0,0,0,5,6,DC00029,Abemaciclib;Pembrolizumab,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 1
2331,TP00668,CDK6;PDCD1,CDK6,PDCD1,CET+CIT,Tclin+Tclin,0.327,0.232,1.0,0,0,0,5,6,DC00029,Abemaciclib;Pembrolizumab,DrugComb,FD00041,Stomach Cancer,Stomach Cancer,Phase 2
2332,TP00668,CDK6;PDCD1,CDK6,PDCD1,CET+CIT,Tclin+Tclin,0.327,0.232,1.0,0,0,0,5,6,DC00027,Abemaciclib;Nivolumab,DrugComb,FD00018,Head and Neck Cancer,Head and Neck Cancer,Phase 1|Phase 2
2333,TP00668,CDK6;PDCD1,CDK6,PDCD1,CET+CIT,Tclin+Tclin,0.327,0.232,1.0,0,0,0,5,6,DC01857,Ribociclib;Spartalizumab,DrugComb,FD00026,Melanoma,Melanoma,Phase 2
2334,TP00668,CDK6;PDCD1,CDK6,PDCD1,CET+CIT,Tclin+Tclin,0.327,0.232,1.0,0,0,0,5,6,DC01650,Palbociclib;Retifanlimab,DrugComb,FD00040,Soft Tissue Sarcoma,Other Cancer,Phase 2
2335,TP00669,CDK6;PIK3CA,CDK6,PIK3CA,CIT+CIT,Tclin+Tclin,0.375,0.553,0.757,20,0,10,3,4,DC01210,Gedatolisib;Palbociclib,DrugComb,FD00018,Head and Neck Cancer,Head and Neck Cancer,Phase 1
2336,TP00669,CDK6;PIK3CA,CDK6,PIK3CA,CIT+CIT,Tclin+Tclin,0.375,0.553,0.757,20,0,10,3,4,DC01210,Gedatolisib;Palbociclib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
2337,TP00669,CDK6;PIK3CA,CDK6,PIK3CA,CIT+CIT,Tclin+Tclin,0.375,0.553,0.757,20,0,10,3,4,DC01210,Gedatolisib;Palbociclib,DrugComb,FD00035,Pancreatic Cancer,Pancreatic Cancer,Phase 1
2340,TP00669,CDK6;PIK3CA,CDK6,PIK3CA,CIT+CIT,Tclin+Tclin,0.375,0.553,0.757,20,0,10,3,4,DC00158,Alpelisib;Ribociclib,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 2
2341,TP00670,CDK6;PTPN11,CDK6,PTPN11,CIT+CIT,Tchem+Tclin,0.455,0.759,0.502,1,1,0,1,1,DC00394,Batoprotafib;Ribociclib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
2342,TP00671,CDK6;RAF1,CDK6,RAF1,CIT+CIT,Tclin+Tclin,0.517,0.632,0.874,16,0,8,1,2,DC01511,Naporafenib;Ribociclib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
2343,TP00671,CDK6;RAF1,CDK6,RAF1,CIT+CIT,Tclin+Tclin,0.517,0.632,0.874,16,0,8,1,2,DC01511,Naporafenib;Ribociclib,DrugComb,FD00026,Melanoma,Melanoma,Phase 1
2344,TP00672,CDK6;SMO,CDK6,SMO,CIT+CIT,Tclin+Tclin,0.499,0.461,0.452,1,0,2,1,1,DC01856,Ribociclib;Sonidegib,DrugComb,FD00025,Medulloblastoma,Other Cancer,Phase 1
2345,TP00673,CDK7;ESR1,CDK7,ESR1,CIT+CIT,Tchem+Tclin,0.358,0.739,0.393,0,0,0,2,2,DC01239,Giredestrant;Samuraciclib,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 1|Phase 2
2346,TP00673,CDK7;ESR1,CDK7,ESR1,CIT+CIT,Tchem+Tclin,0.358,0.739,0.393,0,0,0,2,2,DC01194,Fulvestrant;XL102,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
2347,TP00674,CDK7;ESR2,CDK7,ESR2,CIT+CIT,Tchem+Tclin,0.49,0.678,0.322,0,0,0,2,2,DC01239,Giredestrant;Samuraciclib,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 1|Phase 2
2348,TP00674,CDK7;ESR2,CDK7,ESR2,CIT+CIT,Tchem+Tclin,0.49,0.678,0.322,0,0,0,2,2,DC01194,Fulvestrant;XL102,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
2349,TP00675,CDK9;MS4A1,CDK9,MS4A1,CIT+CIT,Tchem+Tclin,0.198,0.622,0.392,0,0,0,1,2,DC00886,Dinaciclib;Rituximab,DrugComb,FD00021,Leukemia,Hematologic Malignancy,Phase 1
2350,TP00675,CDK9;MS4A1,CDK9,MS4A1,CIT+CIT,Tchem+Tclin,0.198,0.622,0.392,0,0,0,1,2,DC00886,Dinaciclib;Rituximab,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 1
2351,TP00676,CDK9;PDCD1,CDK9,PDCD1,CET+CIT,Tchem+Tclin,0.173,0.327,1.0,0,0,0,2,2,DC00989,Enitociclib;Pembrolizumab,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
2352,TP00676,CDK9;PDCD1,CDK9,PDCD1,CET+CIT,Tchem+Tclin,0.173,0.327,1.0,0,0,0,2,2,DC00885,Dinaciclib;Pembrolizumab,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 1
2353,TP00677,CEACAM1;PDCD1,CEACAM1,PDCD1,CET+CIT,Tbio+Tclin,0.299,0.58,1.0,0,0,0,2,1,DC00783,CM24;Pembrolizumab,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
2355,TP00678,CEACAM5;IL2,CEACAM5,IL2,CET+CIT,Tbio+Tchem,0.262,0.519,0.59,0,0,0,1,1,DC02061,Cergutuzumab Amunaleukin,BsAb,FD00033,Other Cancer,Other Cancer,Phase 1
2356,TP00679,CEACAM5;KDR,CEACAM5,KDR,CET+CIT,Tbio+Tclin,0.194,0.603,0.552,0,0,0,1,1,DC01843,Ramucirumab;Tusamitamab Ravtansine,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 2
2357,TP00680,CEACAM5;PDCD1,CEACAM5,PDCD1,CET+CIT,Tbio+Tclin,0.431,0.652,1.0,0,0,0,6,4,DC00500,BGBB167;Tislelizumab,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
2358,TP00680,CEACAM5;PDCD1,CEACAM5,PDCD1,CET+CIT,Tbio+Tclin,0.431,0.652,1.0,0,0,0,6,4,DC00771,Cibisatamab;Nivolumab,DrugComb,FD00018,Head and Neck Cancer,Head and Neck Cancer,Phase 2
2359,TP00680,CEACAM5;PDCD1,CEACAM5,PDCD1,CET+CIT,Tbio+Tclin,0.431,0.652,1.0,0,0,0,6,4,DC00771,Cibisatamab;Nivolumab,DrugComb,FD00030,Myeloma,Hematologic Malignancy,Phase 2
2360,TP00680,CEACAM5;PDCD1,CEACAM5,PDCD1,CET+CIT,Tbio+Tclin,0.431,0.652,1.0,0,0,0,6,4,DC01536,NEO201;Pembrolizumab,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
2364,TP00681,CEACAM5;SLAMF7,CEACAM5,SLAMF7,CIT+CIT,Tbio+Tclin,0.336,0.652,1.0,0,0,0,1,1,DC00770,Cibisatamab;Elotuzumab,DrugComb,FD00030,Myeloma,Hematologic Malignancy,Phase 1
2365,TP00682,CEACAM5;TNFRSF9,CEACAM5,TNFRSF9,CET+CIT,Tbio+Tbio,0.443,0.693,0.663,0,0,0,1,1,DC02037,BGBB167,BsAb,FD00033,Other Cancer,Other Cancer,Phase 1
2366,TP00683,CEACAM6;PDCD1,CEACAM6,PDCD1,CET+CIT,Tbio+Tclin,0.36,0.639,1.0,0,0,0,2,2,DC01536,NEO201;Pembrolizumab,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
2367,TP00683,CEACAM6;PDCD1,CEACAM6,PDCD1,CET+CIT,Tbio+Tclin,0.36,0.639,1.0,0,0,0,2,2,DC00963,EBC129;Pembrolizumab,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
2368,TP00684,CEBPA;PDCD1,CEBPA,PDCD1,CET+CIT,Tbio+Tclin,0.249,0.198,1.0,0,0,0,1,1,DC01506,MTL501;Pembrolizumab,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
2369,TP00685,CFH;PDCD1,CFH,PDCD1,CET+CET,Tbio+Tclin,0.356,0.289,1.0,0,0,0,1,1,DC01257,GT103;Pembrolizumab,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 2
2370,TP00686,CHEK1;EGFR,CHEK1,EGFR,CIT+CIT,Tchem+Tclin,0.473,0.586,0.706,0,0,1,1,1,DC00753,Cetuximab;Prexasertib,DrugComb,FD00018,Head and Neck Cancer,Head and Neck Cancer,Phase 1
2371,TP00687,CHEK1;MAPK11,CHEK1,MAPK11,CIT+CIT,Tchem+Tchem,0.454,0.745,0.95,2,1,1,1,2,DC01828,Prexasertib;Ralimetinib,DrugComb,FD00011,Colorectal Cancer,Colorectal Cancer,Phase 1
2372,TP00687,CHEK1;MAPK11,CHEK1,MAPK11,CIT+CIT,Tchem+Tchem,0.454,0.745,0.95,2,1,1,1,2,DC01828,Prexasertib;Ralimetinib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
2373,TP00688,CHEK1;MAPK14,CHEK1,MAPK14,CIT+CIT,Tchem+Tchem,0.459,0.749,0.857,2,1,2,1,2,DC01828,Prexasertib;Ralimetinib,DrugComb,FD00011,Colorectal Cancer,Colorectal Cancer,Phase 1
2374,TP00688,CHEK1;MAPK14,CHEK1,MAPK14,CIT+CIT,Tchem+Tchem,0.459,0.749,0.857,2,1,2,1,2,DC01828,Prexasertib;Ralimetinib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
2375,TP00689,CHEK1;MTOR,CHEK1,MTOR,CIT+CIT,Tchem+Tclin,0.43,0.667,0.783,2,0,2,1,2,DC01829,Prexasertib;Samotolisib,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 1
2376,TP00689,CHEK1;MTOR,CHEK1,MTOR,CIT+CIT,Tchem+Tclin,0.43,0.667,0.783,2,0,2,1,2,DC01829,Prexasertib;Samotolisib,DrugComb,FD00011,Colorectal Cancer,Colorectal Cancer,Phase 1
2377,TP00690,CHEK1;PARP1,CHEK1,PARP1,CIT+CIT,Tchem+Tclin,0.512,0.798,0.524,0,0,3,1,1,DC01616,Olaparib;Prexasertib,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
2378,TP00691,CHEK1;PARP2,CHEK1,PARP2,CIT+CIT,Tchem+Tclin,0.459,0.705,0.469,0,0,1,1,1,DC01616,Olaparib;Prexasertib,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
2379,TP00692,CHEK1;PIK3CA,CHEK1,PIK3CA,CIT+CIT,Tchem+Tclin,0.416,0.509,0.794,4,1,2,1,2,DC01829,Prexasertib;Samotolisib,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 1
2380,TP00692,CHEK1;PIK3CA,CHEK1,PIK3CA,CIT+CIT,Tchem+Tclin,0.416,0.509,0.794,4,1,2,1,2,DC01829,Prexasertib;Samotolisib,DrugComb,FD00011,Colorectal Cancer,Colorectal Cancer,Phase 1
2381,TP00693,CLDN18;PDCD1,CLDN18,PDCD1,CET+CIT,Tbio+Tclin,0.275,0.812,1.0,1,0,0,2,2,DC01560,Nivolumab;Osemitamab,DrugComb,FD00035,Pancreatic Cancer,Pancreatic Cancer,Phase 1|Phase 2
2382,TP00693,CLDN18;PDCD1,CLDN18,PDCD1,CET+CIT,Tbio+Tclin,0.275,0.812,1.0,1,0,0,2,2,DC01560,Nivolumab;Osemitamab,DrugComb,FD00041,Stomach Cancer,Stomach Cancer,Phase 1|Phase 2
2384,TP00694,CLDN18;TNFRSF9,CLDN18,TNFRSF9,CET+CIT,Tbio+Tbio,0.227,0.701,0.698,0,0,0,2,3,DC02119,Givastomig,BsAb,FD00014,Esophageal Cancer,Esophageal Cancer,Phase 1
2385,TP00694,CLDN18;TNFRSF9,CLDN18,TNFRSF9,CET+CIT,Tbio+Tbio,0.227,0.701,0.698,0,0,0,2,3,DC02119,Givastomig,BsAb,FD00041,Stomach Cancer,Stomach Cancer,Phase 1
2386,TP00694,CLDN18;TNFRSF9,CLDN18,TNFRSF9,CET+CIT,Tbio+Tbio,0.227,0.701,0.698,0,0,0,2,3,DC02221,PM1032,BsAb,FD00033,Other Cancer,Other Cancer,Phase 1|Phase 2
2387,TP00695,CLDN6;CLDN9,CLDN6,CLDN9,CIT+CIT,Tbio+Tbio,1.0,0.823,1.0,0,1,1,1,2,DC02255,SC004,BsAb,FD00033,Other Cancer,Other Cancer,Phase 1
2388,TP00695,CLDN6;CLDN9,CLDN6,CLDN9,CIT+CIT,Tbio+Tbio,1.0,0.823,1.0,0,1,1,1,2,DC02255,SC004,BsAb,FD00034,Ovarian Cancer,Ovarian Cancer,Phase 1
2389,TP00696,CLDN6;PDCD1,CLDN6,PDCD1,CET+CIT,Tbio+Tclin,0.15,0.803,1.0,0,0,0,1,2,DC00607,Budigalimab;SC004,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
2390,TP00696,CLDN6;PDCD1,CLDN6,PDCD1,CET+CIT,Tbio+Tclin,0.15,0.803,1.0,0,0,0,1,2,DC00607,Budigalimab;SC004,DrugComb,FD00034,Ovarian Cancer,Ovarian Cancer,Phase 1
2391,TP00697,CLDN9;PDCD1,CLDN9,PDCD1,CET+CIT,Tbio+Tclin,0.15,0.683,1.0,1,0,0,1,2,DC00607,Budigalimab;SC004,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
2392,TP00697,CLDN9;PDCD1,CLDN9,PDCD1,CET+CIT,Tbio+Tclin,0.15,0.683,1.0,1,0,0,1,2,DC00607,Budigalimab;SC004,DrugComb,FD00034,Ovarian Cancer,Ovarian Cancer,Phase 1
2393,TP00698,CLEC6A;PDCD1,CLEC6A,PDCD1,CET+CIT,Tbio+Tclin,0.386,1.0,1.0,0,0,0,1,1,DC00407,BDC3042;Pembrolizumab,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
2394,TP00699,CRBN;CTLA4,CRBN,CTLA4,CET+CIT,Tclin+Tclin,0.137,0.627,1.0,0,0,0,1,1,DC01329,Ipilimumab;Lenalidomide,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
2395,TP00700,CRBN;EGFR,CRBN,EGFR,CIT+CIT,Tclin+Tclin,0.195,0.608,0.469,0,0,0,1,1,DC00738,Cetuximab;Lenalidomide,DrugComb,FD00011,Colorectal Cancer,Colorectal Cancer,Phase 2
2396,TP00701,CRBN;HDAC1,CRBN,HDAC1,CIT+CIT,Tclin+Tclin,0.195,0.646,0.47,0,1,0,3,1,DC01403,Lenalidomide;Romidepsin,DrugComb,FD00030,Myeloma,Hematologic Malignancy,Phase 1|Phase 2
2399,TP00702,CRBN;HDAC10,CRBN,HDAC10,CIT+CIT,Tclin+Tclin,0.265,0.759,0.526,0,0,0,2,1,DC01399,Lenalidomide;Panobinostat,DrugComb,FD00030,Myeloma,Hematologic Malignancy,Phase 1
2401,TP00703,CRBN;HDAC11,CRBN,HDAC11,CIT+CIT,Tclin+Tclin,0.25,0.576,0.57,0,0,0,1,1,DC01399,Lenalidomide;Panobinostat,DrugComb,FD00030,Myeloma,Hematologic Malignancy,Phase 1
2402,TP00704,CRBN;HDAC2,CRBN,HDAC2,CIT+CIT,Tclin+Tclin,0.171,0.651,0.489,0,1,0,3,1,DC01399,Lenalidomide;Panobinostat,DrugComb,FD00030,Myeloma,Hematologic Malignancy,Phase 1
2405,TP00705,CRBN;HDAC3,CRBN,HDAC3,CIT+CIT,Tclin+Tclin,0.229,0.722,0.544,0,0,0,3,1,DC01403,Lenalidomide;Romidepsin,DrugComb,FD00030,Myeloma,Hematologic Malignancy,Phase 1|Phase 2
2408,TP00706,CRBN;HDAC4,CRBN,HDAC4,CIT+CIT,Tclin+Tclin,0.238,0.736,0.53,0,0,0,2,1,DC01416,Lenalidomide;Vorinostat,DrugComb,FD00030,Myeloma,Hematologic Malignancy,Phase 1
2410,TP00707,CRBN;HDAC5,CRBN,HDAC5,CIT+CIT,Tclin+Tclin,0.207,0.771,0.593,0,0,0,2,1,DC01416,Lenalidomide;Vorinostat,DrugComb,FD00030,Myeloma,Hematologic Malignancy,Phase 1
2412,TP00708,CRBN;HDAC6,CRBN,HDAC6,CIT+CIT,Tclin+Tclin,0.309,0.64,0.585,0,0,0,2,1,DC01399,Lenalidomide;Panobinostat,DrugComb,FD00030,Myeloma,Hematologic Malignancy,Phase 1
2414,TP00709,CRBN;HDAC7,CRBN,HDAC7,CIT+CIT,Tclin+Tclin,0.298,0.795,0.58,0,0,0,2,1,DC01399,Lenalidomide;Panobinostat,DrugComb,FD00030,Myeloma,Hematologic Malignancy,Phase 1
2416,TP00710,CRBN;HDAC8,CRBN,HDAC8,CIT+CIT,Tclin+Tclin,0.233,0.756,0.695,0,0,0,3,1,DC01399,Lenalidomide;Panobinostat,DrugComb,FD00030,Myeloma,Hematologic Malignancy,Phase 1
2419,TP00711,CRBN;HDAC9,CRBN,HDAC9,CIT+CIT,Tclin+Tclin,0.201,0.705,0.571,0,0,0,2,1,DC01416,Lenalidomide;Vorinostat,DrugComb,FD00030,Myeloma,Hematologic Malignancy,Phase 1
2421,TP00712,CRBN;IFNAR1,CRBN,IFNAR1,CIT+CIT,Tclin+Tclin,0.137,0.498,0.565,0,1,0,2,1,DC01497,Modakafusp Alfa;Pomalidomide,DrugComb,FD00030,Myeloma,Hematologic Malignancy,Phase 1
2423,TP00713,CRBN;IFNAR2,CRBN,IFNAR2,CIT+CIT,Tclin+Tclin,0.135,0.452,0.565,0,0,0,2,1,DC01395,Lenalidomide;Modakafusp Alfa,DrugComb,FD00030,Myeloma,Hematologic Malignancy,Phase 1
2425,TP00714,CRBN;IGF1,CRBN,IGF1,CIT+CIT,Tbio+Tclin,0.176,0.406,0.653,0,0,0,1,1,DC01417,Lenalidomide;Xentuzumab,DrugComb,FD00030,Myeloma,Hematologic Malignancy,Phase 1
2426,TP00715,CRBN;IGF2,CRBN,IGF2,CIT+CIT,Tbio+Tclin,0.175,0.404,0.589,0,0,0,1,1,DC01417,Lenalidomide;Xentuzumab,DrugComb,FD00030,Myeloma,Hematologic Malignancy,Phase 1
2427,TP00716,CRBN;IL6R,CRBN,IL6R,CET+CIT,Tclin+Tclin,0.164,0.439,0.539,0,1,0,1,1,DC01410,Lenalidomide;Tocilizumab,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 1|Phase 2
2428,TP00717,CRBN;ITGA4,CRBN,ITGA4,CET+CIT,Tclin+Tclin,0.114,0.453,0.757,0,1,0,2,1,DC01825,Pomalidomide;Vedolizumab,DrugComb,FD00030,Myeloma,Hematologic Malignancy,Phase 1
2430,TP00718,CRBN;ITGB7,CRBN,ITGB7,CIT+CIT,Tclin+Tclin,0.122,0.473,0.751,0,0,0,2,1,DC01415,Lenalidomide;Vedolizumab,DrugComb,FD00030,Myeloma,Hematologic Malignancy,Phase 1
2432,TP00719,CRBN;MAP2K1,CRBN,MAP2K1,CIT+CIT,Tclin+Tclin,0.19,0.675,0.395,0,0,0,1,1,DC00767,CFT1946;Trametinib,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1|Phase 2
2433,TP00720,CRBN;MAP2K2,CRBN,MAP2K2,CIT+CIT,Tclin+Tclin,0.242,0.649,0.481,0,0,0,1,1,DC00767,CFT1946;Trametinib,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1|Phase 2
2434,TP00721,CRBN;MS4A1,CRBN,MS4A1,CIT+CIT,Tclin+Tclin,0.174,0.495,0.661,0,0,0,6,3,DC01398,Lenalidomide;Ofatumumab,DrugComb,FD00021,Leukemia,Hematologic Malignancy,Phase 2
2435,TP00721,CRBN;MS4A1,CRBN,MS4A1,CIT+CIT,Tclin+Tclin,0.174,0.495,0.661,0,0,0,6,3,DC01398,Lenalidomide;Ofatumumab,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 2
2436,TP00721,CRBN;MS4A1,CRBN,MS4A1,CIT+CIT,Tclin+Tclin,0.174,0.495,0.661,0,0,0,6,3,DC01400,Lenalidomide;Rituximab,DrugComb,FD00019,Hematologic Malignancies,Hematologic Malignancy,Phase 2
2445,TP00722,CRBN;MTOR,CRBN,MTOR,CIT+CIT,Tclin+Tclin,0.207,0.665,0.408,0,0,0,2,2,DC01409,Lenalidomide;Temsirolimus,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
2446,TP00722,CRBN;MTOR,CRBN,MTOR,CIT+CIT,Tclin+Tclin,0.207,0.665,0.408,0,0,0,2,2,DC01103,Everolimus;Lenalidomide,DrugComb,FD00020,Kidney Cancer,Kidney Cancer,Phase 1
2447,TP00723,CRBN;PDCD1,CRBN,PDCD1,CET+CIT,Tclin+Tclin,0.139,0.419,1.0,0,1,0,2,3,DC00332,Avadomide;Nivolumab,DrugComb,FD00022,Liver Cancer,Liver Cancer,Phase 1|Phase 2
2448,TP00723,CRBN;PDCD1,CRBN,PDCD1,CET+CIT,Tclin+Tclin,0.139,0.419,1.0,0,1,0,2,3,DC00332,Avadomide;Nivolumab,DrugComb,FD00026,Melanoma,Melanoma,Phase 2
2449,TP00723,CRBN;PDCD1,CRBN,PDCD1,CET+CIT,Tclin+Tclin,0.139,0.419,1.0,0,1,0,2,3,DC01567,Nivolumab;Pomalidomide,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 1
2450,TP00724,CRBN;RARA,CRBN,RARA,CIT+CIT,Tclin+Tclin,0.152,0.696,0.493,0,0,0,1,1,DC01412,Lenalidomide;Tretinoin,DrugComb,FD00030,Myeloma,Hematologic Malignancy,Phase 1
2451,TP00725,CRBN;RARB,CRBN,RARB,CIT+CIT,Tclin+Tclin,0.149,0.74,0.339,0,0,0,1,1,DC01412,Lenalidomide;Tretinoin,DrugComb,FD00030,Myeloma,Hematologic Malignancy,Phase 1
2452,TP00726,CRBN;RARG,CRBN,RARG,CIT+CIT,Tclin+Tclin,0.153,0.725,0.493,0,0,0,1,1,DC01412,Lenalidomide;Tretinoin,DrugComb,FD00030,Myeloma,Hematologic Malignancy,Phase 1
2453,TP00727,CRBN;SLAMF7,CRBN,SLAMF7,CIT+CIT,Tclin+Tclin,0.125,0.419,0.788,0,0,0,1,1,DC00972,Elotuzumab;Pomalidomide,DrugComb,FD00030,Myeloma,Hematologic Malignancy,Phase 2
2454,TP00728,CRBN;TGFBR1,CRBN,TGFBR1,CIT+CIT,Tchem+Tclin,0.191,0.532,0.542,0,0,0,1,1,DC01824,Pomalidomide;Vactosertib,DrugComb,FD00030,Myeloma,Hematologic Malignancy,Phase 1
2455,TP00729,CRBN;TNFRSF13C,CRBN,TNFRSF13C,CET+CIT,Tbio+Tclin,0.124,0.419,0.224,0,0,0,2,1,DC01267,Ianalumab;Lenalidomide,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 1
2457,TP00730,CRBN;TNFRSF17,CRBN,TNFRSF17,CIT+CIT,Tclin+Tclin,0.164,0.477,0.674,0,0,0,2,1,DC01408,Lenalidomide;Teclistamab,DrugComb,FD00030,Myeloma,Hematologic Malignancy,Phase 3
2459,TP00731,CRBN;TNFRSF8,CRBN,TNFRSF8,CIT+CIT,Tclin+Tclin,0.192,0.652,0.176,0,0,0,1,1,DC00594,Brentuximab Vedotin;Lenalidomide,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 1
2460,TP00732,CRBN;VEGFA,CRBN,VEGFA,CET+CIT,Tclin+Tclin,0.165,0.624,0.596,0,0,0,2,2,DC01414,Lenalidomide;Vanucizumab,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 1|Phase 2
2461,TP00732,CRBN;VEGFA,CRBN,VEGFA,CET+CIT,Tclin+Tclin,0.165,0.624,0.596,0,0,0,2,2,DC00454,Bevacizumab;Lenalidomide,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
2462,TP00733,CREBBP;KDR,CREBBP,KDR,CET+CIT,Tchem+Tclin,0.374,0.547,0.473,0,0,3,1,1,DC00962,E7386;Lenvatinib,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
2463,TP00734,CREBBP;PARP1,CREBBP,PARP1,CIT+CIT,Tchem+Tclin,0.471,0.811,0.622,0,0,1,1,1,DC01324,Inobrodib;Olaparib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
2464,TP00735,CREBBP;PARP2,CREBBP,PARP2,CIT+CIT,Tchem+Tclin,0.402,0.778,0.565,0,0,0,1,1,DC01324,Inobrodib;Olaparib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
2465,TP00736,CSF1;PDCD1,CSF1,PDCD1,CET+CET,Tbio+Tclin,0.304,0.581,1.0,0,0,0,1,4,DC01377,Lacnotuzumab;Spartalizumab,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 1|Phase 2
2466,TP00736,CSF1;PDCD1,CSF1,PDCD1,CET+CET,Tbio+Tclin,0.304,0.581,1.0,0,0,0,1,4,DC01377,Lacnotuzumab;Spartalizumab,DrugComb,FD00026,Melanoma,Melanoma,Phase 1|Phase 2
2467,TP00736,CSF1;PDCD1,CSF1,PDCD1,CET+CET,Tbio+Tclin,0.304,0.581,1.0,0,0,0,1,4,DC01377,Lacnotuzumab;Spartalizumab,DrugComb,FD00034,Ovarian Cancer,Ovarian Cancer,Phase 1|Phase 2
2468,TP00736,CSF1;PDCD1,CSF1,PDCD1,CET+CET,Tbio+Tclin,0.304,0.581,1.0,0,0,0,1,4,DC01377,Lacnotuzumab;Spartalizumab,DrugComb,FD00035,Pancreatic Cancer,Pancreatic Cancer,Phase 1|Phase 2
2469,TP00737,CSF1R;CTLA4,CSF1R,CTLA4,CET+CET,Tclin+Tclin,0.274,0.689,1.0,0,0,1,1,1,DC01456,LY3022855;Tremelimumab,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
2470,TP00738,CSF1R;MAP2K1,CSF1R,MAP2K1,CET+CIT,Tclin+Tclin,0.566,0.598,0.751,7,0,6,1,1,DC00540,Binimetinib;Pexidartinib,DrugComb,FD00040,Soft Tissue Sarcoma,Other Cancer,Phase 1
2471,TP00739,CSF1R;MAP2K2,CSF1R,MAP2K2,CET+CIT,Tclin+Tclin,0.389,0.541,0.749,6,0,6,1,1,DC00540,Binimetinib;Pexidartinib,DrugComb,FD00040,Soft Tissue Sarcoma,Other Cancer,Phase 1
2472,TP00740,CSF1R;MTOR,CSF1R,MTOR,CET+CIT,Tclin+Tclin,0.494,0.581,0.707,3,0,6,1,1,DC01802,Pexidartinib;Sirolimus,DrugComb,FD00040,Soft Tissue Sarcoma,Other Cancer,Phase 1|Phase 2
2473,TP00741,CSF1R;PDCD1,CSF1R,PDCD1,CET+CET,Tclin+Tclin,0.323,0.531,1.0,0,0,0,7,7,DC01698,Pembrolizumab;Q702,DrugComb,FD00014,Esophageal Cancer,Esophageal Cancer,Phase 1|Phase 2
2474,TP00741,CSF1R;PDCD1,CSF1R,PDCD1,CET+CET,Tclin+Tclin,0.323,0.531,1.0,0,0,0,7,7,DC01698,Pembrolizumab;Q702,DrugComb,FD00022,Liver Cancer,Liver Cancer,Phase 1|Phase 2
2475,TP00741,CSF1R;PDCD1,CSF1R,PDCD1,CET+CET,Tclin+Tclin,0.323,0.531,1.0,0,0,0,7,7,DC01698,Pembrolizumab;Q702,DrugComb,FD00034,Ovarian Cancer,Ovarian Cancer,Phase 1|Phase 2
2476,TP00741,CSF1R;PDCD1,CSF1R,PDCD1,CET+CET,Tclin+Tclin,0.323,0.531,1.0,0,0,0,7,7,DC01698,Pembrolizumab;Q702,DrugComb,FD00041,Stomach Cancer,Stomach Cancer,Phase 1|Phase 2
2477,TP00741,CSF1R;PDCD1,CSF1R,PDCD1,CET+CET,Tclin+Tclin,0.323,0.531,1.0,0,0,0,7,7,DC01695,Pembrolizumab;Pexidartinib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
2479,TP00741,CSF1R;PDCD1,CSF1R,PDCD1,CET+CET,Tclin+Tclin,0.323,0.531,1.0,0,0,0,7,7,DC00359,Axatilimab;Nivolumab,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 2
2480,TP00741,CSF1R;PDCD1,CSF1R,PDCD1,CET+CET,Tclin+Tclin,0.323,0.531,1.0,0,0,0,7,7,DC00234,ARRY382;Pembrolizumab,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1|Phase 2
2485,TP00742,CSNK1E;MS4A1,CSNK1E,MS4A1,CIT+CIT,Tclin+Tclin,0.309,0.486,0.424,0,0,0,2,2,DC01870,Rituximab;Umbralisib,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 2
2486,TP00742,CSNK1E;MS4A1,CSNK1E,MS4A1,CIT+CIT,Tclin+Tclin,0.309,0.486,0.424,0,0,0,2,2,DC01984,Ublituximab;Umbralisib,DrugComb,FD00021,Leukemia,Hematologic Malignancy,Phase 2|Phase 3
2488,TP00743,CSNK1E;PDCD1,CSNK1E,PDCD1,CET+CIT,Tclin+Tclin,0.204,0.284,1.0,0,0,0,1,2,DC01757,Pembrolizumab;Umbralisib,DrugComb,FD00021,Leukemia,Hematologic Malignancy,Phase 1
2489,TP00743,CSNK1E;PDCD1,CSNK1E,PDCD1,CET+CIT,Tclin+Tclin,0.204,0.284,1.0,0,0,0,1,2,DC01757,Pembrolizumab;Umbralisib,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 1
2490,TP00744,CSNK1E;TNFRSF8,CSNK1E,TNFRSF8,CIT+CIT,Tclin+Tclin,0.385,0.572,0.176,0,0,0,1,1,DC00598,Brentuximab Vedotin;Umbralisib,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 1
2491,TP00745,CTLA4;EGFR,CTLA4,EGFR,CET+CIT,Tclin+Tclin,0.237,0.66,1.0,0,0,0,5,2,DC01367,Izalontamab;SI-B003,DrugComb,FD00018,Head and Neck Cancer,Head and Neck Cancer,Phase 1|Phase 2
2492,TP00745,CTLA4;EGFR,CTLA4,EGFR,CET+CIT,Tclin+Tclin,0.237,0.66,1.0,0,0,0,5,2,DC01367,Izalontamab;SI-B003,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
2497,TP00746,CTLA4;ERBB2,CTLA4,ERBB2,CET+CIT,Tclin+Tclin,0.297,0.712,1.0,0,0,0,2,3,DC01973,Trastuzumab Deruxtecan;Volrustomig,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
2499,TP00746,CTLA4;ERBB2,CTLA4,ERBB2,CET+CIT,Tclin+Tclin,0.297,0.712,1.0,0,0,0,2,3,DC00201,Anbenitamab;Erfonrilimab,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 2
2500,TP00746,CTLA4;ERBB2,CTLA4,ERBB2,CET+CIT,Tclin+Tclin,0.297,0.712,1.0,0,0,0,2,3,DC00201,Anbenitamab;Erfonrilimab,DrugComb,FD00041,Stomach Cancer,Stomach Cancer,Phase 2
2501,TP00747,CTLA4;ERBB3,CTLA4,ERBB3,CET+CIT,Tclin+Tclin,0.293,0.652,1.0,0,0,0,2,2,DC01367,Izalontamab;SI-B003,DrugComb,FD00018,Head and Neck Cancer,Head and Neck Cancer,Phase 1|Phase 2
2502,TP00747,CTLA4;ERBB3,CTLA4,ERBB3,CET+CIT,Tclin+Tclin,0.293,0.652,1.0,0,0,0,2,2,DC01367,Izalontamab;SI-B003,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
2504,TP00748,CTLA4;FLT1,CTLA4,FLT1,CET+CET,Tclin+Tclin,0.225,0.64,1.0,1,0,0,2,2,DC00361,Axitinib;Ipilimumab,DrugComb,FD00026,Melanoma,Melanoma,Phase 2
2505,TP00748,CTLA4;FLT1,CTLA4,FLT1,CET+CET,Tclin+Tclin,0.225,0.64,1.0,1,0,0,2,2,DC00360,Axitinib;Erfonrilimab,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 2|Phase 3
2506,TP00749,CTLA4;FLT4,CTLA4,FLT4,CET+CET,Tclin+Tclin,0.236,0.695,1.0,0,0,0,2,2,DC00361,Axitinib;Ipilimumab,DrugComb,FD00026,Melanoma,Melanoma,Phase 2
2507,TP00749,CTLA4;FLT4,CTLA4,FLT4,CET+CET,Tclin+Tclin,0.236,0.695,1.0,0,0,0,2,2,DC00360,Axitinib;Erfonrilimab,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 2|Phase 3
2508,TP00750,CTLA4;HDAC1,CTLA4,HDAC1,CET+CIT,Tclin+Tclin,0.188,0.502,1.0,0,0,0,1,1,DC01344,Ipilimumab;Panobinostat,DrugComb,FD00026,Melanoma,Melanoma,Phase 1
2509,TP00751,CTLA4;HDAC10,CTLA4,HDAC10,CET+CIT,Tclin+Tclin,0.147,0.49,1.0,0,0,0,1,1,DC01344,Ipilimumab;Panobinostat,DrugComb,FD00026,Melanoma,Melanoma,Phase 1
2510,TP00752,CTLA4;HDAC11,CTLA4,HDAC11,CET+CIT,Tclin+Tclin,0.096,0.586,1.0,0,0,0,1,1,DC01344,Ipilimumab;Panobinostat,DrugComb,FD00026,Melanoma,Melanoma,Phase 1
2511,TP00753,CTLA4;HDAC2,CTLA4,HDAC2,CET+CIT,Tclin+Tclin,0.21,0.498,1.0,0,0,0,1,1,DC01344,Ipilimumab;Panobinostat,DrugComb,FD00026,Melanoma,Melanoma,Phase 1
2512,TP00754,CTLA4;HDAC3,CTLA4,HDAC3,CET+CIT,Tclin+Tclin,0.226,0.684,1.0,0,0,0,1,1,DC01344,Ipilimumab;Panobinostat,DrugComb,FD00026,Melanoma,Melanoma,Phase 1
2513,TP00755,CTLA4;HDAC4,CTLA4,HDAC4,CET+CIT,Tclin+Tclin,0.193,0.514,1.0,0,0,0,1,1,DC01344,Ipilimumab;Panobinostat,DrugComb,FD00026,Melanoma,Melanoma,Phase 1
2514,TP00756,CTLA4;HDAC5,CTLA4,HDAC5,CET+CIT,Tclin+Tclin,0.177,0.565,1.0,0,0,0,1,1,DC01344,Ipilimumab;Panobinostat,DrugComb,FD00026,Melanoma,Melanoma,Phase 1
2515,TP00757,CTLA4;HDAC6,CTLA4,HDAC6,CET+CIT,Tclin+Tclin,0.185,0.509,1.0,0,0,0,1,1,DC01344,Ipilimumab;Panobinostat,DrugComb,FD00026,Melanoma,Melanoma,Phase 1
2516,TP00758,CTLA4;HDAC7,CTLA4,HDAC7,CET+CIT,Tclin+Tclin,0.164,0.508,1.0,0,0,0,1,1,DC01344,Ipilimumab;Panobinostat,DrugComb,FD00026,Melanoma,Melanoma,Phase 1
2517,TP00759,CTLA4;HDAC8,CTLA4,HDAC8,CET+CIT,Tclin+Tclin,0.115,0.64,1.0,0,0,0,1,1,DC01344,Ipilimumab;Panobinostat,DrugComb,FD00026,Melanoma,Melanoma,Phase 1
2518,TP00760,CTLA4;HDAC9,CTLA4,HDAC9,CET+CIT,Tclin+Tclin,0.179,0.513,1.0,0,0,0,1,1,DC01344,Ipilimumab;Panobinostat,DrugComb,FD00026,Melanoma,Melanoma,Phase 1
2519,TP00761,CTLA4;ICOS,CTLA4,ICOS,CET+CET,Tbio+Tclin,0.458,0.559,1.0,2,0,3,3,2,DC01328,Ipilimumab;Izuralimab,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
2520,TP00761,CTLA4;ICOS,CTLA4,ICOS,CET+CET,Tbio+Tclin,0.458,0.559,1.0,2,0,3,3,2,DC01368,Izuralimab;Pavunalimab,DrugComb,FD00026,Melanoma,Melanoma,Phase 1
2522,TP00762,CTLA4;IDO1,CTLA4,IDO1,CET+CET,Tchem+Tclin,0.383,0.474,0.357,0,0,1,1,1,DC01317,Indoximod;Ipilimumab,DrugComb,FD00026,Melanoma,Melanoma,Phase 1|Phase 2
2523,TP00763,CTLA4;IDO2,CTLA4,IDO2,CET+CIT,Tchem+Tclin,0.258,0.494,0.357,0,0,0,1,1,DC01317,Indoximod;Ipilimumab,DrugComb,FD00026,Melanoma,Melanoma,Phase 1|Phase 2
2524,TP00764,CTLA4;IL15,CTLA4,IL15,CET+CET,Tchem+Tclin,0.378,0.575,1.0,1,0,0,1,3,DC02155,JK08,BsAb,FD00007,Breast Cancer,Breast Cancer,Phase 1|Phase 2
2525,TP00764,CTLA4;IL15,CTLA4,IL15,CET+CET,Tchem+Tclin,0.378,0.575,1.0,1,0,0,1,3,DC02155,JK08,BsAb,FD00011,Colorectal Cancer,Colorectal Cancer,Phase 1|Phase 2
2526,TP00764,CTLA4;IL15,CTLA4,IL15,CET+CET,Tchem+Tclin,0.378,0.575,1.0,1,0,0,1,3,DC02155,JK08,BsAb,FD00026,Melanoma,Melanoma,Phase 1|Phase 2
2527,TP00765,CTLA4;IL2RA,CTLA4,IL2RA,CET+CET,Tclin+Tclin,0.58,0.624,1.0,0,1,3,1,1,DC00114,Aldesleukin;Ipilimumab,DrugComb,FD00026,Melanoma,Melanoma,Phase 1|Phase 2
2528,TP00766,CTLA4;IL2RB,CTLA4,IL2RB,CET+CET,Tclin+Tclin,0.356,0.75,1.0,0,0,1,2,2,DC00228,ANV419;Ipilimumab,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
2529,TP00766,CTLA4;IL2RB,CTLA4,IL2RB,CET+CET,Tclin+Tclin,0.356,0.75,1.0,0,0,1,2,2,DC00114,Aldesleukin;Ipilimumab,DrugComb,FD00026,Melanoma,Melanoma,Phase 1|Phase 2
2530,TP00767,CTLA4;IL2RG,CTLA4,IL2RG,CET+CIT,Tclin+Tclin,0.454,0.761,1.0,0,0,1,1,1,DC00114,Aldesleukin;Ipilimumab,DrugComb,FD00026,Melanoma,Melanoma,Phase 1|Phase 2
2531,TP00768,CTLA4;KDR,CTLA4,KDR,CET+CET,Tclin+Tclin,0.222,0.726,1.0,0,0,1,4,3,DC00360,Axitinib;Erfonrilimab,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 2|Phase 3
2532,TP00768,CTLA4;KDR,CTLA4,KDR,CET+CET,Tclin+Tclin,0.222,0.726,1.0,0,0,1,4,3,DC00637,Cadonilimab;Lenvatinib,DrugComb,FD00022,Liver Cancer,Liver Cancer,Phase 1|Phase 2
2533,TP00768,CTLA4;KDR,CTLA4,KDR,CET+CET,Tclin+Tclin,0.222,0.726,1.0,0,0,1,4,3,DC00361,Axitinib;Ipilimumab,DrugComb,FD00026,Melanoma,Melanoma,Phase 2
2535,TP00769,CTLA4;LAG3,CTLA4,LAG3,CET+CET,Tclin+Tclin,0.599,0.626,1.0,0,0,1,2,2,DC01348,Ipilimumab;Relatlimab,DrugComb,FD00026,Melanoma,Melanoma,Phase 1
2536,TP00769,CTLA4;LAG3,CTLA4,LAG3,CET+CET,Tclin+Tclin,0.599,0.626,1.0,0,0,1,2,2,DC02210,Pavunalimab,BsAb,FD00023,Lung Cancer,Lung Cancer,Phase 1
2538,TP00770,CTLA4;MET,CTLA4,MET,CET+CIT,Tclin+Tclin,0.245,0.643,1.0,0,0,0,1,1,DC00818,Crizotinib;Ipilimumab,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
2539,TP00771,CTLA4;NR1H2,CTLA4,NR1H2,CET+CIT,Tchem+Tclin,0.198,0.51,1.0,0,0,0,1,1,DC00041,Abequolixron;Ipilimumab,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
2540,TP00772,CTLA4;NT5E,CTLA4,NT5E,CET+CIT,Tchem+Tclin,0.153,0.641,1.0,0,0,1,1,2,DC00636,Cadonilimab;Dresbuxelimab,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
2541,TP00772,CTLA4;NT5E,CTLA4,NT5E,CET+CIT,Tchem+Tclin,0.153,0.641,1.0,0,0,1,1,2,DC00636,Cadonilimab;Dresbuxelimab,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1|Phase 2
2542,TP00773,CTLA4;PARP1,CTLA4,PARP1,CET+CIT,Tclin+Tclin,0.249,0.559,1.0,0,0,0,1,1,DC01618,Olaparib;Tremelimumab,DrugComb,FD00034,Ovarian Cancer,Ovarian Cancer,Phase 1
2543,TP00774,CTLA4;PARP2,CTLA4,PARP2,CET+CIT,Tclin+Tclin,0.254,0.376,1.0,0,0,0,1,1,DC01618,Olaparib;Tremelimumab,DrugComb,FD00034,Ovarian Cancer,Ovarian Cancer,Phase 1
2544,TP00775,CTLA4;PDCD1,CTLA4,PDCD1,CET+CET,Tclin+Tclin,0.605,0.616,1.0,2,0,4,28,22,DC01681,Pavunalimab;Pembrolizumab,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
2545,TP00775,CTLA4;PDCD1,CTLA4,PDCD1,CET+CET,Tclin+Tclin,0.605,0.616,1.0,2,0,4,28,22,DC01368,Izuralimab;Pavunalimab,DrugComb,FD00026,Melanoma,Melanoma,Phase 1
2546,TP00775,CTLA4;PDCD1,CTLA4,PDCD1,CET+CET,Tclin+Tclin,0.605,0.616,1.0,2,0,4,28,22,DC00870,Davoceticept;Pembrolizumab,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
2548,TP00775,CTLA4;PDCD1,CTLA4,PDCD1,CET+CET,Tclin+Tclin,0.605,0.616,1.0,2,0,4,28,22,DC01349,Ipilimumab;Sintilimab,DrugComb,FD00018,Head and Neck Cancer,Head and Neck Cancer,Phase 1
2549,TP00775,CTLA4;PDCD1,CTLA4,PDCD1,CET+CET,Tclin+Tclin,0.605,0.616,1.0,2,0,4,28,22,DC01349,Ipilimumab;Sintilimab,DrugComb,FD00022,Liver Cancer,Liver Cancer,Phase 1|Phase 2
2552,TP00775,CTLA4;PDCD1,CTLA4,PDCD1,CET+CET,Tclin+Tclin,0.605,0.616,1.0,2,0,4,28,22,DC01349,Ipilimumab;Sintilimab,DrugComb,FD00041,Stomach Cancer,Stomach Cancer,Phase 1|Phase 2
2553,TP00775,CTLA4;PDCD1,CTLA4,PDCD1,CET+CET,Tclin+Tclin,0.605,0.616,1.0,2,0,4,28,22,DC01332,Ipilimumab;Nivolumab,DrugComb,FD00006,Bladder Cancer,Bladder Cancer,Phase 1
2554,TP00775,CTLA4;PDCD1,CTLA4,PDCD1,CET+CET,Tclin+Tclin,0.605,0.616,1.0,2,0,4,28,22,DC01332,Ipilimumab;Nivolumab,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 2
2555,TP00775,CTLA4;PDCD1,CTLA4,PDCD1,CET+CET,Tclin+Tclin,0.605,0.616,1.0,2,0,4,28,22,DC01332,Ipilimumab;Nivolumab,DrugComb,FD00008,Central Nervous System Tumor,Other Cancer,Phase 2
2556,TP00775,CTLA4;PDCD1,CTLA4,PDCD1,CET+CET,Tclin+Tclin,0.605,0.616,1.0,2,0,4,28,22,DC01332,Ipilimumab;Nivolumab,DrugComb,FD00011,Colorectal Cancer,Colorectal Cancer,Approval
2557,TP00775,CTLA4;PDCD1,CTLA4,PDCD1,CET+CET,Tclin+Tclin,0.605,0.616,1.0,2,0,4,28,22,DC01332,Ipilimumab;Nivolumab,DrugComb,FD00014,Esophageal Cancer,Esophageal Cancer,Approval
2558,TP00775,CTLA4;PDCD1,CTLA4,PDCD1,CET+CET,Tclin+Tclin,0.605,0.616,1.0,2,0,4,28,22,DC01332,Ipilimumab;Nivolumab,DrugComb,FD00017,Glioma,Glioma,Phase 2
2560,TP00775,CTLA4;PDCD1,CTLA4,PDCD1,CET+CET,Tclin+Tclin,0.605,0.616,1.0,2,0,4,28,22,DC01332,Ipilimumab;Nivolumab,DrugComb,FD00020,Kidney Cancer,Kidney Cancer,Approval
2564,TP00775,CTLA4;PDCD1,CTLA4,PDCD1,CET+CET,Tclin+Tclin,0.605,0.616,1.0,2,0,4,28,22,DC01332,Ipilimumab;Nivolumab,DrugComb,FD00029,Mesothelioma,Other Cancer,Approval
2565,TP00775,CTLA4;PDCD1,CTLA4,PDCD1,CET+CET,Tclin+Tclin,0.605,0.616,1.0,2,0,4,28,22,DC01332,Ipilimumab;Nivolumab,DrugComb,FD00030,Myeloma,Hematologic Malignancy,Phase 1|Phase 2
2566,TP00775,CTLA4;PDCD1,CTLA4,PDCD1,CET+CET,Tclin+Tclin,0.605,0.616,1.0,2,0,4,28,22,DC01332,Ipilimumab;Nivolumab,DrugComb,FD00032,Neuroendocrine Tumor,Other Cancer,Phase 2
2568,TP00775,CTLA4;PDCD1,CTLA4,PDCD1,CET+CET,Tclin+Tclin,0.605,0.616,1.0,2,0,4,28,22,DC01332,Ipilimumab;Nivolumab,DrugComb,FD00034,Ovarian Cancer,Ovarian Cancer,Phase 2
2569,TP00775,CTLA4;PDCD1,CTLA4,PDCD1,CET+CET,Tclin+Tclin,0.605,0.616,1.0,2,0,4,28,22,DC01332,Ipilimumab;Nivolumab,DrugComb,FD00035,Pancreatic Cancer,Pancreatic Cancer,Phase 2
2577,TP00775,CTLA4;PDCD1,CTLA4,PDCD1,CET+CET,Tclin+Tclin,0.605,0.616,1.0,2,0,4,28,22,DC00385,Balstilimab;Zalifrelimab,DrugComb,FD00040,Soft Tissue Sarcoma,Other Cancer,Phase 2
2599,TP00775,CTLA4;PDCD1,CTLA4,PDCD1,CET+CET,Tclin+Tclin,0.605,0.616,1.0,2,0,4,28,22,DC02052,Cadonilimab,BsAb,FD00024,Lymphoma,Hematologic Malignancy,Phase 1|Phase 2
2606,TP00775,CTLA4;PDCD1,CTLA4,PDCD1,CET+CET,Tclin+Tclin,0.605,0.616,1.0,2,0,4,28,22,DC02052,Cadonilimab,BsAb,FD00043,Vulvar Cancer,Other Cancer,Phase 2
2612,TP00775,CTLA4;PDCD1,CTLA4,PDCD1,CET+CET,Tclin+Tclin,0.605,0.616,1.0,2,0,4,28,22,DC02294,Vudalimab,BsAb,FD00038,Prostate Cancer,Prostate Cancer,Phase 2
2630,TP00776,CTLA4;PDGFRB,CTLA4,PDGFRB,CET+CIT,Tclin+Tclin,0.247,0.75,1.0,0,0,0,2,2,DC00361,Axitinib;Ipilimumab,DrugComb,FD00026,Melanoma,Melanoma,Phase 2
2631,TP00776,CTLA4;PDGFRB,CTLA4,PDGFRB,CET+CIT,Tclin+Tclin,0.247,0.75,1.0,0,0,0,2,2,DC00360,Axitinib;Erfonrilimab,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 2|Phase 3
2632,TP00777,CTLA4;PMEL,CTLA4,PMEL,CET+CIT,Tclin+Tclin,0.081,0.71,1.0,0,0,0,1,1,DC01950,Tebentafusp;Tremelimumab,DrugComb,FD00026,Melanoma,Melanoma,Phase 1|Phase 2
2633,TP00778,CTLA4;RARA,CTLA4,RARA,CET+CIT,Tclin+Tclin,0.238,0.572,1.0,0,0,0,1,1,DC01352,Ipilimumab;Tretinoin,DrugComb,FD00026,Melanoma,Melanoma,Phase 2
2634,TP00779,CTLA4;RARB,CTLA4,RARB,CET+CIT,Tclin+Tclin,0.315,0.489,0.325,0,0,0,1,1,DC01352,Ipilimumab;Tretinoin,DrugComb,FD00026,Melanoma,Melanoma,Phase 2
2635,TP00780,CTLA4;RARG,CTLA4,RARG,CET+CIT,Tclin+Tclin,0.285,0.583,1.0,0,0,0,1,1,DC01352,Ipilimumab;Tretinoin,DrugComb,FD00026,Melanoma,Melanoma,Phase 2
2636,TP00781,CTLA4;SEMA4D,CTLA4,SEMA4D,CET+CIT,Tbio+Tclin,0.313,0.609,1.0,0,0,0,1,1,DC01346,Ipilimumab;Pepinemab,DrugComb,FD00018,Head and Neck Cancer,Head and Neck Cancer,Phase 1
2637,TP00782,CTLA4;TACSTD2,CTLA4,TACSTD2,CET+CIT,Tclin+Tclin,0.266,0.602,1.0,0,0,0,1,1,DC00869,Datopotamab Deruxtecan;Volrustomig,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
2638,TP00783,CTLA4;TIGIT,CTLA4,TIGIT,CET+CET,Tbio+Tclin,0.281,0.569,1.0,1,0,1,1,2,DC00110,AK127;Cadonilimab,DrugComb,FD00023,Lung Cancer,Lung Cancer,Early Phase 1
2639,TP00783,CTLA4;TIGIT,CTLA4,TIGIT,CET+CET,Tbio+Tclin,0.281,0.569,1.0,1,0,1,1,2,DC00110,AK127;Cadonilimab,DrugComb,FD00033,Other Cancer,Other Cancer,Early Phase 1
2640,TP00784,CTLA4;TLR7,CTLA4,TLR7,CET+CET,Tclin+Tclin,0.259,0.684,1.0,0,0,1,1,1,DC01310,Imiquimod;Zalifrelimab,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
2641,TP00785,CTLA4;TLR9,CTLA4,TLR9,CET+CIT,Tclin+Tclin,0.251,0.657,0.576,0,0,0,1,1,DC01350,Ipilimumab;Tilsotolimod,DrugComb,FD00026,Melanoma,Melanoma,Phase 2
2642,TP00786,CTLA4;TNFRSF18,CTLA4,TNFRSF18,CET+CET,Tbio+Tclin,0.367,0.686,1.0,0,1,0,1,1,DC01347,Ipilimumab;Ragifilimab,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1|Phase 2
2643,TP00787,CTLA4;TNFRSF4,CTLA4,TNFRSF4,CET+CET,Tchem+Tclin,0.413,0.695,1.0,0,0,1,1,1,DC02027,ATOR1015,BsAb,FD00033,Other Cancer,Other Cancer,Phase 1
2644,TP00788,CTLA4;TNFRSF9,CTLA4,TNFRSF9,CET+CET,Tbio+Tclin,0.293,0.679,1.0,0,0,1,1,1,DC00109,AGEN2373;Botensilimab,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
2645,TP00789,CTLA4;TNFSF4,CTLA4,TNFSF4,CET+CIT,Tbio+Tclin,0.371,0.612,1.0,0,0,2,2,2,DC01311,INCAGN01949;Ipilimumab,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1|Phase 2
2646,TP00789,CTLA4;TNFSF4,CTLA4,TNFSF4,CET+CIT,Tbio+Tclin,0.371,0.612,1.0,0,0,2,2,2,DC00563,BMS986178;Ipilimumab,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
2647,TP00790,CTNNB1;KDR,CTNNB1,KDR,CET+CIT,Tchem+Tclin,0.518,0.609,0.602,4,0,9,1,1,DC00962,E7386;Lenvatinib,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
2648,TP00791,CXCR1;KRAS,CXCR1,KRAS,CET+CIT,Tchem+Tclin,0.318,0.558,0.343,2,0,0,1,1,DC01378,Ladarixin;Sotorasib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 2
2649,TP00792,CXCR1;PDCD1,CXCR1,PDCD1,CET+CET,Tchem+Tclin,0.317,0.888,1.0,0,0,0,2,3,DC01515,Navarixin;Pembrolizumab,DrugComb,FD00011,Colorectal Cancer,Colorectal Cancer,Phase 2
2650,TP00792,CXCR1;PDCD1,CXCR1,PDCD1,CET+CET,Tchem+Tclin,0.317,0.888,1.0,0,0,0,2,3,DC01515,Navarixin;Pembrolizumab,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 2
2651,TP00792,CXCR1;PDCD1,CXCR1,PDCD1,CET+CET,Tchem+Tclin,0.317,0.888,1.0,0,0,0,2,3,DC01515,Navarixin;Pembrolizumab,DrugComb,FD00038,Prostate Cancer,Prostate Cancer,Phase 2
2653,TP00793,CXCR2;KRAS,CXCR2,KRAS,CET+CIT,Tchem+Tclin,0.369,0.583,0.343,3,0,1,1,1,DC01378,Ladarixin;Sotorasib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 2
2654,TP00794,CXCR2;PDCD1,CXCR2,PDCD1,CET+CET,Tchem+Tclin,0.307,0.576,1.0,0,0,0,3,3,DC01726,Pembrolizumab;SX682,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 2
2655,TP00794,CXCR2;PDCD1,CXCR2,PDCD1,CET+CET,Tchem+Tclin,0.307,0.576,1.0,0,0,0,3,3,DC01515,Navarixin;Pembrolizumab,DrugComb,FD00011,Colorectal Cancer,Colorectal Cancer,Phase 2
2657,TP00794,CXCR2;PDCD1,CXCR2,PDCD1,CET+CET,Tchem+Tclin,0.307,0.576,1.0,0,0,0,3,3,DC01515,Navarixin;Pembrolizumab,DrugComb,FD00038,Prostate Cancer,Prostate Cancer,Phase 2
2659,TP00795,CXCR4;FLT1,CXCR4,FLT1,CET+CIT,Tclin+Tclin,0.405,0.668,0.472,1,0,0,1,1,DC00362,Axitinib;Mavorixafor,DrugComb,FD00020,Kidney Cancer,Kidney Cancer,Phase 1|Phase 2
2660,TP00796,CXCR4;FLT4,CXCR4,FLT4,CET+CIT,Tclin+Tclin,0.371,0.655,0.488,2,0,2,1,1,DC00362,Axitinib;Mavorixafor,DrugComb,FD00020,Kidney Cancer,Kidney Cancer,Phase 1|Phase 2
2661,TP00797,CXCR4;KDR,CXCR4,KDR,CET+CIT,Tclin+Tclin,0.473,0.787,0.5,1,0,4,1,1,DC00362,Axitinib;Mavorixafor,DrugComb,FD00020,Kidney Cancer,Kidney Cancer,Phase 1|Phase 2
2662,TP00798,CXCR4;PDCD1,CXCR4,PDCD1,CET+CIT,Tclin+Tclin,0.359,0.529,1.0,0,0,2,3,3,DC01468,Mavorixafor;Toripalimab,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 1|Phase 2
2663,TP00798,CXCR4;PDCD1,CXCR4,PDCD1,CET+CIT,Tclin+Tclin,0.359,0.529,1.0,0,0,2,3,3,DC01696,Pembrolizumab;Plerixafor,DrugComb,FD00018,Head and Neck Cancer,Head and Neck Cancer,Phase 2
2664,TP00798,CXCR4;PDCD1,CXCR4,PDCD1,CET+CIT,Tclin+Tclin,0.359,0.529,1.0,0,0,2,3,3,DC01595,Nivolumab;Ulocuplumab,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1|Phase 2
2665,TP00799,CXCR4;PDGFRB,CXCR4,PDGFRB,CIT+CIT,Tclin+Tclin,0.457,0.795,0.569,3,0,3,1,1,DC00362,Axitinib;Mavorixafor,DrugComb,FD00020,Kidney Cancer,Kidney Cancer,Phase 1|Phase 2
2666,TP00800,CYP17A1;EGFR,CYP17A1,EGFR,CIT+CIT,Tclin+Tclin,0.137,0.414,0.252,1,0,0,1,1,DC00043,Abiraterone;Abivertinib,DrugComb,FD00038,Prostate Cancer,Prostate Cancer,Phase 2
2667,TP00801,CYP17A1;ENG,CYP17A1,ENG,CIT+CIT,Tbio+Tclin,0.136,0.311,0.26,0,0,0,1,1,DC00047,Abiraterone;Carotuximab,DrugComb,FD00038,Prostate Cancer,Prostate Cancer,Phase 2
2668,TP00802,CYP17A1;IL23A,CYP17A1,IL23A,CET+CIT,Tclin+Tclin,0.104,0.487,0.266,0,0,0,1,1,DC00053,Abiraterone;Tildrakizumab,DrugComb,FD00038,Prostate Cancer,Prostate Cancer,Phase 1|Phase 2
2669,TP00803,CYP17A1;PARP1,CYP17A1,PARP1,CIT+CIT,Tclin+Tclin,0.177,0.439,0.332,0,0,2,3,1,DC00051,Abiraterone;Olaparib,DrugComb,FD00038,Prostate Cancer,Prostate Cancer,Approval
2672,TP00804,CYP17A1;PARP2,CYP17A1,PARP2,CIT+CIT,Tclin+Tclin,0.204,0.446,0.302,0,0,0,3,1,DC00050,Abiraterone;Niraparib,DrugComb,FD00038,Prostate Cancer,Prostate Cancer,Approval
2675,TP00805,CYP17A1;PGR,CYP17A1,PGR,CIT+CIT,Tclin+Tclin,0.195,0.418,0.315,0,0,0,1,1,DC00052,Abiraterone;Onapristone,DrugComb,FD00038,Prostate Cancer,Prostate Cancer,Phase 1|Phase 2
2676,TP00806,CYP17A1;PIK3CB,CYP17A1,PIK3CB,CIT+CIT,Tchem+Tclin,0.147,0.449,0.218,2,0,0,1,1,DC00372,AZD8186;Abiraterone,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
2677,TP00807,CYP19A1;EGFR,CYP19A1,EGFR,CIT+CIT,Tclin+Tclin,0.264,0.57,0.257,0,0,1,4,2,DC00555,BMS690514;Letrozole,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 2
2679,TP00807,CYP19A1;EGFR,CYP19A1,EGFR,CIT+CIT,Tclin+Tclin,0.264,0.57,0.257,0,0,1,4,2,DC00185,Anastrozole;Erlotinib,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
2681,TP00808,CYP19A1;ERBB2,CYP19A1,ERBB2,CIT+CIT,Tclin+Tclin,0.266,0.581,0.25,0,0,0,5,1,DC01380,Lapatinib;Letrozole,DrugComb,FD00007,Breast Cancer,Breast Cancer,Approval
2686,TP00809,CYP19A1;ERBB3,CYP19A1,ERBB3,CIT+CIT,Tclin+Tclin,0.285,0.496,0.241,0,0,0,2,1,DC01137,Exemestane;Seribantumab,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 2
2688,TP00810,CYP19A1;ESR1,CYP19A1,ESR1,CIT+CIT,Tclin+Tclin,0.446,0.624,0.269,0,0,3,3,1,DC00194,Anastrozole;Tamoxifen,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 3
2691,TP00811,CYP19A1;ESR2,CYP19A1,ESR2,CIT+CIT,Tclin+Tclin,0.236,0.525,0.297,0,0,3,3,1,DC01131,Exemestane;Fulvestrant,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 2
2694,TP00812,CYP19A1;FLT1,CYP19A1,FLT1,CET+CIT,Tclin+Tclin,0.291,0.512,0.239,0,0,0,1,1,DC01437,Letrozole;Vatalanib,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 2
2695,TP00813,CYP19A1;FLT4,CYP19A1,FLT4,CET+CIT,Tclin+Tclin,0.288,0.534,0.244,0,0,0,1,1,DC01437,Letrozole;Vatalanib,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 2
2696,TP00814,CYP19A1;GNRHR,CYP19A1,GNRHR,CIT+CIT,Tclin+Tclin,0.284,0.659,0.173,0,0,0,2,1,DC00875,Degarelix;Letrozole,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 2
2698,TP00815,CYP19A1;HDAC1,CYP19A1,HDAC1,CIT+CIT,Tclin+Tclin,0.249,0.424,0.274,0,0,0,3,1,DC00997,Entinostat;Exemestane,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 3
2701,TP00816,CYP19A1;HDAC10,CYP19A1,HDAC10,CIT+CIT,Tclin+Tclin,0.184,0.503,0.337,0,0,0,1,1,DC01138,Exemestane;Tucidinostat,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 3
2702,TP00817,CYP19A1;HDAC2,CYP19A1,HDAC2,CIT+CIT,Tclin+Tclin,0.265,0.438,0.313,0,0,0,3,1,DC00997,Entinostat;Exemestane,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 3
2705,TP00818,CYP19A1;HDAC3,CYP19A1,HDAC3,CIT+CIT,Tclin+Tclin,0.186,0.553,0.268,0,0,0,3,1,DC00997,Entinostat;Exemestane,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 3
2708,TP00819,CYP19A1;HDAC8,CYP19A1,HDAC8,CIT+CIT,Tclin+Tclin,0.154,0.546,0.31,0,0,0,2,1,DC00997,Entinostat;Exemestane,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 3
2710,TP00820,CYP19A1;HSP90AA1,CYP19A1,HSP90AA1,CIT+CIT,Tchem+Tclin,0.224,0.535,0.278,0,0,0,1,1,DC00784,CNF2024;Exemestane,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 2
2711,TP00821,CYP19A1;HSP90AB1,CYP19A1,HSP90AB1,CIT+CIT,Tchem+Tclin,0.277,0.508,0.28,0,0,0,1,1,DC00784,CNF2024;Exemestane,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 2
2712,TP00822,CYP19A1;IGF1R,CYP19A1,IGF1R,CIT+CIT,Tclin+Tclin,0.295,0.569,0.248,1,0,0,2,1,DC01435,Letrozole;Teprotumumab,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 2
2714,TP00823,CYP19A1;JAK1,CYP19A1,JAK1,CIT+CIT,Tclin+Tclin,0.249,0.614,0.289,0,0,0,1,1,DC01135,Exemestane;Ruxolitinib,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 2
2715,TP00824,CYP19A1;JAK2,CYP19A1,JAK2,CIT+CIT,Tclin+Tclin,0.251,0.503,0.336,0,0,0,1,1,DC01135,Exemestane;Ruxolitinib,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 2
2716,TP00825,CYP19A1;KDR,CYP19A1,KDR,CET+CIT,Tclin+Tclin,0.296,0.645,0.251,0,0,1,2,1,DC00555,BMS690514;Letrozole,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 2
2718,TP00826,CYP19A1;MTOR,CYP19A1,MTOR,CIT+CIT,Tclin+Tclin,0.251,0.587,0.261,0,0,1,8,3,DC00835,Dactolisib;Letrozole,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 1
2722,TP00826,CYP19A1;MTOR,CYP19A1,MTOR,CIT+CIT,Tclin+Tclin,0.251,0.587,0.261,0,0,1,8,3,DC01105,Everolimus;Letrozole,DrugComb,FD00034,Ovarian Cancer,Ovarian Cancer,Phase 2
2726,TP00826,CYP19A1;MTOR,CYP19A1,MTOR,CIT+CIT,Tclin+Tclin,0.251,0.587,0.261,0,0,1,8,3,DC00186,Anastrozole;Everolimus,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
2727,TP00827,CYP19A1;MUC1,CYP19A1,MUC1,CIT+CIT,Tchem+Tclin,0.139,0.554,0.252,0,0,0,1,1,DC01434,Letrozole;Sontuzumab,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 2
2728,TP00828,CYP19A1;PIK3CA,CYP19A1,PIK3CA,CIT+CIT,Tclin+Tclin,0.274,0.554,0.234,1,0,1,6,1,DC01133,Exemestane;PF04691502,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 2
2734,TP00829,CYP19A1;PIK3CB,CYP19A1,PIK3CB,CIT+CIT,Tchem+Tclin,0.245,0.631,0.25,1,0,1,2,1,DC00616,Buparlisib;Letrozole,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 1
2736,TP00830,CYP19A1;PIK3CD,CYP19A1,PIK3CD,CIT+CIT,Tclin+Tclin,0.265,0.623,0.245,1,0,1,3,1,DC00616,Buparlisib;Letrozole,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 1
2739,TP00831,CYP19A1;PIK3CG,CYP19A1,PIK3CG,CIT+CIT,Tclin+Tclin,0.265,0.605,0.243,1,0,1,2,1,DC00616,Buparlisib;Letrozole,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 1
2741,TP00832,CYP19A1;RARA,CYP19A1,RARA,CIT+CIT,Tclin+Tclin,0.345,0.455,0.297,0,0,0,1,1,DC00197,Anastrozole;Tretinoin,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 2
2742,TP00833,CYP19A1;RARB,CYP19A1,RARB,CIT+CIT,Tclin+Tclin,0.285,0.503,0.291,0,0,0,1,1,DC00197,Anastrozole;Tretinoin,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 2
2743,TP00834,CYP19A1;RARG,CYP19A1,RARG,CIT+CIT,Tclin+Tclin,0.327,0.611,0.311,0,0,0,1,1,DC00197,Anastrozole;Tretinoin,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 2
2744,TP00835,CYP19A1;TGFB1,CYP19A1,TGFB1,CET+CIT,Tbio+Tclin,0.263,0.513,0.256,0,0,0,1,1,DC00545,Bintrafusp Alfa;Letrozole,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 2
2745,TP00836,CYP19A1;VEGFA,CYP19A1,VEGFA,CET+CIT,Tclin+Tclin,0.29,0.569,0.247,0,0,0,2,2,DC00455,Bevacizumab;Letrozole,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 2
2746,TP00836,CYP19A1;VEGFA,CYP19A1,VEGFA,CET+CIT,Tclin+Tclin,0.29,0.569,0.247,0,0,0,2,2,DC00182,Anastrozole;Bevacizumab,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
2747,TP00837,DGKZ;PDCD1,DGKZ,PDCD1,CET+CIT,Tchem+Tclin,0.22,0.495,1.0,0,0,0,2,1,DC00238,ASP1570;Pembrolizumab,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1|Phase 2
2749,TP00838,DKK1;PDCD1,DKK1,PDCD1,CET+CET,Tchem+Tclin,0.334,0.589,1.0,0,0,0,1,3,DC01716,Pembrolizumab;Sirexatamab,DrugComb,FD00014,Esophageal Cancer,Esophageal Cancer,Phase 1
2750,TP00838,DKK1;PDCD1,DKK1,PDCD1,CET+CET,Tchem+Tclin,0.334,0.589,1.0,0,0,0,1,3,DC01716,Pembrolizumab;Sirexatamab,DrugComb,FD00034,Ovarian Cancer,Ovarian Cancer,Phase 2
2751,TP00838,DKK1;PDCD1,DKK1,PDCD1,CET+CET,Tchem+Tclin,0.334,0.589,1.0,0,0,0,1,3,DC01716,Pembrolizumab;Sirexatamab,DrugComb,FD00041,Stomach Cancer,Stomach Cancer,Phase 1
2752,TP00839,DLL3;PDCD1,DLL3,PDCD1,CET+CIT,Tbio+Tclin,0.364,1.0,0.657,0,0,0,3,3,DC00507,BI764532;Ezabenlimab,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
2753,TP00839,DLL3;PDCD1,DLL3,PDCD1,CET+CIT,Tbio+Tclin,0.364,1.0,0.657,0,0,0,3,3,DC00507,BI764532;Ezabenlimab,DrugComb,FD00032,Neuroendocrine Tumor,Other Cancer,Phase 1|Phase 2
2755,TP00839,DLL3;PDCD1,DLL3,PDCD1,CET+CIT,Tbio+Tclin,0.364,1.0,0.657,0,0,0,3,3,DC00606,Budigalimab;Rovalpituzumab Tesirine,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
2756,TP00840,DLL4;VEGFA,DLL4,VEGFA,CET+CET,Tbio+Tclin,0.531,0.409,0.585,2,0,3,3,5,DC02198,Navicixizumab,BsAb,FD00007,Breast Cancer,Breast Cancer,Phase 2
2757,TP00840,DLL4;VEGFA,DLL4,VEGFA,CET+CET,Tbio+Tclin,0.531,0.409,0.585,2,0,3,3,5,DC02198,Navicixizumab,BsAb,FD00011,Colorectal Cancer,Colorectal Cancer,Phase 2
2758,TP00840,DLL4;VEGFA,DLL4,VEGFA,CET+CET,Tbio+Tclin,0.531,0.409,0.585,2,0,3,3,5,DC02198,Navicixizumab,BsAb,FD00033,Other Cancer,Other Cancer,Phase 1
2759,TP00840,DLL4;VEGFA,DLL4,VEGFA,CET+CET,Tbio+Tclin,0.531,0.409,0.585,2,0,3,3,5,DC02198,Navicixizumab,BsAb,FD00034,Ovarian Cancer,Ovarian Cancer,Phase 3
2760,TP00840,DLL4;VEGFA,DLL4,VEGFA,CET+CET,Tbio+Tclin,0.531,0.409,0.585,2,0,3,3,5,DC02198,Navicixizumab,BsAb,FD00041,Stomach Cancer,Stomach Cancer,Phase 2
2764,TP00841,EDNRB;PDCD1,EDNRB,PDCD1,CET+CIT,Tclin+Tclin,0.284,0.676,1.0,0,0,0,1,1,DC01765,Pembrolizumab;Vodudeutentan,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1|Phase 2
2765,TP00842,EGFL7;ERBB2,EGFL7,ERBB2,CET+CIT,Tbio+Tclin,0.408,0.356,0.544,0,0,0,1,1,DC01680,Parsatuzumab;Trastuzumab,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 3
2766,TP00843,EGFR;ENG,EGFR,ENG,CIT+CIT,Tbio+Tclin,0.485,0.652,0.617,0,0,0,1,1,DC00677,Carotuximab;Osimertinib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
2767,TP00844,EGFR;ERBB2,EGFR,ERBB2,CIT+CIT,Tclin+Tclin,0.677,0.779,0.798,20,16,16,9,4,DC01082,Erlotinib;Trastuzumab,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 1|Phase 2
2768,TP00844,EGFR;ERBB2,EGFR,ERBB2,CIT+CIT,Tclin+Tclin,0.677,0.779,0.798,20,16,16,9,4,DC01531,Necitumumab;Osimertinib;Trastuzumab,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
2774,TP00844,EGFR;ERBB2,EGFR,ERBB2,CIT+CIT,Tclin+Tclin,0.677,0.779,0.798,20,16,16,9,4,DC00762,Cetuximab;Trastuzumab,DrugComb,FD00035,Pancreatic Cancer,Pancreatic Cancer,Phase 1|Phase 2
2776,TP00844,EGFR;ERBB2,EGFR,ERBB2,CIT+CIT,Tclin+Tclin,0.677,0.779,0.798,20,16,16,9,4,DC00745,Cetuximab;Neratinib,DrugComb,FD00011,Colorectal Cancer,Colorectal Cancer,Phase 1|Phase 2
2777,TP00845,EGFR;ERBB3,EGFR,ERBB3,CIT+CIT,Tclin+Tclin,0.584,0.616,0.746,7,0,4,11,7,DC01358,Istiratumab;MM151,DrugComb,FD00011,Colorectal Cancer,Colorectal Cancer,Phase 1
2778,TP00845,EGFR;ERBB3,EGFR,ERBB3,CIT+CIT,Tclin+Tclin,0.584,0.616,0.746,7,0,4,11,7,DC01358,Istiratumab;MM151,DrugComb,FD00018,Head and Neck Cancer,Head and Neck Cancer,Phase 1
2779,TP00845,EGFR;ERBB3,EGFR,ERBB3,CIT+CIT,Tclin+Tclin,0.584,0.616,0.746,7,0,4,11,7,DC01358,Istiratumab;MM151,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
2786,TP00845,EGFR;ERBB3,EGFR,ERBB3,CIT+CIT,Tclin+Tclin,0.584,0.616,0.746,7,0,4,11,7,DC00756,Cetuximab;Seribantumab,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 1
2793,TP00845,EGFR;ERBB3,EGFR,ERBB3,CIT+CIT,Tclin+Tclin,0.584,0.616,0.746,7,0,4,11,7,DC02153,Izalontamab,BsAb,FD00014,Esophageal Cancer,Esophageal Cancer,Phase 2
2796,TP00845,EGFR;ERBB3,EGFR,ERBB3,CIT+CIT,Tclin+Tclin,0.584,0.616,0.746,7,0,4,11,7,DC02153,Izalontamab,BsAb,FD00033,Other Cancer,Other Cancer,Phase 1
2799,TP00845,EGFR;ERBB3,EGFR,ERBB3,CIT+CIT,Tclin+Tclin,0.584,0.616,0.746,7,0,4,11,7,DC02046,BLB01D1,BsAb,FD00041,Stomach Cancer,Stomach Cancer,Phase 1
2801,TP00846,EGFR;ESR1,EGFR,ESR1,CIT+CIT,Tclin+Tclin,0.53,0.693,0.602,6,5,6,3,2,DC01042,Erlotinib;Fulvestrant,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 2
2803,TP00846,EGFR;ESR1,EGFR,ESR1,CIT+CIT,Tclin+Tclin,0.53,0.693,0.602,6,5,6,3,2,DC01223,Gefitinib;Tamoxifen,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 2
2804,TP00847,EGFR;ESR2,EGFR,ESR2,CIT+CIT,Tclin+Tclin,0.431,0.414,0.54,5,4,3,3,2,DC01157,Fulvestrant;Gefitinib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 2
2805,TP00847,EGFR;ESR2,EGFR,ESR2,CIT+CIT,Tclin+Tclin,0.431,0.414,0.54,5,4,3,3,2,DC01223,Gefitinib;Tamoxifen,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 2
2807,TP00848,EGFR;FCGR1A,EGFR,FCGR1A,CET+CIT,Tclin+Tclin,0.385,0.603,0.545,0,0,0,1,1,DC02189,MDX447,BsAb,FD00017,Glioma,Glioma,Phase 1
2808,TP00849,EGFR;FCGR3A,EGFR,FCGR3A,CET+CIT,Tclin+Tclin,0.275,0.536,0.547,0,0,0,1,3,DC02006,AFM24,BsAb,FD00011,Colorectal Cancer,Colorectal Cancer,Phase 1|Phase 2
2809,TP00849,EGFR;FCGR3A,EGFR,FCGR3A,CET+CIT,Tclin+Tclin,0.275,0.536,0.547,0,0,0,1,3,DC02006,AFM24,BsAb,FD00018,Head and Neck Cancer,Head and Neck Cancer,Phase 1|Phase 2
2810,TP00849,EGFR;FCGR3A,EGFR,FCGR3A,CET+CIT,Tclin+Tclin,0.275,0.536,0.547,0,0,0,1,3,DC02006,AFM24,BsAb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
2811,TP00850,EGFR;FLT1,EGFR,FLT1,CET+CIT,Tclin+Tclin,0.617,0.716,0.743,7,0,9,3,2,DC01049,Erlotinib;Linifanib,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
2812,TP00850,EGFR;FLT1,EGFR,FLT1,CET+CIT,Tclin+Tclin,0.617,0.716,0.743,7,0,9,3,2,DC01080,Erlotinib;Tivozanib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
2814,TP00851,EGFR;FLT3,EGFR,FLT3,CIT+CIT,Tclin+Tclin,0.587,0.724,0.748,5,4,7,2,1,DC01504,MRX2843;Osimertinib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
2816,TP00852,EGFR;FLT4,EGFR,FLT4,CET+CIT,Tclin+Tclin,0.625,0.642,0.76,8,0,8,3,2,DC01151,Fruquintinib;Gefitinib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 2
2818,TP00852,EGFR;FLT4,EGFR,FLT4,CET+CIT,Tclin+Tclin,0.625,0.642,0.76,8,0,8,3,2,DC01049,Erlotinib;Linifanib,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
2819,TP00853,EGFR;FNTB,EGFR,FNTB,CIT+CIT,Tclin+Tclin,0.16,0.39,0.483,0,0,0,1,1,DC01644,Osimertinib;Tipifarnib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
2820,TP00854,EGFR;GLS2,EGFR,GLS2,CIT+CIT,Tchem+Tclin,0.198,0.345,0.449,2,0,1,1,1,DC01640,Osimertinib;Telaglenastat,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
2821,TP00855,EGFR;GPRC5D,EGFR,GPRC5D,CIT+CIT,Tbio+Tclin,0.348,0.591,0.524,0,0,1,1,3,DC01493,MM151;Talquetamab,DrugComb,FD00011,Colorectal Cancer,Colorectal Cancer,Phase 1
2822,TP00855,EGFR;GPRC5D,EGFR,GPRC5D,CIT+CIT,Tbio+Tclin,0.348,0.591,0.524,0,0,1,1,3,DC01493,MM151;Talquetamab,DrugComb,FD00018,Head and Neck Cancer,Head and Neck Cancer,Phase 1
2823,TP00855,EGFR;GPRC5D,EGFR,GPRC5D,CIT+CIT,Tbio+Tclin,0.348,0.591,0.524,0,0,1,1,3,DC01493,MM151;Talquetamab,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
2824,TP00856,EGFR;GSAP,EGFR,GSAP,CIT+CIT,Tchem+Tclin,0.163,0.716,0.455,0,0,0,1,1,DC01071,Erlotinib;RO4929097,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
2825,TP00857,EGFR;HDAC1,EGFR,HDAC1,CIT+CIT,Tclin+Tclin,0.509,0.541,0.561,3,0,2,6,2,DC01386,Lapatinib;Vorinostat,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 1|Phase 2
2826,TP00857,EGFR;HDAC1,EGFR,HDAC1,CIT+CIT,Tclin+Tclin,0.509,0.541,0.561,3,0,2,6,2,DC01226,Gefitinib;Vorinostat,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
2831,TP00858,EGFR;HDAC10,EGFR,HDAC10,CIT+CIT,Tclin+Tclin,0.268,0.486,0.497,0,0,0,4,2,DC01386,Lapatinib;Vorinostat,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 1|Phase 2
2832,TP00858,EGFR;HDAC10,EGFR,HDAC10,CIT+CIT,Tclin+Tclin,0.268,0.486,0.497,0,0,0,4,2,DC01061,Erlotinib;Panobinostat,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
2835,TP00859,EGFR;HDAC11,EGFR,HDAC11,CIT+CIT,Tclin+Tclin,0.178,0.507,0.467,0,0,1,1,1,DC01061,Erlotinib;Panobinostat,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
2836,TP00860,EGFR;HDAC2,EGFR,HDAC2,CIT+CIT,Tclin+Tclin,0.506,0.534,0.581,3,0,2,6,2,DC01386,Lapatinib;Vorinostat,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 1|Phase 2
2837,TP00860,EGFR;HDAC2,EGFR,HDAC2,CIT+CIT,Tclin+Tclin,0.506,0.534,0.581,3,0,2,6,2,DC00996,Entinostat;Erlotinib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 2
2842,TP00861,EGFR;HDAC3,EGFR,HDAC3,CIT+CIT,Tclin+Tclin,0.438,0.631,0.568,0,1,1,6,2,DC01386,Lapatinib;Vorinostat,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 1|Phase 2
2843,TP00861,EGFR;HDAC3,EGFR,HDAC3,CIT+CIT,Tclin+Tclin,0.438,0.631,0.568,0,1,1,6,2,DC00996,Entinostat;Erlotinib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 2
2848,TP00862,EGFR;HDAC4,EGFR,HDAC4,CIT+CIT,Tclin+Tclin,0.416,0.521,0.537,1,0,1,4,2,DC01386,Lapatinib;Vorinostat,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 1|Phase 2
2849,TP00862,EGFR;HDAC4,EGFR,HDAC4,CIT+CIT,Tclin+Tclin,0.416,0.521,0.537,1,0,1,4,2,DC01061,Erlotinib;Panobinostat,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
2852,TP00863,EGFR;HDAC5,EGFR,HDAC5,CIT+CIT,Tclin+Tclin,0.314,0.524,0.546,1,0,1,4,2,DC01386,Lapatinib;Vorinostat,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 1|Phase 2
2853,TP00863,EGFR;HDAC5,EGFR,HDAC5,CIT+CIT,Tclin+Tclin,0.314,0.524,0.546,1,0,1,4,2,DC01084,Erlotinib;Vorinostat,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
2856,TP00864,EGFR;HDAC6,EGFR,HDAC6,CIT+CIT,Tclin+Tclin,0.412,0.581,0.583,0,0,1,5,2,DC01386,Lapatinib;Vorinostat,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 1|Phase 2
2857,TP00864,EGFR;HDAC6,EGFR,HDAC6,CIT+CIT,Tclin+Tclin,0.412,0.581,0.583,0,0,1,5,2,DC00413,Belinostat;Erlotinib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
2861,TP00865,EGFR;HDAC7,EGFR,HDAC7,CIT+CIT,Tclin+Tclin,0.338,0.497,0.545,0,0,1,4,2,DC01386,Lapatinib;Vorinostat,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 1|Phase 2
2862,TP00865,EGFR;HDAC7,EGFR,HDAC7,CIT+CIT,Tclin+Tclin,0.338,0.497,0.545,0,0,1,4,2,DC01061,Erlotinib;Panobinostat,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
2865,TP00866,EGFR;HDAC8,EGFR,HDAC8,CIT+CIT,Tclin+Tclin,0.226,0.598,0.477,0,0,0,6,2,DC01386,Lapatinib;Vorinostat,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 1|Phase 2
2866,TP00866,EGFR;HDAC8,EGFR,HDAC8,CIT+CIT,Tclin+Tclin,0.226,0.598,0.477,0,0,0,6,2,DC01084,Erlotinib;Vorinostat,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
2871,TP00867,EGFR;HDAC9,EGFR,HDAC9,CIT+CIT,Tclin+Tclin,0.316,0.522,0.496,0,0,1,4,2,DC01386,Lapatinib;Vorinostat,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 1|Phase 2
2872,TP00867,EGFR;HDAC9,EGFR,HDAC9,CIT+CIT,Tclin+Tclin,0.316,0.522,0.496,0,0,1,4,2,DC01226,Gefitinib;Vorinostat,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
2875,TP00868,EGFR;HGF,EGFR,HGF,CET+CIT,Tchem+Tclin,0.559,0.524,0.508,14,4,9,4,3,DC01503,MP0250;Osimertinib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
2877,TP00868,EGFR;HGF,EGFR,HGF,CET+CIT,Tchem+Tclin,0.559,0.524,0.508,14,4,9,4,3,DC01667,Panitumumab;Rilotumumab,DrugComb,FD00011,Colorectal Cancer,Colorectal Cancer,Phase 1|Phase 2
2878,TP00868,EGFR;HGF,EGFR,HGF,CET+CIT,Tchem+Tclin,0.559,0.524,0.508,14,4,9,4,3,DC01667,Panitumumab;Rilotumumab,DrugComb,FD00041,Stomach Cancer,Stomach Cancer,Phase 1|Phase 2
2880,TP00869,EGFR;HLA-G,EGFR,HLA-G,CET+CIT,Tbio+Tclin,0.281,0.715,0.512,3,0,2,1,1,DC00763,Cetuximab;TTX080,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
2881,TP00870,EGFR;HSP90AA1,EGFR,HSP90AA1,CIT+CIT,Tchem+Tclin,0.416,0.689,0.646,5,8,8,2,1,DC01051,Erlotinib;Luminespib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
2883,TP00871,EGFR;HSP90AB1,EGFR,HSP90AB1,CIT+CIT,Tchem+Tclin,0.485,0.722,0.666,5,0,4,2,1,DC01051,Erlotinib;Luminespib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
2885,TP00872,EGFR;IGF1,EGFR,IGF1,CIT+CIT,Tbio+Tclin,0.586,0.528,0.476,15,0,10,1,1,DC00103,Afatinib;Xentuzumab,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
2886,TP00873,EGFR;IGF1R,EGFR,IGF1R,CIT+CIT,Tclin+Tclin,0.624,0.696,0.736,18,2,14,10,4,DC01358,Istiratumab;MM151,DrugComb,FD00011,Colorectal Cancer,Colorectal Cancer,Phase 1
2887,TP00873,EGFR;IGF1R,EGFR,IGF1R,CIT+CIT,Tclin+Tclin,0.624,0.696,0.736,18,2,14,10,4,DC01358,Istiratumab;MM151,DrugComb,FD00018,Head and Neck Cancer,Head and Neck Cancer,Phase 1
2888,TP00873,EGFR;IGF1R,EGFR,IGF1R,CIT+CIT,Tclin+Tclin,0.624,0.696,0.736,18,2,14,10,4,DC01358,Istiratumab;MM151,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
2896,TP00873,EGFR;IGF1R,EGFR,IGF1R,CIT+CIT,Tclin+Tclin,0.624,0.696,0.736,18,2,14,10,4,DC01204,Ganitumab;Panitumumab,DrugComb,FD00041,Stomach Cancer,Stomach Cancer,Phase 1|Phase 2
2900,TP00874,EGFR;IGF2,EGFR,IGF2,CIT+CIT,Tbio+Tclin,0.578,0.428,0.476,6,0,4,1,1,DC00103,Afatinib;Xentuzumab,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
2901,TP00875,EGFR;IL15,EGFR,IL15,CET+CIT,Tchem+Tclin,0.47,0.636,0.469,2,0,1,1,1,DC00744,Cetuximab;Nanrilkefusp Alfa,DrugComb,FD00011,Colorectal Cancer,Colorectal Cancer,Phase 2
2902,TP00876,EGFR;IL15RA,EGFR,IL15RA,CET+CIT,Tbio+Tclin,0.226,0.747,0.538,2,0,2,1,1,DC00747,Cetuximab;NKTR255,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1|Phase 2
2903,TP00877,EGFR;ITGA5,EGFR,ITGA5,CET+CIT,Tbio+Tclin,0.523,0.719,0.507,7,1,6,1,1,DC01083,Erlotinib;Volociximab,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 2
2904,TP00878,EGFR;ITGAV,EGFR,ITGAV,CIT+CIT,Tchem+Tclin,0.509,0.707,0.568,7,1,7,1,1,DC00092,Afatinib;Intetumumab,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
2905,TP00879,EGFR;ITGB3,EGFR,ITGB3,CIT+CIT,Tclin+Tclin,0.511,0.745,0.63,8,1,7,1,1,DC00092,Afatinib;Intetumumab,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
2906,TP00880,EGFR;JAK1,EGFR,JAK1,CIT+CIT,Tclin+Tclin,0.459,0.686,0.726,10,1,10,5,1,DC01359,Itacitinib;Osimertinib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
2911,TP00881,EGFR;JAK2,EGFR,JAK2,CIT+CIT,Tclin+Tclin,0.56,0.687,0.71,6,1,11,3,1,DC01060,Erlotinib;Pacritinib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
2914,TP00882,EGFR;KDR,EGFR,KDR,CET+CIT,Tclin+Tclin,0.625,0.793,0.774,8,0,11,11,3,DC01041,Erlotinib;Foretinib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
2915,TP00882,EGFR;KDR,EGFR,KDR,CET+CIT,Tclin+Tclin,0.625,0.793,0.774,8,0,11,11,3,DC01148,Foretinib;Lapatinib,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 1|Phase 2
2918,TP00882,EGFR;KDR,EGFR,KDR,CET+CIT,Tclin+Tclin,0.625,0.793,0.774,8,0,11,11,3,DC01049,Erlotinib;Linifanib,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
2925,TP00883,EGFR;KLRC1,EGFR,KLRC1,CET+CIT,Tbio+Tclin,0.289,0.508,0.545,0,0,0,1,1,DC00742,Cetuximab;Monalizumab,DrugComb,FD00018,Head and Neck Cancer,Head and Neck Cancer,Phase 3
2926,TP00884,EGFR;KRAS,EGFR,KRAS,CIT+CIT,Tclin+Tclin,0.49,0.698,0.461,37,0,23,11,4,DC00740,Cetuximab;LY3499446,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
2928,TP00884,EGFR;KRAS,EGFR,KRAS,CIT+CIT,Tclin+Tclin,0.49,0.698,0.461,37,0,23,11,4,DC00737,Cetuximab;JAB21822,DrugComb,FD00003,Appendix Cancer,Other Cancer,Phase 1|Phase 2
2929,TP00884,EGFR;KRAS,EGFR,KRAS,CIT+CIT,Tclin+Tclin,0.49,0.698,0.461,37,0,23,11,4,DC00737,Cetuximab;JAB21822,DrugComb,FD00011,Colorectal Cancer,Colorectal Cancer,Phase 1|Phase 2
2930,TP00884,EGFR;KRAS,EGFR,KRAS,CIT+CIT,Tclin+Tclin,0.49,0.698,0.461,37,0,23,11,4,DC00737,Cetuximab;JAB21822,DrugComb,FD00039,Small Intestine Cancer,Other Cancer,Phase 1|Phase 2
2940,TP00885,EGFR;LGR5,EGFR,LGR5,CIT+CIT,Tbio+Tclin,0.42,0.579,0.556,0,0,1,1,4,DC02188,MCLA158,BsAb,FD00011,Colorectal Cancer,Colorectal Cancer,Phase 1|Phase 2
2941,TP00885,EGFR;LGR5,EGFR,LGR5,CIT+CIT,Tbio+Tclin,0.42,0.579,0.556,0,0,1,1,4,DC02188,MCLA158,BsAb,FD00018,Head and Neck Cancer,Head and Neck Cancer,Phase 1|Phase 2
2942,TP00885,EGFR;LGR5,EGFR,LGR5,CIT+CIT,Tbio+Tclin,0.42,0.579,0.556,0,0,1,1,4,DC02188,MCLA158,BsAb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
2943,TP00885,EGFR;LGR5,EGFR,LGR5,CIT+CIT,Tbio+Tclin,0.42,0.579,0.556,0,0,1,1,4,DC02188,MCLA158,BsAb,FD00041,Stomach Cancer,Stomach Cancer,Phase 1|Phase 2
2944,TP00886,EGFR;MAP2K1,EGFR,MAP2K1,CIT+CIT,Tclin+Tclin,0.587,0.689,0.699,41,1,25,13,4,DC01384,Lapatinib;Trametinib,DrugComb,FD00011,Colorectal Cancer,Colorectal Cancer,Phase 1|Phase 2
2945,TP00886,EGFR;MAP2K1,EGFR,MAP2K1,CIT+CIT,Tclin+Tclin,0.587,0.689,0.699,41,1,25,13,4,DC01440,Lifirafenib;Mirdametinib,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
2946,TP00886,EGFR;MAP2K1,EGFR,MAP2K1,CIT+CIT,Tclin+Tclin,0.587,0.689,0.699,41,1,25,13,4,DC01081,Erlotinib;Trametinib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
2952,TP00886,EGFR;MAP2K1,EGFR,MAP2K1,CIT+CIT,Tclin+Tclin,0.587,0.689,0.699,41,1,25,13,4,DC01494,MM151;Trametinib,DrugComb,FD00018,Head and Neck Cancer,Head and Neck Cancer,Phase 1
2960,TP00887,EGFR;MAP2K2,EGFR,MAP2K2,CIT+CIT,Tclin+Tclin,0.487,0.675,0.687,38,1,20,13,4,DC01440,Lifirafenib;Mirdametinib,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
2961,TP00887,EGFR;MAP2K2,EGFR,MAP2K2,CIT+CIT,Tclin+Tclin,0.487,0.675,0.687,38,1,20,13,4,DC01384,Lapatinib;Trametinib,DrugComb,FD00011,Colorectal Cancer,Colorectal Cancer,Phase 1|Phase 2
2962,TP00887,EGFR;MAP2K2,EGFR,MAP2K2,CIT+CIT,Tclin+Tclin,0.487,0.675,0.687,38,1,20,13,4,DC01081,Erlotinib;Trametinib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
2967,TP00887,EGFR;MAP2K2,EGFR,MAP2K2,CIT+CIT,Tclin+Tclin,0.487,0.675,0.687,38,1,20,13,4,DC01494,MM151;Trametinib,DrugComb,FD00018,Head and Neck Cancer,Head and Neck Cancer,Phase 1
2976,TP00888,EGFR;MAPK1,EGFR,MAPK1,CIT+CIT,Tchem+Tclin,0.57,0.695,0.73,44,4,34,1,1,DC01034,ERAS007;Osimertinib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
2977,TP00889,EGFR;MAPK3,EGFR,MAPK3,CIT+CIT,Tchem+Tclin,0.591,0.704,0.707,44,4,29,1,1,DC01034,ERAS007;Osimertinib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
2978,TP00890,EGFR;MERTK,EGFR,MERTK,CIT+CIT,Tchem+Tclin,0.517,0.64,0.723,0,0,1,1,1,DC01504,MRX2843;Osimertinib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
2979,TP00891,EGFR;MET,EGFR,MET,CIT+CIT,Tclin+Tclin,0.569,0.617,0.801,18,4,13,31,8,DC01041,Erlotinib;Foretinib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
2980,TP00891,EGFR;MET,EGFR,MET,CIT+CIT,Tclin+Tclin,0.569,0.617,0.801,18,4,13,31,8,DC01148,Foretinib;Lapatinib,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 1|Phase 2
2988,TP00891,EGFR;MET,EGFR,MET,CIT+CIT,Tclin+Tclin,0.569,0.617,0.801,18,4,13,31,8,DC00654,Capmatinib;Cetuximab,DrugComb,FD00011,Colorectal Cancer,Colorectal Cancer,Phase 1
2989,TP00891,EGFR;MET,EGFR,MET,CIT+CIT,Tclin+Tclin,0.569,0.617,0.801,18,4,13,31,8,DC00654,Capmatinib;Cetuximab,DrugComb,FD00018,Head and Neck Cancer,Head and Neck Cancer,Phase 1
3006,TP00891,EGFR;MET,EGFR,MET,CIT+CIT,Tclin+Tclin,0.569,0.617,0.801,18,4,13,31,8,DC02186,MCLA129,BsAb,FD00014,Esophageal Cancer,Esophageal Cancer,Phase 1|Phase 2
3009,TP00891,EGFR;MET,EGFR,MET,CIT+CIT,Tclin+Tclin,0.569,0.617,0.801,18,4,13,31,8,DC02186,MCLA129,BsAb,FD00041,Stomach Cancer,Stomach Cancer,Phase 1|Phase 2
3010,TP00891,EGFR;MET,EGFR,MET,CIT+CIT,Tclin+Tclin,0.569,0.617,0.801,18,4,13,31,8,DC02179,LY3164530,BsAb,FD00033,Other Cancer,Other Cancer,Phase 1
3016,TP00891,EGFR;MET,EGFR,MET,CIT+CIT,Tclin+Tclin,0.569,0.617,0.801,18,4,13,31,8,DC02019,Amivantamab,BsAb,FD00022,Liver Cancer,Liver Cancer,Phase 2
3024,TP00892,EGFR;MTOR,EGFR,MTOR,CIT+CIT,Tclin+Tclin,0.502,0.66,0.695,24,1,18,14,7,DC01383,Lapatinib;Sirolimus,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
3025,TP00892,EGFR;MTOR,EGFR,MTOR,CIT+CIT,Tclin+Tclin,0.502,0.66,0.695,24,1,18,14,7,DC01085,Erlotinib;Voxtalisib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
3026,TP00892,EGFR;MTOR,EGFR,MTOR,CIT+CIT,Tclin+Tclin,0.502,0.66,0.695,24,1,18,14,7,DC00087,AEE788;Everolimus,DrugComb,FD00017,Glioma,Glioma,Phase 1|Phase 2
3029,TP00892,EGFR;MTOR,EGFR,MTOR,CIT+CIT,Tclin+Tclin,0.502,0.66,0.695,24,1,18,14,7,DC01075,Erlotinib;Sirolimus,DrugComb,FD00015,Germ Cell Tumor,Other Cancer,Phase 2
3032,TP00892,EGFR;MTOR,EGFR,MTOR,CIT+CIT,Tclin+Tclin,0.502,0.66,0.695,24,1,18,14,7,DC01039,Erlotinib;Everolimus,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 1
3033,TP00892,EGFR;MTOR,EGFR,MTOR,CIT+CIT,Tclin+Tclin,0.502,0.66,0.695,24,1,18,14,7,DC01039,Erlotinib;Everolimus,DrugComb,FD00018,Head and Neck Cancer,Head and Neck Cancer,Phase 2
3035,TP00892,EGFR;MTOR,EGFR,MTOR,CIT+CIT,Tclin+Tclin,0.502,0.66,0.695,24,1,18,14,7,DC00759,Cetuximab;Temsirolimus,DrugComb,FD00011,Colorectal Cancer,Colorectal Cancer,Phase 1
3041,TP00893,EGFR;MUC1,EGFR,MUC1,CIT+CIT,Tchem+Tclin,0.285,0.62,0.49,0,0,0,1,2,DC02181,M1231,BsAb,FD00014,Esophageal Cancer,Esophageal Cancer,Phase 1
3042,TP00893,EGFR;MUC1,EGFR,MUC1,CIT+CIT,Tchem+Tclin,0.285,0.62,0.49,0,0,0,1,2,DC02181,M1231,BsAb,FD00023,Lung Cancer,Lung Cancer,Phase 1
3043,TP00894,EGFR;NT5E,EGFR,NT5E,CIT+CIT,Tchem+Tclin,0.187,0.616,0.464,0,0,0,1,1,DC01620,Oleclumab;Osimertinib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
3044,TP00895,EGFR;PARP1,EGFR,PARP1,CIT+CIT,Tclin+Tclin,0.469,0.614,0.597,0,0,1,3,2,DC01551,Niraparib;Osimertinib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
3045,TP00895,EGFR;PARP1,EGFR,PARP1,CIT+CIT,Tclin+Tclin,0.469,0.614,0.597,0,0,1,3,2,DC01552,Niraparib;Panitumumab,DrugComb,FD00011,Colorectal Cancer,Colorectal Cancer,Phase 2
3047,TP00896,EGFR;PARP2,EGFR,PARP2,CIT+CIT,Tclin+Tclin,0.315,0.382,0.561,0,0,0,3,2,DC01552,Niraparib;Panitumumab,DrugComb,FD00011,Colorectal Cancer,Colorectal Cancer,Phase 2
3048,TP00896,EGFR;PARP2,EGFR,PARP2,CIT+CIT,Tclin+Tclin,0.315,0.382,0.561,0,0,0,3,2,DC01551,Niraparib;Osimertinib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
3050,TP00897,EGFR;PDCD1,EGFR,PDCD1,CET+CIT,Tclin+Tclin,0.266,0.424,1.0,1,0,1,19,5,DC00403,BCA101;Pembrolizumab,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
3051,TP00897,EGFR;PDCD1,EGFR,PDCD1,CET+CIT,Tclin+Tclin,0.266,0.424,1.0,1,0,1,19,5,DC01367,Izalontamab;SI-B003,DrugComb,FD00018,Head and Neck Cancer,Head and Neck Cancer,Phase 1|Phase 2
3054,TP00897,EGFR;PDCD1,EGFR,PDCD1,CET+CIT,Tclin+Tclin,0.266,0.424,1.0,1,0,1,19,5,DC00701,Cemiplimab;REGN7075,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1|Phase 2
3055,TP00897,EGFR;PDCD1,EGFR,PDCD1,CET+CIT,Tclin+Tclin,0.266,0.424,1.0,1,0,1,19,5,DC01090,Etevritamab;Zeluvalimab,DrugComb,FD00017,Glioma,Glioma,Phase 1
3066,TP00897,EGFR;PDCD1,EGFR,PDCD1,CET+CIT,Tclin+Tclin,0.266,0.424,1.0,1,0,1,19,5,DC00751,Cetuximab;Pembrolizumab,DrugComb,FD00034,Ovarian Cancer,Ovarian Cancer,Phase 2
3071,TP00898,EGFR;PIK3CA,EGFR,PIK3CA,CIT+CIT,Tclin+Tclin,0.518,0.597,0.649,37,11,21,10,3,DC01809,Pilaralisib;Tesevatinib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
3074,TP00898,EGFR;PIK3CA,EGFR,PIK3CA,CIT+CIT,Tclin+Tclin,0.518,0.597,0.649,37,11,21,10,3,DC00145,Alpelisib;Cetuximab,DrugComb,FD00018,Head and Neck Cancer,Head and Neck Cancer,Phase 1
3079,TP00898,EGFR;PIK3CA,EGFR,PIK3CA,CIT+CIT,Tclin+Tclin,0.518,0.597,0.649,37,11,21,10,3,DC00618,Buparlisib;Panitumumab,DrugComb,FD00011,Colorectal Cancer,Colorectal Cancer,Phase 1|Phase 2
3081,TP00899,EGFR;PIK3CB,EGFR,PIK3CB,CIT+CIT,Tchem+Tclin,0.472,0.646,0.6,37,4,17,4,2,DC01809,Pilaralisib;Tesevatinib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
3082,TP00899,EGFR;PIK3CB,EGFR,PIK3CB,CIT+CIT,Tchem+Tclin,0.472,0.646,0.6,37,4,17,4,2,DC00618,Buparlisib;Panitumumab,DrugComb,FD00011,Colorectal Cancer,Colorectal Cancer,Phase 1|Phase 2
3085,TP00900,EGFR;PIK3CD,EGFR,PIK3CD,CIT+CIT,Tclin+Tclin,0.456,0.591,0.593,37,3,19,8,3,DC01085,Erlotinib;Voxtalisib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
3087,TP00900,EGFR;PIK3CD,EGFR,PIK3CD,CIT+CIT,Tclin+Tclin,0.456,0.591,0.593,37,3,19,8,3,DC00723,Cetuximab;Copanlisib,DrugComb,FD00018,Head and Neck Cancer,Head and Neck Cancer,Phase 1|Phase 2
3090,TP00900,EGFR;PIK3CD,EGFR,PIK3CD,CIT+CIT,Tclin+Tclin,0.456,0.591,0.593,37,3,19,8,3,DC00618,Buparlisib;Panitumumab,DrugComb,FD00011,Colorectal Cancer,Colorectal Cancer,Phase 1|Phase 2
3093,TP00901,EGFR;PIK3CG,EGFR,PIK3CG,CIT+CIT,Tclin+Tclin,0.452,0.586,0.682,3,0,8,4,2,DC01809,Pilaralisib;Tesevatinib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
3094,TP00901,EGFR;PIK3CG,EGFR,PIK3CG,CIT+CIT,Tclin+Tclin,0.452,0.586,0.682,3,0,8,4,2,DC00618,Buparlisib;Panitumumab,DrugComb,FD00011,Colorectal Cancer,Colorectal Cancer,Phase 1|Phase 2
3097,TP00902,EGFR;PPARG,EGFR,PPARG,CIT+CIT,Tclin+Tclin,0.491,0.532,0.585,1,0,2,1,1,DC00964,Efatutazone;Erlotinib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
3098,TP00903,EGFR;PRKCB,EGFR,PRKCB,CIT+CIT,Tchem+Tclin,0.47,0.604,0.667,22,0,12,1,1,DC01021,Enzastaurin;Erlotinib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
3099,TP00904,EGFR;PTK2,EGFR,PTK2,CET+CIT,Tclin+Tclin,0.621,0.628,0.742,11,3,16,1,1,DC00128,Alflutinib;Ifebemtinib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
3100,TP00905,EGFR;PTPN11,EGFR,PTPN11,CIT+CIT,Tchem+Tclin,0.495,0.557,0.531,7,4,6,2,1,DC00401,BBP398;Osimertinib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
3102,TP00906,EGFR;RAF1,EGFR,RAF1,CIT+CIT,Tclin+Tclin,0.578,0.593,0.758,40,0,27,2,2,DC01510,Naporafenib;Nazartinib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
3103,TP00906,EGFR;RAF1,EGFR,RAF1,CIT+CIT,Tclin+Tclin,0.578,0.593,0.758,40,0,27,2,2,DC00761,Cetuximab;Tovorafenib,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
3104,TP00907,EGFR;RET,EGFR,RET,CIT+CIT,Tclin+Tclin,0.604,0.678,0.741,6,1,2,1,1,DC01636,Osimertinib;Selpercatinib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 2
3105,TP00908,EGFR;RPS6KB1,EGFR,RPS6KB1,CIT+CIT,Tchem+Tclin,0.477,0.585,0.725,18,0,10,1,1,DC01052,Erlotinib;LY2584702,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
3106,TP00909,EGFR;RXRA,EGFR,RXRA,CIT+CIT,Tclin+Tclin,0.438,0.533,0.566,7,0,3,3,1,DC00490,Bexarotene;Gefitinib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
3109,TP00910,EGFR;RXRB,EGFR,RXRB,CIT+CIT,Tclin+Tclin,0.406,0.494,0.489,5,0,2,3,1,DC00489,Bexarotene;Erlotinib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 2
3112,TP00911,EGFR;TACSTD2,EGFR,TACSTD2,CIT+CIT,Tclin+Tclin,0.274,0.655,1.0,0,0,1,2,1,DC01638,Osimertinib;SKB264,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 2
3114,TP00912,EGFR;TBL1X,EGFR,TBL1X,CIT+CIT,Tbio+Tclin,0.331,0.387,0.53,0,1,0,1,1,DC01639,Osimertinib;Tegavivint,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
3115,TP00913,EGFR;TBL1Y,EGFR,TBL1Y,CIT+CIT,Tbio+Tclin,0.171,0.361,0.458,0,0,0,1,1,DC01639,Osimertinib;Tegavivint,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
3116,TP00914,EGFR;TGFB1,EGFR,TGFB1,CET+CIT,Tbio+Tclin,0.603,0.651,0.538,9,0,10,2,1,DC00331,Aumolertinib;Retlirafusp Alfa,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
3118,TP00915,EGFR;TLR8,EGFR,TLR8,CET+CIT,Tchem+Tclin,0.336,0.644,0.385,1,0,0,1,1,DC00743,Cetuximab;Motolimod,DrugComb,FD00018,Head and Neck Cancer,Head and Neck Cancer,Phase 1
3119,TP00916,EGFR;TLR9,EGFR,TLR9,CIT+CIT,Tclin+Tclin,0.435,0.753,0.416,1,0,0,2,2,DC00107,Agatolimod;Erlotinib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 2
3120,TP00916,EGFR;TLR9,EGFR,TLR9,CIT+CIT,Tclin+Tclin,0.435,0.753,0.416,1,0,0,2,2,DC00727,Cetuximab;EMD1201081,DrugComb,FD00018,Head and Neck Cancer,Head and Neck Cancer,Phase 2
3121,TP00917,EGFR;TNFRSF10B,EGFR,TNFRSF10B,CIT+CIT,Tbio+Tclin,0.409,0.487,0.542,0,0,0,1,1,DC00797,Conatumumab;Panitumumab,DrugComb,FD00011,Colorectal Cancer,Colorectal Cancer,Phase 1|Phase 2
3122,TP00918,EGFR;TNFRSF9,EGFR,TNFRSF9,CET+CIT,Tbio+Tclin,0.232,0.444,0.536,0,0,0,2,3,DC00764,Cetuximab;Urelumab,DrugComb,FD00011,Colorectal Cancer,Colorectal Cancer,Phase 1
3123,TP00918,EGFR;TNFRSF9,EGFR,TNFRSF9,CET+CIT,Tbio+Tclin,0.232,0.444,0.536,0,0,0,2,3,DC00764,Cetuximab;Urelumab,DrugComb,FD00018,Head and Neck Cancer,Head and Neck Cancer,Phase 1
3124,TP00918,EGFR;TNFRSF9,EGFR,TNFRSF9,CET+CIT,Tbio+Tclin,0.232,0.444,0.536,0,0,0,2,3,DC02128,HLX35,BsAb,FD00023,Lung Cancer,Lung Cancer,Phase 1
3125,TP00919,EGFR;VEGFA,EGFR,VEGFA,CET+CIT,Tclin+Tclin,0.572,0.629,0.506,18,1,13,10,6,DC00452,Bevacizumab;Lapatinib,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 2
3126,TP00919,EGFR;VEGFA,EGFR,VEGFA,CET+CIT,Tclin+Tclin,0.572,0.629,0.506,18,1,13,10,6,DC00452,Bevacizumab;Lapatinib,DrugComb,FD00013,Ependymoma,Other Cancer,Phase 2
3127,TP00919,EGFR;VEGFA,EGFR,VEGFA,CET+CIT,Tclin+Tclin,0.572,0.629,0.506,18,1,13,10,6,DC01503,MP0250;Osimertinib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
3131,TP00919,EGFR;VEGFA,EGFR,VEGFA,CET+CIT,Tclin+Tclin,0.572,0.629,0.506,18,1,13,10,6,DC00446,Bevacizumab;Erlotinib,DrugComb,FD00017,Glioma,Glioma,Phase 2
3132,TP00919,EGFR;VEGFA,EGFR,VEGFA,CET+CIT,Tclin+Tclin,0.572,0.629,0.506,18,1,13,10,6,DC00446,Bevacizumab;Erlotinib,DrugComb,FD00018,Head and Neck Cancer,Head and Neck Cancer,Phase 2
3133,TP00919,EGFR;VEGFA,EGFR,VEGFA,CET+CIT,Tclin+Tclin,0.572,0.629,0.506,18,1,13,10,6,DC00446,Bevacizumab;Erlotinib,DrugComb,FD00022,Liver Cancer,Liver Cancer,Phase 2
3139,TP00920,ENG;PDCD1,ENG,PDCD1,CET+CIT,Tbio+Tclin,0.294,0.644,1.0,0,0,0,1,1,DC00676,Carotuximab;Nivolumab,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
3140,TP00921,ENG;VEGFA,ENG,VEGFA,CET+CIT,Tbio+Tclin,0.555,0.614,0.6,0,0,1,1,3,DC00434,Bevacizumab;Carotuximab,DrugComb,FD00010,Choriocarcinoma,Other Cancer,Phase 2
3141,TP00921,ENG;VEGFA,ENG,VEGFA,CET+CIT,Tbio+Tclin,0.555,0.614,0.6,0,0,1,1,3,DC00434,Bevacizumab;Carotuximab,DrugComb,FD00017,Glioma,Glioma,Phase 2
3142,TP00921,ENG;VEGFA,ENG,VEGFA,CET+CIT,Tbio+Tclin,0.555,0.614,0.6,0,0,1,1,3,DC00434,Bevacizumab;Carotuximab,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
3143,TP00922,ENTPD1;PDCD1,ENTPD1,PDCD1,CET+CET,Tchem+Tclin,0.18,0.705,1.0,0,0,1,2,2,DC00609,Budigalimab;TTX030,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
3144,TP00922,ENTPD1;PDCD1,ENTPD1,PDCD1,CET+CET,Tchem+Tclin,0.18,0.705,1.0,0,0,1,2,2,DC01751,Pembrolizumab;TTX030,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 1
3146,TP00923,ENTPD1;TGFBR2,ENTPD1,TGFBR2,CET+CIT,Tchem+Tchem,0.158,0.666,0.361,0,0,0,1,1,DC02100,ES014,BsAb,FD00033,Other Cancer,Other Cancer,Phase 1
3147,TP00924,EP300;PARP1,EP300,PARP1,CIT+CIT,Tchem+Tclin,0.486,0.843,0.614,0,0,1,1,1,DC01324,Inobrodib;Olaparib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
3148,TP00925,EP300;PARP2,EP300,PARP2,CIT+CIT,Tchem+Tclin,0.329,0.721,0.529,0,0,0,1,1,DC01324,Inobrodib;Olaparib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
3149,TP00926,EPAS1;KDR,EPAS1,KDR,CET+CIT,Tclin+Tclin,0.496,0.461,0.448,0,0,2,1,1,DC00419,Belzutifan;Lenvatinib,DrugComb,FD00020,Kidney Cancer,Kidney Cancer,Phase 3
3150,TP00927,EPHA2;PDCD1,EPHA2,PDCD1,CET+CIT,Tclin+Tclin,0.312,0.532,1.0,0,0,0,1,1,DC00601,BT5528;Nivolumab,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
3151,TP00928,EPO;HDAC1,EPO,HDAC1,CET+CIT,Tbio+Tclin,0.442,0.365,0.455,1,0,1,1,1,DC01031,Epoetin Alfa;Panobinostat,DrugComb,FD00030,Myeloma,Hematologic Malignancy,Phase 2
3152,TP00929,EPO;HDAC10,EPO,HDAC10,CET+CIT,Tbio+Tclin,0.266,0.381,0.429,0,0,0,1,1,DC01031,Epoetin Alfa;Panobinostat,DrugComb,FD00030,Myeloma,Hematologic Malignancy,Phase 2
3153,TP00930,EPO;HDAC11,EPO,HDAC11,CET+CIT,Tbio+Tclin,0.157,0.328,0.497,0,0,0,1,1,DC01031,Epoetin Alfa;Panobinostat,DrugComb,FD00030,Myeloma,Hematologic Malignancy,Phase 2
3154,TP00931,EPO;HDAC2,EPO,HDAC2,CET+CIT,Tbio+Tclin,0.503,0.323,0.464,1,0,1,1,1,DC01031,Epoetin Alfa;Panobinostat,DrugComb,FD00030,Myeloma,Hematologic Malignancy,Phase 2
3155,TP00932,EPO;HDAC3,EPO,HDAC3,CET+CIT,Tbio+Tclin,0.404,0.347,0.513,0,0,0,1,1,DC01031,Epoetin Alfa;Panobinostat,DrugComb,FD00030,Myeloma,Hematologic Malignancy,Phase 2
3156,TP00933,EPO;HDAC4,EPO,HDAC4,CET+CIT,Tbio+Tclin,0.452,0.357,0.44,0,0,0,1,1,DC01031,Epoetin Alfa;Panobinostat,DrugComb,FD00030,Myeloma,Hematologic Malignancy,Phase 2
3157,TP00934,EPO;HDAC5,EPO,HDAC5,CET+CIT,Tbio+Tclin,0.352,0.365,0.488,0,0,0,1,1,DC01031,Epoetin Alfa;Panobinostat,DrugComb,FD00030,Myeloma,Hematologic Malignancy,Phase 2
3158,TP00935,EPO;HDAC6,EPO,HDAC6,CET+CIT,Tbio+Tclin,0.37,0.38,0.533,0,0,0,1,1,DC01031,Epoetin Alfa;Panobinostat,DrugComb,FD00030,Myeloma,Hematologic Malignancy,Phase 2
3159,TP00936,EPO;HDAC7,EPO,HDAC7,CET+CIT,Tbio+Tclin,0.286,0.386,0.475,0,0,0,1,1,DC01031,Epoetin Alfa;Panobinostat,DrugComb,FD00030,Myeloma,Hematologic Malignancy,Phase 2
3160,TP00937,EPO;HDAC8,EPO,HDAC8,CET+CIT,Tbio+Tclin,0.218,0.359,0.512,0,0,0,1,1,DC01031,Epoetin Alfa;Panobinostat,DrugComb,FD00030,Myeloma,Hematologic Malignancy,Phase 2
3161,TP00938,EPO;HDAC9,EPO,HDAC9,CET+CIT,Tbio+Tclin,0.332,0.346,0.462,0,0,0,1,1,DC01031,Epoetin Alfa;Panobinostat,DrugComb,FD00030,Myeloma,Hematologic Malignancy,Phase 2
3162,TP00939,ERBB2;ERBB3,ERBB2,ERBB3,CIT+CIT,Tclin+Tclin,0.704,0.78,0.86,7,0,4,3,7,DC00970,Elgemtumab;Trastuzumab,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 1
3163,TP00939,ERBB2;ERBB3,ERBB2,ERBB3,CIT+CIT,Tclin+Tclin,0.704,0.78,0.86,7,0,4,3,7,DC00970,Elgemtumab;Trastuzumab,DrugComb,FD00041,Stomach Cancer,Stomach Cancer,Phase 1
3165,TP00939,ERBB2;ERBB3,ERBB2,ERBB3,CIT+CIT,Tclin+Tclin,0.704,0.78,0.86,7,0,4,3,7,DC02305,Zenocutuzumab,BsAb,FD00023,Lung Cancer,Lung Cancer,Phase 2
3166,TP00939,ERBB2;ERBB3,ERBB2,ERBB3,CIT+CIT,Tclin+Tclin,0.704,0.78,0.86,7,0,4,3,7,DC02305,Zenocutuzumab,BsAb,FD00035,Pancreatic Cancer,Pancreatic Cancer,Phase 2
3167,TP00939,ERBB2;ERBB3,ERBB2,ERBB3,CIT+CIT,Tclin+Tclin,0.704,0.78,0.86,7,0,4,3,7,DC02305,Zenocutuzumab,BsAb,FD00038,Prostate Cancer,Prostate Cancer,Phase 2
3169,TP00939,ERBB2;ERBB3,ERBB2,ERBB3,CIT+CIT,Tclin+Tclin,0.704,0.78,0.86,7,0,4,3,7,DC02193,MM111,BsAb,FD00014,Esophageal Cancer,Esophageal Cancer,Phase 2
3170,TP00939,ERBB2;ERBB3,ERBB2,ERBB3,CIT+CIT,Tclin+Tclin,0.704,0.78,0.86,7,0,4,3,7,DC02193,MM111,BsAb,FD00033,Other Cancer,Other Cancer,Phase 1
3172,TP00940,ERBB2;ESR1,ERBB2,ESR1,CIT+CIT,Tclin+Tclin,0.497,0.733,0.5,4,4,5,6,1,DC01186,Fulvestrant;Trastuzumab,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 2
3178,TP00941,ERBB2;ESR2,ERBB2,ESR2,CIT+CIT,Tclin+Tclin,0.467,0.429,0.496,3,3,3,6,1,DC01167,Fulvestrant;Neratinib;Trastuzumab,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 2
3184,TP00942,ERBB2;EZH1,ERBB2,EZH1,CIT+CIT,Tchem+Tclin,0.304,0.314,0.509,0,0,0,1,1,DC01972,Trastuzumab Deruxtecan;Valemetostat,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 1
3185,TP00943,ERBB2;EZH2,ERBB2,EZH2,CIT+CIT,Tclin+Tclin,0.484,0.521,0.451,1,0,0,1,1,DC01972,Trastuzumab Deruxtecan;Valemetostat,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 1
3186,TP00944,ERBB2;FGFR1,ERBB2,FGFR1,CIT+CIT,Tclin+Tclin,0.678,0.845,0.829,9,0,5,1,1,DC01786,Pemigatinib;Trastuzumab,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
3187,TP00945,ERBB2;FGFR2,ERBB2,FGFR2,CIT+CIT,Tclin+Tclin,0.6,0.773,0.819,8,0,5,1,1,DC01786,Pemigatinib;Trastuzumab,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
3188,TP00946,ERBB2;FGFR3,ERBB2,FGFR3,CIT+CIT,Tclin+Tclin,0.66,0.732,0.866,8,0,5,1,1,DC01786,Pemigatinib;Trastuzumab,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
3189,TP00947,ERBB2;FLT1,ERBB2,FLT1,CET+CIT,Tclin+Tclin,0.685,0.705,0.851,5,0,2,1,1,DC01980,Trastuzumab;Vatalanib,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 1|Phase 2
3190,TP00948,ERBB2;FLT4,ERBB2,FLT4,CET+CIT,Tclin+Tclin,0.678,0.762,0.869,6,0,2,1,1,DC01980,Trastuzumab;Vatalanib,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 1|Phase 2
3191,TP00949,ERBB2;HDAC1,ERBB2,HDAC1,CIT+CIT,Tclin+Tclin,0.518,0.554,0.493,2,0,1,3,1,DC01386,Lapatinib;Vorinostat,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 1|Phase 2
3194,TP00950,ERBB2;HDAC10,ERBB2,HDAC10,CIT+CIT,Tclin+Tclin,0.283,0.517,0.499,0,0,0,3,1,DC01386,Lapatinib;Vorinostat,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 1|Phase 2
3197,TP00951,ERBB2;HDAC11,ERBB2,HDAC11,CIT+CIT,Tclin+Tclin,0.264,0.595,0.519,0,0,0,1,1,DC01673,Panobinostat;Trastuzumab,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 1|Phase 2
3198,TP00952,ERBB2;HDAC2,ERBB2,HDAC2,CIT+CIT,Tclin+Tclin,0.48,0.539,0.513,2,0,1,3,1,DC01386,Lapatinib;Vorinostat,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 1|Phase 2
3201,TP00953,ERBB2;HDAC3,ERBB2,HDAC3,CIT+CIT,Tclin+Tclin,0.426,0.693,0.545,0,0,0,3,1,DC01386,Lapatinib;Vorinostat,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 1|Phase 2
3204,TP00954,ERBB2;HDAC4,ERBB2,HDAC4,CIT+CIT,Tclin+Tclin,0.479,0.56,0.516,1,0,0,3,1,DC01386,Lapatinib;Vorinostat,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 1|Phase 2
3207,TP00955,ERBB2;HDAC5,ERBB2,HDAC5,CIT+CIT,Tclin+Tclin,0.353,0.562,0.536,1,0,0,3,1,DC01386,Lapatinib;Vorinostat,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 1|Phase 2
3210,TP00956,ERBB2;HDAC6,ERBB2,HDAC6,CIT+CIT,Tclin+Tclin,0.423,0.588,0.556,0,0,0,3,1,DC01386,Lapatinib;Vorinostat,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 1|Phase 2
3213,TP00957,ERBB2;HDAC7,ERBB2,HDAC7,CIT+CIT,Tclin+Tclin,0.374,0.551,0.525,0,0,0,3,1,DC01386,Lapatinib;Vorinostat,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 1|Phase 2
3216,TP00958,ERBB2;HDAC8,ERBB2,HDAC8,CIT+CIT,Tclin+Tclin,0.237,0.684,0.525,0,0,0,3,1,DC01386,Lapatinib;Vorinostat,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 1|Phase 2
3219,TP00959,ERBB2;HDAC9,ERBB2,HDAC9,CIT+CIT,Tclin+Tclin,0.367,0.539,0.506,0,0,0,3,1,DC01386,Lapatinib;Vorinostat,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 1|Phase 2
3222,TP00960,ERBB2;HSP90AA1,ERBB2,HSP90AA1,CIT+CIT,Tchem+Tclin,0.41,0.695,0.602,3,16,1,2,2,DC01851,Retaspimycin;Trastuzumab,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 2
3224,TP00960,ERBB2;HSP90AA1,ERBB2,HSP90AA1,CIT+CIT,Tchem+Tclin,0.41,0.695,0.602,3,16,1,2,2,DC01453,Luminespib;Trastuzumab,DrugComb,FD00041,Stomach Cancer,Stomach Cancer,Phase 2
3225,TP00961,ERBB2;HSP90AB1,ERBB2,HSP90AB1,CIT+CIT,Tchem+Tclin,0.46,0.696,0.599,3,0,1,2,2,DC01453,Luminespib;Trastuzumab,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 1|Phase 2
3226,TP00961,ERBB2;HSP90AB1,ERBB2,HSP90AB1,CIT+CIT,Tchem+Tclin,0.46,0.696,0.599,3,0,1,2,2,DC01453,Luminespib;Trastuzumab,DrugComb,FD00041,Stomach Cancer,Stomach Cancer,Phase 2
3228,TP00962,ERBB2;IGF1,ERBB2,IGF1,CIT+CIT,Tbio+Tclin,0.568,0.467,0.534,10,0,5,1,1,DC00103,Afatinib;Xentuzumab,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
3229,TP00963,ERBB2;IGF1R,ERBB2,IGF1R,CIT+CIT,Tclin+Tclin,0.59,0.734,0.809,11,0,7,1,1,DC01205,Ganitumab;Trastuzumab,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 1|Phase 2
3230,TP00964,ERBB2;IGF2,ERBB2,IGF2,CIT+CIT,Tbio+Tclin,0.543,0.374,0.512,4,0,1,1,1,DC00103,Afatinib;Xentuzumab,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
3231,TP00965,ERBB2;IL2RA,ERBB2,IL2RA,CET+CIT,Tclin+Tclin,0.392,0.542,0.588,2,1,1,1,1,DC00117,Aldesleukin;Trastuzumab,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 2
3232,TP00966,ERBB2;IL2RB,ERBB2,IL2RB,CET+CIT,Tclin+Tclin,0.381,0.751,0.606,2,1,1,1,1,DC00117,Aldesleukin;Trastuzumab,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 2
3233,TP00967,ERBB2;IL2RG,ERBB2,IL2RG,CIT+CIT,Tclin+Tclin,0.402,0.79,0.617,2,1,1,1,1,DC00117,Aldesleukin;Trastuzumab,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 2
3234,TP00968,ERBB2;IL6R,ERBB2,IL6R,CET+CIT,Tclin+Tclin,0.487,0.666,0.637,4,0,2,1,1,DC01796,Pertuzumab;Tocilizumab;Trastuzumab,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 1
3235,TP00969,ERBB2;ITGAV,ERBB2,ITGAV,CIT+CIT,Tchem+Tclin,0.472,0.65,0.592,4,0,2,1,1,DC00092,Afatinib;Intetumumab,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
3236,TP00970,ERBB2;ITGB3,ERBB2,ITGB3,CIT+CIT,Tclin+Tclin,0.514,0.651,0.635,4,0,1,1,1,DC00092,Afatinib;Intetumumab,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
3237,TP00971,ERBB2;JAK1,ERBB2,JAK1,CIT+CIT,Tclin+Tclin,0.56,0.677,0.772,4,1,6,2,2,DC00098,Afatinib;Ruxolitinib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
3238,TP00971,ERBB2;JAK1,ERBB2,JAK1,CIT+CIT,Tclin+Tclin,0.56,0.677,0.772,4,1,6,2,2,DC01885,Ruxolitinib;Trastuzumab,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 1|Phase 2
3239,TP00972,ERBB2;JAK2,ERBB2,JAK2,CIT+CIT,Tclin+Tclin,0.559,0.662,0.756,3,1,6,2,2,DC00098,Afatinib;Ruxolitinib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
3240,TP00972,ERBB2;JAK2,ERBB2,JAK2,CIT+CIT,Tclin+Tclin,0.559,0.662,0.756,3,1,6,2,2,DC01885,Ruxolitinib;Trastuzumab,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 1|Phase 2
3241,TP00973,ERBB2;KDR,ERBB2,KDR,CET+CIT,Tclin+Tclin,0.621,0.769,0.848,6,0,3,2,1,DC01148,Foretinib;Lapatinib,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 1|Phase 2
3243,TP00974,ERBB2;KRAS,ERBB2,KRAS,CIT+CIT,Tclin+Tclin,0.493,0.646,0.509,16,0,15,3,1,DC01923,Sotorasib;Tarloxotinib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
3246,TP00975,ERBB2;MAP2K1,ERBB2,MAP2K1,CIT+CIT,Tclin+Tclin,0.625,0.715,0.742,18,0,14,3,2,DC01384,Lapatinib;Trametinib,DrugComb,FD00011,Colorectal Cancer,Colorectal Cancer,Phase 1|Phase 2
3247,TP00975,ERBB2;MAP2K1,ERBB2,MAP2K1,CIT+CIT,Tclin+Tclin,0.625,0.715,0.742,18,0,14,3,2,DC00099,Afatinib;Selumetinib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
3249,TP00976,ERBB2;MAP2K2,ERBB2,MAP2K2,CIT+CIT,Tclin+Tclin,0.51,0.652,0.722,16,0,14,3,2,DC00099,Afatinib;Selumetinib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
3250,TP00976,ERBB2;MAP2K2,ERBB2,MAP2K2,CIT+CIT,Tclin+Tclin,0.51,0.652,0.722,16,0,14,3,2,DC01384,Lapatinib;Trametinib,DrugComb,FD00011,Colorectal Cancer,Colorectal Cancer,Phase 1|Phase 2
3252,TP00977,ERBB2;MET,ERBB2,MET,CIT+CIT,Tclin+Tclin,0.614,0.734,0.906,12,4,5,2,1,DC01148,Foretinib;Lapatinib,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 1|Phase 2
3254,TP00978,ERBB2;MTOR,ERBB2,MTOR,CIT+CIT,Tclin+Tclin,0.51,0.602,0.7,13,1,11,8,4,DC00100,Afatinib;Sirolimus,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
3255,TP00978,ERBB2;MTOR,ERBB2,MTOR,CIT+CIT,Tclin+Tclin,0.51,0.602,0.7,13,1,11,8,4,DC01683,Paxalisib;Trastuzumab,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 2
3256,TP00978,ERBB2;MTOR,ERBB2,MTOR,CIT+CIT,Tclin+Tclin,0.51,0.602,0.7,13,1,11,8,4,DC01383,Lapatinib;Sirolimus,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
3257,TP00978,ERBB2;MTOR,ERBB2,MTOR,CIT+CIT,Tclin+Tclin,0.51,0.602,0.7,13,1,11,8,4,DC00087,AEE788;Everolimus,DrugComb,FD00017,Glioma,Glioma,Phase 1|Phase 2
3262,TP00979,ERBB2;PARP1,ERBB2,PARP1,CIT+CIT,Tclin+Tclin,0.426,0.594,0.567,0,0,1,3,3,DC01554,Niraparib;Trastuzumab,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 1|Phase 2
3263,TP00979,ERBB2;PARP1,ERBB2,PARP1,CIT+CIT,Tclin+Tclin,0.426,0.594,0.567,0,0,1,3,3,DC01892,Saruparib;Trastuzumab Deruxtecan,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
3264,TP00979,ERBB2;PARP1,ERBB2,PARP1,CIT+CIT,Tclin+Tclin,0.426,0.594,0.567,0,0,1,3,3,DC01555,Niraparib;Trastuzumab Duocarmazine,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
3265,TP00980,ERBB2;PARP2,ERBB2,PARP2,CIT+CIT,Tclin+Tclin,0.358,0.398,0.515,0,0,0,3,3,DC01555,Niraparib;Trastuzumab Duocarmazine,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
3266,TP00980,ERBB2;PARP2,ERBB2,PARP2,CIT+CIT,Tclin+Tclin,0.358,0.398,0.515,0,0,0,3,3,DC01554,Niraparib;Trastuzumab,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 1|Phase 2
3267,TP00980,ERBB2;PARP2,ERBB2,PARP2,CIT+CIT,Tclin+Tclin,0.358,0.398,0.515,0,0,0,3,3,DC01892,Saruparib;Trastuzumab Deruxtecan,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
3268,TP00981,ERBB2;PDCD1,ERBB2,PDCD1,CET+CIT,Tclin+Tclin,0.289,0.574,1.0,0,0,0,17,10,DC00097,Afatinib;Pembrolizumab,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 2
3269,TP00981,ERBB2;PDCD1,ERBB2,PDCD1,CET+CIT,Tclin+Tclin,0.289,0.574,1.0,0,0,0,17,10,DC01591,Nivolumab;Trastuzumab imbotolimod,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1|Phase 2
3272,TP00981,ERBB2;PDCD1,ERBB2,PDCD1,CET+CIT,Tclin+Tclin,0.289,0.574,1.0,0,0,0,17,10,DC01744,Pembrolizumab;Trastuzumab Deruxtecan,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 1
3274,TP00981,ERBB2;PDCD1,ERBB2,PDCD1,CET+CIT,Tclin+Tclin,0.289,0.574,1.0,0,0,0,17,10,DC01743,Pembrolizumab;Trastuzumab,DrugComb,FD00020,Kidney Cancer,Kidney Cancer,Approval
3275,TP00981,ERBB2;PDCD1,ERBB2,PDCD1,CET+CIT,Tclin+Tclin,0.289,0.574,1.0,0,0,0,17,10,DC01743,Pembrolizumab;Trastuzumab,DrugComb,FD00026,Melanoma,Melanoma,Approval
3276,TP00981,ERBB2;PDCD1,ERBB2,PDCD1,CET+CIT,Tclin+Tclin,0.289,0.574,1.0,0,0,0,17,10,DC01743,Pembrolizumab;Trastuzumab,DrugComb,FD00030,Myeloma,Hematologic Malignancy,Approval
3277,TP00981,ERBB2;PDCD1,ERBB2,PDCD1,CET+CIT,Tclin+Tclin,0.289,0.574,1.0,0,0,0,17,10,DC01743,Pembrolizumab;Trastuzumab,DrugComb,FD00034,Ovarian Cancer,Ovarian Cancer,Approval
3278,TP00981,ERBB2;PDCD1,ERBB2,PDCD1,CET+CIT,Tclin+Tclin,0.289,0.574,1.0,0,0,0,17,10,DC01743,Pembrolizumab;Trastuzumab,DrugComb,FD00041,Stomach Cancer,Stomach Cancer,Approval
3279,TP00981,ERBB2;PDCD1,ERBB2,PDCD1,CET+CIT,Tclin+Tclin,0.289,0.574,1.0,0,0,0,17,10,DC00892,Disitamab Vedotin;Tislelizumab,DrugComb,FD00006,Bladder Cancer,Bladder Cancer,Phase 2
3280,TP00981,ERBB2;PDCD1,ERBB2,PDCD1,CET+CIT,Tclin+Tclin,0.289,0.574,1.0,0,0,0,17,10,DC00892,Disitamab Vedotin;Tislelizumab,DrugComb,FD00011,Colorectal Cancer,Colorectal Cancer,Phase 2
3294,TP00982,ERBB2;PIK3CA,ERBB2,PIK3CA,CIT+CIT,Tclin+Tclin,0.502,0.631,0.675,17,7,14,7,2,DC01683,Paxalisib;Trastuzumab,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 2
3295,TP00982,ERBB2;PIK3CA,ERBB2,PIK3CA,CIT+CIT,Tclin+Tclin,0.502,0.631,0.675,17,7,14,7,2,DC01809,Pilaralisib;Tesevatinib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
3301,TP00983,ERBB2;PIK3CB,ERBB2,PIK3CB,CIT+CIT,Tchem+Tclin,0.506,0.696,0.655,17,4,11,3,2,DC01809,Pilaralisib;Tesevatinib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
3302,TP00983,ERBB2;PIK3CB,ERBB2,PIK3CB,CIT+CIT,Tchem+Tclin,0.506,0.696,0.655,17,4,11,3,2,DC00623,Buparlisib;Trastuzumab,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 1|Phase 2
3304,TP00984,ERBB2;PIK3CD,ERBB2,PIK3CD,CIT+CIT,Tclin+Tclin,0.483,0.654,0.648,17,3,10,5,2,DC01809,Pilaralisib;Tesevatinib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
3305,TP00984,ERBB2;PIK3CD,ERBB2,PIK3CD,CIT+CIT,Tclin+Tclin,0.483,0.654,0.648,17,3,10,5,2,DC00807,Copanlisib;Trastuzumab Emtansine,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 1
3309,TP00985,ERBB2;PIK3CG,ERBB2,PIK3CG,CIT+CIT,Tclin+Tclin,0.457,0.636,0.726,1,0,5,3,2,DC01809,Pilaralisib;Tesevatinib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
3310,TP00985,ERBB2;PIK3CG,ERBB2,PIK3CG,CIT+CIT,Tclin+Tclin,0.457,0.636,0.726,1,0,5,3,2,DC01810,Pilaralisib;Trastuzumab,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 1|Phase 2
3312,TP00986,ERBB2;SIRPA,ERBB2,SIRPA,CIT+CIT,Tbio+Tclin,0.348,0.615,0.453,0,0,1,1,1,DC00910,DS1103a;Trastuzumab Deruxtecan,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 1
3313,TP00987,ERBB2;TLR9,ERBB2,TLR9,CIT+CIT,Tclin+Tclin,0.453,0.775,0.456,0,0,0,1,1,DC00108,Agatolimod;Trastuzumab,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 2
3314,TP00988,ERBB2;TNFRSF9,ERBB2,TNFRSF9,CET+CIT,Tbio+Tclin,0.269,0.571,0.618,0,0,0,3,4,DC01976,Trastuzumab Emtansine;Utomilumab,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 1
3315,TP00988,ERBB2;TNFRSF9,ERBB2,TNFRSF9,CET+CIT,Tbio+Tclin,0.269,0.571,0.618,0,0,0,3,4,DC01999,ABL105,BsAb,FD00033,Other Cancer,Other Cancer,Phase 1|Phase 2
3316,TP00988,ERBB2;TNFRSF9,ERBB2,TNFRSF9,CET+CIT,Tbio+Tclin,0.269,0.571,0.618,0,0,0,3,4,DC02064,Cinrebafusp Alfa,BsAb,FD00006,Bladder Cancer,Bladder Cancer,Phase 1
3318,TP00988,ERBB2;TNFRSF9,ERBB2,TNFRSF9,CET+CIT,Tbio+Tclin,0.269,0.571,0.618,0,0,0,3,4,DC02064,Cinrebafusp Alfa,BsAb,FD00041,Stomach Cancer,Stomach Cancer,Phase 2
3319,TP00989,ERBB2;VEGFA,ERBB2,VEGFA,CET+CIT,Tclin+Tclin,0.585,0.556,0.555,11,1,6,1,2,DC00452,Bevacizumab;Lapatinib,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 2
3320,TP00989,ERBB2;VEGFA,ERBB2,VEGFA,CET+CIT,Tclin+Tclin,0.585,0.556,0.555,11,1,6,1,2,DC00452,Bevacizumab;Lapatinib,DrugComb,FD00013,Ependymoma,Other Cancer,Phase 2
3321,TP00990,ERBB3;IGF1R,ERBB3,IGF1R,CIT+CIT,Tclin+Tclin,0.556,0.658,0.708,4,0,2,1,5,DC02150,Istiratumab,BsAb,FD00011,Colorectal Cancer,Colorectal Cancer,Phase 1
3322,TP00990,ERBB3;IGF1R,ERBB3,IGF1R,CIT+CIT,Tclin+Tclin,0.556,0.658,0.708,4,0,2,1,5,DC02150,Istiratumab,BsAb,FD00018,Head and Neck Cancer,Head and Neck Cancer,Phase 1
3323,TP00990,ERBB3;IGF1R,ERBB3,IGF1R,CIT+CIT,Tclin+Tclin,0.556,0.658,0.708,4,0,2,1,5,DC02150,Istiratumab,BsAb,FD00022,Liver Cancer,Liver Cancer,Phase 1
3324,TP00990,ERBB3;IGF1R,ERBB3,IGF1R,CIT+CIT,Tclin+Tclin,0.556,0.658,0.708,4,0,2,1,5,DC02150,Istiratumab,BsAb,FD00023,Lung Cancer,Lung Cancer,Phase 1
3325,TP00990,ERBB3;IGF1R,ERBB3,IGF1R,CIT+CIT,Tclin+Tclin,0.556,0.658,0.708,4,0,2,1,5,DC02150,Istiratumab,BsAb,FD00035,Pancreatic Cancer,Pancreatic Cancer,Phase 2
3326,TP00991,ERBB3;MAP2K1,ERBB3,MAP2K1,CIT+CIT,Tclin+Tclin,0.601,0.476,0.747,6,0,3,1,1,DC00686,CDX3379;Trametinib,DrugComb,FD00026,Melanoma,Melanoma,Phase 1|Phase 2
3327,TP00992,ERBB3;MAP2K2,ERBB3,MAP2K2,CIT+CIT,Tclin+Tclin,0.44,0.406,0.707,6,0,3,1,1,DC00686,CDX3379;Trametinib,DrugComb,FD00026,Melanoma,Melanoma,Phase 1|Phase 2
3328,TP00993,ERBB3;PDCD1,ERBB3,PDCD1,CET+CIT,Tclin+Tclin,0.416,0.667,1.0,0,0,0,2,2,DC00551,BLB01D1;SI-B003,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 2
3329,TP00993,ERBB3;PDCD1,ERBB3,PDCD1,CET+CIT,Tclin+Tclin,0.416,0.667,1.0,0,0,0,2,2,DC01367,Izalontamab;SI-B003,DrugComb,FD00018,Head and Neck Cancer,Head and Neck Cancer,Phase 1|Phase 2
3331,TP00994,ERBB4;IGF1,ERBB4,IGF1,CIT+CIT,Tbio+Tclin,0.558,0.469,0.469,3,0,0,1,1,DC00103,Afatinib;Xentuzumab,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
3332,TP00995,ERBB4;IGF2,ERBB4,IGF2,CIT+CIT,Tbio+Tclin,0.555,0.399,0.448,3,0,0,1,1,DC00103,Afatinib;Xentuzumab,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
3333,TP00996,ERBB4;ITGAV,ERBB4,ITGAV,CIT+CIT,Tchem+Tclin,0.448,0.602,0.513,2,0,0,1,1,DC00092,Afatinib;Intetumumab,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
3334,TP00997,ERBB4;ITGB3,ERBB4,ITGB3,CIT+CIT,Tclin+Tclin,0.487,0.723,0.562,2,0,0,1,1,DC00092,Afatinib;Intetumumab,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
3335,TP00998,ERBB4;JAK1,ERBB4,JAK1,CIT+CIT,Tclin+Tclin,0.507,0.576,0.741,1,0,0,1,1,DC00098,Afatinib;Ruxolitinib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
3336,TP00999,ERBB4;JAK2,ERBB4,JAK2,CIT+CIT,Tclin+Tclin,0.561,0.713,0.744,1,0,1,1,1,DC00098,Afatinib;Ruxolitinib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
3337,TP01000,ERBB4;KRAS,ERBB4,KRAS,CIT+CIT,Tclin+Tclin,0.464,0.586,0.434,4,0,2,3,1,DC00101,Afatinib;Sotorasib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
3340,TP01001,ERBB4;MAP2K1,ERBB4,MAP2K1,CIT+CIT,Tclin+Tclin,0.62,0.657,0.728,4,0,3,1,1,DC00099,Afatinib;Selumetinib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
3341,TP01002,ERBB4;MAP2K2,ERBB4,MAP2K2,CIT+CIT,Tclin+Tclin,0.434,0.627,0.723,4,0,2,1,1,DC00099,Afatinib;Selumetinib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
3342,TP01003,ERBB4;MTOR,ERBB4,MTOR,CIT+CIT,Tclin+Tclin,0.467,0.604,0.777,4,0,1,1,1,DC00100,Afatinib;Sirolimus,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
3343,TP01004,ERBB4;PDCD1,ERBB4,PDCD1,CET+CIT,Tclin+Tclin,0.35,0.462,1.0,0,0,0,1,1,DC00097,Afatinib;Pembrolizumab,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 2
3344,TP01005,ESR1;FGFR1,ESR1,FGFR1,CIT+CIT,Tclin+Tclin,0.411,0.762,0.46,3,0,2,1,1,DC01182,Fulvestrant;Tasurgratinib,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 1
3345,TP01006,ESR1;FGFR2,ESR1,FGFR2,CIT+CIT,Tclin+Tclin,0.531,0.768,0.432,1,0,1,1,1,DC01182,Fulvestrant;Tasurgratinib,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 1
3346,TP01007,ESR1;FGFR3,ESR1,FGFR3,CIT+CIT,Tclin+Tclin,0.391,0.689,0.45,1,0,1,1,1,DC01182,Fulvestrant;Tasurgratinib,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 1
3347,TP01008,ESR1;FLT1,ESR1,FLT1,CET+CIT,Tclin+Tclin,0.387,0.594,0.433,0,0,0,1,1,DC00690,Cediranib;Fulvestrant,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 2
3348,TP01009,ESR1;FLT4,ESR1,FLT4,CET+CIT,Tclin+Tclin,0.396,0.728,0.457,2,0,2,1,1,DC00690,Cediranib;Fulvestrant,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 2
3349,TP01010,ESR1;FNTB,ESR1,FNTB,CIT+CIT,Tclin+Tclin,0.127,0.514,0.498,0,0,0,2,1,DC01183,Fulvestrant;Tipifarnib,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 2
3351,TP01011,ESR1;GNRHR,ESR1,GNRHR,CIT+CIT,Tclin+Tclin,0.336,0.526,0.248,0,0,0,1,1,DC01250,Goserelin;Tamoxifen,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 3
3352,TP01012,ESR1;HDAC1,ESR1,HDAC1,CIT+CIT,Tclin+Tclin,0.568,0.806,0.622,2,1,1,2,1,DC00998,Entinostat;Fulvestrant,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 2
3354,TP01013,ESR1;HDAC10,ESR1,HDAC10,CIT+CIT,Tclin+Tclin,0.339,0.643,0.493,0,0,0,1,1,DC01188,Fulvestrant;Tucidinostat,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 2
3355,TP01014,ESR1;HDAC2,ESR1,HDAC2,CIT+CIT,Tclin+Tclin,0.513,0.795,0.553,2,0,1,2,1,DC00998,Entinostat;Fulvestrant,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 2
3357,TP01015,ESR1;HDAC3,ESR1,HDAC3,CIT+CIT,Tclin+Tclin,0.434,0.818,0.567,1,0,1,2,1,DC01188,Fulvestrant;Tucidinostat,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 2
3359,TP01016,ESR1;HDAC8,ESR1,HDAC8,CIT+CIT,Tclin+Tclin,0.346,0.729,0.484,0,0,0,1,1,DC00998,Entinostat;Fulvestrant,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 2
3360,TP01017,ESR1;HSP90AA1,ESR1,HSP90AA1,CIT+CIT,Tchem+Tclin,0.337,0.726,0.593,3,3,3,1,1,DC01156,Fulvestrant;Ganetespib,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 2
3361,TP01018,ESR1;HSP90AB1,ESR1,HSP90AB1,CIT+CIT,Tchem+Tclin,0.41,0.722,0.581,3,2,2,1,1,DC01156,Fulvestrant;Ganetespib,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 2
3362,TP01019,ESR1;IGF1R,ESR1,IGF1R,CIT+CIT,Tclin+Tclin,0.48,0.722,0.474,4,1,2,2,1,DC01190,Fulvestrant;Veligrotug,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 2
3364,TP01020,ESR1;KAT6A,ESR1,KAT6A,CIT+CIT,Tchem+Tclin,0.457,0.699,0.542,0,0,0,1,1,DC01174,Fulvestrant;PF07248144,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
3365,TP01021,ESR1;KDR,ESR1,KDR,CET+CIT,Tclin+Tclin,0.46,0.691,0.473,1,0,1,1,1,DC00690,Cediranib;Fulvestrant,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 2
3366,TP01022,ESR1;MAP2K1,ESR1,MAP2K1,CIT+CIT,Tclin+Tclin,0.505,0.689,0.417,8,0,5,1,1,DC01165,Fulvestrant;Mirdametinib,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1|Phase 2
3367,TP01023,ESR1;MAP2K2,ESR1,MAP2K2,CIT+CIT,Tclin+Tclin,0.378,0.633,0.432,8,0,3,1,1,DC01165,Fulvestrant;Mirdametinib,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1|Phase 2
3368,TP01024,ESR1;MAPK11,ESR1,MAPK11,CIT+CIT,Tchem+Tclin,0.391,0.662,0.409,3,0,0,1,1,DC01840,Ralimetinib;Tamoxifen,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 2
3369,TP01025,ESR1;MAPK14,ESR1,MAPK14,CIT+CIT,Tchem+Tclin,0.51,0.659,0.463,3,0,2,1,1,DC01840,Ralimetinib;Tamoxifen,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 2
3370,TP01026,ESR1;MTOR,ESR1,MTOR,CIT+CIT,Tclin+Tclin,0.4,0.695,0.479,6,1,3,6,4,DC01180,Fulvestrant;Samotolisib,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 1
3371,TP01026,ESR1;MTOR,ESR1,MTOR,CIT+CIT,Tclin+Tclin,0.4,0.695,0.479,6,1,3,6,4,DC01180,Fulvestrant;Samotolisib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
3372,TP01026,ESR1;MTOR,ESR1,MTOR,CIT+CIT,Tclin+Tclin,0.4,0.695,0.479,6,1,3,6,4,DC01180,Fulvestrant;Samotolisib,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 1
3375,TP01026,ESR1;MTOR,ESR1,MTOR,CIT+CIT,Tclin+Tclin,0.4,0.695,0.479,6,1,3,6,4,DC01193,Fulvestrant;Vistusertib,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
3379,TP01027,ESR1;PARP1,ESR1,PARP1,CIT+CIT,Tclin+Tclin,0.428,0.832,0.618,0,0,3,2,2,DC01663,Pamiparib;Tamoxifen,DrugComb,FD00034,Ovarian Cancer,Ovarian Cancer,Phase 2
3380,TP01027,ESR1;PARP1,ESR1,PARP1,CIT+CIT,Tclin+Tclin,0.428,0.832,0.618,0,0,3,2,2,DC00639,Camizestrant;Saruparib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
3381,TP01028,ESR1;PARP2,ESR1,PARP2,CIT+CIT,Tclin+Tclin,0.247,0.579,0.512,0,0,0,2,2,DC00639,Camizestrant;Saruparib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
3382,TP01028,ESR1;PARP2,ESR1,PARP2,CIT+CIT,Tclin+Tclin,0.247,0.579,0.512,0,0,0,2,2,DC01663,Pamiparib;Tamoxifen,DrugComb,FD00034,Ovarian Cancer,Ovarian Cancer,Phase 2
3383,TP01029,ESR1;PDCD1,ESR1,PDCD1,CET+CIT,Tclin+Tclin,0.271,0.477,1.0,0,0,0,1,1,DC01171,Fulvestrant;Pembrolizumab,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 2
3384,TP01030,ESR1;PGR,ESR1,PGR,CIT+CIT,Tclin+Tclin,0.636,0.646,0.857,3,4,4,1,1,DC00969,Elacestrant;Onapristone,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 1|Phase 2
3385,TP01031,ESR1;PIK3CA,ESR1,PIK3CA,CIT+CIT,Tclin+Tclin,0.413,0.627,0.374,8,4,4,11,4,DC00232,Apitolisib;Fulvestrant,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 2
3387,TP01031,ESR1;PIK3CA,ESR1,PIK3CA,CIT+CIT,Tclin+Tclin,0.413,0.627,0.374,8,4,4,11,4,DC01180,Fulvestrant;Samotolisib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
3388,TP01031,ESR1;PIK3CA,ESR1,PIK3CA,CIT+CIT,Tclin+Tclin,0.413,0.627,0.374,8,4,4,11,4,DC01180,Fulvestrant;Samotolisib,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 1
3393,TP01031,ESR1;PIK3CA,ESR1,PIK3CA,CIT+CIT,Tclin+Tclin,0.413,0.627,0.374,8,4,4,11,4,DC00799,Copanlisib;Fulvestrant,DrugComb,FD00034,Ovarian Cancer,Ovarian Cancer,Phase 2
3399,TP01032,ESR1;PIK3CB,ESR1,PIK3CB,CIT+CIT,Tchem+Tclin,0.403,0.76,0.394,8,3,2,2,1,DC00613,Buparlisib;Fulvestrant,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 3
3401,TP01033,ESR1;PIK3CD,ESR1,PIK3CD,CIT+CIT,Tclin+Tclin,0.362,0.66,0.382,8,3,3,5,2,DC01184,Fulvestrant;TQ-B3525,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 1|Phase 2
3403,TP01033,ESR1;PIK3CD,ESR1,PIK3CD,CIT+CIT,Tclin+Tclin,0.362,0.66,0.382,8,3,3,5,2,DC00799,Copanlisib;Fulvestrant,DrugComb,FD00034,Ovarian Cancer,Ovarian Cancer,Phase 2
3407,TP01034,ESR1;PIK3CG,ESR1,PIK3CG,CIT+CIT,Tclin+Tclin,0.366,0.648,0.382,0,0,1,2,1,DC00613,Buparlisib;Fulvestrant,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 3
3409,TP01035,ESR1;PRKCB,ESR1,PRKCB,CIT+CIT,Tchem+Tclin,0.493,0.689,0.504,5,0,1,1,1,DC01022,Enzastaurin;Fulvestrant,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 2
3410,TP01036,ESR1;TTK,ESR1,TTK,CIT+CIT,Tchem+Tclin,0.242,0.708,0.438,0,0,0,1,1,DC01164,Fulvestrant;Luvixasertib,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 1|Phase 2
3411,TP01037,ESR2;FGFR1,ESR2,FGFR1,CIT+CIT,Tclin+Tclin,0.331,0.509,0.413,2,0,2,1,1,DC01182,Fulvestrant;Tasurgratinib,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 1
3412,TP01038,ESR2;FGFR2,ESR2,FGFR2,CIT+CIT,Tclin+Tclin,0.279,0.481,0.383,1,0,1,1,1,DC01182,Fulvestrant;Tasurgratinib,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 1
3413,TP01039,ESR2;FGFR3,ESR2,FGFR3,CIT+CIT,Tclin+Tclin,0.355,0.526,0.396,1,0,1,1,1,DC01182,Fulvestrant;Tasurgratinib,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 1
3414,TP01040,ESR2;FLT1,ESR2,FLT1,CET+CIT,Tclin+Tclin,0.316,0.363,0.391,0,0,0,1,1,DC00690,Cediranib;Fulvestrant,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 2
3415,TP01041,ESR2;FLT4,ESR2,FLT4,CET+CIT,Tclin+Tclin,0.312,0.51,0.421,2,0,2,1,1,DC00690,Cediranib;Fulvestrant,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 2
3416,TP01042,ESR2;FNTB,ESR2,FNTB,CIT+CIT,Tclin+Tclin,0.148,0.451,0.475,0,0,0,2,1,DC01183,Fulvestrant;Tipifarnib,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 2
3418,TP01043,ESR2;GNRHR,ESR2,GNRHR,CIT+CIT,Tclin+Tclin,0.381,0.282,0.293,0,0,0,1,1,DC01250,Goserelin;Tamoxifen,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 3
3419,TP01044,ESR2;HDAC1,ESR2,HDAC1,CIT+CIT,Tclin+Tclin,0.451,0.707,0.573,1,0,2,2,1,DC00998,Entinostat;Fulvestrant,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 2
3421,TP01045,ESR2;HDAC10,ESR2,HDAC10,CIT+CIT,Tclin+Tclin,0.442,0.82,0.462,0,0,0,1,1,DC01188,Fulvestrant;Tucidinostat,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 2
3422,TP01046,ESR2;HDAC2,ESR2,HDAC2,CIT+CIT,Tclin+Tclin,0.413,0.78,0.52,1,0,1,2,1,DC01188,Fulvestrant;Tucidinostat,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 2
3424,TP01047,ESR2;HDAC3,ESR2,HDAC3,CIT+CIT,Tclin+Tclin,0.49,0.685,0.468,0,0,0,2,1,DC01188,Fulvestrant;Tucidinostat,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 2
3426,TP01048,ESR2;HDAC8,ESR2,HDAC8,CIT+CIT,Tclin+Tclin,0.458,0.766,0.452,0,0,0,1,1,DC00998,Entinostat;Fulvestrant,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 2
3427,TP01049,ESR2;HSP90AA1,ESR2,HSP90AA1,CIT+CIT,Tchem+Tclin,0.305,0.534,0.544,3,2,1,1,1,DC01156,Fulvestrant;Ganetespib,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 2
3428,TP01050,ESR2;HSP90AB1,ESR2,HSP90AB1,CIT+CIT,Tchem+Tclin,0.335,0.481,0.537,3,1,1,1,1,DC01156,Fulvestrant;Ganetespib,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 2
3429,TP01051,ESR2;IGF1R,ESR2,IGF1R,CIT+CIT,Tclin+Tclin,0.411,0.431,0.449,3,1,2,2,1,DC01190,Fulvestrant;Veligrotug,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 2
3431,TP01052,ESR2;KAT6A,ESR2,KAT6A,CIT+CIT,Tchem+Tclin,0.536,0.819,0.534,0,0,0,1,1,DC01174,Fulvestrant;PF07248144,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
3432,TP01053,ESR2;KDR,ESR2,KDR,CET+CIT,Tclin+Tclin,0.308,0.499,0.44,0,0,1,1,1,DC00690,Cediranib;Fulvestrant,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 2
3433,TP01054,ESR2;MAP2K1,ESR2,MAP2K1,CIT+CIT,Tclin+Tclin,0.407,0.659,0.344,7,0,2,1,1,DC01165,Fulvestrant;Mirdametinib,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1|Phase 2
3434,TP01055,ESR2;MAP2K2,ESR2,MAP2K2,CIT+CIT,Tclin+Tclin,0.54,0.586,0.372,7,0,2,1,1,DC01165,Fulvestrant;Mirdametinib,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1|Phase 2
3435,TP01056,ESR2;MAPK11,ESR2,MAPK11,CIT+CIT,Tchem+Tclin,0.404,0.786,0.332,2,0,0,1,1,DC01840,Ralimetinib;Tamoxifen,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 2
3436,TP01057,ESR2;MAPK14,ESR2,MAPK14,CIT+CIT,Tchem+Tclin,0.407,0.703,0.407,2,0,0,1,1,DC01840,Ralimetinib;Tamoxifen,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 2
3437,TP01058,ESR2;MTOR,ESR2,MTOR,CIT+CIT,Tclin+Tclin,0.344,0.581,0.431,4,1,3,6,4,DC01180,Fulvestrant;Samotolisib,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 1
3438,TP01058,ESR2;MTOR,ESR2,MTOR,CIT+CIT,Tclin+Tclin,0.344,0.581,0.431,4,1,3,6,4,DC01180,Fulvestrant;Samotolisib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
3439,TP01058,ESR2;MTOR,ESR2,MTOR,CIT+CIT,Tclin+Tclin,0.344,0.581,0.431,4,1,3,6,4,DC01180,Fulvestrant;Samotolisib,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 1
3443,TP01058,ESR2;MTOR,ESR2,MTOR,CIT+CIT,Tclin+Tclin,0.344,0.581,0.431,4,1,3,6,4,DC01193,Fulvestrant;Vistusertib,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
3446,TP01059,ESR2;PARP1,ESR2,PARP1,CIT+CIT,Tclin+Tclin,0.407,0.717,0.597,0,0,3,2,2,DC00639,Camizestrant;Saruparib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
3447,TP01059,ESR2;PARP1,ESR2,PARP1,CIT+CIT,Tclin+Tclin,0.407,0.717,0.597,0,0,3,2,2,DC01663,Pamiparib;Tamoxifen,DrugComb,FD00034,Ovarian Cancer,Ovarian Cancer,Phase 2
3448,TP01060,ESR2;PARP2,ESR2,PARP2,CIT+CIT,Tclin+Tclin,0.313,0.878,0.469,0,0,0,2,2,DC01663,Pamiparib;Tamoxifen,DrugComb,FD00034,Ovarian Cancer,Ovarian Cancer,Phase 2
3449,TP01060,ESR2;PARP2,ESR2,PARP2,CIT+CIT,Tclin+Tclin,0.313,0.878,0.469,0,0,0,2,2,DC00639,Camizestrant;Saruparib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
3450,TP01061,ESR2;PDCD1,ESR2,PDCD1,CET+CIT,Tclin+Tclin,0.196,0.229,1.0,0,0,0,1,1,DC01171,Fulvestrant;Pembrolizumab,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 2
3451,TP01062,ESR2;PGR,ESR2,PGR,CIT+CIT,Tclin+Tclin,0.695,0.796,0.924,3,1,4,1,1,DC00969,Elacestrant;Onapristone,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 1|Phase 2
3452,TP01063,ESR2;PIK3CA,ESR2,PIK3CA,CIT+CIT,Tclin+Tclin,0.337,0.363,0.291,7,4,2,11,4,DC00232,Apitolisib;Fulvestrant,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 2
3454,TP01063,ESR2;PIK3CA,ESR2,PIK3CA,CIT+CIT,Tclin+Tclin,0.337,0.363,0.291,7,4,2,11,4,DC01180,Fulvestrant;Samotolisib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
3455,TP01063,ESR2;PIK3CA,ESR2,PIK3CA,CIT+CIT,Tclin+Tclin,0.337,0.363,0.291,7,4,2,11,4,DC01180,Fulvestrant;Samotolisib,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 1
3460,TP01063,ESR2;PIK3CA,ESR2,PIK3CA,CIT+CIT,Tclin+Tclin,0.337,0.363,0.291,7,4,2,11,4,DC00799,Copanlisib;Fulvestrant,DrugComb,FD00034,Ovarian Cancer,Ovarian Cancer,Phase 2
3466,TP01064,ESR2;PIK3CB,ESR2,PIK3CB,CIT+CIT,Tchem+Tclin,0.389,0.628,0.323,7,3,1,2,1,DC00621,Buparlisib;Tamoxifen,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 2
3468,TP01065,ESR2;PIK3CD,ESR2,PIK3CD,CIT+CIT,Tclin+Tclin,0.33,0.395,0.301,7,3,2,5,2,DC00799,Copanlisib;Fulvestrant,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 1|Phase 2
3469,TP01065,ESR2;PIK3CD,ESR2,PIK3CD,CIT+CIT,Tclin+Tclin,0.33,0.395,0.301,7,3,2,5,2,DC00799,Copanlisib;Fulvestrant,DrugComb,FD00034,Ovarian Cancer,Ovarian Cancer,Phase 2
3474,TP01066,ESR2;PIK3CG,ESR2,PIK3CG,CIT+CIT,Tclin+Tclin,0.32,0.375,0.304,0,0,0,2,1,DC00613,Buparlisib;Fulvestrant,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 3
3476,TP01067,ESR2;PRKCB,ESR2,PRKCB,CIT+CIT,Tchem+Tclin,0.513,0.599,0.397,3,0,1,1,1,DC01022,Enzastaurin;Fulvestrant,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 2
3477,TP01068,ESR2;TTK,ESR2,TTK,CIT+CIT,Tchem+Tclin,0.223,0.697,0.366,0,0,0,1,1,DC01164,Fulvestrant;Luvixasertib,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 1|Phase 2
3478,TP01069,EZH1;PDCD1,EZH1,PDCD1,CET+CIT,Tchem+Tclin,0.193,0.202,1.0,0,0,0,1,1,DC01760,Pembrolizumab;Valemetostat,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
3479,TP01070,EZH2;MS4A1,EZH2,MS4A1,CIT+CIT,Tclin+Tclin,0.242,0.48,0.428,0,0,0,1,1,DC01866,Rituximab;Tazemetostat,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 2
3480,TP01071,EZH2;PARP1,EZH2,PARP1,CIT+CIT,Tclin+Tclin,0.452,0.73,0.546,0,0,0,1,1,DC01940,Talazoparib;Tazemetostat,DrugComb,FD00038,Prostate Cancer,Prostate Cancer,Phase 1
3481,TP01072,EZH2;PARP2,EZH2,PARP2,CIT+CIT,Tclin+Tclin,0.306,0.758,0.575,0,0,0,1,1,DC01940,Talazoparib;Tazemetostat,DrugComb,FD00038,Prostate Cancer,Prostate Cancer,Phase 1
3482,TP01073,EZH2;PDCD1,EZH2,PDCD1,CET+CIT,Tclin+Tclin,0.23,0.24,1.0,0,0,0,3,2,DC01760,Pembrolizumab;Valemetostat,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
3484,TP01073,EZH2;PDCD1,EZH2,PDCD1,CET+CIT,Tclin+Tclin,0.23,0.24,1.0,0,0,0,3,2,DC01728,Pembrolizumab;Tazemetostat,DrugComb,FD00018,Head and Neck Cancer,Head and Neck Cancer,Phase 1
3485,TP01074,EZH2;PIK3CD,EZH2,PIK3CD,CIT+CIT,Tclin+Tclin,0.331,0.469,0.333,2,0,2,1,1,DC01949,Tazemetostat;Zandelisib,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 1|Phase 2
3486,TP01075,F3;PDCD1,F3,PDCD1,CET+CIT,Tclin+Tclin,0.187,0.692,1.0,0,0,0,2,2,DC01601,Nivolumab;XB002,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
3488,TP01075,F3;PDCD1,F3,PDCD1,CET+CIT,Tclin+Tclin,0.187,0.692,1.0,0,0,0,2,2,DC01735,Pembrolizumab;Tisotumab Vedotin,DrugComb,FD00034,Ovarian Cancer,Ovarian Cancer,Phase 1|Phase 2
3489,TP01076,F3;VEGFA,F3,VEGFA,CET+CIT,Tclin+Tclin,0.443,0.634,0.542,1,0,1,2,2,DC00482,Bevacizumab;Tisotumab Vedotin,DrugComb,FD00034,Ovarian Cancer,Ovarian Cancer,Phase 1|Phase 2
3490,TP01076,F3;VEGFA,F3,VEGFA,CET+CIT,Tclin+Tclin,0.443,0.634,0.542,1,0,1,2,2,DC00488,Bevacizumab;XB002,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
3491,TP01077,FAP;IL2RA,FAP,IL2RA,CET+CIT,Tchem+Tclin,0.292,0.48,0.452,0,0,0,1,6,DC02263,Simlukafusp Alfa,BsAb,FD00007,Breast Cancer,Breast Cancer,Phase 1
3492,TP01077,FAP;IL2RA,FAP,IL2RA,CET+CIT,Tchem+Tclin,0.292,0.48,0.452,0,0,0,1,6,DC02263,Simlukafusp Alfa,BsAb,FD00018,Head and Neck Cancer,Head and Neck Cancer,Phase 2
3493,TP01077,FAP;IL2RA,FAP,IL2RA,CET+CIT,Tchem+Tclin,0.292,0.48,0.452,0,0,0,1,6,DC02263,Simlukafusp Alfa,BsAb,FD00020,Kidney Cancer,Kidney Cancer,Phase 1
3494,TP01077,FAP;IL2RA,FAP,IL2RA,CET+CIT,Tchem+Tclin,0.292,0.48,0.452,0,0,0,1,6,DC02263,Simlukafusp Alfa,BsAb,FD00026,Melanoma,Melanoma,Phase 1
3495,TP01077,FAP;IL2RA,FAP,IL2RA,CET+CIT,Tchem+Tclin,0.292,0.48,0.452,0,0,0,1,6,DC02263,Simlukafusp Alfa,BsAb,FD00034,Ovarian Cancer,Ovarian Cancer,Phase 2
3496,TP01077,FAP;IL2RA,FAP,IL2RA,CET+CIT,Tchem+Tclin,0.292,0.48,0.452,0,0,0,1,6,DC02263,Simlukafusp Alfa,BsAb,FD00041,Stomach Cancer,Stomach Cancer,Phase 2
3497,TP01078,FAP;IL2RB,FAP,IL2RB,CET+CIT,Tchem+Tclin,0.283,0.643,0.408,0,0,0,1,6,DC02263,Simlukafusp Alfa,BsAb,FD00007,Breast Cancer,Breast Cancer,Phase 1
3498,TP01078,FAP;IL2RB,FAP,IL2RB,CET+CIT,Tchem+Tclin,0.283,0.643,0.408,0,0,0,1,6,DC02263,Simlukafusp Alfa,BsAb,FD00018,Head and Neck Cancer,Head and Neck Cancer,Phase 2
3499,TP01078,FAP;IL2RB,FAP,IL2RB,CET+CIT,Tchem+Tclin,0.283,0.643,0.408,0,0,0,1,6,DC02263,Simlukafusp Alfa,BsAb,FD00020,Kidney Cancer,Kidney Cancer,Phase 1
3500,TP01078,FAP;IL2RB,FAP,IL2RB,CET+CIT,Tchem+Tclin,0.283,0.643,0.408,0,0,0,1,6,DC02263,Simlukafusp Alfa,BsAb,FD00026,Melanoma,Melanoma,Phase 1
3501,TP01078,FAP;IL2RB,FAP,IL2RB,CET+CIT,Tchem+Tclin,0.283,0.643,0.408,0,0,0,1,6,DC02263,Simlukafusp Alfa,BsAb,FD00034,Ovarian Cancer,Ovarian Cancer,Phase 2
3502,TP01078,FAP;IL2RB,FAP,IL2RB,CET+CIT,Tchem+Tclin,0.283,0.643,0.408,0,0,0,1,6,DC02263,Simlukafusp Alfa,BsAb,FD00041,Stomach Cancer,Stomach Cancer,Phase 2
3503,TP01079,FAP;IL2RG,FAP,IL2RG,CIT+CIT,Tchem+Tclin,0.252,0.653,0.397,0,0,0,1,6,DC02263,Simlukafusp Alfa,BsAb,FD00007,Breast Cancer,Breast Cancer,Phase 1
3504,TP01079,FAP;IL2RG,FAP,IL2RG,CIT+CIT,Tchem+Tclin,0.252,0.653,0.397,0,0,0,1,6,DC02263,Simlukafusp Alfa,BsAb,FD00018,Head and Neck Cancer,Head and Neck Cancer,Phase 2
3505,TP01079,FAP;IL2RG,FAP,IL2RG,CIT+CIT,Tchem+Tclin,0.252,0.653,0.397,0,0,0,1,6,DC02263,Simlukafusp Alfa,BsAb,FD00020,Kidney Cancer,Kidney Cancer,Phase 1
3506,TP01079,FAP;IL2RG,FAP,IL2RG,CIT+CIT,Tchem+Tclin,0.252,0.653,0.397,0,0,0,1,6,DC02263,Simlukafusp Alfa,BsAb,FD00026,Melanoma,Melanoma,Phase 1
3507,TP01079,FAP;IL2RG,FAP,IL2RG,CIT+CIT,Tchem+Tclin,0.252,0.653,0.397,0,0,0,1,6,DC02263,Simlukafusp Alfa,BsAb,FD00034,Ovarian Cancer,Ovarian Cancer,Phase 2
3508,TP01079,FAP;IL2RG,FAP,IL2RG,CIT+CIT,Tchem+Tclin,0.252,0.653,0.397,0,0,0,1,6,DC02263,Simlukafusp Alfa,BsAb,FD00041,Stomach Cancer,Stomach Cancer,Phase 2
3509,TP01080,FAP;PDCD1,FAP,PDCD1,CET+CIT,Tchem+Tclin,0.33,0.553,1.0,0,0,1,3,3,DC00510,BI765179;Ezabenlimab,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
3510,TP01080,FAP;PDCD1,FAP,PDCD1,CET+CIT,Tchem+Tclin,0.33,0.553,1.0,0,0,1,3,3,DC01542,NG641;Pembrolizumab,DrugComb,FD00018,Head and Neck Cancer,Head and Neck Cancer,Phase 1
3511,TP01080,FAP;PDCD1,FAP,PDCD1,CET+CIT,Tchem+Tclin,0.33,0.553,1.0,0,0,1,3,3,DC01715,Pembrolizumab;Simlukafusp Alfa,DrugComb,FD00026,Melanoma,Melanoma,Phase 1
3512,TP01081,FAP;TNFRSF9,FAP,TNFRSF9,CET+CIT,Tbio+Tchem,0.403,0.504,0.476,0,0,1,3,2,DC02243,RO7122290,BsAb,FD00011,Colorectal Cancer,Colorectal Cancer,Phase 1|Phase 2
3513,TP01081,FAP;TNFRSF9,FAP,TNFRSF9,CET+CIT,Tbio+Tchem,0.403,0.504,0.476,0,0,1,3,2,DC02196,MP0310,BsAb,FD00033,Other Cancer,Other Cancer,Phase 1
3515,TP01082,FASN;VEGFA,FASN,VEGFA,CET+CIT,Tchem+Tclin,0.276,0.676,0.376,0,0,1,1,1,DC00441,Bevacizumab;Denifanstat,DrugComb,FD00004,Astrocytoma,Other Cancer,Phase 2
3516,TP01083,FCGR3A;IL3RA,FCGR3A,IL3RA,CET+CIT,Tclin+Tclin,0.327,0.675,0.718,0,0,0,1,1,DC02007,AFM28,BsAb,FD00021,Leukemia,Hematologic Malignancy,Phase 1
3517,TP01084,FCGR3A;PDCD1,FCGR3A,PDCD1,CET+CET,Tclin+Tclin,0.483,0.721,1.0,0,0,0,1,1,DC00068,Acimtamig;Pembrolizumab,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 1
3518,TP01085,FCGR3A;TNFRSF17,FCGR3A,TNFRSF17,CET+CIT,Tclin+Tclin,0.522,0.651,0.744,0,0,0,1,1,DC02245,RO7297089,BsAb,FD00030,Myeloma,Hematologic Malignancy,Phase 1
3519,TP01086,FCGR3A;TNFRSF8,FCGR3A,TNFRSF8,CET+CIT,Tclin+Tclin,0.348,0.766,1.0,0,0,0,1,2,DC02004,Acimtamig,BsAb,FD00019,Hematologic Malignancies,Hematologic Malignancy,Phase 1|Phase 2
3520,TP01086,FCGR3A;TNFRSF8,FCGR3A,TNFRSF8,CET+CIT,Tclin+Tclin,0.348,0.766,1.0,0,0,0,1,2,DC02004,Acimtamig,BsAb,FD00024,Lymphoma,Hematologic Malignancy,Phase 2
3521,TP01087,FGFR1;MAP2K1,FGFR1,MAP2K1,CIT+CIT,Tclin+Tclin,0.582,0.706,0.735,13,0,13,1,1,DC00532,Binimetinib;Futibatinib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
3522,TP01088,FGFR1;MAP2K2,FGFR1,MAP2K2,CIT+CIT,Tclin+Tclin,0.472,0.676,0.731,12,0,13,1,1,DC00532,Binimetinib;Futibatinib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
3523,TP01089,FGFR1;MET,FGFR1,MET,CIT+CIT,Tclin+Tclin,0.632,0.815,0.856,10,0,8,1,1,DC01455,LY2874455;Merestinib,DrugComb,FD00021,Leukemia,Hematologic Malignancy,Phase 1
3524,TP01090,FGFR1;PDCD1,FGFR1,PDCD1,CET+CIT,Tclin+Tclin,0.299,0.603,1.0,0,0,0,8,4,DC01469,MAX40279;Toripalimab,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
3525,TP01090,FGFR1;PDCD1,FGFR1,PDCD1,CET+CIT,Tclin+Tclin,0.299,0.603,1.0,0,0,0,8,4,DC01452,Lucitanib;Nivolumab,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
3529,TP01090,FGFR1;PDCD1,FGFR1,PDCD1,CET+CIT,Tclin+Tclin,0.299,0.603,1.0,0,0,0,8,4,DC01784,Pemigatinib;Retifanlimab,DrugComb,FD00034,Ovarian Cancer,Ovarian Cancer,Phase 2
3531,TP01090,FGFR1;PDCD1,FGFR1,PDCD1,CET+CIT,Tclin+Tclin,0.299,0.603,1.0,0,0,0,8,4,DC01693,Pembrolizumab;Pemigatinib,DrugComb,FD00006,Bladder Cancer,Bladder Cancer,Phase 2
3536,TP01091,FGFR1;PIK3CA,FGFR1,PIK3CA,CIT+CIT,Tclin+Tclin,0.487,0.604,0.673,11,1,14,1,1,DC00151,Alpelisib;Infigratinib,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
3537,TP01092,FGFR2;MAP2K1,FGFR2,MAP2K1,CIT+CIT,Tclin+Tclin,0.529,0.686,0.736,11,0,13,1,1,DC00532,Binimetinib;Futibatinib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
3538,TP01093,FGFR2;MAP2K2,FGFR2,MAP2K2,CIT+CIT,Tclin+Tclin,0.235,0.673,0.732,11,0,13,1,1,DC00532,Binimetinib;Futibatinib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
3539,TP01094,FGFR2;MET,FGFR2,MET,CIT+CIT,Tclin+Tclin,0.53,0.755,0.847,9,0,9,1,1,DC01455,LY2874455;Merestinib,DrugComb,FD00021,Leukemia,Hematologic Malignancy,Phase 1
3540,TP01095,FGFR2;PDCD1,FGFR2,PDCD1,CET+CIT,Tclin+Tclin,0.39,0.537,1.0,0,0,0,7,4,DC01452,Lucitanib;Nivolumab,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
3541,TP01095,FGFR2;PDCD1,FGFR2,PDCD1,CET+CIT,Tclin+Tclin,0.39,0.537,1.0,0,0,0,7,4,DC00369,AZD4547;Tislelizumab,DrugComb,FD00006,Bladder Cancer,Bladder Cancer,Phase 2
3543,TP01095,FGFR2;PDCD1,FGFR2,PDCD1,CET+CIT,Tclin+Tclin,0.39,0.537,1.0,0,0,0,7,4,DC01784,Pemigatinib;Retifanlimab,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 2
3544,TP01095,FGFR2;PDCD1,FGFR2,PDCD1,CET+CIT,Tclin+Tclin,0.39,0.537,1.0,0,0,0,7,4,DC01784,Pemigatinib;Retifanlimab,DrugComb,FD00034,Ovarian Cancer,Ovarian Cancer,Phase 2
3551,TP01096,FGFR2;PIK3CA,FGFR2,PIK3CA,CIT+CIT,Tclin+Tclin,0.463,0.639,0.669,10,1,14,1,1,DC00151,Alpelisib;Infigratinib,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
3552,TP01097,FGFR3;MAP2K1,FGFR3,MAP2K1,CIT+CIT,Tclin+Tclin,0.545,0.775,0.763,11,0,12,1,1,DC00532,Binimetinib;Futibatinib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
3553,TP01098,FGFR3;MAP2K2,FGFR3,MAP2K2,CIT+CIT,Tclin+Tclin,0.465,0.744,0.762,11,0,12,1,1,DC00532,Binimetinib;Futibatinib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
3554,TP01099,FGFR3;MET,FGFR3,MET,CIT+CIT,Tclin+Tclin,0.562,0.748,0.906,9,0,8,1,1,DC01455,LY2874455;Merestinib,DrugComb,FD00021,Leukemia,Hematologic Malignancy,Phase 1
3555,TP01100,FGFR3;PDCD1,FGFR3,PDCD1,CET+CIT,Tclin+Tclin,0.325,0.468,1.0,0,0,0,8,4,DC01452,Lucitanib;Nivolumab,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
3556,TP01100,FGFR3;PDCD1,FGFR3,PDCD1,CET+CIT,Tclin+Tclin,0.325,0.468,1.0,0,0,0,8,4,DC01693,Pembrolizumab;Pemigatinib,DrugComb,FD00006,Bladder Cancer,Bladder Cancer,Phase 2
3558,TP01100,FGFR3;PDCD1,FGFR3,PDCD1,CET+CIT,Tclin+Tclin,0.325,0.468,1.0,0,0,0,8,4,DC01693,Pembrolizumab;Pemigatinib,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 2
3562,TP01100,FGFR3;PDCD1,FGFR3,PDCD1,CET+CIT,Tclin+Tclin,0.325,0.468,1.0,0,0,0,8,4,DC01784,Pemigatinib;Retifanlimab,DrugComb,FD00034,Ovarian Cancer,Ovarian Cancer,Phase 2
3567,TP01101,FGFR3;PIK3CA,FGFR3,PIK3CA,CIT+CIT,Tclin+Tclin,0.443,0.511,0.694,9,1,11,1,1,DC00151,Alpelisib;Infigratinib,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
3568,TP01102,FGFR4;MAP2K1,FGFR4,MAP2K1,CIT+CIT,Tclin+Tclin,0.557,0.736,0.72,7,0,8,1,1,DC00532,Binimetinib;Futibatinib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
3569,TP01103,FGFR4;MAP2K2,FGFR4,MAP2K2,CIT+CIT,Tclin+Tclin,0.482,0.748,0.714,7,0,9,1,1,DC00532,Binimetinib;Futibatinib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
3570,TP01104,FGFR4;MET,FGFR4,MET,CIT+CIT,Tclin+Tclin,0.56,0.707,0.831,6,4,7,1,1,DC01455,LY2874455;Merestinib,DrugComb,FD00021,Leukemia,Hematologic Malignancy,Phase 1
3571,TP01105,FGFR4;PDCD1,FGFR4,PDCD1,CET+CIT,Tclin+Tclin,0.228,0.468,1.0,0,0,0,2,2,DC01196,Futibatinib;Zimberelimab,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
3572,TP01105,FGFR4;PDCD1,FGFR4,PDCD1,CET+CIT,Tclin+Tclin,0.228,0.468,1.0,0,0,0,2,2,DC00719,Cetrelimab;Erdafitinib,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
3573,TP01106,FGFR4;PIK3CA,FGFR4,PIK3CA,CIT+CIT,Tclin+Tclin,0.445,0.555,0.669,6,7,9,1,1,DC00151,Alpelisib;Infigratinib,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
3574,TP01107,FLT1;GSAP,FLT1,GSAP,CET+CIT,Tchem+Tclin,0.128,0.452,0.409,0,0,0,1,1,DC00692,Cediranib;RO4929097,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
3575,TP01108,FLT1;MTOR,FLT1,MTOR,CET+CIT,Tclin+Tclin,0.395,0.427,0.702,2,0,8,3,3,DC00087,AEE788;Everolimus,DrugComb,FD00017,Glioma,Glioma,Phase 1|Phase 2
3576,TP01108,FLT1;MTOR,FLT1,MTOR,CET+CIT,Tclin+Tclin,0.395,0.427,0.702,2,0,8,3,3,DC01122,Everolimus;Tivozanib,DrugComb,FD00041,Stomach Cancer,Stomach Cancer,Phase 1|Phase 2
3577,TP01108,FLT1;MTOR,FLT1,MTOR,CET+CIT,Tclin+Tclin,0.395,0.427,0.702,2,0,8,3,3,DC01951,Temsirolimus;Tivozanib,DrugComb,FD00020,Kidney Cancer,Kidney Cancer,Phase 1
3578,TP01109,FLT1;PARP1,FLT1,PARP1,CET+CIT,Tclin+Tclin,0.353,0.516,0.515,0,0,1,1,4,DC00691,Cediranib;Olaparib,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 1|Phase 2
3579,TP01109,FLT1;PARP1,FLT1,PARP1,CET+CIT,Tclin+Tclin,0.353,0.516,0.515,0,0,1,1,4,DC00691,Cediranib;Olaparib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 2
3580,TP01109,FLT1;PARP1,FLT1,PARP1,CET+CIT,Tclin+Tclin,0.353,0.516,0.515,0,0,1,1,4,DC00691,Cediranib;Olaparib,DrugComb,FD00034,Ovarian Cancer,Ovarian Cancer,Phase 2
3581,TP01109,FLT1;PARP1,FLT1,PARP1,CET+CIT,Tclin+Tclin,0.353,0.516,0.515,0,0,1,1,4,DC00691,Cediranib;Olaparib,DrugComb,FD00038,Prostate Cancer,Prostate Cancer,Phase 2
3582,TP01110,FLT1;PARP2,FLT1,PARP2,CET+CIT,Tclin+Tclin,0.315,0.352,0.451,0,0,0,1,4,DC00691,Cediranib;Olaparib,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 1|Phase 2
3583,TP01110,FLT1;PARP2,FLT1,PARP2,CET+CIT,Tclin+Tclin,0.315,0.352,0.451,0,0,0,1,4,DC00691,Cediranib;Olaparib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 2
3584,TP01110,FLT1;PARP2,FLT1,PARP2,CET+CIT,Tclin+Tclin,0.315,0.352,0.451,0,0,0,1,4,DC00691,Cediranib;Olaparib,DrugComb,FD00034,Ovarian Cancer,Ovarian Cancer,Phase 2
3585,TP01110,FLT1;PARP2,FLT1,PARP2,CET+CIT,Tclin+Tclin,0.315,0.352,0.451,0,0,0,1,4,DC00691,Cediranib;Olaparib,DrugComb,FD00038,Prostate Cancer,Prostate Cancer,Phase 2
3586,TP01111,FLT1;PDCD1,FLT1,PDCD1,CET+CET,Tclin+Tclin,0.291,0.513,1.0,0,0,0,15,8,DC01600,Nivolumab;Vorolanib,DrugComb,FD00022,Liver Cancer,Liver Cancer,Phase 1
3587,TP01111,FLT1;PDCD1,FLT1,PDCD1,CET+CET,Tclin+Tclin,0.291,0.513,1.0,0,0,0,15,8,DC01600,Nivolumab;Vorolanib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
3588,TP01111,FLT1;PDCD1,FLT1,PDCD1,CET+CET,Tclin+Tclin,0.291,0.513,1.0,0,0,0,15,8,DC01600,Nivolumab;Vorolanib,DrugComb,FD00041,Stomach Cancer,Stomach Cancer,Phase 1
3589,TP01111,FLT1;PDCD1,FLT1,PDCD1,CET+CET,Tclin+Tclin,0.291,0.513,1.0,0,0,0,15,8,DC01600,Nivolumab;Vorolanib,DrugComb,FD00042,Thymic Carcinoma,Other Cancer,Phase 1|Phase 2
3593,TP01111,FLT1;PDCD1,FLT1,PDCD1,CET+CET,Tclin+Tclin,0.291,0.513,1.0,0,0,0,15,8,DC00368,Axitinib;Toripalimab,DrugComb,FD00020,Kidney Cancer,Kidney Cancer,Phase 2
3595,TP01111,FLT1;PDCD1,FLT1,PDCD1,CET+CET,Tclin+Tclin,0.291,0.513,1.0,0,0,0,15,8,DC00368,Axitinib;Toripalimab,DrugComb,FD00026,Melanoma,Melanoma,Phase 2
3603,TP01111,FLT1;PDCD1,FLT1,PDCD1,CET+CET,Tclin+Tclin,0.291,0.513,1.0,0,0,0,15,8,DC01155,Fruquintinib;Toripalimab,DrugComb,FD00011,Colorectal Cancer,Colorectal Cancer,Phase 2
3604,TP01111,FLT1;PDCD1,FLT1,PDCD1,CET+CET,Tclin+Tclin,0.291,0.513,1.0,0,0,0,15,8,DC01154,Fruquintinib;Tislelizumab,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 2
3610,TP01112,FLT1;PIK3CA,FLT1,PIK3CA,CET+CIT,Tclin+Tclin,0.483,0.492,0.684,5,0,7,1,1,DC01809,Pilaralisib;Tesevatinib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
3611,TP01113,FLT1;PIK3CB,FLT1,PIK3CB,CET+CIT,Tchem+Tclin,0.508,0.508,0.658,5,0,5,1,1,DC01809,Pilaralisib;Tesevatinib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
3612,TP01114,FLT1;PIK3CD,FLT1,PIK3CD,CET+CIT,Tclin+Tclin,0.559,0.533,0.65,5,0,5,1,1,DC01809,Pilaralisib;Tesevatinib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
3613,TP01115,FLT1;PIK3CG,FLT1,PIK3CG,CET+CIT,Tclin+Tclin,0.494,0.515,0.735,1,0,3,1,1,DC01809,Pilaralisib;Tesevatinib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
3614,TP01116,FLT1;VEGFA,FLT1,VEGFA,CET+CET,Tclin+Tclin,0.581,0.6,0.491,8,1,9,1,1,DC00435,Bevacizumab;Cediranib,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
3615,TP01117,FLT3;IL2RB,FLT3,IL2RB,CET+CIT,Tclin+Tclin,0.438,0.739,0.622,3,1,2,1,1,DC00424,Bempegaldesleukin;Mivavotinib,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 1
3616,TP01118,FLT3;PDCD1,FLT3,PDCD1,CET+CIT,Tclin+Tclin,0.353,0.48,1.0,0,0,0,2,4,DC01476,Mivavotinib;Nivolumab,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 1
3617,TP01118,FLT3;PDCD1,FLT3,PDCD1,CET+CIT,Tclin+Tclin,0.353,0.48,1.0,0,0,0,2,4,DC01476,Mivavotinib;Nivolumab,DrugComb,FD00018,Head and Neck Cancer,Head and Neck Cancer,Phase 1
3618,TP01118,FLT3;PDCD1,FLT3,PDCD1,CET+CIT,Tclin+Tclin,0.353,0.48,1.0,0,0,0,2,4,DC01476,Mivavotinib;Nivolumab,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
3619,TP01118,FLT3;PDCD1,FLT3,PDCD1,CET+CIT,Tclin+Tclin,0.353,0.48,1.0,0,0,0,2,4,DC01469,MAX40279;Toripalimab,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
3620,TP01119,FLT3;PIK3CA,FLT3,PIK3CA,CIT+CIT,Tclin+Tclin,0.48,0.574,0.658,5,7,5,1,1,DC01477,Mivavotinib;Serabelisib,DrugComb,FD00041,Stomach Cancer,Stomach Cancer,Phase 1
3621,TP01120,FLT3;SYK,FLT3,SYK,CIT+CIT,Tclin+Tclin,0.465,0.741,0.755,1,1,1,1,1,DC01232,Gilteritinib;Lanraplenib,DrugComb,FD00021,Leukemia,Hematologic Malignancy,Phase 1|Phase 2
3622,TP01121,FLT4;GSAP,FLT4,GSAP,CET+CIT,Tchem+Tclin,0.137,0.411,0.474,0,0,0,1,1,DC00692,Cediranib;RO4929097,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
3623,TP01122,FLT4;MTOR,FLT4,MTOR,CET+CIT,Tclin+Tclin,0.415,0.585,0.699,3,0,6,3,3,DC00087,AEE788;Everolimus,DrugComb,FD00017,Glioma,Glioma,Phase 1|Phase 2
3624,TP01122,FLT4;MTOR,FLT4,MTOR,CET+CIT,Tclin+Tclin,0.415,0.585,0.699,3,0,6,3,3,DC01951,Temsirolimus;Tivozanib,DrugComb,FD00020,Kidney Cancer,Kidney Cancer,Phase 1
3625,TP01122,FLT4;MTOR,FLT4,MTOR,CET+CIT,Tclin+Tclin,0.415,0.585,0.699,3,0,6,3,3,DC01122,Everolimus;Tivozanib,DrugComb,FD00041,Stomach Cancer,Stomach Cancer,Phase 1|Phase 2
3626,TP01123,FLT4;PARP1,FLT4,PARP1,CET+CIT,Tclin+Tclin,0.367,0.634,0.54,0,0,1,1,4,DC00691,Cediranib;Olaparib,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 1|Phase 2
3627,TP01123,FLT4;PARP1,FLT4,PARP1,CET+CIT,Tclin+Tclin,0.367,0.634,0.54,0,0,1,1,4,DC00691,Cediranib;Olaparib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 2
3628,TP01123,FLT4;PARP1,FLT4,PARP1,CET+CIT,Tclin+Tclin,0.367,0.634,0.54,0,0,1,1,4,DC00691,Cediranib;Olaparib,DrugComb,FD00034,Ovarian Cancer,Ovarian Cancer,Phase 2
3629,TP01123,FLT4;PARP1,FLT4,PARP1,CET+CIT,Tclin+Tclin,0.367,0.634,0.54,0,0,1,1,4,DC00691,Cediranib;Olaparib,DrugComb,FD00038,Prostate Cancer,Prostate Cancer,Phase 2
3630,TP01124,FLT4;PARP2,FLT4,PARP2,CET+CIT,Tclin+Tclin,0.317,0.52,0.479,0,0,0,1,4,DC00691,Cediranib;Olaparib,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 1|Phase 2
3631,TP01124,FLT4;PARP2,FLT4,PARP2,CET+CIT,Tclin+Tclin,0.317,0.52,0.479,0,0,0,1,4,DC00691,Cediranib;Olaparib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 2
3632,TP01124,FLT4;PARP2,FLT4,PARP2,CET+CIT,Tclin+Tclin,0.317,0.52,0.479,0,0,0,1,4,DC00691,Cediranib;Olaparib,DrugComb,FD00034,Ovarian Cancer,Ovarian Cancer,Phase 2
3633,TP01124,FLT4;PARP2,FLT4,PARP2,CET+CIT,Tclin+Tclin,0.317,0.52,0.479,0,0,0,1,4,DC00691,Cediranib;Olaparib,DrugComb,FD00038,Prostate Cancer,Prostate Cancer,Phase 2
3634,TP01125,FLT4;PDCD1,FLT4,PDCD1,CET+CET,Tclin+Tclin,0.37,0.57,1.0,0,0,0,16,8,DC01770,Pembrolizumab;Vorolanib,DrugComb,FD00022,Liver Cancer,Liver Cancer,Phase 1
3635,TP01125,FLT4;PDCD1,FLT4,PDCD1,CET+CET,Tclin+Tclin,0.37,0.57,1.0,0,0,0,16,8,DC01770,Pembrolizumab;Vorolanib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
3636,TP01125,FLT4;PDCD1,FLT4,PDCD1,CET+CET,Tclin+Tclin,0.37,0.57,1.0,0,0,0,16,8,DC01770,Pembrolizumab;Vorolanib,DrugComb,FD00041,Stomach Cancer,Stomach Cancer,Phase 1
3640,TP01125,FLT4;PDCD1,FLT4,PDCD1,CET+CET,Tclin+Tclin,0.37,0.57,1.0,0,0,0,16,8,DC01600,Nivolumab;Vorolanib,DrugComb,FD00042,Thymic Carcinoma,Other Cancer,Phase 1|Phase 2
3641,TP01125,FLT4;PDCD1,FLT4,PDCD1,CET+CET,Tclin+Tclin,0.37,0.57,1.0,0,0,0,16,8,DC00363,Axitinib;Nivolumab,DrugComb,FD00020,Kidney Cancer,Kidney Cancer,Phase 2
3645,TP01125,FLT4;PDCD1,FLT4,PDCD1,CET+CET,Tclin+Tclin,0.37,0.57,1.0,0,0,0,16,8,DC00368,Axitinib;Toripalimab,DrugComb,FD00026,Melanoma,Melanoma,Phase 2
3653,TP01125,FLT4;PDCD1,FLT4,PDCD1,CET+CET,Tclin+Tclin,0.37,0.57,1.0,0,0,0,16,8,DC01155,Fruquintinib;Toripalimab,DrugComb,FD00011,Colorectal Cancer,Colorectal Cancer,Phase 2
3656,TP01125,FLT4;PDCD1,FLT4,PDCD1,CET+CET,Tclin+Tclin,0.37,0.57,1.0,0,0,0,16,8,DC01154,Fruquintinib;Tislelizumab,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 2
3660,TP01126,FLT4;PIK3CA,FLT4,PIK3CA,CET+CIT,Tclin+Tclin,0.533,0.596,0.681,6,0,6,1,1,DC01809,Pilaralisib;Tesevatinib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
3661,TP01127,FLT4;PIK3CB,FLT4,PIK3CB,CET+CIT,Tchem+Tclin,0.493,0.719,0.66,6,0,5,1,1,DC01809,Pilaralisib;Tesevatinib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
3662,TP01128,FLT4;PIK3CD,FLT4,PIK3CD,CET+CIT,Tclin+Tclin,0.502,0.66,0.653,6,0,6,1,1,DC01809,Pilaralisib;Tesevatinib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
3663,TP01129,FLT4;PIK3CG,FLT4,PIK3CG,CET+CIT,Tclin+Tclin,0.461,0.631,0.73,1,0,3,1,1,DC01809,Pilaralisib;Tesevatinib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
3664,TP01130,FLT4;VEGFA,FLT4,VEGFA,CET+CET,Tclin+Tclin,0.621,0.599,0.556,7,1,4,1,1,DC00435,Bevacizumab;Cediranib,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
3665,TP01131,FNTB;PIK3CA,FNTB,PIK3CA,CIT+CIT,Tclin+Tclin,0.163,0.539,0.353,0,0,0,1,1,DC00160,Alpelisib;Tipifarnib,DrugComb,FD00018,Head and Neck Cancer,Head and Neck Cancer,Phase 1|Phase 2
3666,TP01132,FNTB;RARA,FNTB,RARA,CIT+CIT,Tclin+Tclin,0.136,0.551,0.49,0,0,0,1,1,DC01144,Fenretinide;Lonafarnib,DrugComb,FD00018,Head and Neck Cancer,Head and Neck Cancer,Phase 1
3667,TP01133,FNTB;RARB,FNTB,RARB,CIT+CIT,Tclin+Tclin,0.101,0.576,0.386,0,0,0,1,1,DC01144,Fenretinide;Lonafarnib,DrugComb,FD00018,Head and Neck Cancer,Head and Neck Cancer,Phase 1
3668,TP01134,FNTB;RARG,FNTB,RARG,CIT+CIT,Tclin+Tclin,0.101,0.521,0.487,0,0,0,1,1,DC01144,Fenretinide;Lonafarnib,DrugComb,FD00018,Head and Neck Cancer,Head and Neck Cancer,Phase 1
3669,TP01135,FOLH1;FOLR1,FOLH1,FOLR1,CET+CIT,Tclin+Tclin,0.144,0.691,0.282,0,0,1,1,1,DC02055,CBP1018,BsAb,FD00033,Other Cancer,Other Cancer,Phase 1
3670,TP01136,FOLR1;PARP1,FOLR1,PARP1,CIT+CIT,Tclin+Tclin,0.254,0.552,0.487,0,0,0,1,2,DC00371,AZD5335;Saruparib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
3671,TP01136,FOLR1;PARP1,FOLR1,PARP1,CIT+CIT,Tclin+Tclin,0.254,0.552,0.487,0,0,0,1,2,DC00371,AZD5335;Saruparib,DrugComb,FD00034,Ovarian Cancer,Ovarian Cancer,Phase 1|Phase 2
3672,TP01137,FOLR1;PARP2,FOLR1,PARP2,CIT+CIT,Tclin+Tclin,0.2,0.419,0.402,0,0,0,1,2,DC00371,AZD5335;Saruparib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
3673,TP01137,FOLR1;PARP2,FOLR1,PARP2,CIT+CIT,Tclin+Tclin,0.2,0.419,0.402,0,0,0,1,2,DC00371,AZD5335;Saruparib,DrugComb,FD00034,Ovarian Cancer,Ovarian Cancer,Phase 1|Phase 2
3674,TP01138,FOLR1;PDCD1,FOLR1,PDCD1,CET+CIT,Tclin+Tclin,0.22,0.474,1.0,0,0,0,1,1,DC01475,Mirvetuximab Soravtansine;Pembrolizumab,DrugComb,FD00034,Ovarian Cancer,Ovarian Cancer,Phase 1|Phase 2
3675,TP01139,FOLR1;TRPV6,FOLR1,TRPV6,CIT+CIT,Tchem+Tclin,0.143,0.437,0.477,0,0,0,1,1,DC02054,CBP1008,BsAb,FD00033,Other Cancer,Other Cancer,Phase 1
3676,TP01140,FOLR1;VEGFA,FOLR1,VEGFA,CET+CIT,Tclin+Tclin,0.3,0.596,0.535,0,0,0,2,1,DC00456,Bevacizumab;Luveltamab Tazevibulin,DrugComb,FD00034,Ovarian Cancer,Ovarian Cancer,Phase 1
3678,TP01141,GEM;MS4A1,GEM,MS4A1,CIT+CIT,Tbio+Tclin,0.459,0.616,0.484,0,0,0,1,1,DC01442,Lirilumab;Rituximab,DrugComb,FD00021,Leukemia,Hematologic Malignancy,Phase 2
3679,TP01142,GLS2;MTOR,GLS2,MTOR,CIT+CIT,Tchem+Tclin,0.203,0.478,0.38,2,1,2,2,2,DC01890,Sapanisertib;Telaglenastat,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
3680,TP01142,GLS2;MTOR,GLS2,MTOR,CIT+CIT,Tchem+Tclin,0.203,0.478,0.38,2,1,2,2,2,DC01120,Everolimus;Telaglenastat,DrugComb,FD00020,Kidney Cancer,Kidney Cancer,Phase 2
3681,TP01143,GLS2;PARP1,GLS2,PARP1,CIT+CIT,Tchem+Tclin,0.251,0.518,0.503,0,0,0,1,2,DC01941,Talazoparib;Telaglenastat,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1|Phase 2
3682,TP01143,GLS2;PARP1,GLS2,PARP1,CIT+CIT,Tchem+Tclin,0.251,0.518,0.503,0,0,0,1,2,DC01941,Talazoparib;Telaglenastat,DrugComb,FD00038,Prostate Cancer,Prostate Cancer,Phase 2
3683,TP01144,GLS2;PARP2,GLS2,PARP2,CIT+CIT,Tchem+Tclin,0.341,0.626,0.43,0,0,0,1,2,DC01941,Talazoparib;Telaglenastat,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1|Phase 2
3684,TP01144,GLS2;PARP2,GLS2,PARP2,CIT+CIT,Tchem+Tclin,0.341,0.626,0.43,0,0,0,1,2,DC01941,Talazoparib;Telaglenastat,DrugComb,FD00038,Prostate Cancer,Prostate Cancer,Phase 2
3685,TP01145,GLS2;PDCD1,GLS2,PDCD1,CET+CIT,Tchem+Tclin,0.278,0.185,1.0,0,0,0,1,3,DC01585,Nivolumab;Telaglenastat,DrugComb,FD00020,Kidney Cancer,Kidney Cancer,Phase 1|Phase 2
3686,TP01145,GLS2;PDCD1,GLS2,PDCD1,CET+CIT,Tchem+Tclin,0.278,0.185,1.0,0,0,0,1,3,DC01585,Nivolumab;Telaglenastat,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
3687,TP01145,GLS2;PDCD1,GLS2,PDCD1,CET+CIT,Tchem+Tclin,0.278,0.185,1.0,0,0,0,1,3,DC01585,Nivolumab;Telaglenastat,DrugComb,FD00026,Melanoma,Melanoma,Phase 1|Phase 2
3688,TP01146,GNA11;GNAQ,GNA11,GNAQ,CIT+CIT,Tbio+Tchem,0.607,0.935,0.932,19,9,9,1,1,DC02084,DYP688,BsAb,FD00026,Melanoma,Melanoma,Phase 1|Phase 2
3689,TP01147,GSAP;IGF1,GSAP,IGF1,CIT+CIT,Tbio+Tchem,0.163,0.371,0.636,0,0,0,1,1,DC01557,Nirogacestat;Xentuzumab,DrugComb,FD00030,Myeloma,Hematologic Malignancy,Phase 1
3690,TP01148,GSAP;IGF2,GSAP,IGF2,CIT+CIT,Tbio+Tchem,0.174,0.293,0.569,0,0,0,1,1,DC01557,Nirogacestat;Xentuzumab,DrugComb,FD00030,Myeloma,Hematologic Malignancy,Phase 1
3691,TP01149,GSAP;KDR,GSAP,KDR,CET+CIT,Tchem+Tclin,0.117,0.805,0.5,0,0,0,1,1,DC00692,Cediranib;RO4929097,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
3692,TP01150,GSAP;TNFRSF17,GSAP,TNFRSF17,CIT+CIT,Tchem+Tclin,0.109,0.407,0.645,0,0,0,1,1,DC01556,Nirogacestat;Teclistamab,DrugComb,FD00030,Myeloma,Hematologic Malignancy,Phase 1
3693,TP01151,HAVCR2;PDCD1,HAVCR2,PDCD1,CET+CET,Tchem+Tclin,0.33,0.678,1.0,0,0,1,9,7,DC01934,Surzebiclimab;Tislelizumab,DrugComb,FD00018,Head and Neck Cancer,Head and Neck Cancer,Phase 2
3694,TP01151,HAVCR2;PDCD1,HAVCR2,PDCD1,CET+CET,Tchem+Tclin,0.33,0.678,1.0,0,0,1,9,7,DC01934,Surzebiclimab;Tislelizumab,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
3696,TP01151,HAVCR2;PDCD1,HAVCR2,PDCD1,CET+CET,Tchem+Tclin,0.33,0.678,1.0,0,0,1,9,7,DC01788,Penpulimab;TQB2618,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 1|Phase 2
3697,TP01151,HAVCR2;PDCD1,HAVCR2,PDCD1,CET+CET,Tchem+Tclin,0.33,0.678,1.0,0,0,1,9,7,DC00791,Cobolimab;Dostarlimab,DrugComb,FD00022,Liver Cancer,Liver Cancer,Phase 2
3699,TP01151,HAVCR2;PDCD1,HAVCR2,PDCD1,CET+CET,Tchem+Tclin,0.33,0.678,1.0,0,0,1,9,7,DC01967,TQB2618;Teriprizumab,DrugComb,FD00026,Melanoma,Melanoma,Phase 1
3700,TP01151,HAVCR2;PDCD1,HAVCR2,PDCD1,CET+CET,Tchem+Tclin,0.33,0.678,1.0,0,0,1,9,7,DC01937,Sym021;Sym023,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
3705,TP01151,HAVCR2;PDCD1,HAVCR2,PDCD1,CET+CET,Tchem+Tclin,0.33,0.678,1.0,0,0,1,9,7,DC02176,Lomvastomig,BsAb,FD00014,Esophageal Cancer,Esophageal Cancer,Phase 2
3708,TP01152,HDAC1;JAK1,HDAC1,JAK1,CIT+CIT,Tclin+Tclin,0.338,0.646,0.469,4,1,2,2,2,DC01962,Tofacitinib;Tucidinostat,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 2
3709,TP01152,HDAC1;JAK1,HDAC1,JAK1,CIT+CIT,Tclin+Tclin,0.338,0.646,0.469,4,1,2,2,2,DC01670,Panobinostat;Ruxolitinib,DrugComb,FD00030,Myeloma,Hematologic Malignancy,Phase 1|Phase 2
3710,TP01153,HDAC1;JAK2,HDAC1,JAK2,CIT+CIT,Tclin+Tclin,0.479,0.646,0.52,1,2,3,2,2,DC01670,Panobinostat;Ruxolitinib,DrugComb,FD00030,Myeloma,Hematologic Malignancy,Phase 1|Phase 2
3711,TP01153,HDAC1;JAK2,HDAC1,JAK2,CIT+CIT,Tclin+Tclin,0.479,0.646,0.52,1,2,3,2,2,DC01962,Tofacitinib;Tucidinostat,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 2
3712,TP01154,HDAC1;JAK3,HDAC1,JAK3,CIT+CIT,Tclin+Tclin,0.4,0.515,0.466,3,1,1,1,1,DC01962,Tofacitinib;Tucidinostat,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 2
3713,TP01155,HDAC1;MS4A1,HDAC1,MS4A1,CIT+CIT,Tclin+Tclin,0.22,0.473,0.476,0,0,0,1,1,DC01669,Panobinostat;Rituximab,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 2
3714,TP01156,HDAC1;MTOR,HDAC1,MTOR,CIT+CIT,Tclin+Tclin,0.413,0.646,0.516,7,1,4,4,4,DC01110,Everolimus;Panobinostat,DrugComb,FD00017,Glioma,Glioma,Phase 2
3715,TP01156,HDAC1;MTOR,HDAC1,MTOR,CIT+CIT,Tclin+Tclin,0.413,0.646,0.516,7,1,4,4,4,DC01110,Everolimus;Panobinostat,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 1|Phase 2
3716,TP01156,HDAC1;MTOR,HDAC1,MTOR,CIT+CIT,Tclin+Tclin,0.413,0.646,0.516,7,1,4,4,4,DC01954,Temsirolimus;Vorinostat,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
3717,TP01156,HDAC1;MTOR,HDAC1,MTOR,CIT+CIT,Tclin+Tclin,0.413,0.646,0.516,7,1,4,4,4,DC01954,Temsirolimus;Vorinostat,DrugComb,FD00038,Prostate Cancer,Prostate Cancer,Phase 1
3720,TP01157,HDAC1;PDCD1,HDAC1,PDCD1,CET+CIT,Tclin+Tclin,0.297,0.233,1.0,0,1,0,12,7,DC01902,Sintilimab;Tucidinostat,DrugComb,FD00011,Colorectal Cancer,Colorectal Cancer,Phase 2
3721,TP01157,HDAC1;PDCD1,HDAC1,PDCD1,CET+CIT,Tclin+Tclin,0.297,0.233,1.0,0,1,0,12,7,DC01902,Sintilimab;Tucidinostat,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 2
3722,TP01157,HDAC1;PDCD1,HDAC1,PDCD1,CET+CIT,Tclin+Tclin,0.297,0.233,1.0,0,1,0,12,7,DC01902,Sintilimab;Tucidinostat,DrugComb,FD00032,Neuroendocrine Tumor,Other Cancer,Phase 2
3723,TP01157,HDAC1;PDCD1,HDAC1,PDCD1,CET+CIT,Tclin+Tclin,0.297,0.233,1.0,0,1,0,12,7,DC01769,Pembrolizumab;Vorinostat,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 2
3726,TP01157,HDAC1;PDCD1,HDAC1,PDCD1,CET+CIT,Tclin+Tclin,0.297,0.233,1.0,0,1,0,12,7,DC01001,Entinostat;Pembrolizumab,DrugComb,FD00026,Melanoma,Melanoma,Phase 2
3727,TP01157,HDAC1;PDCD1,HDAC1,PDCD1,CET+CIT,Tclin+Tclin,0.297,0.233,1.0,0,1,0,12,7,DC01001,Entinostat;Pembrolizumab,DrugComb,FD00030,Myeloma,Hematologic Malignancy,Phase 1
3728,TP01157,HDAC1;PDCD1,HDAC1,PDCD1,CET+CIT,Tclin+Tclin,0.297,0.233,1.0,0,1,0,12,7,DC01000,Entinostat;Nivolumab,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1|Phase 2
3738,TP01158,HDAC1;PIK3CA,HDAC1,PIK3CA,CIT+CIT,Tclin+Tclin,0.407,0.477,0.402,9,0,2,1,1,DC00804,Copanlisib;Romidepsin,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 1
3739,TP01159,HDAC1;PIK3CD,HDAC1,PIK3CD,CIT+CIT,Tclin+Tclin,0.346,0.486,0.397,9,0,1,5,1,DC01881,Romidepsin;Tenalisib,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 1|Phase 2
3744,TP01160,HDAC1;PIK3CG,HDAC1,PIK3CG,CIT+CIT,Tclin+Tclin,0.316,0.478,0.417,0,0,0,2,1,DC00958,Duvelisib;Romidepsin,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 1
3746,TP01161,HDAC1;RXRA,HDAC1,RXRA,CIT+CIT,Tclin+Tclin,0.478,0.825,0.633,3,1,2,3,3,DC01357,Isotretinoin;Vorinostat,DrugComb,FD00020,Kidney Cancer,Kidney Cancer,Phase 1|Phase 2
3747,TP01161,HDAC1;RXRA,HDAC1,RXRA,CIT+CIT,Tclin+Tclin,0.478,0.825,0.633,3,1,2,3,3,DC01357,Isotretinoin;Vorinostat,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 1
3748,TP01161,HDAC1;RXRA,HDAC1,RXRA,CIT+CIT,Tclin+Tclin,0.478,0.825,0.633,3,1,2,3,3,DC01357,Isotretinoin;Vorinostat,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
3751,TP01162,HDAC1;RXRB,HDAC1,RXRB,CIT+CIT,Tclin+Tclin,0.466,0.797,0.573,3,0,1,3,3,DC01357,Isotretinoin;Vorinostat,DrugComb,FD00020,Kidney Cancer,Kidney Cancer,Phase 1|Phase 2
3752,TP01162,HDAC1;RXRB,HDAC1,RXRB,CIT+CIT,Tclin+Tclin,0.466,0.797,0.573,3,0,1,3,3,DC01357,Isotretinoin;Vorinostat,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 1
3753,TP01162,HDAC1;RXRB,HDAC1,RXRB,CIT+CIT,Tclin+Tclin,0.466,0.797,0.573,3,0,1,3,3,DC01357,Isotretinoin;Vorinostat,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
3756,TP01163,HDAC1;RXRG,HDAC1,RXRG,CIT+CIT,Tclin+Tclin,0.483,0.765,0.57,3,0,1,2,3,DC01357,Isotretinoin;Vorinostat,DrugComb,FD00020,Kidney Cancer,Kidney Cancer,Phase 1|Phase 2
3757,TP01163,HDAC1;RXRG,HDAC1,RXRG,CIT+CIT,Tclin+Tclin,0.483,0.765,0.57,3,0,1,2,3,DC01357,Isotretinoin;Vorinostat,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 1
3758,TP01163,HDAC1;RXRG,HDAC1,RXRG,CIT+CIT,Tclin+Tclin,0.483,0.765,0.57,3,0,1,2,3,DC01357,Isotretinoin;Vorinostat,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
3760,TP01164,HDAC1;VEGFA,HDAC1,VEGFA,CET+CIT,Tclin+Tclin,0.486,0.448,0.49,3,0,3,3,4,DC00485,Bevacizumab;Tucidinostat,DrugComb,FD00014,Esophageal Cancer,Esophageal Cancer,Phase 2
3761,TP01164,HDAC1;VEGFA,HDAC1,VEGFA,CET+CIT,Tclin+Tclin,0.486,0.448,0.49,3,0,3,3,4,DC00485,Bevacizumab;Tucidinostat,DrugComb,FD00041,Stomach Cancer,Stomach Cancer,Phase 2
3762,TP01164,HDAC1;VEGFA,HDAC1,VEGFA,CET+CIT,Tclin+Tclin,0.486,0.448,0.49,3,0,3,3,4,DC00487,Bevacizumab;Vorinostat,DrugComb,FD00020,Kidney Cancer,Kidney Cancer,Phase 1|Phase 2
3763,TP01164,HDAC1;VEGFA,HDAC1,VEGFA,CET+CIT,Tclin+Tclin,0.486,0.448,0.49,3,0,3,3,4,DC00469,Bevacizumab;Panobinostat,DrugComb,FD00017,Glioma,Glioma,Phase 1|Phase 2
3764,TP01165,HDAC10;JAK1,HDAC10,JAK1,CIT+CIT,Tclin+Tclin,0.237,0.713,0.5,1,0,0,2,2,DC01670,Panobinostat;Ruxolitinib,DrugComb,FD00030,Myeloma,Hematologic Malignancy,Phase 1|Phase 2
3765,TP01165,HDAC10;JAK1,HDAC10,JAK1,CIT+CIT,Tclin+Tclin,0.237,0.713,0.5,1,0,0,2,2,DC01962,Tofacitinib;Tucidinostat,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 2
3766,TP01166,HDAC10;JAK2,HDAC10,JAK2,CIT+CIT,Tclin+Tclin,0.236,0.622,0.549,0,0,0,2,2,DC01670,Panobinostat;Ruxolitinib,DrugComb,FD00030,Myeloma,Hematologic Malignancy,Phase 1|Phase 2
3767,TP01166,HDAC10;JAK2,HDAC10,JAK2,CIT+CIT,Tclin+Tclin,0.236,0.622,0.549,0,0,0,2,2,DC01962,Tofacitinib;Tucidinostat,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 2
3768,TP01167,HDAC10;JAK3,HDAC10,JAK3,CIT+CIT,Tclin+Tclin,0.223,0.517,0.455,1,0,0,1,1,DC01962,Tofacitinib;Tucidinostat,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 2
3769,TP01168,HDAC10;MS4A1,HDAC10,MS4A1,CIT+CIT,Tclin+Tclin,0.135,0.516,0.467,0,0,0,1,1,DC01669,Panobinostat;Rituximab,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 2
3770,TP01169,HDAC10;MTOR,HDAC10,MTOR,CIT+CIT,Tclin+Tclin,0.278,0.641,0.423,1,0,0,4,4,DC01110,Everolimus;Panobinostat,DrugComb,FD00017,Glioma,Glioma,Phase 2
3771,TP01169,HDAC10;MTOR,HDAC10,MTOR,CIT+CIT,Tclin+Tclin,0.278,0.641,0.423,1,0,0,4,4,DC01110,Everolimus;Panobinostat,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 1|Phase 2
3772,TP01169,HDAC10;MTOR,HDAC10,MTOR,CIT+CIT,Tclin+Tclin,0.278,0.641,0.423,1,0,0,4,4,DC01911,Sirolimus;Vorinostat,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
3775,TP01169,HDAC10;MTOR,HDAC10,MTOR,CIT+CIT,Tclin+Tclin,0.278,0.641,0.423,1,0,0,4,4,DC01954,Temsirolimus;Vorinostat,DrugComb,FD00038,Prostate Cancer,Prostate Cancer,Phase 1
3776,TP01170,HDAC10;PDCD1,HDAC10,PDCD1,CET+CIT,Tclin+Tclin,0.114,0.262,1.0,0,0,0,6,5,DC01769,Pembrolizumab;Vorinostat,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 2
3777,TP01170,HDAC10;PDCD1,HDAC10,PDCD1,CET+CIT,Tclin+Tclin,0.114,0.262,1.0,0,0,0,6,5,DC01902,Sintilimab;Tucidinostat,DrugComb,FD00011,Colorectal Cancer,Colorectal Cancer,Phase 2
3778,TP01170,HDAC10;PDCD1,HDAC10,PDCD1,CET+CIT,Tclin+Tclin,0.114,0.262,1.0,0,0,0,6,5,DC01902,Sintilimab;Tucidinostat,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 2
3779,TP01170,HDAC10;PDCD1,HDAC10,PDCD1,CET+CIT,Tclin+Tclin,0.114,0.262,1.0,0,0,0,6,5,DC01902,Sintilimab;Tucidinostat,DrugComb,FD00032,Neuroendocrine Tumor,Other Cancer,Phase 2
3782,TP01170,HDAC10;PDCD1,HDAC10,PDCD1,CET+CIT,Tclin+Tclin,0.114,0.262,1.0,0,0,0,6,5,DC01672,Panobinostat;Spartalizumab,DrugComb,FD00026,Melanoma,Melanoma,Phase 1
3785,TP01171,HDAC10;PIK3CD,HDAC10,PIK3CD,CIT+CIT,Tclin+Tclin,0.206,0.519,0.348,2,0,0,1,1,DC01678,Parsaclisib;Tucidinostat,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 1|Phase 2
3786,TP01172,HDAC10;RXRA,HDAC10,RXRA,CIT+CIT,Tclin+Tclin,0.374,0.725,0.446,0,0,0,2,3,DC01357,Isotretinoin;Vorinostat,DrugComb,FD00020,Kidney Cancer,Kidney Cancer,Phase 1|Phase 2
3787,TP01172,HDAC10;RXRA,HDAC10,RXRA,CIT+CIT,Tclin+Tclin,0.374,0.725,0.446,0,0,0,2,3,DC01357,Isotretinoin;Vorinostat,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 1
3788,TP01172,HDAC10;RXRA,HDAC10,RXRA,CIT+CIT,Tclin+Tclin,0.374,0.725,0.446,0,0,0,2,3,DC01357,Isotretinoin;Vorinostat,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
3790,TP01173,HDAC10;RXRB,HDAC10,RXRB,CIT+CIT,Tclin+Tclin,0.374,0.879,0.398,0,0,0,2,3,DC01357,Isotretinoin;Vorinostat,DrugComb,FD00020,Kidney Cancer,Kidney Cancer,Phase 1|Phase 2
3791,TP01173,HDAC10;RXRB,HDAC10,RXRB,CIT+CIT,Tclin+Tclin,0.374,0.879,0.398,0,0,0,2,3,DC01357,Isotretinoin;Vorinostat,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 1
3792,TP01173,HDAC10;RXRB,HDAC10,RXRB,CIT+CIT,Tclin+Tclin,0.374,0.879,0.398,0,0,0,2,3,DC01357,Isotretinoin;Vorinostat,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
3794,TP01174,HDAC10;RXRG,HDAC10,RXRG,CIT+CIT,Tclin+Tclin,0.296,0.827,0.424,0,0,0,1,3,DC01357,Isotretinoin;Vorinostat,DrugComb,FD00020,Kidney Cancer,Kidney Cancer,Phase 1|Phase 2
3795,TP01174,HDAC10;RXRG,HDAC10,RXRG,CIT+CIT,Tclin+Tclin,0.296,0.827,0.424,0,0,0,1,3,DC01357,Isotretinoin;Vorinostat,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 1
3796,TP01174,HDAC10;RXRG,HDAC10,RXRG,CIT+CIT,Tclin+Tclin,0.296,0.827,0.424,0,0,0,1,3,DC01357,Isotretinoin;Vorinostat,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
3797,TP01175,HDAC10;VEGFA,HDAC10,VEGFA,CET+CIT,Tclin+Tclin,0.199,0.492,0.494,0,0,0,3,4,DC00487,Bevacizumab;Vorinostat,DrugComb,FD00020,Kidney Cancer,Kidney Cancer,Phase 1|Phase 2
3798,TP01175,HDAC10;VEGFA,HDAC10,VEGFA,CET+CIT,Tclin+Tclin,0.199,0.492,0.494,0,0,0,3,4,DC00485,Bevacizumab;Tucidinostat,DrugComb,FD00014,Esophageal Cancer,Esophageal Cancer,Phase 2
3799,TP01175,HDAC10;VEGFA,HDAC10,VEGFA,CET+CIT,Tclin+Tclin,0.199,0.492,0.494,0,0,0,3,4,DC00485,Bevacizumab;Tucidinostat,DrugComb,FD00041,Stomach Cancer,Stomach Cancer,Phase 2
3800,TP01175,HDAC10;VEGFA,HDAC10,VEGFA,CET+CIT,Tclin+Tclin,0.199,0.492,0.494,0,0,0,3,4,DC00469,Bevacizumab;Panobinostat,DrugComb,FD00017,Glioma,Glioma,Phase 1|Phase 2
3801,TP01176,HDAC11;JAK1,HDAC11,JAK1,CIT+CIT,Tclin+Tclin,0.226,0.566,0.468,1,0,0,1,1,DC01670,Panobinostat;Ruxolitinib,DrugComb,FD00030,Myeloma,Hematologic Malignancy,Phase 1|Phase 2
3802,TP01177,HDAC11;JAK2,HDAC11,JAK2,CIT+CIT,Tclin+Tclin,0.161,0.579,0.536,0,0,0,1,1,DC01670,Panobinostat;Ruxolitinib,DrugComb,FD00030,Myeloma,Hematologic Malignancy,Phase 1|Phase 2
3803,TP01178,HDAC11;MS4A1,HDAC11,MS4A1,CIT+CIT,Tclin+Tclin,0.15,0.66,0.554,0,0,0,1,1,DC01669,Panobinostat;Rituximab,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 2
3804,TP01179,HDAC11;MTOR,HDAC11,MTOR,CIT+CIT,Tclin+Tclin,0.2,0.523,0.412,1,0,0,1,2,DC01110,Everolimus;Panobinostat,DrugComb,FD00017,Glioma,Glioma,Phase 2
3805,TP01179,HDAC11;MTOR,HDAC11,MTOR,CIT+CIT,Tclin+Tclin,0.2,0.523,0.412,1,0,0,1,2,DC01110,Everolimus;Panobinostat,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 1|Phase 2
3806,TP01180,HDAC11;PDCD1,HDAC11,PDCD1,CET+CIT,Tclin+Tclin,0.153,0.584,1.0,0,0,0,2,2,DC01672,Panobinostat;Spartalizumab,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
3807,TP01180,HDAC11;PDCD1,HDAC11,PDCD1,CET+CIT,Tclin+Tclin,0.153,0.584,1.0,0,0,0,2,2,DC01672,Panobinostat;Spartalizumab,DrugComb,FD00026,Melanoma,Melanoma,Phase 1
3809,TP01181,HDAC11;VEGFA,HDAC11,VEGFA,CET+CIT,Tclin+Tclin,0.194,0.395,0.546,0,0,0,1,1,DC00469,Bevacizumab;Panobinostat,DrugComb,FD00017,Glioma,Glioma,Phase 1|Phase 2
3810,TP01182,HDAC2;JAK1,HDAC2,JAK1,CIT+CIT,Tclin+Tclin,0.335,0.651,0.485,4,1,2,2,2,DC01670,Panobinostat;Ruxolitinib,DrugComb,FD00030,Myeloma,Hematologic Malignancy,Phase 1|Phase 2
3811,TP01182,HDAC2;JAK1,HDAC2,JAK1,CIT+CIT,Tclin+Tclin,0.335,0.651,0.485,4,1,2,2,2,DC01962,Tofacitinib;Tucidinostat,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 2
3812,TP01183,HDAC2;JAK2,HDAC2,JAK2,CIT+CIT,Tclin+Tclin,0.538,0.654,0.544,1,2,2,2,2,DC01962,Tofacitinib;Tucidinostat,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 2
3813,TP01183,HDAC2;JAK2,HDAC2,JAK2,CIT+CIT,Tclin+Tclin,0.538,0.654,0.544,1,2,2,2,2,DC01670,Panobinostat;Ruxolitinib,DrugComb,FD00030,Myeloma,Hematologic Malignancy,Phase 1|Phase 2
3814,TP01184,HDAC2;JAK3,HDAC2,JAK3,CIT+CIT,Tclin+Tclin,0.385,0.492,0.484,3,1,1,1,1,DC01962,Tofacitinib;Tucidinostat,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 2
3815,TP01185,HDAC2;MS4A1,HDAC2,MS4A1,CIT+CIT,Tclin+Tclin,0.212,0.509,0.495,0,0,0,1,1,DC01669,Panobinostat;Rituximab,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 2
3816,TP01186,HDAC2;MTOR,HDAC2,MTOR,CIT+CIT,Tclin+Tclin,0.457,0.649,0.495,7,1,2,4,4,DC01954,Temsirolimus;Vorinostat,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
3817,TP01186,HDAC2;MTOR,HDAC2,MTOR,CIT+CIT,Tclin+Tclin,0.457,0.649,0.495,7,1,2,4,4,DC01954,Temsirolimus;Vorinostat,DrugComb,FD00038,Prostate Cancer,Prostate Cancer,Phase 1
3819,TP01186,HDAC2;MTOR,HDAC2,MTOR,CIT+CIT,Tclin+Tclin,0.457,0.649,0.495,7,1,2,4,4,DC01110,Everolimus;Panobinostat,DrugComb,FD00017,Glioma,Glioma,Phase 2
3820,TP01186,HDAC2;MTOR,HDAC2,MTOR,CIT+CIT,Tclin+Tclin,0.457,0.649,0.495,7,1,2,4,4,DC01110,Everolimus;Panobinostat,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 1|Phase 2
3822,TP01187,HDAC2;PDCD1,HDAC2,PDCD1,CET+CIT,Tclin+Tclin,0.264,0.224,1.0,0,1,0,10,7,DC01672,Panobinostat;Spartalizumab,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
3823,TP01187,HDAC2;PDCD1,HDAC2,PDCD1,CET+CIT,Tclin+Tclin,0.264,0.224,1.0,0,1,0,10,7,DC01672,Panobinostat;Spartalizumab,DrugComb,FD00026,Melanoma,Melanoma,Phase 1
3825,TP01187,HDAC2;PDCD1,HDAC2,PDCD1,CET+CIT,Tclin+Tclin,0.264,0.224,1.0,0,1,0,10,7,DC01000,Entinostat;Nivolumab,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1|Phase 2
3827,TP01187,HDAC2;PDCD1,HDAC2,PDCD1,CET+CIT,Tclin+Tclin,0.264,0.224,1.0,0,1,0,10,7,DC01902,Sintilimab;Tucidinostat,DrugComb,FD00011,Colorectal Cancer,Colorectal Cancer,Phase 2
3828,TP01187,HDAC2;PDCD1,HDAC2,PDCD1,CET+CIT,Tclin+Tclin,0.264,0.224,1.0,0,1,0,10,7,DC01902,Sintilimab;Tucidinostat,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 2
3829,TP01187,HDAC2;PDCD1,HDAC2,PDCD1,CET+CIT,Tclin+Tclin,0.264,0.224,1.0,0,1,0,10,7,DC01902,Sintilimab;Tucidinostat,DrugComb,FD00032,Neuroendocrine Tumor,Other Cancer,Phase 2
3833,TP01187,HDAC2;PDCD1,HDAC2,PDCD1,CET+CIT,Tclin+Tclin,0.264,0.224,1.0,0,1,0,10,7,DC01001,Entinostat;Pembrolizumab,DrugComb,FD00030,Myeloma,Hematologic Malignancy,Phase 1
3838,TP01188,HDAC2;PIK3CA,HDAC2,PIK3CA,CIT+CIT,Tclin+Tclin,0.408,0.451,0.4,9,0,1,1,1,DC00804,Copanlisib;Romidepsin,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 1
3839,TP01189,HDAC2;PIK3CD,HDAC2,PIK3CD,CIT+CIT,Tclin+Tclin,0.328,0.455,0.397,9,0,1,5,1,DC00958,Duvelisib;Romidepsin,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 1
3844,TP01190,HDAC2;PIK3CG,HDAC2,PIK3CG,CIT+CIT,Tclin+Tclin,0.335,0.449,0.421,0,0,0,2,1,DC00958,Duvelisib;Romidepsin,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 1
3846,TP01191,HDAC2;RXRA,HDAC2,RXRA,CIT+CIT,Tclin+Tclin,0.439,0.817,0.561,3,1,1,3,3,DC01357,Isotretinoin;Vorinostat,DrugComb,FD00020,Kidney Cancer,Kidney Cancer,Phase 1|Phase 2
3847,TP01191,HDAC2;RXRA,HDAC2,RXRA,CIT+CIT,Tclin+Tclin,0.439,0.817,0.561,3,1,1,3,3,DC01357,Isotretinoin;Vorinostat,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 1
3848,TP01191,HDAC2;RXRA,HDAC2,RXRA,CIT+CIT,Tclin+Tclin,0.439,0.817,0.561,3,1,1,3,3,DC01357,Isotretinoin;Vorinostat,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
3851,TP01192,HDAC2;RXRB,HDAC2,RXRB,CIT+CIT,Tclin+Tclin,0.425,0.831,0.47,3,0,1,3,3,DC01357,Isotretinoin;Vorinostat,DrugComb,FD00020,Kidney Cancer,Kidney Cancer,Phase 1|Phase 2
3852,TP01192,HDAC2;RXRB,HDAC2,RXRB,CIT+CIT,Tclin+Tclin,0.425,0.831,0.47,3,0,1,3,3,DC01357,Isotretinoin;Vorinostat,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 1
3853,TP01192,HDAC2;RXRB,HDAC2,RXRB,CIT+CIT,Tclin+Tclin,0.425,0.831,0.47,3,0,1,3,3,DC01357,Isotretinoin;Vorinostat,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
3856,TP01193,HDAC2;RXRG,HDAC2,RXRG,CIT+CIT,Tclin+Tclin,0.437,0.798,0.478,3,0,1,2,3,DC01357,Isotretinoin;Vorinostat,DrugComb,FD00020,Kidney Cancer,Kidney Cancer,Phase 1|Phase 2
3857,TP01193,HDAC2;RXRG,HDAC2,RXRG,CIT+CIT,Tclin+Tclin,0.437,0.798,0.478,3,0,1,2,3,DC01357,Isotretinoin;Vorinostat,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 1
3858,TP01193,HDAC2;RXRG,HDAC2,RXRG,CIT+CIT,Tclin+Tclin,0.437,0.798,0.478,3,0,1,2,3,DC01357,Isotretinoin;Vorinostat,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
3860,TP01194,HDAC2;VEGFA,HDAC2,VEGFA,CET+CIT,Tclin+Tclin,0.482,0.436,0.505,3,0,1,3,4,DC00485,Bevacizumab;Tucidinostat,DrugComb,FD00014,Esophageal Cancer,Esophageal Cancer,Phase 2
3861,TP01194,HDAC2;VEGFA,HDAC2,VEGFA,CET+CIT,Tclin+Tclin,0.482,0.436,0.505,3,0,1,3,4,DC00485,Bevacizumab;Tucidinostat,DrugComb,FD00041,Stomach Cancer,Stomach Cancer,Phase 2
3862,TP01194,HDAC2;VEGFA,HDAC2,VEGFA,CET+CIT,Tclin+Tclin,0.482,0.436,0.505,3,0,1,3,4,DC00469,Bevacizumab;Panobinostat,DrugComb,FD00017,Glioma,Glioma,Phase 1|Phase 2
3863,TP01194,HDAC2;VEGFA,HDAC2,VEGFA,CET+CIT,Tclin+Tclin,0.482,0.436,0.505,3,0,1,3,4,DC00487,Bevacizumab;Vorinostat,DrugComb,FD00020,Kidney Cancer,Kidney Cancer,Phase 1|Phase 2
3864,TP01195,HDAC3;JAK1,HDAC3,JAK1,CIT+CIT,Tclin+Tclin,0.285,0.737,0.516,1,0,0,2,2,DC01962,Tofacitinib;Tucidinostat,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 2
3865,TP01195,HDAC3;JAK1,HDAC3,JAK1,CIT+CIT,Tclin+Tclin,0.285,0.737,0.516,1,0,0,2,2,DC01670,Panobinostat;Ruxolitinib,DrugComb,FD00030,Myeloma,Hematologic Malignancy,Phase 1|Phase 2
3866,TP01196,HDAC3;JAK2,HDAC3,JAK2,CIT+CIT,Tclin+Tclin,0.418,0.722,0.555,0,0,0,2,2,DC01670,Panobinostat;Ruxolitinib,DrugComb,FD00030,Myeloma,Hematologic Malignancy,Phase 1|Phase 2
3867,TP01196,HDAC3;JAK2,HDAC3,JAK2,CIT+CIT,Tclin+Tclin,0.418,0.722,0.555,0,0,0,2,2,DC01962,Tofacitinib;Tucidinostat,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 2
3868,TP01197,HDAC3;JAK3,HDAC3,JAK3,CIT+CIT,Tclin+Tclin,0.344,0.673,0.518,1,0,0,1,1,DC01962,Tofacitinib;Tucidinostat,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 2
3869,TP01198,HDAC3;MS4A1,HDAC3,MS4A1,CIT+CIT,Tclin+Tclin,0.202,0.62,0.539,0,0,0,1,1,DC01669,Panobinostat;Rituximab,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 2
3870,TP01199,HDAC3;MTOR,HDAC3,MTOR,CIT+CIT,Tclin+Tclin,0.393,0.68,0.47,2,1,0,4,4,DC01954,Temsirolimus;Vorinostat,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
3871,TP01199,HDAC3;MTOR,HDAC3,MTOR,CIT+CIT,Tclin+Tclin,0.393,0.68,0.47,2,1,0,4,4,DC01954,Temsirolimus;Vorinostat,DrugComb,FD00038,Prostate Cancer,Prostate Cancer,Phase 1
3872,TP01199,HDAC3;MTOR,HDAC3,MTOR,CIT+CIT,Tclin+Tclin,0.393,0.68,0.47,2,1,0,4,4,DC01110,Everolimus;Panobinostat,DrugComb,FD00017,Glioma,Glioma,Phase 2
3873,TP01199,HDAC3;MTOR,HDAC3,MTOR,CIT+CIT,Tclin+Tclin,0.393,0.68,0.47,2,1,0,4,4,DC01110,Everolimus;Panobinostat,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 1|Phase 2
3876,TP01200,HDAC3;PDCD1,HDAC3,PDCD1,CET+CIT,Tclin+Tclin,0.252,0.404,1.0,0,0,0,10,7,DC01902,Sintilimab;Tucidinostat,DrugComb,FD00011,Colorectal Cancer,Colorectal Cancer,Phase 2
3877,TP01200,HDAC3;PDCD1,HDAC3,PDCD1,CET+CIT,Tclin+Tclin,0.252,0.404,1.0,0,0,0,10,7,DC01902,Sintilimab;Tucidinostat,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 2
3878,TP01200,HDAC3;PDCD1,HDAC3,PDCD1,CET+CIT,Tclin+Tclin,0.252,0.404,1.0,0,0,0,10,7,DC01902,Sintilimab;Tucidinostat,DrugComb,FD00032,Neuroendocrine Tumor,Other Cancer,Phase 2
3879,TP01200,HDAC3;PDCD1,HDAC3,PDCD1,CET+CIT,Tclin+Tclin,0.252,0.404,1.0,0,0,0,10,7,DC01000,Entinostat;Nivolumab,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1|Phase 2
3881,TP01200,HDAC3;PDCD1,HDAC3,PDCD1,CET+CIT,Tclin+Tclin,0.252,0.404,1.0,0,0,0,10,7,DC01001,Entinostat;Pembrolizumab,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
3882,TP01200,HDAC3;PDCD1,HDAC3,PDCD1,CET+CIT,Tclin+Tclin,0.252,0.404,1.0,0,0,0,10,7,DC01001,Entinostat;Pembrolizumab,DrugComb,FD00026,Melanoma,Melanoma,Phase 2
3883,TP01200,HDAC3;PDCD1,HDAC3,PDCD1,CET+CIT,Tclin+Tclin,0.252,0.404,1.0,0,0,0,10,7,DC01001,Entinostat;Pembrolizumab,DrugComb,FD00030,Myeloma,Hematologic Malignancy,Phase 1
3892,TP01201,HDAC3;PIK3CA,HDAC3,PIK3CA,CIT+CIT,Tclin+Tclin,0.373,0.585,0.409,3,0,0,1,1,DC00804,Copanlisib;Romidepsin,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 1
3893,TP01202,HDAC3;PIK3CD,HDAC3,PIK3CD,CIT+CIT,Tclin+Tclin,0.295,0.63,0.404,3,0,0,5,1,DC01881,Romidepsin;Tenalisib,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 1|Phase 2
3898,TP01203,HDAC3;PIK3CG,HDAC3,PIK3CG,CIT+CIT,Tclin+Tclin,0.311,0.608,0.429,0,0,0,2,1,DC00958,Duvelisib;Romidepsin,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 1
3900,TP01204,HDAC3;RXRA,HDAC3,RXRA,CIT+CIT,Tclin+Tclin,0.446,0.777,0.479,1,9,0,3,3,DC01357,Isotretinoin;Vorinostat,DrugComb,FD00020,Kidney Cancer,Kidney Cancer,Phase 1|Phase 2
3901,TP01204,HDAC3;RXRA,HDAC3,RXRA,CIT+CIT,Tclin+Tclin,0.446,0.777,0.479,1,9,0,3,3,DC01357,Isotretinoin;Vorinostat,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 1
3902,TP01204,HDAC3;RXRA,HDAC3,RXRA,CIT+CIT,Tclin+Tclin,0.446,0.777,0.479,1,9,0,3,3,DC01357,Isotretinoin;Vorinostat,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
3905,TP01205,HDAC3;RXRB,HDAC3,RXRB,CIT+CIT,Tclin+Tclin,0.417,0.77,0.418,1,2,0,3,3,DC00491,Bexarotene;Vorinostat,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 1
3906,TP01205,HDAC3;RXRB,HDAC3,RXRB,CIT+CIT,Tclin+Tclin,0.417,0.77,0.418,1,2,0,3,3,DC01357,Isotretinoin;Vorinostat,DrugComb,FD00020,Kidney Cancer,Kidney Cancer,Phase 1|Phase 2
3908,TP01205,HDAC3;RXRB,HDAC3,RXRB,CIT+CIT,Tclin+Tclin,0.417,0.77,0.418,1,2,0,3,3,DC01357,Isotretinoin;Vorinostat,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
3910,TP01206,HDAC3;RXRG,HDAC3,RXRG,CIT+CIT,Tclin+Tclin,0.358,0.723,0.438,1,0,0,2,3,DC01357,Isotretinoin;Vorinostat,DrugComb,FD00020,Kidney Cancer,Kidney Cancer,Phase 1|Phase 2
3911,TP01206,HDAC3;RXRG,HDAC3,RXRG,CIT+CIT,Tclin+Tclin,0.358,0.723,0.438,1,0,0,2,3,DC01357,Isotretinoin;Vorinostat,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 1
3912,TP01206,HDAC3;RXRG,HDAC3,RXRG,CIT+CIT,Tclin+Tclin,0.358,0.723,0.438,1,0,0,2,3,DC01357,Isotretinoin;Vorinostat,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
3914,TP01207,HDAC3;VEGFA,HDAC3,VEGFA,CET+CIT,Tclin+Tclin,0.365,0.521,0.54,0,0,0,3,4,DC00485,Bevacizumab;Tucidinostat,DrugComb,FD00014,Esophageal Cancer,Esophageal Cancer,Phase 2
3915,TP01207,HDAC3;VEGFA,HDAC3,VEGFA,CET+CIT,Tclin+Tclin,0.365,0.521,0.54,0,0,0,3,4,DC00485,Bevacizumab;Tucidinostat,DrugComb,FD00041,Stomach Cancer,Stomach Cancer,Phase 2
3916,TP01207,HDAC3;VEGFA,HDAC3,VEGFA,CET+CIT,Tclin+Tclin,0.365,0.521,0.54,0,0,0,3,4,DC00487,Bevacizumab;Vorinostat,DrugComb,FD00020,Kidney Cancer,Kidney Cancer,Phase 1|Phase 2
3917,TP01207,HDAC3;VEGFA,HDAC3,VEGFA,CET+CIT,Tclin+Tclin,0.365,0.521,0.54,0,0,0,3,4,DC00469,Bevacizumab;Panobinostat,DrugComb,FD00017,Glioma,Glioma,Phase 1|Phase 2
3918,TP01208,HDAC4;JAK1,HDAC4,JAK1,CIT+CIT,Tclin+Tclin,0.325,0.701,0.517,1,0,0,1,1,DC01670,Panobinostat;Ruxolitinib,DrugComb,FD00030,Myeloma,Hematologic Malignancy,Phase 1|Phase 2
3919,TP01209,HDAC4;JAK2,HDAC4,JAK2,CIT+CIT,Tclin+Tclin,0.419,0.635,0.58,0,0,0,1,1,DC01670,Panobinostat;Ruxolitinib,DrugComb,FD00030,Myeloma,Hematologic Malignancy,Phase 1|Phase 2
3920,TP01210,HDAC4;MS4A1,HDAC4,MS4A1,CIT+CIT,Tclin+Tclin,0.275,0.51,0.488,0,0,0,1,1,DC01669,Panobinostat;Rituximab,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 2
3921,TP01211,HDAC4;MTOR,HDAC4,MTOR,CIT+CIT,Tclin+Tclin,0.389,0.667,0.562,3,0,5,4,4,DC01126,Everolimus;Vorinostat,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
3923,TP01211,HDAC4;MTOR,HDAC4,MTOR,CIT+CIT,Tclin+Tclin,0.389,0.667,0.562,3,0,5,4,4,DC01954,Temsirolimus;Vorinostat,DrugComb,FD00038,Prostate Cancer,Prostate Cancer,Phase 1
3925,TP01211,HDAC4;MTOR,HDAC4,MTOR,CIT+CIT,Tclin+Tclin,0.389,0.667,0.562,3,0,5,4,4,DC01110,Everolimus;Panobinostat,DrugComb,FD00017,Glioma,Glioma,Phase 2
3926,TP01211,HDAC4;MTOR,HDAC4,MTOR,CIT+CIT,Tclin+Tclin,0.389,0.667,0.562,3,0,5,4,4,DC01110,Everolimus;Panobinostat,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 1|Phase 2
3927,TP01212,HDAC4;PDCD1,HDAC4,PDCD1,CET+CIT,Tclin+Tclin,0.211,0.248,1.0,0,0,1,2,2,DC01769,Pembrolizumab;Vorinostat,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 2
3929,TP01212,HDAC4;PDCD1,HDAC4,PDCD1,CET+CIT,Tclin+Tclin,0.211,0.248,1.0,0,0,1,2,2,DC01672,Panobinostat;Spartalizumab,DrugComb,FD00026,Melanoma,Melanoma,Phase 1
3930,TP01213,HDAC4;RXRA,HDAC4,RXRA,CIT+CIT,Tclin+Tclin,0.426,0.82,0.674,0,1,0,2,3,DC00491,Bexarotene;Vorinostat,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 1
3931,TP01213,HDAC4;RXRA,HDAC4,RXRA,CIT+CIT,Tclin+Tclin,0.426,0.82,0.674,0,1,0,2,3,DC01357,Isotretinoin;Vorinostat,DrugComb,FD00020,Kidney Cancer,Kidney Cancer,Phase 1|Phase 2
3933,TP01213,HDAC4;RXRA,HDAC4,RXRA,CIT+CIT,Tclin+Tclin,0.426,0.82,0.674,0,1,0,2,3,DC01357,Isotretinoin;Vorinostat,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
3934,TP01214,HDAC4;RXRB,HDAC4,RXRB,CIT+CIT,Tclin+Tclin,0.427,0.834,0.61,0,0,0,2,3,DC01357,Isotretinoin;Vorinostat,DrugComb,FD00020,Kidney Cancer,Kidney Cancer,Phase 1|Phase 2
3935,TP01214,HDAC4;RXRB,HDAC4,RXRB,CIT+CIT,Tclin+Tclin,0.427,0.834,0.61,0,0,0,2,3,DC01357,Isotretinoin;Vorinostat,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 1
3936,TP01214,HDAC4;RXRB,HDAC4,RXRB,CIT+CIT,Tclin+Tclin,0.427,0.834,0.61,0,0,0,2,3,DC01357,Isotretinoin;Vorinostat,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
3938,TP01215,HDAC4;RXRG,HDAC4,RXRG,CIT+CIT,Tclin+Tclin,0.438,0.792,0.615,0,0,0,1,3,DC01357,Isotretinoin;Vorinostat,DrugComb,FD00020,Kidney Cancer,Kidney Cancer,Phase 1|Phase 2
3939,TP01215,HDAC4;RXRG,HDAC4,RXRG,CIT+CIT,Tclin+Tclin,0.438,0.792,0.615,0,0,0,1,3,DC01357,Isotretinoin;Vorinostat,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 1
3940,TP01215,HDAC4;RXRG,HDAC4,RXRG,CIT+CIT,Tclin+Tclin,0.438,0.792,0.615,0,0,0,1,3,DC01357,Isotretinoin;Vorinostat,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
3941,TP01216,HDAC4;VEGFA,HDAC4,VEGFA,CET+CIT,Tclin+Tclin,0.421,0.485,0.508,1,0,3,2,2,DC00487,Bevacizumab;Vorinostat,DrugComb,FD00020,Kidney Cancer,Kidney Cancer,Phase 1|Phase 2
3942,TP01216,HDAC4;VEGFA,HDAC4,VEGFA,CET+CIT,Tclin+Tclin,0.421,0.485,0.508,1,0,3,2,2,DC00469,Bevacizumab;Panobinostat,DrugComb,FD00017,Glioma,Glioma,Phase 1|Phase 2
3943,TP01217,HDAC5;JAK1,HDAC5,JAK1,CIT+CIT,Tclin+Tclin,0.313,0.735,0.543,1,0,0,1,1,DC01670,Panobinostat;Ruxolitinib,DrugComb,FD00030,Myeloma,Hematologic Malignancy,Phase 1|Phase 2
3944,TP01218,HDAC5;JAK2,HDAC5,JAK2,CIT+CIT,Tclin+Tclin,0.348,0.657,0.605,0,0,1,1,1,DC01670,Panobinostat;Ruxolitinib,DrugComb,FD00030,Myeloma,Hematologic Malignancy,Phase 1|Phase 2
3945,TP01219,HDAC5;MS4A1,HDAC5,MS4A1,CIT+CIT,Tclin+Tclin,0.298,0.532,0.538,0,0,0,1,1,DC01669,Panobinostat;Rituximab,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 2
3946,TP01220,HDAC5;MTOR,HDAC5,MTOR,CIT+CIT,Tclin+Tclin,0.369,0.698,0.566,3,1,3,4,4,DC01954,Temsirolimus;Vorinostat,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
3947,TP01220,HDAC5;MTOR,HDAC5,MTOR,CIT+CIT,Tclin+Tclin,0.369,0.698,0.566,3,1,3,4,4,DC01954,Temsirolimus;Vorinostat,DrugComb,FD00038,Prostate Cancer,Prostate Cancer,Phase 1
3948,TP01220,HDAC5;MTOR,HDAC5,MTOR,CIT+CIT,Tclin+Tclin,0.369,0.698,0.566,3,1,3,4,4,DC01110,Everolimus;Panobinostat,DrugComb,FD00017,Glioma,Glioma,Phase 2
3949,TP01220,HDAC5;MTOR,HDAC5,MTOR,CIT+CIT,Tclin+Tclin,0.369,0.698,0.566,3,1,3,4,4,DC01110,Everolimus;Panobinostat,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 1|Phase 2
3952,TP01221,HDAC5;PDCD1,HDAC5,PDCD1,CET+CIT,Tclin+Tclin,0.178,0.255,1.0,0,0,0,2,2,DC01769,Pembrolizumab;Vorinostat,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 2
3954,TP01221,HDAC5;PDCD1,HDAC5,PDCD1,CET+CIT,Tclin+Tclin,0.178,0.255,1.0,0,0,0,2,2,DC01672,Panobinostat;Spartalizumab,DrugComb,FD00026,Melanoma,Melanoma,Phase 1
3955,TP01222,HDAC5;RXRA,HDAC5,RXRA,CIT+CIT,Tclin+Tclin,0.431,0.768,0.663,0,0,0,2,3,DC01357,Isotretinoin;Vorinostat,DrugComb,FD00020,Kidney Cancer,Kidney Cancer,Phase 1|Phase 2
3956,TP01222,HDAC5;RXRA,HDAC5,RXRA,CIT+CIT,Tclin+Tclin,0.431,0.768,0.663,0,0,0,2,3,DC01357,Isotretinoin;Vorinostat,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 1
3957,TP01222,HDAC5;RXRA,HDAC5,RXRA,CIT+CIT,Tclin+Tclin,0.431,0.768,0.663,0,0,0,2,3,DC01357,Isotretinoin;Vorinostat,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
3959,TP01223,HDAC5;RXRB,HDAC5,RXRB,CIT+CIT,Tclin+Tclin,0.431,0.854,0.601,0,0,0,2,3,DC01357,Isotretinoin;Vorinostat,DrugComb,FD00020,Kidney Cancer,Kidney Cancer,Phase 1|Phase 2
3960,TP01223,HDAC5;RXRB,HDAC5,RXRB,CIT+CIT,Tclin+Tclin,0.431,0.854,0.601,0,0,0,2,3,DC01357,Isotretinoin;Vorinostat,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 1
3961,TP01223,HDAC5;RXRB,HDAC5,RXRB,CIT+CIT,Tclin+Tclin,0.431,0.854,0.601,0,0,0,2,3,DC01357,Isotretinoin;Vorinostat,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
3963,TP01224,HDAC5;RXRG,HDAC5,RXRG,CIT+CIT,Tclin+Tclin,0.395,0.806,0.605,0,0,0,1,3,DC01357,Isotretinoin;Vorinostat,DrugComb,FD00020,Kidney Cancer,Kidney Cancer,Phase 1|Phase 2
3964,TP01224,HDAC5;RXRG,HDAC5,RXRG,CIT+CIT,Tclin+Tclin,0.395,0.806,0.605,0,0,0,1,3,DC01357,Isotretinoin;Vorinostat,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 1
3965,TP01224,HDAC5;RXRG,HDAC5,RXRG,CIT+CIT,Tclin+Tclin,0.395,0.806,0.605,0,0,0,1,3,DC01357,Isotretinoin;Vorinostat,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
3966,TP01225,HDAC5;VEGFA,HDAC5,VEGFA,CET+CIT,Tclin+Tclin,0.334,0.512,0.543,1,0,1,2,2,DC00469,Bevacizumab;Panobinostat,DrugComb,FD00017,Glioma,Glioma,Phase 1|Phase 2
3967,TP01225,HDAC5;VEGFA,HDAC5,VEGFA,CET+CIT,Tclin+Tclin,0.334,0.512,0.543,1,0,1,2,2,DC00487,Bevacizumab;Vorinostat,DrugComb,FD00020,Kidney Cancer,Kidney Cancer,Phase 1|Phase 2
3968,TP01226,HDAC6;JAK1,HDAC6,JAK1,CIT+CIT,Tclin+Tclin,0.33,0.678,0.582,1,0,0,1,1,DC01670,Panobinostat;Ruxolitinib,DrugComb,FD00030,Myeloma,Hematologic Malignancy,Phase 1|Phase 2
3969,TP01227,HDAC6;JAK2,HDAC6,JAK2,CIT+CIT,Tclin+Tclin,0.406,0.674,0.58,0,0,0,1,1,DC01670,Panobinostat;Ruxolitinib,DrugComb,FD00030,Myeloma,Hematologic Malignancy,Phase 1|Phase 2
3970,TP01228,HDAC6;MAP2K1,HDAC6,MAP2K1,CIT+CIT,Tclin+Tclin,0.384,0.645,0.508,2,0,0,1,1,DC00412,Belinostat;Binimetinib,DrugComb,FD00026,Melanoma,Melanoma,Phase 2
3971,TP01229,HDAC6;MAP2K2,HDAC6,MAP2K2,CIT+CIT,Tclin+Tclin,0.321,0.661,0.525,1,0,0,1,1,DC00412,Belinostat;Binimetinib,DrugComb,FD00026,Melanoma,Melanoma,Phase 2
3972,TP01230,HDAC6;MS4A1,HDAC6,MS4A1,CIT+CIT,Tclin+Tclin,0.216,0.505,0.569,0,0,0,1,1,DC01669,Panobinostat;Rituximab,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 2
3973,TP01231,HDAC6;MTOR,HDAC6,MTOR,CIT+CIT,Tclin+Tclin,0.441,0.656,0.555,2,0,0,4,4,DC01954,Temsirolimus;Vorinostat,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
3974,TP01231,HDAC6;MTOR,HDAC6,MTOR,CIT+CIT,Tclin+Tclin,0.441,0.656,0.555,2,0,0,4,4,DC01954,Temsirolimus;Vorinostat,DrugComb,FD00038,Prostate Cancer,Prostate Cancer,Phase 1
3975,TP01231,HDAC6;MTOR,HDAC6,MTOR,CIT+CIT,Tclin+Tclin,0.441,0.656,0.555,2,0,0,4,4,DC01110,Everolimus;Panobinostat,DrugComb,FD00017,Glioma,Glioma,Phase 2
3976,TP01231,HDAC6;MTOR,HDAC6,MTOR,CIT+CIT,Tclin+Tclin,0.441,0.656,0.555,2,0,0,4,4,DC01110,Everolimus;Panobinostat,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 1|Phase 2
3979,TP01232,HDAC6;PARP1,HDAC6,PARP1,CIT+CIT,Tclin+Tclin,0.436,0.567,0.634,0,0,0,1,3,DC00414,Belinostat;Talazoparib,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 1
3980,TP01232,HDAC6;PARP1,HDAC6,PARP1,CIT+CIT,Tclin+Tclin,0.436,0.567,0.634,0,0,0,1,3,DC00414,Belinostat;Talazoparib,DrugComb,FD00034,Ovarian Cancer,Ovarian Cancer,Phase 1
3981,TP01232,HDAC6;PARP1,HDAC6,PARP1,CIT+CIT,Tclin+Tclin,0.436,0.567,0.634,0,0,0,1,3,DC00414,Belinostat;Talazoparib,DrugComb,FD00038,Prostate Cancer,Prostate Cancer,Phase 1
3982,TP01233,HDAC6;PARP2,HDAC6,PARP2,CIT+CIT,Tclin+Tclin,0.323,0.512,0.561,0,0,0,1,3,DC00414,Belinostat;Talazoparib,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 1
3983,TP01233,HDAC6;PARP2,HDAC6,PARP2,CIT+CIT,Tclin+Tclin,0.323,0.512,0.561,0,0,0,1,3,DC00414,Belinostat;Talazoparib,DrugComb,FD00034,Ovarian Cancer,Ovarian Cancer,Phase 1
3984,TP01233,HDAC6;PARP2,HDAC6,PARP2,CIT+CIT,Tclin+Tclin,0.323,0.512,0.561,0,0,0,1,3,DC00414,Belinostat;Talazoparib,DrugComb,FD00038,Prostate Cancer,Prostate Cancer,Phase 1
3985,TP01234,HDAC6;PDCD1,HDAC6,PDCD1,CET+CIT,Tclin+Tclin,0.169,0.29,1.0,0,0,0,3,2,DC01672,Panobinostat;Spartalizumab,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
3986,TP01234,HDAC6;PDCD1,HDAC6,PDCD1,CET+CIT,Tclin+Tclin,0.169,0.29,1.0,0,0,0,3,2,DC01672,Panobinostat;Spartalizumab,DrugComb,FD00026,Melanoma,Melanoma,Phase 1
3989,TP01235,HDAC6;RXRA,HDAC6,RXRA,CIT+CIT,Tclin+Tclin,0.346,0.603,0.629,0,0,0,2,3,DC01357,Isotretinoin;Vorinostat,DrugComb,FD00020,Kidney Cancer,Kidney Cancer,Phase 1|Phase 2
3990,TP01235,HDAC6;RXRA,HDAC6,RXRA,CIT+CIT,Tclin+Tclin,0.346,0.603,0.629,0,0,0,2,3,DC01357,Isotretinoin;Vorinostat,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 1
3991,TP01235,HDAC6;RXRA,HDAC6,RXRA,CIT+CIT,Tclin+Tclin,0.346,0.603,0.629,0,0,0,2,3,DC01357,Isotretinoin;Vorinostat,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
3993,TP01236,HDAC6;RXRB,HDAC6,RXRB,CIT+CIT,Tclin+Tclin,0.296,0.65,0.6,0,0,0,2,3,DC01357,Isotretinoin;Vorinostat,DrugComb,FD00020,Kidney Cancer,Kidney Cancer,Phase 1|Phase 2
3994,TP01236,HDAC6;RXRB,HDAC6,RXRB,CIT+CIT,Tclin+Tclin,0.296,0.65,0.6,0,0,0,2,3,DC01357,Isotretinoin;Vorinostat,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 1
3995,TP01236,HDAC6;RXRB,HDAC6,RXRB,CIT+CIT,Tclin+Tclin,0.296,0.65,0.6,0,0,0,2,3,DC01357,Isotretinoin;Vorinostat,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
3997,TP01237,HDAC6;RXRG,HDAC6,RXRG,CIT+CIT,Tclin+Tclin,0.297,0.619,0.608,0,0,0,1,3,DC01357,Isotretinoin;Vorinostat,DrugComb,FD00020,Kidney Cancer,Kidney Cancer,Phase 1|Phase 2
3998,TP01237,HDAC6;RXRG,HDAC6,RXRG,CIT+CIT,Tclin+Tclin,0.297,0.619,0.608,0,0,0,1,3,DC01357,Isotretinoin;Vorinostat,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 1
3999,TP01237,HDAC6;RXRG,HDAC6,RXRG,CIT+CIT,Tclin+Tclin,0.297,0.619,0.608,0,0,0,1,3,DC01357,Isotretinoin;Vorinostat,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
4000,TP01238,HDAC6;VEGFA,HDAC6,VEGFA,CET+CIT,Tclin+Tclin,0.401,0.512,0.548,0,0,0,2,2,DC00469,Bevacizumab;Panobinostat,DrugComb,FD00017,Glioma,Glioma,Phase 1|Phase 2
4001,TP01238,HDAC6;VEGFA,HDAC6,VEGFA,CET+CIT,Tclin+Tclin,0.401,0.512,0.548,0,0,0,2,2,DC00487,Bevacizumab;Vorinostat,DrugComb,FD00020,Kidney Cancer,Kidney Cancer,Phase 1|Phase 2
4002,TP01239,HDAC7;JAK1,HDAC7,JAK1,CIT+CIT,Tclin+Tclin,0.347,0.75,0.549,1,0,0,1,1,DC01670,Panobinostat;Ruxolitinib,DrugComb,FD00030,Myeloma,Hematologic Malignancy,Phase 1|Phase 2
4003,TP01240,HDAC7;JAK2,HDAC7,JAK2,CIT+CIT,Tclin+Tclin,0.311,0.648,0.615,0,0,1,1,1,DC01670,Panobinostat;Ruxolitinib,DrugComb,FD00030,Myeloma,Hematologic Malignancy,Phase 1|Phase 2
4004,TP01241,HDAC7;MS4A1,HDAC7,MS4A1,CIT+CIT,Tclin+Tclin,0.195,0.509,0.5,0,0,0,1,1,DC01669,Panobinostat;Rituximab,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 2
4005,TP01242,HDAC7;MTOR,HDAC7,MTOR,CIT+CIT,Tclin+Tclin,0.306,0.665,0.475,1,1,4,4,4,DC01911,Sirolimus;Vorinostat,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
4008,TP01242,HDAC7;MTOR,HDAC7,MTOR,CIT+CIT,Tclin+Tclin,0.306,0.665,0.475,1,1,4,4,4,DC01954,Temsirolimus;Vorinostat,DrugComb,FD00038,Prostate Cancer,Prostate Cancer,Phase 1
4009,TP01242,HDAC7;MTOR,HDAC7,MTOR,CIT+CIT,Tclin+Tclin,0.306,0.665,0.475,1,1,4,4,4,DC01110,Everolimus;Panobinostat,DrugComb,FD00017,Glioma,Glioma,Phase 2
4010,TP01242,HDAC7;MTOR,HDAC7,MTOR,CIT+CIT,Tclin+Tclin,0.306,0.665,0.475,1,1,4,4,4,DC01110,Everolimus;Panobinostat,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 1|Phase 2
4011,TP01243,HDAC7;PDCD1,HDAC7,PDCD1,CET+CIT,Tclin+Tclin,0.205,0.268,1.0,0,0,0,2,2,DC01672,Panobinostat;Spartalizumab,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
4012,TP01243,HDAC7;PDCD1,HDAC7,PDCD1,CET+CIT,Tclin+Tclin,0.205,0.268,1.0,0,0,0,2,2,DC01672,Panobinostat;Spartalizumab,DrugComb,FD00026,Melanoma,Melanoma,Phase 1
4014,TP01244,HDAC7;RXRA,HDAC7,RXRA,CIT+CIT,Tclin+Tclin,0.368,0.759,0.465,0,0,0,2,3,DC01357,Isotretinoin;Vorinostat,DrugComb,FD00020,Kidney Cancer,Kidney Cancer,Phase 1|Phase 2
4015,TP01244,HDAC7;RXRA,HDAC7,RXRA,CIT+CIT,Tclin+Tclin,0.368,0.759,0.465,0,0,0,2,3,DC01357,Isotretinoin;Vorinostat,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 1
4016,TP01244,HDAC7;RXRA,HDAC7,RXRA,CIT+CIT,Tclin+Tclin,0.368,0.759,0.465,0,0,0,2,3,DC01357,Isotretinoin;Vorinostat,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
4018,TP01245,HDAC7;RXRB,HDAC7,RXRB,CIT+CIT,Tclin+Tclin,0.356,0.876,0.426,0,0,0,2,3,DC01357,Isotretinoin;Vorinostat,DrugComb,FD00020,Kidney Cancer,Kidney Cancer,Phase 1|Phase 2
4019,TP01245,HDAC7;RXRB,HDAC7,RXRB,CIT+CIT,Tclin+Tclin,0.356,0.876,0.426,0,0,0,2,3,DC01357,Isotretinoin;Vorinostat,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 1
4020,TP01245,HDAC7;RXRB,HDAC7,RXRB,CIT+CIT,Tclin+Tclin,0.356,0.876,0.426,0,0,0,2,3,DC01357,Isotretinoin;Vorinostat,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
4022,TP01246,HDAC7;RXRG,HDAC7,RXRG,CIT+CIT,Tclin+Tclin,0.346,0.828,0.446,0,0,0,1,3,DC01357,Isotretinoin;Vorinostat,DrugComb,FD00020,Kidney Cancer,Kidney Cancer,Phase 1|Phase 2
4023,TP01246,HDAC7;RXRG,HDAC7,RXRG,CIT+CIT,Tclin+Tclin,0.346,0.828,0.446,0,0,0,1,3,DC01357,Isotretinoin;Vorinostat,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 1
4024,TP01246,HDAC7;RXRG,HDAC7,RXRG,CIT+CIT,Tclin+Tclin,0.346,0.828,0.446,0,0,0,1,3,DC01357,Isotretinoin;Vorinostat,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
4025,TP01247,HDAC7;VEGFA,HDAC7,VEGFA,CET+CIT,Tclin+Tclin,0.385,0.516,0.513,0,0,2,2,2,DC00487,Bevacizumab;Vorinostat,DrugComb,FD00020,Kidney Cancer,Kidney Cancer,Phase 1|Phase 2
4026,TP01247,HDAC7;VEGFA,HDAC7,VEGFA,CET+CIT,Tclin+Tclin,0.385,0.516,0.513,0,0,2,2,2,DC00469,Bevacizumab;Panobinostat,DrugComb,FD00017,Glioma,Glioma,Phase 1|Phase 2
4027,TP01248,HDAC8;JAK1,HDAC8,JAK1,CIT+CIT,Tclin+Tclin,0.172,0.72,0.555,1,0,0,1,1,DC01670,Panobinostat;Ruxolitinib,DrugComb,FD00030,Myeloma,Hematologic Malignancy,Phase 1|Phase 2
4028,TP01249,HDAC8;JAK2,HDAC8,JAK2,CIT+CIT,Tclin+Tclin,0.213,0.726,0.582,0,0,0,1,1,DC01670,Panobinostat;Ruxolitinib,DrugComb,FD00030,Myeloma,Hematologic Malignancy,Phase 1|Phase 2
4029,TP01250,HDAC8;MS4A1,HDAC8,MS4A1,CIT+CIT,Tclin+Tclin,0.157,0.704,0.555,0,0,0,1,1,DC01669,Panobinostat;Rituximab,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 2
4030,TP01251,HDAC8;MTOR,HDAC8,MTOR,CIT+CIT,Tclin+Tclin,0.233,0.657,0.434,1,0,0,4,4,DC01954,Temsirolimus;Vorinostat,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
4031,TP01251,HDAC8;MTOR,HDAC8,MTOR,CIT+CIT,Tclin+Tclin,0.233,0.657,0.434,1,0,0,4,4,DC01954,Temsirolimus;Vorinostat,DrugComb,FD00038,Prostate Cancer,Prostate Cancer,Phase 1
4032,TP01251,HDAC8;MTOR,HDAC8,MTOR,CIT+CIT,Tclin+Tclin,0.233,0.657,0.434,1,0,0,4,4,DC01110,Everolimus;Panobinostat,DrugComb,FD00017,Glioma,Glioma,Phase 2
4033,TP01251,HDAC8;MTOR,HDAC8,MTOR,CIT+CIT,Tclin+Tclin,0.233,0.657,0.434,1,0,0,4,4,DC01110,Everolimus;Panobinostat,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 1|Phase 2
4036,TP01252,HDAC8;PDCD1,HDAC8,PDCD1,CET+CIT,Tclin+Tclin,0.135,0.465,1.0,0,0,0,6,6,DC01672,Panobinostat;Spartalizumab,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
4037,TP01252,HDAC8;PDCD1,HDAC8,PDCD1,CET+CIT,Tclin+Tclin,0.135,0.465,1.0,0,0,0,6,6,DC01672,Panobinostat;Spartalizumab,DrugComb,FD00026,Melanoma,Melanoma,Phase 1
4039,TP01252,HDAC8;PDCD1,HDAC8,PDCD1,CET+CIT,Tclin+Tclin,0.135,0.465,1.0,0,0,0,6,6,DC01001,Entinostat;Pembrolizumab,DrugComb,FD00011,Colorectal Cancer,Colorectal Cancer,Phase 1|Phase 2
4042,TP01252,HDAC8;PDCD1,HDAC8,PDCD1,CET+CIT,Tclin+Tclin,0.135,0.465,1.0,0,0,0,6,6,DC01001,Entinostat;Pembrolizumab,DrugComb,FD00030,Myeloma,Hematologic Malignancy,Phase 1
4043,TP01252,HDAC8;PDCD1,HDAC8,PDCD1,CET+CIT,Tclin+Tclin,0.135,0.465,1.0,0,0,0,6,6,DC01706,Pembrolizumab;Romidepsin,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 1|Phase 2
4044,TP01252,HDAC8;PDCD1,HDAC8,PDCD1,CET+CIT,Tclin+Tclin,0.135,0.465,1.0,0,0,0,6,6,DC01000,Entinostat;Nivolumab,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1|Phase 2
4046,TP01253,HDAC8;PIK3CA,HDAC8,PIK3CA,CIT+CIT,Tclin+Tclin,0.211,0.569,0.346,2,0,0,1,1,DC00804,Copanlisib;Romidepsin,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 1
4047,TP01254,HDAC8;PIK3CD,HDAC8,PIK3CD,CIT+CIT,Tclin+Tclin,0.153,0.619,0.348,2,0,0,4,1,DC01675,Parsaclisib;Romidepsin,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 1
4051,TP01255,HDAC8;PIK3CG,HDAC8,PIK3CG,CIT+CIT,Tclin+Tclin,0.153,0.593,0.372,0,0,0,2,1,DC00958,Duvelisib;Romidepsin,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 1
4053,TP01256,HDAC8;RXRA,HDAC8,RXRA,CIT+CIT,Tclin+Tclin,0.367,0.704,0.448,0,0,0,3,3,DC01357,Isotretinoin;Vorinostat,DrugComb,FD00020,Kidney Cancer,Kidney Cancer,Phase 1|Phase 2
4054,TP01256,HDAC8;RXRA,HDAC8,RXRA,CIT+CIT,Tclin+Tclin,0.367,0.704,0.448,0,0,0,3,3,DC01357,Isotretinoin;Vorinostat,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 1
4055,TP01256,HDAC8;RXRA,HDAC8,RXRA,CIT+CIT,Tclin+Tclin,0.367,0.704,0.448,0,0,0,3,3,DC01357,Isotretinoin;Vorinostat,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
4058,TP01257,HDAC8;RXRB,HDAC8,RXRB,CIT+CIT,Tclin+Tclin,0.405,0.826,0.414,0,0,0,3,3,DC01357,Isotretinoin;Vorinostat,DrugComb,FD00020,Kidney Cancer,Kidney Cancer,Phase 1|Phase 2
4059,TP01257,HDAC8;RXRB,HDAC8,RXRB,CIT+CIT,Tclin+Tclin,0.405,0.826,0.414,0,0,0,3,3,DC01357,Isotretinoin;Vorinostat,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 1
4060,TP01257,HDAC8;RXRB,HDAC8,RXRB,CIT+CIT,Tclin+Tclin,0.405,0.826,0.414,0,0,0,3,3,DC01357,Isotretinoin;Vorinostat,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
4063,TP01258,HDAC8;RXRG,HDAC8,RXRG,CIT+CIT,Tclin+Tclin,0.312,0.779,0.446,0,0,0,2,3,DC01357,Isotretinoin;Vorinostat,DrugComb,FD00020,Kidney Cancer,Kidney Cancer,Phase 1|Phase 2
4064,TP01258,HDAC8;RXRG,HDAC8,RXRG,CIT+CIT,Tclin+Tclin,0.312,0.779,0.446,0,0,0,2,3,DC01357,Isotretinoin;Vorinostat,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 1
4065,TP01258,HDAC8;RXRG,HDAC8,RXRG,CIT+CIT,Tclin+Tclin,0.312,0.779,0.446,0,0,0,2,3,DC01357,Isotretinoin;Vorinostat,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
4067,TP01259,HDAC8;VEGFA,HDAC8,VEGFA,CET+CIT,Tclin+Tclin,0.194,0.512,0.548,0,0,0,2,2,DC00469,Bevacizumab;Panobinostat,DrugComb,FD00017,Glioma,Glioma,Phase 1|Phase 2
4068,TP01259,HDAC8;VEGFA,HDAC8,VEGFA,CET+CIT,Tclin+Tclin,0.194,0.512,0.548,0,0,0,2,2,DC00487,Bevacizumab;Vorinostat,DrugComb,FD00020,Kidney Cancer,Kidney Cancer,Phase 1|Phase 2
4069,TP01260,HDAC9;JAK1,HDAC9,JAK1,CIT+CIT,Tclin+Tclin,0.335,0.661,0.529,1,0,0,1,1,DC01670,Panobinostat;Ruxolitinib,DrugComb,FD00030,Myeloma,Hematologic Malignancy,Phase 1|Phase 2
4070,TP01261,HDAC9;JAK2,HDAC9,JAK2,CIT+CIT,Tclin+Tclin,0.33,0.609,0.584,0,0,0,1,1,DC01670,Panobinostat;Ruxolitinib,DrugComb,FD00030,Myeloma,Hematologic Malignancy,Phase 1|Phase 2
4071,TP01262,HDAC9;MS4A1,HDAC9,MS4A1,CIT+CIT,Tclin+Tclin,0.296,0.512,0.487,0,0,0,1,1,DC01669,Panobinostat;Rituximab,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 2
4072,TP01263,HDAC9;MTOR,HDAC9,MTOR,CIT+CIT,Tclin+Tclin,0.372,0.653,0.446,1,0,3,4,4,DC01110,Everolimus;Panobinostat,DrugComb,FD00017,Glioma,Glioma,Phase 2
4073,TP01263,HDAC9;MTOR,HDAC9,MTOR,CIT+CIT,Tclin+Tclin,0.372,0.653,0.446,1,0,3,4,4,DC01110,Everolimus;Panobinostat,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 1|Phase 2
4074,TP01263,HDAC9;MTOR,HDAC9,MTOR,CIT+CIT,Tclin+Tclin,0.372,0.653,0.446,1,0,3,4,4,DC01911,Sirolimus;Vorinostat,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
4077,TP01263,HDAC9;MTOR,HDAC9,MTOR,CIT+CIT,Tclin+Tclin,0.372,0.653,0.446,1,0,3,4,4,DC01954,Temsirolimus;Vorinostat,DrugComb,FD00038,Prostate Cancer,Prostate Cancer,Phase 1
4078,TP01264,HDAC9;PDCD1,HDAC9,PDCD1,CET+CIT,Tclin+Tclin,0.209,0.237,1.0,0,0,0,2,2,DC01769,Pembrolizumab;Vorinostat,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 2
4080,TP01264,HDAC9;PDCD1,HDAC9,PDCD1,CET+CIT,Tclin+Tclin,0.209,0.237,1.0,0,0,0,2,2,DC01672,Panobinostat;Spartalizumab,DrugComb,FD00026,Melanoma,Melanoma,Phase 1
4081,TP01265,HDAC9;RXRA,HDAC9,RXRA,CIT+CIT,Tclin+Tclin,0.363,0.828,0.467,0,0,0,2,3,DC01357,Isotretinoin;Vorinostat,DrugComb,FD00020,Kidney Cancer,Kidney Cancer,Phase 1|Phase 2
4082,TP01265,HDAC9;RXRA,HDAC9,RXRA,CIT+CIT,Tclin+Tclin,0.363,0.828,0.467,0,0,0,2,3,DC01357,Isotretinoin;Vorinostat,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 1
4083,TP01265,HDAC9;RXRA,HDAC9,RXRA,CIT+CIT,Tclin+Tclin,0.363,0.828,0.467,0,0,0,2,3,DC01357,Isotretinoin;Vorinostat,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
4085,TP01266,HDAC9;RXRB,HDAC9,RXRB,CIT+CIT,Tclin+Tclin,0.347,0.835,0.413,0,0,0,2,3,DC01357,Isotretinoin;Vorinostat,DrugComb,FD00020,Kidney Cancer,Kidney Cancer,Phase 1|Phase 2
4086,TP01266,HDAC9;RXRB,HDAC9,RXRB,CIT+CIT,Tclin+Tclin,0.347,0.835,0.413,0,0,0,2,3,DC01357,Isotretinoin;Vorinostat,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 1
4087,TP01266,HDAC9;RXRB,HDAC9,RXRB,CIT+CIT,Tclin+Tclin,0.347,0.835,0.413,0,0,0,2,3,DC01357,Isotretinoin;Vorinostat,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
4089,TP01267,HDAC9;RXRG,HDAC9,RXRG,CIT+CIT,Tclin+Tclin,0.392,0.788,0.433,0,0,0,1,3,DC01357,Isotretinoin;Vorinostat,DrugComb,FD00020,Kidney Cancer,Kidney Cancer,Phase 1|Phase 2
4090,TP01267,HDAC9;RXRG,HDAC9,RXRG,CIT+CIT,Tclin+Tclin,0.392,0.788,0.433,0,0,0,1,3,DC01357,Isotretinoin;Vorinostat,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 1
4091,TP01267,HDAC9;RXRG,HDAC9,RXRG,CIT+CIT,Tclin+Tclin,0.392,0.788,0.433,0,0,0,1,3,DC01357,Isotretinoin;Vorinostat,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
4092,TP01268,HDAC9;VEGFA,HDAC9,VEGFA,CET+CIT,Tclin+Tclin,0.384,0.459,0.506,0,0,2,2,2,DC00469,Bevacizumab;Panobinostat,DrugComb,FD00017,Glioma,Glioma,Phase 1|Phase 2
4093,TP01268,HDAC9;VEGFA,HDAC9,VEGFA,CET+CIT,Tclin+Tclin,0.384,0.459,0.506,0,0,2,2,2,DC00487,Bevacizumab;Vorinostat,DrugComb,FD00020,Kidney Cancer,Kidney Cancer,Phase 1|Phase 2
4094,TP01269,HGF;VEGFA,HGF,VEGFA,CET+CET,Tchem+Tclin,0.566,0.801,0.788,11,2,9,1,1,DC02195,MP0250,BsAb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
4095,TP01270,HLA-DRB1;MS4A1,HLA-DRB1,MS4A1,CET+CIT,Tchem+Tclin,0.408,0.663,0.633,1,0,0,1,2,DC00233,Apolizumab;Rituximab,DrugComb,FD00021,Leukemia,Hematologic Malignancy,Phase 1
4096,TP01270,HLA-DRB1;MS4A1,HLA-DRB1,MS4A1,CET+CIT,Tchem+Tclin,0.408,0.663,0.633,1,0,0,1,2,DC00233,Apolizumab;Rituximab,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 1
4097,TP01271,HLA-G;PDCD1,HLA-G,PDCD1,CET+CET,Tbio+Tclin,0.439,0.512,1.0,1,0,0,1,1,DC01752,Pembrolizumab;TTX080,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
4098,TP01272,HSP90AA1;JAK1,HSP90AA1,JAK1,CIT+CIT,Tchem+Tclin,0.333,0.658,0.589,5,3,4,1,1,DC01888,Ruxolitinib;Zelavespib,DrugComb,FD00030,Myeloma,Hematologic Malignancy,Phase 1
4099,TP01273,HSP90AA1;JAK2,HSP90AA1,JAK2,CIT+CIT,Tchem+Tclin,0.422,0.643,0.608,6,2,4,1,1,DC01888,Ruxolitinib;Zelavespib,DrugComb,FD00030,Myeloma,Hematologic Malignancy,Phase 1
4100,TP01274,HSP90AA1;MET,HSP90AA1,MET,CIT+CIT,Tchem+Tclin,0.37,0.512,0.569,2,0,3,2,1,DC00817,Crizotinib;Ganetespib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
4102,TP01275,HSP90AA1;MTOR,HSP90AA1,MTOR,CIT+CIT,Tchem+Tclin,0.408,0.697,0.553,5,2,5,2,2,DC01203,Ganetespib;Sirolimus,DrugComb,FD00040,Soft Tissue Sarcoma,Other Cancer,Phase 1|Phase 2
4103,TP01275,HSP90AA1;MTOR,HSP90AA1,MTOR,CIT+CIT,Tchem+Tclin,0.408,0.697,0.553,5,2,5,2,2,DC01113,Everolimus;Retaspimycin,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
4104,TP01276,HSP90AA1;PDCD1,HSP90AA1,PDCD1,CET+CIT,Tchem+Tclin,0.249,0.358,1.0,0,1,0,1,1,DC01814,Pimitespib;Zimberelimab,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
4105,TP01277,HSP90AA1;PIK3CA,HSP90AA1,PIK3CA,CIT+CIT,Tchem+Tclin,0.378,0.611,0.49,9,6,4,1,1,DC00155,Alpelisib;Luminespib,DrugComb,FD00041,Stomach Cancer,Stomach Cancer,Phase 1
4106,TP01278,HSP90AB1;JAK1,HSP90AB1,JAK1,CIT+CIT,Tchem+Tclin,0.376,0.637,0.586,5,2,3,1,1,DC01888,Ruxolitinib;Zelavespib,DrugComb,FD00030,Myeloma,Hematologic Malignancy,Phase 1
4107,TP01279,HSP90AB1;JAK2,HSP90AB1,JAK2,CIT+CIT,Tchem+Tclin,0.484,0.646,0.614,6,1,3,1,1,DC01888,Ruxolitinib;Zelavespib,DrugComb,FD00030,Myeloma,Hematologic Malignancy,Phase 1
4108,TP01280,HSP90AB1;MET,HSP90AB1,MET,CIT+CIT,Tchem+Tclin,0.392,0.56,0.572,2,0,3,2,1,DC00821,Crizotinib;Onalespib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
4110,TP01281,HSP90AB1;MTOR,HSP90AB1,MTOR,CIT+CIT,Tchem+Tclin,0.435,0.684,0.56,5,1,3,2,2,DC01203,Ganetespib;Sirolimus,DrugComb,FD00040,Soft Tissue Sarcoma,Other Cancer,Phase 1|Phase 2
4111,TP01281,HSP90AB1;MTOR,HSP90AB1,MTOR,CIT+CIT,Tchem+Tclin,0.435,0.684,0.56,5,1,3,2,2,DC01113,Everolimus;Retaspimycin,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
4112,TP01282,HSP90AB1;PDCD1,HSP90AB1,PDCD1,CET+CIT,Tchem+Tclin,0.23,0.385,1.0,0,1,0,1,1,DC01814,Pimitespib;Zimberelimab,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
4113,TP01283,HSP90AB1;PIK3CA,HSP90AB1,PIK3CA,CIT+CIT,Tchem+Tclin,0.414,0.614,0.534,9,0,3,1,1,DC00155,Alpelisib;Luminespib,DrugComb,FD00041,Stomach Cancer,Stomach Cancer,Phase 1
4114,TP01284,ICOS;LAG3,ICOS,LAG3,CET+CET,Tbio+Tclin,0.386,0.958,1.0,0,0,0,1,1,DC01368,Izuralimab;Pavunalimab,DrugComb,FD00026,Melanoma,Melanoma,Phase 1
4115,TP01285,ICOS;PDCD1,ICOS,PDCD1,CET+CET,Tbio+Tclin,0.477,0.849,1.0,2,0,3,4,3,DC01816,Pimivalimab;Vopratelimab,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 2
4119,TP01285,ICOS;PDCD1,ICOS,PDCD1,CET+CET,Tbio+Tclin,0.477,0.849,1.0,2,0,3,4,3,DC02154,Izuralimab,BsAb,FD00026,Melanoma,Melanoma,Phase 1
4120,TP01285,ICOS;PDCD1,ICOS,PDCD1,CET+CET,Tbio+Tclin,0.477,0.849,1.0,2,0,3,4,3,DC02154,Izuralimab,BsAb,FD00040,Soft Tissue Sarcoma,Other Cancer,Phase 2
4121,TP01286,IDH1;PDCD1,IDH1,PDCD1,CET+CIT,Tclin+Tclin,0.193,0.251,1.0,0,0,0,1,1,DC01768,Pembrolizumab;Vorasidenib,DrugComb,FD00004,Astrocytoma,Other Cancer,Phase 1
4122,TP01287,IDH2;JAK1,IDH2,JAK1,CIT+CIT,Tclin+Tclin,0.146,0.608,0.286,0,0,0,1,1,DC00981,Enasidenib;Ruxolitinib,DrugComb,FD00030,Myeloma,Hematologic Malignancy,Phase 2
4123,TP01288,IDH2;JAK2,IDH2,JAK2,CIT+CIT,Tclin+Tclin,0.115,0.52,0.25,0,0,0,1,1,DC00981,Enasidenib;Ruxolitinib,DrugComb,FD00030,Myeloma,Hematologic Malignancy,Phase 2
4124,TP01289,IDH2;PDCD1,IDH2,PDCD1,CET+CIT,Tclin+Tclin,0.122,0.24,0.311,0,0,0,1,1,DC01768,Pembrolizumab;Vorasidenib,DrugComb,FD00004,Astrocytoma,Other Cancer,Phase 1
4125,TP01290,IDO1;JAK1,IDO1,JAK1,CET+CIT,Tchem+Tclin,0.213,0.659,0.302,0,0,1,1,1,DC01025,Epacadostat;Itacitinib,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
4126,TP01291,IDO1;MTOR,IDO1,MTOR,CET+CIT,Tchem+Tclin,0.287,0.499,0.241,0,0,2,1,1,DC01029,Epacadostat;Sirolimus,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
4127,TP01292,IDO1;PDCD1,IDO1,PDCD1,CET+CET,Tchem+Tclin,0.389,0.293,0.357,0,0,1,7,9,DC00565,BMS986242;Nivolumab,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1|Phase 2
4128,TP01292,IDO1;PDCD1,IDO1,PDCD1,CET+CET,Tchem+Tclin,0.389,0.293,0.357,0,0,1,7,9,DC01026,Epacadostat;Nivolumab,DrugComb,FD00011,Colorectal Cancer,Colorectal Cancer,Phase 1|Phase 2
4129,TP01292,IDO1;PDCD1,IDO1,PDCD1,CET+CET,Tchem+Tclin,0.389,0.293,0.357,0,0,1,7,9,DC01026,Epacadostat;Nivolumab,DrugComb,FD00017,Glioma,Glioma,Phase 1|Phase 2
4130,TP01292,IDO1;PDCD1,IDO1,PDCD1,CET+CET,Tchem+Tclin,0.389,0.293,0.357,0,0,1,7,9,DC01026,Epacadostat;Nivolumab,DrugComb,FD00018,Head and Neck Cancer,Head and Neck Cancer,Phase 1|Phase 2
4131,TP01292,IDO1;PDCD1,IDO1,PDCD1,CET+CET,Tchem+Tclin,0.389,0.293,0.357,0,0,1,7,9,DC01026,Epacadostat;Nivolumab,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
4132,TP01292,IDO1;PDCD1,IDO1,PDCD1,CET+CET,Tchem+Tclin,0.389,0.293,0.357,0,0,1,7,9,DC01026,Epacadostat;Nivolumab,DrugComb,FD00026,Melanoma,Melanoma,Phase 1|Phase 2
4133,TP01292,IDO1;PDCD1,IDO1,PDCD1,CET+CET,Tchem+Tclin,0.389,0.293,0.357,0,0,1,7,9,DC01026,Epacadostat;Nivolumab,DrugComb,FD00034,Ovarian Cancer,Ovarian Cancer,Phase 1|Phase 2
4137,TP01292,IDO1;PDCD1,IDO1,PDCD1,CET+CET,Tchem+Tclin,0.389,0.293,0.357,0,0,1,7,9,DC01027,Epacadostat;Pembrolizumab,DrugComb,FD00006,Bladder Cancer,Bladder Cancer,Phase 3
4139,TP01292,IDO1;PDCD1,IDO1,PDCD1,CET+CET,Tchem+Tclin,0.389,0.293,0.357,0,0,1,7,9,DC01027,Epacadostat;Pembrolizumab,DrugComb,FD00020,Kidney Cancer,Kidney Cancer,Phase 3
4144,TP01293,IDO2;PDCD1,IDO2,PDCD1,CET+CIT,Tchem+Tclin,0.267,0.318,0.357,0,0,0,2,1,DC01318,Indoximod;Nivolumab,DrugComb,FD00026,Melanoma,Melanoma,Phase 2
4146,TP01294,IFNAR1;MS4A1,IFNAR1,MS4A1,CIT+CIT,Tclin+Tclin,0.387,0.625,0.551,0,0,0,1,1,DC02096,Eramkafusp Alfa,BsAb,FD00024,Lymphoma,Hematologic Malignancy,Phase 1
4147,TP01295,IFNAR1;PDCD1,IFNAR1,PDCD1,CET+CIT,Tclin+Tclin,0.187,0.629,1.0,0,1,0,1,1,DC01496,Modakafusp Alfa;Pembrolizumab,DrugComb,FD00026,Melanoma,Melanoma,Phase 1|Phase 2
4148,TP01296,IFNAR1;VEGFA,IFNAR1,VEGFA,CET+CIT,Tclin+Tclin,0.204,0.495,0.544,4,0,3,1,1,DC00451,Bevacizumab;Interferon alfa-2a,DrugComb,FD00020,Kidney Cancer,Kidney Cancer,Phase 3
4149,TP01297,IFNAR2;MS4A1,IFNAR2,MS4A1,CIT+CIT,Tclin+Tclin,0.442,0.749,0.551,0,0,1,1,1,DC02096,Eramkafusp Alfa,BsAb,FD00024,Lymphoma,Hematologic Malignancy,Phase 1
4150,TP01298,IFNAR2;PDCD1,IFNAR2,PDCD1,CET+CIT,Tclin+Tclin,0.213,0.739,1.0,0,0,1,1,1,DC01496,Modakafusp Alfa;Pembrolizumab,DrugComb,FD00026,Melanoma,Melanoma,Phase 1|Phase 2
4151,TP01299,IFNAR2;VEGFA,IFNAR2,VEGFA,CET+CIT,Tclin+Tclin,0.2,0.572,0.544,4,0,3,1,1,DC00451,Bevacizumab;Interferon alfa-2a,DrugComb,FD00020,Kidney Cancer,Kidney Cancer,Phase 3
4152,TP01300,IGF1;IGF2,IGF1,IGF2,CIT+CIT,Tbio+Tbio,0.559,0.811,0.927,5,5,9,1,3,DC02296,Xentuzumab,BsAb,FD00007,Breast Cancer,Breast Cancer,Phase 1
4153,TP01300,IGF1;IGF2,IGF1,IGF2,CIT+CIT,Tbio+Tbio,0.559,0.811,0.927,5,5,9,1,3,DC02296,Xentuzumab,BsAb,FD00023,Lung Cancer,Lung Cancer,Phase 1
4154,TP01300,IGF1;IGF2,IGF1,IGF2,CIT+CIT,Tbio+Tbio,0.559,0.811,0.927,5,5,9,1,3,DC02296,Xentuzumab,BsAb,FD00038,Prostate Cancer,Prostate Cancer,Phase 1
4155,TP01301,IGF1R;MAP2K1,IGF1R,MAP2K1,CIT+CIT,Tclin+Tclin,0.526,0.638,0.724,22,0,13,1,1,DC00533,Binimetinib;Ganitumab,DrugComb,FD00035,Pancreatic Cancer,Pancreatic Cancer,Phase 1|Phase 2
4156,TP01302,IGF1R;MAP2K2,IGF1R,MAP2K2,CIT+CIT,Tclin+Tclin,0.373,0.572,0.72,19,0,12,1,1,DC00533,Binimetinib;Ganitumab,DrugComb,FD00035,Pancreatic Cancer,Pancreatic Cancer,Phase 1|Phase 2
4157,TP01303,IGF1R;MTOR,IGF1R,MTOR,CIT+CIT,Tclin+Tclin,0.471,0.623,0.7,15,0,17,3,1,DC00842,Dalotuzumab;Ridaforolimus,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
4160,TP01304,IGF1R;NOTCH1,IGF1R,NOTCH1,CIT+CIT,Tchem+Tclin,0.483,0.677,0.544,3,0,4,1,1,DC00840,Dalotuzumab;MK0752,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
4161,TP01305,IGF1R;NOTCH2,IGF1R,NOTCH2,CIT+CIT,Tchem+Tclin,0.451,0.741,0.537,3,0,3,1,1,DC00840,Dalotuzumab;MK0752,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
4162,TP01306,IGF1R;PIK3CA,IGF1R,PIK3CA,CIT+CIT,Tclin+Tclin,0.56,0.64,0.682,22,1,15,1,1,DC00150,Alpelisib;Ganitumab,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1|Phase 2
4163,TP01307,IGF1R;TNFRSF10B,IGF1R,TNFRSF10B,CIT+CIT,Tbio+Tclin,0.406,0.533,0.537,0,0,1,1,1,DC00796,Conatumumab;Ganitumab,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 2
4164,TP01308,IGSF1;PDCD1,IGSF1,PDCD1,CET+CIT,Tbio+Tclin,0.138,0.709,1.0,0,0,0,1,1,DC01772,Pembrolizumab;WM-A1-3389,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
4165,TP01309,IKZF2;PDCD1,IKZF2,PDCD1,CET+CIT,Tbio+Tclin,0.231,0.183,1.0,0,0,0,1,1,DC00899,DKY709;Spartalizumab,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
4166,TP01310,IL10;TLR9,IL10,TLR9,CET+CIT,Tbio+Tclin,0.575,0.384,0.427,4,0,0,1,1,DC01483,MK1966;SD101,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
4167,TP01311,IL10RA;PDCD1,IL10RA,PDCD1,CET+CET,Tbio+Tclin,0.159,0.727,1.0,0,0,0,2,1,DC01691,Pegilodecakin;Pembrolizumab,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 2
4169,TP01312,IL12RB1;PDCD1,IL12RB1,PDCD1,CET+CET,Tbio+Tclin,0.29,0.697,0.788,0,0,0,1,1,DC00883,DF6002;Nivolumab,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1|Phase 2
4170,TP01313,IL15;IL15RA,IL15,IL15RA,CET+CET,Tbio+Tchem,0.348,0.7,0.564,5,1,1,1,2,DC02298,XmAb24306,BsAb,FD00030,Myeloma,Hematologic Malignancy,Phase 1
4171,TP01313,IL15;IL15RA,IL15,IL15RA,CET+CET,Tbio+Tchem,0.348,0.7,0.564,5,1,1,1,2,DC02298,XmAb24306,BsAb,FD00033,Other Cancer,Other Cancer,Phase 1
4172,TP01314,IL15;PDCD1,IL15,PDCD1,CET+CET,Tchem+Tclin,0.33,0.334,1.0,0,0,0,2,2,DC01508,Nanrilkefusp Alfa;Pembrolizumab,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 2
4173,TP01314,IL15;PDCD1,IL15,PDCD1,CET+CET,Tchem+Tclin,0.33,0.334,1.0,0,0,0,2,2,DC02254,SAR445877,BsAb,FD00033,Other Cancer,Other Cancer,Phase 1|Phase 2
4174,TP01315,IL15;TGFBR2,IL15,TGFBR2,CET+CIT,Tchem+Tchem,0.464,0.462,0.447,3,0,1,1,2,DC02126,HCW9218,BsAb,FD00033,Other Cancer,Other Cancer,Phase 1
4175,TP01315,IL15;TGFBR2,IL15,TGFBR2,CET+CIT,Tchem+Tchem,0.464,0.462,0.447,3,0,1,1,2,DC02126,HCW9218,BsAb,FD00035,Pancreatic Cancer,Pancreatic Cancer,Phase 1|Phase 2
4176,TP01316,IL15RA;PDCD1,IL15RA,PDCD1,CET+CET,Tbio+Tclin,0.185,0.564,1.0,0,0,0,2,1,DC00168,ALT803;Nivolumab,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 2
4178,TP01317,IL18R1;PDCD1,IL18R1,PDCD1,CET+CET,Tbio+Tclin,0.368,0.729,1.0,0,0,0,1,1,DC01723,Pembrolizumab;ST-067,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
4179,TP01318,IL1B;PDCD1,IL1B,PDCD1,CET+CET,Tclin+Tclin,0.255,0.308,1.0,0,0,1,3,3,DC00649,Canakinumab;Spartalizumab,DrugComb,FD00020,Kidney Cancer,Kidney Cancer,Early Phase 1
4180,TP01318,IL1B;PDCD1,IL1B,PDCD1,CET+CET,Tclin+Tclin,0.255,0.308,1.0,0,0,1,3,3,DC00649,Canakinumab;Spartalizumab,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
4181,TP01318,IL1B;PDCD1,IL1B,PDCD1,CET+CET,Tclin+Tclin,0.255,0.308,1.0,0,0,1,3,3,DC00649,Canakinumab;Spartalizumab,DrugComb,FD00026,Melanoma,Melanoma,Phase 2
4184,TP01319,IL1RAP;PDCD1,IL1RAP,PDCD1,CET+CIT,Tclin+Tclin,0.307,0.671,0.504,0,0,0,1,1,DC01546,Nidanilimab;Pembrolizumab,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
4185,TP01320,IL2;PDCD1,IL2,PDCD1,CET+CET,Tchem+Tclin,0.369,0.355,1.0,1,0,3,1,2,DC02135,IBI363,BsAb,FD00024,Lymphoma,Hematologic Malignancy,Phase 1
4186,TP01320,IL2;PDCD1,IL2,PDCD1,CET+CET,Tchem+Tclin,0.369,0.355,1.0,1,0,3,1,2,DC02135,IBI363,BsAb,FD00033,Other Cancer,Other Cancer,Phase 1
4187,TP01321,IL21;PDCD1,IL21,PDCD1,CET+CET,Tbio+Tclin,0.247,0.355,1.0,0,0,1,1,1,DC02168,Latikafusp,BsAb,FD00033,Other Cancer,Other Cancer,Phase 1
4188,TP01322,IL21R;PDCD1,IL21R,PDCD1,CET+CIT,Tbio+Tclin,0.251,1.0,1.0,0,0,0,1,1,DC00876,Denenicokin;Nivolumab,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
4189,TP01323,IL27;PDCD1,IL27,PDCD1,CET+CET,Tbio+Tclin,0.298,0.318,1.0,0,0,0,2,1,DC00680,Casdozokitug;Pembrolizumab,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
4191,TP01324,IL2RA;KDR,IL2RA,KDR,CET+CET,Tclin+Tclin,0.31,0.503,0.532,1,0,2,1,6,DC01229,GI101;Lenvatinib,DrugComb,FD00006,Bladder Cancer,Bladder Cancer,Phase 1|Phase 2
4192,TP01324,IL2RA;KDR,IL2RA,KDR,CET+CET,Tclin+Tclin,0.31,0.503,0.532,1,0,2,1,6,DC01229,GI101;Lenvatinib,DrugComb,FD00018,Head and Neck Cancer,Head and Neck Cancer,Phase 1|Phase 2
4193,TP01324,IL2RA;KDR,IL2RA,KDR,CET+CET,Tclin+Tclin,0.31,0.503,0.532,1,0,2,1,6,DC01229,GI101;Lenvatinib,DrugComb,FD00020,Kidney Cancer,Kidney Cancer,Phase 1|Phase 2
4194,TP01324,IL2RA;KDR,IL2RA,KDR,CET+CET,Tclin+Tclin,0.31,0.503,0.532,1,0,2,1,6,DC01229,GI101;Lenvatinib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
4195,TP01324,IL2RA;KDR,IL2RA,KDR,CET+CET,Tclin+Tclin,0.31,0.503,0.532,1,0,2,1,6,DC01229,GI101;Lenvatinib,DrugComb,FD00026,Melanoma,Melanoma,Phase 1|Phase 2
4196,TP01324,IL2RA;KDR,IL2RA,KDR,CET+CET,Tclin+Tclin,0.31,0.503,0.532,1,0,2,1,6,DC01229,GI101;Lenvatinib,DrugComb,FD00040,Soft Tissue Sarcoma,Other Cancer,Phase 1|Phase 2
4197,TP01325,IL2RA;MS4A1,IL2RA,MS4A1,CET+CIT,Tclin+Tclin,0.422,0.664,0.605,1,0,0,2,1,DC00879,Denileukin Diftitox;Rituximab,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 2
4199,TP01326,IL2RA;PDCD1,IL2RA,PDCD1,CET+CET,Tclin+Tclin,0.484,0.824,1.0,0,0,1,11,9,DC01230,GI101;Pembrolizumab,DrugComb,FD00006,Bladder Cancer,Bladder Cancer,Phase 1|Phase 2
4200,TP01326,IL2RA;PDCD1,IL2RA,PDCD1,CET+CET,Tclin+Tclin,0.484,0.824,1.0,0,0,1,11,9,DC01230,GI101;Pembrolizumab,DrugComb,FD00018,Head and Neck Cancer,Head and Neck Cancer,Phase 1|Phase 2
4201,TP01326,IL2RA;PDCD1,IL2RA,PDCD1,CET+CET,Tclin+Tclin,0.484,0.824,1.0,0,0,1,11,9,DC01230,GI101;Pembrolizumab,DrugComb,FD00020,Kidney Cancer,Kidney Cancer,Phase 1|Phase 2
4202,TP01326,IL2RA;PDCD1,IL2RA,PDCD1,CET+CET,Tclin+Tclin,0.484,0.824,1.0,0,0,1,11,9,DC01230,GI101;Pembrolizumab,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
4203,TP01326,IL2RA;PDCD1,IL2RA,PDCD1,CET+CET,Tclin+Tclin,0.484,0.824,1.0,0,0,1,11,9,DC01230,GI101;Pembrolizumab,DrugComb,FD00026,Melanoma,Melanoma,Phase 1|Phase 2
4204,TP01326,IL2RA;PDCD1,IL2RA,PDCD1,CET+CET,Tclin+Tclin,0.484,0.824,1.0,0,0,1,11,9,DC01230,GI101;Pembrolizumab,DrugComb,FD00040,Soft Tissue Sarcoma,Other Cancer,Phase 1|Phase 2
4213,TP01326,IL2RA;PDCD1,IL2RA,PDCD1,CET+CET,Tclin+Tclin,0.484,0.824,1.0,0,0,1,11,9,DC00878,Denileukin Diftitox;Pembrolizumab,DrugComb,FD00034,Ovarian Cancer,Ovarian Cancer,Phase 1|Phase 2
4215,TP01326,IL2RA;PDCD1,IL2RA,PDCD1,CET+CET,Tclin+Tclin,0.484,0.824,1.0,0,0,1,11,9,DC01535,Nemvaleukin Alfa;Pembrolizumab,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1|Phase 2
4219,TP01326,IL2RA;PDCD1,IL2RA,PDCD1,CET+CET,Tclin+Tclin,0.484,0.824,1.0,0,0,1,11,9,DC01773,Pembrolizumab;WTX124,DrugComb,FD00021,Leukemia,Hematologic Malignancy,Phase 1
4221,TP01327,IL2RA;VEGFA,IL2RA,VEGFA,CET+CET,Tclin+Tclin,0.261,0.397,0.569,2,0,4,1,1,DC00112,Aldesleukin;Bevacizumab,DrugComb,FD00020,Kidney Cancer,Kidney Cancer,Phase 2
4222,TP01328,IL2RB;MS4A1,IL2RB,MS4A1,CET+CIT,Tclin+Tclin,0.527,0.745,0.508,0,0,0,2,1,DC00879,Denileukin Diftitox;Rituximab,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 2
4224,TP01329,IL2RB;PDCD1,IL2RB,PDCD1,CET+CET,Tclin+Tclin,0.326,0.686,1.0,0,0,1,14,11,DC01715,Pembrolizumab;Simlukafusp Alfa,DrugComb,FD00026,Melanoma,Melanoma,Phase 1
4225,TP01329,IL2RB;PDCD1,IL2RB,PDCD1,CET+CET,Tclin+Tclin,0.326,0.686,1.0,0,0,1,14,11,DC00002,AB248;Pembrolizumab,DrugComb,FD00018,Head and Neck Cancer,Head and Neck Cancer,Phase 1
4226,TP01329,IL2RB;PDCD1,IL2RB,PDCD1,CET+CET,Tclin+Tclin,0.326,0.686,1.0,0,0,1,14,11,DC00002,AB248;Pembrolizumab,DrugComb,FD00020,Kidney Cancer,Kidney Cancer,Phase 1
4227,TP01329,IL2RB;PDCD1,IL2RB,PDCD1,CET+CET,Tclin+Tclin,0.326,0.686,1.0,0,0,1,14,11,DC00002,AB248;Pembrolizumab,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
4235,TP01329,IL2RB;PDCD1,IL2RB,PDCD1,CET+CET,Tclin+Tclin,0.326,0.686,1.0,0,0,1,14,11,DC01482,MK1484;Pembrolizumab,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
4238,TP01329,IL2RB;PDCD1,IL2RB,PDCD1,CET+CET,Tclin+Tclin,0.326,0.686,1.0,0,0,1,14,11,DC00425,Bempegaldesleukin;Nivolumab,DrugComb,FD00006,Bladder Cancer,Bladder Cancer,Phase 2
4242,TP01329,IL2RB;PDCD1,IL2RB,PDCD1,CET+CET,Tclin+Tclin,0.326,0.686,1.0,0,0,1,14,11,DC00425,Bempegaldesleukin;Nivolumab,DrugComb,FD00035,Pancreatic Cancer,Pancreatic Cancer,Phase 1
4243,TP01329,IL2RB;PDCD1,IL2RB,PDCD1,CET+CET,Tclin+Tclin,0.326,0.686,1.0,0,0,1,14,11,DC00699,Cemiplimab;Pegenzileukin,DrugComb,FD00012,Cutaneous Squamous Cell Carcinoma,Other Cancer,Phase 1|Phase 2
4248,TP01329,IL2RB;PDCD1,IL2RB,PDCD1,CET+CET,Tclin+Tclin,0.326,0.686,1.0,0,0,1,14,11,DC01690,Pegenzileukin;Pembrolizumab,DrugComb,FD00037,Pleural Mesothelioma,Other Cancer,Phase 2
4249,TP01329,IL2RB;PDCD1,IL2RB,PDCD1,CET+CET,Tclin+Tclin,0.326,0.686,1.0,0,0,1,14,11,DC00878,Denileukin Diftitox;Pembrolizumab,DrugComb,FD00034,Ovarian Cancer,Ovarian Cancer,Phase 1|Phase 2
4250,TP01329,IL2RB;PDCD1,IL2RB,PDCD1,CET+CET,Tclin+Tclin,0.326,0.686,1.0,0,0,1,14,11,DC01773,Pembrolizumab;WTX124,DrugComb,FD00021,Leukemia,Hematologic Malignancy,Phase 1
4252,TP01330,IL2RB;SYK,IL2RB,SYK,CET+CIT,Tclin+Tclin,0.344,0.681,0.46,1,1,2,1,1,DC00424,Bempegaldesleukin;Mivavotinib,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 1
4253,TP01331,IL2RB;TLR7,IL2RB,TLR7,CET+CET,Tclin+Tclin,0.336,0.673,0.558,1,0,2,1,2,DC01970,TransCon IL-2 beta/gamma;TransCon TLR7/8 Agonist,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
4254,TP01331,IL2RB;TLR7,IL2RB,TLR7,CET+CET,Tclin+Tclin,0.336,0.673,0.558,1,0,2,1,2,DC01970,TransCon IL-2 beta/gamma;TransCon TLR7/8 Agonist,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1|Phase 2
4255,TP01332,IL2RB;TLR8,IL2RB,TLR8,CET+CET,Tchem+Tclin,0.313,0.688,0.428,0,0,1,1,2,DC01970,TransCon IL-2 beta/gamma;TransCon TLR7/8 Agonist,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
4256,TP01332,IL2RB;TLR8,IL2RB,TLR8,CET+CET,Tchem+Tclin,0.313,0.688,0.428,0,0,1,1,2,DC01970,TransCon IL-2 beta/gamma;TransCon TLR7/8 Agonist,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1|Phase 2
4257,TP01333,IL2RB;VEGFA,IL2RB,VEGFA,CET+CET,Tclin+Tclin,0.256,0.676,0.522,2,0,3,1,1,DC00112,Aldesleukin;Bevacizumab,DrugComb,FD00020,Kidney Cancer,Kidney Cancer,Phase 2
4258,TP01334,IL2RG;MS4A1,IL2RG,MS4A1,CIT+CIT,Tclin+Tclin,0.5,0.715,0.47,0,0,0,2,1,DC00116,Aldesleukin;Rituximab,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 2
4260,TP01335,IL2RG;PDCD1,IL2RG,PDCD1,CET+CIT,Tclin+Tclin,0.355,0.657,1.0,0,0,1,11,9,DC01715,Pembrolizumab;Simlukafusp Alfa,DrugComb,FD00026,Melanoma,Melanoma,Phase 1
4261,TP01335,IL2RG;PDCD1,IL2RG,PDCD1,CET+CIT,Tclin+Tclin,0.355,0.657,1.0,0,0,1,11,9,DC00002,AB248;Pembrolizumab,DrugComb,FD00018,Head and Neck Cancer,Head and Neck Cancer,Phase 1
4262,TP01335,IL2RG;PDCD1,IL2RG,PDCD1,CET+CIT,Tclin+Tclin,0.355,0.657,1.0,0,0,1,11,9,DC00002,AB248;Pembrolizumab,DrugComb,FD00020,Kidney Cancer,Kidney Cancer,Phase 1
4263,TP01335,IL2RG;PDCD1,IL2RG,PDCD1,CET+CIT,Tclin+Tclin,0.355,0.657,1.0,0,0,1,11,9,DC00002,AB248;Pembrolizumab,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
4266,TP01335,IL2RG;PDCD1,IL2RG,PDCD1,CET+CIT,Tclin+Tclin,0.355,0.657,1.0,0,0,1,11,9,DC01741,Pembrolizumab;TransCon IL-2 beta/gamma,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1|Phase 2
4273,TP01335,IL2RG;PDCD1,IL2RG,PDCD1,CET+CIT,Tclin+Tclin,0.355,0.657,1.0,0,0,1,11,9,DC01690,Pegenzileukin;Pembrolizumab,DrugComb,FD00037,Pleural Mesothelioma,Other Cancer,Phase 2
4275,TP01335,IL2RG;PDCD1,IL2RG,PDCD1,CET+CIT,Tclin+Tclin,0.355,0.657,1.0,0,0,1,11,9,DC01773,Pembrolizumab;WTX124,DrugComb,FD00021,Leukemia,Hematologic Malignancy,Phase 1
4276,TP01335,IL2RG;PDCD1,IL2RG,PDCD1,CET+CIT,Tclin+Tclin,0.355,0.657,1.0,0,0,1,11,9,DC00699,Cemiplimab;Pegenzileukin,DrugComb,FD00012,Cutaneous Squamous Cell Carcinoma,Other Cancer,Phase 1|Phase 2
4278,TP01335,IL2RG;PDCD1,IL2RG,PDCD1,CET+CIT,Tclin+Tclin,0.355,0.657,1.0,0,0,1,11,9,DC00878,Denileukin Diftitox;Pembrolizumab,DrugComb,FD00034,Ovarian Cancer,Ovarian Cancer,Phase 1|Phase 2
4280,TP01336,IL2RG;TLR7,IL2RG,TLR7,CET+CIT,Tclin+Tclin,0.398,0.731,0.583,1,0,2,1,2,DC01970,TransCon IL-2 beta/gamma;TransCon TLR7/8 Agonist,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
4281,TP01336,IL2RG;TLR7,IL2RG,TLR7,CET+CIT,Tclin+Tclin,0.398,0.731,0.583,1,0,2,1,2,DC01970,TransCon IL-2 beta/gamma;TransCon TLR7/8 Agonist,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1|Phase 2
4282,TP01337,IL2RG;TLR8,IL2RG,TLR8,CET+CIT,Tchem+Tclin,0.395,0.667,0.442,0,0,1,1,2,DC01970,TransCon IL-2 beta/gamma;TransCon TLR7/8 Agonist,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
4283,TP01337,IL2RG;TLR8,IL2RG,TLR8,CET+CIT,Tchem+Tclin,0.395,0.667,0.442,0,0,1,1,2,DC01970,TransCon IL-2 beta/gamma;TransCon TLR7/8 Agonist,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1|Phase 2
4284,TP01338,IL2RG;VEGFA,IL2RG,VEGFA,CET+CIT,Tclin+Tclin,0.246,0.67,0.498,2,1,3,1,1,DC00112,Aldesleukin;Bevacizumab,DrugComb,FD00020,Kidney Cancer,Kidney Cancer,Phase 2
4285,TP01339,IL4R;PDCD1,IL4R,PDCD1,CET+CET,Tclin+Tclin,0.345,0.633,1.0,0,0,1,1,1,DC00693,Cemiplimab;Dupilumab,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
4286,TP01340,IL6R;PDCD1,IL6R,PDCD1,CET+CET,Tclin+Tclin,0.297,0.665,1.0,0,1,0,1,1,DC00705,Cemiplimab;Sarilumab,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
4287,TP01341,IL7R;PDCD1,IL7R,PDCD1,CET+CIT,Tbio+Tclin,0.4,0.71,1.0,0,0,0,2,3,DC00965,Efineptakin Alfa;Nivolumab,DrugComb,FD00014,Esophageal Cancer,Esophageal Cancer,Phase 1
4288,TP01341,IL7R;PDCD1,IL7R,PDCD1,CET+CIT,Tbio+Tclin,0.4,0.71,1.0,0,0,0,2,3,DC00965,Efineptakin Alfa;Nivolumab,DrugComb,FD00041,Stomach Cancer,Stomach Cancer,Phase 1
4289,TP01341,IL7R;PDCD1,IL7R,PDCD1,CET+CIT,Tbio+Tclin,0.4,0.71,1.0,0,0,0,2,3,DC00966,Efineptakin Alfa;Pembrolizumab,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
4290,TP01342,ITGA5;VEGFA,ITGA5,VEGFA,CET+CET,Tbio+Tclin,0.474,0.59,0.691,5,0,3,1,1,DC00459,Bevacizumab;MINT1526A,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
4291,TP01343,ITGAV;PDCD1,ITGAV,PDCD1,CET+CIT,Tchem+Tclin,0.26,0.557,1.0,1,0,0,1,1,DC01804,PF06940434;Sasanlimab,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
4292,TP01344,ITGAV;VEGFA,ITGAV,VEGFA,CET+CIT,Tchem+Tclin,0.492,0.556,0.613,7,0,6,1,1,DC00437,Bevacizumab;Cilengitide,DrugComb,FD00017,Glioma,Glioma,Phase 2
4293,TP01345,ITGB3;VEGFA,ITGB3,VEGFA,CET+CIT,Tclin+Tclin,0.506,0.518,0.717,8,1,5,1,1,DC00437,Bevacizumab;Cilengitide,DrugComb,FD00017,Glioma,Glioma,Phase 2
4294,TP01346,JAK1;MAP2K1,JAK1,MAP2K1,CIT+CIT,Tclin+Tclin,0.515,0.853,0.717,15,1,24,2,3,DC01884,Ruxolitinib;Trametinib,DrugComb,FD00011,Colorectal Cancer,Colorectal Cancer,Phase 1
4295,TP01346,JAK1;MAP2K1,JAK1,MAP2K1,CIT+CIT,Tclin+Tclin,0.515,0.853,0.717,15,1,24,2,3,DC01884,Ruxolitinib;Trametinib,DrugComb,FD00035,Pancreatic Cancer,Pancreatic Cancer,Phase 1
4296,TP01346,JAK1;MAP2K1,JAK1,MAP2K1,CIT+CIT,Tclin+Tclin,0.515,0.853,0.717,15,1,24,2,3,DC01500,Momelotinib;Trametinib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
4297,TP01347,JAK1;MAP2K2,JAK1,MAP2K2,CIT+CIT,Tclin+Tclin,0.468,0.771,0.768,13,1,20,2,3,DC01884,Ruxolitinib;Trametinib,DrugComb,FD00011,Colorectal Cancer,Colorectal Cancer,Phase 1
4298,TP01347,JAK1;MAP2K2,JAK1,MAP2K2,CIT+CIT,Tclin+Tclin,0.468,0.771,0.768,13,1,20,2,3,DC01884,Ruxolitinib;Trametinib,DrugComb,FD00035,Pancreatic Cancer,Pancreatic Cancer,Phase 1
4299,TP01347,JAK1;MAP2K2,JAK1,MAP2K2,CIT+CIT,Tclin+Tclin,0.468,0.771,0.768,13,1,20,2,3,DC01500,Momelotinib;Trametinib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
4300,TP01348,JAK1;MDM2,JAK1,MDM2,CIT+CIT,Tchem+Tclin,0.38,0.69,0.591,6,0,7,1,1,DC01520,Navtemadlin;Ruxolitinib,DrugComb,FD00030,Myeloma,Hematologic Malignancy,Phase 1|Phase 2
4301,TP01349,JAK1;MTOR,JAK1,MTOR,CIT+CIT,Tclin+Tclin,0.375,0.644,0.671,11,0,18,1,1,DC01102,Everolimus;Itacitinib,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 1|Phase 2
4302,TP01350,JAK1;PDCD1,JAK1,PDCD1,CET+CIT,Tclin+Tclin,0.25,0.399,1.0,1,1,0,4,10,DC01361,Itacitinib;Pembrolizumab,DrugComb,FD00006,Bladder Cancer,Bladder Cancer,Phase 1
4303,TP01350,JAK1;PDCD1,JAK1,PDCD1,CET+CIT,Tclin+Tclin,0.25,0.399,1.0,1,1,0,4,10,DC01361,Itacitinib;Pembrolizumab,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 1
4304,TP01350,JAK1;PDCD1,JAK1,PDCD1,CET+CIT,Tclin+Tclin,0.25,0.399,1.0,1,1,0,4,10,DC01361,Itacitinib;Pembrolizumab,DrugComb,FD00011,Colorectal Cancer,Colorectal Cancer,Phase 1
4305,TP01350,JAK1;PDCD1,JAK1,PDCD1,CET+CIT,Tclin+Tclin,0.25,0.399,1.0,1,1,0,4,10,DC01361,Itacitinib;Pembrolizumab,DrugComb,FD00018,Head and Neck Cancer,Head and Neck Cancer,Phase 1
4306,TP01350,JAK1;PDCD1,JAK1,PDCD1,CET+CIT,Tclin+Tclin,0.25,0.399,1.0,1,1,0,4,10,DC01361,Itacitinib;Pembrolizumab,DrugComb,FD00020,Kidney Cancer,Kidney Cancer,Phase 1
4307,TP01350,JAK1;PDCD1,JAK1,PDCD1,CET+CIT,Tclin+Tclin,0.25,0.399,1.0,1,1,0,4,10,DC01361,Itacitinib;Pembrolizumab,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 2
4308,TP01350,JAK1;PDCD1,JAK1,PDCD1,CET+CIT,Tclin+Tclin,0.25,0.399,1.0,1,1,0,4,10,DC01361,Itacitinib;Pembrolizumab,DrugComb,FD00026,Melanoma,Melanoma,Phase 1
4309,TP01350,JAK1;PDCD1,JAK1,PDCD1,CET+CIT,Tclin+Tclin,0.25,0.399,1.0,1,1,0,4,10,DC01361,Itacitinib;Pembrolizumab,DrugComb,FD00034,Ovarian Cancer,Ovarian Cancer,Phase 1
4310,TP01350,JAK1;PDCD1,JAK1,PDCD1,CET+CIT,Tclin+Tclin,0.25,0.399,1.0,1,1,0,4,10,DC01361,Itacitinib;Pembrolizumab,DrugComb,FD00035,Pancreatic Cancer,Pancreatic Cancer,Phase 1
4311,TP01350,JAK1;PDCD1,JAK1,PDCD1,CET+CIT,Tclin+Tclin,0.25,0.399,1.0,1,1,0,4,10,DC01576,Nivolumab;Ruxolitinib,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 1|Phase 2
4314,TP01351,JAK1;PIK3CA,JAK1,PIK3CA,CIT+CIT,Tclin+Tclin,0.404,0.661,0.661,21,2,17,1,1,DC00619,Buparlisib;Ruxolitinib,DrugComb,FD00030,Myeloma,Hematologic Malignancy,Phase 1
4315,TP01352,JAK1;PIK3CB,JAK1,PIK3CB,CIT+CIT,Tchem+Tclin,0.443,0.761,0.636,21,2,9,1,1,DC00619,Buparlisib;Ruxolitinib,DrugComb,FD00030,Myeloma,Hematologic Malignancy,Phase 1
4316,TP01353,JAK1;PIK3CD,JAK1,PIK3CD,CIT+CIT,Tclin+Tclin,0.459,0.711,0.628,21,1,12,3,2,DC01676,Parsaclisib;Ruxolitinib,DrugComb,FD00030,Myeloma,Hematologic Malignancy,Phase 2
4317,TP01353,JAK1;PIK3CD,JAK1,PIK3CD,CIT+CIT,Tclin+Tclin,0.459,0.711,0.628,21,1,12,3,2,DC01360,Itacitinib;Parsaclisib,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1|Phase 2
4319,TP01354,JAK1;PIK3CG,JAK1,PIK3CG,CIT+CIT,Tclin+Tclin,0.403,0.69,0.7,3,0,5,1,1,DC00619,Buparlisib;Ruxolitinib,DrugComb,FD00030,Myeloma,Hematologic Malignancy,Phase 1
4320,TP01355,JAK1;PIM1,JAK1,PIM1,CIT+CIT,Tchem+Tclin,0.421,0.774,0.748,2,1,1,1,1,DC01886,Ruxolitinib;Uzansertib,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1|Phase 2
4321,TP01356,JAK1;PIM2,JAK1,PIM2,CIT+CIT,Tchem+Tclin,0.363,1.0,0.75,0,0,1,1,1,DC01886,Ruxolitinib;Uzansertib,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1|Phase 2
4322,TP01357,JAK1;PIM3,JAK1,PIM3,CIT+CIT,Tchem+Tclin,0.369,0.68,0.75,0,0,0,1,1,DC01886,Ruxolitinib;Uzansertib,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1|Phase 2
4323,TP01358,JAK1;SMO,JAK1,SMO,CIT+CIT,Tclin+Tclin,0.362,0.51,0.459,1,0,1,1,1,DC01882,Ruxolitinib;Sonidegib,DrugComb,FD00030,Myeloma,Hematologic Malignancy,Phase 1|Phase 2
4324,TP01359,JAK1;SYK,JAK1,SYK,CIT+CIT,Tclin+Tclin,0.446,0.671,0.795,8,4,4,1,1,DC01150,Fostamatinib;Ruxolitinib,DrugComb,FD00030,Myeloma,Hematologic Malignancy,Phase 2
4325,TP01360,JAK2;MAP2K1,JAK2,MAP2K1,CIT+CIT,Tclin+Tclin,0.526,0.735,0.739,14,7,24,2,3,DC01884,Ruxolitinib;Trametinib,DrugComb,FD00011,Colorectal Cancer,Colorectal Cancer,Phase 1
4326,TP01360,JAK2;MAP2K1,JAK2,MAP2K1,CIT+CIT,Tclin+Tclin,0.526,0.735,0.739,14,7,24,2,3,DC01884,Ruxolitinib;Trametinib,DrugComb,FD00035,Pancreatic Cancer,Pancreatic Cancer,Phase 1
4327,TP01360,JAK2;MAP2K1,JAK2,MAP2K1,CIT+CIT,Tclin+Tclin,0.526,0.735,0.739,14,7,24,2,3,DC01500,Momelotinib;Trametinib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
4328,TP01361,JAK2;MAP2K2,JAK2,MAP2K2,CIT+CIT,Tclin+Tclin,0.393,0.668,0.755,12,7,18,2,3,DC01884,Ruxolitinib;Trametinib,DrugComb,FD00011,Colorectal Cancer,Colorectal Cancer,Phase 1
4329,TP01361,JAK2;MAP2K2,JAK2,MAP2K2,CIT+CIT,Tclin+Tclin,0.393,0.668,0.755,12,7,18,2,3,DC01884,Ruxolitinib;Trametinib,DrugComb,FD00035,Pancreatic Cancer,Pancreatic Cancer,Phase 1
4330,TP01361,JAK2;MAP2K2,JAK2,MAP2K2,CIT+CIT,Tclin+Tclin,0.393,0.668,0.755,12,7,18,2,3,DC01500,Momelotinib;Trametinib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
4331,TP01362,JAK2;MDM2,JAK2,MDM2,CIT+CIT,Tchem+Tclin,0.421,0.71,0.607,2,0,3,1,1,DC01520,Navtemadlin;Ruxolitinib,DrugComb,FD00030,Myeloma,Hematologic Malignancy,Phase 1|Phase 2
4332,TP01363,JAK2;PDCD1,JAK2,PDCD1,CET+CIT,Tclin+Tclin,0.274,0.401,1.0,1,1,0,2,1,DC01576,Nivolumab;Ruxolitinib,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 1|Phase 2
4334,TP01364,JAK2;PIK3CA,JAK2,PIK3CA,CIT+CIT,Tclin+Tclin,0.507,0.568,0.705,17,6,18,1,1,DC00619,Buparlisib;Ruxolitinib,DrugComb,FD00030,Myeloma,Hematologic Malignancy,Phase 1
4335,TP01365,JAK2;PIK3CB,JAK2,PIK3CB,CIT+CIT,Tchem+Tclin,0.472,0.731,0.679,17,4,8,1,1,DC00619,Buparlisib;Ruxolitinib,DrugComb,FD00030,Myeloma,Hematologic Malignancy,Phase 1
4336,TP01366,JAK2;PIK3CD,JAK2,PIK3CD,CIT+CIT,Tclin+Tclin,0.5,0.59,0.662,17,3,9,2,1,DC01676,Parsaclisib;Ruxolitinib,DrugComb,FD00030,Myeloma,Hematologic Malignancy,Phase 2
4338,TP01367,JAK2;PIK3CG,JAK2,PIK3CG,CIT+CIT,Tclin+Tclin,0.508,0.576,0.745,5,1,8,1,1,DC00619,Buparlisib;Ruxolitinib,DrugComb,FD00030,Myeloma,Hematologic Malignancy,Phase 1
4339,TP01368,JAK2;PIM1,JAK2,PIM1,CIT+CIT,Tchem+Tclin,0.417,0.763,0.737,3,1,1,1,1,DC01886,Ruxolitinib;Uzansertib,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1|Phase 2
4340,TP01369,JAK2;PIM2,JAK2,PIM2,CIT+CIT,Tchem+Tclin,0.396,1.0,0.737,0,0,1,1,1,DC01886,Ruxolitinib;Uzansertib,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1|Phase 2
4341,TP01370,JAK2;PIM3,JAK2,PIM3,CIT+CIT,Tchem+Tclin,0.309,0.488,0.737,0,0,0,1,1,DC01886,Ruxolitinib;Uzansertib,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1|Phase 2
4342,TP01371,JAK2;SMO,JAK2,SMO,CIT+CIT,Tclin+Tclin,0.478,0.548,0.529,1,0,1,1,1,DC01882,Ruxolitinib;Sonidegib,DrugComb,FD00030,Myeloma,Hematologic Malignancy,Phase 1|Phase 2
4343,TP01372,JAK2;SYK,JAK2,SYK,CIT+CIT,Tclin+Tclin,0.6,0.66,0.835,4,3,3,1,1,DC01150,Fostamatinib;Ruxolitinib,DrugComb,FD00030,Myeloma,Hematologic Malignancy,Phase 2
4344,TP01373,KDM1A;PDCD1,KDM1A,PDCD1,CET+CET,Tchem+Tclin,0.195,0.217,1.0,0,1,0,1,1,DC01568,Nivolumab;Pulrodemstat,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 2
4345,TP01374,KDR;MET,KDR,MET,CET+CIT,Tclin+Tclin,0.58,0.657,0.859,8,0,9,3,4,DC01471,Merestinib;Ramucirumab,DrugComb,FD00011,Colorectal Cancer,Colorectal Cancer,Phase 1
4346,TP01374,KDR;MET,KDR,MET,CET+CIT,Tclin+Tclin,0.58,0.657,0.859,8,0,9,3,4,DC01471,Merestinib;Ramucirumab,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 1
4347,TP01374,KDR;MET,KDR,MET,CET+CIT,Tclin+Tclin,0.58,0.657,0.859,8,0,9,3,4,DC00980,Emibetuzumab;Ramucirumab,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
4348,TP01374,KDR;MET,KDR,MET,CET+CIT,Tclin+Tclin,0.58,0.657,0.859,8,0,9,3,4,DC01266,HS10241;Rivoceranib,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
4349,TP01375,KDR;MTOR,KDR,MTOR,CET+CIT,Tclin+Tclin,0.461,0.593,0.719,3,0,10,4,5,DC00087,AEE788;Everolimus,DrugComb,FD00017,Glioma,Glioma,Phase 1|Phase 2
4350,TP01375,KDR;MTOR,KDR,MTOR,CET+CIT,Tclin+Tclin,0.461,0.593,0.719,3,0,10,4,5,DC01104,Everolimus;Lenvatinib,DrugComb,FD00008,Central Nervous System Tumor,Other Cancer,Phase 1|Phase 2
4351,TP01375,KDR;MTOR,KDR,MTOR,CET+CIT,Tclin+Tclin,0.461,0.593,0.719,3,0,10,4,5,DC01104,Everolimus;Lenvatinib,DrugComb,FD00020,Kidney Cancer,Kidney Cancer,Approval
4352,TP01375,KDR;MTOR,KDR,MTOR,CET+CIT,Tclin+Tclin,0.461,0.593,0.719,3,0,10,4,5,DC01104,Everolimus;Lenvatinib,DrugComb,FD00032,Neuroendocrine Tumor,Other Cancer,Phase 2
4353,TP01375,KDR;MTOR,KDR,MTOR,CET+CIT,Tclin+Tclin,0.461,0.593,0.719,3,0,10,4,5,DC01122,Everolimus;Tivozanib,DrugComb,FD00041,Stomach Cancer,Stomach Cancer,Phase 1|Phase 2
4355,TP01376,KDR;PARP1,KDR,PARP1,CET+CIT,Tclin+Tclin,0.387,0.621,0.559,0,0,2,3,4,DC01198,Fuzuloparib;Rivoceranib,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 1
4356,TP01376,KDR;PARP1,KDR,PARP1,CET+CIT,Tclin+Tclin,0.387,0.621,0.559,0,0,2,3,4,DC01198,Fuzuloparib;Rivoceranib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 2
4357,TP01376,KDR;PARP1,KDR,PARP1,CET+CIT,Tclin+Tclin,0.387,0.621,0.559,0,0,2,3,4,DC01198,Fuzuloparib;Rivoceranib,DrugComb,FD00034,Ovarian Cancer,Ovarian Cancer,Phase 1
4362,TP01376,KDR;PARP1,KDR,PARP1,CET+CIT,Tclin+Tclin,0.387,0.621,0.559,0,0,2,3,4,DC00691,Cediranib;Olaparib,DrugComb,FD00038,Prostate Cancer,Prostate Cancer,Phase 2
4363,TP01377,KDR;PARP2,KDR,PARP2,CET+CIT,Tclin+Tclin,0.272,0.456,0.512,0,0,0,3,4,DC00691,Cediranib;Olaparib,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 1|Phase 2
4364,TP01377,KDR;PARP2,KDR,PARP2,CET+CIT,Tclin+Tclin,0.272,0.456,0.512,0,0,0,3,4,DC00691,Cediranib;Olaparib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 2
4365,TP01377,KDR;PARP2,KDR,PARP2,CET+CIT,Tclin+Tclin,0.272,0.456,0.512,0,0,0,3,4,DC00691,Cediranib;Olaparib,DrugComb,FD00034,Ovarian Cancer,Ovarian Cancer,Phase 2
4366,TP01377,KDR;PARP2,KDR,PARP2,CET+CIT,Tclin+Tclin,0.272,0.456,0.512,0,0,0,3,4,DC00691,Cediranib;Olaparib,DrugComb,FD00038,Prostate Cancer,Prostate Cancer,Phase 2
4371,TP01378,KDR;PDCD1,KDR,PDCD1,CET+CET,Tclin+Tclin,0.316,0.49,1.0,0,0,0,32,18,DC00368,Axitinib;Toripalimab,DrugComb,FD00020,Kidney Cancer,Kidney Cancer,Phase 2
4372,TP01378,KDR;PDCD1,KDR,PDCD1,CET+CET,Tclin+Tclin,0.316,0.49,1.0,0,0,0,32,18,DC00368,Axitinib;Toripalimab,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 2
4373,TP01378,KDR;PDCD1,KDR,PDCD1,CET+CET,Tclin+Tclin,0.316,0.49,1.0,0,0,0,32,18,DC00368,Axitinib;Toripalimab,DrugComb,FD00026,Melanoma,Melanoma,Phase 2
4377,TP01378,KDR;PDCD1,KDR,PDCD1,CET+CET,Tclin+Tclin,0.316,0.49,1.0,0,0,0,32,18,DC01600,Nivolumab;Vorolanib,DrugComb,FD00022,Liver Cancer,Liver Cancer,Phase 1
4379,TP01378,KDR;PDCD1,KDR,PDCD1,CET+CET,Tclin+Tclin,0.316,0.49,1.0,0,0,0,32,18,DC01600,Nivolumab;Vorolanib,DrugComb,FD00041,Stomach Cancer,Stomach Cancer,Phase 1
4380,TP01378,KDR;PDCD1,KDR,PDCD1,CET+CET,Tclin+Tclin,0.316,0.49,1.0,0,0,0,32,18,DC01600,Nivolumab;Vorolanib,DrugComb,FD00042,Thymic Carcinoma,Other Cancer,Phase 1|Phase 2
4389,TP01378,KDR;PDCD1,KDR,PDCD1,CET+CET,Tclin+Tclin,0.316,0.49,1.0,0,0,0,32,18,DC01753,Pembrolizumab;TU2218,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1|Phase 2
4392,TP01378,KDR;PDCD1,KDR,PDCD1,CET+CET,Tclin+Tclin,0.316,0.49,1.0,0,0,0,32,18,DC00647,Camrelizumab;Rivoceranib,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 2
4393,TP01378,KDR;PDCD1,KDR,PDCD1,CET+CET,Tclin+Tclin,0.316,0.49,1.0,0,0,0,32,18,DC00647,Camrelizumab;Rivoceranib,DrugComb,FD00011,Colorectal Cancer,Colorectal Cancer,Phase 1|Phase 2
4394,TP01378,KDR;PDCD1,KDR,PDCD1,CET+CET,Tclin+Tclin,0.316,0.49,1.0,0,0,0,32,18,DC00647,Camrelizumab;Rivoceranib,DrugComb,FD00014,Esophageal Cancer,Esophageal Cancer,Phase 3
4395,TP01378,KDR;PDCD1,KDR,PDCD1,CET+CET,Tclin+Tclin,0.316,0.49,1.0,0,0,0,32,18,DC00647,Camrelizumab;Rivoceranib,DrugComb,FD00016,Gestational Trophoblastic Neoplasia,Other Cancer,Phase 2
4396,TP01378,KDR;PDCD1,KDR,PDCD1,CET+CET,Tclin+Tclin,0.316,0.49,1.0,0,0,0,32,18,DC00647,Camrelizumab;Rivoceranib,DrugComb,FD00018,Head and Neck Cancer,Head and Neck Cancer,Phase 2
4399,TP01378,KDR;PDCD1,KDR,PDCD1,CET+CET,Tclin+Tclin,0.316,0.49,1.0,0,0,0,32,18,DC00647,Camrelizumab;Rivoceranib,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 1|Phase 2
4401,TP01378,KDR;PDCD1,KDR,PDCD1,CET+CET,Tclin+Tclin,0.316,0.49,1.0,0,0,0,32,18,DC00647,Camrelizumab;Rivoceranib,DrugComb,FD00034,Ovarian Cancer,Ovarian Cancer,Phase 2
4402,TP01378,KDR;PDCD1,KDR,PDCD1,CET+CET,Tclin+Tclin,0.316,0.49,1.0,0,0,0,32,18,DC00647,Camrelizumab;Rivoceranib,DrugComb,FD00035,Pancreatic Cancer,Pancreatic Cancer,Phase 2
4413,TP01378,KDR;PDCD1,KDR,PDCD1,CET+CET,Tclin+Tclin,0.316,0.49,1.0,0,0,0,32,18,DC01419,Lenvatinib;Pembrolizumab,DrugComb,FD00030,Myeloma,Hematologic Malignancy,Approval
4417,TP01378,KDR;PDCD1,KDR,PDCD1,CET+CET,Tclin+Tclin,0.316,0.49,1.0,0,0,0,32,18,DC01419,Lenvatinib;Pembrolizumab,DrugComb,FD00043,Vulvar Cancer,Other Cancer,Phase 2
4427,TP01378,KDR;PDCD1,KDR,PDCD1,CET+CET,Tclin+Tclin,0.316,0.49,1.0,0,0,0,32,18,DC01621,Olinvacimab;Pembrolizumab,DrugComb,FD00017,Glioma,Glioma,Phase 1
4442,TP01379,KDR;PIK3CA,KDR,PIK3CA,CET+CIT,Tclin+Tclin,0.548,0.541,0.688,8,1,12,1,1,DC01809,Pilaralisib;Tesevatinib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
4443,TP01380,KDR;PIK3CB,KDR,PIK3CB,CET+CIT,Tchem+Tclin,0.535,0.647,0.666,8,1,7,1,1,DC01809,Pilaralisib;Tesevatinib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
4444,TP01381,KDR;PIK3CD,KDR,PIK3CD,CET+CIT,Tclin+Tclin,0.535,0.57,0.66,8,0,7,1,1,DC01809,Pilaralisib;Tesevatinib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
4445,TP01382,KDR;PIK3CG,KDR,PIK3CG,CET+CIT,Tclin+Tclin,0.492,0.556,0.745,1,0,3,1,1,DC01809,Pilaralisib;Tesevatinib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
4446,TP01383,KDR;ROS1,KDR,ROS1,CET+CIT,Tclin+Tclin,0.509,0.573,0.864,0,0,0,1,1,DC01451,Lorlatinib;Ramucirumab,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
4447,TP01384,KDR;TGFBR1,KDR,TGFBR1,CET+CIT,Tchem+Tclin,0.612,0.798,0.75,1,0,2,1,1,DC01200,Galunisertib;Ramucirumab,DrugComb,FD00022,Liver Cancer,Liver Cancer,Phase 2
4448,TP01385,KDR;VEGFA,KDR,VEGFA,CET+CET,Tclin+Tclin,0.722,0.62,0.546,10,1,16,1,1,DC00435,Bevacizumab;Cediranib,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
4449,TP01386,KLK2;PDCD1,KLK2,PDCD1,CET+CIT,Tchem+Tclin,0.114,0.306,0.099,0,0,0,1,1,DC00720,Cetrelimab;JNJ78278343,DrugComb,FD00038,Prostate Cancer,Prostate Cancer,Phase 1
4450,TP01387,KLRC1;PDCD1,KLRC1,PDCD1,CET+CET,Tbio+Tclin,0.469,0.786,1.0,0,0,0,1,1,DC00704,Cemiplimab;S095029,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
4451,TP01388,KRAS;MAP2K1,KRAS,MAP2K1,CIT+CIT,Tclin+Tclin,0.478,0.739,0.392,73,3,37,3,1,DC00072,Adagrasib;Avutometinib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
4454,TP01389,KRAS;MAP2K2,KRAS,MAP2K2,CIT+CIT,Tclin+Tclin,0.413,0.688,0.39,67,3,33,3,1,DC00072,Adagrasib;Avutometinib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
4457,TP01390,KRAS;MAPK1,KRAS,MAPK1,CIT+CIT,Tchem+Tclin,0.482,0.645,0.429,79,3,44,1,1,DC01035,ERAS007;Sotorasib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
4458,TP01391,KRAS;MAPK3,KRAS,MAPK3,CIT+CIT,Tchem+Tclin,0.433,0.696,0.457,79,3,38,1,1,DC01035,ERAS007;Sotorasib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
4459,TP01392,KRAS;MTOR,KRAS,MTOR,CIT+CIT,Tclin+Tclin,0.38,0.682,0.424,36,0,23,2,1,DC00078,Adagrasib;Nab-sirolimus,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
4461,TP01393,KRAS;PARP1,KRAS,PARP1,CIT+CIT,Tclin+Tclin,0.319,0.491,0.471,1,0,1,1,1,DC00080,Adagrasib;Olaparib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
4462,TP01394,KRAS;PARP2,KRAS,PARP2,CIT+CIT,Tclin+Tclin,0.292,0.371,0.402,1,0,0,1,1,DC00080,Adagrasib;Olaparib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
4463,TP01395,KRAS;PDCD1,KRAS,PDCD1,CET+CIT,Tclin+Tclin,0.281,0.513,1.0,2,0,0,10,1,DC01705,Pembrolizumab;RMC6291,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
4473,TP01396,KRAS;PIK3CA,KRAS,PIK3CA,CIT+CIT,Tclin+Tclin,0.424,0.677,0.322,68,1,29,1,1,DC00897,Divarasib;Inavolisib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
4474,TP01397,KRAS;PTK2,KRAS,PTK2,CET+CIT,Tclin+Tclin,0.462,0.73,0.505,15,0,12,1,1,DC01207,Garsorasib;Ifebemtinib,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1|Phase 2
4475,TP01398,KRAS;PTPN11,KRAS,PTPN11,CIT+CIT,Tchem+Tclin,0.41,0.561,0.45,12,2,8,8,4,DC01369,JAB21822;JAB3312,DrugComb,FD00011,Colorectal Cancer,Colorectal Cancer,Phase 1|Phase 2
4476,TP01398,KRAS;PTPN11,KRAS,PTPN11,CIT+CIT,Tchem+Tclin,0.41,0.561,0.45,12,2,8,8,4,DC01369,JAB21822;JAB3312,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
4477,TP01398,KRAS;PTPN11,KRAS,PTPN11,CIT+CIT,Tchem+Tclin,0.41,0.561,0.45,12,2,8,8,4,DC01369,JAB21822;JAB3312,DrugComb,FD00035,Pancreatic Cancer,Pancreatic Cancer,Phase 1|Phase 2
4481,TP01398,KRAS;PTPN11,KRAS,PTPN11,CIT+CIT,Tchem+Tclin,0.41,0.561,0.45,12,2,8,8,4,DC00073,Adagrasib;Batoprotafib,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1|Phase 2
4485,TP01399,KRAS;RAF1,KRAS,RAF1,CIT+CIT,Tclin+Tclin,0.496,0.755,0.434,72,3,38,2,1,DC00357,Avutometinib;Sotorasib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
4487,TP01400,KRAS;SOS1,KRAS,SOS1,CIT+CIT,Tchem+Tclin,0.445,0.629,0.414,46,1,32,3,1,DC00077,Adagrasib;MRTX0902,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
4490,TP01401,KRAS;ULK1,KRAS,ULK1,CET+CIT,Tchem+Tclin,0.36,0.696,0.548,6,0,4,1,1,DC00872,DCC3116;Sotorasib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
4491,TP01402,KRAS;ULK2,KRAS,ULK2,CET+CIT,Tchem+Tclin,0.343,0.569,0.431,4,0,2,1,1,DC00872,DCC3116;Sotorasib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
4492,TP01403,KRAS;VEGFA,KRAS,VEGFA,CET+CIT,Tclin+Tclin,0.431,0.602,0.498,19,0,10,1,1,DC00442,Bevacizumab;Divarasib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
4493,TP01404,LAG3;PDCD1,LAG3,PDCD1,CET+CET,Tclin+Tclin,0.508,0.913,1.0,0,0,0,19,15,DC01368,Izuralimab;Pavunalimab,DrugComb,FD00026,Melanoma,Melanoma,Phase 1
4494,TP01404,LAG3;PDCD1,LAG3,PDCD1,CET+CET,Tclin+Tclin,0.508,0.913,1.0,0,0,0,19,15,DC01681,Pavunalimab;Pembrolizumab,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
4495,TP01404,LAG3;PDCD1,LAG3,PDCD1,CET+CET,Tclin+Tclin,0.508,0.913,1.0,0,0,0,19,15,DC01388,LBL007;Tislelizumab,DrugComb,FD00018,Head and Neck Cancer,Head and Neck Cancer,Phase 2
4497,TP01404,LAG3;PDCD1,LAG3,PDCD1,CET+CET,Tclin+Tclin,0.508,0.913,1.0,0,0,0,19,15,DC01573,Nivolumab;Relatlimab,DrugComb,FD00011,Colorectal Cancer,Colorectal Cancer,Phase 2
4499,TP01404,LAG3;PDCD1,LAG3,PDCD1,CET+CET,Tclin+Tclin,0.508,0.913,1.0,0,0,0,19,15,DC01573,Nivolumab;Relatlimab,DrugComb,FD00019,Hematologic Malignancies,Hematologic Malignancy,Phase 1|Phase 2
4500,TP01404,LAG3;PDCD1,LAG3,PDCD1,CET+CET,Tclin+Tclin,0.508,0.913,1.0,0,0,0,19,15,DC01573,Nivolumab;Relatlimab,DrugComb,FD00020,Kidney Cancer,Kidney Cancer,Approval
4501,TP01404,LAG3;PDCD1,LAG3,PDCD1,CET+CET,Tclin+Tclin,0.508,0.913,1.0,0,0,0,19,15,DC01573,Nivolumab;Relatlimab,DrugComb,FD00022,Liver Cancer,Liver Cancer,Phase 2
4503,TP01404,LAG3;PDCD1,LAG3,PDCD1,CET+CET,Tclin+Tclin,0.508,0.913,1.0,0,0,0,19,15,DC01573,Nivolumab;Relatlimab,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 1|Phase 2
4505,TP01404,LAG3;PDCD1,LAG3,PDCD1,CET+CET,Tclin+Tclin,0.508,0.913,1.0,0,0,0,19,15,DC01573,Nivolumab;Relatlimab,DrugComb,FD00030,Myeloma,Hematologic Malignancy,Approval
4506,TP01404,LAG3;PDCD1,LAG3,PDCD1,CET+CET,Tclin+Tclin,0.508,0.913,1.0,0,0,0,19,15,DC01573,Nivolumab;Relatlimab,DrugComb,FD00034,Ovarian Cancer,Ovarian Cancer,Approval
4507,TP01404,LAG3;PDCD1,LAG3,PDCD1,CET+CET,Tclin+Tclin,0.508,0.913,1.0,0,0,0,19,15,DC01573,Nivolumab;Relatlimab,DrugComb,FD00041,Stomach Cancer,Stomach Cancer,Approval
4509,TP01404,LAG3;PDCD1,LAG3,PDCD1,CET+CET,Tclin+Tclin,0.508,0.913,1.0,0,0,0,19,15,DC00506,BI754111;Ezabenlimab,DrugComb,FD00033,Other Cancer,Other Cancer,Early Phase 1
4514,TP01404,LAG3;PDCD1,LAG3,PDCD1,CET+CET,Tclin+Tclin,0.508,0.913,1.0,0,0,0,19,15,DC01303,Ieramilimab;Spartalizumab,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 2
4524,TP01404,LAG3;PDCD1,LAG3,PDCD1,CET+CET,Tclin+Tclin,0.508,0.913,1.0,0,0,0,19,15,DC02279,Tobemstomig,BsAb,FD00006,Bladder Cancer,Bladder Cancer,Phase 2
4526,TP01404,LAG3;PDCD1,LAG3,PDCD1,CET+CET,Tclin+Tclin,0.508,0.913,1.0,0,0,0,19,15,DC02279,Tobemstomig,BsAb,FD00014,Esophageal Cancer,Esophageal Cancer,Phase 2
4542,TP01405,LAG3;TIGIT,LAG3,TIGIT,CET+CET,Tbio+Tclin,0.398,0.827,0.712,0,0,0,1,1,DC02307,ZGGS15,BsAb,FD00033,Other Cancer,Other Cancer,Phase 1
4543,TP01406,LAIR1;PDCD1,LAIR1,PDCD1,CET+CET,Tbio+Tclin,1.0,0.73,1.0,0,0,0,2,1,DC01528,NC410;Pembrolizumab,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
4545,TP01407,LGALS3;PDCD1,LGALS3,PDCD1,CET+CIT,Tchem+Tclin,0.325,0.475,1.0,0,0,1,1,1,DC00411,Belapectin;Pembrolizumab,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
4546,TP01408,LILRB1;LILRB2,LILRB1,LILRB2,CET+CET,Tbio+Tbio,0.578,0.736,0.892,2,1,0,1,1,DC02201,NGM707,BsAb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
4547,TP01409,LILRB1;PDCD1,LILRB1,PDCD1,CET+CET,Tbio+Tclin,0.383,0.841,1.0,0,0,0,1,1,DC01544,NGM707;Pembrolizumab,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
4548,TP01410,LILRB2;PDCD1,LILRB2,PDCD1,CET+CET,Tbio+Tclin,0.373,0.576,1.0,0,0,0,4,2,DC01544,NGM707;Pembrolizumab,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
4549,TP01410,LILRB2;PDCD1,LILRB2,PDCD1,CET+CET,Tbio+Tclin,0.373,0.576,1.0,0,0,0,4,2,DC01815,Pimivalimab;Polzastobart,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1|Phase 2
4552,TP01411,LILRB4;PDCD1,LILRB4,PDCD1,CET+CET,Tbio+Tclin,0.356,0.632,1.0,0,0,0,2,1,DC01479,MK0482;Pembrolizumab,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 2
4554,TP01412,LRRC32;PDCD1,LRRC32,PDCD1,CET+CET,Tbio+Tclin,0.207,0.505,1.0,0,0,0,1,1,DC00604,Budigalimab;Livmoniplimab,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
4555,TP01413,MAGEA4;MAGEA8,MAGEA4,MAGEA8,CIT+CIT,Tbio+Tbio,0.513,1.0,1.0,0,0,0,1,1,DC02139,IMA401,BsAb,FD00033,Other Cancer,Other Cancer,Phase 1
4556,TP01414,MAP2K1;MAPK1,MAP2K1,MAPK1,CIT+CIT,Tchem+Tclin,0.649,0.844,0.774,90,11,91,2,4,DC00788,Cobimetinib;Ravoxertinib,DrugComb,FD00011,Colorectal Cancer,Colorectal Cancer,Phase 1
4557,TP01414,MAP2K1;MAPK1,MAP2K1,MAPK1,CIT+CIT,Tchem+Tclin,0.649,0.844,0.774,90,11,91,2,4,DC00788,Cobimetinib;Ravoxertinib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
4558,TP01414,MAP2K1;MAPK1,MAP2K1,MAPK1,CIT+CIT,Tchem+Tclin,0.649,0.844,0.774,90,11,91,2,4,DC00788,Cobimetinib;Ravoxertinib,DrugComb,FD00026,Melanoma,Melanoma,Phase 1
4559,TP01414,MAP2K1;MAPK1,MAP2K1,MAPK1,CIT+CIT,Tchem+Tclin,0.649,0.844,0.774,90,11,91,2,4,DC01491,MK8353;Selumetinib,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
4560,TP01415,MAP2K1;MAPK3,MAP2K1,MAPK3,CIT+CIT,Tchem+Tclin,0.643,0.895,0.789,90,12,78,2,4,DC00788,Cobimetinib;Ravoxertinib,DrugComb,FD00011,Colorectal Cancer,Colorectal Cancer,Phase 1
4561,TP01415,MAP2K1;MAPK3,MAP2K1,MAPK3,CIT+CIT,Tchem+Tclin,0.643,0.895,0.789,90,12,78,2,4,DC00788,Cobimetinib;Ravoxertinib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
4562,TP01415,MAP2K1;MAPK3,MAP2K1,MAPK3,CIT+CIT,Tchem+Tclin,0.643,0.895,0.789,90,12,78,2,4,DC00788,Cobimetinib;Ravoxertinib,DrugComb,FD00026,Melanoma,Melanoma,Phase 1
4563,TP01415,MAP2K1;MAPK3,MAP2K1,MAPK3,CIT+CIT,Tchem+Tclin,0.643,0.895,0.789,90,12,78,2,4,DC01491,MK8353;Selumetinib,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
4564,TP01416,MAP2K1;MDM2,MAP2K1,MDM2,CIT+CIT,Tchem+Tclin,0.424,0.672,0.522,15,0,14,3,3,DC01906,Siremadlin;Trametinib,DrugComb,FD00011,Colorectal Cancer,Colorectal Cancer,Phase 1
4565,TP01416,MAP2K1;MDM2,MAP2K1,MDM2,CIT+CIT,Tchem+Tclin,0.424,0.672,0.522,15,0,14,3,3,DC01522,Navtemadlin;Trametinib,DrugComb,FD00021,Leukemia,Hematologic Malignancy,Phase 1
4566,TP01416,MAP2K1;MDM2,MAP2K1,MDM2,CIT+CIT,Tchem+Tclin,0.424,0.672,0.522,15,0,14,3,3,DC01811,Pimasertib;SAR405838,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
4567,TP01417,MAP2K1;MET,MAP2K1,MET,CIT+CIT,Tclin+Tclin,0.599,0.44,0.733,16,0,12,1,1,DC00664,Capmatinib;Trametinib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
4568,TP01418,MAP2K1;MTOR,MAP2K1,MTOR,CIT+CIT,Tclin+Tclin,0.466,0.625,0.721,35,0,37,7,5,DC01209,Gedatolisib;Mirdametinib,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
4569,TP01418,MAP2K1;MTOR,MAP2K1,MTOR,CIT+CIT,Tclin+Tclin,0.466,0.625,0.721,35,0,37,7,5,DC01813,Pimasertib;Voxtalisib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
4571,TP01418,MAP2K1;MTOR,MAP2K1,MTOR,CIT+CIT,Tclin+Tclin,0.466,0.625,0.721,35,0,37,7,5,DC00356,Avutometinib;Everolimus,DrugComb,FD00030,Myeloma,Hematologic Malignancy,Phase 1
4572,TP01418,MAP2K1;MTOR,MAP2K1,MTOR,CIT+CIT,Tclin+Tclin,0.466,0.625,0.721,35,0,37,7,5,DC01123,Everolimus;Trametinib,DrugComb,FD00017,Glioma,Glioma,Phase 1
4573,TP01418,MAP2K1;MTOR,MAP2K1,MTOR,CIT+CIT,Tclin+Tclin,0.466,0.625,0.721,35,0,37,7,5,DC01896,Selumetinib;Sirolimus,DrugComb,FD00040,Soft Tissue Sarcoma,Other Cancer,Phase 2
4576,TP01419,MAP2K1;PARP1,MAP2K1,PARP1,CIT+CIT,Tclin+Tclin,0.396,0.611,0.511,1,0,3,1,1,DC01617,Olaparib;Selumetinib,DrugComb,FD00034,Ovarian Cancer,Ovarian Cancer,Phase 1
4577,TP01420,MAP2K1;PARP2,MAP2K1,PARP2,CIT+CIT,Tclin+Tclin,0.325,0.568,0.447,1,0,0,1,1,DC01617,Olaparib;Selumetinib,DrugComb,FD00034,Ovarian Cancer,Ovarian Cancer,Phase 1
4578,TP01421,MAP2K1;PDCD1,MAP2K1,PDCD1,CET+CIT,Tclin+Tclin,0.297,0.391,1.0,2,0,1,3,3,DC01714,Pembrolizumab;Selumetinib,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
4579,TP01421,MAP2K1;PDCD1,MAP2K1,PDCD1,CET+CIT,Tclin+Tclin,0.297,0.391,1.0,2,0,1,3,3,DC01929,Spartalizumab;Trametinib,DrugComb,FD00018,Head and Neck Cancer,Head and Neck Cancer,Phase 2
4580,TP01421,MAP2K1;PDCD1,MAP2K1,PDCD1,CET+CIT,Tclin+Tclin,0.297,0.391,1.0,2,0,1,3,3,DC01929,Spartalizumab;Trametinib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
4582,TP01422,MAP2K1;PIK3CA,MAP2K1,PIK3CA,CIT+CIT,Tclin+Tclin,0.476,0.588,0.816,71,0,44,6,2,DC01209,Gedatolisib;Mirdametinib,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
4583,TP01422,MAP2K1;PIK3CA,MAP2K1,PIK3CA,CIT+CIT,Tclin+Tclin,0.476,0.588,0.816,71,0,44,6,2,DC01813,Pimasertib;Voxtalisib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
4588,TP01423,MAP2K1;PIK3CB,MAP2K1,PIK3CB,CIT+CIT,Tchem+Tclin,0.473,0.71,0.64,71,0,30,1,1,DC00622,Buparlisib;Trametinib,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
4589,TP01424,MAP2K1;PIK3CD,MAP2K1,PIK3CD,CIT+CIT,Tclin+Tclin,0.481,0.631,0.633,71,0,32,3,2,DC01813,Pimasertib;Voxtalisib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
4590,TP01424,MAP2K1;PIK3CD,MAP2K1,PIK3CD,CIT+CIT,Tclin+Tclin,0.481,0.631,0.633,71,0,32,3,2,DC00787,Cobimetinib;Pictilisib,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
4592,TP01425,MAP2K1;PIK3CG,MAP2K1,PIK3CG,CIT+CIT,Tclin+Tclin,0.444,0.611,0.761,9,0,18,1,1,DC00622,Buparlisib;Trametinib,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
4593,TP01426,MAP2K1;PTK2,MAP2K1,PTK2,CET+CIT,Tclin+Tclin,0.569,0.788,0.735,16,0,24,2,4,DC00355,Avutometinib;Defactinib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 2
4594,TP01426,MAP2K1;PTK2,MAP2K1,PTK2,CET+CIT,Tclin+Tclin,0.569,0.788,0.735,16,0,24,2,4,DC00355,Avutometinib;Defactinib,DrugComb,FD00034,Ovarian Cancer,Ovarian Cancer,Phase 1
4595,TP01426,MAP2K1;PTK2,MAP2K1,PTK2,CET+CIT,Tclin+Tclin,0.569,0.788,0.735,16,0,24,2,4,DC00355,Avutometinib;Defactinib,DrugComb,FD00035,Pancreatic Cancer,Pancreatic Cancer,Phase 1
4596,TP01426,MAP2K1;PTK2,MAP2K1,PTK2,CET+CIT,Tclin+Tclin,0.569,0.788,0.735,16,0,24,2,4,DC01253,GSK2256098;Trametinib,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
4597,TP01427,MAP2K1;RAF1,MAP2K1,RAF1,CIT+CIT,Tclin+Tclin,0.603,0.758,0.804,79,9,77,5,5,DC01440,Lifirafenib;Mirdametinib,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
4599,TP01427,MAP2K1;RAF1,MAP2K1,RAF1,CIT+CIT,Tclin+Tclin,0.603,0.758,0.804,79,9,77,5,5,DC01969,Trametinib;XP102,DrugComb,FD00011,Colorectal Cancer,Colorectal Cancer,Phase 1|Phase 2
4600,TP01427,MAP2K1;RAF1,MAP2K1,RAF1,CIT+CIT,Tclin+Tclin,0.603,0.758,0.804,79,9,77,5,5,DC01969,Trametinib;XP102,DrugComb,FD00018,Head and Neck Cancer,Head and Neck Cancer,Phase 1|Phase 2
4601,TP01427,MAP2K1;RAF1,MAP2K1,RAF1,CIT+CIT,Tclin+Tclin,0.603,0.758,0.804,79,9,77,5,5,DC01969,Trametinib;XP102,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
4602,TP01427,MAP2K1;RAF1,MAP2K1,RAF1,CIT+CIT,Tclin+Tclin,0.603,0.758,0.804,79,9,77,5,5,DC01969,Trametinib;XP102,DrugComb,FD00026,Melanoma,Melanoma,Phase 1|Phase 2
4606,TP01428,MAP2K1;ROS1,MAP2K1,ROS1,CIT+CIT,Tclin+Tclin,0.533,0.373,0.762,0,0,0,1,1,DC00535,Binimetinib;Lorlatinib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
4607,TP01429,MAP2K1;SOS1,MAP2K1,SOS1,CIT+CIT,Tchem+Tclin,0.531,0.592,0.418,46,0,52,2,1,DC00504,BI1701963;Trametinib,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
4609,TP01430,MAP2K1;TGFB1,MAP2K1,TGFB1,CET+CIT,Tbio+Tclin,0.538,0.616,0.442,16,0,15,1,1,DC00546,Bintrafusp Alfa;Pimasertib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
4610,TP01431,MAP2K1;ULK1,MAP2K1,ULK1,CET+CIT,Tchem+Tclin,0.46,0.632,0.775,4,0,4,2,1,DC00873,DCC3116;Trametinib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
4612,TP01432,MAP2K1;ULK2,MAP2K1,ULK2,CET+CIT,Tchem+Tclin,0.387,0.555,0.803,4,0,3,2,1,DC00525,Binimetinib;DCC3116,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
4614,TP01433,MAP2K2;MAPK1,MAP2K2,MAPK1,CIT+CIT,Tchem+Tclin,0.436,0.798,0.774,78,12,75,1,1,DC01491,MK8353;Selumetinib,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
4615,TP01434,MAP2K2;MAPK3,MAP2K2,MAPK3,CIT+CIT,Tchem+Tclin,0.49,0.818,0.79,78,11,67,1,1,DC01491,MK8353;Selumetinib,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
4616,TP01435,MAP2K2;MDM2,MAP2K2,MDM2,CIT+CIT,Tchem+Tclin,0.307,0.623,0.531,15,0,13,3,3,DC01522,Navtemadlin;Trametinib,DrugComb,FD00021,Leukemia,Hematologic Malignancy,Phase 1
4617,TP01435,MAP2K2;MDM2,MAP2K2,MDM2,CIT+CIT,Tchem+Tclin,0.307,0.623,0.531,15,0,13,3,3,DC01811,Pimasertib;SAR405838,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
4618,TP01435,MAP2K2;MDM2,MAP2K2,MDM2,CIT+CIT,Tchem+Tclin,0.307,0.623,0.531,15,0,13,3,3,DC01906,Siremadlin;Trametinib,DrugComb,FD00011,Colorectal Cancer,Colorectal Cancer,Phase 1
4619,TP01436,MAP2K2;MET,MAP2K2,MET,CIT+CIT,Tclin+Tclin,0.435,0.431,0.728,15,0,11,1,1,DC00664,Capmatinib;Trametinib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
4620,TP01437,MAP2K2;MTOR,MAP2K2,MTOR,CIT+CIT,Tclin+Tclin,0.349,0.607,0.706,34,0,33,7,5,DC01209,Gedatolisib;Mirdametinib,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
4621,TP01437,MAP2K2;MTOR,MAP2K2,MTOR,CIT+CIT,Tclin+Tclin,0.349,0.607,0.706,34,0,33,7,5,DC01813,Pimasertib;Voxtalisib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
4623,TP01437,MAP2K2;MTOR,MAP2K2,MTOR,CIT+CIT,Tclin+Tclin,0.349,0.607,0.706,34,0,33,7,5,DC00356,Avutometinib;Everolimus,DrugComb,FD00030,Myeloma,Hematologic Malignancy,Phase 1
4624,TP01437,MAP2K2;MTOR,MAP2K2,MTOR,CIT+CIT,Tclin+Tclin,0.349,0.607,0.706,34,0,33,7,5,DC01123,Everolimus;Trametinib,DrugComb,FD00017,Glioma,Glioma,Phase 1
4625,TP01437,MAP2K2;MTOR,MAP2K2,MTOR,CIT+CIT,Tclin+Tclin,0.349,0.607,0.706,34,0,33,7,5,DC01896,Selumetinib;Sirolimus,DrugComb,FD00040,Soft Tissue Sarcoma,Other Cancer,Phase 2
4628,TP01438,MAP2K2;PARP1,MAP2K2,PARP1,CIT+CIT,Tclin+Tclin,0.365,0.568,0.518,1,0,2,1,1,DC01617,Olaparib;Selumetinib,DrugComb,FD00034,Ovarian Cancer,Ovarian Cancer,Phase 1
4629,TP01439,MAP2K2;PARP2,MAP2K2,PARP2,CIT+CIT,Tclin+Tclin,0.382,0.503,0.431,1,0,0,1,1,DC01617,Olaparib;Selumetinib,DrugComb,FD00034,Ovarian Cancer,Ovarian Cancer,Phase 1
4630,TP01440,MAP2K2;PDCD1,MAP2K2,PDCD1,CET+CIT,Tclin+Tclin,0.154,0.32,1.0,2,0,1,3,3,DC01929,Spartalizumab;Trametinib,DrugComb,FD00018,Head and Neck Cancer,Head and Neck Cancer,Phase 2
4631,TP01440,MAP2K2;PDCD1,MAP2K2,PDCD1,CET+CIT,Tclin+Tclin,0.154,0.32,1.0,2,0,1,3,3,DC01929,Spartalizumab;Trametinib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
4633,TP01440,MAP2K2;PDCD1,MAP2K2,PDCD1,CET+CIT,Tclin+Tclin,0.154,0.32,1.0,2,0,1,3,3,DC01714,Pembrolizumab;Selumetinib,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
4634,TP01441,MAP2K2;PIK3CA,MAP2K2,PIK3CA,CIT+CIT,Tclin+Tclin,0.342,0.589,0.76,63,0,39,5,2,DC01209,Gedatolisib;Mirdametinib,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
4635,TP01441,MAP2K2;PIK3CA,MAP2K2,PIK3CA,CIT+CIT,Tclin+Tclin,0.342,0.589,0.76,63,0,39,5,2,DC01813,Pimasertib;Voxtalisib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
4639,TP01442,MAP2K2;PIK3CB,MAP2K2,PIK3CB,CIT+CIT,Tchem+Tclin,0.377,0.656,0.613,63,0,28,1,1,DC00622,Buparlisib;Trametinib,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
4640,TP01443,MAP2K2;PIK3CD,MAP2K2,PIK3CD,CIT+CIT,Tclin+Tclin,0.336,0.565,0.604,63,0,29,2,2,DC01813,Pimasertib;Voxtalisib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
4641,TP01443,MAP2K2;PIK3CD,MAP2K2,PIK3CD,CIT+CIT,Tclin+Tclin,0.336,0.565,0.604,63,0,29,2,2,DC00622,Buparlisib;Trametinib,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
4642,TP01444,MAP2K2;PIK3CG,MAP2K2,PIK3CG,CIT+CIT,Tclin+Tclin,0.343,0.55,0.732,7,0,15,1,1,DC00622,Buparlisib;Trametinib,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
4643,TP01445,MAP2K2;PTK2,MAP2K2,PTK2,CET+CIT,Tclin+Tclin,0.405,0.718,0.731,14,0,18,2,4,DC00355,Avutometinib;Defactinib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 2
4644,TP01445,MAP2K2;PTK2,MAP2K2,PTK2,CET+CIT,Tclin+Tclin,0.405,0.718,0.731,14,0,18,2,4,DC00355,Avutometinib;Defactinib,DrugComb,FD00034,Ovarian Cancer,Ovarian Cancer,Phase 1
4645,TP01445,MAP2K2;PTK2,MAP2K2,PTK2,CET+CIT,Tclin+Tclin,0.405,0.718,0.731,14,0,18,2,4,DC00355,Avutometinib;Defactinib,DrugComb,FD00035,Pancreatic Cancer,Pancreatic Cancer,Phase 1
4646,TP01445,MAP2K2;PTK2,MAP2K2,PTK2,CET+CIT,Tclin+Tclin,0.405,0.718,0.731,14,0,18,2,4,DC01253,GSK2256098;Trametinib,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
4647,TP01446,MAP2K2;RAF1,MAP2K2,RAF1,CIT+CIT,Tclin+Tclin,0.461,0.689,0.855,71,9,64,5,5,DC00767,CFT1946;Trametinib,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1|Phase 2
4649,TP01446,MAP2K2;RAF1,MAP2K2,RAF1,CIT+CIT,Tclin+Tclin,0.461,0.689,0.855,71,9,64,5,5,DC01969,Trametinib;XP102,DrugComb,FD00011,Colorectal Cancer,Colorectal Cancer,Phase 1|Phase 2
4650,TP01446,MAP2K2;RAF1,MAP2K2,RAF1,CIT+CIT,Tclin+Tclin,0.461,0.689,0.855,71,9,64,5,5,DC01969,Trametinib;XP102,DrugComb,FD00018,Head and Neck Cancer,Head and Neck Cancer,Phase 1|Phase 2
4651,TP01446,MAP2K2;RAF1,MAP2K2,RAF1,CIT+CIT,Tclin+Tclin,0.461,0.689,0.855,71,9,64,5,5,DC01969,Trametinib;XP102,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
4652,TP01446,MAP2K2;RAF1,MAP2K2,RAF1,CIT+CIT,Tclin+Tclin,0.461,0.689,0.855,71,9,64,5,5,DC01969,Trametinib;XP102,DrugComb,FD00026,Melanoma,Melanoma,Phase 1|Phase 2
4656,TP01447,MAP2K2;ROS1,MAP2K2,ROS1,CIT+CIT,Tclin+Tclin,0.511,0.346,0.76,0,0,0,1,1,DC00535,Binimetinib;Lorlatinib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
4657,TP01448,MAP2K2;SOS1,MAP2K2,SOS1,CIT+CIT,Tchem+Tclin,0.369,0.545,0.403,43,0,43,2,1,DC00504,BI1701963;Trametinib,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
4659,TP01449,MAP2K2;TGFB1,MAP2K2,TGFB1,CET+CIT,Tbio+Tclin,0.37,0.649,0.447,14,0,12,1,1,DC00546,Bintrafusp Alfa;Pimasertib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
4660,TP01450,MAP2K2;ULK1,MAP2K2,ULK1,CET+CIT,Tchem+Tclin,0.395,0.608,0.774,4,0,4,2,1,DC00873,DCC3116;Trametinib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
4662,TP01451,MAP2K2;ULK2,MAP2K2,ULK2,CET+CIT,Tchem+Tclin,0.41,0.53,0.806,4,0,3,2,1,DC00873,DCC3116;Trametinib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
4664,TP01452,MAP4K1;PDCD1,MAP4K1,PDCD1,CET+CET,Tchem+Tclin,0.174,0.687,1.0,0,0,0,4,2,DC01805,PF07265028;Sasanlimab,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
4666,TP01452,MAP4K1;PDCD1,MAP4K1,PDCD1,CET+CET,Tchem+Tclin,0.174,0.687,1.0,0,0,0,4,2,DC01529,NDI101150;Pembrolizumab,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1|Phase 2
4668,TP01453,MAP4K1;TNFSF4,MAP4K1,TNFSF4,CET+CIT,Tbio+Tchem,0.211,0.687,0.451,0,0,0,1,1,DC00493,BGB15025;BGBA445,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 2
4669,TP01454,MAPK1;PDCD1,MAPK1,PDCD1,CET+CIT,Tchem+Tclin,0.289,0.336,1.0,2,0,0,1,1,DC01490,MK8353;Pembrolizumab,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
4670,TP01455,MAPK1;PTPN11,MAPK1,PTPN11,CIT+CIT,Tchem+Tchem,0.494,0.617,0.519,14,7,34,2,2,DC01955,Temuterkib;Vociprotafib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
4671,TP01455,MAPK1;PTPN11,MAPK1,PTPN11,CIT+CIT,Tchem+Tchem,0.494,0.617,0.519,14,7,34,2,2,DC01033,ERAS007;ERAS601,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1|Phase 2
4672,TP01456,MAPK1;RAF1,MAPK1,RAF1,CIT+CIT,Tchem+Tclin,0.537,0.733,0.865,82,10,84,1,2,DC01512,Naporafenib;Rineterkib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
4673,TP01456,MAPK1;RAF1,MAPK1,RAF1,CIT+CIT,Tchem+Tclin,0.537,0.733,0.865,82,10,84,1,2,DC01512,Naporafenib;Rineterkib,DrugComb,FD00026,Melanoma,Melanoma,Phase 2
4674,TP01457,MAPK11;PDCD1,MAPK11,PDCD1,CET+CIT,Tchem+Tclin,0.251,0.284,1.0,2,0,0,1,1,DC01565,Nivolumab;Pexmetinib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
4675,TP01458,MAPK14;PDCD1,MAPK14,PDCD1,CET+CIT,Tchem+Tclin,0.283,0.263,1.0,2,0,0,1,1,DC01565,Nivolumab;Pexmetinib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
4676,TP01459,MAPK3;PDCD1,MAPK3,PDCD1,CET+CIT,Tchem+Tclin,0.252,0.364,1.0,2,0,1,1,1,DC01490,MK8353;Pembrolizumab,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
4677,TP01460,MAPK3;PTPN11,MAPK3,PTPN11,CIT+CIT,Tchem+Tchem,0.477,0.68,0.539,14,7,28,2,2,DC01955,Temuterkib;Vociprotafib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
4678,TP01460,MAPK3;PTPN11,MAPK3,PTPN11,CIT+CIT,Tchem+Tchem,0.477,0.68,0.539,14,7,28,2,2,DC01033,ERAS007;ERAS601,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1|Phase 2
4679,TP01461,MAPK3;RAF1,MAPK3,RAF1,CIT+CIT,Tchem+Tclin,0.566,0.81,0.893,82,10,70,1,2,DC01512,Naporafenib;Rineterkib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
4680,TP01461,MAPK3;RAF1,MAPK3,RAF1,CIT+CIT,Tchem+Tclin,0.566,0.81,0.893,82,10,70,1,2,DC01512,Naporafenib;Rineterkib,DrugComb,FD00026,Melanoma,Melanoma,Phase 2
4681,TP01462,MAPK8;PDCD1,MAPK8,PDCD1,CET+CIT,Tchem+Tclin,0.272,0.262,1.0,1,0,0,1,1,DC00568,BMS986360;Nivolumab,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
4682,TP01463,MAT2A;PRMT5,MAT2A,PRMT5,CIT+CIT,Tchem+Tchem,0.213,0.563,0.499,0,0,0,1,1,DC00174,AMG193;IDE397,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
4683,TP01464,MCL1;PDCD1,MCL1,PDCD1,CET+CIT,Tchem+Tclin,0.41,0.458,1.0,0,0,0,1,2,DC01472,Mifcemalimab;Toripalimab,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 1
4684,TP01464,MCL1;PDCD1,MCL1,PDCD1,CET+CIT,Tchem+Tclin,0.41,0.458,1.0,0,0,0,1,2,DC01472,Mifcemalimab;Toripalimab,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
4685,TP01465,MDM2;MS4A1,MDM2,MS4A1,CIT+CIT,Tchem+Tclin,0.228,0.621,0.571,0,0,0,2,1,DC01294,Idasanutlin;Rituximab,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 1|Phase 2
4687,TP01466,MDM2;PDCD1,MDM2,PDCD1,CET+CIT,Tchem+Tclin,0.272,0.397,1.0,0,0,0,5,3,DC01519,Navtemadlin;Pembrolizumab,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
4690,TP01466,MDM2;PDCD1,MDM2,PDCD1,CET+CIT,Tchem+Tclin,0.272,0.397,1.0,0,0,0,5,3,DC00162,Alrizomadlin;Pembrolizumab,DrugComb,FD00026,Melanoma,Melanoma,Phase 1|Phase 2
4691,TP01466,MDM2;PDCD1,MDM2,PDCD1,CET+CIT,Tchem+Tclin,0.272,0.397,1.0,0,0,0,5,3,DC00163,Alrizomadlin;Toripalimab,DrugComb,FD00040,Soft Tissue Sarcoma,Other Cancer,Phase 1|Phase 2
4692,TP01467,MELTF;TNFRSF9,MELTF,TNFRSF9,CET+CET,Tbio+Tbio,0.182,0.49,0.659,0,0,0,1,5,DC02258,SGNBB228,BsAb,FD00011,Colorectal Cancer,Colorectal Cancer,Phase 1
4693,TP01467,MELTF;TNFRSF9,MELTF,TNFRSF9,CET+CET,Tbio+Tbio,0.182,0.49,0.659,0,0,0,1,5,DC02258,SGNBB228,BsAb,FD00023,Lung Cancer,Lung Cancer,Phase 1
4694,TP01467,MELTF;TNFRSF9,MELTF,TNFRSF9,CET+CET,Tbio+Tbio,0.182,0.49,0.659,0,0,0,1,5,DC02258,SGNBB228,BsAb,FD00026,Melanoma,Melanoma,Phase 1
4695,TP01467,MELTF;TNFRSF9,MELTF,TNFRSF9,CET+CET,Tbio+Tbio,0.182,0.49,0.659,0,0,0,1,5,DC02258,SGNBB228,BsAb,FD00029,Mesothelioma,Other Cancer,Phase 1
4696,TP01467,MELTF;TNFRSF9,MELTF,TNFRSF9,CET+CET,Tbio+Tbio,0.182,0.49,0.659,0,0,0,1,5,DC02258,SGNBB228,BsAb,FD00035,Pancreatic Cancer,Pancreatic Cancer,Phase 1
4697,TP01468,MERTK;PDCD1,MERTK,PDCD1,CET+CIT,Tchem+Tclin,0.367,0.538,1.0,0,0,0,2,5,DC01698,Pembrolizumab;Q702,DrugComb,FD00014,Esophageal Cancer,Esophageal Cancer,Phase 1|Phase 2
4698,TP01468,MERTK;PDCD1,MERTK,PDCD1,CET+CIT,Tchem+Tclin,0.367,0.538,1.0,0,0,0,2,5,DC01698,Pembrolizumab;Q702,DrugComb,FD00022,Liver Cancer,Liver Cancer,Phase 1|Phase 2
4699,TP01468,MERTK;PDCD1,MERTK,PDCD1,CET+CIT,Tchem+Tclin,0.367,0.538,1.0,0,0,0,2,5,DC01698,Pembrolizumab;Q702,DrugComb,FD00034,Ovarian Cancer,Ovarian Cancer,Phase 1|Phase 2
4700,TP01468,MERTK;PDCD1,MERTK,PDCD1,CET+CIT,Tchem+Tclin,0.367,0.538,1.0,0,0,0,2,5,DC01698,Pembrolizumab;Q702,DrugComb,FD00041,Stomach Cancer,Stomach Cancer,Phase 1|Phase 2
4701,TP01468,MERTK;PDCD1,MERTK,PDCD1,CET+CIT,Tchem+Tclin,0.367,0.538,1.0,0,0,0,2,5,DC01314,INCB081776;Retifanlimab,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
4702,TP01469,MET;PDCD1,MET,PDCD1,CET+CIT,Tclin+Tclin,0.319,0.714,1.0,0,0,0,11,5,DC01665,Pamufetinib;Zimberelimab,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
4705,TP01469,MET;PDCD1,MET,PDCD1,CET+CIT,Tclin+Tclin,0.319,0.714,1.0,0,0,0,11,5,DC00663,Capmatinib;Spartalizumab,DrugComb,FD00014,Esophageal Cancer,Esophageal Cancer,Phase 2
4706,TP01469,MET;PDCD1,MET,PDCD1,CET+CIT,Tclin+Tclin,0.319,0.714,1.0,0,0,0,11,5,DC00663,Capmatinib;Spartalizumab,DrugComb,FD00022,Liver Cancer,Liver Cancer,Phase 1|Phase 2
4708,TP01469,MET;PDCD1,MET,PDCD1,CET+CIT,Tclin+Tclin,0.319,0.714,1.0,0,0,0,11,5,DC00663,Capmatinib;Spartalizumab,DrugComb,FD00026,Melanoma,Melanoma,Phase 2
4709,TP01469,MET;PDCD1,MET,PDCD1,CET+CIT,Tclin+Tclin,0.319,0.714,1.0,0,0,0,11,5,DC00663,Capmatinib;Spartalizumab,DrugComb,FD00041,Stomach Cancer,Stomach Cancer,Phase 2
4717,TP01470,MET;PIK3CA,MET,PIK3CA,CIT+CIT,Tclin+Tclin,0.514,0.521,0.666,17,5,10,1,1,DC00611,Buparlisib;Capmatinib,DrugComb,FD00017,Glioma,Glioma,Phase 1|Phase 2
4718,TP01471,MET;PIK3CB,MET,PIK3CB,CIT+CIT,Tchem+Tclin,0.539,0.505,0.636,17,4,9,1,1,DC00611,Buparlisib;Capmatinib,DrugComb,FD00017,Glioma,Glioma,Phase 1|Phase 2
4719,TP01472,MET;PIK3CD,MET,PIK3CD,CIT+CIT,Tclin+Tclin,0.479,0.579,0.627,17,3,9,1,1,DC00611,Buparlisib;Capmatinib,DrugComb,FD00017,Glioma,Glioma,Phase 1|Phase 2
4720,TP01473,MET;PIK3CG,MET,PIK3CG,CIT+CIT,Tclin+Tclin,0.464,0.557,0.731,1,0,4,1,1,DC00611,Buparlisib;Capmatinib,DrugComb,FD00017,Glioma,Glioma,Phase 1|Phase 2
4721,TP01474,MET;ROS1,MET,ROS1,CIT+CIT,Tclin+Tclin,0.58,0.766,0.936,0,0,0,1,1,DC00819,Crizotinib;Lorlatinib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
4722,TP01475,MET;VEGFA,MET,VEGFA,CET+CIT,Tclin+Tclin,0.522,0.609,0.506,12,0,7,3,2,DC00433,Bevacizumab;Capmatinib,DrugComb,FD00017,Glioma,Glioma,Phase 1
4724,TP01475,MET;VEGFA,MET,VEGFA,CET+CIT,Tclin+Tclin,0.522,0.609,0.506,12,0,7,3,2,DC00439,Bevacizumab;Crizotinib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 2
4725,TP01476,MICA;PDCD1,MICA,PDCD1,CET+CET,Tbio+Tclin,0.385,0.728,1.0,0,0,0,1,1,DC00781,CLN619;Pembrolizumab,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
4726,TP01477,MICB;PDCD1,MICB,PDCD1,CET+CET,Tbio+Tclin,0.445,0.858,0.657,0,0,0,1,1,DC00781,CLN619;Pembrolizumab,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
4727,TP01478,MKNK1;PDCD1,MKNK1,PDCD1,CET+CIT,Tchem+Tclin,0.161,0.284,1.0,0,0,0,1,1,DC01739,Pembrolizumab;Tomivosertib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 2
4728,TP01479,MKNK2;PDCD1,MKNK2,PDCD1,CET+CIT,Tchem+Tclin,0.269,0.264,1.0,0,0,0,1,1,DC01739,Pembrolizumab;Tomivosertib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 2
4729,TP01480,MMP9;PDCD1,MMP9,PDCD1,CET+CET,Tchem+Tclin,0.337,0.299,1.0,0,0,0,1,1,DC00202,Andecaliximab;Nivolumab,DrugComb,FD00041,Stomach Cancer,Stomach Cancer,Phase 2
4730,TP01481,MS4A1;MTOR,MS4A1,MTOR,CIT+CIT,Tclin+Tclin,0.232,0.492,0.451,0,0,0,2,1,DC01115,Everolimus;Rituximab,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 2
4732,TP01482,MS4A1;PDCD1,MS4A1,PDCD1,CET+CIT,Tclin+Tclin,0.367,0.66,1.0,0,0,1,1,1,DC01808,Pidilizumab;Rituximab,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 2
4733,TP01483,MS4A1;PIK3CA,MS4A1,PIK3CA,CIT+CIT,Tclin+Tclin,0.281,0.508,0.332,0,0,0,2,1,DC00801,Copanlisib;Obinutuzumab,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 2
4735,TP01484,MS4A1;PIK3CD,MS4A1,PIK3CD,CIT+CIT,Tclin+Tclin,0.429,0.557,0.364,0,0,0,9,2,DC01984,Ublituximab;Umbralisib,DrugComb,FD00021,Leukemia,Hematologic Malignancy,Phase 2|Phase 3
4736,TP01484,MS4A1;PIK3CD,MS4A1,PIK3CD,CIT+CIT,Tclin+Tclin,0.429,0.557,0.364,0,0,0,9,2,DC01984,Ublituximab;Umbralisib,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 2|Phase 3
4747,TP01485,MS4A1;PIK3CG,MS4A1,PIK3CG,CIT+CIT,Tclin+Tclin,0.353,0.539,0.371,0,0,0,1,1,DC00957,Duvelisib;Rituximab,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 3
4748,TP01486,MS4A1;SIRPA,MS4A1,SIRPA,CIT+CIT,Tbio+Tclin,0.212,0.758,0.482,0,0,0,2,1,DC00624,BYON4228;Rituximab,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 1
4750,TP01487,MS4A1;SLAMF7,MS4A1,SLAMF7,CIT+CIT,Tclin+Tclin,0.419,0.66,1.0,0,0,1,1,1,DC00973,Elotuzumab;Rituximab,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 1
4751,TP01488,MS4A1;SUMO1,MS4A1,SUMO1,CIT+CIT,Tbio+Tclin,0.186,0.659,0.597,0,0,0,1,1,DC01865,Rituximab;Subasumstat,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 1|Phase 2
4752,TP01489,MS4A1;SUMO2,MS4A1,SUMO2,CIT+CIT,Tbio+Tclin,0.057,0.465,0.601,0,0,0,1,1,DC01865,Rituximab;Subasumstat,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 1|Phase 2
4753,TP01490,MS4A1;SUMO3,MS4A1,SUMO3,CIT+CIT,Tbio+Tclin,0.106,0.507,0.639,0,0,0,1,1,DC01865,Rituximab;Subasumstat,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 1|Phase 2
4754,TP01491,MS4A1;TACSTD2,MS4A1,TACSTD2,CIT+CIT,Tclin+Tclin,0.23,0.75,1.0,0,0,0,1,1,DC01609,Obinutuzumab;Sacituzumab Govitecan,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 2
4755,TP01492,MS4A1;TIGIT,MS4A1,TIGIT,CET+CIT,Tbio+Tclin,0.124,0.7,0.783,0,0,0,1,2,DC01867,Rituximab;Tiragolumab,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 1
4756,TP01492,MS4A1;TIGIT,MS4A1,TIGIT,CET+CIT,Tbio+Tclin,0.124,0.7,0.783,0,0,0,1,2,DC01867,Rituximab;Tiragolumab,DrugComb,FD00030,Myeloma,Hematologic Malignancy,Phase 1
4757,TP01493,MS4A1;TNFRSF10A,MS4A1,TNFRSF10A,CIT+CIT,Tchem+Tclin,0.38,0.683,0.652,0,0,0,1,1,DC00915,Dulanermin;Rituximab,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 1|Phase 2
4758,TP01494,MS4A1;TNFRSF10B,MS4A1,TNFRSF10B,CIT+CIT,Tbio+Tclin,0.37,0.7,0.587,0,0,0,2,1,DC00909,Drozitumab;Rituximab,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 2
4760,TP01495,MS4A1;TNFRSF9,MS4A1,TNFRSF9,CET+CIT,Tbio+Tclin,0.21,0.718,0.645,0,0,0,2,3,DC01871,Rituximab;Urelumab,DrugComb,FD00021,Leukemia,Hematologic Malignancy,Phase 2
4761,TP01495,MS4A1;TNFRSF9,MS4A1,TNFRSF9,CET+CIT,Tbio+Tclin,0.21,0.718,0.645,0,0,0,2,3,DC01871,Rituximab;Urelumab,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 2
4762,TP01495,MS4A1;TNFRSF9,MS4A1,TNFRSF9,CET+CIT,Tbio+Tclin,0.21,0.718,0.645,0,0,0,2,3,DC01872,Rituximab;Utomilumab,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
4763,TP01496,MS4A1;VEGFA,MS4A1,VEGFA,CET+CIT,Tclin+Tclin,0.243,0.615,0.633,0,0,0,1,1,DC00473,Bevacizumab;Rituximab,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 2
4764,TP01497,MSLN;PDCD1,MSLN,PDCD1,CET+CIT,Tbio+Tclin,0.274,0.574,1.0,0,0,0,2,2,DC01322,Inezetamab;Zeluvalimab,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
4765,TP01497,MSLN;PDCD1,MSLN,PDCD1,CET+CIT,Tbio+Tclin,0.274,0.574,1.0,0,0,0,2,2,DC01844,RC88;Toripalimab,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
4766,TP01498,MTOR;NOTCH1,MTOR,NOTCH1,CIT+CIT,Tchem+Tclin,0.475,0.682,0.444,6,0,8,2,4,DC00811,Crenigacestat;Samotolisib,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 1
4767,TP01498,MTOR;NOTCH1,MTOR,NOTCH1,CIT+CIT,Tchem+Tclin,0.475,0.682,0.444,6,0,8,2,4,DC00811,Crenigacestat;Samotolisib,DrugComb,FD00011,Colorectal Cancer,Colorectal Cancer,Phase 1
4768,TP01498,MTOR;NOTCH1,MTOR,NOTCH1,CIT+CIT,Tchem+Tclin,0.475,0.682,0.444,6,0,8,2,4,DC00811,Crenigacestat;Samotolisib,DrugComb,FD00022,Liver Cancer,Liver Cancer,Phase 1
4769,TP01498,MTOR;NOTCH1,MTOR,NOTCH1,CIT+CIT,Tchem+Tclin,0.475,0.682,0.444,6,0,8,2,4,DC01480,MK0752;Ridaforolimus,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
4770,TP01499,MTOR;NOTCH2,MTOR,NOTCH2,CIT+CIT,Tchem+Tclin,0.397,0.679,0.401,7,0,4,1,1,DC01480,MK0752;Ridaforolimus,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
4771,TP01500,MTOR;PARP1,MTOR,PARP1,CIT+CIT,Tclin+Tclin,0.412,0.667,0.549,1,0,3,2,2,DC01211,Gedatolisib;Talazoparib,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 1|Phase 2
4773,TP01500,MTOR;PARP1,MTOR,PARP1,CIT+CIT,Tclin+Tclin,0.412,0.667,0.549,1,0,3,2,2,DC01108,Everolimus;Niraparib,DrugComb,FD00034,Ovarian Cancer,Ovarian Cancer,Phase 1
4774,TP01501,MTOR;PARP2,MTOR,PARP2,CIT+CIT,Tclin+Tclin,0.274,0.538,0.506,0,0,1,2,2,DC01211,Gedatolisib;Talazoparib,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 1|Phase 2
4776,TP01501,MTOR;PARP2,MTOR,PARP2,CIT+CIT,Tclin+Tclin,0.274,0.538,0.506,0,0,1,2,2,DC01108,Everolimus;Niraparib,DrugComb,FD00034,Ovarian Cancer,Ovarian Cancer,Phase 1
4777,TP01502,MTOR;PDCD1,MTOR,PDCD1,CET+CIT,Tclin+Tclin,0.234,0.301,1.0,1,0,0,3,3,DC01579,Nivolumab;SF1126,DrugComb,FD00022,Liver Cancer,Liver Cancer,Phase 1
4778,TP01502,MTOR;PDCD1,MTOR,PDCD1,CET+CIT,Tclin+Tclin,0.234,0.301,1.0,1,0,0,3,3,DC01624,Onatasertib;Toripalimab,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1|Phase 2
4779,TP01502,MTOR;PDCD1,MTOR,PDCD1,CET+CIT,Tclin+Tclin,0.234,0.301,1.0,1,0,0,3,3,DC01119,Everolimus;Spartalizumab,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
4780,TP01503,MTOR;PIK3CA,MTOR,PIK3CA,CIT+CIT,Tclin+Tclin,0.517,0.553,0.742,43,2,38,2,4,DC01889,Sapanisertib;Serabelisib,DrugComb,FD00020,Kidney Cancer,Kidney Cancer,Phase 2
4781,TP01503,MTOR;PIK3CA,MTOR,PIK3CA,CIT+CIT,Tclin+Tclin,0.517,0.553,0.742,43,2,38,2,4,DC01889,Sapanisertib;Serabelisib,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
4782,TP01503,MTOR;PIK3CA,MTOR,PIK3CA,CIT+CIT,Tclin+Tclin,0.517,0.553,0.742,43,2,38,2,4,DC01889,Sapanisertib;Serabelisib,DrugComb,FD00034,Ovarian Cancer,Ovarian Cancer,Phase 2
4783,TP01503,MTOR;PIK3CA,MTOR,PIK3CA,CIT+CIT,Tclin+Tclin,0.517,0.553,0.742,43,2,38,2,4,DC00612,Buparlisib;Everolimus,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
4784,TP01504,MTOR;PIK3CB,MTOR,PIK3CB,CIT+CIT,Tchem+Tclin,0.412,0.707,0.678,43,1,23,2,1,DC00373,AZD8186;Vistusertib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
4786,TP01505,MTOR;PIK3CD,MTOR,PIK3CD,CIT+CIT,Tclin+Tclin,0.419,0.557,0.674,43,1,22,2,3,DC01100,Everolimus;Idelalisib,DrugComb,FD00021,Leukemia,Hematologic Malignancy,Phase 1
4787,TP01505,MTOR;PIK3CD,MTOR,PIK3CD,CIT+CIT,Tclin+Tclin,0.419,0.557,0.674,43,1,22,2,3,DC01100,Everolimus;Idelalisib,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 1
4788,TP01505,MTOR;PIK3CD,MTOR,PIK3CD,CIT+CIT,Tclin+Tclin,0.419,0.557,0.674,43,1,22,2,3,DC00612,Buparlisib;Everolimus,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
4789,TP01506,MTOR;PIK3CG,MTOR,PIK3CG,CIT+CIT,Tclin+Tclin,0.423,0.551,0.788,4,0,14,1,1,DC00612,Buparlisib;Everolimus,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
4790,TP01507,MTOR;PTK7,MTOR,PTK7,CIT+CIT,Tbio+Tclin,0.392,0.281,0.695,0,0,0,1,1,DC00792,Cofetuzumab Pelidotin;Gedatolisib,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 1
4791,TP01508,MTOR;RAF1,MTOR,RAF1,CIT+CIT,Tclin+Tclin,0.459,0.689,0.789,35,0,36,1,2,DC00356,Avutometinib;Everolimus,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
4792,TP01508,MTOR;RAF1,MTOR,RAF1,CIT+CIT,Tclin+Tclin,0.459,0.689,0.789,35,0,36,1,2,DC00356,Avutometinib;Everolimus,DrugComb,FD00030,Myeloma,Hematologic Malignancy,Phase 1
4793,TP01509,MTOR;RPS6KB1,MTOR,RPS6KB1,CIT+CIT,Tchem+Tclin,0.495,0.726,0.776,29,1,34,1,1,DC01106,Everolimus;LY2584702,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
4794,TP01510,MTOR;SMO,MTOR,SMO,CIT+CIT,Tclin+Tclin,0.406,0.573,0.387,2,0,1,2,2,DC01910,Sirolimus;Vismodegib,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
4795,TP01510,MTOR;SMO,MTOR,SMO,CIT+CIT,Tclin+Tclin,0.406,0.573,0.387,2,0,1,2,2,DC01116,Everolimus;Sonidegib,DrugComb,FD00014,Esophageal Cancer,Esophageal Cancer,Phase 1
4796,TP01511,MTOR;SSTR1,MTOR,SSTR1,CIT+CIT,Tclin+Tclin,0.301,0.518,0.359,1,0,0,1,3,DC01111,Everolimus;Pasireotide,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 2
4797,TP01511,MTOR;SSTR1,MTOR,SSTR1,CIT+CIT,Tclin+Tclin,0.301,0.518,0.359,1,0,0,1,3,DC01111,Everolimus;Pasireotide,DrugComb,FD00030,Myeloma,Hematologic Malignancy,Phase 2
4798,TP01511,MTOR;SSTR1,MTOR,SSTR1,CIT+CIT,Tclin+Tclin,0.301,0.518,0.359,1,0,0,1,3,DC01111,Everolimus;Pasireotide,DrugComb,FD00032,Neuroendocrine Tumor,Other Cancer,Phase 1
4799,TP01512,MTOR;SSTR2,MTOR,SSTR2,CIT+CIT,Tclin+Tclin,0.303,0.484,0.374,1,0,1,2,4,DC01111,Everolimus;Pasireotide,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 2
4800,TP01512,MTOR;SSTR2,MTOR,SSTR2,CIT+CIT,Tclin+Tclin,0.303,0.484,0.374,1,0,1,2,4,DC01111,Everolimus;Pasireotide,DrugComb,FD00030,Myeloma,Hematologic Malignancy,Phase 2
4801,TP01512,MTOR;SSTR2,MTOR,SSTR2,CIT+CIT,Tclin+Tclin,0.303,0.484,0.374,1,0,1,2,4,DC01111,Everolimus;Pasireotide,DrugComb,FD00032,Neuroendocrine Tumor,Other Cancer,Phase 1
4802,TP01512,MTOR;SSTR2,MTOR,SSTR2,CIT+CIT,Tclin+Tclin,0.303,0.484,0.374,1,0,1,2,4,DC01109,Everolimus;Octreotide,DrugComb,FD00027,Meningioma,Other Cancer,Phase 2
4803,TP01513,MTOR;SSTR3,MTOR,SSTR3,CIT+CIT,Tclin+Tclin,0.31,0.503,0.38,1,0,0,1,3,DC01111,Everolimus;Pasireotide,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 2
4804,TP01513,MTOR;SSTR3,MTOR,SSTR3,CIT+CIT,Tclin+Tclin,0.31,0.503,0.38,1,0,0,1,3,DC01111,Everolimus;Pasireotide,DrugComb,FD00030,Myeloma,Hematologic Malignancy,Phase 2
4805,TP01513,MTOR;SSTR3,MTOR,SSTR3,CIT+CIT,Tclin+Tclin,0.31,0.503,0.38,1,0,0,1,3,DC01111,Everolimus;Pasireotide,DrugComb,FD00032,Neuroendocrine Tumor,Other Cancer,Phase 1
4806,TP01514,MTOR;SSTR5,MTOR,SSTR5,CIT+CIT,Tclin+Tclin,0.225,0.321,0.359,1,0,0,2,4,DC01111,Everolimus;Pasireotide,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 2
4807,TP01514,MTOR;SSTR5,MTOR,SSTR5,CIT+CIT,Tclin+Tclin,0.225,0.321,0.359,1,0,0,2,4,DC01111,Everolimus;Pasireotide,DrugComb,FD00030,Myeloma,Hematologic Malignancy,Phase 2
4808,TP01514,MTOR;SSTR5,MTOR,SSTR5,CIT+CIT,Tclin+Tclin,0.225,0.321,0.359,1,0,0,2,4,DC01111,Everolimus;Pasireotide,DrugComb,FD00032,Neuroendocrine Tumor,Other Cancer,Phase 1
4809,TP01514,MTOR;SSTR5,MTOR,SSTR5,CIT+CIT,Tclin+Tclin,0.225,0.321,0.359,1,0,0,2,4,DC01109,Everolimus;Octreotide,DrugComb,FD00027,Meningioma,Other Cancer,Phase 2
4810,TP01515,MTOR;VEGFA,MTOR,VEGFA,CET+CIT,Tclin+Tclin,0.475,0.513,0.476,11,0,13,5,7,DC00472,Bevacizumab;Ridaforolimus,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
4811,TP01515,MTOR;VEGFA,MTOR,VEGFA,CET+CIT,Tclin+Tclin,0.475,0.513,0.476,11,0,13,5,7,DC00447,Bevacizumab;Everolimus,DrugComb,FD00020,Kidney Cancer,Kidney Cancer,Phase 2
4812,TP01515,MTOR;VEGFA,MTOR,VEGFA,CET+CIT,Tclin+Tclin,0.475,0.513,0.476,11,0,13,5,7,DC00447,Bevacizumab;Everolimus,DrugComb,FD00032,Neuroendocrine Tumor,Other Cancer,Phase 2
4813,TP01515,MTOR;VEGFA,MTOR,VEGFA,CET+CIT,Tclin+Tclin,0.475,0.513,0.476,11,0,13,5,7,DC00447,Bevacizumab;Everolimus,DrugComb,FD00040,Soft Tissue Sarcoma,Other Cancer,Phase 2
4814,TP01515,MTOR;VEGFA,MTOR,VEGFA,CET+CIT,Tclin+Tclin,0.475,0.513,0.476,11,0,13,5,7,DC00478,Bevacizumab;Sirolimus,DrugComb,FD00022,Liver Cancer,Liver Cancer,Phase 1
4817,TP01515,MTOR;VEGFA,MTOR,VEGFA,CET+CIT,Tclin+Tclin,0.475,0.513,0.476,11,0,13,5,7,DC00481,Bevacizumab;Temsirolimus,DrugComb,FD00034,Ovarian Cancer,Ovarian Cancer,Phase 2
4818,TP01515,MTOR;VEGFA,MTOR,VEGFA,CET+CIT,Tclin+Tclin,0.475,0.513,0.476,11,0,13,5,7,DC00457,Bevacizumab;ME344,DrugComb,FD00011,Colorectal Cancer,Colorectal Cancer,Phase 1
4819,TP01516,MUC16;PDCD1,MUC16,PDCD1,CET+CIT,Tbio+Tclin,0.313,0.649,1.0,0,0,0,1,1,DC00707,Cemiplimab;Ubamatamab,DrugComb,FD00034,Ovarian Cancer,Ovarian Cancer,Phase 1|Phase 2
4820,TP01517,NAMPT;PDCD1,NAMPT,PDCD1,CET+CIT,Tchem+Tclin,0.209,0.308,1.0,0,0,0,1,2,DC01561,Nivolumab;Padnarsertib,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 1
4821,TP01517,NAMPT;PDCD1,NAMPT,PDCD1,CET+CIT,Tchem+Tclin,0.209,0.308,1.0,0,0,0,1,2,DC01561,Nivolumab;Padnarsertib,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
4822,TP01518,NANOG;STAT3,NANOG,STAT3,CIT+CIT,Tbio+Tchem,0.463,0.735,0.812,0,3,0,1,1,DC00171,Amcasertib;Napabucasin,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
4823,TP01519,NCR3LG1;PDCD1,NCR3LG1,PDCD1,CET+CET,Tbio+Tclin,1.0,0.941,1.0,0,0,0,1,5,DC00508,BI765049;Ezabenlimab,DrugComb,FD00011,Colorectal Cancer,Colorectal Cancer,Phase 1
4824,TP01519,NCR3LG1;PDCD1,NCR3LG1,PDCD1,CET+CET,Tbio+Tclin,1.0,0.941,1.0,0,0,0,1,5,DC00508,BI765049;Ezabenlimab,DrugComb,FD00018,Head and Neck Cancer,Head and Neck Cancer,Phase 1
4825,TP01519,NCR3LG1;PDCD1,NCR3LG1,PDCD1,CET+CET,Tbio+Tclin,1.0,0.941,1.0,0,0,0,1,5,DC00508,BI765049;Ezabenlimab,DrugComb,FD00022,Liver Cancer,Liver Cancer,Phase 1
4826,TP01519,NCR3LG1;PDCD1,NCR3LG1,PDCD1,CET+CET,Tbio+Tclin,1.0,0.941,1.0,0,0,0,1,5,DC00508,BI765049;Ezabenlimab,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
4827,TP01519,NCR3LG1;PDCD1,NCR3LG1,PDCD1,CET+CET,Tbio+Tclin,1.0,0.941,1.0,0,0,0,1,5,DC00508,BI765049;Ezabenlimab,DrugComb,FD00035,Pancreatic Cancer,Pancreatic Cancer,Phase 1
4828,TP01520,NECTIN4;PDCD1,NECTIN4,PDCD1,CET+CIT,Tclin+Tclin,0.094,0.73,1.0,0,0,0,3,2,DC01712,Pembrolizumab;SBT6290,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
4829,TP01520,NECTIN4;PDCD1,NECTIN4,PDCD1,CET+CIT,Tclin+Tclin,0.094,0.73,1.0,0,0,0,3,2,DC00988,Enfortumab Vedotin;Pembrolizumab,DrugComb,FD00006,Bladder Cancer,Bladder Cancer,Approval
4831,TP01521,NECTIN4;TNFRSF9,NECTIN4,TNFRSF9,CET+CIT,Tbio+Tclin,0.147,0.634,0.705,0,0,0,1,1,DC02051,BT7480,BsAb,FD00033,Other Cancer,Other Cancer,Phase 1|Phase 2
4832,TP01522,NEDD8;PDCD1,NEDD8,PDCD1,CET+CIT,Tchem+Tclin,0.166,0.274,1.0,0,0,1,1,1,DC01694,Pembrolizumab;Pevonedistat,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1|Phase 2
4833,TP01523,NOS1;PDCD1,NOS1,PDCD1,CET+CET,Tchem+Tclin,0.178,0.413,1.0,0,0,0,1,2,DC01734,Pembrolizumab;Tilarginine,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
4834,TP01523,NOS1;PDCD1,NOS1,PDCD1,CET+CET,Tchem+Tclin,0.178,0.413,1.0,0,0,0,1,2,DC01734,Pembrolizumab;Tilarginine,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 1
4835,TP01524,NOS2;PDCD1,NOS2,PDCD1,CET+CIT,Tchem+Tclin,0.211,0.423,1.0,0,0,0,1,2,DC01734,Pembrolizumab;Tilarginine,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
4836,TP01524,NOS2;PDCD1,NOS2,PDCD1,CET+CIT,Tchem+Tclin,0.211,0.423,1.0,0,0,0,1,2,DC01734,Pembrolizumab;Tilarginine,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 1
4837,TP01525,NOS3;PDCD1,NOS3,PDCD1,CET+CET,Tchem+Tclin,0.284,0.446,1.0,0,0,0,1,2,DC01734,Pembrolizumab;Tilarginine,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
4838,TP01525,NOS3;PDCD1,NOS3,PDCD1,CET+CET,Tchem+Tclin,0.284,0.446,1.0,0,0,0,1,2,DC01734,Pembrolizumab;Tilarginine,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 1
4839,TP01526,NOTCH1;PIK3CA,NOTCH1,PIK3CA,CIT+CIT,Tchem+Tclin,0.432,0.566,0.348,7,0,7,1,3,DC00811,Crenigacestat;Samotolisib,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 1
4840,TP01526,NOTCH1;PIK3CA,NOTCH1,PIK3CA,CIT+CIT,Tchem+Tclin,0.432,0.566,0.348,7,0,7,1,3,DC00811,Crenigacestat;Samotolisib,DrugComb,FD00011,Colorectal Cancer,Colorectal Cancer,Phase 1
4841,TP01526,NOTCH1;PIK3CA,NOTCH1,PIK3CA,CIT+CIT,Tchem+Tclin,0.432,0.566,0.348,7,0,7,1,3,DC00811,Crenigacestat;Samotolisib,DrugComb,FD00022,Liver Cancer,Liver Cancer,Phase 1
4842,TP01527,NOTCH1;SMO,NOTCH1,SMO,CIT+CIT,Tchem+Tclin,0.589,0.566,0.622,1,0,2,1,3,DC00812,Crenigacestat;Taladegib,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 1
4843,TP01527,NOTCH1;SMO,NOTCH1,SMO,CIT+CIT,Tchem+Tclin,0.589,0.566,0.622,1,0,2,1,3,DC00812,Crenigacestat;Taladegib,DrugComb,FD00011,Colorectal Cancer,Colorectal Cancer,Phase 1
4844,TP01527,NOTCH1;SMO,NOTCH1,SMO,CIT+CIT,Tchem+Tclin,0.589,0.566,0.622,1,0,2,1,3,DC00812,Crenigacestat;Taladegib,DrugComb,FD00022,Liver Cancer,Liver Cancer,Phase 1
4845,TP01528,NR3C1;PDCD1,NR3C1,PDCD1,CET+CIT,Tclin+Tclin,0.253,0.251,1.0,0,1,0,1,1,DC01702,Pembrolizumab;Relacorilant,DrugComb,FD00001,Adrenocortical Carcinoma,Other Cancer,Phase 1
4846,TP01529,NT5E;PDCD1,NT5E,PDCD1,CET+CIT,Tchem+Tclin,0.151,0.662,1.0,0,0,1,9,2,DC00636,Cadonilimab;Dresbuxelimab,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
4847,TP01529,NT5E;PDCD1,NT5E,PDCD1,CET+CIT,Tchem+Tclin,0.151,0.662,1.0,0,0,1,9,2,DC00636,Cadonilimab;Dresbuxelimab,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1|Phase 2
4857,TP01530,NT5E;TGFB1,NT5E,TGFB1,CET+CIT,Tbio+Tchem,0.178,0.664,0.569,0,0,3,1,2,DC02076,Dalutrafusp Alfa,BsAb,FD00033,Other Cancer,Other Cancer,Phase 1
4858,TP01530,NT5E;TGFB1,NT5E,TGFB1,CET+CIT,Tbio+Tchem,0.178,0.664,0.569,0,0,3,1,2,DC02076,Dalutrafusp Alfa,BsAb,FD00035,Pancreatic Cancer,Pancreatic Cancer,Phase 2
4859,TP01531,NT5E;VEGFA,NT5E,VEGFA,CET+CIT,Tchem+Tclin,0.137,0.658,0.542,0,0,2,1,2,DC00908,Dresbuxelimab;Ivonescimab,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
4860,TP01531,NT5E;VEGFA,NT5E,VEGFA,CET+CIT,Tchem+Tclin,0.137,0.658,0.542,0,0,2,1,2,DC00908,Dresbuxelimab;Ivonescimab,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1|Phase 2
4861,TP01532,PAK4;PDCD1,PAK4,PDCD1,CET+CIT,Tchem+Tclin,0.375,0.274,1.0,0,0,0,1,2,DC01561,Nivolumab;Padnarsertib,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 1
4862,TP01532,PAK4;PDCD1,PAK4,PDCD1,CET+CIT,Tchem+Tclin,0.375,0.274,1.0,0,0,0,1,2,DC01561,Nivolumab;Padnarsertib,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
4863,TP01533,PARP1;PDCD1,PARP1,PDCD1,CET+CIT,Tclin+Tclin,0.203,0.31,1.0,0,0,0,9,8,DC00721,Cetrelimab;Niraparib,DrugComb,FD00038,Prostate Cancer,Prostate Cancer,Phase 1|Phase 2
4864,TP01533,PARP1;PDCD1,PARP1,PDCD1,CET+CIT,Tclin+Tclin,0.203,0.31,1.0,0,0,0,9,8,DC00905,Dostarlimab;Niraparib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 2
4865,TP01533,PARP1;PDCD1,PARP1,PDCD1,CET+CIT,Tclin+Tclin,0.203,0.31,1.0,0,0,0,9,8,DC00905,Dostarlimab;Niraparib,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 2
4866,TP01533,PARP1;PDCD1,PARP1,PDCD1,CET+CIT,Tclin+Tclin,0.203,0.31,1.0,0,0,0,9,8,DC00905,Dostarlimab;Niraparib,DrugComb,FD00034,Ovarian Cancer,Ovarian Cancer,Phase 2
4867,TP01533,PARP1;PDCD1,PARP1,PDCD1,CET+CIT,Tclin+Tclin,0.203,0.31,1.0,0,0,0,9,8,DC00905,Dostarlimab;Niraparib,DrugComb,FD00036,Penile Cancer,Other Cancer,Phase 2
4868,TP01533,PARP1;PDCD1,PARP1,PDCD1,CET+CIT,Tclin+Tclin,0.203,0.31,1.0,0,0,0,9,8,DC01615,Olaparib;Pembrolizumab,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 2
4869,TP01533,PARP1;PDCD1,PARP1,PDCD1,CET+CIT,Tclin+Tclin,0.203,0.31,1.0,0,0,0,9,8,DC01615,Olaparib;Pembrolizumab,DrugComb,FD00022,Liver Cancer,Liver Cancer,Phase 2
4870,TP01533,PARP1;PDCD1,PARP1,PDCD1,CET+CIT,Tclin+Tclin,0.203,0.31,1.0,0,0,0,9,8,DC01615,Olaparib;Pembrolizumab,DrugComb,FD00026,Melanoma,Melanoma,Phase 2
4884,TP01534,PARP1;PIK3CA,PARP1,PIK3CA,CIT+CIT,Tclin+Tclin,0.415,0.468,0.458,2,0,1,3,3,DC01211,Gedatolisib;Talazoparib,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 1|Phase 2
4885,TP01534,PARP1;PIK3CA,PARP1,PIK3CA,CIT+CIT,Tclin+Tclin,0.415,0.468,0.458,2,0,1,3,3,DC00156,Alpelisib;Olaparib,DrugComb,FD00034,Ovarian Cancer,Ovarian Cancer,Phase 3
4886,TP01534,PARP1;PIK3CA,PARP1,PIK3CA,CIT+CIT,Tclin+Tclin,0.415,0.468,0.458,2,0,1,3,3,DC00805,Copanlisib;Rucaparib,DrugComb,FD00038,Prostate Cancer,Prostate Cancer,Phase 1|Phase 2
4887,TP01535,PARP1;PIK3CD,PARP1,PIK3CD,CIT+CIT,Tclin+Tclin,0.342,0.484,0.467,2,0,1,1,1,DC00805,Copanlisib;Rucaparib,DrugComb,FD00038,Prostate Cancer,Prostate Cancer,Phase 1|Phase 2
4888,TP01536,PARP1;TACSTD2,PARP1,TACSTD2,CIT+CIT,Tclin+Tclin,0.222,0.595,1.0,0,0,0,1,1,DC00868,Datopotamab Deruxtecan;Saruparib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
4889,TP01537,PARP1;TGFB1,PARP1,TGFB1,CET+CIT,Tbio+Tclin,0.472,0.537,0.582,1,0,4,1,1,DC01197,Fuzuloparib;Retlirafusp Alfa,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 2
4890,TP01538,PARP1;VEGFA,PARP1,VEGFA,CET+CIT,Tclin+Tclin,0.364,0.462,0.545,0,0,1,5,3,DC00465,Bevacizumab;Olaparib,DrugComb,FD00011,Colorectal Cancer,Colorectal Cancer,Phase 3
4891,TP01538,PARP1;VEGFA,PARP1,VEGFA,CET+CIT,Tclin+Tclin,0.364,0.462,0.545,0,0,1,5,3,DC00465,Bevacizumab;Olaparib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 2
4892,TP01538,PARP1;VEGFA,PARP1,VEGFA,CET+CIT,Tclin+Tclin,0.364,0.462,0.545,0,0,1,5,3,DC00465,Bevacizumab;Olaparib,DrugComb,FD00034,Ovarian Cancer,Ovarian Cancer,Approval
4897,TP01539,PARP1;WEE1,PARP1,WEE1,CIT+CIT,Tchem+Tclin,0.244,0.675,0.535,0,0,0,1,1,DC00379,Azenosertib;Niraparib,DrugComb,FD00034,Ovarian Cancer,Ovarian Cancer,Phase 1|Phase 2
4898,TP01540,PARP2;PDCD1,PARP2,PDCD1,CET+CIT,Tclin+Tclin,0.201,0.22,1.0,0,0,0,7,8,DC00905,Dostarlimab;Niraparib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 2
4899,TP01540,PARP2;PDCD1,PARP2,PDCD1,CET+CIT,Tclin+Tclin,0.201,0.22,1.0,0,0,0,7,8,DC00905,Dostarlimab;Niraparib,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 2
4900,TP01540,PARP2;PDCD1,PARP2,PDCD1,CET+CIT,Tclin+Tclin,0.201,0.22,1.0,0,0,0,7,8,DC00905,Dostarlimab;Niraparib,DrugComb,FD00034,Ovarian Cancer,Ovarian Cancer,Phase 2
4901,TP01540,PARP2;PDCD1,PARP2,PDCD1,CET+CIT,Tclin+Tclin,0.201,0.22,1.0,0,0,0,7,8,DC00905,Dostarlimab;Niraparib,DrugComb,FD00036,Penile Cancer,Other Cancer,Phase 2
4902,TP01540,PARP2;PDCD1,PARP2,PDCD1,CET+CIT,Tclin+Tclin,0.201,0.22,1.0,0,0,0,7,8,DC01553,Niraparib;Pembrolizumab,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 1|Phase 2
4906,TP01540,PARP2;PDCD1,PARP2,PDCD1,CET+CIT,Tclin+Tclin,0.201,0.22,1.0,0,0,0,7,8,DC01615,Olaparib;Pembrolizumab,DrugComb,FD00022,Liver Cancer,Liver Cancer,Phase 2
4907,TP01540,PARP2;PDCD1,PARP2,PDCD1,CET+CIT,Tclin+Tclin,0.201,0.22,1.0,0,0,0,7,8,DC01615,Olaparib;Pembrolizumab,DrugComb,FD00026,Melanoma,Melanoma,Phase 2
4912,TP01540,PARP2;PDCD1,PARP2,PDCD1,CET+CIT,Tclin+Tclin,0.201,0.22,1.0,0,0,0,7,8,DC00721,Cetrelimab;Niraparib,DrugComb,FD00038,Prostate Cancer,Prostate Cancer,Phase 1|Phase 2
4914,TP01541,PARP2;PIK3CA,PARP2,PIK3CA,CIT+CIT,Tclin+Tclin,0.304,0.31,0.391,1,0,0,2,2,DC01211,Gedatolisib;Talazoparib,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 1|Phase 2
4915,TP01541,PARP2;PIK3CA,PARP2,PIK3CA,CIT+CIT,Tclin+Tclin,0.304,0.31,0.391,1,0,0,2,2,DC00156,Alpelisib;Olaparib,DrugComb,FD00034,Ovarian Cancer,Ovarian Cancer,Phase 3
4916,TP01542,PARP2;TACSTD2,PARP2,TACSTD2,CIT+CIT,Tclin+Tclin,0.186,0.49,1.0,0,0,0,1,1,DC00868,Datopotamab Deruxtecan;Saruparib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
4917,TP01543,PARP2;TGFB1,PARP2,TGFB1,CET+CIT,Tbio+Tclin,0.282,0.466,0.516,0,0,0,1,1,DC01197,Fuzuloparib;Retlirafusp Alfa,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 2
4918,TP01544,PARP2;VEGFA,PARP2,VEGFA,CET+CIT,Tclin+Tclin,0.224,0.342,0.505,0,0,0,4,3,DC00448,Bevacizumab;Fuzuloparib,DrugComb,FD00034,Ovarian Cancer,Ovarian Cancer,Phase 2
4919,TP01544,PARP2;VEGFA,PARP2,VEGFA,CET+CIT,Tclin+Tclin,0.224,0.342,0.505,0,0,0,4,3,DC00465,Bevacizumab;Olaparib,DrugComb,FD00011,Colorectal Cancer,Colorectal Cancer,Phase 3
4920,TP01544,PARP2;VEGFA,PARP2,VEGFA,CET+CIT,Tclin+Tclin,0.224,0.342,0.505,0,0,0,4,3,DC00465,Bevacizumab;Olaparib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 2
4924,TP01545,PARP2;WEE1,PARP2,WEE1,CIT+CIT,Tchem+Tclin,0.31,0.871,0.447,0,0,0,1,1,DC00379,Azenosertib;Niraparib,DrugComb,FD00034,Ovarian Cancer,Ovarian Cancer,Phase 1|Phase 2
4925,TP01546,PCSK9;PDCD1,PCSK9,PDCD1,CET+CET,Tclin+Tclin,0.306,0.367,1.0,0,0,0,1,1,DC00131,Alirocumab;Cemiplimab,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 2
4926,TP01547,PDCD1;PDGFRA,PDCD1,PDGFRA,CET+CIT,Tclin+Tclin,0.301,0.511,1.0,0,0,0,4,6,DC01963,Toripalimab;Vorolanib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 2
4927,TP01547,PDCD1;PDGFRA,PDCD1,PDGFRA,CET+CIT,Tclin+Tclin,0.301,0.511,1.0,0,0,0,4,6,DC01963,Toripalimab;Vorolanib,DrugComb,FD00026,Melanoma,Melanoma,Phase 2
4928,TP01547,PDCD1;PDGFRA,PDCD1,PDGFRA,CET+CIT,Tclin+Tclin,0.301,0.511,1.0,0,0,0,4,6,DC01770,Pembrolizumab;Vorolanib,DrugComb,FD00022,Liver Cancer,Liver Cancer,Phase 1
4930,TP01547,PDCD1;PDGFRA,PDCD1,PDGFRA,CET+CIT,Tclin+Tclin,0.301,0.511,1.0,0,0,0,4,6,DC01770,Pembrolizumab;Vorolanib,DrugComb,FD00041,Stomach Cancer,Stomach Cancer,Phase 1
4934,TP01547,PDCD1;PDGFRA,PDCD1,PDGFRA,CET+CIT,Tclin+Tclin,0.301,0.511,1.0,0,0,0,4,6,DC01600,Nivolumab;Vorolanib,DrugComb,FD00042,Thymic Carcinoma,Other Cancer,Phase 1|Phase 2
4935,TP01547,PDCD1;PDGFRA,PDCD1,PDGFRA,CET+CIT,Tclin+Tclin,0.301,0.511,1.0,0,0,0,4,6,DC01619,Olaratumab;Pembrolizumab,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
4936,TP01548,PDCD1;PDGFRB,PDCD1,PDGFRB,CET+CIT,Tclin+Tclin,0.301,0.491,1.0,0,0,0,8,6,DC00367,Axitinib;Tislelizumab,DrugComb,FD00020,Kidney Cancer,Kidney Cancer,Phase 2
4938,TP01548,PDCD1;PDGFRB,PDCD1,PDGFRB,CET+CIT,Tclin+Tclin,0.301,0.491,1.0,0,0,0,8,6,DC01600,Nivolumab;Vorolanib,DrugComb,FD00022,Liver Cancer,Liver Cancer,Phase 1
4939,TP01548,PDCD1;PDGFRB,PDCD1,PDGFRB,CET+CIT,Tclin+Tclin,0.301,0.491,1.0,0,0,0,8,6,DC01600,Nivolumab;Vorolanib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
4940,TP01548,PDCD1;PDGFRB,PDCD1,PDGFRB,CET+CIT,Tclin+Tclin,0.301,0.491,1.0,0,0,0,8,6,DC01600,Nivolumab;Vorolanib,DrugComb,FD00041,Stomach Cancer,Stomach Cancer,Phase 1
4941,TP01548,PDCD1;PDGFRB,PDCD1,PDGFRB,CET+CIT,Tclin+Tclin,0.301,0.491,1.0,0,0,0,8,6,DC01600,Nivolumab;Vorolanib,DrugComb,FD00042,Thymic Carcinoma,Other Cancer,Phase 1|Phase 2
4944,TP01548,PDCD1;PDGFRB,PDCD1,PDGFRB,CET+CIT,Tclin+Tclin,0.301,0.491,1.0,0,0,0,8,6,DC00368,Axitinib;Toripalimab,DrugComb,FD00026,Melanoma,Melanoma,Phase 2
4952,TP01549,PDCD1;PIK3CA,PDCD1,PIK3CA,CET+CIT,Tclin+Tclin,0.306,0.489,1.0,2,0,1,3,4,DC01579,Nivolumab;SF1126,DrugComb,FD00022,Liver Cancer,Liver Cancer,Phase 1
4953,TP01549,PDCD1;PIK3CA,PDCD1,PIK3CA,CET+CIT,Tclin+Tclin,0.306,0.489,1.0,2,0,1,3,4,DC00800,Copanlisib;Nivolumab,DrugComb,FD00018,Head and Neck Cancer,Head and Neck Cancer,Phase 1
4955,TP01549,PDCD1;PIK3CA,PDCD1,PIK3CA,CET+CIT,Tclin+Tclin,0.306,0.489,1.0,2,0,1,3,4,DC00800,Copanlisib;Nivolumab,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
4956,TP01549,PDCD1;PIK3CA,PDCD1,PIK3CA,CET+CIT,Tclin+Tclin,0.306,0.489,1.0,2,0,1,3,4,DC00800,Copanlisib;Nivolumab,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 1
4958,TP01550,PDCD1;PIK3CB,PDCD1,PIK3CB,CET+CIT,Tchem+Tclin,0.258,0.461,1.0,2,0,0,1,1,DC01254,GSK2636771;Pembrolizumab,DrugComb,FD00026,Melanoma,Melanoma,Phase 1|Phase 2
4959,TP01551,PDCD1;PIK3CD,PDCD1,PIK3CD,CET+CIT,Tclin+Tclin,0.311,0.592,1.0,2,0,0,9,13,DC01757,Pembrolizumab;Umbralisib,DrugComb,FD00021,Leukemia,Hematologic Malignancy,Phase 1
4960,TP01551,PDCD1;PIK3CD,PDCD1,PIK3CD,CET+CIT,Tclin+Tclin,0.311,0.592,1.0,2,0,0,9,13,DC01757,Pembrolizumab;Umbralisib,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 1
4963,TP01551,PDCD1;PIK3CD,PDCD1,PIK3CD,CET+CIT,Tclin+Tclin,0.311,0.592,1.0,2,0,0,9,13,DC00955,Duvelisib;Nivolumab,DrugComb,FD00026,Melanoma,Melanoma,Phase 1|Phase 2
4964,TP01551,PDCD1;PIK3CD,PDCD1,PIK3CD,CET+CIT,Tclin+Tclin,0.311,0.592,1.0,2,0,0,9,13,DC00800,Copanlisib;Nivolumab,DrugComb,FD00018,Head and Neck Cancer,Head and Neck Cancer,Phase 1
4965,TP01551,PDCD1;PIK3CD,PDCD1,PIK3CD,CET+CIT,Tclin+Tclin,0.311,0.592,1.0,2,0,0,9,13,DC00800,Copanlisib;Nivolumab,DrugComb,FD00022,Liver Cancer,Liver Cancer,Phase 1
4966,TP01551,PDCD1;PIK3CD,PDCD1,PIK3CD,CET+CIT,Tclin+Tclin,0.311,0.592,1.0,2,0,0,9,13,DC00800,Copanlisib;Nivolumab,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
4969,TP01551,PDCD1;PIK3CD,PDCD1,PIK3CD,CET+CIT,Tclin+Tclin,0.311,0.592,1.0,2,0,0,9,13,DC00954,Duvelisib;Enlonstobart,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1|Phase 2
4970,TP01551,PDCD1;PIK3CD,PDCD1,PIK3CD,CET+CIT,Tclin+Tclin,0.311,0.592,1.0,2,0,0,9,13,DC01674,Parsaclisib;Pembrolizumab,DrugComb,FD00006,Bladder Cancer,Bladder Cancer,Phase 1
4971,TP01551,PDCD1;PIK3CD,PDCD1,PIK3CD,CET+CIT,Tclin+Tclin,0.311,0.592,1.0,2,0,0,9,13,DC01674,Parsaclisib;Pembrolizumab,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 1
4972,TP01551,PDCD1;PIK3CD,PDCD1,PIK3CD,CET+CIT,Tclin+Tclin,0.311,0.592,1.0,2,0,0,9,13,DC01674,Parsaclisib;Pembrolizumab,DrugComb,FD00011,Colorectal Cancer,Colorectal Cancer,Phase 1
4974,TP01551,PDCD1;PIK3CD,PDCD1,PIK3CD,CET+CIT,Tclin+Tclin,0.311,0.592,1.0,2,0,0,9,13,DC01674,Parsaclisib;Pembrolizumab,DrugComb,FD00020,Kidney Cancer,Kidney Cancer,Phase 1
4977,TP01551,PDCD1;PIK3CD,PDCD1,PIK3CD,CET+CIT,Tclin+Tclin,0.311,0.592,1.0,2,0,0,9,13,DC01674,Parsaclisib;Pembrolizumab,DrugComb,FD00034,Ovarian Cancer,Ovarian Cancer,Phase 1
4978,TP01551,PDCD1;PIK3CD,PDCD1,PIK3CD,CET+CIT,Tclin+Tclin,0.311,0.592,1.0,2,0,0,9,13,DC01674,Parsaclisib;Pembrolizumab,DrugComb,FD00035,Pancreatic Cancer,Pancreatic Cancer,Phase 1
4982,TP01552,PDCD1;PIK3CG,PDCD1,PIK3CG,CET+CIT,Tclin+Tclin,0.307,0.561,1.0,0,0,0,5,7,DC00968,Eganelisib;Nivolumab,DrugComb,FD00006,Bladder Cancer,Bladder Cancer,Phase 2
4983,TP01552,PDCD1;PIK3CG,PDCD1,PIK3CG,CET+CIT,Tclin+Tclin,0.307,0.561,1.0,0,0,0,5,7,DC00968,Eganelisib;Nivolumab,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
4984,TP01552,PDCD1;PIK3CG,PDCD1,PIK3CG,CET+CIT,Tclin+Tclin,0.307,0.561,1.0,0,0,0,5,7,DC01732,Pembrolizumab;Tenalisib,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 1
4985,TP01552,PDCD1;PIK3CG,PDCD1,PIK3CG,CET+CIT,Tclin+Tclin,0.307,0.561,1.0,0,0,0,5,7,DC00955,Duvelisib;Nivolumab,DrugComb,FD00021,Leukemia,Hematologic Malignancy,Phase 1
4987,TP01552,PDCD1;PIK3CG,PDCD1,PIK3CG,CET+CIT,Tclin+Tclin,0.307,0.561,1.0,0,0,0,5,7,DC00955,Duvelisib;Nivolumab,DrugComb,FD00026,Melanoma,Melanoma,Phase 1|Phase 2
4988,TP01552,PDCD1;PIK3CG,PDCD1,PIK3CG,CET+CIT,Tclin+Tclin,0.307,0.561,1.0,0,0,0,5,7,DC00954,Duvelisib;Enlonstobart,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1|Phase 2
4989,TP01552,PDCD1;PIK3CG,PDCD1,PIK3CG,CET+CIT,Tclin+Tclin,0.307,0.561,1.0,0,0,0,5,7,DC00956,Duvelisib;Pembrolizumab,DrugComb,FD00018,Head and Neck Cancer,Head and Neck Cancer,Phase 1|Phase 2
4990,TP01553,PDCD1;PLK1,PDCD1,PLK1,CET+CIT,Tchem+Tclin,0.18,0.244,1.0,0,0,0,1,1,DC01574,Nivolumab;Rigosertib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
4991,TP01554,PDCD1;PMEL,PDCD1,PMEL,CET+CIT,Tclin+Tclin,0.087,0.494,1.0,0,0,0,1,1,DC01729,Pembrolizumab;Tebentafusp,DrugComb,FD00026,Melanoma,Melanoma,Phase 2|Phase 3
4992,TP01555,PDCD1;PORCN,PDCD1,PORCN,CET+CIT,Tchem+Tclin,0.14,0.447,0.788,0,0,0,2,1,DC01089,ETC1922159;Pembrolizumab,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
4994,TP01556,PDCD1;PPARA,PDCD1,PPARA,CET+CIT,Tclin+Tclin,0.241,0.233,1.0,0,0,0,1,1,DC01589,Nivolumab;TPST1120,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
4995,TP01557,PDCD1;PTGER2,PDCD1,PTGER2,CET+CIT,Tclin+Tclin,0.206,0.809,0.102,0,0,0,1,1,DC01740,Pembrolizumab;TPST1495,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
4996,TP01558,PDCD1;PTGER4,PDCD1,PTGER4,CET+CIT,Tclin+Tclin,0.33,0.941,1.0,0,0,0,5,3,DC00384,Balstilimab;CR6086,DrugComb,FD00011,Colorectal Cancer,Colorectal Cancer,Phase 1|Phase 2
4997,TP01558,PDCD1;PTGER4,PDCD1,PTGER4,CET+CIT,Tclin+Tclin,0.33,0.941,1.0,0,0,0,5,3,DC01740,Pembrolizumab;TPST1495,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
4998,TP01558,PDCD1;PTGER4,PDCD1,PTGER4,CET+CIT,Tclin+Tclin,0.33,0.941,1.0,0,0,0,5,3,DC00566,BMS986310;Nivolumab,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
5001,TP01559,PDCD1;PTK2,PDCD1,PTK2,CET+CET,Tclin+Tclin,0.285,0.41,1.0,0,0,0,1,1,DC00874,Defactinib;Pembrolizumab,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
5002,TP01560,PDCD1;PTPN11,PDCD1,PTPN11,CET+CIT,Tchem+Tclin,0.267,0.276,1.0,2,1,1,3,1,DC00400,BBP398;Nivolumab,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
5005,TP01561,PDCD1;PVRIG,PDCD1,PVRIG,CET+CET,Tbio+Tclin,0.481,0.941,1.0,0,0,0,1,1,DC00795,COM701;Nivolumab,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
5006,TP01562,PDCD1;RAF1,PDCD1,RAF1,CET+CIT,Tclin+Tclin,0.391,0.443,1.0,2,0,1,1,1,DC01588,Nivolumab;Tovorafenib,DrugComb,FD00026,Melanoma,Melanoma,Phase 1
5007,TP01563,PDCD1;RIGI,PDCD1,RIGI,CET+CIT,Tbio+Tclin,,,,0,0,0,1,1,DC01487,MK4621;Pembrolizumab,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
5008,TP01564,PDCD1;RIPK1,PDCD1,RIPK1,CET+CIT,Tchem+Tclin,0.332,0.469,1.0,0,1,0,1,1,DC01255,GSK3145095;Pembrolizumab,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 2
5009,TP01565,PDCD1;RNF43,PDCD1,RNF43,CET+CIT,Tbio+Tclin,0.184,0.637,1.0,0,0,0,1,1,DC00608,Budigalimab;SC006,DrugComb,FD00011,Colorectal Cancer,Colorectal Cancer,Phase 1
5010,TP01566,PDCD1;RORC,PDCD1,RORC,CET+CIT,Tchem+Tclin,0.245,0.233,1.0,0,0,0,1,1,DC00775,Cintirorgon;Pembrolizumab,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
5011,TP01567,PDCD1;SEMA4D,PDCD1,SEMA4D,CET+CIT,Tbio+Tclin,0.36,0.731,1.0,0,0,0,1,1,DC01564,Nivolumab;Pepinemab,DrugComb,FD00018,Head and Neck Cancer,Head and Neck Cancer,Phase 1
5012,TP01568,PDCD1;SEZ6,PDCD1,SEZ6,CET+CIT,Tclin+Tdark,0.284,0.553,1.0,0,0,0,1,1,DC00003,ABBV011;Budigalimab,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
5013,TP01569,PDCD1;SIGLEC15,PDCD1,SIGLEC15,CET+CET,Tbio+Tclin,0.186,0.821,,0,0,0,1,1,DC01527,NC318;Pembrolizumab,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 2
5014,TP01570,PDCD1;SIRPA,PDCD1,SIRPA,CET+CIT,Tbio+Tclin,0.219,0.585,0.687,0,0,0,2,1,DC00511,BI770371;Ezabenlimab,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
5016,TP01571,PDCD1;SLAMF7,PDCD1,SLAMF7,CET+CIT,Tclin+Tclin,0.392,1.0,0.788,0,0,1,1,1,DC00971,Elotuzumab;Nivolumab,DrugComb,FD00030,Myeloma,Hematologic Malignancy,Phase 2
5017,TP01572,PDCD1;SLC39A6,PDCD1,SLC39A6,CET+CIT,Tbio+Tclin,0.063,0.659,0.1,0,0,0,1,1,DC01379,Ladiratuzumab Vedotin;Pembrolizumab,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 2
5018,TP01573,PDCD1;SMO,PDCD1,SMO,CET+CIT,Tclin+Tclin,0.368,0.499,1.0,0,0,0,1,1,DC01720,Pembrolizumab;Sonidegib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
5019,TP01574,PDCD1;STAB1,PDCD1,STAB1,CET+CET,Tbio+Tclin,0.249,0.711,1.0,0,0,0,1,1,DC00492,Bexmarilimab;Pembrolizumab,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
5020,TP01575,PDCD1;STAT3,PDCD1,STAT3,CET+CIT,Tchem+Tclin,0.251,0.437,1.0,1,0,2,2,2,DC01509,Napabucasin;Pembrolizumab,DrugComb,FD00011,Colorectal Cancer,Colorectal Cancer,Phase 1|Phase 2
5021,TP01575,PDCD1;STAT3,PDCD1,STAT3,CET+CIT,Tchem+Tclin,0.251,0.437,1.0,1,0,2,2,2,DC01750,Pembrolizumab;TTI101,DrugComb,FD00022,Liver Cancer,Liver Cancer,Phase 1|Phase 2
5022,TP01576,PDCD1;STING1,PDCD1,STING1,CET+CET,Tchem+Tclin,0.219,0.372,1.0,0,0,0,5,4,DC01727,Pembrolizumab;TAK500,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
5023,TP01576,PDCD1;STING1,PDCD1,STING1,CET+CET,Tchem+Tclin,0.219,0.372,1.0,0,0,0,5,4,DC01756,Pembrolizumab;Ulevostinag,DrugComb,FD00018,Head and Neck Cancer,Head and Neck Cancer,Phase 2
5024,TP01576,PDCD1;STING1,PDCD1,STING1,CET+CET,Tchem+Tclin,0.219,0.372,1.0,0,0,0,5,4,DC01756,Pembrolizumab;Ulevostinag,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 1
5025,TP01576,PDCD1;STING1,PDCD1,STING1,CET+CET,Tchem+Tclin,0.219,0.372,1.0,0,0,0,5,4,DC01756,Pembrolizumab;Ulevostinag,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
5029,TP01577,PDCD1;SUMO1,PDCD1,SUMO1,CET+CIT,Tbio+Tclin,0.181,0.348,1.0,0,0,0,1,1,DC01725,Pembrolizumab;Subasumstat,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1|Phase 2
5030,TP01578,PDCD1;SUMO2,PDCD1,SUMO2,CET+CIT,Tbio+Tclin,0.059,0.204,1.0,0,0,0,1,1,DC01725,Pembrolizumab;Subasumstat,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1|Phase 2
5031,TP01579,PDCD1;SUMO3,PDCD1,SUMO3,CET+CIT,Tbio+Tclin,0.105,0.257,1.0,0,0,0,1,1,DC01725,Pembrolizumab;Subasumstat,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1|Phase 2
5032,TP01580,PDCD1;SYK,PDCD1,SYK,CET+CIT,Tclin+Tclin,0.285,0.502,1.0,0,1,1,1,3,DC01476,Mivavotinib;Nivolumab,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 1
5033,TP01580,PDCD1;SYK,PDCD1,SYK,CET+CIT,Tclin+Tclin,0.285,0.502,1.0,0,1,1,1,3,DC01476,Mivavotinib;Nivolumab,DrugComb,FD00018,Head and Neck Cancer,Head and Neck Cancer,Phase 1
5034,TP01580,PDCD1;SYK,PDCD1,SYK,CET+CIT,Tclin+Tclin,0.285,0.502,1.0,0,1,1,1,3,DC01476,Mivavotinib;Nivolumab,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
5035,TP01581,PDCD1;TACSTD2,PDCD1,TACSTD2,CET+CIT,Tclin+Tclin,0.297,0.614,1.0,0,0,0,7,2,DC00869,Datopotamab Deruxtecan;Volrustomig,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
5038,TP01581,PDCD1;TACSTD2,PDCD1,TACSTD2,CET+CIT,Tclin+Tclin,0.297,0.614,1.0,0,0,0,7,2,DC00547,BIO106;Pembrolizumab,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1|Phase 2
5042,TP01582,PDCD1;TGFB1,PDCD1,TGFB1,CET+CET,Tbio+Tclin,0.238,0.438,1.0,0,0,2,4,2,DC00403,BCA101;Pembrolizumab,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
5043,TP01582,PDCD1;TGFB1,PDCD1,TGFB1,CET+CET,Tbio+Tclin,0.238,0.438,1.0,0,0,2,4,2,DC00569,BMS986416;Nivolumab,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
5046,TP01583,PDCD1;TGFB3,PDCD1,TGFB3,CET+CET,Tbio+Tclin,0.333,0.488,1.0,0,0,2,1,1,DC00569,BMS986416;Nivolumab,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
5047,TP01584,PDCD1;TGFBR1,PDCD1,TGFBR1,CET+CIT,Tchem+Tclin,0.358,0.473,1.0,0,0,0,5,6,DC01753,Pembrolizumab;TU2218,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1|Phase 2
5048,TP01584,PDCD1;TGFBR1,PDCD1,TGFBR1,CET+CIT,Tchem+Tclin,0.358,0.473,1.0,0,0,0,5,6,DC01199,Galunisertib;Nivolumab,DrugComb,FD00022,Liver Cancer,Liver Cancer,Phase 1|Phase 2
5049,TP01584,PDCD1;TGFBR1,PDCD1,TGFBR1,CET+CIT,Tchem+Tclin,0.358,0.473,1.0,0,0,0,5,6,DC01199,Galunisertib;Nivolumab,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
5052,TP01584,PDCD1;TGFBR1,PDCD1,TGFBR1,CET+CIT,Tchem+Tclin,0.358,0.473,1.0,0,0,0,5,6,DC01759,Pembrolizumab;Vactosertib,DrugComb,FD00011,Colorectal Cancer,Colorectal Cancer,Phase 1|Phase 2
5054,TP01584,PDCD1;TGFBR1,PDCD1,TGFBR1,CET+CIT,Tchem+Tclin,0.358,0.473,1.0,0,0,0,5,6,DC01759,Pembrolizumab;Vactosertib,DrugComb,FD00026,Melanoma,Melanoma,Phase 2
5055,TP01584,PDCD1;TGFBR1,PDCD1,TGFBR1,CET+CIT,Tchem+Tclin,0.358,0.473,1.0,0,0,0,5,6,DC01759,Pembrolizumab;Vactosertib,DrugComb,FD00041,Stomach Cancer,Stomach Cancer,Phase 1|Phase 2
5056,TP01585,PDCD1;TGFBR2,PDCD1,TGFBR2,CET+CIT,Tchem+Tclin,0.365,0.72,1.0,0,0,1,2,2,DC02162,JS201,BsAb,FD00023,Lung Cancer,Lung Cancer,Phase 2
5057,TP01585,PDCD1;TGFBR2,PDCD1,TGFBR2,CET+CIT,Tchem+Tclin,0.365,0.72,1.0,0,0,1,2,2,DC02162,JS201,BsAb,FD00033,Other Cancer,Other Cancer,Phase 1
5059,TP01586,PDCD1;TIGIT,PDCD1,TIGIT,CET+CET,Tbio+Tclin,0.165,0.872,1.0,1,0,1,16,5,DC00110,AK127;Cadonilimab,DrugComb,FD00023,Lung Cancer,Lung Cancer,Early Phase 1
5060,TP01586,PDCD1;TIGIT,PDCD1,TIGIT,CET+CET,Tbio+Tclin,0.165,0.872,1.0,1,0,1,16,5,DC00110,AK127;Cadonilimab,DrugComb,FD00033,Other Cancer,Other Cancer,Early Phase 1
5063,TP01586,PDCD1;TIGIT,PDCD1,TIGIT,CET+CET,Tbio+Tclin,0.165,0.872,1.0,1,0,1,16,5,DC01613,Ociperlimab;Tislelizumab,DrugComb,FD00034,Ovarian Cancer,Ovarian Cancer,Phase 2
5075,TP01586,PDCD1;TIGIT,PDCD1,TIGIT,CET+CET,Tbio+Tclin,0.165,0.872,1.0,1,0,1,16,5,DC02242,Rilvegostomig,BsAb,FD00018,Head and Neck Cancer,Head and Neck Cancer,Phase 2
5077,TP01586,PDCD1;TIGIT,PDCD1,TIGIT,CET+CET,Tbio+Tclin,0.165,0.872,1.0,1,0,1,16,5,DC02242,Rilvegostomig,BsAb,FD00041,Stomach Cancer,Stomach Cancer,Phase 2
5079,TP01587,PDCD1;TIPARP,PDCD1,TIPARP,CET+CIT,Tbio+Tclin,0.309,0.183,0.357,0,0,0,1,1,DC00243,Atamparib;Pembrolizumab,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
5080,TP01588,PDCD1;TLR7,PDCD1,TLR7,CET+CET,Tclin+Tclin,0.219,0.456,1.0,0,1,2,5,1,DC01591,Nivolumab;Trastuzumab imbotolimod,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1|Phase 2
5085,TP01589,PDCD1;TLR8,PDCD1,TLR8,CET+CET,Tchem+Tclin,0.258,0.69,0.325,0,0,1,6,3,DC01591,Nivolumab;Trastuzumab imbotolimod,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1|Phase 2
5086,TP01589,PDCD1;TLR8,PDCD1,TLR8,CET+CET,Tchem+Tclin,0.258,0.69,0.325,0,0,1,6,3,DC01712,Pembrolizumab;SBT6290,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
5089,TP01589,PDCD1;TLR8,PDCD1,TLR8,CET+CET,Tchem+Tclin,0.258,0.69,0.325,0,0,1,6,3,DC01502,Motolimod;Nivolumab,DrugComb,FD00018,Head and Neck Cancer,Head and Neck Cancer,Phase 1
5091,TP01590,PDCD1;TLR9,PDCD1,TLR9,CET+CIT,Tclin+Tclin,0.216,0.475,0.576,1,1,0,4,3,DC01764,Pembrolizumab;Vidutolimod,DrugComb,FD00018,Head and Neck Cancer,Head and Neck Cancer,Phase 2
5092,TP01590,PDCD1;TLR9,PDCD1,TLR9,CET+CIT,Tclin+Tclin,0.216,0.475,0.576,1,1,0,4,3,DC01764,Pembrolizumab;Vidutolimod,DrugComb,FD00026,Melanoma,Melanoma,Phase 1
5093,TP01590,PDCD1;TLR9,PDCD1,TLR9,CET+CIT,Tclin+Tclin,0.216,0.475,0.576,1,1,0,4,3,DC00708,Cemiplimab;Vidutolimod,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 2
5096,TP01591,PDCD1;TNF,PDCD1,TNF,CET+CET,Tclin+Tclin,0.245,0.641,1.0,1,0,3,1,1,DC01323,Infliximab;Pembrolizumab,DrugComb,FD00026,Melanoma,Melanoma,Phase 2
5097,TP01592,PDCD1;TNFRSF10B,PDCD1,TNFRSF10B,CET+CIT,Tbio+Tclin,0.414,0.872,1.0,0,0,0,1,2,DC00913,DS8273a;Nivolumab,DrugComb,FD00011,Colorectal Cancer,Colorectal Cancer,Phase 1
5098,TP01592,PDCD1;TNFRSF10B,PDCD1,TNFRSF10B,CET+CIT,Tbio+Tclin,0.414,0.872,1.0,0,0,0,1,2,DC00913,DS8273a;Nivolumab,DrugComb,FD00026,Melanoma,Melanoma,Phase 1
5099,TP01593,PDCD1;TNFRSF18,PDCD1,TNFRSF18,CET+CET,Tbio+Tclin,0.42,0.818,1.0,0,0,0,8,2,DC01593,Nivolumab;TRX518,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
5105,TP01593,PDCD1;TNFRSF18,PDCD1,TNFRSF18,CET+CET,Tbio+Tclin,0.42,0.818,1.0,0,0,0,8,2,DC01838,Ragifilimab;Retifanlimab,DrugComb,FD00018,Head and Neck Cancer,Head and Neck Cancer,Phase 2
5107,TP01594,PDCD1;TNFRSF1B,PDCD1,TNFRSF1B,CET+CET,Tbio+Tclin,0.394,0.542,1.0,0,0,0,1,1,DC01260,HFB200301;Tislelizumab,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
5108,TP01595,PDCD1;TNFRSF8,PDCD1,TNFRSF8,CET+CIT,Tclin+Tclin,0.316,0.749,0.176,0,0,0,3,4,DC00068,Acimtamig;Pembrolizumab,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 1
5110,TP01595,PDCD1;TNFRSF8,PDCD1,TNFRSF8,CET+CIT,Tclin+Tclin,0.316,0.749,0.176,0,0,0,3,4,DC00596,Brentuximab Vedotin;Pembrolizumab,DrugComb,FD00018,Head and Neck Cancer,Head and Neck Cancer,Phase 2
5111,TP01595,PDCD1;TNFRSF8,PDCD1,TNFRSF8,CET+CIT,Tclin+Tclin,0.316,0.749,0.176,0,0,0,3,4,DC00596,Brentuximab Vedotin;Pembrolizumab,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 2
5113,TP01595,PDCD1;TNFRSF8,PDCD1,TNFRSF8,CET+CIT,Tclin+Tclin,0.316,0.749,0.176,0,0,0,3,4,DC00596,Brentuximab Vedotin;Pembrolizumab,DrugComb,FD00026,Melanoma,Melanoma,Phase 2
5114,TP01596,PDCD1;TNFRSF9,PDCD1,TNFRSF9,CET+CET,Tbio+Tclin,0.374,0.89,1.0,0,0,1,12,7,DC00500,BGBB167;Tislelizumab,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
5115,TP01596,PDCD1;TNFRSF9,PDCD1,TNFRSF9,CET+CET,Tbio+Tclin,0.374,0.89,1.0,0,0,1,12,7,DC00994,Enristomig;Pembrolizumab,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 2
5116,TP01596,PDCD1;TNFRSF9,PDCD1,TNFRSF9,CET+CET,Tbio+Tclin,0.374,0.89,1.0,0,0,1,12,7,DC01730,Pembrolizumab;Tecaginlimab,DrugComb,FD00011,Colorectal Cancer,Colorectal Cancer,Phase 1|Phase 2
5117,TP01596,PDCD1;TNFRSF9,PDCD1,TNFRSF9,CET+CET,Tbio+Tclin,0.374,0.89,1.0,0,0,1,12,7,DC01730,Pembrolizumab;Tecaginlimab,DrugComb,FD00018,Head and Neck Cancer,Head and Neck Cancer,Phase 1|Phase 2
5119,TP01596,PDCD1;TNFRSF9,PDCD1,TNFRSF9,CET+CET,Tbio+Tclin,0.374,0.89,1.0,0,0,1,12,7,DC01730,Pembrolizumab;Tecaginlimab,DrugComb,FD00026,Melanoma,Melanoma,Phase 1|Phase 2
5120,TP01596,PDCD1;TNFRSF9,PDCD1,TNFRSF9,CET+CET,Tbio+Tclin,0.374,0.89,1.0,0,0,1,12,7,DC01730,Pembrolizumab;Tecaginlimab,DrugComb,FD00035,Pancreatic Cancer,Pancreatic Cancer,Phase 1|Phase 2
5124,TP01596,PDCD1;TNFRSF9,PDCD1,TNFRSF9,CET+CET,Tbio+Tclin,0.374,0.89,1.0,0,0,1,12,7,DC01596,Nivolumab;Urelumab,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 1|Phase 2
5131,TP01597,PDCD1;TNFSF11,PDCD1,TNFSF11,CET+CIT,Tclin+Tclin,0.293,0.64,1.0,0,0,0,2,2,DC00882,Denosumab;Nivolumab;Pembrolizumab,DrugComb,FD00026,Melanoma,Melanoma,Phase 2
5132,TP01597,PDCD1;TNFSF11,PDCD1,TNFSF11,CET+CIT,Tclin+Tclin,0.293,0.64,1.0,0,0,0,2,2,DC00881,Denosumab;Nivolumab,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 2
5133,TP01598,PDCD1;TNFSF4,PDCD1,TNFSF4,CET+CIT,Tbio+Tclin,0.303,0.702,1.0,0,0,1,8,5,DC00499,BGBA445;Tislelizumab,DrugComb,FD00006,Bladder Cancer,Bladder Cancer,Phase 1|Phase 2
5134,TP01598,PDCD1;TNFSF4,PDCD1,TNFSF4,CET+CIT,Tbio+Tclin,0.303,0.702,1.0,0,0,1,8,5,DC00499,BGBA445;Tislelizumab,DrugComb,FD00020,Kidney Cancer,Kidney Cancer,Phase 1|Phase 2
5135,TP01598,PDCD1;TNFSF4,PDCD1,TNFSF4,CET+CIT,Tbio+Tclin,0.303,0.702,1.0,0,0,1,8,5,DC00499,BGBA445;Tislelizumab,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 2
5136,TP01598,PDCD1;TNFSF4,PDCD1,TNFSF4,CET+CIT,Tbio+Tclin,0.303,0.702,1.0,0,0,1,8,5,DC00499,BGBA445;Tislelizumab,DrugComb,FD00026,Melanoma,Melanoma,Phase 1|Phase 2
5138,TP01598,PDCD1;TNFSF4,PDCD1,TNFSF4,CET+CIT,Tbio+Tclin,0.303,0.702,1.0,0,0,1,8,5,DC01313,INCAGN01949;Nivolumab,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1|Phase 2
5144,TP01599,PDCD1;TP53,PDCD1,TP53,CET+CIT,Tchem+Tclin,0.29,0.23,1.0,0,0,1,2,1,DC01032,Eprenetapopt;Pembrolizumab,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
5146,TP01600,PDCD1;TREM1,PDCD1,TREM1,CET+CET,Tbio+Tclin,0.438,0.849,0.788,0,0,0,1,1,DC01831,PY159;Pembrolizumab,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
5147,TP01601,PDCD1;TREM2,PDCD1,TREM2,CET+CET,Tbio+Tclin,0.263,0.797,1.0,0,0,0,1,1,DC01832,PY314;Pembrolizumab,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
5148,TP01602,PDCD1;VEGFA,PDCD1,VEGFA,CET+CET,Tclin+Tclin,0.305,0.43,1.0,0,0,1,10,12,DC00515,BI836880;Ezabenlimab,DrugComb,FD00002,Anal Cancer,Other Cancer,Phase 2
5149,TP01602,PDCD1;VEGFA,PDCD1,VEGFA,CET+CET,Tclin+Tclin,0.305,0.43,1.0,0,0,1,10,12,DC00515,BI836880;Ezabenlimab,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
5150,TP01602,PDCD1;VEGFA,PDCD1,VEGFA,CET+CET,Tclin+Tclin,0.305,0.43,1.0,0,0,1,10,12,DC00515,BI836880;Ezabenlimab,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
5151,TP01602,PDCD1;VEGFA,PDCD1,VEGFA,CET+CET,Tclin+Tclin,0.305,0.43,1.0,0,0,1,10,12,DC00463,Bevacizumab;Nivolumab,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 2
5152,TP01602,PDCD1;VEGFA,PDCD1,VEGFA,CET+CET,Tclin+Tclin,0.305,0.43,1.0,0,0,1,10,12,DC00463,Bevacizumab;Nivolumab,DrugComb,FD00017,Glioma,Glioma,Phase 2
5153,TP01602,PDCD1;VEGFA,PDCD1,VEGFA,CET+CET,Tclin+Tclin,0.305,0.43,1.0,0,0,1,10,12,DC00463,Bevacizumab;Nivolumab,DrugComb,FD00022,Liver Cancer,Liver Cancer,Phase 2
5156,TP01602,PDCD1;VEGFA,PDCD1,VEGFA,CET+CET,Tclin+Tclin,0.305,0.43,1.0,0,0,1,10,12,DC00470,Bevacizumab;Pembrolizumab,DrugComb,FD00020,Kidney Cancer,Kidney Cancer,Approval
5158,TP01602,PDCD1;VEGFA,PDCD1,VEGFA,CET+CET,Tclin+Tclin,0.305,0.43,1.0,0,0,1,10,12,DC00470,Bevacizumab;Pembrolizumab,DrugComb,FD00026,Melanoma,Melanoma,Approval
5159,TP01602,PDCD1;VEGFA,PDCD1,VEGFA,CET+CET,Tclin+Tclin,0.305,0.43,1.0,0,0,1,10,12,DC00470,Bevacizumab;Pembrolizumab,DrugComb,FD00030,Myeloma,Hematologic Malignancy,Approval
5160,TP01602,PDCD1;VEGFA,PDCD1,VEGFA,CET+CET,Tclin+Tclin,0.305,0.43,1.0,0,0,1,10,12,DC00470,Bevacizumab;Pembrolizumab,DrugComb,FD00034,Ovarian Cancer,Ovarian Cancer,Approval
5161,TP01602,PDCD1;VEGFA,PDCD1,VEGFA,CET+CET,Tclin+Tclin,0.305,0.43,1.0,0,0,1,10,12,DC00470,Bevacizumab;Pembrolizumab,DrugComb,FD00041,Stomach Cancer,Stomach Cancer,Approval
5166,TP01602,PDCD1;VEGFA,PDCD1,VEGFA,CET+CET,Tclin+Tclin,0.305,0.43,1.0,0,0,1,10,12,DC00483,Bevacizumab;Toripalimab,DrugComb,FD00011,Colorectal Cancer,Colorectal Cancer,Phase 2
5179,TP01603,PDCD1;VSIR,PDCD1,VSIR,CET+CET,Tbio+Tclin,0.312,0.941,1.0,1,0,1,3,2,DC01265,HMBD002;Pembrolizumab,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
5181,TP01603,PDCD1;VSIR,PDCD1,VSIR,CET+CET,Tbio+Tclin,0.312,0.941,1.0,1,0,1,3,2,DC01771,Pembrolizumab;W0180,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
5182,TP01604,PDCD1;XIAP,PDCD1,XIAP,CET+CIT,Tchem+Tclin,0.369,0.265,1.0,0,0,0,6,6,DC01389,LCL161;Spartalizumab,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
5183,TP01604,PDCD1;XIAP,PDCD1,XIAP,CET+CIT,Tchem+Tclin,0.369,0.265,1.0,0,0,0,6,6,DC01774,Pembrolizumab;Xevinapant,DrugComb,FD00011,Colorectal Cancer,Colorectal Cancer,Phase 1
5184,TP01604,PDCD1;XIAP,PDCD1,XIAP,CET+CIT,Tchem+Tclin,0.369,0.265,1.0,0,0,0,6,6,DC01774,Pembrolizumab;Xevinapant,DrugComb,FD00035,Pancreatic Cancer,Pancreatic Cancer,Phase 1
5186,TP01604,PDCD1;XIAP,PDCD1,XIAP,CET+CIT,Tchem+Tclin,0.369,0.265,1.0,0,0,0,6,6,DC00516,BI891065;Ezabenlimab,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
5187,TP01604,PDCD1;XIAP,PDCD1,XIAP,CET+CIT,Tchem+Tclin,0.369,0.265,1.0,0,0,0,6,6,DC01738,Pembrolizumab;Tolinapant,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 1
5188,TP01604,PDCD1;XIAP,PDCD1,XIAP,CET+CIT,Tchem+Tclin,0.369,0.265,1.0,0,0,0,6,6,DC01738,Pembrolizumab;Tolinapant,DrugComb,FD00034,Ovarian Cancer,Ovarian Cancer,Phase 1
5191,TP01605,PDCD1;XPO1,PDCD1,XPO1,CET+CIT,Tclin+Tclin,0.107,0.328,1.0,0,0,0,2,3,DC01713,Pembrolizumab;Selinexor,DrugComb,FD00011,Colorectal Cancer,Colorectal Cancer,Phase 1|Phase 2
5192,TP01605,PDCD1;XPO1,PDCD1,XPO1,CET+CIT,Tclin+Tclin,0.107,0.328,1.0,0,0,0,2,3,DC01713,Pembrolizumab;Selinexor,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
5193,TP01605,PDCD1;XPO1,PDCD1,XPO1,CET+CIT,Tclin+Tclin,0.107,0.328,1.0,0,0,0,2,3,DC01713,Pembrolizumab;Selinexor,DrugComb,FD00026,Melanoma,Melanoma,Phase 2
5195,TP01606,PIK3CA;PIM1,PIK3CA,PIM1,CIT+CIT,Tchem+Tclin,0.396,0.626,0.724,5,1,3,1,1,DC00154,Alpelisib;LGH447,DrugComb,FD00030,Myeloma,Hematologic Malignancy,Phase 1
5196,TP01607,PIK3CA;PIM2,PIK3CA,PIM2,CIT+CIT,Tchem+Tclin,0.365,1.0,0.764,0,0,3,1,1,DC00154,Alpelisib;LGH447,DrugComb,FD00030,Myeloma,Hematologic Malignancy,Phase 1
5197,TP01608,PIK3CA;PIM3,PIK3CA,PIM3,CIT+CIT,Tchem+Tclin,0.325,0.572,0.764,0,0,0,1,1,DC00154,Alpelisib;LGH447,DrugComb,FD00030,Myeloma,Hematologic Malignancy,Phase 1
5198,TP01609,PIK3CA;PRKCB,PIK3CA,PRKCB,CIT+CIT,Tchem+Tclin,0.455,0.6,0.678,41,0,16,1,1,DC00159,Alpelisib;Sotrastaurin Acetate,DrugComb,FD00026,Melanoma,Melanoma,Phase 1
5199,TP01610,PIK3CA;PTK7,PIK3CA,PTK7,CIT+CIT,Tbio+Tclin,0.448,0.511,0.707,0,0,0,1,1,DC00792,Cofetuzumab Pelidotin;Gedatolisib,DrugComb,FD00007,Breast Cancer,Breast Cancer,Phase 1
5200,TP01611,PIK3CA;SMO,PIK3CA,SMO,CIT+CIT,Tclin+Tclin,0.426,0.506,0.293,3,0,2,1,2,DC00620,Buparlisib;Sonidegib,DrugComb,FD00005,Basal Cell Carcinoma,Other Cancer,Phase 2
5201,TP01611,PIK3CA;SMO,PIK3CA,SMO,CIT+CIT,Tclin+Tclin,0.426,0.506,0.293,3,0,2,1,2,DC00620,Buparlisib;Sonidegib,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
5202,TP01612,PIK3CA;SYK,PIK3CA,SYK,CIT+CIT,Tclin+Tclin,0.483,0.633,0.733,15,5,3,1,1,DC01477,Mivavotinib;Serabelisib,DrugComb,FD00041,Stomach Cancer,Stomach Cancer,Phase 1
5203,TP01613,PIK3CA;VEGFA,PIK3CA,VEGFA,CET+CIT,Tclin+Tclin,0.505,0.633,0.399,20,0,13,1,1,DC00431,Bevacizumab;Buparlisib,DrugComb,FD00017,Glioma,Glioma,Phase 1|Phase 2
5204,TP01614,PIK3CB;SMO,PIK3CB,SMO,CIT+CIT,Tchem+Tclin,0.394,0.579,0.349,3,0,2,1,2,DC00620,Buparlisib;Sonidegib,DrugComb,FD00005,Basal Cell Carcinoma,Other Cancer,Phase 2
5205,TP01614,PIK3CB;SMO,PIK3CB,SMO,CIT+CIT,Tchem+Tclin,0.394,0.579,0.349,3,0,2,1,2,DC00620,Buparlisib;Sonidegib,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
5206,TP01615,PIK3CB;VEGFA,PIK3CB,VEGFA,CET+CIT,Tchem+Tclin,0.463,0.583,0.447,20,0,8,1,1,DC00431,Bevacizumab;Buparlisib,DrugComb,FD00017,Glioma,Glioma,Phase 1|Phase 2
5207,TP01616,PIK3CD;PIM1,PIK3CD,PIM1,CIT+CIT,Tchem+Tclin,0.34,0.695,0.639,5,0,2,1,1,DC01679,Parsaclisib;Uzansertib,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 1
5208,TP01617,PIK3CD;PIM2,PIK3CD,PIM2,CIT+CIT,Tchem+Tclin,0.31,1.0,0.674,0,0,2,1,1,DC01679,Parsaclisib;Uzansertib,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 1
5209,TP01618,PIK3CD;PIM3,PIK3CD,PIM3,CIT+CIT,Tchem+Tclin,0.274,0.656,0.674,0,0,0,1,1,DC01679,Parsaclisib;Uzansertib,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 1
5210,TP01619,PIK3CD;SMO,PIK3CD,SMO,CIT+CIT,Tclin+Tclin,0.393,0.499,0.313,3,0,2,1,2,DC00620,Buparlisib;Sonidegib,DrugComb,FD00005,Basal Cell Carcinoma,Other Cancer,Phase 2
5211,TP01619,PIK3CD;SMO,PIK3CD,SMO,CIT+CIT,Tclin+Tclin,0.393,0.499,0.313,3,0,2,1,2,DC00620,Buparlisib;Sonidegib,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
5212,TP01620,PIK3CD;SYK,PIK3CD,SYK,CIT+CIT,Tclin+Tclin,0.571,0.687,0.682,15,2,3,1,2,DC01002,Entospletinib;Idelalisib,DrugComb,FD00021,Leukemia,Hematologic Malignancy,Phase 2
5213,TP01620,PIK3CD;SYK,PIK3CD,SYK,CIT+CIT,Tclin+Tclin,0.571,0.687,0.682,15,2,3,1,2,DC01002,Entospletinib;Idelalisib,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 2
5214,TP01621,PIK3CD;TNFRSF8,PIK3CD,TNFRSF8,CIT+CIT,Tclin+Tclin,0.357,0.707,0.176,0,0,0,1,1,DC00598,Brentuximab Vedotin;Umbralisib,DrugComb,FD00024,Lymphoma,Hematologic Malignancy,Phase 1
5215,TP01622,PIK3CD;VEGFA,PIK3CD,VEGFA,CET+CIT,Tclin+Tclin,0.477,0.642,0.432,20,0,7,1,1,DC00431,Bevacizumab;Buparlisib,DrugComb,FD00017,Glioma,Glioma,Phase 1|Phase 2
5216,TP01623,PIK3CG;SMO,PIK3CG,SMO,CIT+CIT,Tclin+Tclin,0.357,0.488,0.314,0,0,1,1,2,DC00620,Buparlisib;Sonidegib,DrugComb,FD00005,Basal Cell Carcinoma,Other Cancer,Phase 2
5217,TP01623,PIK3CG;SMO,PIK3CG,SMO,CIT+CIT,Tclin+Tclin,0.357,0.488,0.314,0,0,1,1,2,DC00620,Buparlisib;Sonidegib,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
5218,TP01624,PIK3CG;VEGFA,PIK3CG,VEGFA,CET+CIT,Tclin+Tclin,0.441,0.629,0.428,2,0,6,1,1,DC00431,Bevacizumab;Buparlisib,DrugComb,FD00017,Glioma,Glioma,Phase 1|Phase 2
5219,TP01625,PROM1;STAT3,PROM1,STAT3,CIT+CIT,Tbio+Tchem,0.191,0.521,0.481,0,0,0,1,1,DC00171,Amcasertib;Napabucasin,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
5220,TP01626,PTK2;RAF1,PTK2,RAF1,CET+CIT,Tclin+Tclin,0.609,0.683,0.785,15,0,22,1,3,DC00355,Avutometinib;Defactinib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 2
5221,TP01626,PTK2;RAF1,PTK2,RAF1,CET+CIT,Tclin+Tclin,0.609,0.683,0.785,15,0,22,1,3,DC00355,Avutometinib;Defactinib,DrugComb,FD00034,Ovarian Cancer,Ovarian Cancer,Phase 1
5222,TP01626,PTK2;RAF1,PTK2,RAF1,CET+CIT,Tclin+Tclin,0.609,0.683,0.785,15,0,22,1,3,DC00355,Avutometinib;Defactinib,DrugComb,FD00035,Pancreatic Cancer,Pancreatic Cancer,Phase 1
5223,TP01627,PTPN11;ROS1,PTPN11,ROS1,CIT+CIT,Tchem+Tclin,0.436,0.455,0.488,0,0,0,1,1,DC00392,Batoprotafib;Lorlatinib,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1|Phase 2
5224,TP01628,PVRIG;TIGIT,PVRIG,TIGIT,CET+CET,Tbio+Tbio,0.198,0.878,0.743,0,0,0,4,2,DC00794,COM701;COM902,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
5226,TP01628,PVRIG;TIGIT,PVRIG,TIGIT,CET+CET,Tbio+Tbio,0.198,0.878,0.743,0,0,0,4,2,DC02259,SHR2002,BsAb,FD00033,Other Cancer,Other Cancer,Phase 1
5229,TP01629,SLAMF7;TNFRSF9,SLAMF7,TNFRSF9,CET+CIT,Tbio+Tclin,0.217,0.89,0.788,0,0,0,1,1,DC00974,Elotuzumab;Urelumab,DrugComb,FD00030,Myeloma,Hematologic Malignancy,Phase 1
5230,TP01630,TACSTD2;TIGIT,TACSTD2,TIGIT,CET+CIT,Tbio+Tclin,0.15,0.643,1.0,0,0,0,1,1,DC00867,Datopotamab Deruxtecan;Rilvegostomig,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
5231,TP01631,TGFB1;TIGIT,TGFB1,TIGIT,CET+CET,Tbio+Tbio,0.166,0.544,0.758,0,0,1,1,1,DC02010,AK130,BsAb,FD00033,Other Cancer,Other Cancer,Phase 1
5232,TP01632,TGFB1;VEGFA,TGFB1,VEGFA,CET+CET,Tbio+Tclin,0.592,0.818,0.736,8,2,17,2,1,DC02123,HB002T,BsAb,FD00033,Other Cancer,Other Cancer,Phase 1
5234,TP01633,TIGIT;TNFRSF8,TIGIT,TNFRSF8,CET+CIT,Tbio+Tclin,0.348,0.744,0.176,0,0,0,1,1,DC00597,Brentuximab Vedotin;SEA-TGT,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
5235,TP01634,TLR9;TNFSF4,TLR9,TNFSF4,CIT+CIT,Tbio+Tclin,0.676,0.496,0.4,0,0,0,1,1,DC01854,Revdofilimab;Tilsotolimod,DrugComb,FD00033,Other Cancer,Other Cancer,Phase 1
5236,TP01635,TNFRSF10B;XIAP,TNFRSF10B,XIAP,CIT+CIT,Tbio+Tchem,0.51,0.346,0.468,2,1,2,1,1,DC00548,Birinapant;Conatumumab,DrugComb,FD00034,Ovarian Cancer,Ovarian Cancer,Phase 1
5237,TP01636,TNFRSF18;TNFRSF4,TNFRSF18,TNFRSF4,CET+CET,Tbio+Tchem,0.308,0.886,0.886,1,1,1,1,1,DC02008,AGEN1223,BsAb,FD00033,Other Cancer,Other Cancer,Phase 1
5238,TP01637,TNFRSF4;TNFRSF9,TNFRSF4,TNFRSF9,CET+CET,Tbio+Tchem,0.19,0.932,0.727,1,1,1,1,1,DC02109,FS120,BsAb,FD00033,Other Cancer,Other Cancer,Phase 1
5239,TP01638,TNFRSF9;VTCN1,TNFRSF9,VTCN1,CET+CIT,Tbio+Tbio,0.279,0.809,0.623,0,0,1,1,1,DC02125,HBM7008,BsAb,FD00033,Other Cancer,Other Cancer,Phase 1
5240,TP01639,VEGFA;WEE1,VEGFA,WEE1,CET+CIT,Tchem+Tclin,0.224,0.493,0.473,0,0,0,1,1,DC00376,Azenosertib;Bevacizumab,DrugComb,FD00023,Lung Cancer,Lung Cancer,Phase 1
5241,TP01640,VEGFA;XPO1,VEGFA,XPO1,CET+CIT,Tclin+Tclin,0.125,0.527,0.559,0,0,0,1,1,DC00475,Bevacizumab;Selinexor,DrugComb,FD00017,Glioma,Glioma,Phase 1|Phase 2
